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The American Academy of Ophthalmology (AAO), 
an internationally recognized medical organization,  
offers a wide variety of valuable benefits designed  
to give you the advantages needed to support you  
throughout your training and your career.
AAO Member Benefits
•  No registration fee for the Academy’s  
Annual Meeting
• Print subscription to Ophthalmology
•  Access to the Ophthalmic News &  
Education (ONE®) Network
• Discounts on Academy products and services
• Access to the Academy Online Community
AND MUCH MORE…For an application and a complete  
list of benefits, visit www.aao.org/member.
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AT YOUR SERVICE.
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Indication
JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL,  
is a proteolytic enzyme indicated for the treatment of 
symptomatic vitreomacular adhesion.
Important Safety Information
Warnings and Precautions
• A decrease of ≥ 3 lines of best-corrected visual acuity 
(BCVA) was experienced by 5.6% of patients treated 
with JETREA and 3.2% of patients treated with vehicle 
in the controlled trials. The majority of these decreases 
in vision were due to progression of the condition 
with traction and many required surgical intervention. 
Patients should be monitored appropriately.
• Intravitreal injections are associated with intraocular 
inflammation/infection, intraocular hemorrhage and  
increased intraocular pressure (IOP). Patients should 
be monitored and instructed to report any symptoms 
without delay. In the controlled trials, intraocular 
inflammation occurred in 7.1% of patients injected with 
JETREA vs 3.7% of patients injected with vehicle. Most 
of the post-injection intraocular inflammation events 
were mild and transient. If the contralateral eye requires 
treatment with JETREA, it is not recommended within 7 
days of the initial injection in order to monitor the post-
injection course in the injected eye. 
 
• Potential for lens subluxation.
• In the controlled trials, the incidence of retinal 
detachment was 0.9% in the JETREA group and 1.6% 
in the vehicle group, while the incidence of retinal tear 
(without detachment) was 1.1% in the JETREA group 
and 2.7% in the vehicle group. Most of these events 
occurred during or after vitrectomy in both groups.
• Dyschromatopsia (generally described as 
yellowish vision) was reported in 2% of all patients 
injected with JETREA. In approximately half of 
these dyschromatopsia cases there were also 
electroretinographic (ERG) changes reported (a- and 
b-wave amplitude decrease).
Adverse Reactions 
• The most commonly reported reactions (≥ 5%) in 
patients treated with JETREA were vitreous floaters, 
conjunctival hemorrhage, eye pain, photopsia, blurred 
vision, macular hole, reduced visual acuity, visual 
impairment, and retinal edema.
Please see Brief Summary of full Prescribing  
Information on adjacent page.
(ocriplasmin)
Intravitreal Injection, 2.5 mg/mL 
TAKE ACTION WITH JETREA®
(ocriplasmin) Intravitreal Injection, 2.5 mg/mL
The FIRST and ONLY pharmacologic treatment 
for symptomatic Vitreomacular Adhesion (VMA).1
ONE INJECTION,
EARLY INTERVENTION.
LEARN MORE AT JETREA.com
VISIT BOOTH #4553 AT 
THE AAO ANNUAL MEETING
BRIEF SUMMARY OF FULL PRESCRIBING 
INFORMATION
Please see the JETREA® package insert for full 
Prescribing Information.
1  INDICATIONS AND USAGE
JETREA is a proteolytic enzyme indicated for the treatment of 
symptomatic vitreomacular adhesion.
2  DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
Must be diluted before use. For single-use ophthalmic 
intravitreal injection only. JETREA must only be administered 
by a quali ed physician.  
2.2 Dosing
The recommended dose is 0.125 mg (0.1 mL of the diluted 
solution) administered by intravitreal injection to the a ected 
eye once as a single dose.
2.3 Preparation for Administration
Remove the vial (2.5 mg/mL corresponding to 0.5 mg 
ocriplasmin) from the freezer and allow to thaw at room 
temperature (within a few minutes). Once completely 
thawed, remove the protective polypropylene  ip-o  cap 
from the vial. The top of the vial should be disinfected with 
an alcohol wipe. Using aseptic technique, add 0.2 mL of 
0.9% w/v Sodium Chloride Injection, USP (sterile, 
preservative-free) into the JETREA vial and gently swirl the 
vial until the solutions are mixed.
Visually inspect the vial for particulate matter. Only a clear, 
colorless solution without visible particles should be used. 
Using aseptic technique, withdraw all of the diluted solution 
using a sterile #19 gauge needle (slightly tilt the vial to ease 
withdrawal) and discard the needle after withdrawal of 
the vial contents. Do not use this needle for the intravitreal 
injection. 
Replace the needle with a sterile #30 gauge needle, carefully 
expel the air bubbles and excess drug from the syringe 
and adjust the dose to the 0.1 mL mark on the syringe 
(corresponding to 0.125 mg ocriplasmin). THE SOLUTION 
SHOULD BE USED IMMEDIATELY AS IT CONTAINS NO 
PRESERVATIVES. Discard the vial and any unused portion of 
the diluted solution after single use.
2.4 Administration and Monitoring
The intravitreal injection procedure should be carried out 
under controlled aseptic conditions, which include the use 
of sterile gloves, a sterile drape and a sterile eyelid speculum 
(or equivalent). Adequate anesthesia and a broad spectrum 
microbiocide should be administered according to standard 
medical practice.
The injection needle should be inserted 3.5 - 4.0 mm posterior 
to the limbus aiming towards the center of the vitreous cavity, 
avoiding the horizontal meridian. The injection volume of 
0.1 mL is then delivered into the mid-vitreous.
Immediately following the intravitreal injection, patients 
should be monitored for elevation in intraocular pressure. 
Appropriate monitoring may consist of a check for perfusion 
of the optic nerve head or tonometry. If required, a sterile 
paracentesis needle should be available.
Following intravitreal injection, patients should be instructed 
to report any symptoms suggestive of endophthalmitis 
or retinal detachment (e.g., eye pain, redness of the eye, 
photophobia, blurred or decreased vision) without delay [see 
Patient Counseling Information].
Each vial should only be used to provide a single injection 
for the treatment of a single eye. If the contralateral eye 
requires treatment, a new vial should be used and the sterile 
 eld, syringe, gloves, drapes, eyelid speculum, and injection 
needles should be changed before JETREA is administered to 
the other eye, however, treatment with JETREA in the other 
eye is not recommended within 7 days of the initial injection 
in order to monitor the post-injection course including the 
potential for decreased vision in the injected eye.
Repeated administration of JETREA in the same eye is not 
recommended [see Nonclinical Toxicology].
After injection, any unused product must be discarded.
No special dosage modi cation is required for any of the 
populations that have been studied (e.g. gender, elderly).
3  DOSAGE FORMS AND STRENGTHS
Single-use glass vial containing JETREA 0.5 mg in 0.2 mL 
solution for intravitreal injection (2.5 mg/mL).
4  CONTRAINDICATIONS
None
5  WARNINGS AND PRECAUTIONS
5.1 Decreased Vision
A decrease of ≥ 3 line of best corrected visual acuity (BCVA) 
was experienced by 5.6% of patients treated with JETREA and 
3.2% of patients treated with vehicle in the controlled trials 
[see Clinical Studies].
The majority of these decreases in vision were due to 
progression of the condition with traction and many 
required surgical intervention. Patients should be monitored 
appropriately [see Dosage and Administration].
5.2 Intravitreal Injection Procedure Associated 
E ects
Intravitreal injections are associated with intraocular 
in ammation / infection, intraocular hemorrhage and increased 
intraocular pressure (IOP). In the controlled trials, intraocular 
in ammation occurred in 7.1% of patients injected with 
JETREA vs. 3.7% of patients injected with vehicle. Most of the 
post-injection intraocular in ammation events were mild and 
transient. Intraocular hemorrhage occurred in 2.4% vs. 3.7% 
of patients injected with JETREA vs. vehicle, respectively. 
Increased intraocular pressure occurred in 4.1% vs. 5.3% of 
patients injected with JETREA vs. vehicle, respectively.
5.3 Potential for Lens Subluxation
One case of lens subluxation was reported in a patient who 
received an intravitreal injection of 0.175 mg (1.4 times 
higher than the recommended dose). Lens subluxation was 
observed in three animal species (monkey, rabbit, minipig) 
following a single intravitreal injection that achieved vitreous 
concentrations of ocriplasmin 1.4 times higher than achieved 
with the recommended treatment dose. Administration of a 
second intravitreal dose in monkeys, 28 days apart, produced 
lens subluxation in 100% of the treated eyes [see Nonclinical 
Toxicology]. 
5.4 Retinal Breaks
In the controlled trials, the incidence of retinal detachment 
was 0.9% in the JETREA group and 1.6% in the vehicle group, 
while the incidence of retinal tear (without detachment) was 
1.1% in the JETREA group and 2.7% in the vehicle group. Most 
of these events occurred during or after vitrectomy in both 
groups. The incidence of retinal detachment that occurred 
pre-vitrectomy was 0.4% in the JETREA group and none in 
the vehicle group, while the incidence of retinal tear (without 
detachment) that occurred pre-vitrectomy was none in the 
JETREA group and 0.5% in the vehicle group.
5.5 Dyschromatopsia
Dyschromatopsia (generally described as yellowish vision) 
was reported in 2% of all patients injected with JETREA. In 
approximately half of these dyschromatopsia cases there were 
also electroretinographic (ERG) changes reported (a- and 
b-wave amplitude decrease).
6  ADVERSE REACTIONS
The following adverse reactions are described below and 
elsewhere in the labeling:
• Decreased Vision [see Warnings and Precautions]
• Intravitreal Injection Procedure Associated E ects 
[see Warnings and Precautions and Dosage and 
Administration]
• Potential for Lens Subluxation [see Warnings 
and Precautions]
• Retinal Breaks [see Warnings and Precautions and 
Dosage and Administration]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying 
conditions, adverse reaction rates in one clinical trial of a drug 
cannot be directly compared with rates in the clinical trials 
of the same or another drug and may not re ect the rates 
observed in practice.
Approximately 800 patients have been treated with an 
intravitreal injection of JETREA. Of these, 465 patients 
received an intravitreal injection of ocriplasmin 0.125 mg 
(187 patients received vehicle) in the 2 vehicle-controlled 
studies (Study 1 and Study 2).
The most common adverse reactions (incidence 5% - 20% 
listed in descending order of frequency) in the vehicle-
controlled clinical studies were: vitreous  oaters, conjunctival 
hemorrhage, eye pain, photopsia, blurred vision, macular 
hole, reduced visual acuity, visual impairment, and  retinal 
edema.
Less common adverse reactions observed in the studies at 
a frequency of 2% - < 5% in patients treated with JETREA 
included macular edema, increased intraocular pressure, 
anterior chamber cell, photophobia, vitreous detachment, 
ocular discomfort, iritis, cataract, dry eye, metamorphopsia, 
conjunctival hyperemia, and retinal degeneration.
Dyschromatopsia was reported in 2% of patients injected 
with JETREA, with the majority of cases reported from two 
uncontrolled clinical studies. In approximately half of these 
dyschromatopsia cases there were also electroretinographic 
(ERG) changes reported (a- and b-wave amplitude decrease).
6.2 Immunogenicity
As with all therapeutic proteins, there is potential for 
immunogenicity. Immunogenicity for this product has not 
been evaluated.
8  USE IN SPECIFIC POPULATIONS
8.1 Pregnancy:  Teratogenic E ects
Pregnancy Category C. Animal reproduction studies have not 
been conducted with ocriplasmin. There are no adequate and 
well-controlled studies of ocriplasmin in pregnant women. It 
is not known whether ocriplasmin can cause fetal harm when 
administered to a pregnant woman or can a ect reproduction 
capacity. The systemic exposure to ocriplasmin is expected to 
be low after intravitreal injection of a single 0.125 mg dose. 
Assuming 100% systemic absorption (and a plasma volume 
of 2700 mL), the estimated plasma concentration is 46 ng/mL. 
JETREA should be given to a pregnant woman only if clearly 
needed. 
8.3 Nursing Mothers
It is not known whether ocriplasmin is excreted in human 
milk. Because many drugs are excreted in human milk, and 
because the potential for absorption and harm to infant 
growth and development exists, caution should be exercised 
when JETREA is administered to a nursing woman. 
8.4 Pediatric Use
Safety and e ectiveness in pediatric patients have not been 
established.
8.5 Geriatric Use
In the clinical studies, 384 and 145 patients were ≥ 65 years 
and of these 192 and 73 patients were ≥ 75 years in the 
JETREA and vehicle groups respectively. No signi cant 
di erences in e  cacy or safety were seen with increasing age 
in these studies.
10  OVERDOSAGE
The clinical data on the e ects of JETREA overdose are limited. 
One case of accidental overdose of 0.250 mg ocriplasmin 
(twice the recommended dose) was reported to be associated 
with in ammation and a decrease in visual acuity.
13  NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment 
of Fertility
No carcinogenicity, mutagenicity or reproductive and 
developmental toxicity studies were conducted with 
ocriplasmin.
13.2 Animal Toxicology and/or Pharmacology
The ocular toxicity of ocriplasmin after a single intravitreal 
dose has been evaluated in rabbits, monkeys and minipigs. 
Ocriplasmin induced an in ammatory response and transient 
ERG changes in rabbits and monkeys, which tended to resolve 
over time. Lens subluxation was observed in the 3 species 
at ocriplasmin concentrations in the vitreous at or above 
41 mcg/mL, a concentration 1.4-fold above the intended 
clinical concentration in the vitreous of 29 mcg/mL. Intraocular 
hemorrhage was observed in rabbits and monkeys.
A second intravitreal administration of ocriplasmin 
(28 days apart) in monkeys at doses of 75 mcg/eye (41 mcg/
mL vitreous) or 125 mcg/eye (68 mcg/mL vitreous) was 
associated with lens subluxation in all ocriplasmin treated eyes. 
Sustained increases in IOP occurred in two animals with lens 
subluxation. Microscopic  ndings in the eye included vitreous 
liquefaction, degeneration/disruption of the hyaloideo-
capsular ligament (with loss of ciliary zonular  bers), lens 
degeneration, mononuclear cell in ltration of the vitreous, 
and vacuolation of the retinal inner nuclear cell layer. 
These doses are 1.4-fold and 2.3-fold the intended clinical 
concentration in the vitreous of 29 mcg/mL, respectively.
14  CLINICAL STUDIES
The e  cacy and safety of JETREA was demonstrated in two 
multicenter, randomized, double masked, vehicle-controlled, 
6 month studies in patients with symptomatic vitreomacular 
adhesion (VMA). A total of 652 patients (JETREA 464, 
vehicle 188) were randomized in these 2 studies. 
Randomization was 2:1 (JETREA:vehicle) in Study 1 and 3:1 
in Study 2.
Patients were treated with a single injection of JETREA or 
vehicle. In both of the studies, the proportion of patients who 
achieved VMA resolution at Day 28 (i.e., achieved success 
on the primary endpoint) was signi cantly higher in the 
ocriplasmin group compared with the vehicle group through 
Month 6.   
The number of patients with at least 3 lines increase in visual 
acuity was numerically higher in the ocriplasmin group 
compared to vehicle in both trials, however, the number of 
patients with at least a 3 lines decrease in visual acuity was 
also higher in the ocriplasmin group in one of the studies 
(Table 1 and Figure 1).
Table 1: Categorical Change from Baseline in BCVA 
at Month 6, Irrespective of Vitrectomy (Study 1 
and Study 2)
Figure 1: Percentage of Patients with Gain or Loss 
of ≥ 3 Lines of BCVA at Protocol-Speci ed Visits
16  HOW SUPPLIED/STORAGE AND HANDLING
Each vial of JETREA contains 0.5 mg ocriplasmin in 0.2 mL 
citric-bu ered solution (2.5 mg/mL). JETREA is supplied in a 
2 mL glass vial with a latex free rubber stopper. Vials are for 
single use only.  
Storage
Store frozen at or below  -4˚F ( -20˚C). Protect the vials from 
light by storing in the original package until time of use.
17  PATIENT COUNSELING INFORMATION
In the days following JETREA administration, patients are at 
risk of developing intraocular in ammation/infection. Advise 
patients to seek immediate care from an ophthalmologist if 
the eye becomes red, sensitive to light, painful, or develops a 
change in vision [see Warnings and Precautions].
Patients may experience temporary visual impairment after 
receiving an intravitreal injection of JETREA [see Warnings 
and Precautions]. Advise patients to not drive or operate heavy 
machinery until this visual impairment has resolved. If visual 
impairment persists or decreases further, advise patients to 
seek care from an ophthalmologist. 
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N=219 N=107 (95% CI)
≥ 3 line Improvement in BCVA
Month 6 28 (12.8%) 9 (8.4%) 4.4 (-2.5, 11.2)
> 3 line Worsening in BCVA
Month 6 16 (7.3%) 2 (1.9%) 5.4 (1.1, 9.7)
Study 2
JETREA Vehicle Di erence
N=245 N=81 (95% CI)
≥ 3 line Improvement in BCVA
Month 6 29 (11.8%) 3 (3.8%) 8.1 (2.3, 13.9)
> 3 line Worsening in BCVA
Month 6 10 (4.1%) 4 (5.0%) -0.9 (-6.3, 4.5)
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Symposia
There are 47 Symposia available throughout the Annual 
Meeting that are free of charge and open to all attendees. 
Big Data Drives Better Outcomes: The Power 
and Benefits of the IRIS™ Registry
SYM57, Sunday, Nov. 17, 12:45 - 1:45 PM 
La Nouvelle Orleans C
Explore the vision of the IRIS Registry, how it can help 
ophthalmologists to comply with the changing regulatory 
landscape and enhance their ability to improve the out-
comes of their patients.
The Affordable Care Act and Health Care Re-
form in 2013: Pearls and Potential Perils
SYM24, Monday, Nov. 18, 10:15  - 11:45 AM 
New Orleans Theater C
A combined meeting with the National Medical Association 
(NMA), this session will discuss the law, impact on physi-
cian shortage and changing payment methods.
HIGHLIGHTS
2013 Annual Meeting of the American Academy of Ophthalmology
Opening Session
Sunday, Nov. 17, 8:30 – 1
0:00 AM 
The Great Hall
Don’t miss the presentation and
 panel discussion moderated 
by Michael X. Repka, MD, titled
: The IRIS™ Registry: 
Ophthalmology’s Moon Shot?. C
elebrate those honored with 
awards, including the presentat
ion of the 2013 Laureate 
Award to Daniel Albert, MD. Th
en hear the Jackson Memorial 
Lecture: The History and Evolut
ion of Lasers in Ophthalmology:
 
A Review of the Interactions Be
tween Physicians, Patients and
 
Photons, given by Mark S. Blum
enkranz, MD.
Interactive Learning
There are hundreds of small gro
up learning opportunities where
 
you can contribute to the dialog
ue. Start your day with a Break-
fast With the Experts roundtabl
e, grab a cup of coffee and stay
 
for the panel discussion at the A
cademy Café, continue the 
conversation on the hottest top
ics in the relaxed atmosphere 
of the Learning Lounge or atten
d poster tours moderated by 
colleagues.
2013 Annual Meeting Highlights
xHIGHLIGHTS
2013 Annual Meeting of the American Academy of Ophthalmology
Cataract Monday, Nov. 18
Join the Academy on Monday to focus on cataracts:
Spotlight on Cataract Complications: M&M Rounds – 
Learning from My Mistakes
SPO2, Monday, Nov. 18, 8:15 AM – 12:15 PM, The Great Hall
Hear from 18 different experts who will each courageously 
present a case where something went wrong and a complication 
occurred that taught them a valuable lesson. The symposium will 
conclude with the 9th Annual Kelman Lecture given by Samuel 
Masket, MD on “25 Years of the JCRS Consultation Section.”
The Management of Glaucoma in the Cataract Patient
SYM33, 2:00 - 4:00 PM, The Great Hall
Combined meeting with the American Society of Cataract and 
Refractive Surgery (ASCRS) 
Cataract Monday is sponsored in part by Alcon and Bausch + 
Lomb.
Additional cataract sessions on Monday, include:
Phacoemulsification and Advanced Techniques Skills: The 
Core Curriculum
LAB120A, 8:00 – 9:30 AM, Room 356
Learning Phaco Chop: Pearls and Pitfalls
368, 2:00 – 4:15 PM, Room R06
Comprehensive Cataract Coding
404, 3:15 – 5:30 PM, Room 296
At the Movies: Femtolaser Cataract Surgery
9:00 – 10:00 AM, Learning Lounge, Booth 3647, Theater 1
Cataract Poster Tour
12:30 – 1:30 PM, “Meeting Point” near Scientific Posters Online/
Videos on Demand in Hall C, Booth 100
AAOE Program: Celebrating 
10 Years of Practice 
Management
The AAOE Program at the Annual Meeting provides over 100 courses 
to help you manage the business side of your ophthalmic practice, 
including intensive half-day coding sessions on Saturday, Nov. 16. 
Look for additional Saturday sessions, including billing operations, 
Excel and human resources/compliance workshops. Strengthen the 
working partnership between physician-owners and administrators 
through the new physician-administrator track.
New! AAO Virtual Meeting
This year the Academy is offering an online component to the An-
nual Meeting. The AAO Virtual Meeting will live stream one hour 
of content a day and have additional recorded content available 
as well.  It is FREE to all Annual Meeting attendees and Academy 
members. View elements you may have missed while onsite or  
share the event experience with someone else.  
Register for the event at www.aao.org/virtual-meeting.
New Named Lectures
Don’t miss these inaugural lectures:
Michael F Marmor MD Lecture in Ophthalmology and 
the Arts
SYM54, Sunday, Nov. 17, 11:30 AM – 12:00 PM, Room 255
“Degas, New Orleans and Eyes Greatly in Need of Care,” 
presented by Richard Kendall, Curator-at-Large, Clark Art 
Institute. Mr. Kendall is an internationally known art historian 
and curator as well as being a leading Degas expert.
The Bruce E Spivey MD Lecture in Risk Management & 
Patient Safety and OMIC Forum
SPE17, Sunday, Nov. 17, at 2:00 – 4:00 PM, New Orleans 
Theater C
Susan Day, MD will lecture on risk management and patient 
safety risks as they relate to ophthalmology. The lecture 
will be followed by the OMIC Forum, which highlights the 
successful strategies OMIC has developed in collaboration 
with the Academy to decrease the frequency and severity of 
claims against ophthalmologists.
In the Spotlight 
This year the Academy is shining its spotlight on Cataracts 
(see below) and the following areas:
Spotlight on Ophthalmic Office Emergencies: Things 
You Don’t Want to Miss
SPO3, Sunday, Nov. 17 10:30 AM – 12:00 PM
La Nouvelle Orleans AB
Learn how to recognize, triage and manage emergencies 
through case studies.
Spotlight on OCT
SPO1, Sunday, Nov. 17, 3:45 – 5:15 PM 
The Great Hall
This session reviews the current state-of-the-art in clinical 
OCT imaging and looks ahead to the future.
Haag-Streit Innovation Brought To Life.
Haag-Streit is more than the sum of its parts. Our mission is 
innovation, which leads to the development of important 
diagnostic devices and equipment. Used by doctors in nearly 
every country, they’re noted for accuracy, durability and 
engineering. It’s what your patients expect, and you demand. 
Watch for what’s coming out of Haag-Streit next. Science. 
Brilliance. Certainty.
Visit us at AAO Booth #745.
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OctopusHaag-Streit Xoma™ SurgicalLENSTAR®
800.787.5426
haag-streit-usa.com
The Superior Practice.
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I AM
AN
ADVOCATE
It is easy to become an advocate 
for ophthalmology and patients.
Discover how during the 2013 Annual Meeting.  
Visit the OPHTHPAC® and Surgical Scope Fund  
Advocacy Booth in Lobby B2.
The success of the Academy’s legislative agenda  
starts with members. 
Brilliant from 
Beginning to End.™
Protection you can count on for 
every phase of cataract surgery. 
The first and only viscous dispersive, DisCoVisc® OVD 
provides the flexibility of both cohesive and dispersive 
properties in a single syringe. DisCoVisc® OVD combines 
the excellent endothelial protection of chondroitin 
sulfate with the mechanical protection of superior
space maintenance and clarity. 
To see how DisCoVisc® OVD can help protect your outcomes,
visit AlconOVD.com.
Only One 
System Delivers
the Shield of
PROTECTION.
DuoVisc® Viscoelastic System offers both
the endothelial protection of chondroitin 
sulfate in Viscoat®OVD with the proven 
mechanical protection and space 
maintenance found in ProVisc®OVD.
One System. No Compromises.
© 2013 Novartis     9/13     VIS13035JAD
Please refer to the important safety 
information on the adjacent page.
A
AO
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© 2013 Novartis     4/13     INT13016JAD
1. Johansson, C. Comparison of Motorized IOL Insertion to Traditional Manual IOL Delivery. ASCRS Presentation, 2011.
2. Allen, D. Experience with Electro-Assisted IOL Injection Device. ASCRS Presentation, 2011.
For important safety information, please see adjacent page.
DO YOU PREFER
MORE CONTROL  
OR
MORE CONSISTENCY?
Do more through less.™
Incision Lens 
Removal
IOL
Implantation
Achieve smoother, more controlled IOL
delivery for smaller incision sizes with 
the fully automated INTREPID® AutoSert® 
IOL Injector. An ideal solution for MICS 
procedures, the INTREPID® AutoSert® IOL 
Injector optimizes surgical control while 
helping to minimize wound disruption
and trauma.
YES.
Automated lens delivery with the INTREPID® AutoSert® IOL Injector.
To learn how the INTREPID® AutoSert® 
IOL Injector can help improve your 
surgical outcomes, talk to your local 
Alcon  representative.
A
AO
 Final Program
In partnership with the 
European Society of Ophthalmology
The American Academy of Ophthalmology is accredited by the Accreditation Council for 
Continuing Medical Education to provide continuing medical education for physicians.
AAO 2014
October 18–21
Subspecialty Day
October 17–18
AAOE Program
October 18–21
SAVE THE DATE!
Learn in hands-on Skills Transfer labs and 
lively small-group sessions. Collaborate 
in thought-provoking presentations from 
ophthalmology luminaries. Interact in face-to-
face conversations with colleagues from around 
the world. Engage! Only at AAO 2014.
ENGAGE!
AAO 2014
Where all of ophthalmology meets
www.aao.org/2014  Chicago
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MULTIFOCAL IOLs
© 2013 Novartis     9/13     RES13076JAD     AlconSurgical.com 
ReSTOR® IOLs deliver more.
For cataract patients who desire decreased spectacle dependence for the broadest range of vision, 
the AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL delivers more:
     •  The strength of true performance at all distances 1
     •  The confidence of the trusted AcrySof® IQ platform
     •  The reassurance of over 93% patient satisfaction2
For information about the lenses that give your patients more, visit AlconSurgical.com 
or contact your Alcon sales representative today.
Recommend AcrySof® IQ ReSTOR® +3.0 D 
Multifocal IOLs for the broadest range of vision.†
†. Broadest range of vision across all AcrySof® IOLs.
1. AcrySof® IQ ReSTOR® IOL Directions for Use.
2. AcrySof® IQ ReSTOR® IOL Clinical trial data on file (models SN6AD1 and SN6AD3). Fort Worth, TX; Alcon Laboratories, Inc.
Please refer to the Important Safety Information on the accompanying page.
Deliver More
A
AO
 Final Program

Image.
Plan.
Guide.
Introducing the new 
VERION™ Image Guided System*:
Designed to help you consistently 
hit your refractive target.
EXPERIENCE THE VERION™ 
IMAGE GUIDED SYSTEM* AT 
THE ALCON BOOTH.*The VERION™ Image Guided System is composed of the 
VERION™ Reference Unit and the VERION™ Digital Marker.
For important safety information, 
please see adjacent page.
THE CATARACT REFRACTIVE SUITE BY ALCON©2013 Novartis     8/13     VRN13015JAD
Pre-op
Pre-op
Intra-op
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IS MATERIALISTIC
LEGENDARY
14-ply birch. Forged iron. Tough, hand-sewn upholstery. These 
are the materials of a legend. Built into our ultra-durable exam 
chairs and stands to make them last for decades. And they’re 
virtually maintenance free.
Call us materialistic. We’re okay with that. Because it’s what 
makes Reliance Medical Products Brutishly Durable Since 1898.
Find your legendary exam chair and instrument stand at 
reliance-medical.com, or call 800.735.0357.
Visit us at AAO Booth #745.
 
The Superior Practice.
800.735.0357
haag-streit-usa.com
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The Council
The Council
Russell N Van Gelder MD PhD – Chair
Ann A Warn MD MBA – Vice Chair
Councilors representing State Societies
Alabama Academy of Ophthalmology
Wonsuck Kim DO 
Alaska Society of Eye Physicians and Surgeons
Scott A Limstrom MD 
Arizona Ophthalmological Society
Thomas J McPhee MD 
Arkansas Ophthalmological Society
Justine W Charton MD
California Academy of Eye Physicians and 
Surgeons
Kimberly Cockerham MD FACS
Lynn K Gordon MD PhD
Craig H Kliger MD
Asa Dan Morton III MD
Colorado Society of Eye Physicians and 
Surgeons
Robert A King MD 
Connecticut Society of Eye Physicians
Jeffrey R Sandler MD 
Delaware Academy of Ophthalmology
David C Larned MD 
Florida Society of Ophthalmology 
Gary B Schemmer MD 
Stephen G Schwartz MD MBA 
Michael W Stewart MD 
Georgia Society of Ophthalmology
James Gerard Brooks Jr MD 
Hawaii Ophthalmological Society
George Nardin MD 
Idaho Society of Ophthalmology
Adam C Reynolds MD 
Illinois Association of Ophthalmology
Sohail J Hasan MD PhD 
David K Yoo MD 
Indiana Academy of Ophthalmology
Derek T Sprunger MD 
Iowa Academy of Ophthalmology 
Brandt M Riley DO 
Kansas Society of Eye Physicians and Surgeons
William S Clifford MD 
Kentucky Academy of Eye Physicians and 
Surgeons
David E Jones MD 
Louisiana Ophthalmology Association
Keith Kellum MD DVM 
Maine Society of Eye Physicians and Surgeons
Cynthia A Self MD 
Maryland Society of Eye Physicians and 
Surgeons
Sanjay D Goel MD 
John T Thompson MD 
Massachusetts Society of Eye Physicians and 
Surgeons 
Robert A Lytle MD 
Michael J Price MD 
Michigan Society of Eye Physicians and 
Surgeons
Arezo Amirikia MD 
James E Puklin MD 
Minnesota Academy of Ophthalmology
Eugene O Gullingsrud MD 
Mississippi Academy of Eye Physicians and 
Surgeons  
Curtis D Whittington Jr MD 
Missouri Society of Eye Physicians and 
Surgeons
Melissa G Toyos MD 
Montana Academy of Ophthalmology
Brian D Sippy MD PhD 
Nebraska Academy of Eye Physicians and 
Surgeons  
David D Ingvoldstad MD
Nevada Academy of Ophthalmology
Steve M Friedlander MD FACS 
New Hampshire Society of Eye Physicians and 
Surgeons
John J Dagianis MD 
New Jersey Academy of Ophthalmology
David M Ringel DO 
John R Stabile MD 
New Mexico Academy of Ophthalmology 
Kamalesh J Ramaiya MD 
New York State Ophthalmological Society
Gary S Hirshfield MD 
James A Kinsey MD 
Arnold S Prywes MD 
Stephen G Spitzer MD  
North Carolina Society of Eye Physicians and 
Surgeons
J Stuart McCracken MD 
North Dakota Society of Eye Physicians and 
Surgeons
Lance K Bergstrom MD 
Ohio Ophthalmological Society
Anita Dash-Modi MD 
Bernard D Perla MD 
Oklahoma Academy of Ophthalmology
Amalia Miranda MD 
Oregon Academy of Ophthalmology
Mary P DeFrank MD 
Pennsylvania Academy of Ophthalmology
James B Dickey MD 
Joanna M Fisher MD 
Karl R Olsen MD 
Puerto Rican Society of Ophthalmology
Emilio A Arce-Lopez MD 
Rhode Island Society of Eye Physicians and 
Surgeons  
Robert H Janigian Jr MD 
South Carolina Society of Ophthalmology
Kurt Frederick Heitman MD 
South Dakota Academy of Ophthalmology
Dustin L Dierks MD 
Tennessee Academy of Ophthalmology
Erich Bryan Groos MD 
Texas Ophthalmological Association
John R Fish MD 
Victor H Gonzalez MD  
Aaron M Miller MD
Utah Ophthalmology Society
Rachel Benator MD 
Vermont Ophthalmological Society
Brian Y Kim MD
Virginia Society of Eye Physicians and Surgeons
Anthony J Viti MD 
Washington Academy of Eye Physicians and 
Surgeons  
Brian E Bowe MD 
Washington DC Metropolitan Ophthalmological 
Society  
Reshma Katira MD 
The Council serves as the advisory body to the Board of Trustees. The Council was established in accordance with section 7.01 of the Bylaws of the 
American Academy of Ophthalmology.
The Council
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West Virginia Academy of Eye Physicians and 
Surgeons 
Mark D Mayle MD 
Wisconsin Academy of Ophthalmology
Deborah W Bernstein MD 
Wyoming Ophthalmological Society
Anne Elizabeth Miller MD
Councilors representing Subspecialty 
and Specialized Interest Societies
American Academy of Pediatrics, Section on 
Ophthalmology
George S Ellis Jr MD FAAO FACS 
American Association for Pediatric 
Ophthalmology and Strabismus
David A Plager MD 
American Association of Ophthalmic 
Oncologists and Pathologists
George Harocopos MD 
American Board of Ophthalmology
John E Sutphin MD 
American College of Surgeons, Advisory 
Council for Ophthalmic Surgery 
Vikram D Durairaj MD 
Sarwat Salim MD 
American Glaucoma Society
Thomas W Samuelson MD
American Ophthalmological Society
Thomas J Liesegang MD
American Osteopathic Colleges of 
Ophthalmology and Otolaryngology
Kristin E Reidy DO 
American Society of Cataract and Refractive 
Surgery 
David A Goldman MD  
Thomas M Harvey MD 
American Society of Ocular Trauma
Michael P Grant MD PhD 
American Society of Ophthalmic Plastic and 
Reconstructive Surgery
Louise A Mawn MD 
American Society of Retina Specialists
Peter K Kaiser MD 
Mathew W MacCumber MD PhD 
American Uveitis Society
Justine R Smith MD 
Association for Research in Vision and 
Ophthalmology
Robert B Nussenblatt MD 
Association of University Professors of 
Ophthalmology
Joel S Schuman MD 
Association of Veterans Affairs 
Ophthalmologists
Mary Gilbert Lawrence MD MPH 
Canadian Ophthalmological Society
Paul E Rafuse MD PhD 
Contact Lens Association of Ophthalmologists
Thomas L Steinemann MD 
Cornea Society
Shahzad I Mian MD 
Eye Bank Association of America 
Woodford S Van Meter MD FACS 
Macula Society
Michael J Elman MD 
National Medical Association, Ophthalmology 
Section
Eydie G Miller-Ellis MD 
North American Neuro-Ophthalmology Society
Matthew Dean Kay MD 
Ocular Microbiology and Immunology Group 
Bradley Dean Fouraker MD 
Outpatient Ophthalmic Surgery Society
Y Ralph Chu MD 
Pan-American Association of Ophthalmology
Stephanie Jones Marioneaux MD 
Retina Society
Thomas M Aaberg Jr MD 
Society of Military Ophthalmologists
Jonathan S Collins MD 
Women in Ophthalmology
Laura J King MD 
The Academy’s Council is integral to Academy 
relations with state, subspecialty and 
specialized interest ophthalmic societies.  
www.aao.org/council
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Friday, November 15
A New Era: Introducing the Centurion® Vision System
 
New Orleans Marriott (555 Canal Street) - Marriott Carondelet Room
 
5:30 pm - 7:00 pm
 
Moderator: Dr. Kerry Solomon
Faculty: Dr. John Berdahl
   Dr. Alan Crandall
   Dr. Richard Mackool
   Dr. Lawrence Woodard
Experience the new era in phacoemulsification. Surgeons will  
share observations, pearls and future possibilities using the new  
Centurion® Vision System. Discussion will cover Active Fluidics™  
Technology, Balanced Energy™ Technology and Applied  
Integration™ Technology available with this new platform.
Saturday, November 16
Fixed Combination Therapy, Surgical Research  
Findings, and Reimbursement
New Orleans Downtown Marriott at the Convention Center  
(859 Convention Center Blvd.) - Blaine Kern Ballroom
6:30 am - 8:00 am
Moderator: Dr. Robert Fechtner
Faculty: Dr. Andrew Iwach
   Dr. Jonathan Myers
   Nancy Tuffin
An update on treatment options for elevated intraocular pressure  
inpatients  with open-angle glaucoma or ocular hypertension.
Saturday, November 16
Live Surgery: Advancements in Techniques  
and Technologies TELECAST in High Definition!
New Orleans Marriott (555 Canal Street) - Marriott Grand Ballroom
6:00 pm - 8:00 pm
Surgeons: Dr. Stephen Brint - Host Surgeon
   Dr. James Davison
   Dr. Richard Mackool 
   Dr. Kerry Solomon
Moderator: Dr. Donald Serafano
Faculty: Dr. Stephen Lane 
   Dr. Michael Lawless 
   Dr. RJ Mackool
   Dr. Arnaldo Espaillat Matos
Register now to learn from world-acclaimed surgeons 
demonstrating their techniques using the latest Alcon® 
technologies in cataract surgery. 
Sunday, November 17
Experience the New Cataract Refractive Suite by Alcon
The Roosevelt New Orleans (123 Baronne Street) -  
Roosevelt Cresent City Ballroom
5:30 pm - 7:00 pm
Moderator: Dr. Robert Cionni
Faculty: Dr. Jonathan Frantz 
   Dr. Warren Hill
   Dr. Stephen Slade
   Dr. Richard Tipperman
Discover the best in class, innovative technologies, designed 
to streamline and guide your plan through the entire cataract 
procedure, to reach new efficiencies in the OR during the pre-op, 
intra-op and post-op period.
Please see next page for important safety information.
Register Online Now!  
http://www.seeuthere.com/AlconAAO2013
Register Online Now! http://www.seeuthere.com/AlconAAO2013
Please note that attendance at this meeting is limited to healthcare professionals. 
 
As a part of Alcon’s commitment to complying with relevant legal requirements, we regret that we cannot provide meals for the healthcare 
professionals licensed in Vermont. In addition, we may be unable to provide meals for healthcare professionals affiliated with state or federal 
institutions. If you are licensed in Vermont, affiliated with a state or federal institution, or are otherwise unable to accept a meal, other options 
may be available. 
 
For important safety information about the Alcon products discussed in these programs, please visit the Alcon booth. 
 
These programs are not affiliated with the Academy’s official program of the Annual Meeting.
CENTURION® Vision System Important Safety Information
Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician. As part of a properly maintained 
surgical environment, it is recommended that a backup IOL Injector be made available in the event the AutoSert® IOL Injector 
Handpiece does not perform as expected. 
 
Indication: The CENTURION® Vision system is indicated for emulsification, separation, irrigation, and aspiration of cataracts, residual 
cortical material and lens epithelial cells, vitreous aspiration and cutting associated with anterior vitrectomy, bipolar coagulation, 
and intraocular lens injection. The AutoSert® IOL Injector Handpiece is intended to deliver qualified AcrySof® intraocular lenses 
into the eye following cataract removal. The AutoSert® IOL Injector Handpiece achieves the functionality of injection of intraocular 
lenses. The AutoSert® IOL Injector Handpiece is indicated for use with the AcrySof® lenses SN6OWF, SN6AD1, SN6AT3 through 
SN6AT9, as well as approved AcrySof® lenses that are specifically indicated for use with this inserter, as indicated in the approved 
labeling of those lenses. 
 
Warnings: Appropriate use of CENTURION® Vision System parameters and accessories is important for successful procedures. 
Use of low vacuum limits, low flow rates, low bottle heights, high power settings, extended power usage, power usage during 
occlusion conditions (beeping tones), failure to sufficiently aspirate viscoelastic prior to using power, excessively tight incisions, 
and combinations of the above actions may result in significant temperature increases at incision site and inside the eye, and lead 
to severe thermal eye tissue damage. Good clinical practice dictates the testing for adequate irrigation and aspiration flow prior 
to entering the eye. Ensure that tubings are not occluded or pinched during any phase of operation. The consumables used in 
conjunction with ALCON® instrument products constitute a complete surgical system. Use of consumables and handpieces other 
than those manufactured by Alcon may affect system performance and create potential hazards. 
 
AEs/Complications: Inadvertent actuation of Prime or Tune while a handpiece is in the eye can create a hazardous condition that 
may result in patient injury. During any ultrasonic procedure, metal particles may result from inadvertent touching of the ultrasonic 
tip with a second instrument. Another potential source of metal particles resulting from any ultrasonic handpiece may be the result 
of ultrasonic energy causing micro abrasion of the ultrasonic tip. 
 
ATTENTION: Refer to the Directions for Use and Operator’s Manual for a complete listing of  
indications, warnings, cautions and notes.
Alcon in New Orleans
November 15-19, 2013 | New Orleans, Louisiana
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Thursday, Nov. 14
Event Time
Registration Attendees 4:00 - 6:00 pm
Exhibitors 7:30 am - 6:00 pm
Ticketed Events 4:00 - 6:00 pm
Friday, Nov. 15
Event Time
Alumni & Related Group Functions All Day
Registration
Attendees 7:00 am - 5:00 pm
Exhibitors 7:30 am - 6:00 pm
Special Meetings & Events 7:30 am - 3:00 pm
Subspecialty Day Meetings  Refractive Surgery 8:00 am - 5:17 pm
Refractive Surgery E-posters 7:00 am - 5:30 pm
Retina 8:00 am - 5:12 pm
Retina Exhibits 9:30 am - 3:30 pm
Saturday, Nov. 16 (cont.)
Event Time
AAOE/Practice Management Conquering ICD-10-CM for Ophthalmology 8:00 - 11:00 am
AAOE/Practice Management Coding Camp 12:30 - 3:30 pm
AAOE/Practice Management Saturday Programs 8:30 am - 4:00 pm
Academy Café 1:00 - 3:45 pm
Alumni & Related Group Functions << 8:30 am & 5:30 pm >>
Exhibition 9:00 am - 5:00 pm
Learning Lounge 12:00 - 5:00 pm
Registration Attendees 7:00 am - 5:00 pm
Exhibitors 7:00 am - 5:00 pm
Scientific Posters 9:00 am - 5:00 pm
Scientific Posters Online/Videos on Demand 9:00 am - 5:00 pm
Special Meetings & Events 9:00 am - 4:00 pm
Subspecialty Day Meetings Cornea 8:00 am - 5:30 pm
Glaucoma 8:00 am - 5:00 pm
Neuro-Ophthalmology 8:00 am - 5:05 pm
Oculofacial Plastic Surgery 8:00 am - 5:05 pm
Pediatric Ophthalmology 8:00 am - 5:20 pm
Refractive Surgery 8:00 am - 5:30 pm
Refractive Surgery E-posters 7:00 am - 5:30 pm
Retina 8:00 am - 5:38 pm
Symposia 2:00 - 3:30 pm
Technology Pavilion 9:30 am - 5:00 pm
Ticketed Events 7:00 am - 5:00 pm
2013 Annual Meeting Overview
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Sunday, Nov. 17
Event Time
AAOE/Practice Management Courses 2:00 pm - 5:30 pm
AAOE/Practice Management General Session 10:00 am - 12:00 pm
Academy Business Meeting 10:00 - 10:30 am
Academy Café 10:30 am - 3:45 pm
Alumni & Related Group Functions << 8:00 am & 5:30 pm >>
Breakfast With the Experts 7:30 - 8:30 am
Exhibition 9:00 am - 5:00 pm
Fall Council Meeting 11:30 am - 5:30 pm
Instruction Courses 9:00 am - 5:30 pm
Learning Lounge 10:30 am - 5:00 pm
Opening Session 8:30 - 10:00 am
Orbital Gala 6:00 - 10:00 pm
Original Paper Sessions 10:15 am - 5:15pm
Registration Attendees 8:00 am - 5:00 pm
Exhibitors 7:30 am - 5:00 pm
Scientific Posters 7:30 am - 5:00 pm
Scientific Posters Online/Videos on Demand 7:30 am - 5:00 pm
Scientific Poster Tours 12:30 - 1:30 pm
Skills Transfer Courses 8:00 am - 5:30 pm
Special Meetings & Events 6:30 am - 4:00 pm
Symposia and Spotlight Sessions 8:00 am - 5:15 pm
Technology Pavilion 9:30 am - 5:00 pm
Ticketed Events 7:00 am - 5:00 pm
Young Ophthalmologist (YO) Program 10:00 am - 2:00 pm
Monday, Nov. 18 (cont.)
Event Time
AAOE/Practice Management Courses 9:00 am - 5:30 pm
Academy Café 8:30 - 11:45 am
Alumni & Related Group Functions << 8:00 am & 5:30 pm >>
Breakfast With the Experts 7:30 - 8:30 am
Exhibition 9:00 am - 5:00 pm 
Instruction Courses 9:00 am - 5:30 pm
Learning Lounge 9:00 am - 5:00 pm
Original Paper Sessions 8:30 am - 5:15 pm
Registration Attendees 8:00 am - 5:00 pm
Exhibitors 7:30 am - 5:00 pm
Scientific Posters 7:30 am - 5:00 pm
Scientific Posters Online/Videos on Demand 7:30 am - 5:00 pm
xxxiAcademy staff are available at the Academy Resource Center, Hall G, Booth 3239, to answer any questions you may have.
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Monday, Nov. 18 (cont.)
Event Time
Scientific Poster Tours 12:30 - 1:30 pm
Senior Ophthalmologist (SO) Program 2:30 - 5:00 pm
Skills Transfer Courses 7:30 am - 5:30 pm
Special Meetings & Events 12:30 - 5:00 pm
Symposia and Spotlight Sessions 8:15 am - 5:15 pm
Technology Pavilion 9:30 am - 5:00 pm
Ticketed Events 7:00 am - 5:00 pm
Tuesday, Nov. 19
Event Time
AAOE/Practice Management Courses 9:00 am - 3:00 pm
Academy Café 8:30 - 9:45 am
Alumni & Related Group Functions << 8:00 am & 5:30 pm >>
Breakfast With the Experts 7:30 - 8:30 am
Exhibition 9:00 am - 1:00 pm
Instruction Courses 9:00 am - 5:30 pm
Learning Lounge 9:00 am - 12:00 pm
Original Paper Sessions 8:30 am - 12:00 pm
Registration Attendees 8:00 am - 1:00 pm
Exhibitors 7:30 am - 1:00 pm
Scientific Posters 7:30 am - 3:00 pm
Scientific Posters Online/Videos on Demand 7:30 am - 5:30 pm
Skills Transfer Courses 7:30 am - 5:00 pm
Symposia 8:30 am - 12:00 pm
Technology Pavilion 9:30 am - 12:30 pm
Ticketed Events 7:00 am - 3:00 pm
Wednesday, Nov. 20
Event Time
27° Lo Mejor de la Academia en Español 2013 (The Best of the Academy in Spanish 2013) 7:00 am - 5:00  pm
CONGRESSIONAL
ADVOCACY DAY
April 9 – 10, 2014
Washington, DC
Save the Date!
There’s strength in numbers. Lobby on Capitol Hill for 
ophthalmology’s top legislative issues including advocating 
for fair Medicare physician payment, reducing regulatory 
burdens and vision research. Meet face-to-face with your 
Members of Congress and show the might of our members 
at this important opportunity. It’s the most effective way to 
protect the interests of our profession and our patients.
“Congressional Advocacy Day  
is a vital part of your membership  
and a fantastic opportunity  
to get updated on critical issues  
related to ophthalmic advocacy. 
Each year hundreds of Academy 
members advocate for our  
profession and patients.  
Join me and your colleagues  
in Washington, D.C. in 2014”
Paul Sternberg, Jr., MD
Academy President
Registration opens in January 2014. 
Congressional Advocacy Day is open to all  
Academy members and registration is free.
www.aao.org/myf
More Experts. 
More Insights. More Solutions.
Important Safety Information
INDICATION: The OptiMedica® Catalys™ Precision Laser System is indicated for use in patients undergoing cataract surgery for removal of the crystalline lens. 
Intended uses in cataract surgery include anterior capsulotomy, phacofragmentation, and the creation of single plane and multi-plane arc cuts/incisions in the cornea, 
each of which may be performed either individually or consecutively during the same procedure. ADVERSE EFFECTS: Complications associated with the Catalys® 
System include mild Petechiae and subconjunctival hemorrhage due to vacuum pressure of the Liquid Optics™ Interface suction ring. Potential complications and 
adverse events include those generally associated with the performance of capsulotomy and lens fragmentation, or creation of a partial-thickness or full-thickness 
cut or incision of the cornea. CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. The system should be used only by qualified 
physicians who have extensive knowledge of the use of this device and have been trained and certified by OptiMedica.
Join us at the Abbott Medical Optics Speakers Forum 
at the 2013 AAO Annual Meeting
Visit www.AbbottMedicalOptics.com/forums  
to register early and organize your conference calendar*
  10:15 am–10:45 am
   New Phaco Techniques for Laser  
Cataract Surgery
  Tal Raviv MD – Moderator
  William Culbertson MD, Robert Rivera MD
  11:00 am–11:45 am 
   IOL Customization and Premium Lens 
Design for High-Quality Visual Outcomes
  Roger Steinert MD – Moderator
  Daniel Chang MD, Jessica Ciralsky MD
  12:00 pm–12:45 pm
   Innovation in Laser Cataract Surgery  
With the Catalys® Precision Laser System
  William Wiley MD – Moderator
  Burkhard Dick MD, PhD; Shachar Tauber MD
  1:00 pm–1:45 pm
   Optimizing Premium IOL Outcomes  
With Laser Cataract Surgery
  Mark Blecher MD – Moderator
  Shamik Bafna MD, Jason Jones MD
  2:00 pm–3:00 pm
   Surgical Surprises: Pearls for Managing 
Complicated Cases
  David Chang MD – Moderator
  Steven Dewey MD, Sam Garg MD, David Yan MD
Saturday, November 16th Sunday, November 17th
  10:30 am–11:15 am
   Successful Management of Astigmatic 
Correction With a New Toric IOL
  Doug Koch MD – Moderator
  Ike Ahmed MD, Elizabeth Yeu MD
  11:30 am–12:15 pm
   The Business Case and Workflow Integration 
for Laser Cataract Surgery
  Subba Gollamudi MD – Moderator 
  James Khodabakhsh MD, Mike Mann MD 
  1:00 pm–1:45 pm
   Evaluating the Cornea and Ocular Surface: 
Keys to Successful Surgical Outcomes
  Kenneth Greenberg MD – Moderator
  Sandy Feldman MD, James Loden MD
  2:00 pm–2:45 pm
   Expanding Your Refractive Cataract Practice 
With Premium IOLs
  Kerry Assil MD – Moderator
   Elizabeth Davis MD, Keith Walter MD
  3:00 pm–3:45 pm
   The Advantages of Using the Liquid Optics 
Interface in Laser Cataract Surgery
  Jonathan Talamo MD – Moderator
  Lisa Arbisser MD, Barry Seibel MD
*Speakers subject to change. Booth presentations are not affiliated with the official program of the meeting. 
Catalys and Liquid Optics are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affliates.
©2013 Abbott Medical Optics Inc.  www.AbbottMedicalOptics.com  2013.08.28-Me7419
OptiMedica is now part of 
Abbott Medical Optics.
Visit 
Booth 1326
The source of more twinkling eyes.
The Haag-Streit LED.
Need to amp up the twinkle in your eye? Enter the Haag-Streit 
LED slit lamp powered by blue-shift illumination. It visualizes 
your subject in stunning detail with our celebrated optics. 
But don’t just take our word for it. See for yourself. Call 
800.787.5426 for more information, or visit haag-streit-usa.com.
Visit us at AAO Booth #745.
800.787.5426
haag-streit-usa.com
The Superior Practice.
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xxxvAcademy staff are available at the Academy Resource Center, Hall G, Booth 3239, to answer any questions you may have.
Meeting Directory
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irectory
All locations are in the Ernest N. Morial Convention Center, New Orleans, unless otherwise indicated.
AAO Meetings On Demand (Subspecialty Day and Annual Meeting Content) Lobby G; Hall G, Booth 3643; The Great Hall Lobby (Fri. - Mon.)
AAOE Coding Sessions (Saturday) Room 293
AAOE Practice Management and Coding Center,  
ICD-10-CM, Conversations With the Experts
Academy Resource Center, Hall G, Booth 3239
AAOE Member Lounge Room 298
AAOE Program Rooms 283 - 297
Academy Café Room 271
Academy Resource Center Hall G, Booth 3239
Bags and Programs Hall C
Bistro AAO Café Hall I1, Booth 5223
Breakfast With the Experts Hall C
Business Center/UPS Store Lobby E
Chicago 2014 Lobby E
CME Reporting/Proof-of-Attendance Lobby B2; Lobby G; Academy Resource Center, Hall G, Booth 3239 
Coat and Bag Check Lobby E; also Lobby B and Lobby H (Mon. & Tues. only)
Evaluation Help Desk Ticketed Events, Hall C
Executive Offices Room 261
Exhibition Halls D – I1
Exhibitor Locator Booth Hall G, Booth 3105
Exhibitor Lounge (Wi-Fi available) Hall E, Booth 2571
Exhibitor Registration Hall C
Exhibitor Service Center/Exhibitions Office Hall E, Booth 1071 
First Aid Lobby F and Lobby H
Foundation of the American Academy of Ophthalmology (FAAO) Academy Resource Center, Hall G, Booth 3239 
Global Alliance Office Room 264
Hotel Assistance Lobby E
Informational Posters Hall I1, Booth 5113 
International Center Hall I1, Booth 5313 
International Society of Refractive Surgery Academy Resource Center, Hall G, Booth 3239
Internet Access and Email Lobby G; Rest Stops Hall D & Hall I1
Learning Lounge Hall G, Booth 3647
Lost and Found Meetings Office, Room 265
Meditation/Prayer Room Room J121
Meeting Information Lobby B & Lobby G
Meetings Office Room 265
Mobile Device Charging Stations Rest Stops Hall D & Hall I1
Mobile Meeting Guide Assistance Tech Bar - Rest Stop Hall I1
Mobile Meeting Guide Download www.aao.org/mobile
Museum of Vision® Hall G, Booth 3147
Newsroom Room 276
Ophthalmic Mutual Insurance Company (OMIC) Hall G, Booth 3139
Ophthalmology Job Center Room 280
OPHTHPAC/Surgical Scope Lobby B
Proof-of-Attendance/CME Reporting Lobby G; Lobby B2; Academy Resource Center, Hall G, Booth 3239
Publishers’ Row Hall H
Registration Hall C
Rest Stop Hall D Booth 153
Rest Stop Hall I1 Booth 5444
Meeting Directory
xxxvi Academy staff are available at the Academy Resource Center, Hall G, Booth 3239, to answer any questions you may have.
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Restaurant Reservations Lobby E
Ribbons Bags & Programs, Hall C
Scientific Posters Hall C
Scientific Poster Tours Meeting Point, Hall C
Scientific Posters Online/Videos on Demand Hall C, Booth 100 
Seated Massage Stations Rest Stop Hall I1
Senior Ophthalmologist (SO) Lounge Room 242
Shuttle Bus Pick-up and Drop-off Routes 1-4: Hall A/B; Routes 5-7: Hall D/E;  
Routes 8-10: Hall I
Speaker Ready Room #1 Rivergate Ballroom
Speaker Ready Room #2 Room 267
Subspecialty Day
Cornea
Glaucoma
Neuro Ophthalmology
Oculofacial Plastic Surgery
Pediatric Ophthalmology
Refractive Surgery
Refractive Surgery E-Posters
Refractive Surgery Free Papers (Friday only)
Retina
Retina Exhibits (Friday only)
La Nouvelle Orleans C
New Orleans Theatre AB
New Orleans Theatre C
Room 243
Hall B Session Room
La Nouvelle Orleans AB
La Nouvelle Orleans Lobby
La Nouvelle Orleans C
The Great Hall
Hall B
Tech Bar Rest Stop Hall I1
Technology Pavilion Hall I1, Booth 5145
The Electronic Office (IHE) Hall G, Booth 3851
Ticketed Events Hall C
Tour Program Departures Lobby D/E
Videos on Demand/ Scientific Posters Online Hall C, Booth 100
Wi-Fi Access Rest Stops Hall D & Hall I1
Young Ophthalmologist (YO) Lounge Room 278

Haag-Streit Innovation Brought To Life.
Haag-Streit is more than the sum of its parts. Our mission is 
innovation, which leads to the development of important 
diagnostic devices and equipment. Used by doctors in nearly 
every country, they’re noted for accuracy, durability and 
engineering. It’s what your patients expect, and you demand. 
Watch for what’s coming out of Haag-Streit next. Science. 
Brilliance. Certainty.
Visit us at AAO Booth #745.
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OctopusHaag-Streit Xoma™ SurgicalLENSTAR®
800.787.5426
haag-streit-usa.com
The Superior Practice.
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Shuttle Bus Schedule
Shuttle B
us  Schedule
Continuous shuttle bus service will operate between most of the official Academy hotels and Ernest N. Morial Convention Center from Friday, Nov. 15 
through Tuesday, Nov. 19.  Times of operation and boarding locations are subject to change. Check the route list to determine which route serves your hotel. 
Shuttles will drop off and pickup curbside at: Routes 1-4, Hall A/B; Routes 5-7, Hall D/E; and Routes 8-10, Hall I. Additional shuttle information and updates 
will be available at your hotel and the Morial Convention Center.  Please note: Hotel rates include $8 to partially defray shuttle costs.
Friday
Saturday
Sunday
Monday
Tuesday
 During peak hours shuttles will run every 12 to 15 minutes.
 During non-peak hours shuttles will run every 20 to 25 minutes.
Hotel Address in New Orleans Phone Route # Boarding Location
Ambassador Hotel 535 Tchoupitoulas Street (504) 527-5271 4 Loews New Orleans Hotel
Astor Crowne Plaza Hotel 739 Canal Street (504) 962-0500 7 Curbside on Canal St
Best Western PLUS St. Christopher Hotel 114 Magazine Street (504) 648-0444 8 Country Inn & Suites New Orleans
Bienville House Hotel 320 Decatur Street (504) 529-2345 1 Corner of Bienville & Chartres Streets
Blake Hotel New Orleans 500 St. Charles Avenue (504) 522-9000 9 Whitney Wyndham Hotel
Bourbon Orleans Hotel 717 Orleans Street (504) 523-2222 2 Corner of Toulouse & Bourbon Streets
Country Inn & Suites New Orleans 315 Magazine Street (504) 324-5400 8 Across Street from Hotel on Magazine St
Courtyard New Orleans Convention Center 300 Julia Street (504) 598-9898 walk N/A
Courtyard New Orleans Dwntwn/French Quarter 124 St. Charles Avenue (504) 581-9005 6 JW Marriott New Orleans
Courtyard New Orleans Iberville 910 Iberville Street (504) 523-2400 7 Ritz-Carlton New Orleans
Dauphine Orleans Hotel 415 Dauphine Street (504) 586-1800 1 Corner of Bienville & Dauphine Streets
Doubletree Hotel New Orleans 300 Canal Street (504) 581-1300 5 On Tchoupitoulas, Across Street from Hotel
Drury Inn & Suites New Orleans 820 Poydras Street (504) 529-7800 9 Curbside on Poydras St
Embassy Suites New Orleans Conv Center 315 Julia Street (504) 525-1993 walk N/A
Four Points by Sheraton French Quarter 541 Bourbon Street (504) 524-7611 2 Corner of Toulouse & Bourbon Streets
Hampton Inn & Suites New Orleans Conv Center 1201 Convention Center Blvd. (504) 566-9990 walk N/A
Hampton Inn New Orleans Downtown 226 Carondelet Street (504) 529-9990 8 Curbside on Carondelet St
Harrah’s New Orleans 228 Poydras Street (504) 533-6000 4 Loews New Orleans Hotel
Hilton Garden Inn New Orleans Convention Center 1001 S Peters Street (504) 525-0044 walk N/A
Hilton Garden Inn  French Quarter/CBD 821 Gravier Street (504) 324-6000 8 Hampton Inn New Orleans Downtown
Hilton New Orleans Riverside 2 Poydras Street (504) 561-0500 walk N/A
Hilton New Orleans St. Charles Ave. 333 St. Charles Avenue (504) 524-8890 8 Curbside on Poydras St at St. Charles Ave.
Holiday Inn New Orleans Downtown Superdome 330 Loyola Avenue (504) 581-1600 10 Curbside in Front of Hotel
Hotel Le Marais 717 Conti Street (504) 525-2300 1 Corner of Bienville & Royal Streets
Hotel Mazarin 730 Bienville Street (504) 581-7300 1 Corner of Bienville & Royal Streets
Hotel Monteleone 214 Royal Street (504) 523-3341 3 New Orleans Marriott
Hotel Provincial 1024 Chartres Street (504) 581-4995 2 Corner of Toulouse & Chartres Streets
Hyatt French Quarter 800 Iberville Street (504) 586-0800 7 Ritz-Carlton New Orleans
Hyatt Place New Orleans Conv Center 881 Convention Center Blvd. (504) 524-1881 walk N/A
Hyatt Regency New Orleans 601 Loyola Avenue (504) 561-1234 9 Tunnel/Breezeway to Front Desk Lobby Area
InterContinental New Orleans 444 St. Charles Avenue (504) 525-5566 8 Curbside on Poydras St at St. Charles Ave.
International House 221 Camp Street (504) 553-9550 4 Corner of Camp & Gravier Streets
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Hotel Address in New Orleans Phone Route # Boarding Location
JW Marriott New Orleans 614 Canal Street (504) 525-6500 6 Curbside on Canal St
La Quinta Inn & Suites New Orleans Downtown 301 Camp Street (504) 598-9977 4 Corner on Camp & Gravier Streets
Le Pavillon Hotel 833 Poydras Street (504) 581-3111 10 Across Street on Baronne St
Loews New Orleans Hotel 300 Poydras Street (504) 595-3300 4 Curbside on Poydras St
Maison Dupuy Hotel 1001 Toulouse Street (504) 586-8000 2 Corner of Toulouse & Burgundy Streets
New Orleans Marriott 555 Canal Street (504) 581-1000 3 Curbside on Canal St
New Orleans Marriott at the Conv Center 859 Convention Center Blvd. (504) 613-2888 walk N/A
Omni Royal Crescent Hotel 535 Gravier Street (504) 527-0006 4 Corner of Camp & Gravier Streets
Omni Royal Orleans Hotel 621 St. Louis Street (504) 529-5333 2 Corner of Toulouse & Chartres Streets
Renaissance New Orleans Arts Hotel 700 Tchoupitoulas Street (504) 613-2330 walk N/A
Renaissance New Orleans Pere Marquette Hotel 817 Common Street (504) 525-1111 8 Hampton Inn New Orleans Downtown
Residence Inn New Orleans Conv Center 345 St. Joseph Street (504) 522-1300 walk N/A
Ritz-Carlton New Orleans 921 Canal Street (504) 524-1331 7 Curbside on Canal St
Roosevelt New Orleans, A Waldorf Astoria Hotel 123 Baronne Street (504) 648-1200 10 Curbside on Baronne St
Royal Sonesta Hotel 300 Bourbon Street (504) 586-0300 1 Corner of Bienville & Bourbon Streets
Royal St. Charles Hotel 135 St. Charles Avenue (504) 599-2119 6 JW Marriott New Orleans
Saint Hotel New Orleans 931 Canal Street (504) 522-5400 7 Ritz-Carlton New Orleans
Saint James Hotel 330 Magazine Street (504) 304-4000 8 Country Inn & Suites New Orleans
Sheraton New Orleans Hotel 500 Canal Street (504) 525-2500 6 Curbside on Canal St
SpringHill Suites New Orleans Conv Center 301 St. Joseph Street (504) 522-3100 walk N/A
Staybridge Suites New Orleans 501 Tchoupitoulas Street (504) 571-1818 4 Loews New Orleans Hotel
W New Orleans French Quarter 316 Chartres Street (504) 581-1200 1 Corner of Bienville & Chartres Streets
W New Orleans Hotel 333 Poydras Street (504) 525-9444 5 Corner of Tchoupitoulas & Poydras Streets
Westin New Orleans Canal Place 100 Rue Iberville (504) 566-7006 5 Front Entrance on Iberville St
Whitney Wyndham Hotel 610 Poydras Street (504) 581-4222 9 Curbside on Poydras Street
Windsor Court Hotel 300 Gravier Street (504) 523-6000 5 Doubletree Hotel New Orleans
Wyndham Garden Baronne Plaza New Orleans 201 Baronne Street (504) 522-0083 10 Curbside on Baronne St
Wyndham New Orleans French Quarter 124 Royal Street (504) 529-7211 7 Ritz-Carlton New Orleans
Wyndham Riverfront New Orleans 701 Convention Center Blvd. (504) 524-8200 walk N/A
Recommend the AcrySof® IQ Toric IOL 
for your astigmatic cataract patients.CONFIDENCE
Recognize both. 
Recommend AcrySof® IQ Toric IOL.
For important safety information, please see adjacent page.
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WHERE ALL OF OPHTHALMOLOGY MEETS
In September 2002, the Board of Trustees approved an award program to induct individuals as Academy 
Laureates—outstanding ophthalmologists whose significant scientific contribution to the field has 
shaped the way modern ophthalmology is practiced. The Laureate award program recognizes individuals 
from around the world who have made exceptional scientific contributions to the betterment of eye care, 
leading to the prevention of blindness and the restoration of sight worldwide.
The Laureate Recognition Award may be given to individuals who have:
• Developed new techniques now accepted worldwide
• Designed a seminal invention or an adaptation of previous technology
• Developed a new treatment modality
• Discovered the etiology of a disease state
• Reassessed previous findings resulting in a significant shift in treatment
• Established new standards of quality care in ophthalmology
• Made a breakthrough in genetic understanding
• Led primary research in new pharmacological products
• Focused on eye care for people worldwide
On behalf of the Board of Trustees, we are pleased to announce the 2013 Academy Laureate.
Laureate Recognition Award
Awards
Laureate Recognition Award
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2013 Laureate Award
Daniel M Albert MD
Daniel M. Albert is a native of Newark, New Jersey. He graduated cum laude with a bachelor of science 
degree from Franklin and Marshall College in Lancaster, Pennsylvania and went on to receive his medical 
schooling at the University of Pennsylvania School of Medicine. An ophthalmology residency followed at 
the same institution under the legendary Dr. Harold Scheie.
Fellowship training was next for Dr. Albert. He undertook two of them: the first as a clinical associate 
at the National Institute of Neurological Diseases and Blindness, the forerunner of the National Eye 
Institute; the second as an NIH Special Fellow in Ophthalmic Pathology at the Armed Forces Institute of 
Pathology under the tutelage of the late Academy Laureate Lorenz E. Zimmerman, putatively the father 
of ophthalmic pathology. During this fellowship, Dr. Albert formulated what has turned out to be the 
research foundation of his entire laboratory career as he described the ultrastructure of retinoblastoma 
and melanoma and established animal models of these tumors.
Dr. Albert’s academic career began at Yale University and continued at Harvard University and the 
Massachusetts Eye and Ear Infirmary. In Boston, Dr. Albert was a protégée and long-time close friend 
of the late and renowned Dr. David Cogan, Director of the Howe Laboratory at Harvard Medical School. 
Particularly meaningful for Dr. Albert was his being appointed in 1983 to the Cogan Chair in Ophthalmol-
ogy at Harvard.
Since 1992, when Dr. Albert moved to Madison to become department chair, he has been on the faculty 
of the University of Wisconsin Medical School where he is now Chair Emeritus of Ophthalmology and 
Visual Sciences, the Frederick Allison Davis Chair, the Lorenz Zimmerman Professor and Founding Direc-
tor of the McPherson Eye Research Institute. There, he continues to study tumor growth and inhibition, 
the subject of his interest throughout his career. Having delved in depth into the antitumor properties of 
vitamin D compounds and finding that they can cause apoptosis and block tumor angiogenesis to inhibit 
growth of retinoblastoma cells in vitro, Dr. Albert is hopeful that an effective treatment molecule will 
evolve to treat this tumor. More recently, Dr. Albert has studied resveratrol which he has found to inhibit 
and sometimes block tumor growth in animal models of cancer, one of which is uveal melanoma. He is 
hopeful that compatible formulations of resveratrol and effective ways to deliver the drug will serve as 
an efficacious treatment for melanoma and for prevention or treatment of metastatic disease. At pres-
ent, Dr. Albert’s research extends his tumor inhibition studies to employ antiangiogenesis compounds 
to treat wet age-related macular degeneration. He is a co-investigator on a new federal grant with 
responsibility for the pathology studies on animal models in pre-clinical testing.
A prolific contributor to the medical literature, Dr. Albert has well over 800 publications to his credit 
including peer-reviewed papers, editorials, textbooks and book chapters. A widely used general ophthal-
mology text, Principles and Practice of Ophthalmology, is now in its third edition with Dr. Albert continu-
ing as its senior editor. Notably, the book’s original edition received the Association of American Publish-
ers Best Medical Book award in 1993. Beyond his outsized record of laboratory and clinical publications, 
Dr. Albert is a renowned ophthalmic historian, having published widely in the field including texts that 
encompass the breadth of ophthalmic history. What is more, Dr. Albert has served the profession as an 
editorial board member of nine scientific journals, most notable of which was his recently-completed 20-
year stint as editor-in-chief of Archives of Ophthalmology—newly re-named as JAMA Ophthalmology.
Also serving the profession through organizational activities, notable involvement includes Dr. Albert’s 
role as a director of the American Board of Ophthalmology from 1997-2005 and his selection as Presi-
dent of the American Ophthalmological Society from 2005-2006.
As one might imagine, Dr. Albert’s enormous achievements have been recognized time and again with 
important awards and recognition. Notable examples include the Friedenwald Award from the Associa-
tion for Research in Vision and Ophthalmology, the Zimmerman Medal of the American Association of 
Ocular Pathologists, the Humboldt Research Award of the Alexander Humboldt Foundation, the Pisart 
Vision Award, the Albert C. Muse Prize for excellence in ophthalmology, the Research to Prevent Blind-
ness Special Research Scholar Award and the Lucien Howe Medal from the American Ophthalmological 
Society. In addition, Dr. Albert was among the youngest individuals ever elected to membership in Aca-
demia Ophthalmologica Internationalis. To recognize Dr. Albert’s achievements, in 2008 the University 
of Wisconsin-Madison School of Medicine and Public Health established the Daniel M. Albert Chair in 
Visual Sciences.
The Academy is pleased to present its 2013 Laureate Award to Daniel M. Albert, M.D., in recognition of 
his seminal contributions to Ophthalmology including those in patient care, education, research, ophthal-
mic history, medical ethics, journal editing and administration. 
3Laureate Awards
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2012
Stephen J Ryan MD
Recognized for his valuable and innumerable contribu-
tions to the field of vitreoretinal disease and ocular 
trauma. Dr. Ryan’s key leadership in major national 
and international organizations has reshaped not only 
ophthalmology but the entire field of medicine.
2011
Alfred Sommer MD MHS
Recognized for his remarkable career and lasting con-
tributions to ophthalmology, epidemiology and public 
health worldwide through his discovery of the link 
between vitamin A deficiency and childhood blindness 
and mortality.
2010
Bradley R Straatsma MD JD
Recognized for his unique contributions to the sci-
ence of ophthalmology through innovative research 
in posterior segment pathology and his leadership 
in enhancing ophthalmic education institutions and 
organizations worldwide.
2009
Bernard Becker MD
Recognized as a pioneer in ophthalmic research, 
clinical care, education and leadership. He is widely 
accepted as a world expert on the treatment of 
intraocular pressure regulation and neuroprotection of 
the optic nerve.
2008
Professor Alan C Bird MD
Recognized as a pioneer in ophthalmic research, 
teaching and clinical medicine. He is one of the 
world’s experts on the treatment of retinal vascular 
disease and genetic and degenerative retinal disorder.
2007
Claes H Dohlman MD
Recognized as the founder of modern corneal science 
and for his years of teaching and educating young 
ophthalmologists in the field of cornea.
2006 
Lorenz E Zimmerman MD
Widely recognized for his many contributions to our 
understanding of a broad spectrum of diseases of 
the eye and for his ability to clearly communicate his 
cogent observations to ophthalmologists in clinical 
practice through a series of seminal publications and 
lucid lectures.
Laureate Recognition Awardees
2005
Arnall Patz MD
A gifted teacher and clinician who saved the sight of 
an untold number of newborns when he suspected 
oxygen had a role in the alarming number of retrolen-
tal fibroplasia cases among premature infants.
2004
Danièle S Aron Rosa MD PhD
Honorary Professor and Chair of Ophthalmology, Park 
University and Chair of Ophthalmology at Hospital 
Robert Debrè and Foundation Rothschild in Paris and 
inventor of the YAG Laser for the treatment of poste-
rior capsule opacity (secondary cataract).
J Donald M Gass MD
Professor at both the University of Miami School of 
Medicine and Vanderbilt University in Nashville, well 
known for his research on diseases of the retina, 
macula and uvea, much of which was done in Miami.
Marshall M Parks MD
Almost single-handedly created the subspecialty 
field of pediatric ophthalmology and world-renowned 
for his contributions to understanding and treating 
amblyopia and strabismus.
2003
Charles D Kelman MD
New York Medical College clinical professor of oph-
thalmology and attending surgeon at the New York 
Eye and Ear Infirmary and the Manhattan Eye, Ear and 
Throat Hospital, pioneered phacoemulsification and 
invented the cryoprobe.
Robert Machemer MD
Former chairman of the Department of Ophthalmology, 
Duke University, Durham, N.C., invented the vitreous 
infusion suction cutter, which allowed surgeons to 
more safely remove vitreous from the eye.
Charles L Schepens MD
Harvard Medical School clinical professor emeritus, 
and president of the Eye Research Institute of the 
Retina Foundation, is the father of modern retinal 
surgery.
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WHERE ALL OF OPHTHALMOLOGY MEETS
Recipients of the following awards attend the Annual Meeting as guests of the president. The Academy 
formally presents them with an award during the opening ceremonies. Descriptions of each award 
bestowed by the Academy are below; however, not all awards are presented each year.
Guests of Honor
Each president has the privilege of selecting individuals as Guests of Honor at the Annual Meeting. 
Individuals are selected in recognition of their significant contribution to ophthalmology and to the 
Academy.
Distinguished Service Award
The Distinguished Service Award honors an individual or organization for ongoing notable service to 
ophthalmology and to the Academy. The president has the honor of selecting the recipient of this award, 
with approval of the Board of Trustees.
Special Recognition Award
First awarded in 1991, the Special Recognition Award is presented to an individual or organization for 
outstanding service in a specific effort or cause that improves the quality of eye care. The recipient need 
not be an ophthalmologist. The president has the honor of selecting the recipient of this award, with 
approval of the Board of Trustees.
Outstanding Humanitarian Service Award
First awarded in 1992, the Outstanding Humanitarian Service Award recognizes the contributions 
of Academy Fellows and Members in selflessly providing medical eye care. Each year this award is 
presented to individuals for their participation in charitable activities, indigent care, community service, 
or other humanitarian activities. The Academy’s Awards Committee reviews nominations and selects 
awardees, with final approval by the Board of Trustees.
Straatsma Award for Excellence in Resident Education
Established through the Academy, the Association of University Professors of Ophthalmology (AUPO), 
and private funds, the Straatsma Award for Excellence in Resident Education is given to a program 
director dedicated to the principles and significance of residency education.
International Blindness Prevention Award
Established in 1992, the International Blindness Prevention Award honors individuals who have made 
significant contributions to the prevention of blindness or the restoration of sight around the world.
Outstanding Advocate Award
The Outstanding Advocate award, established in 2008, recognizes Academy members’ participation in 
advocacy-related efforts at either the state and/or federal levels. The Academy’s Awards Committee 
reviews nominations and selects awardees, with final approval by the Board of Trustees.
 Special Awards
Special Awards
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Guest of Honor
Thomas M Aaberg Sr MD 
It is with great respect that the American Academy of Ophthalmology recognizes Thomas M Aaberg Sr., MD as 
a Guest of Honor at the 2013 Annual Meeting. He is recognized for his outstanding contributions to the profes-
sion of ophthalmology and to the many careers he has inspired through his leadership and example. 
A graduate of Dartmouth College, Dr. Aaberg received his medical degree from Harvard Medical School and 
completed his residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary. He then worked in the 
U.S. Public Health Service for two years and graduated from the University of Oklahoma with a master of sci-
ence in public health before starting an 18- month fellowship in retinal disease and surgery at Bascom Palmer 
Eye Institute. While in Miami, he collaborated with Robert Machemer in developing a primate model to study 
retinal detachment and giant retinal tears. They also worked together in developing early instrumentation and 
techniques for vitreous surgery. Upon completing his fellowship, Dr. Aaberg became assistant professor of 
ophthalmology and director of the Retina Service at the Medical College of Wisconsin, remaining on the fac-
ulty for nearly 18 years. Under his direction, the MCW vitreoretinal fellowship training program became one of 
the top-rated programs in the country with graduates of the program currently directing vitreoretinal divisions 
and ophthalmology departments nationwide.
In 1988, Dr. Aaberg was appointed chair of ophthalmology at Emory University School of Medicine, Phinizy 
Calhoun Sr. Professor of Ophthalmology, and director of the Emory Eye Center. He built on the work of his 
predecessors to develop the Emory Department of Ophthalmology into a nationally respected and highly 
ranked program in clinical, education, and discovery. Through his career, he has personally been involved in the 
training of hundreds of residents and vitreoretinal fellows who are in academic or private practice throughout 
the United States and Canada.  Dr. Aaberg’s trainees revere him for his kindness, clinical acumen, skill as a 
surgical instructor, and unwavering concern for his patients.
Dr. Aaberg was senior associate editor of the American Journal of Ophthalmology from 1982 to 2002 and 
is past president of the Macula Society and of the Association of University Professors of Ophthalmology 
(AUPO). He has given 38 named lectureships, including the Academy’s Edward Jackson Memorial Lecture and 
the Hermann Wacker Lecture, Club Jules Gonin. 
The focus of Dr. Aaberg’s surgical and research activities has been the management of complicated retinal 
detachment and diabetic retinopathy, but he also has a strong interest in medical retinal disorders. His 
main career interest, however, has been teaching. He has been honored with Clinical Teaching Awards from 
residents at the Medical College of Wisconsin and at Emory University School of Medicine, where in 2006 the 
annual Clinical Teaching Award was named the Thomas Aaberg Sr MD Clinical Teaching Award.
For all that he has contributed to our profession and to all the students and colleagues he has inspired and 
challenged, it is with great pleasure that the Academy honors Dr. Aaberg Sr. as a Guest of Honor.
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Guest of Honor
William B Snyder MD
It is with great pride that the American Academy of Ophthalmology recognizes William B. Snyder, MD, as a 
Guest of Honor at the 2013 Annual Meeting. He is recognized for his impressive contributions to ophthalmol-
ogy and of his unwavering support for colleagues and his profession. 
Born in Cleveland, OH, Dr. Snyder was raised in Kentucky, received his medical degree at Vanderbilt University 
in 1957 and his Master of Science degree at the University of Iowa in 1961. He finished his internship at the 
University of Iowa in 1958 and went on to a residency in ophthalmology there in 1961. Following residency, 
he completed a retina fellowship in at the University of Iowa and became certified by the American Board of 
Ophthalmology. Upon completion of his fellowship, he practiced for a short time in Kentucky before returning 
to join the faculty at University of Iowa. In 1966, he was recruited to the faculty of the University of Texas 
Southwestern Medical School as an Associate Professor.  In 1968, he cofounded Texas Retina Associates, 
a private practice in Dallas, Texas. Over the ensuing decades, TRA grew to become one of the largest retina 
practices in the United States, pioneering the concept of satellite offices in order to provide “top-notch” care 
from specialists to patients who otherwise would not have had access due to their remote location. In addi-
tion, TRA was one of the first private practices to actively participate in numerous critical multicenter retina 
clinical trials. Dr. Snyder retired from practice in 2012.  
Dr. Snyder complimented his active clinical practice with a keen interest in vision science and research. He 
helped found the Retina Foundation of the Southwest, an institution dedicated to prevent and restore vision 
loss through innovative research and treatment. He also has been a loyal and committed alumnus of Vander-
bilt School of Medicine, establishing the Phyllis G. and William B. Snyder Chair in Ophthalmology and serving 
as the inaugural chairman of the Vanderbilt Eye Institute Advisory Board.
He is an active member of many organizations including American Medical Association, American Academy 
of Ophthalmology, Dallas Academy of Ophthalmology, Dallas County Medical Society (life member), Texas 
Medical Association, The Retina Society and the American Society of Retinal Specialists. He has served as a 
clinical professor of ophthalmology at the University of Texas Southwestern Medical School for many years.  
Dr. Snyder is the cofounder of Texas Retina Associates and Retina Foundation of the Southwest. His generous 
gifts and amazing gestures have been an inspiration to the entire vitreoretinal community.  It is the American 
Academy of Ophthalmology’s great pleasure to acknowledge Dr. Snyder as a Guest of Honor for 2013.
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Guest of Honor
Andrew P Schachat MD
It is with great pride that the American Academy of Ophthalmology recognizes Andrew P. Schachat, MD as a 
Guest of Honor during the 2013 Annual Meeting in New Orleans. His exceptional contributions to the Acad-
emy and the profession of ophthalmology and his continued thoughtfulness and support of his colleagues over 
the years are unparalleled. 
Andrew P. Schachat, MD, served as editor-in-chief of Ophthalmology from 2003 - 2012. Under his direction, 
the journal achieved the highest impact factor among ophthalmology and vision research publications and was 
recognized for the high quality of its manuscripts and the efficient and timely turnaround on submissions. He 
is a past member of the Academy’s Board of Trustees and also served as the secretary for quality of care from 
1996 to 2001. In his quality of care role, he led a major initiative in rolling out numerous clinical care pathways 
or Preferred Practice Practice Patterns (PPPs). He also served on numerous Academy committees over the 
years including: the EyeNet editorial advisory board, Bylaws and Rules committee, Outcomes Program commit-
tee, and Basic and Clinical Science Course committee.
He was born in New York City and attended Princeton University graduating in 1975. Dr. Schachat received his 
medical degree in 1979 at Johns Hopkins University and completed his ophthalmology residency training at 
the Wilmer Institute at Johns Hopkins, followed by a retina and oncology fellowship at the Wills Eye hospital 
in Philadelphia.
In 1984 he served as assistant chief of service (chief resident) at Wilmer, and eventually became the Karl 
Hagen professor of ophthalmology at Johns Hopkins University, where he was also a professor of oncology. 
He is recognized as a superb clinician, balancing a busy clinical practice with his multiple administrative 
responsibilities and academic activities. He was president of the Maryland Society of Eye Physicians and 
Surgeons in 2001. He is a former associate editor of the Archives of Ophthalmology. As well, he has served as 
an editor of the landmark multivolume text “Ryan’s Retina,” which is now in its fifth edition (2013). Currently, 
Dr. Schachat is the vice chairman of clinical affairs at the Cole Eye Institute, Cleveland Clinic, and director of 
clinical research.
Dr. Schachat’s integrity and discipline, as well as his commitment to the highest standards of clinical and 
academic excellence, sets the highest standard for current and aspiring ophthalmologists. It is the American 
Academy of Ophthalmology’s great pleasure to acknowledge Dr. Schachat as a Guest of Honor for 2013. 
8 Special Awards
        
 S
pe
ci
al
 A
w
ar
ds
Distinguished Service Award
Public Trustees of the American Academy of Ophthalmology  
Board of Trustees 
The Academy is privileged to recognize the Public Trustees of the American Academy of Ophthalmology Board 
of Trustees as the recipients of the 2013 Distinguished Service Award. We honor them for their continued 
contribution to the Academy and to the profession of ophthalmology by providing valuable and unique 
perspectives to board discussions and decision-making deliberations. Public trustees are vital members of 
the Academy’s leadership team.  Since the Academy appointed its first public trustee in 1994, the board has 
enjoyed the input and perspective of a diverse group, including experts in the fields of health policy, public 
service and business. While public trustees are not ophthalmologists and do not vote on matters of Academy 
governance or policy, they lend a public perspective to this organization whose members serve the public. Cur-
rently, there are two public trustees serving on the board, Mr. Humphrey Taylor and Dr. Paul Ginsburg.
Appointed in 1994, Humphrey Taylor is the Academy’s first and longest serving public trustee. Mr. Taylor is the 
chairman of the Harris Poll, a service of Harris Interactive. He directs surveys of health care consumers, physi-
cians and other providers, employers and legislators on a broad range of health care issues. Harris Interactive’s 
clients include over 80 health care companies, government agencies and foundations. Mr. Taylor has spoken 
in the White House, written extensively on healthcare matters, and has provided testimony to congressional 
committees and subcommittees on a variety of topics related to health care. He is also a noted author on the 
subject of survey research and public policy. Having had the overall responsibility for more than 8,000 surveys 
in 80 countries, Mr. Taylor’s experience has been an invaluable asset to the Academy.
Paul B. Ginsburg, PhD was appointed to the board in 2004 and for the past decade, the Academy has been 
well served by Dr. Ginsburg’s expertise in the areas of health care systems and future outlook. Dr. Ginsburg is 
the founding president of the Center for Studying Health System Change (HSC), which conducts research to 
inform policymakers and other audiences about changes in organization, financing and delivery of care and 
their effects on individuals and communities. Dr. Ginsburg is a noted speaker and consultant on the changes 
taking place in health care and has provided presentations on numerous topics including: health care reform, 
cost trends and drivers, provider payment and competition in health care. He has been named by Modern 
Healthcare as one of the 100 most powerful persons in health care six separate times.   
Prior Public Trustees:
James H.S. Cooper: (1996-1998) – member of the U.S. House of Representatives from 1993 – 1995 and from 
2003 through the present.   
Edward A. Brennan: (1999-2001)- CEO of Sears, Roebuck and Company from 1984 – 1995, Chairman of the 
Board of American Airlines (2003-2004) and an active participant on a number of boards, including McDonald’s 
Corporation and Rush University Medical Center.  
Thomas J. Campbell: (2001-2003) – member of the U.S. House of Representatives from 1989-1993 and 1995-
2001. Mr. Campbell was also a member of the California State Senate from 1993 – 1995 and a professor of 
law at Stanford University and then became Dean of the Haas Business School at the University of California, 
Berkeley in 2002.  
Humphrey J F Taylor
Paul B Ginsburg PhD
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Special Recognition Award
Leadership Development Program (LDP) 
Recognizing the critically important task of developing future leaders of the profession, key Academy physician leaders and staff developed a year-long 
program to provide future leaders identified by state, subspecialty and specialized interest societies with the training and experience to help them reach 
their leadership potential. The Academy’s first Leadership Development Program enrollees graduated in 1999. To date, 269 Eye M.D.s have graduated 
from the program. Fourteen graduates have acceded to service on the Academy’s Board of Trustees or Committee of Secretaries. A significant number 
currently populate the leadership of other ophthalmic societies. Based on the success of the Academy’s Leadership Development Program (LDP), major 
supranational and national societies have developed similar programs with the active input of Academy’s LDP leaders. In addition, several state medi-
cal associations and other national medical specialty societies have emulated the Academy’s LDP. Current and Immediate Past LDP Directors Aaron P. 
Weingeist, MD and David W. Johnson, MD, both also alumni of the program, will accept this award on behalf of the Academy LDP graduates. Others 
critical to the development of the LDP include co-founders Paul Sternberg Jr., MD and Michael W. Brennan, MD along with previous LDP Directors 
Daniel J. Briceland, MD and William R. Penland, MD.
It is with great appreciation and respect that we honor the following AAO LDP graduates and their sponsors as 2013 Special Recognition Award recipients:
Thomas M Aaberg Jr MD, LDP IX, Retina Society
Ari Daniel Abel MD, LDP IX, Delaware Academy 
of Ophthalmology
Nisha Acharya MD, LDP XV, American Uveitis 
Society
Wesley H Adams MD, LDP XV, Montana Acad-
emy of Ophthalmology
Natalie A Afshari MD, LDP XIV, Ocular Microbiol-
ogy and Immunology Group
Lama A Al-Aswad MD, LDP XV, Women in 
Ophthalmology
Chris Albanis MD, LDP XI, Illinois Association of 
Ophthalmology
Arezo Amirikia MD, LDP IX, Michigan Society of 
Eye Physicians and Surgeons
Anthony C Arnold MD, LDP IV, North American 
Neuro-Ophthalmology Society
Everton L Arrindell MD, LDP IV, National Medical 
Association, Ophthalmology Section
Steven Awner MD, LDP VI, New York State 
Ophthalmological Society
Mayssa Aziz-Toppino MD FACS, LDP V, Florida 
Society of Ophthalmology
Arlene Bagga MD, LDP XII, New Mexico Acad-
emy of Ophthalmology
Robert Bentley MD, LDP III, Oregon Academy of 
Ophthalmology
Abdhish R Bhavsar MD, LDP III, Minnesota 
Academy of Ophthalmology
Evan H Black MD, LDP XIII, Michigan Society of 
Eye Physicians and Surgeons
Barbara Ann Blodi MD, LDP VI, Macula Society
Charles P Bogie MD, LDP VIII, Oklahoma Acad-
emy of Ophthalmology
Craig A Bolton MD, LDP I, Texas Ophthalmologi-
cal Association
Michael J Borne MD, LDP XV, Mississippi Acad-
emy of Eye Physicians and Surgeons
Manal Bouhaimed MBChB PhD, LDP X, Middle 
East Africa Council of Ophthalmology
Ronald A Braswell MD, LDP XIV, Alabama Acad-
emy of Ophthalmology
Daniel J Briceland MD, LDP II, Arizona Ophthal-
mological Society
William Z Bridges Jr MD, LDP IV, North Carolina 
Society of Eye Physicians and Surgeons
James S Brown III MD, LDP XIII, Mississippi 
Academy of Eye Physicians and Surgeons
Beth K Bruening MD, LDP VI, Iowa Academy of 
Ophthalmology
Paul J Bryar MD, LDP IX, American Association 
of Ophthalmic Oncologists and Pathologists
Dawn C Buckingham MD, FACS, LDP IX, Texas 
Ophthalmological Association
Susan K Burden MD, LDP XIV, North Carolina 
Society of Eye Physicians and Surgeons
Brandon G Busbee MD, LDP IX, Tennessee 
Academy of Ophthalmology
Andrew F Calman MD PhD, LDP III, California 
Academy of Eye Physicians & Surgeons
Jeffrey A Carlisle MD, LDP V, Georgia Society of 
Ophthalmology
Marcia D Carney MD, LDP IV, Retina Society / 
Virginia Society of Eye Physicians and Surgeons
Britton B Carter MD, LDP XI, Alabama Academy 
of Ophthalmology
Keith D Carter MD FACS, LDP V, Association of 
University Professors of Ophthalmology
Kristin Carter MD, LDP XI, Arizona Ophthalmo-
logical Society
Denise R Chamblee MD, LDP XV, Ophthalmic 
Mutual Insurance Co.
James Chodosh MD MPH, LDP VII, Ocular Micro-
biology and Immunology Group
G Gregory Clark MD, LDP II, Indiana Academy of 
Ophthalmology
William S Clifford MD, LDP I, Kansas Society of 
Eye Physicians and Surgeons
Kimberly Cockerham MD FACS, LDP IX, California 
Academy of Eye Physicians & Surgeons
John W Collins MD, LDP I, Kentucky Academy of 
Eye Physicians and Surgeons
Joseph M Coney MD, LDP X, National Medical 
Association, Ophthalmology Section
Robert A Copeland, Jr. MD, LDP VIII, Washington 
DC Metropolitan Ophthalmological Society
Zelia M Correa MD, LDP V, Council of Brazilian 
Ophthalmology / Pan-American Association of 
Ophthalmology
James W Culclasure MD, LDP XIII, South Caro-
lina Society of Ophthalmology
Philip L Custer MD, LDP X, American Society of 
Ophthalmic Plastic & Reconstructive Surgery
Charles Barry Dabbs MD FACS, LDP III, Alabama 
Academy of Ophthalmology
Roger A Dailey MD, LDP VII, American Society of 
Ophthalmic Plastic & Reconstructive Surgery
Robert W Daly MD, LDP VIII, Maine Society of 
Eye Physicians and Surgeons
Anita Dash-Modi MD, LDP VII, Ohio Ophthalmo-
logical Society
Garvin H Davis MD, LDP XIII, National Medical 
Association, Ophthalmology Section
Romona Davis MD, LDP XIII, Arkansas Ophthal-
mological Society
Mary P DeFrank MD, LDP X, Oregon Academy of 
Ophthalmology
Manuel F Del Toro MD, LDP III, Puerto Rican Soci-
ety of Ophthalmology
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Society of Eye Physicians and Surgeons
Andrew P Doan MD PhD, LDP XIII, California 
Academy of Eye Physicians & Surgeons
Mark W Doubrava MD, LDP IV, Nevada Academy 
of Ophthalmology
Steven Dunn MD, LDP VII, Texas Ophthalmologi-
cal Association
Geoffrey G Emerson MD PhD, LDP XIV, American 
Society of Retina Specialists
K David Epley MD, LDP VII, Washington Academy 
of Eye Physicians and Surgeons
Arash Eshghabadi, MD, LDP XIII, Middle East 
Africa Council of Ophthalmology
David W Faber MD, LDP VI, Utah Ophthalmology 
Society
Philip Mark Fiore MD, LDP I, New Jersey Acad-
emy of Ophthalmology
Terry L Forrest MD, LDP I, North Carolina Society 
of Eye Physicians and Surgeons
Tamara R Fountain MD, LDP I, Illinois Association 
of Ophthalmology
Bradley Dean Fouraker MD, LDP X, Florida 
Society of Ophthalmology / Ocular Microbiology 
& Immunology Group
Shahar Frenkel, MD, LDP XII, Israel Ophthalmo-
logical Society
Steve M Friedlander MD FACS, LDP X, Nevada 
Academy of Ophthalmology
David J Gajda MD, LDP III, Wyoming Ophthalmo-
logical Society
Edgar C Gamponia MD, LDP VII, West Virginia 
Academy of Eye Physicians and Surgeons
Dasa Gangadhar, MD, LDP III, Kansas Society of 
Eye Physicians and Surgeons
JoAnn A Giaconi MD, LDP XI, California Academy 
of Eye Physicians & Surgeons
Sidney K Gicheru MD, LDP XIV, Texas Ophthalmo-
logical Association
James W Gigantelli MD, LDP IX, American Col-
lege of Surgeons, Advisory Council for Ophthal-
mic Surgery
Carl G Glittenberg MD, LDP XI, European Society 
of Ophthalmology
Ravi D Goel MD, LDP VI, New Jersey Academy of 
Ophthalmology
Sanjay D Goel MD, LDP V, Maryland Society of 
Eye Physicians and Surgeons
David A Goldman MD, LDP XV, American Society 
of Cataract & Refractive Surgery
Michael H Goldstein MD, LDP XIII, Massachu-
setts Society of Eye Physicians and Surgeons
Lynn K Gordon MD PhD, LDP X, North American 
Neuro-Ophthalmology Society
Peter A Gordon MD, LDP I, Georgia Society of 
Ophthalmology
Thomas A Graul MD, LDP VI, Nebraska Academy 
of Eye Physicians and Surgeons
Paul B Griggs MD, LDP II, Washington Academy 
of Eye Physicians and Surgeons
Erich Bryan Groos, MD, LDP VI, Tennessee Acad-
emy of Ophthalmology
Neeru Gupta MD PhD, LDP XIV, Association for 
Research in Vision and Ophthalmology
Dean P Hainsworth MD, LDP XIII, Missouri 
Society of Eye Physicians and Surgeons
Bryan J Hammer MD, LDP VI, South Dakota 
Academy of Ophthalmology
Diana Hampton MD, LDP XII, Oklahoma Academy 
of Ophthalmology
S Akbar Hasan, MD, LDP VIII, Florida Society of 
Ophthalmology
Christopher L Haupert MD, LDP XII, Iowa Acad-
emy of Ophthalmology
Marko Hawlina MD, LDP VII, European Society of 
Ophthalmology
Isaac J Hearne MD, LDP XIII, Nevada Academy of 
Ophthalmology
James M Heltzer MD, LDP X, Washington DC 
Metropolitan Ophthalmological Society
Bryan P Hemard MD, LDP IV, Louisiana Ophthal-
mology Association
Paul M Henry MD, LDP VI, Arkansas Ophthalmo-
logical Society
Leon W Herndon MD, LDP VII, American Glau-
coma Society
Gary S Hirshfield MD, LDP XIII, New York State 
Ophthalmological Society
Michael R Hodges MD, LDP XIII, Indiana Acad-
emy of Ophthalmology
Nancy M Holekamp MD, LDP VII, Missouri 
Society of Eye Physicians and Surgeons
Aaron C Holtebeck MD, LDP XII, Wisconsin 
Academy of Ophthalmology
Odette Houghton MD, LDP XII, North Carolina 
Society of Eye Physicians and Surgeons
Todd M Hovis MD, LDP IV, Texas Ophthalmologi-
cal Association
Ana G Huaman MD, LDP III, New Mexico Acad-
emy of Ophthalmology
David D Ingvoldstad MD, LDP XII, Nebraska 
Academy of Eye Physicians and Surgeons
Michael S Ip MD, LDP XII, Macula Society
Mohamad S Jaafar MD FACS, LDP II, Washing-
ton DC Metropolitan Ophthalmological Society
Martine J Jager MD, LDP IX, Association for 
Research in Vision and Ophthalmology
Johanna Jensen MD, LDP VII, Idaho Society of 
Ophthalmology
David W Johnson MD, LDP V, Colorado Society of 
Eye Physicians and Surgeons
David E Jones MD, LDP IV, Kentucky Academy of 
Eye Physicians and Surgeons
Leslie S Jones MD, LDP V, Washington DC 
Metropolitan Ophthalmological Society
Paul C Kang MD, LDP XIII, Washington DC Met-
ropolitan Ophthalmological Society
Anne Keating MD, LDP XV, North Dakota Society 
of Eye Physicians and Surgeons
Don O Kikkawa MD, LDP XIV, American Society 
of Ophthalmic Plastic & Reconstructive Surgery
Judy E Kim MD, LDP XV, Macula Society
Terry Kim MD, LDP IX, American Society of 
Cataract & Refractive Surgery
Wonsuck Kim DO, LDP V, Alabama Academy of 
Ophthalmology
Alan E Kimura MD, LDP XIV, Colorado Society of 
Eye Physicians and Surgeons
Laura J King MD, LDP III, Women in Ophthalmol-
ogy
John W Kitchens MD, LDP XI, Kentucky Academy 
of Eye Physicians and Surgeons
Kenneth J Knudtson MD, LDP VIII, South Dakota 
Academy of Ophthalmology
David E Korber MD, LDP I, Oklahoma Academy of 
Ophthalmology
Vera O Kowal MD, LDP II, South Dakota Academy 
of Ophthalmology
Diane Jean Kraus MD, LDP III, New York State 
Ophthalmological Society
Lance J Kugler MD, LDP X, Nebraska Academy of 
Eye Physicians & Surgeons
Joseph M Lally Jr MD, LDP III, South Carolina 
Society of Ophthalmology
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Kathleen A Lamping MD, LDP III, Ohio Ophthal-
mological Society
Michael J Landolfi DO, LDP X, New Jersey 
Academy of Ophthalmology
Paul D Langer MD, LDP VIII, Association of 
University Professors of Ophthalmology
David P Lawlor MD, LDP V, Vermont Ophthalmo-
logical Society
Mary Gilbert Lawrence MD MPH, LDP V, Associa-
tion of Veterans Affairs Ophthalmologists
Katherine A Lee MD PhD, LDP XII, American 
Association for Pediatric Ophthalmology and 
Strabismus
William Barry Lee MD, LDP XII, Eye Bank As-
sociation of America
Leah Levi MD, LDP VIII, North American Neuro-
Ophthalmology Society
Helen Ka-Fun Li MD, LDP VII, Women in Ophthal-
mology
Steven J Lichtenstein MD FACS, LDP V, American 
Academy of Pediatrics, Section on Ophthalmol-
ogy
Edward S Lim MD, LDP XII, Connecticut Society 
of Eye Physicians
Scott A Limstrom MD, LDP VI, Alaska Society of 
Eye Physicians and Surgeons
Gregg T Lueder MD, LDP X, American Academy 
of Pediatrics, Section on Ophthalmology
Robert A Lytle MD, LDP V, Massachusetts Soci-
ety of Eye Physicians and Surgeons
Mathew W MacCumber MD PhD, LDP VII, Ameri-
can Society of Retina Specialists
Susan M MacDonald MD, LDP XIII, Women in 
Ophthalmology
John C Maher MD, LDP II, Pennsylvania Academy 
of Ophthalmology
Jeff S Maltzman MD, LDP IX, Arizona Ophthal-
mological Society
Linn M Mangano MD, LDP VII, Indiana Academy 
of Ophthalmology
Steven L Mansberger MD MPH, LDP IX, Ameri-
can Glaucoma Society
Mark Christophe Maria MD, LDP IV, Pennsylvania 
Academy of Ophthalmology
Daniel F Martin MD, LDP IV, Macula Society
James W Matthews MD, LDP VIII, Kentucky 
Academy of Eye Physicians and Surgeons
Connie S McCaa MD, LDP V, Mississippi Acad-
emy of Eye Physicians and Surgeons
Gregory J McCormick MD, LDP X, Vermont 
Ophthalmological Society
David H McCullough MD, LDP XV, Connecticut 
Society of Eye Physicians
Timothy Francis McDevitt MD, LDP I, Hawaii 
Ophthalmological Society
M Lisa McHam MD, LDP VIII, Massachusetts 
Society of Eye Physicians and Surgeons
Timothy J McInnis MD, LDP III, Montana Acad-
emy of Ophthalmology
Rickey Dene Medlock MD, LDP II, Arkansas 
Ophthalmological Society
Robert F Melendez, MD MBA, LDP X, New 
Mexico Academy of Ophthalmology
Mark R Melson MD, LDP XIV, Tennessee Acad-
emy of Ophthalmology
Jennifer H Merritt MD, LDP X, South Carolina 
Society of Ophthalmology
Shahzad I Mian, MD, LDP X, Cornea Society
Mark Michels MD FACS, LDP I, Florida Society of 
Ophthalmology
Aaron M Miller MD, LDP XI, Texas Ophthalmo-
logical Association
Eydie G Miller-Ellis MD, LDP V, American Glau-
coma Society
Michael L Miller MD, LDP II, Colorado Society of 
Eye Physicians and Surgeons
Tatyana Milman, MD, LDP XIV, American 
Association of Ophthalmic Oncologists and 
Pathologists
Jeffrey B Minkovitz MD, LDP IV, Delaware Acad-
emy of Ophthalmology
Christie L Morse MD, LDP V, New Hampshire 
Society of Eye Physicians and Surgeons
Susan K Mosier MD, LDP IX, Kansas Society of 
Eye Physicians and Surgeons
Michael L Murphy, MD FACS, LDP II, Wisconsin 
Academy of Ophthalmology
Anne M Nachazel MD, LDP III, Michigan Society 
of Eye Physicians and Surgeons
Srilata S Naidu MD, LDP VIII, Contact Lens As-
sociation of Ophthalmologists
George Nardin MD, LDP VI, Hawaii Ophthalmo-
logical Society
Sundaram Natarajan MD, LDP VIII, All India 
Ophthalmological Society
Daniel E Neely MD, LDP XIV, American Associa-
tion for Pediatric Ophthalmology and Strabismus
Robert E Neger MD, LDP I, California Academy of 
Eye Physicians & Surgeons
John H Niffenegger MD FACS, LDP V, Ohio 
Ophthalmological Society
Thomas A Oetting MD, LDP II, Iowa Academy of 
Ophthalmology
Mary A O’Hara MD, LDP V, Society of Military 
Ophthalmologists
Mildred M G Olivier MD, LDP IX, Women in 
Ophthalmology
Pecos T A Olurin MBBS, LDP XII, Delaware 
Academy of Ophthalmology
Mark Packer MD, LDP VI, American Society of 
Cataract & Refractive Surgery
Brenda Pagan-Duran MD, LDP XIII, New Jersey 
Academy of Ophthalmology
Millicent Palmer MD, LDP XIV, Nebraska Acad-
emy of Eye Physicians and Surgeons
David S Pao MD, LDP VII, Pennsylvania Academy 
of Ophthalmology
Ron W Pelton MD PhD, LDP XI, Colorado Society 
of Eye Physicians and Surgeons
David B Petersen MD, LDP XII, Utah Ophthalmol-
ogy Society
Jeff H Pettey MD, LDP XIV, Utah Ophthalmology 
Society
Lawrence Piazza MD, LDP XI, Maine Society of 
Eye Physicians and Surgeons
David A Plager MD, LDP X, American Association 
for Pediatric Ophthalmology and Strabismus
Michael J Price MD, LDP XI, Massachusetts 
Society of Eye Physicians and Surgeons
Andrew M Prince MD, LDP I, New York State 
Ophthalmological Society
Brian Privett MD, LDP XV, Iowa Academy of 
Ophthalmology
Nathan M Radcliffe MD, LDP XIV, American Glau-
coma Society
Jean E Ramsey MD MPH, LDP II, Massachusetts 
Society of Eye Physicians and Surgeons
J. Bradley Randleman MD, LDP XI, American 
Society of Cataract & Refractive Surgery
Ann Ranelle DO, LDP XII, American Osteopathic 
College of Ophthalmology
P Kumar Rao, MD, LDP XV, Missouri Society of 
Eye Physicians & Surgeons
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Nathan Ravi MD, LDP VIII, Association of Veter-
ans Affairs Ophthalmologists
Kristin E Reidy DO, LDP VIII, New Mexico Acad-
emy of Ophthalmology
Rachel C J Reinhardt MD, LDP XIII, Washington 
Academy of Eye Physicians and Surgeons
Adam C Reynolds MD, LDP XV, Idaho Society of 
Ophthalmology
William W Richardson II MD, LDP XIV, Kentucky 
Academy of Eye Physicians and Surgeons
David R Rivera MD, LDP IX, Rhode Island Society 
of Eye Physicians and Surgeons
Philip R Rizzuto, MD FACS, LDP IV, Rhode Island 
Society of Eye Physicians and Surgeons
John Denis Roarty MD, LDP II, Michigan Society 
of Eye Physicians and Surgeons
Joy Dixon Robinson MD, LDP VI, Virginia Society 
of Eye Physicians and Surgeons
Prin Rojanapongpun, MD, LDP XIV, Asia Pacific 
Academy of Ophthalmology / Royal College of 
Ophthalmologists of Thailand
James F Ronk MD, LDP VI, Oklahoma Academy 
of Ophthalmology
James B Ruben MD, LDP VII, American Academy 
of Pediatrics, Section on Ophthalmology
Arvind Saini MD, LDP XV, Wisconsin Academy of 
Ophthalmology
Sarwat Salim MD, LDP XII, American College 
of Surgeons, Advisory Council for Ophthalmic 
Surgery
Jonathan Salvin MD, LDP XV, Delaware Academy 
of Ophthalmology
Scott T Schaefer MD, LDP XI, Minnesota Acad-
emy of Ophthalmology
William R Schlichtemeier MD, LDP II, Nebraska 
Academy of Eye Physicians and Surgeons
Elwin G Schwartz MD, LDP I, Connecticut Society 
of Eye Physicians
Gail F Schwartz MD, LDP I, Maryland Society of 
Eye Physicians and Surgeons
Gary S Schwartz MD, LDP I, Minnesota Academy 
of Ophthalmology
Stephen G Schwartz, MD MBA, LDP XII, Florida 
Society of Ophthalmology
Kevin R Scott MD, LDP II, Virginia Society of Eye 
Physicians and Surgeons
Cynthia A Self MD, LDP XIII, Maine Society of 
Eye Physicians and Surgeons
Susan H Senft MD, LDP IV, Hawaii Ophthalmo-
logical Society
Stefan Seregard MD, LDP VI, European Society of 
Ophthalmology
Gaurav K Shah MD, LDP XII, American Society of 
Retina Specialists
John W Shore MD, LDP III, American Society of 
Ophthalmic Plastic & Reconstructive Surgery
Sirtaz S Sibia DO, LDP XV, American Osteopathic 
College of Ophthalmology
Sidney K Simonian DO, LDP VIII, American Osteo-
pathic College of Ophthalmology
Chasidy D Singleton MD, LDP XV, National Medi-
cal Association, Ophthalmology Section
Brian D Sippy MD PhD, LDP VIII, Montana Acad-
emy of Ophthalmology
Arthur J Sit MD, LDP XI, American Glaucoma 
Society
Jennifer H Smith MD, LDP VI, Illinois Association 
of Ophthalmology
Justine R Smith MD, LDP IX, American Uveitis 
Society
Lee A Snyder MD, LDP XV, Maryland Society of 
Eye Physicians and Surgeons
Samuel Solish MD, LDP IV, Maine Society of Eye 
Physicians and Surgeons
Sharon D Solomon MD, LDP X, American Society 
of Retina Specialists
Derek T Sprunger MD, LDP V, Indiana Academy of 
Ophthalmology
Scott M Steidl MD, LDP VIII, Maryland Society of 
Eye Physicians and Surgeons
Prem S Subramanian MD PhD, LDP XIII, North 
American Neuro-Ophthalmology Society
Eric Suhler MD, LDP XI, American Uveitis Society
Michael E Sulewski MD, LDP XII, Association of 
Veterans Affairs Ophthalmologists
Steven H Swedberg MD, LDP IX, Washington 
Academy of Eye Physicians and Surgeons
Christopher N Ta MD, LDP X, Association of 
University Professors of Ophthalmology
Gareth A Tabor MD PhD, LDP I, Oregon Academy 
of Ophthalmology
Andrew W Tharp MD, LDP X, Indiana Academy 
of Ophthalmology
Steven B Thom MD, LDP III, North Dakota Society 
of Eye Physicians and Surgeons
Eric R Thomas MD, LDP XIV, South Dakota Acad-
emy of Ophthalmology
Steven C Thornquist MD, LDP VI, Connecticut 
Society of Eye Physicians
Mark F Torres MD, LDP XIII, Society of Military 
Ophthalmologists
Melissa G Toyos, MD, LDP IX, Missouri Society of 
Eye Physicians and Surgeons
James C Tsai, MD MBA, LDP III, Tennessee 
Academy of Ophthalmology
Linda M Tsai MD, LDP XI, Missouri Society of Eye 
Physicians and Surgeons
Scott A Uttley MD, LDP VII, Minnesota Academy 
of Ophthalmology
Russell N Van Gelder MD PhD, LDP VI, American 
Uveitis Society
Michael P Varley MD FACS, LDP IV, West Virginia 
Academy of Eye Physicians and Surgeons
Gurunadh Atma Vemulakonda MD, LDP XV, 
Washington Academy of Eye Physicians and 
Surgeons
Anthony J Viti MD, LDP XIV, Virginia Society of 
Eye Physicians and Surgeons
Tamara R Vrabec MD, LDP XI, Retina Society
Alan L Wagner MD FACS, LDP XI, Virginia Soci-
ety of Eye Physicians and Surgeons
David K Wallace MD MPH, LDP VIII, North Caro-
lina Society of Eye Physicians and Surgeons
Thomas Peter Ward MD, LDP VII, Society of 
Military Ophthalmologists
Ann A Warn MD MBA, LDP III, Oklahoma Acad-
emy of Ophthalmology
Aaron P Weingeist MD, LDP IV, Washington 
Academy of Eye Physicians and Surgeons
John A Wells III MD, LDP VII, South Carolina 
Society of Ophthalmology
Constance E West, MD, LDP IV, American 
Association for Pediatric Ophthalmology and 
Strabismus
Thomas J Whittaker MD, LDP II, Missouri Society 
of Eye Physicians and Surgeons
Craig L Wilkerson MD, LDP X, Montana Academy 
of Ophthalmology
Daniel V Will MD, LDP XI, Pennsylvania Academy 
of Ophthalmology
Jun-Shyan Wong MBBS, LDP IX, Asia-Pacific 
Academy of Ophthalmology
Joseph M Zobian MD, LDP XII, Hawaii Ophthal-
mological Society
Special Recognition Award
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Outstanding Humanitarian Service Award
Mario R Angi MD
Mario R. Angi, MD was nominated by the Societá Oftalmologica Italiana to receive this year’s Outstanding 
Humanitarian Service Award. 
As President of the Christian Blind Mission Italy (CBM Italia), Dr. Angi worked to ensure that countless people, 
young and old, were able to see the world through their own eyes. Dr. Angi’s leadership has been two-fold. 
He frequently traveled to clinics in developing countries to serve patients as a frontline care provider and he 
worked tirelessly to develop resources needed to sustain and support CBM Italia’s projects around the globe. 
Dr. Angi started his voluntary work as an ophthalmologist at age 29 after specializing in ophthalmology at Uni-
versity Padua in Italy. He served as a volunteer ophthalmologist with Rotary International in Mali in 1982 and 
1987. He then took his family to Ibarra, Ecuador in support of a young ophthalmologist who had also studied 
at the University Padua. Dr. Angi equipped the eye department of Ibarra’s public hospital with an ophthalmic 
microscope, as well as surgical and optical instruments, enabling the hospital to perform cataract surgeries. 
Additionally, Dr. Angi promoted two agreements of cooperation between the University of Padua and the 
University of Quito. He organized three scientific conferences in Ecuador. He sent five senior ophthalmologists 
to Ibarra as tutors and he invited 12 Ecuadorian residents in ophthalmology to the University of Padua for 
three-month rotations. Dr. Angi also organized visual screening for 6,000 indigent children in Quito and Ibarra 
and provided free glasses to children with high ametropia. 
In 1996 a missionary friend of the Angi family requested his assistance with ophthalmic work in Africa. In 
1997 Dr. Angi equipped an ophthalmic clinic in Nazareth, Ethiopia. He ran the clinic for two years and recruited 
volunteer Italian ophthalmologists to work with him.
Dr. Angi is a founding member of the Rotary Club in Abano Terme Montegrotto Terme. With humanitarian con-
tributions from the Rotary Foundation and in cooperation with CBM Italia, he created the Cooper Eye Hospital 
in Monrovia, Liberia; the Eye Department of Eva Peron hospital in Santiago del Estero, Argentina; and the Eye 
Department of St. Luke Hospital in Wolisso, Ethopia.
Under Dr. Angi’s leadership from 2002 to 2012 CBM Italia supported a total of 231 projects and programs in 
conjunction with various international healthcare groups, non-governmental organizations, and local partners. 
During Dr. Angi’s tenure, CBM Italia supported projects around the world, including Mali, Uganda, Ethiopia, 
Zambia, Afghanistan, Vietnam, Brazil and many others. 
At present Dr. Angi continues his work in Africa. In Ethiopia, he is participating in an agreement of cooperation 
between the University of Padua and the University of Addis Ababa. In cooperation with CBM in the Demo-
cratic Republic of Congo he has opened an Eye Hospital in Isiro and with support from Rotary he equipped the 
Eye Clinic of Butembo. At the clinic in Isiro he started a program for the control of sight related problems and 
provided glasses for school children in the area.
A colleague quoted Mother Theresa that “unless a life is lived for others, it is not worthwhile”. Dr. Angi’s lead-
ership of CBM Italia and his dedication to preventing blindness are testament to the fact that Dr. Angi leads a 
worthwhile life as a man for others.
The Academy is privileged to honor Dr. Angi with this year’s Outstanding Humanitarian Service Award.
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Outstanding Humanitarian Service Award
Gullapalli N Rao MD
Gullapalli N. Rao, MD was nominated by The Cornea Society to receive this year’s Outstanding Humanitarian 
Service Award.
Dr. Rao completed his ophthalmology residency at the prestigious All India Institute of Medical Sciences, 
followed by a cornea fellowship at Tufts University. He then moved to Rochester, New York for another fellow-
ship with Dr. James Aquavella and continued there on the clinical faculty of University of Rochester. In 1986 
he decided to leave his thriving academic career to establish a comprehensive, high quality, sustainable eye 
care system in his home state of Andhra Pradesh, India.  
Through Dr. Rao’s entrepreneurial spirit he created the L.V. Prasad Eye Institute, a system that encompasses 
all levels of eye care from the most basic screening to the most complex care and extends from the most 
rural areas of the state to the finest tertiary care hospitals in the cities. The L.V. Prasad Eye Institute is one of 
the largest eye care systems in the world. It was established and remains a not-for-profit, non-government 
institution. It was founded with the Vision of “Excellence and Equity” and provides equal care for all patients, 
whether they can afford to pay or not (over 50% cannot). 
This model of care is based on a pyramid, the base of which is in the communities. The apex is the tertiary eye 
centers and the center of excellence. There are currently almost a hundred primary care centers, ten secondary 
care centers, three tertiary care centers and the main campus center of excellence in Hyderabad. The concept 
has been so successful that it has been replicated in other states in India and other countries around the 
world. The scalability of this vision center model, combined with Dr. Rao’s dedication to propagating the model 
to other states in India and to other developing countries, has made quality eye care available to millions of 
individuals who previously did not have access to even rudimentary ophthalmic care.
In addition to the impressive prevention programs and clinical care, L.V. Prasad is well known for its educa-
tional programs for all cadres of eye care personnel, all areas of eye research, eye banking and a very robust 
rehabilitation program for those with irreversible blindness and low vision.
As the Secretary General and later on Chairman/CEO of the International Agency for the Prevention of Blind-
ness an organization was established in 1975 as an umbrella group to lead and coordinate international efforts 
to prevent blindness, Dr. Rao played an important role in the initiation and execution of its current initiative, 
VISION2020: The Right to Sight, whose goal is to reduce burden of avoidable blindness by 2020.
Dr. Rao’s endless devotion and dedication has improved the quality of life for millions, not only in India but 
internationally. As a board member of The Cornea Society, Dr. Rao provides an international perspective, con-
stantly thinking about ways to improve international eye health and educate his international colleagues. He 
is a tireless advocate for advancing availability of care to underserved areas, encouraging the Cornea Society 
to support the training of ophthalmologists in those areas. He is constantly thinking about ways to improve 
international eye health, the education of international colleagues and cooperation between various eye care 
organizations. The Academy is proud to honor Dr. Gullapalli Rao with this year’s Outstanding Humanitarian 
Service Award.
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Outstanding Advocate Award
Michael W Brennan MD
Michael W. Brennan, MD was nominated by the North Carolina Society of Eye Physicians and Surgeons to 
receive this year’s Outstanding Advocate Award. 
Over his many years of service at the state, national and international level, Dr. Brennan’s name has become 
synonymous with advocacy leadership. Dr. Brennan has led the way to educate leaders of supra-national/
national ophthalmic organizations about professionalism issues. Dr. Brennan has dedicated countless hours in 
convening meetings of society leaders at global events to discuss quality patient eye care and has offered his 
personal assistance as well as Academy resources to those in need of such support. At the 2011 AAO World 
Ophthalmic Leaders Forum in Education, which takes place each year in conjunction with the Academy Annual 
Meeting, Dr. Brennan was the headline presenter on the topic, Global Optometry: Changing and Challenging, 
Non-Physician Providers - Lessons Learned Around the World. One of  his many recent  global visits was with 
leaders of the Ophthalmic  Society of the  West Indies (OSWI) where he  joined  Secretary for  State Affairs, 
Daniel J. Briceland, MD  to meet the Minister  of Health of the Republic of Trinidad and Tobago. Over the last 
several years he has visited the Ministers of Health in Syria, Iraq, Yemen and Libya to formulate physician 
leadership initiatives.
Dr. Brennan served as the Academy’s secretary for state affairs from 1997 to 2013. During his tenure, Dr. Bren-
nan was instrumental in implementing the American Academy of Ophthalmology’s Leadership Development 
Program which has since developed into a global effort with complementary programs within PAAO, SOE, 
AIOS, APAO, MEACO and RANZCO. The Academy Surgical Scope Fund evolved as a critical tool in the Surgery 
by Surgeons campaign under Dr. Brennan’s leadership. Dr. Brennan championed state ophthalmology society 
executive directors and physician leaders in their legislative battles to pro-actively represent the profession 
of ophthalmology for patients and continues to provide wisdom and support to Academy secretariat for state 
affairs efforts.
Dr. Brennan is a past president of both the North Carolina Society of Eye Physicians and Surgeons and the 
American Academy of Ophthalmology. He promoted adoption of a Leadership College within the North Caro-
lina Medical Society modeled after the Academy’s Leadership Development Program and saw its potential 
to fill a leadership gap in organized medicine. This model has been disseminated and adapted by many other 
national and state medical societies across the country. 
Lastly, Dr. Brennan, as a retired Army officer, has been effective as a champion of our military, active duty and 
veterans, and our military and VA ophthalmology colleagues who deliver their eye care in often challenging 
environments. 
A recollection from a colleague and former AAO Councilor from North Carolina notes that, “Dr. Brennan 
essentially singlehandedly, organized the response in North Carolina to the latest optometric attempt at incur-
sion into the practice of medicine. He is and has always been a source of wisdom for dealing with the most 
controversial issues”. 
Dr. Brennan has generously given his time and energy to countless efforts and his years of service at all levels 
are a legacy that would be difficult to match. The Academy is privileged to honor Dr. Brennan with this year’s 
Outstanding Advocate Award.
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International Blindness Prevention Award  
Prof. Mohammad Daud Khan
Prof. Mohammad Daud Khan was trained as a doctor in Peshawar, Pakistan and as an ophthalmologist in the 
United Kingdom. After 32 years of services in Peshawar, he retired from the government service in April 2009. 
However he continues to serve as the Chairman of Comprehensive Health and Education Forum International 
(CHEF International), a nongovernmental organization (NGO) with a commitment to making a difference in 
general health, education and cross disability in Pakistan and other developing countries. 
Prof. Khan served as a teacher in Khyber Medical College and Postgraduate Medical Institute Peshawar since 
1977 and has made major contributions to teaching and training and evaluation in ophthalmology throughout 
Pakistan and other developing countries. He has also served on the Editorial Board of eight national and 
international ophthalmic journals. 
During the last two years of his service, Prof. Khan served as the Founder Vice Chancellor of Khyber Medical 
University. 
He has played a key role in humanitarian work in Pakistan and other developing countries. 
He is on the Board of Trustees of Layton Rahmatulla Benevolent Trust, one other largest and finest NGO in 
Pakistan since 1984. He is also on the Board of Governors of the Khyber Eye Foundation. 
He served as a National Coordinator and Chairman National Committee for Prevention of Blindness in Pakistan 
for 14 years, and was responsible for organizing and supervising Pakistan’s 2nd National Survey on blindness 
and visual impairment in 2001-2003, which was conducted with the help of the World Health Organization 
(WHO), International Centre for Eye Health (ICEH) and a of number of international NGOs. 
Prof. Khan serves as an advisor to WHO since 1994. Prof. Khan also served as a Councilor and President of 
Asia Pacific Academy of Ophthalmology (APAO), Councilor Afro-Asian Academy of Ophthalmology, President 
SAARC Academy of Ophthalmology, President of Ophthalmological Society of Pakistan (OSP), Vice President 
of International Agency for the Prevention of Blindness, Eastern Mediterranean Region and Vice President of 
College of Physicians and Surgeons Pakistan. Prof. Khan also served as a member of the International Council 
of Ophthalmology (ICO) for six years.  
Prof. Khan has been a recipient of many national and international awards including, President of Pakistan 
Pride of Performance Award, President of Pakistan OSP Ramzan Ali Syed Gold Medal, APAO Jose Rizal Gold 
Medal, ICO Duke Elder International Award, SAARC Academy of Ophthalmology Lifetime Achievement Award 
and APAO, Saudi Arabia and Taiwan Prevention of Blindness Awards. 
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Straatsma Award for Excellence in Resident Education
Andreas K Lauer MD 
Dr. Andreas Lauer completed medical school and internship at University of Oklahoma College of Medicine 
and completed residency and retina fellowship training at Casey Eye Institute (CEI) – Oregon Health & Sci-
ences University (OHSU). He was appointed as faculty to the CEI Retina Service and served as Retina Fellow-
ship Program Director between 2006 and 2010. He has been Retina Division Chief since 2007 and Residency 
Program Director since 2001. Recently, Dr. Lauer was appointed Vice-Chair for Education.
Throughout Dr. Lauer’s career, residency education has been a continual focus of his efforts. Dr. Lauer insti-
tuted a structured review and assessment process that encouraged and increased resident effort in teaching, 
learning, research and public service. Under his tenure, the Ophthalmic Knowledge Assessment Program 
(OKAP) performance of residents at CEI rose from average performance to performance consistently at the 
1st standard deviation above the national mean for the last 6 years. In cooperation with the leadership of the 
Oregon Academy of Ophthalmology (OAO), he developed the OAO Resident Mentor program that promotes 
interaction between residents and non-university based ophthalmologists through quarterly mentorship 
meetings, clinical experiences and resident representation on the OAO board. Dr. Lauer garnered philanthropic 
support for educational activities, organized for awards to recognize residents who have excelled in the areas 
of research, teaching, and medical knowledge acquisition and created awards to recognize faculty members 
in their teaching efforts. He has received the Robert C. Watzke department teaching award, OHSU’s Graduate 
Medical Education Service Award and three times received the Casey Eye Distinguished Service award. 
On a national level, he was elected to the Association of University Professors in Ophthalmology (AUPO) 
Program Director’s Council (PDC) and served as its president in 2012. Through this organization, he directed na-
tional symposia and served as liaison to the San Francisco Ophthalmology Matching Program to improve resi-
dent candidate application management and match notification process. He has served as liaison to the AAO 
in improving the electronic administration of the OKAP exam and has worked with the Accreditation Council 
for Graduate Medical Education Ophthalmology Review Committee to assemble national program director 
input on resident surgical experience.  In 2012, Dr. Lauer received the AAO Secretariat Award for promoting 
AAO initiatives in teaching and education. For the American Board of Ophthalmology, he has served as Oral 
Examiner, Item Writer for Maintenance of Certification and member of the Retina Content Outline Rating and 
Exam Development Committees. In addition to serving as lecturer at national conferences, Dr. Lauer has been 
invited as teaching faculty internationally in Brazil, China, Hong Kong, and Japan. In 2014, he will co-chair the 
World Education Colloquium to address global accreditation of residency programs at the quadrennial World 
Ophthalmology Congress in Tokyo, Japan. 
In addition to residency education, Dr. Lauer has mentored over 20 vitreoretinal fellows and served on the 
American Society of Retina Specialists (ASRS) Board of Directors to foster the education and inclusion of 
early-career retina specialists. He received the ASRS Honor Award in 2005. Presently, he serves on the Board 
of Managers of the AUPO-Fellowship Compliance Committee. 
For research, Dr. Lauer has been OHSU’s principal investigator (PI) for protocols sponsored by Diabetic Reti-
nopathy Clinical Research network and has participated in their executive and manuscript-writing committees. 
He serves as PI and surgeon in a novel phase 1 clinical trial in humans studying the subretinal viral vector 
delivery to treat neovascular age-related macular degeneration and is co-investigator and surgeon in phase 1 
clinical trials studying viral vector delivery in humans with Stargardt disease and Usher Syndrome. Dr. Lauer 
has served as local PI and writing committee member for the NIH-sponsored studies in retinal vein occlusion 
and has served as examining and treating ophthalmologist for the landmark Early Treatment for Retinopathy of 
Prematurity (ROP) Study that has vastly improved the visual outcomes of children who developed severe ROP 
as infants.
In postgraduate education, accountability, motivation and engagement are integral to both learners and teach-
ers in the objective of training competent physicians and surgeons. Dr. Lauer is interested in strategies that 
promote motivation and engagement in the educational process of transforming students into professionals 
and lifelong learners. 
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The Secretariat Award recognizes ophthalmologists and non-ophthalmologists for special contributions 
to the Academy and the field of ophthalmology. Senior secretaries and secretaries in their respective 
areas select award recipients with approval from the Board of Trustees. 
This annual award was developed to increase opportunities for individuals to be recognized for contribu-
tions that are outside the scope of the current Achievement Award program.
Secretariat Award
Secretariat Award
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Ann Louise Coleman MD PhD, Secretary for Quality Care; 
Jeffrey A Nerad MD, Secretary for Knowledge Base 
Development; Christopher J Rapuano, Secretary for 
Ophthalmic Knowledge; Jeffrey S Heier MD, Secretary for 
Online Education/eLearning; Robert F Melendez MD, Editor-in-
Chief, the ONE Network;  Louis B Cantor MD, Senior Secretary 
for Clinical Education honor:
Lisa B Arbisser MD Bettendorf, IA
Jason Bacharach MD Petaluma, CA
Christopher L Blanton MD Ontario, CA
Donald C Fletcher MD San Francisco, CA
Rod Foroozan MD Houston, TX
Jeffrey D Henderer MD Philadelphia, PA
Stephen McLeod MD San Francisco, CA
David C Musch Phd Ann Arbor, MI
Sara S O’Connell MD Overland Park, KS
Timothy W Olsen MD Atlanta, GA 
Chirag P Shah MD MPH Boston, MA
Steven C Schallhorn MD San Diego, CA
Edwin M Stone MD PhD Iowa City, IA
C Gail Summers MD Minneapolis, MN
Roger E Turbin MD Livingston, NJ
Russell N Van Gelder MD Seattle, WA
Evan L Waxman MD Pittsburgh, PA
Robert E Wiggins MD  Asheville, NC
David A Durfee MD, Senior Secretary for Ophthalmic Practice 
honors:
Elise Levine MA CRC OCS Mission Hills, CA
Derek Peece MBA Incline Village, NV
Robert Wiggins Jr MD MHA Asheville, NC
  
Daniel J Briceland, MD, Secretary for State Affairs; Gregory P 
Kwasny MD, Secretary for Federal Affairs; Michael X Repka 
MD, AAO Medical Director for Governmental Affairs; William 
L Rich III MD, AAO Medical Directory of Health Policy; Cynthia 
Ann Bradford MD, Senior Secretary for Advocacy honor:
Michael V Boland MD Baltimore, MD
Amy Chomsky MD Nashville, TN
Mary Louise Z Collins MD Baltimore, MD
Geoffrey G Emerson MD Minneapolis, MN 
Donald A Gagliano MD National Harbor, MD
Elena M Jimenez MD San Juan, Puerto Rico
David W Johnson MD Denver, CO
James Luetkemeyer MD Jefferson City, MO
Robert E Tibolt MD Salem, OR
Phillip R Rizzuto MD, Secretary for Communications honors:
Gary S Hirshfield MD Fresh Meadows, NY
Elena M Jimenez MD San Juan, Puerto Rico
Monica Monica MD Meterie, LA
Ivan R Schwab MD Sacramento, CA
Jeffrey Whitman MD Dallas, TX
Jonathan B Rubenstein MD, Secretary for Annual Meeting 
honors:
Gary S Schwartz  MD St. Paul, MN
George B Bartley MD, Ophthalmology Editor honors:
Boel Bengtsson PhD Malmo, Sweden
William R Freeman MD La Jolla, CA 
Ian Morgan MD Camberra, Australia
Michael X Repka MD Baltimore, MD 
Peter AD Rubin MD Palm Beach Gardens, FL 
Tamara R Fountain MD, Secretary for Member Services 
honors:
Laurie Gray Barber MD Litle Rock, AR
R V Paul Chan MD New York, NY
Allan D Jensen MD Baltimore, MD
Ronald E Smith MD Los Angeles, CA
Geoffrey O Wilkes MD San Francisco, CA
Richard P Mills MD MPH, Chief Medical Editor, EyeNet 
honors:
Santanu Mitra MBBS Howrah, India
Sonal S Tuli MD Gainesville, FL
Richard L Abbott MD, Secretary for Global Alliance honors:
Joseph Colin MD (in memoriam) Bordeaux, France
Zelia Correa MD Cincinnati, OH
Baxter F McLendon, MD Brunson, SC
Fernando Pena MD Bogota, Colombia
Victoria Sheffield Kensington, MD
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The Achievement Award program recognizes individuals for their contributions to the Academy, its 
scientific and educational programs and to ophthalmology.
Categories of contribution for participation in the Annual Meeting include:
• Instruction Course, Skills or Breakfast With the Experts
• Scientific E-Poster presentation
• Film or Video Production
• Scientific Exhibitor
• Scientific Paper Presentation
• Symposia
• Scientific Poster Presentation
• Subspecialty Day
Informational Posters and Exhibits are not awarded points toward the Achievement Award program.
Other categories of contribution for Academy service include:
• Committee Members
• Trustees
• State Society Presidents
• Participants in the Academy’s Leadership Development Program 
• Representatives
• Authors, Co-Authors and Reviewers of Academy Educational Material
• Councilors
• Support of Advocacy Efforts
The program is based on a cumulative point system; one point is awarded per category of contribu-
tion. An individual can earn a maximum of three points per year. For example, an individual serving 
on a committee and presenting two scientific papers, one instruction course and one scientific poster 
during the Annual Meeting receives one point for committee participation, one point for the instruction 
course and one point for the paper. The individual would not receive a fourth point for the poster or the 
additional paper. 
Individuals who earn 10 points receive the Achievement Award. Individuals who earn 30 points receive 
the Senior Achievement Award. Individuals who earn 60 points are eligible to receive the Life Achieve-
ment Honor Award. The Awards Committee reviews all nominees and submits their recommendations to 
the Board of Trustees for final approval.
On behalf of the Board of Trustees, we are pleased to announce the recipients of the 2013 Achievement 
Award, Senior Achievement Award and Life Achievement Honor Award.
The 2013 Awards Committee of the American Academy of Ophthalmology:
Achievement Award Program
Jane C Edmond MD - Chair
Cynthia Ann Bradford MD 
Daniel J Briceland MD 
Louis B Cantor MD 
John J Dagianis MD 
Bradley Dean Fouraker MD
Amalia Miranda MD
Jonathan B Rubenstein MD
Achievement Award Program
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 Melvin I Freeman MD FACS
Bellevue, WA
 William R Freeman MD
La Jolla, CA
 Henry J Kaplan MD
Louisville, KY
John L Keltner MD
Sacramento, CA
 Burton J Kushner MD
Madison, WI
 Jeffrey M Liebmann MD
New York, NY
 Scott M MacRae MD
Rochester, NY
Harry A Quigley MD
Baltimore, MD
 Frederick T Fraunfelder MD
Portland, OR
 Daniel S Durrie MD
Overland Park, KS
 Richard K Dortzbach MD
Madison, WI
 Eric D Donnenfeld MD
Rockville Centre, NY
Alan S Crandall MD,
Salt Lake City, UT 
 Emily Y Chew MD
Bethesda, MD
 Massimo Busin MD
Forli, Italy
A Jan Berlin MD FACS
Portland, ME
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Joel S Schuman MD
Pittsburgh, PA
Gregory L Skuta MD
Oklahoma City, OK
Ira J Udell MD
Great Neck, NY
Woodford S Van Meter MD 
Lexington, KY
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Leon W Herndon MD
Durham, NC
John J McGetrick MD FACS
Winter Haven, FL
Byron L Lam MD
Miami, FL
Shigeru Kinoshita MD
Kyoto, Japan
Stephen C Kaufman MD PhD
Minneapolis, MN
Matthew Dean Kay MD
Pompano Beach, FL
Paul L Kaufman MD
Madison, WI
Suber S Huang MD MBA
Cleveland, OH
Jonathan M Holmes MD
Rochester, MN
Richard S Hoffman MD
Eugene, OR
Tarek S Hassan MD
Royal Oak, MI
Alain Gaudric MD 
Paris, France
Prashant Garg MD
Hyderabad, India
Jane C Edmond MD
Houston, TX
Deepinder K Dhaliwal MD
Pittsburgh, PA
James A Davison MD
Marshalltown, IA
Emmett T Cunningham Jr MD PhD 
Hillsborough, CA
William S Clifford MD
Garden City, KS
Donald J Cinotti MD
Jersey City, NJ
Chi-Chao Chan MD
Bethesda, MD
Kurt A Buzard MD
Henderson, NV
Robert A Braunstein MD
Morristown, NJ
Rosa Braga-Mele MD
North York, Canada
Alay S Banker MD
Ahmedabad, India
Iqbal K Ahmed MD
Mississauga, Canada
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Terri L Young MD MBA
Durham, NC
Michael T Yen MD
Houston, TX
Lihteh Wu MD
San Jose, Costa Rica
Kevin Lee Waltz MD
Indianapolis, IN
Rasik B Vajpayee MD
New Delhi, India
William B Trattler MD
Miami, FL
Gustavo E Tamayo MD
Bogota, Colombia
Renée Solomon MD
New York, NY
Julian D Stevens DO
London, United Kingdom
Masoud Soheilian MD
Tehran, Iran
Michael E Snyder MD
Cincinnati, OH
John D Sheppard MD
Norfolk, VA
Namrata Sharma MD MBBS-
Noida, India
James A Savage MD
Memphis, TN
Roy Scott Rubinfeld MD
Chevy Chase, MD
Kenneth J Rosenthal MD FACS 
Great Neck, NY
Douglas J Rhee MD
Boston, MA
Franco M Recchia MD
Nashville, TN
Evelyn A Paysse MD
Houston, TX
David W Parke MD
North Branford, CT
Masahito Ohji MD
Otsu, Japan
Robert J Noecker MD
Fairfield, CT
Christie L Morse MD
Concord, NH
No Photo 
Available
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Shishir Agrawal MS DNB FRCS 
Meerut, India
Ibrahim A Aljadaan MD
Riyadh, Saudi Arabia
Richard C Allen MD PhD
Iowa City, IA
Rando   PhD
New York, NY
Noel A Alpins MD FACS
Cheltenham, Australia
Timothy J Archer MS
London, United Kingdom
Brandon Ayres MD
Bala Cynwyd, PA
Michael R Banitt MD
Miami Beach, FL
Rafael I Barraquer Compte MD 
Barcelona, Spain
David A Belyea MD MBA FACS 
Washington, DC
John P Berdahl MD
Sioux Falls, SD
Rahul Bhola MD
Louisville, KY
Preston H Blomquist MD
Dallas, TX
Manal Bouhaimed MBChB PhD 
Safat, Kuwait
Bert Bowden MD
Huntsville, AL
Angela N Buffenn MD MPH
Los Angeles, CA
David G Charteris MD MBChB 
London, United Kingdom
Kelvin Kam Lung Chong MD
Hong Kong (SAR), Hong Kong
Vikas Chopra MD
Santa Monica, CA
Amy Grossman Coburn MD
Houston, TX
Cecilia Contreras MD
Lima, Peru
James E Croley III MD
Cape Coral, FL
John J Dagianis MD
Nashua, NH
 
Paulo Elias C Dantas MD
Sao Paulo, Brazil
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Mary P DeFrank MD
Hillsboro, OR
Dimitri D Dementiev MD
Milan, Italy
Vincent A Deramo MD
Great Neck, NY
Manuel  Diaz Llopis MD PhD 
Valencia, Spain
Peter J Dolman MD
Vancouver, Canada
Angela M Dolmetsch MD
Orlando, FL
Raymond S Douglas MD PhD
Ann Arbor, MI
Jason S Ehrlich MD
Austin, TX
Tracy L Emond MS COE
Birmingham, AL
Marjan Farid MD
Irvine, CA
Antonio Ferreras MD PhD
Zaragoza, Spain
Rajesh Fogla MD FRCS
Hyderabad, India
Joseph L Fontenot MD
Daphne, AL
James F Freeman MD
Memphis, TN
Steve M Friedlander MD FACS 
Reno, NV
Traci Fritz COE OCS
Saint Clair Shores, MI
Ronald C Gentile MD
Manhasset, NY
Carl G Glittenberg MD
Vienna, Austria
Todd Alan Goodglick MD
Chevy Chase, MD
Raj K Goyal MD MPH FACS
Burr Ridge, IL
Cynthia L Grosskreutz MD PhD
Cambridge, MA
Francisco J Gutierrez-Carmona MD PhD
Madrid, Spain
Nabil E Habib FRCOphth
Plymouth, England
Samer Hamada MD FRCOphth 
Birmingham, England
 
Masanori Hangai MD
Kyoto, Japan
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ards Christos Haritoglou MDMunich, Germany
Kurt F Heitman MD
Greenville, SC
Akito Hirakata MD
Tokyo, Japan
Erich P Horn MD
Oakland, CA
Eliza N Hoskins MD
Orinda, CA
Donna W Howell JD
Atlanta, GA
Maria T Iradier MD PhD
Madrid, Spain
Anthony J Johnson MD
San Antonio, TX
Richard H Johnston MD
Edina, MN
Albert S Jun MD PhD
Lutherville, MD
Alon Kahana MD PhD
Ann Arbor, MI
James A Katz MD
Deerfield, IL
Ramesh Kekunnaya MD FRCS 
Hyderabad, India
Tae-Woo Kim MD PhD
Seongnam, Korea
John W Kitchens MD
Lexington, KY
Sylvia R Kodsi MD
New York, NY
William Howard Koon II
Cols Grove, OH
Rohit Krishna MD
Overland Park, KS
Wico W Lai MD FACS
Midlevels, Hong Kong
Wai-Ching Lam MD
Toronto, Canada
Michele Lanza MD
Naples, Italy
Andreas K Lauer MD
Portland, OR
Dongho Lee MD PhD
Seoul, Korea
Hui Bae Harold Lee MD
Indianapolis, IN
 
Richard K Lee MD
Miami, FL
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Flora Lum MD
San Francisco, CA
David A L Maberley MD
Vancouver, Canada
Susan M MacDonald MD
Concord, MA
Francois Malecaze MD
Toulouse Cedex, France
Maria Martinez-Castellanos MD
Mexico City, Mexico
Eduardo P Mayorga MD
Buenos Aires, Argentina
Tara A McCannel MD
Los Angeles, CA
Charles McGhee PhD FRCOphth  
Auckland, New Zealand
Siamak Moradian MD
Tehran, Iran
Andrew A Moshfeghi MD MBA 
Palm Beach Gardens, FL
Joaquim N Murta MD PhD
Coimbra, Portugal
Alejandro Navas MD
Mexico City, Mexico
Herbert J Nevyas MD
Bala Cynwyd, PA
Anita Nevyas-Wallace MD
Bala Cynwyd, PA
Donald R Nixon MD
Orillia, Canada
Anil D Patel MD
Oklahoma City, OK
Susan M Pepin MD
Hanover, NH
Juan J Perez-Santonja MD
Alicante, Spain
Norbert Pfeiffer MD
Mainz, Germany
Jagat Ram MBBS MS
Chandigarh, India
Pradeep Y Ramulu MD PhD
Clarksville, MD
Sherman W Reeves MD MPH 
Plymouth, MN
Gill Roper-Hall DBOT CO
Saint Louis, MO
Vincenzo Sarnicola MD
Grosseto, Italy
 
Denise Satterfield MD
Sacramento, CA
29
Achievement Awards
A
chievem
ent  Aw
ards Adam J Scheiner MDTampa, FL
Michael J Shapiro MD
Des Plaines, IL
Allison Weber Shuren MSN JD 
Washington, DC
Kimberly C Sippel MD
New York, NY
Lucia Sobrin MD MPH
Boston, MA
Wayne A Solley MD
Westlake, TX
Barrie D Soloway MD
Long Beach, NY
Robert C Spurny MD
Mesa, AZ
Giovanni Staurenghi MD
Milan, Italy
Joshua D Stein MD MS
Ann Arbor, MI
Sandra Stinnett DrPH
Durham, NC
Aleksandar Stojanovic MD 
Tromso, Norway
Thomas I Strinden MD
Fargo, ND
Rishi Swarup MBBS  FRCS
Hyderabad, India
Dorota Tarnawska MD
Katowice, Poland
Roxana Ursea MD
Tucson, AZ
Canan A Utine MD FEBO FICO 
Istanbul, Turkey
Jorge E Valdez-Garcia MD
San Pedro, Mexico
Andrew J Velazquez MD
Birmingham, AL
George O Waring IV MD
Charleston, SC
Duane A Wiggins MD
Farmington, NM
Edward J Wladis MD
Glenmont, NY
S Chien Wong MBBS FRCS
London, United Kingdom
May-Yung Yen MD
Taipei, Taiwan
 
Norihiko - MD PhD
Kyoto,Japan
No Photo 
Available
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Young Hee Yoon MD
Seoul, Korea
Nagahisa Yoshimura MD PhD
Kyoto, Japan
Renzo A Zaldivar MD
Durham, NC
Kang Zhang MD PhD
LA Jolla, CA
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International Ophthalmologist Education Award Recipients
The International Ophthalmologist Education Award was developed to recognize international Academy members who pursue lifelong education 
in ophthalmology. To qualify, international members need to earn 90 Continuing Medical Education (CME) credits over a period of three years. 
Half of these credits (45) must be from Academy-sponsored CME activities. After applying for the award, members are responsible for recording 
their Academy and non-Academy credits on their online CME transcript.
Khalil M Al-Salem MBBS (Jordan)
Khaled G Ammar MBBS (Egypt)
Khaled Bairi MD (France)
Antonio Barloggio MD (Switzerland)
Lovre Bojic MD (Croatia, Hrvatska)
Joaquim Campos Lopes MD (Portugal)
Wanessa Furtado Carneiro MD (Brazil)
Emilio  Dorronzoro, MD (Spain)
F Javier Farina MD (Spain)
Valentina Franco Cardenas, MD (Mexico)
Howard V Gimbel MD MPH FRCSC (Canada)
Stefanos F Glaros MD (Greece)
Marta Hovan MD (England)
Soosan Jacob FRCS (India)
Ramesh Kekunnaya MBBS, MD (India)
Mounir A Khalifa MD (Egypt)
Thomas Kohnen MD (Germany)
Igor J Lundqvist MD (Netherlands)
Ahmad B Maqsood MBBS (Pakistan)
Andrzej Mierzejewski MD (Poland)
Lizette L Mowatt, MBBS (Jamaica)
Leo J Noordzij MD (Netherlands)
Bizimana Nzabamwita MD (Rwanda)
Annabelle A Okada MD (Japan)
Alina Oprina MD (France)
Heitor Panetta MD (Brazil)
Mohammad M Parvaresh Rizi MD (Iran, Islamic Republic Of)
Ana Cristina Perez MD (Ecuador)
Alicia M Ponce MD (Honduras)
Luis Danilo D Ponce MD (Honduras)
Muhammad S Raja MBBS (United Kingdom)
Arturo J Ramirez-Miranda MD (Mexico)
Frederic Scholtes MD (France)
Nobuyuki Shoji MD (Japan)
Hisham H Soliman MBBCh (United Arab Emirates)
Jeannine Srourian MD (Syrian Arab Republic)
Gustavo E Tamayo MD (Colombia)
Masoud Teimory MBChB (England)
Colin G Thompson MBBS (Australia)
Constantino Trapatsas MD (Panama)
Paulo Jorge Vale MD (Portugal)
Paolo Vinciguerra MD (Italy)
Enzo M Vingolo MD PhD (Italy)
Leandro C Zacharias MD (Brazil)
International Scholar Award Recipients
The International Scholar Award honors international Academy members who have demonstrated their dedication to lifelong education in 
ophthalmology.
To qualify, international members must have already received the International Ophthalmologist Education Award. They need to earn 60  
Continuing Medical Education (CME) credits within two years of applying and half of the credits (30) must be from AAO sponsored CME  
activities. They must also successfully complete a timed, online self-assessment test.
Iordanis P Besmertis, MD (Greece)
Mario A Chica MD (El Salvador)
Luis H De La O MD (Mexico)
Matthias Christian Grieshaber MD (Switzerland)
Tsukasa Hanemoto MD (Japan)
Sergio Hernandez-Da Mota MD (Mexico)
Choun-ki Joo MD (Korea, Republic of)
Dieudonne Kaimbo Wa Kaimbo MD (Congo)
Antonios Kotzampasis MD (Greece)
Ramesh Murthy MBBS (India)
Erkan Mutlukan MD PhD (United Kingdom)
Georgios P Paleokastritis MD (Greece)
Prasan M Rao, MBBS, MS (United Arab Emirates)
Carlos A Restrepo Pelaez MD (Colombia)
Jan E Siegersma MD (Norway)
Lihteh Wu MD (Costa Rica)
International Awards
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Industry Support
The Academy would like to thank the following companies 
for their generous support of the 2013 Annual Meeting and 
Subspecialty Day.
Annual Meeting Gold Support Level
Genentech, Inc.
Regeneron Pharmaceuticals, Inc. 
Glaucoma Subspecialty Day
Merck & Co., Inc.
Retina Subspecialty Day
Genentech, Inc.
Regeneron Pharmaceuticals, Inc.
Cataract Monday
Alcon, Inc. 
Bausch + Lomb
2012 Corporate and Organizational Donors
The Academy and its Foundation greatly appreciate the support* 
provided by the following corporations and organizations.
$250,000 to $499,999
Alcon, Inc.  ............................................................................ $327,500
Genentech, Inc. ..................................................................... $287,500
Allergan, Inc. ......................................................................... $255,000
Knights Templar Eye Foundation, Inc. .................................. $250,000
$100,000 to $249,999
Abbott Medical Optics, Inc. ................................................. $112,500
$50,000 to $99,999
Merck & Co., Inc. .....................................................................$60,000
Regeneron Pharmaceuticals, Inc. ...........................................$60,000
Ophthalmic Mutual Insurance Company (OMIC) ....................$57,500
Retina Research Foundation ...................................................$50,478
Bausch + Lomb ........................................................................$50,000
$25,000 to $49,999
The Allergan Foundation .........................................................$25,000
Vistakon Johnson & Johnson Visioncare, Inc. .......................$25,000
$10,000 to $24,999
AcuFocus, Inc. ..........................................................................$17,500
Santen, Inc. ..............................................................................$12,500
CareCredit ................................................................................$10,000
Horncrest Foundation, Inc. ......................................................$10,000
Up to $10,000
Freeman .....................................................................................$7,500
Oculus Optikgeraete GMBH ......................................................$7,500
Sea Island Rotary Club ..............................................................$4,000
Roanoke Rotary Club .................................................................$2,500
Rotary Club of Morgantown ......................................................$2,000
*This list recognizes gifts and pledges made from January 1 –  
December 31, 2012, with cumulative support of $1,000 or greater.
The Visionary Society
The Academy greatly appreciates the generous support 
provided by the following individuals, corporations, and orga-
nizations. The Visionary Society recognizes donors who have 
contributed $1 million or more to the Academy Foundation.
Platinum Members
(One-time contributions of $1 million or more in two or more 
fiscal years)
Alcon, Inc.
Pfizer Ophthalmics
Gold Members
(One-time contributions of $1 million or more in any one fiscal 
year)
Alice R. McPherson, MD
Dr. Charles R. and Judith G. Munnerlyn
Stanley M. Truhlsen, MD
Allergan, Inc.
Members
(Cumulative giving of $1 million or more)
Knights Templar Eye Foundation, Inc.
Abbott Medical Optics, Inc.
Eli Lilly and Company
Genentech, Inc.
Merck & Co., Inc.
Visionary Society, Corporate and Organizational 
Donors

Scan this code to learn more and 
access the Mobile Meeting Guide.
MOBILE GUIDE
Starting Oct. 16, access the 2013 Mobile Meeting 
Guide for your mobile device at www.aao.org/mobile.
Use the Mobile Meeting Guide to:
• Search the scientific program
• Save courses and sessions to your Planner
• Sync your calendar created during 
registration with your Planner
• Use the Happening Now feature to view 
courses and sessions taking place at that 
moment
• Search for an exhibitor or product and 
save to your Planner
• View Alumni and Related Group events
• View Satellite Symposia events hosted by 
industry
• Follow the Academy on Twitter, Facebook 
and AAO Community
The Mobile Meeting Guide contains:
• Complete program content including 
abstracts, course handouts and 
evaluations
• Technology Pavilion and Learning Lounge 
schedules
• Meeting directory and information
• Hotel and shuttle bus information
• Exhibitor information 
• Convention center floor plans
• New Orleans restaurant information
Access the Mobile Meeting Guide on your 
smartphone or tablet. The easy to use 
wireless Web App is available for any web-
enabled mobile device. 
Visit the Tech Bar, Rest Stop Hall I1, Booth 5444 
for assistance or email support@apprisor.org.
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The Annual Meeting Program Committee is responsible for the Annual 
Meeting Scientific Program, including Breakfast With the Experts, Instruc-
tion Courses, Symposia, and Scientific Papers, Posters and Videos.
Each subcommittee has five reviewers who grade the instruction courses 
and paper/poster abstracts, and three subcommittee members who 
review the grades and select the courses and abstracts for presenta-
tion. The chair of the subcommittee represents the group on the Annual 
Meeting Program Committee. This peer-review selection process ensures 
the quality and integrity of Academy educational programs and allows 
broader input from Academy Members. 
The Annual Meeting Program Committee monitors the scientific program 
by reviewing evaluation data, the post-Annual Meeting survey and reports 
from independent course/symposium monitors.
Volunteer to be a reviewer by visiting Member Services on the Academy’s 
website and completing the online volunteer form. Volunteer to be a 
course/symposium monitor by e-mailing the Meetings Division at meet-
ings@aao.org.
Secretary for Annual Meeting
Jonathan B Rubenstein MD*
Associate Secretary for the Annual Meeting Program
Cynthia Mattox MD FACS*
Annual Meeting Program Committee
Keith D Carter MD FACS
Kathryn A Colby MD PhD*
William J Fishkind MD*
Jacqueline A Leavitt MD
Sonia H Yoo MD*
Carla J Siegfried MD*
John T Thompson MD*
Terri L Young MD*
Subcommittee for: Cataract
Chair
William J Fishkind MD*
Subcommittee Members
Steven Henry Dewey MD*
Mitchell P Weikert MD*
Subcommittee Reviewers
George Beiko MD*
Nicole R Fram MD*
Luther Fry MD*
Colleen P Halfpenny MD
Kevin M Miller MD*
Subcommittee for: Cornea, External Disease
Chair
Kathryn A Colby MD PhD*
Subcommittee Members
Bennie H Jeng MD
Shahzad I Mian MD*
Subcommittee Reviewers
Jessica B Ciralsky MD*
Darren G Gregory MD*
Christina R Prescott MD
Robert L Schultze MD*
Sonal S Tuli MBBS
Subcommittee for: Glaucoma
Chair
Carla J Siegfried MD*
Subcommittee Members
Malik Y Kahook MD*
Molly Walsh MD MPH*
Subcommittee Reviewers
Husam Ansari MD PhD*
Steven J Gedde MD*
Martha Motuz Leen MD*
Steven L Mansberger MD MPH*
Thasarat S Vajaranant MD
Subcommittee for: Neuro-Ophthalmology, Computers/
Information Technology, Ethics, Electronic Health 
Records, General Medical Care, Global Ophthalmology, 
Medical Education, Ophthalmic History and Vision 
Rehabilitation
Chair
Jacqueline A Leavitt MD
Subcommittee Members
Sophia Mihe Chung MD*
Michael S Lee MD*
Subcommittee Reviewers
Madhu R Agarwal MD
John B Kerrison MD
Howard D Pomeranz MD
Kenneth S Shindler MD PhD
Prem S Subramanian MD PhD*
Subcommittee for: Ocular Tumors, Pathology, and Orbit, 
Lacrimal Plastic Surgery
Chair
Keith D Carter MD FACS
Subcommittee Members
Don O Kikkawa MD*
Matthew W Wilson MD
Subcommittee Reviewers
Vikram D Durairaj MD*
Bobby S Korn MD PhD FACS*
Jill S Melicher Larson MD
Julian D Perry MD*
Erin M Shriver MD
Subcommittee for: Pediatric Ophthalmology, Strabismus
Chair
Terri L Young MD*
Subcommittee Members
Hilda Capo MD
Michael F Chiang MD*
Subcommittee Reviewers
Arlene V Drack MD*
Judith E Gurland MD
Anthony Pruett Johnson MD FACS
Natalie C Kerr MD
Martha P Schatz MD
Courses and Breakfasts
Selection Committees
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Subcommittee for: Refractive Surgery and Optics,  
Refraction, Contact Lenses
Chair
Sonia H Yoo MD*
Subcommittee Members
Karl G Stonecipher MD*
John Allan Vukich MD*
Subcommittee Reviewers
David A Goldman MD*
Daniel F Goodman MD FACS
Rajesh K Rajpal MD*
William B Trattler MD*
Elizabeth Yeu MD*
Subcommittee for: Retina, Vitreous and Intraocular 
Inflammation, Uveitis
Chair
John T Thompson MD*
Subcommittee Members
Janet Louise Davis MD*
Srinivas R Sadda MD*
Subcommittee Reviewers
Ron Afshari Adelman MD MPH
J Fernando Arevalo MD*
Alay S Banker MD
Sharon Fekrat MD
Christina J Flaxel MD
Mathew W MacCumber MD PhD*
Colin A McCannel MD*
Dante Pieramici MD*
Sharon D Solomon MD
Homayoun Tabandeh MD MS FRCP FRCOphth*
Special Projects Committee
The Special Projects Committee is responsible for developing Annual 
Meeting programs to complement those that are submitted by members 
or societies. 
Associate Secretary
Maria M Aaron MD
Committee Members
Ali R Djalilian MD
Jill S Melicher Larson MD
Scott C Oliver MD*
Douglas J Rhee MD*
Nicholas J Volpe MD*
Tammy L Yanovitch MD
Skills Transfer Advisory Committee
The Skills Transfer Advisory Committee is responsible for selecting the 
Skills Transfer courses and labs.
Associate Secretary
Thomas W Samuelson MD*
Committee Members
Iqbal K Ahmed MD*
Susan R Carter MD
Jack A Cohen MD FACS
William Barry Lee MD*
Kevin M Miller MD*
David D Verdier MD
AAOE Program
The AAOE Program Committee, with the AAOE Board of Directors, are 
responsible for selecting the AAOE Program and Practice Management 
Breakfast With the Experts roundtables.
Chair
Sandra Dixon Curd MBA COE COA OCS
Board Members
Nancy Baker
Tim D Couch
David A Durfee MD
Elise Levine MA CRC OCS
Rajiv R Rathod MD
Andrew Wang COE FACHE MHSA MBA
Robert E Wiggins MD MHA*
Annual Meeting Program Committee Members
Albert Castillo
Heather Hambrick Dunn COA
Traci Fritz COE OCS
Laura G Hobbs
Barbara Krzeszowski LPN COT
Julia Lee JD OCS
Rosa Montes OCS
Mark M Prussian
Academy Staff
Julia Fennell
Sangeeta Fernandes
Brandi Garrigus
Susan Oslar
Melanie Rafaty
Michael Rhea*
Debra Rosencrance
Elizabeth Washburn
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Friday, Nov. 15
Time Type No. $ Title Topic Room Page
7:30 AM - 3:00 PM SPE SPE01 DICOM Working Group 9 - Eye Care Marriot New 
Orleans, 
Tchoupitoulas
243
8:00 AM - 5:00 PM SUB $ Retina 2013: Let the Good Times Roll RET The Great Hall
8:00 AM - 5:11 PM SUB $ Refractive Surgery 2013: Perfecting Vision REF La Nouvelle 
Orleans AB
Saturday, Nov.16 (cont.)
Time Type No. $ Title Topic Room Page
8:00 AM - 5:00 PM SUB $ The Future Is Now! #Glaucoma2013 GLA New Orleans 
Theater AB
SUB $ Neuro-Ophthalmology 2013: What to Make of This? Recognizing 
the Distinctive Neuro-Ophthalmic Symptom, Sign, or Test
NEURO New Orleans 
Theater C
SUB $ Oculofacial Plastic Surgery 2013: Blues, Blephs, and Blowouts PLAST 243
8:00 AM - 5:20 PM SUB $ Pediatric Ophthalmology 2013: Preparing for the Next Generation PEDS Hall B, Session 
Room
8:00 AM - 5:30 PM SUB $ Cornea 2013: Through the Looking Glass − Where We Are, Where 
We’re Headed
COR La Nouvelle 
Orleans C
SUB $ Refractive Surgery 2013: Perfecting Vision REF La Nouvelle 
Orleans AB
8:00 AM - 5:40 PM SUB $ Retina 2013: Let the Good Times Roll RET The Great Hall
8:00 - 11:00 AM ICD $ Conquering ICD-10-CM for Ophthalmology PM-REMB 293 258
8:00 AM - 12:00 PM AAOESP SPE06 $ The Profitable Practice: Managing Your Billing Operations PM-BUS 286 272
8:30 AM - 12:30 PM AAOESP SPE03 $ Whiz Through Excel — Your Data Management Wizard PM-BUS 290 272
9:00 AM - 12:00 PM SPE SPE05 $ Selling and Purchasing on eBay, Craigslist, and other Mediums: 
How to Clean Your Office with Profit
COM 350 243
9:00 AM - 4:00 PM AAOESP SPE04 $ Keeping Your Practice Out of Legal Hot Water: An HR and 
Compliance Workshop
PM-BUS 283 272
9:30 AM - 5:00 PM TP Technology Pavilion Hall I1,  
Booth 5145
252
12:00 - 4:00 PM AAOESP SPE07 Bending the ASC Performance Curve PM-ASC 288 272
12:00 - 5:00 PM LL Learning Lounge Hall G,  
Booth 3647
246
12:30 - 3:30 PM CAMP $ Coding Camp PM-REMB 293 258
1:00 - 2:15 PM ACADCAFE SYM45 Academy Cafe: Maintenance of Certification Update NON 271 241
1:00 - 4:00 PM SPE SPE08 $ Use Blogging & Social Networking to Super Charge Your Website 
& Internet Marketing
COM 350 243
2:00 - 3:00 PM SPE SPE26 Q&A with FDA NON 224 243
2:00 - 3:30 PM SYM SYM01 What are the Opportunities and Resources for Working in 
Developing Countries?
GO 255 119
2:30 - 3:45 PM ACADCAFE SYM44 Academy Cafe: Cataract CAT 271 241
Topic Key
CAT - Cataract
COM - Computers, Information Technology
COR - Cornea, External Disease
EHR - Elecgtronic Health Records
ETH - Ethics
GEN - General Medical Care
GLA - Glaucoma
GO - Global Ophthalmology
HIST - Ophthalmic History
INTRA - Intraocular Inflammation, Uveitis
MEDED - Medical Education
NEURO - Neuro-Ophthalmology
NON - General Non-Medical
OPTIC - Optics, Refraction, Contact Lenses
PATH - Ocular Tumors, Pathology
PEDS - Pediatric Ophthalmology, Strabismus
PLAST - Orbit, Lacrimal, Plastic Surgery
REF - Refractive Surgery
RET - Retina, Vitreous
VIS - Vision Rehabilitation
PRACTICE MANAGEMENT/AAOE 
PM-ASC - Ambulatory Surgery Centers 
PM-BUS - Business Operations & Finance
PM-EHR - Electronic Health Records 
PM-HMR - Human Resources
PM-IMT - Information Technology
PM-MKT - Marketing & Business Development
PM-OPT - Optical Dispensing
PM-PROF - Professional Growth
PM-REMB - Coding & Reimbursement
PM-RISK - Compliance & Risk Management
Programs-by-Day
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Sunday, Nov. 17 (cont.)
Time Type No. $ Title Topic Room Page
6:30 AM - 7:30 PM SPE SPE25 $ 28th Annual Run for Vision NON 243
7:30 - 8:30 AM BWE $ Breakfast With the Experts Roundtables HALL C 50
8:00 - 10:30 AM SKILLS LAB100 $ Basic Oculoplastic Surgery PLAST 349 107
8:00 - 11:00 AM SYM SYM02 Introduction to Cornea and Lens-Based Refractive Surgery for Residents REF 228 119
8:30 - 10:00 AM OPSESS SYM53 Opening Session NON The Great 
Hall
117
9:00 - 11:00 AM SKILLS LAB101 $ Is It Time to Replace Gonioscopy by Anterior Segment Imaging in the 
Diagnosis and Management of Angle-Closure Glaucoma?
GLA 343 104
9:00 - 11:15 AM SKILLS LEC102/102 + Advanced Refractive Cataract Surgery and Anterior Segment 
Reconstruction
CAT 211 99
SKILLS LEC103/103 + Computerized Scanning Imaging of the Optic Nerve and Retinal Nerve 
Fiber Layer
GLA 225 104
SKILLS LEC104/104 + Surgery for Severe Corneal and Ocular Surface Disease COR 214 102
SKILLS LEC105/105 + Glaucoma Laser Therapy: Innovations and Advice From the Experts GLA R03 104
SKILLS LEC106/106 + Management of Vitreous for the Anterior Segment Surgeon CAT R04 99
9:30 AM - 12:00 PM SKILLS LAB107 $ Soft Contact Lens Fitting for the Practicing Ophthalmologist OPTIC 350 107
9:30 AM - 5:00 PM TP Technology Pavillion Hall I1, Booth 
5145
252
10:00 - 10:30 AM SPE SPE11 Annual Business Meeting NON The Great 
Hall
243
10:00 AM - 12:00 PM AAOESP SPE09 AAOE General Session: Creating the Ultimate Patient Experience and 
Patients for Life!
PM-BUS 291 272
10:00 AM - 2:00 PM SPE SPE10 + 2013 Young Ophthalmologist Program — It’s YO World: Jumpstart Your 
Career
NON 252 243
10:15 - 11:15 AM IC 161 + Visual Electrophysiology Testing: Principles and Clinical Applications RET 340 91
OP OP02 Intraocular Inflamation, Uveitis Original Paper Session INTRA 255 146
10:15 AM - 12:30 PM SKILLS LEC108/108 + The Surgical Correction of Astigmatism REF 355 111
SKILLS LEC109/109 + Phakic IOLs REF R02 112
SKILLS LEC110/110 + Macular OCT: Mastering the Basics RET R08 113
SKILLS LEC111/111 + Cosmetic Botulinum Toxin and Facial Fillers: An Introductory Course PLAST 338 107
SKILLS LEC112/112 + Fundamental Facelifting Techniques PLAST 215 108
IC 150 + Periocular Tumors and Techniques of Eyelid Reconstruction PLAST 335 82
IC 151 + The Boston Keratoprosthesis: Case-Based Presentations Highlighting 
the Essentials for Beginning and Experienced Surgeons
COR 209 64
IC 152 + Code Red: Mastering Phaco Nightmares and Worst-Case Scenarios — 
A Video-Based Course
CAT 218 57
IC 153 + Facial Fracture Repair: Better Outcomes and Improved Technique PLAST 223 84
IC 154 + Conquering Capsule Complications: A Video Primer CAT R06 65
IC 155 + Endothelial Keratoplasty (DSEK/DSAEK/DMEK/DMAEK): Current 
Strategies to Improve Results and Avoid Complications
COR R05 64
IC 156 + Management of Pediatric Cataracts PEDS 222 86
IC 157 + Review of Clinical Optics OPTIC 217 81
IC 158 + Managing Angle-Closure Glaucoma With Crystalline Lens Removal and 
Adjunctive Procedures
GLA 224 72
IC 159 + Retinaws: A Comprehensive Video-Oriented Course on Challenging 
Retinal Cases in the Operating Room
RET 221 90
IC 160 + Mystery Retina 2013: Interactive Discussion of Challenging Cases RET 346 90
IC 162 + Fundamentals of Anterior Segment Reconstruction CAT 210 57
IC 163 + Extreme Corneal Ectasia: Battle of the Bulge COR R01 65
IC 164 + Stereo Anatomy of the Orbit, Eyelid, and Lacrimal System: A Surgeon’s 
Perspective
PLAST 333 82
IC 165 + Basic Browlift: Principles and Techniques PLAST 220 82
IC 166 + ROP Screening and Treatment: What You Wanted to Know but Were 
Afraid to Ask (Intermediate/Advanced)
PEDS 208 86
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Sunday, Nov. 17 (cont.)
Time Type No. $ Title Topic Room Page
10:30 - 11:45 AM ACADCAFE SYM46 Academy Cafe: Oculoplastics PLAST 271 241
10:30 AM - 12:00 PM SYM SYM03 Innovation in Ophthalmology: From Theory to Therapy MEDED New Orleans 
Theater C
120
SYM SYM04 Detection of Glaucomatous Progression GLA La Nouvelle 
Orleans C
120
SYM SYM05 Evidence Base for Vision Rehabilitation VIS 342 120
SPOTLIT SPO3 Spotlight on Ophthalmic Office Emergencies: Things You Don’t Want 
to Miss
GEN La Nouvelle 
Orleans AB
119
10:30 AM - 12:15 PM OP OP01 Cataract Original Paper Session CAT 243 138
10:30 AM- 5:00 PM LL Learning Lounge Hall G,
Booth 3647
246
10:45 AM - 12:00 PM SYM SYM06 The Great Debate: Retina RET The Great 
Hall
120
11:30 AM - 12:00 PM SYM SYM54 Michael F Marmor MD Lecture in Ophthalmology and the Arts NON 255 120
11:30 AM - 12:30 PM IC 167 + Breakthrough to Social Media COM 340 64
IC 168 + Tips for Cosmetic Eyelid Surgery in Asian Patients PLAST 211 82
IC 169 + Cell Biology, Genetics, and Outflow Biochemistry of Glaucoma in 2013 
and Beyond
GLA 214 73
IC 170 + Normal-Tension Glaucoma: Evaluation and Treatment GLA 225 73
IC 171 + Femto Laser:Diagnosis and Management of Intraoperative and 
Postoperative Complications With the Use of a Femtosecond Laser for 
LASIK Surgery
REF R03 88
11:30 AM - 1:00 PM SKILLS LAB106A $ Management of Vitreous for the Anterior Segment Surgeon
Prerequisite: LEC106
CAT 356 99
11:30 AM - 2:00 PM SKILLS LAB113 $ Enucleation and Evisceration: Theory and Practice PLAST 349 108
11:30 AM - 5:00 PM SPE SPE24 Fall Council Meeting GEN Sheraton, 
Grand 
Ballroom C
243
12:00 - 2:00 PM SKILLS LAB103A $ Computerized Scanning Imaging of the Optic Nerve and Retinal Nerve 
Fiber Layer Prerequisite: LEC103
GLA 343 104
12:15 - 1:45 PM SYM SYM07 Extreme Vision: Science Fiction or Truth HIST 255 121
SYM SYM08 Cataract Surgery: The Cutting Edge CAT The Great 
Hall
121
SPE SPE12 2014 Medicare Update GEN New Orleans 
Theater C
244
12:30 - 1:30 PM PT Scientific Poster Tours Meeting Pt.,
Hall C
156
12:30 - 2:30 PM SKILLS LAB105A $ Glaucoma Laser Therapy: Innovations and Advice From the Experts 
Prerequisite: LEC105
GLA 354 104
12:45 - 1:45 PM SYM SYM57 Big Data Drives Better Outcomes: The Power and Benefits of the IRIS™ 
Registry
EHR La Nouvelle 
Orleans C
122
SPE SPE13 Ergonomics/Musculoskeletal Disorders in Ophthalmologists GEN 342 244
SPE SPE14 The Resident Hub User Group Session GEN 223 244
SPE SPE15 American Board of Ophthalmology: Panel Presentation and Q&A with 
Board of Directors
NON 222 244
SYM SYM25 Seeing Patients Is What I Want to Do: Adjusting to the Challenge of 
Extending My Career in Ophthalmology
NON 243 122
1:00 - 2:15 PM ACADCAFE SYM47 Academy Cafe: Cornea, External Disease COR 271 241
1:00 - 2:30 PM SKILLS LAB108A $ The Surgical Correction of Astigmatism Prerequisite: LEC108 REF 345 112
1:30 - 1:45 PM SPE SPE16 OMIC Annual Members Meeting NON 224 244
1:30 - 3:00 PM SKILLS LAB109A $ Phakic IOLs Prerequisite: LEC109 REF 356 112
SKILLS LAB111A $ Cosmetic Botulinum Toxin and Facial Fillers: An Introductory Course 
Prerequisite: LEC111
PLAST 352 107
1:30 - 3:30 PM SKILLS LAB114 $ The iPhone for Ophthalmologists (Basic) COM 350 101
2:00 - 3:00 PM SKILLS LEC115/115 + Fat Grafting and Volume Restoration PLAST 335 108
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SKILLS LEC117/117 + New Techniques for Strabismus Surgery PEDS 217 111
IC 172 + Glaucoma Filtration Device Mini-shunt: Friend or Foe? GLA 346 73
AAOEIC 173 + Top 10 Topics Ophthalmology Practices Ask Us About PM-BUS 286 259
IC 177 + Continuous 24-Hour IOP Monitoring for Glaucoma GLA 355 73
IC 179 + Cell-Based Therapy for Ocular Surface Reconstruction COR 340 65
IC 181 + Evolution’s Witness: How Eyes Evolved HIST 208 81
AAOEIC 182 + Compounding Pharmacies: Legal and Regulatory Issues PM-RISK 291 265
IC 183 + IOL Power Calculation: Problems With LASIK Eyes CAT 211 57
AAOEIC 188 + Website 101: Three Steps to Creating Your First Website PM-MKT 295 268
AAOEIC 193 + Ophthalmic ASC Administration, Operations and Procedures PM-OPT 290 259
AAOEIC 194 + Internal Financial Controls for the Small Practice PM-BUS 296 259
IC 197 + An Approach to Selecting and Implementing Electronic Health Records 
in Your Practice
EHR 215 71
IC 199 + Retinal OCT Interpretation 101 RET R08 91
AAOEIC 200 + Quit Writing Policies: Create a Culture Using Core Values PM-HRM 294 267
IC 201 + The Management of Neovascular Glaucoma in 2013 GLA 214 73
AAOEIC 204 + Ophthalmology for Non-Clinical Personnel PM-PROF 293 270
SYM SYM56 Best of NANOS 2013: Featuring Best Papers from the North American 
Neuro-Ophthalmology Society
NEURO 255 122
2:00 - 3:15 PM SYM SYM09 The Great Debate: Glaucoma GLA The Great 
Hall
122
2:00 - 3:30 PM SYM SYM10 Innovations in Pediatric Eye Surgery PEDS La Nouvelle 
Orleans AB
123
SYM SYM11 Scientific Advancements in Ophthalmic Plastics: Implications for the 
Practicing Ophthalmologist
PLAST La Nouvelle 
Orleans C
123
SYM SYM12 Keratoconus: Past, Present, and Future OPTIC 243 124
2:00 - 4:00 PM SPE SPE17 The Bruce E Spivey MD Lecture in Risk Management & Patient Safety 
and OMIC Forum
NON New Orleans 
Theater C
244
2:00 - 4:15 PM SKILLS LEC116/116 + Blepharoplasty PLAST 225 108
IC 174 + Current Topics in Cornea/External Disease: Highlights of the Basic and 
Clinical Science Course 8
COR 223 65
IC 175 + Diagnosis and Treatment of Polypoidal Choroidal Vasculopathy RET R03 91
IC 176 + Low Vision Rehabilitation for Ophthalmologists VIS R01 96
IC 178 + A Step-by-Step Primer to Starting LASIK in 2013 REF 209 88
IC 184 + Glaucoma Postop Care in the Office: A Video Compendium of 
Techniques—When and How to Intervene
GLA R02 73
IC 185 + Cataract Surgery in the Setting of Ocular Comorbidities and High-Risk 
Features for Intraoperative and Postoperative Complications
CAT 218 57
IC 186 + Update on Treatments for Diabetic Retinopathy: Clinically Relevant 
Results from the Diabetic Retinopathy Clinical Research Network
RET R05 91
IC 187 + Danger Zone: Refractive Surgery Nightmares and Worst-Case 
Scenarios: A Video-Based Course
REF 222 89
IC 189 + Medical and Surgical Therapy and Diagnosis of Uveitis INTRA 220 78
IC 190 + Understanding Nystagmus: A Practical Approach for the Clinician NEURO R04 79
IC 191 + Diagnostic and Therapeutic Dilemmas in Neuro-Ophthalmology NEURO 333 79
IC 192 + Spectral Domain OCT Interpretation for the General Ophthalmologist RET 228 91
AAOEIC 195 + Doctors and Administrators: Working Together to Make Sound Financial 
Decisions
PM-BUS 288 259
IC 196 + Retinal and Choroidal Manifestations of Selected Systemic Diseases 
2013
RET R06 91
IC 198 + Ocular Surface Disease Management: Moving From Adequate to Expert COR 338 65
AAOEIC 202 + A Practical Guide to Understanding and Negotiating Your First 
Employment Agreement
PM-PROF 297 270
2:00 - 4:15 PM IC 203 + Help! A Corneal Ulcer Just Walked In! What Do I Do Next? COR 210 65
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AAOEIC 307 + When to Use E/M and When to Use Eye Codes PM-REMB 283 263
2:30 - 3:45 PM ACADCAFE SYM48 Academy Cafe: Retina RET 271 241
3:00 - 4:30 PM SYM SYM55 2013 Modern Technologies and Techniques for Young Ophthalmologists 
to Know
GEN 252 124
3:00 - 5:00 PM SKILLS LAB110A $ Macular OCT: Mastering the Basics  Prerequisite: LEC110 RET 343 113
3:00 - 5:30 PM SKILLS LAB118 $ Oculoplastic Surgery: Anatomic Foundations, Surgical Techniques, and 
Enhanced Results
PLAST 349 109
3:15 - 4:15 PM AAOEIC 205 + A Physician’s Guide to Avoiding Embezzlement PM-RISK 295 265
IC 207 + Allergic Eye Disease: An Enigma for Physicians COR 215 66
IC 208 + Simplifying Treatment of Diabetic Retinopathy for the Comprehensive 
Ophthalmologist: What You Really Need to Know in 2013
RET 217 92
AAOEIC 209 + Forecasting Staffing Needs: A Volume-Based Model PM-HRM 296 267
AAOEIC 210 + Meaningful Use Stage 2 and How to Survive a Meaningful Use Audit PM-EHR 291 266
AAOEIC 211 + How to Monitor and Maintain an Efficient Practice PM-BUS 294 259
AAOEIC 212 + Strategic Planning by Fact PM-BUS 293 259
AAOEIC 213 + How to Become a Better Leader PM-PROF 290 270
3:15 - 5:30 PM SKILLS LEC119/119 + Trabeculotomy by Internal Approach Surgery for Adult Open-Angle 
Glaucoma
GLA 340 105
SKILLS LEC120/120 + Phacoemulsification and Advanced Techniques: The Core Curriculum CAT 211 99
SKILLS LEC121/121 + Endothelial Keratoplasty Techniques COR 342 102
SKILLS LEC122/122 + Endothelial Keratoplasty Surgery: Comprehensive Overview and 
Surgical Pearls
COR 208 103
SKILLS LEC123/123 + Manual Extracapsular Cataract Extraction Surgery: Indications and 
Techniques
CAT 346 100
SKILLS LEC124/124 + Glaucoma Filtration Surgery GLA 335 105
SKILLS LEC125/125 + Schlemm Canal Surgery GLA 214 105
IC 206 + Tackling Weak Zonules and Using Capsular Tension Devices CAT R08 58
3:30 - 5:10 PM OP OP03 Cataract Original Paper Session CAT 255 139
3:30 - 5:30 PM SKILLS LAB102A $ Advanced Refractive Cataract Surgery and Anterior Segment 
Reconstruction Prerequisite: LEC102
CAT 356 99
SKILLS LAB104A $ Surgery for Severe Corneal and Ocular Surface Disease
Prerequisite: LEC104
COR 345 102
SKILLS LAB117A $ New Techniques for Strabismus Surgery Prerequisite: LEC117 PEDS 354 111
3:45 - 5:00 PM SYM SYM14 Best of the Anterior Segment Specialty Meetings 2013 GEN La Nouvelle 
Orleans C
125
3:45 - 5:15 PM SPOTLIT SPO1 Spotlight on OCT GLA The Great 
Hall
125
SYM SYM15 A Sticky Problem: Evaluation and Management of Chronic Socket 
Discharge
PLAST 243 125
SYM SYM16 Mythbusters: Examining the Orthoptic and Surgical Management of the 
Most Puzzling Childhood Syndromes
PEDS La Nouvelle 
Orleans AB
126
4:00 - 5:30 PM SKILLS LAB126 $ Workshop in Techniques of Lacrimal Intubation PLAST 352 109
4:15 - 5:15 PM SYM SYM13 International Opportunities for Young Ophthalmologists GO New Orleans 
Theater C
126
4:30 - 5:30 PM IC 214 + Anterior Segment Imaging: A Practical Guide for Ophthalmologists COR 333 66
AAOEIC 215 + Top 10 Success Tips for Your EHR Implementation PM-EHR 288 266
IC 216 + Approach to Genetic Eye Diseases for the Comprehensive 
Ophthalmologist
PEDS R03 86
IC 217 + Pearls for Evaluating Corneal Topography in Patients Scheduled for 
Cataract Surgery
CAT 218 58
IC 218 + How to Successfully Accomplish Endothelial Keratoplasty in the 
Presence of Significant Ocular Comorbidities
COR 221 66
4:30 - 5:30 PM IC 219 + Canal, Trab, or Tube: What Should I Do? GLA R04 74
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IC 220 + The Institutional Review Board Submission Process: Why Should I Care, 
and What If I Don’t?
ETH 217 71
IC 221 + Canal-Based Glaucoma Surgery: Canaloplasty vs. Microstent 
Implantation: Everything You Want to Know
GLA 223 74
IC 222 + Diagnosis, Optic Neuropathy: Now What? NEURO 224 79
IC 223 + Electronic Health Record and Image Data Management 
Implementation: Rapid-Fire Presentations and Panel Discussion
EHR 222 71
IC 224 + Visual Fields in Neuro-Ophthalmology NEURO R02 79
AAOEIC 225 + Financial Analysis and Reporting PM-BUS 283 260
IC 226 + Diagnosis And Management of Corneal Perforation COR R05 66
IC 227 + Contact Lens in Ophthalmology Practice OPTIC 209 81
AAOEIC 228 + Impact of Electronic Health Records on Malpractice Claims Against 
Ophthalmologists
PM-EHR 295 266
IC 229 + Artificial Iris Implantation CAT 210 58
AAOEIC 230 + Financial Benchmarking for the Retina Practice PM-BUS 296 260
AAOEIC 231 + Transition From Training to Practice PM-PROF 293 270
AAOEIC 232 + Optical Dispensing: Is It Financially Feasible for Your Practice? PM-OPT 290 269
AAOEIC 233 + The First Few Years of Practice: Some Key Concepts for Young 
Ophthalmologists
PM-PROF 297 270
IC 234 + Where Neuro-Ophthalmology and Oculoplastics Collide: Challenging 
Cases and Topics
PLAST 338 83
IC 235 + Toric IOL Implantation: How to Improve Results and Manage 
Complications
CAT 225 59
AAOEIC 236 + Ophthalmology Practice Buy-In and Pay-Out Arrangements PM-BUS 294 260
IC 237 + Diplopia After Cataract and Refractive Surgery PEDS 215 86
AAOEIC 238 + ICD-10-CM: Simplifying the Complex PM-REMB 291 263
IC 239 + How to Get the Most Out of Your Pathologist PATH R01 80
IC 240 + Anterior Segment Surgery in 3-D CAT R06 59
IC 241 + Intraoperative Floppy Iris Syndrome: Pearls for Management and 
Prevention
CAT 228 59
Monday, Nov. 18 (cont.)
Time Type No. $ Title Topic Room Page
7:30 - 8:30 AM BWE $ Breakfast With the Experts Rountables Hall C 50
SKILLS LAB119A $ Trabeculotomy by Internal Approach Surgery for Adult Open-Angle 
Glaucoma Prerequisite: LEC119
GLA 354 105
8:00 - 9:30 AM SKILLS LAB120A $ Phacoemulsification and Advanced Techniques: The Core Curriculum
Prerequisite: LEC120
CAT 356 100
8:00 - 10:00 AM SKILLS LAB115A $ Fat Grafting and Volume Restoration Prerequisite: LEC115 PLAST 352 108
SKILLS LAB121A $ Endothelial Keratoplasty Techniques Prerequisite: LEC121 COR 345 103
SKILLS LAB127 $ Neuroimaging in Ophthalmology NEURO 343 107
8:00 - 11:00 AM SKILLS LAB128 $ Orbitofacial Fracture Repair: Plating Workshop PLAST 349 109
8:15 - 10:15 AM SYM SYM20 Advances in Keratoplasty: Where We Are in 2013 COR La Nouvelle 
Orleans C
126
8:15 AM - 12:15 PM SPOTLIT SPO2 Spotlight on Cataract Complications: M&M Rounds—Learning From My 
Mistakes
CAT The Great 
Hall
120
8:30 - 9:45 AM ACADCAFE SYM49 Academy Cafe: Glaucoma GLA 271 241
8:30 - 10:00 AM SYM SYM17 Quality Measures in Ophthalmology: The Future Landscape GEN New Orleans 
Theater C
127
SYM SYM18 Changing Paradigms in the Management of Venous Occlusive Disease RET La Nouvelle 
Orleans AB
128
SYM SYM19 Fitness for Duty: What’s Age Have to Do With It? GEN 243 128
OP OP04 Oculoplastics Original Paper Session PLAST 255 147
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8:30 - 11:00 AM SYM SYM21 2013 Global Forum: A Kaleidoscope of Volunteering in Developing 
Countries — Global Ophthalmology, Making a Difference
GO 252 128
9:00 - 10:00 AM SKILLS LAB119B $ Trabeculotomy by Internal Approach Surgery for Adult Open-Angle 
Glaucoma Prerequisite: LEC119
GLA 354 105
AAOEIC 303 + Creating a Clinical Trial Unit PM-BUS 297 260
IC 305 + Phacoemulsification in Eyes With Complex Corneal Situations CAT 355 59
IC 309 + Implanting the Add-On Mirror Telescopic Intraocular Implant in AMD 
Eyes: Patient Selection, Surgical Technique and Clinical Results
CAT 225 59
IC 310 + Evaluation and Treatment of Lower Lid Ectropion, Entropion, and 
Retraction
PLAST 210 83
IC 313 + Evaluation and Management of Orbital Cellulitis PLAST 340 83
AAOEIC 315 + Managing Up! PM-PROF 293 270
AAOEIC 317 + Advanced Ophthalmology Billing PM-BUS 296 260
IC 320 + Pediatric Corneal Infections: A Systematic Approach to Diagnosis and 
Management
COR 221 67
AAOEIC 324 + Securing Access in the Age of ACOs PM-BUS 286 260
IC 325 + Should My Visually Impaired Patient Be Driving? VIS 209 96
AAOEIC 327 + Key Performance Indicators: Numbers Can Lie PM-BUS 283 260
AAOEIC 328 + How to Create an Effective Dispensary Website Tab That Gets Results PM-OPT 290 269
AAOEIC 329 + Budgeting for the Ophthalmology Practice PM-BUS 294 261
IC 330 + From Cadaver Eyes to Virtual Reality: Surgical Simulators 101 CAT 335 60
AAOEIC 331 + Independent Contractors vs. Employees: The Risks of Misclassification PM-RISK 295 265
9:00 - 11:00 AM SKILLS LAB129 $ The iPhone for Ophthalmologists (Advanced) COM 350 102
9:00 - 11:15 AM AAOEIC 180 + Audits: It’s Not a Matter of If, but When PM-REMB 288 263
IC 300 + Difficult Strabismus Problems: Diagnosis and Management 2013 PEDS 223 87
IC 301 + Advanced IOL Power Calculations for the Cataract and Refractive 
Surgeon
CAT R06 59
IC 302 + Electronic Health Records: Compliance and Medicolegal Issues EHR 333 71
IC 304 + Thyroid Eye Disease PLAST 211 59
IC 306 + How to Interpret Fundus Fluorescein Angiography and Autofluorescence RET 228 92
IC 308 + Challenging Cases in Neovascular AMD RET R04 92
IC 311 + Management of High-Risk ROP in the 21st Century: Thermal-Destructive 
vs. Pharmacologic Treatment
RET 217 92
IC 312 + Femtosecond Laser for Cornea Surgery: The Actual Options REF R02 89
IC 314 + Recent Developments in the Diagnosis and Management of 
Conjunctival Tumors
COR 215 66
IC 316 + Vitreoretinal Surgery: Video Presentation and Discussion RET R03 92
IC 318 + How to Evaluate a Patient With Uveitis INTRA R08 78
IC 319 + Improving Success in Filtration Surgery: Intraoperative Surgical 
Techniques and Postoperative Management of the Failing Filter
GLA 338 74
IC 321 + The Developmental Glaucomas: Diagnosis and Management in 2013 PEDS R05 87
IC 322 + Pterygium: The Outcome Measure Is Now Cosmesis, Not Recurrence COR 214 67
IC 323 + Understanding Ophthalmic Viscosurgical Devices to Optimize Their Use 
in Cataract Surgery and Complications
CAT 224 59
IC 326 + How to Successfully Accomplish Endothelial Keratoplasty in the 
Presence of Significant Ocular Comorbidities
COR 346 67
9:00 AM - 5:00 PM LL Learning Lounge Hall G, 
Booth 3647
246
9:30 AM - 5:00 PM TP Technology Pavilion Hall I1, 
Booth 5145
252
10:15 - 11:15 AM AAOEIC 334 + Success Traits of Market Leaders PM-MKT 290 269
AAOEIC 340 + Social Media and Social Networking in the Physician Office PM-RISK 293 265
AAOEIC 341 + Managing Difficult Employees and Reducing Conflict in the Practice PM-HRM 295 267
AAOEIC 342 + Strategic Planning for Ophthalmology Practices PM-BUS 294 261
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10:15 - 11:15 AM AAOEIC 343 + Step 1 to Running on Time: Scheduling PM-BUS 291 261
IC 344 + Your First 20 Dates With the Internal Limiting Membrane: Tips on 
Macular Surgery Techniques for Beginners
RET 210 93
AAOEIC 345 + Going Lean: Tools for Efficiency and Effectiveness in the Ophthalmology 
Practice
PM-BUS 283 261
10:15 - 11:30 AM SYM SYM22 Best of the Posterior Segment Specialty Meetings 2013 RET La Nouvelle 
Orleans AB
129
10:15 - 11:45 AM SYM SYM23 Teaching and Learning in Ophthalmology—”Give Me Something to 
Make Me a Better Teacher!” Faculty Development Modules
MEDED 243 129
SYM SYM24 The Affordable Care Act and Health Care Reform in 2013: Pearls and 
Potential Perils
GEN New Orleans 
Theater C
130
10:15 AM - 12:00 PM OP OP05 Refractive Surgery Original Paper Session REF 255 150
10:15 AM - 12:30 PM SKILLS LEC130/130 + Astigmatism in the Cataract Patient CAT 355 101
SKILLS LEC131/131 + Anterior Lamellar Keratoplasty: Principles and Practice COR 342 103
SKILLS LEC132/132 + Computerized Perimetry Lecture: Visual Field Testing and Interpretation, 
Emphasizing Glaucoma
GLA 335 106
AAOEIC 332 + Website Design and Marketing Fundamentals PM-MKT 297 268
IC 333 + Nightmares in Pediatric Cataract Surgery PEDS 221 87
IC 335 + Extreme Cornea: Diagnostic and Management Dilemmas in Your 
Practice
COR 218 67
IC 336 + Update Your Anterior Chamber Angle Skills: How to Best Examine, 
Grade, and Treat
GLA 220 75
AAOEIC 337 + Payer Contracting and Payer Relations: What You Need to Know to 
Improve Your Rates and Contract Language
PM-HRM 286 267
AAOEIC 338 + Income Division for Group Practices: Structuring Appropriate Physician 
Compensation Arrangements
PM-BUS 296 261
IC 339 + Diabetic Macular Edema: 2013 Update on Management RET 225 92
10:30 - 11:45 AM ACADCAFE SYM50 Academy Cafe: Uveitis 271 241
10:30 AM - 12:00 PM SKILLS LAB123A $ Manual Extracapsular Cataract Extraction Surgery: Indications and 
Techniques Prerequisite: LEC123
CAT 356 100
10:45 - 11:45 AM SYM SYM52 Blast Eye Injuries: Lessons Learned from Boston, West, Texas, Iraq, and 
Afghanistan
GEN La Nouvelle 
Orleans C
130
11:00 AM - 12:30 PM SKILLS LAB124A $ Glaucoma Filtration Surgery Prerequisite: LEC124 GLA 354 105
11:00 AM - 1:00 PM SKILLS LAB103B $ Computerized Scanning Imaging of the Optic Nerve and Retinal Nerve 
Fiber Layer Prerequisite: LEC103
GLA 343 104
SKILLS LAB112A $ Fundamental Facelifting Techniques Prerequisite: LEC112 PLAST 352 108
SKILLS LAB122A $ Endothelial Keratoplasty Surgery: Comprehensive Overview and 
Surgical Pearls Prerequisite: LEC122
COR 345 103
11:30 AM - 12:30 PM AAOEIC 346 + Tracking Your Dollars: Financial Policies to Avoid Fraud and 
Embezzlement
PM-BUS 293 261
AAOEIC 347 + Electronic Health Records Implementation: Overcoming Resistance to 
Change
PM-EHR 291 259
IC 348 + What’s Your Next Step? Case Studies in Glaucoma Management GLA 338 75
IC 349 + Advanced Corneal Topographic Analysis REF 228 89
IC 350 + Top 10 Pitfalls, Problem Solving, and Interpretive Strategy for 
Automated Threshold Perimetry
GLA 222 75
IC 351 + Inflammatory Orbital Disorders and Their Differential Diagnoses PLAST 215 79
AAOEIC 352 + Hanging a Shingle in the 21st Century: Is a Start-up Solo Practice 
Possible in 2013?
PM-PROF 294 271
IC 353 + The Art and Science of Glaucoma Drainage Devices: How to Optimize 
Your Surgical Results
GLA R01 75
AAOEIC 354 + How To Diagnose a Sick Dispensary PM-OPT 290 269
IC 355 + Argon Laser Peripheral Iridoplasty: All You Need to Know GLA 214 75
IC 356 + Keys to Successful Publication in the Good Ophthalmology Journal MEDED R02 79
IC 357 + Diabetic Vitrectomy RET R08 93
CANCELED
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11:30 AM - 12:30 PM IC 358 + Controversies and Advances in Pediatric Oculoplastic Surgery PLAST 333 84
IC 359 + Case-Based Approach to Isolated Eye Pain NEURO R04 80
IC 360 + Cataract Surgery and Uveitis: Controlling Inflammation, Difficult Pupils, 
and Distorted Anatomy
CAT R06 60
AAOEIC 361 + Making the Most With Modifiers PM-REMB 288 264
IC 362 + Medical Therapy for Open-Angle Glaucoma: A Complete Review of the 
Pharmacodynamics, Pharmacokinetics, and Toxicity of All Potentially 
Useful Drugs
GLA 346 75
AAOEIC 363 + Smile ... Even If It Kills You: Training for Excellent Customer Service PM-HRM 295 267
AAOEIC 364 + American Academy of Ophthalmic Executives Book Club: Professional 
Growth and Development
PM-PROF 283 271
IC 365 + The Vertical Diplopia Dilemma, Made Simple NEURO 211 80
IC 366 + Complications Following Glaucoma Filtering Surgery: Face Them Boldly, 
Manage Them Efficiently
GLA R05 75
12:15 - 1:45 PM SYM SYM26 Ergonomics: Preventing Work-Related Injury in the Ophthalmologist NON 255 130
12:30 -1:30 PM PT Scientific Poster Tours Meeting Pt., 
Hall C
156
12:30 - 1:45 PM SPE SPE19 Welcome to the Real World: Reality 101 for Residents and Fellows GEN 252 244
12:45 - 1:45 PM SPE SPE21 VA and DOD: Leading the Way in Simulation in Eye Care GEN 217 244
SYM SYM27 Stage 2 of Meaningful Use: What You Need to Do to Qualify for 
Payment
EHR New Orleans 
Theater C
131
SYM SYM28 Management of Corneal Edema, Opacification, and Ectasia in the 21st 
Century: Diagnostic and Treatment Strategies From the New Preferred 
Practice Pattern® Guideline
COR 215 131
SYM SYM29 Why Take the Risk? How to Create an Effective Risk Management 
Strategy With Patient Education and Informed Consent Documents
NON 224 131
1:00 - 2:30 PM SKILLS LAB106B $ Management of Vitreous for the Anterior Segment Surgeon
Prerequisite: LEC106
CAT 356 99
SKILLS LAB133 $ Enhancing Your Presentation Using Keynote by Apple, Inc. for the 
Intermediate User
COM 350 102
1:00 - 3:00 PM SKILLS LAB134 $ Workshop in Flap Techniques in Oculoplastic Surgery PLAST 349 109
1:30 - 3:00 PM SKILLS LAB130A $ Astigmatism in the Cataract Patient Prerequisite: LEC130 CAT 345 101
1:30 - 3:30 PM SKILLS LAB125A $ Schlemm Canal Surgery Prerequisite: LEC125 GLA 354 106
2:00 - 3:00 PM SKILLS LEC135/135 + Endoscopic Transnasal Lacrimal Surgery: Principles and Practice PLAST 340 109
SPE SPE20 Ethics and Risk Management Issues Facing Ophthalmology, Featuring 
Robin Cook
GEN New Orleans 
Theater C
244
IC 367 + Failed Graft: Never Say Die! COR 225 67
AAOEIC 370 + Coding for Ophthalmic Testing Services PM-REMB 294 264
IC 371 + Cataract Surgery in Patients With Retinal Disease CAT 210 60
IC 375 + Advancing Technology and Technique With Femtosecond Lasers in 
Refractive Cataract Surgery: A Video Review
CAT 209 60
IC 376 + Anterior Segment OCT REF 338 89
IC 377 + Strabismus Surgery: A Comprehensive Approach PEDS 222 87
AAOEIC 378 + Incorporating the Four Agreements Into Your Practice PM-PROF 283 271
IC 379 + Achieving Proper Centration and Alignment for Vision Correction in 
Keratorefractive and Intraocular Surgery
CAT 220 60
AAOEIC 380 + Managing Generation Y Employees PM-HRM 286 267
IC 381 + State-of-the-Art Use of the Femtosecond Laser for Keratoplasty, 
Cataract Surgery, and Astigmatic Incisions
REF R08 89
AAOEIC 383 + Yes, It Can be Done ... Creating a Workable Master Schedule PM-BUS 296 261
AAOEIC 384 + The Art of Benchmarking PM-BUS 295 261
AAOEIC 385 + How to Run a Lean, Mean Refractive Practice in Today’s Tough 
Economic Times
PM-BUS 297 262
IC 388 + Cliffhanger: Vitrectomy by the Anterior Segment Surgeon for the Broken 
Posterior Capsule, the Sinking Nucleus, and the Dangling IOL
CAT R03 61
CANCELED
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2:00 - 3:00 PM AAOEIC 391 + Capital Budgeting Basics: Can I Afford This New Piece of Equipment? PM-BUS 293 262
2:00 - 3:30 PM SYM SYM30 Advances in Glaucoma: Medical and Surgical Therapy GLA La Nouvelle 
Orleans C
131
SYM SYM31 New Drug or New Delivery System? The Way Forward in Combating 
Infectious and Inflammatory Diseases
INTRA 243 132
SYM SYM32 Advanced Retinal Imaging and Its Impact on Therapeutic Strategies RET La Nouvelle 
Orleans AB
132
OP OP07 Pediatric Ophthalmology, Strabismus Original Paper Session PEDS 255 149
2:00 - 4:00 PM SKILLS LAB116A $ Blepharoplasty Prerequisite: LEC116 PLAST 352 109
SKILLS LAB132A $ Computerized Perimetry Lecture: Visual Field Testing and Interpretation, 
Emphasizing Glaucoma Prerequisite: LEC132
GLA 343 106
SYM SYM33 The Management of Glaucoma in the Cataract Patient CAT The Great 
Hall
132
2:00 - 4:15 PM SKILLS LEC137/137 + Implantation of Glaucoma Drainage Devices GLA 342 106
IC 368 + Learning Phaco Chop: Pearls and Pitfalls CAT R06 60
IC 369 + Emergency Neuro-Ophthalmology: Diagnosis and Management NEURO 228 80
IC 372 + Diagnostic Ophthalmic Ultrasonography RET R04 93
AAOEIC 373 + Getting Ready for 2014: Compliance! Compliance! Compliance! PM-RISK 288 265
IC 374 + Next-Generation Technologies for the Diagnosis and Treatment of Dry 
Eye and Meibomian Gland Dysfunction
COR R05 68
AAOEIC 382 + Surgery Billing Made Easy for All Specialties PM-REMB 291 264
IC 386 + Herpes Simplex Keratitis: When Herpes Isn’t a Dendrite, and Vice Versa COR 218 68
AAOEIC 387 + Enhancing Your Practice With Mobile Technology and Social Media PM-IMT 290 268
IC 389 + Defending the Ophthalmologist in a Medical Malpractice Lawsuit GEN R02 72
IC 390 + Tubes, Ties, and Videotape: Surgical Video of Baerveldt Glaucoma 
Implants and Managing Complications
GLA 211 76
2:00 - 4:45 PM OP OP06 Cornea, External Disease Original Paper Session COR 271 141
2:30 - 5:00 PM SPE SPE22 Senior Ophthalmologist Special Program and Reception NON 252 245
3:15 - 4:15 PM AAOEIC 394 + Questions About EHR Implementation? Ask Us! PM-EHR 294 266
AAOEIC 398 + Training the Front Office Staff 286 268
AAOEIC 400 + Getting Clean Data: Practice Management Software Setup PM-BUS 295 262
IC 401 + Peripheral Ulcerative Keratitis: Diagnosis and Management COR 210 68
AAOEIC 405 + Employee Discipline for the Smaller Practice: The New Manager, the 
Seasoned Manager, and the Doctor
PM-HRM 283 268
IC 406 + Managing Uveitic Glaucoma GLA 338 76
IC 407 + Diplopia Made Ridiculously Simple: Management of Diplopia for the 
Comprehensive Ophthalmologist
PEDS R03 87
AAOEIC 409 + Opening an Ophthalmology Optical Dispensary PM-OPT 297 269
3:15 - 5:30 PM SKILLS LEC138/138 + Introduction to Aesthetic Facial Surgery by Fractional Lasers, Intense 
Pulsed Light, Radiofrequency, and Ultrasound Devices
PLAST 335 110
SKILLS LEC139/139 + Diabetes 2013: Course on Diabetic Retinopathy RET 333 113
SKILLS LEC140/140 + Endoscopic Forehead and Eyebrow Elevation PLAST 340 110
SKILLS LEC141/141 + ISRS Laser Refractive Surgery Course REF 346 112
IC 392 + Advanced Vitreoretinal Surgical Techniques and Instrumentation RET 221 93
IC 393 + Evidence-Based Guidelines in the Management of Glaucoma GLA 214 76
IC 395 + Innovative Uses of Adhesives in Anterior Segment Surgery COR 220 68
IC 396 + Techniques and Devices for Surgical Reconstruction of Traumatic and 
Developmental Iris Defects
CAT 209 61
AAOEIC 397 + Large Practice Executive Forum PM-BUS 293 262
IC 399 + Keratoconus 360° COR 215 68
IC 402 + Retinal Pharmacotherapy RET 225 93
IC 403 + Corneal Topographic Analysis and Anterior Segment Imaging: Pearls for 
Your Clinical Practice
REF 217 89
AAOEIC 404 + Comprehensive Cataract Coding PM-REMB 296 264
CANCELED
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Monday, Nov. 18 (cont.)
Time Type No. $ Title Topic Room Page
3:15 - 5:30 PM IC 408 + A Video Bouquet of Phaco Complications That Should Never Have 
Occurred, With Tips on Damage Control and Prevention to Optimize 
Postoperative Outcome
CAT R08 61
IC 410 + Clinical Decisions in the Management of Complications of Cataract and 
IOL Surgery
CAT 355 61
3:30 - 5:30 PM SKILLS LAB102B $ Advanced Refractive Cataract Surgery and Anterior Segment 
Reconstruction Prerequisite: LEC102
CAT 356 99
SKILLS LAB131A $ Anterior Lamellar Keratoplasty: Principles and Practice
Prerequisite: LEC131
COR 345 103
3:45 - 4:45 PM SYM SYM34 Reading With Low Vision: Rehabilitation and Neuroplasticity VIS 243 133
SYM SYM35 How Do We Maintain Quality, Improve Efficiency, and Sustain the 
Physician-Patient Relationship?
NON New Orleans 
Theater C
133
3:45 - 5:15 PM SYM SYM36 The Optical Biopsy: Ocular Imaging Modalities and Correlation With 
Histopathology
PATH La Nouvelle 
Orleans C
134
SYM SYM37 Advanced Applications of Femtosecond Lasers for Refractive Surgery REF La Nouvelle 
Orleans AB
134
OP OP08 Retina, Vitreous Original Paper Session RET 255 152
4:00 - 5:00 PM SKILLS LAB142 $ An Innovative Approach to Iris Fixation of an IOL Without Capsular 
Support: Hands-on and Practical
CAT 349 101
4:00 - 5:30 PM SKILLS LAB124B $ Glaucoma Surgical Lab for Ophthalmology Residents
Prerequisite: LEC124
GLA 354 105
4:30 - 5:30 PM IC 411 + Meibomian Gland Dysfunction and Chronic Blepharitis COR R05 68
AAOEIC 412 + Questions About “Meaningful Use” EHR Incentives? Ask Us! PM-EHR 288 266
IC 413 + Lifestyle Intervention for the Treatment/Prevention of Age-related Eye 
Disorders: Practical Application
GLA R04 76
IC 414 + Management of Ocular Chemical Injuries COR 210 68
AAOEIC 415 + Medicare Postoperative Cataract Eyewear: Coding, Billing, and Supplier 
Compliance
PM-REMB 295 264
AAOEIC 416 + How to Be Seen: A How to Guide to Medical Marketing PM-MKT 290 269
IC 417 + Follow the Cornea: Do You Know Where Your Corneal Transplant Tissue 
Comes From?
COR R01 69
IC 418 + Strategy and Statistics in Clinical Research: A Nonstatistician’s Guide 
to Thinking, Designing, and Executing
MEDED R02 79
AAOEIC 419 + Step 1 to Running on Time: Scheduling PM-BUS 286 262
IC 420 + Temporal, Manual, Small- Incision Cataract Surgery: A Technique for 
the Developing and Developed World
CAT R03 61
IC 421 + 3-D Optic Disc Viewing: Top 10 Pitfalls in Identifying Glaucoma Damage 
and Progression
GLA 222 76
AAOEIC 422 + Seeking Shelter Under the Hospital Umbrella: From Employment 
Agreements to Professional Services Agreements
PM-PROF 294 271
AAOEIC 423 + HIPAA Privacy and Security: Trends, Developments, and Issues  PM-RISK 291 265
IC 424 + Vitreoretinal Surgical Rounds, Unleashed! RET 338 94
IC 425 + Management of Strabismus in Thyroid Eye Disease PEDS 224 87
AAOEIC 426 + Toward the Electronic Practice PM-IMT 297 268
IC 427 + Avoiding and Managing Blepharoplasty Complications PLAST 211 84
Tuesday, Nov.19 (cont.)
Time Type No. $ Title Topic Room Page
7:30 - 8:30 AM BWE $ Breakfast With the Experts Roundtables Hall C 50
7:30 - 10:00 AM SKILLS LAB140A $ Endoscopic Forehead and Eyebrow Elevation Prerequisite: LEC140 PLAST 352 110
8:00 - 9:30 AM SKILLS LAB120B $ Phacoemulsification and Advanced Techniques: The Core Curriculum 
Prerequisite: LEC120
CAT 356 100
8:00 - 10:00 AM SKILLS LAB137A $ Implantation of Glaucoma Drainage Devices Prerequisite: LEC137 GLA 354 106
SKILLS LAB141A $ ISRS Laser Refractive Surgery Course Prerequisite: LEC141 REF 345 112
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Tuesday, Nov.19 (cont.)
Time Type No. $ Title Topic Room Page
8:00 - 10:30 AM SKILLS LAB139A $ Diabetes 2013: Course on Diabetic Retinopathy  
Prerequisite: LEC139
RET 343 113
SKILLS LAB143 $ Surgical Anatomy of the Eyelids: Cadaver Demonstration PLAST 349 110
8:30 - 9:45 AM ACADCAFE SYM51 Academy Cafe: Cataract CAT 271 241
8:30 - 10:00 AM SYM SYM38 Management of Vitreoretinal Interface Diseases RET La Nouvelle 
Orleans C
135
SYM SYM39 So You Want to Be a Leader in Ophthalmology? NON 243 135
8:30 - 10:30 AM SYM SYM40 A Multidisciplinary Approach to Emerging Therapies in Neuro-
Ophthalmology
NEURO La Nouvelle 
Orleans AB
135
8:30 - 11:30 AM OP OP09 Glaucoma Original Paper Session GLA 255 143
9:00 - 10:00 AM AAOEIC 500 + Employment Law Basics for the Small Ophthalmology Practice PM-HRM 286 268
AAOEIC 503 + CodeFest PM-REMB 291 264
AAOEIC 504 + Analyzing Medical Legal Tools: The Key to Lawsuit Prevention and Tax 
Reduction
PM-RISK 294 265
IC 509 + Evaluation of Early-Onset Hereditary Retinal Degeneration in Infants 
and Children
RET 342 94
IC 510 + Digital Devices & Patient Care: Confidentiality, Encryption, HIPAA and 
Ethical Considerations
ETH 220 72
AAOEIC 511 + Content Marketing: Getting Your Web Page Ranked PM-MKT 288 269
IC 512 + Pediatric Uveitis: What You Need to Know PEDS 209 87
AAOEIC 516 + Negotiating Your Buy-In PM-PROF 297 271
AAOEIC 519 + How to Develop a Successful Ophthalmic Ambulatory Surgery Center PM-ASC 290 259
IC 521 + Atypical Keratitis COR 340 69
IC 522 + Intraocular Foreign Body Injuries: An Update RET R01 94
AAOEIC 526 + Optical Shops: Sales Strategies for Today’s Economy PM-OPT 293 269
AAOEIC 528 + Tools and Tips to Build a Budget for a Dynamic Practice PM-BUS 283 262
AAOEIC 529 + Billing for Beginners PM-BUS 296 262
IC 530 + Pediatric Ocular Tumors PATH 217 81
9:00 - 11:15 AM IC 501 + Engineering and Physics Principles: A Primer for the Vitreoretinal 
Surgeon
RET 214 94
AAOEIC 502 + Big Practice Problems: What the Experts Recommend PM-BUS 295 262
IC 505 + Practical Ocular Oncology for the Comprehensive Ophthalmologist: 
What You Should Know
PATH R03 81
IC 506 + Decoding the Uveitis Workup: Why, When, and What to Order INTRA 223 78
IC 507 + Anterior Segment Reconstruction Following Trauma COR 208 69
IC 508 + Management of Orbital Tumors: Case Presentation and Discussion PLAST R08 84
IC 513 + A Video Symposium of Challenging Cases and the Management of 
Intraoperative Complications During Cataract Surgery
CAT R06 61
IC 514 + Surgical Strategies for Recurrent Pterygium With or Without Motility 
Restriction
COR 346 69
IC 515 + Big Bubble Technique of Deep Anterior Lamellar Keratoplasty: A 
Simplified Approach to Successful Surgery
COR 211 69
IC 517 + Advanced Techniques With Laser Cataract Surgery CAT 228 61
IC 518 + Phaco Pearls for the Beginner CAT 333 62
IC 520 + Management of Malpositioned IOLs CAT R04 62
IC 523 + What You Need to Know About Headache: A Pain for the Patient and a 
Pain for the Doctor
NEURO 338 80
IC 524 + Optimizing Outcomes and Minimizing Complications in Oculofacial 
Plastic Procedures: A Case-Based Approach
PLAST 221 85
IC 525 + Descemet Membrane Endothelial Keratoplasty (DMEK and Thin Cut 
DSAEK) and Related Advanced Endothelial Keratoplasty Techniques
COR R05 69
IC 527 + Multifocal and Accommodative IOLs: Face the Challenge CAT 218 62
IC 531 + Angle Closure and Angle-Closure Glaucoma GLA 215 77
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Tuesday, Nov.19 (cont.)
Time Type No. $ Title Topic Room Page
9:00 AM - 12:00 PM LL Learning Lounge Hall G, 
Booth 3647
246
9:30 AM - 12:30 PM TP Technology Pavilion Hall I1, 
Booth 5145
252
10:00 AM - 12:00 PM OP OP10 Retina, Vitreous Original Paper Session RET 271 153
10:15 - 11:15 AM AAOEIC 532 + Compounding Pharmacies: Legal and Regulatory Issues PM-RISK 288 271
AAOEIC 535 + Optimizing Patient and Staff Efficiency and Satisfaction Through Facility 
Design
PM-BUS 286 263
IC 537 + Maximizing Your Electronic Health Records System’s Productivity and 
Financial Benefits
EHR 355 71
AAOEIC 541 + Ophthalmic Coding Specialist Prep Course PM-REMB 296 264
AAOEIC 542 + Associate Employment Contracts: How to Avoid Signing a Bad Contract PM-PROF 294 271
AAOEIC 544 + Electronic Health Records: “Great Expectations” PM-EHR 291 267
AAOEIC 546 + ASC Benchmarking PM-ASC 290 259
10:15 - 11:45 AM SYM SYM41 Anterior Segment Reconstruction CAT 243 136
SYM SYM42 Late Breakers Symposium GEN La Nouvelle 
Orleans C
136
10:15 AM - 12:30 PM SKILLS LEC144/144 + Microsurgical Suturing Techniques CAT 340 101
SKILLS LEC145/145 + Advanced Techniques in Orbital Decompression and Expansion PLAST 342 111
IC 533 + Refractive and Cataract Surgery Nightmares: Management and 
Prevention of Most Common Complications
CAT 252 62
IC 534 + Lotions, Potions, Botulinum Toxin, and Fillers: Nonlaser Rejuvenation for 
the Ophthalmologist
PLAST 209 85
AAOEIC 536 + Do I Look Like Your Mother?! Or, How to Manage the Difficult Employee PM-HRM 283 268
AAOEIC 538 + Detecting and Preventing Fraud and Abuse in the Optical Dispensary 
and Medical Practice
PM-OPT 293 270
IC 539 + Complete Guide to the Evaluation and Management of Ptosis PLAST 210 85
IC 540 + Combined Cataract Surgery With Glaucoma Surgery: Guidelines, 
Indications, Methods, Techniques, and Postoperative Management
GLA 225 77
IC 543 + Better Surgery Through Chemicals CAT 220 62
AAOEIC 545 + Let’s Make a (Practice) Deal: A Step-by-Step Approach PM-BUS 297 263
10:30 AM - 12:00 PM SKILLS LAB123B $ Manual Extracapsular Cataract Extraction Surgery: Indications and 
Techniques Prerequisite: LEC123
CAT 356 100
10:30 AM - 12:30 PM SKILLS LAB141B $ Laser Refractive Surgery for Ophthalmology Residents
Prerequisite: LEC141
REF 345 112
10:45 AM - 12:00 PM SYM SYM43 Grand Rounds: Cases and Experts From Across the Nation GEN La Nouvelle 
Orleans AB
136
11:00 AM - 1:00 PM SKILLS LAB138A $ Introduction to Aesthetic Facial Surgery by Fractional Lasers, Intense 
Pulsed Light, Radiofrequency, and Ultrasound Devices
Prerequisite: LEC138
PLAST 354 110
11:00 AM - 1:30 PM SKILLS LAB135A $ Endoscopic Transnasal Lacrimal Surgery: Principles and Practice
Prerequisite: LEC135
PLAST 352 110
11:30 AM - 12:30 PM IC 547 + Facial Nerve Palsy: Anatomy, Etiology, Evaluation, and Management PLAST 346 85
AAOEIC 548 + Hiring an Ophthalmologist for Your Practice: Avoiding the Pitfalls PM-PROF 294 271
IC 549 + Needling for Failed Blebs: All You Need to Know GLA 228 77
IC 550 + Surgical Management of Astigmatism in Cataract and Refractive 
Surgery
CAT 208 63
IC 551 + The Art of Achieving Success With Presbyopia-Correcting Intraocular 
Implants: The Consultation, the IOLs, and Correcting Residual Refractive 
Errors
CAT R08 63
IC 552 + Global Initiatives for Cataract Surgery Efficiency and Sustainability GO 355 78
IC 553 + Practical Considerations for Telemedicine Diabetic Retinopathy 
Screening
RET R05 94
IC 555 + What’s New in Normal-Tension Glaucoma? GLA 333 77
IC 556 + Endothelial Keratoplasty in Challenging Cases COR 217 69
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Tuesday, Nov.19 (cont.)
Time Type No. $ Title Topic Room Page
11:30 AM - 12:30 PM IC 557 + Surgical Education: Improving Upon and Going Beyond the Apprentice 
Model
MEDED R01 79
AAOEIC 558 + Valuing, Buying, Selling, and Transitioning Your Practice PM-BUS 286 263
IC 559 + Swollen Disks, Headache, and Vision Loss: A Case-Based Approach to 
Pseudotumor Cerebri
NEURO 223 80
IC 560 + Ophthalmoscopic Evaluation of the Optic Disc and Retinal Nerve Fiber 
Layer
GLA 338 77
IC 561 + Ocular Surface Diseases in Cancer Patients: Update on Clinical 
Spectrum and Treatment
COR R04 70
IC 562 + Complications in Collagen Crosslinking : Diagnosis, Management, and 
Prevention
COR 221 70
IC 563 + Enucleation, Evisceration, and Care of the Anophthalmic Socket PLAST 218 85
IC 564 + Epiretinal Membranes: Etiologies, Perioperative Management, Surgical 
Techniques, and Case Discussions
RET 214 94
IC 565 + Uveal Melanoma Therapies: Protons, Plaques, and Eyewall Resection PATH R02 81
IC 566 + Top 10 Essentials of Gonioscopy: 3-D Viewing and Interpretation GLA 222 77
AAOEIC 567 + Financial Decision Making in the Eye Care Practice PM-BUS 290 263
12:00 - 2:00 PM SKILLS LAB146 $ Surgical Anatomy of the Orbit and Lacrimal System: Cadaver 
Demonstration
PLAST 349 111
12:45 - 1:45 PM IC 573 + Controversies in the Management of Open-Globe Injuries Involving the 
Posterior Segment
RET R02 95
IC 574 + Refractive Lensectomy: Indications, Lenses, Formulas, Outcomes REF 342 90
IC 576 + Understanding and Utilizing Glaucoma Imaging GLA 209 78
IC 578 + Oculoplastic Office Procedures: Video Clips PLAST R05 85
IC 582 + Vision and the Artist HIST 215 81
IC 585 + Secrets of Highly Successful Refractive Cataract Surgery Practices REF 218 90
IC 586 + Oculoplastic Procedures for the General Ophthalmologist PLAST 223 86
IC 590 + Drug-Related Adverse Effects of Clinical Importance to the 
Ophthalmologist
GEN 355 72
IC 592 + Abandoned Phaco: Convert to No-Stitch Manual Small-Incision Cataract 
Surgery
CAT 335 64
IC 594 + Diagnosis and Management of Essential Blepharospasm and 
Hemifacial Spasm
PLAST 222 86
12:45 - 3:00 PM AAOEIC 554 + Buying or Selling a Practice: Creating Win-Win Transactions PM-BUS 288 263
IC 568 + OCT: Interpretation and Clinical Applications RET 228 94
IC 569 + What’s New and Important in Pediatric Ophthalmology and Strabismus 
for 2013
PEDS 221 88
IC 570 + Curbside Consultation in Neuro-Ophthalmology NEURO R08 80
IC 571 + Scleral Fixation of IOL With Fibrin Glue CAT 208 63
IC 572 + Best of the Best : An Update in Cataract Surgery CAT R06 63
IC 575 + International (Dis)Agreement on Infectious Uveitis INTRA R01 78
IC 577 + Imaging Studies in Strabismus PEDS 346 88
IC 94 + Retinoblastoma 2013: They Live and See! RET 210 95
IC 580 + Mastering Transepithelial and Epithelial-Off Corneal Collagen 
Crosslinking for Keratoconus and Post-LASIK Ectasia
COR 211 70
IC 581 + Descemet-Stripping Automated Endothelial Keratoplasty Cliffhangers COR R04 70
IC 583 + Cataract Surgery Crisis Management 101 CAT 338 63
AAOEIC 584 + Steps for Successful Retina Coding PM-REMB 295 264
IC 587 + Comprehensive Strategy for Unplanned Vitrectomy Technique for the 
Anterior Segment Surgeon
CAT 220 63
IC 588 + Endoscopic-Assisted Ophthalmic Surgery: Anterior and Posterior 
Segment Techniques
RET R03 95
IC 589 + Ocular Ultrasound RET 214 95
IC 591 + State-of-the-Art Techniques and Technologies for Microincision 
Vitrectomy Surgery to Treat Complex Vitreoretinal Diseases
RET 225 95
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Tuesday, Nov.19 (cont.)
Time Type No. $ Title Topic Room Page
12:45 - 3:00 PM IC 593 + Surgery of Retinal Detachment RET 333 95
IC 595 + Principles of Pediatric Vitreoretinal Surgery in Retinopathy of 
Prematurity
RET 340 96
IC 596 + Peering to the Periphery: Applications of Wide-Angle Retinal Imaging RET 217 96
IC 597 + Descemet Membrane Endothelial Keratoplasty COR 224 70
1:00 - 3:00 PM SKILLS LAB120C $ Phacoemulsification and Advanced Techniques Lab for Ophthalmology 
Residents
Prerequisite: LEC120
CAT 356 100
1:30 - 3:30 PM SKILLS LAB144A $ Microsurgical Suturing Techniques
Prerequisite: LEC144
CAT 345 101
2:00 - 4:15 PM IC 598 + Secure Posterior Chamber IOL Placement Without Adequate Capsular or 
Zonular Support
CAT 215 64
IC 599 + Advances in Treatment of Severe Ocular Surface Disease: Views From 
Experts on the Front Lines
COR 209 70
2:30 - 5:00 PM SKILLS LAB145A $ Advanced Techniques in Orbital Decompression and Expansion
Prerequisite: LEC145
PLAST 352 111
3:15 - 5:30 PM IC 600 + Solving the High Myopia Problem With Phakic IOLs REF 335 90
IC 601 + Top 10 Hot Corneal Surgical Tips for 2013 COR 210 71
IC 602 + Systemic Therapeutic Agents and Retinal Toxicity RET 338 96
Wednesday, Nov. 20
Time Type No. $ Title Topic Room Page
7:00 AM - 5:00 PM SPE SPE23 $ Lo Mejor de la Academia en Español Sheraton, 
Armstrong 
Ballroom
245
50 Academy staff are available at the Academy Resource Center, Hall G, Booth 3239, to answer any questions you may have.
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WHERE ALL OF OPHTHALMOLOGY MEETS
Sunday – Tuesday, Nov. 17 - 19
7:30 - 8:30 AM
Hall C
Roundtable discussions are moderated by leading experts in the field. Attendees are encouraged to 
bring their individual questions and cases for discussion.
Registration fee is $40 onsite and includes a buffet breakfast. Breakfast With the Experts are ticketed 
events; they are not included in the Academy Plus course pass. Members in Training automatically 
receive a 50% discount on all roundtables.
After breakfast, feel free to use the roundtables area to meet-up with colleagues and network.
Selection Committee
Practice Management roundtables were selected by the AAOE Program Committee.
The Annual Meeting Program Committee selected all other roundtables. 
See page 33 for committee details.
Breakfast With the Experts
Breakast With the Experts
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Sunday, Nov. 17
Cataract
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Society of Cataract and Refractive Surgery (ASCRS)
Roundtable B100
Complex Axial Length Measurement and Unusual IOL Power 
Calculations
Moderator: Mitchell P Weikert MD*
Roundtable B101
Management of the Broken Posterior Capsule and Advanced 
Vitrectomy Technique for the Cataract Surgeon
Moderator: Louis D Skip Nichamin MD*
Roundtable B102
Phacoemulsification Pearls
Moderator: Bonnie A Henderson MD*
Roundtable B103
Surgical Management of Cataract and Glaucoma
Moderator: Douglas J Rhee MD*
Roundtable B104
Managing the Broken Capsule: Pearls for Vitrectomy
Moderator: Rosa Braga-Mele MD*
Cornea, External Disease
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Cornea Society
Roundtable B105
Endothelial Keratoplasty
Moderator: Natalie A Afshari MD
Roundtable B106
Deep Anterior Lamellar Keratoplasty: Patient Selection, Technique, 
and Outcomes
Moderator: Donald Tan MD FRCS FRCOphth*
Ethics
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Ethics Committee
Roundtable B107
Ethical Research: A ‘Need to Know Basis’ for You and Your Patients
Moderator: Carla J Siegfried MD*
Glaucoma
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Glaucoma Society (AGS)
Roundtable B108
Minimally Invasive Glaucoma Surgery: Ready for Primetime
Moderator: Arthur J Sit MD*
Roundtable B109
Optic Nerve Imaging: Is This Patient Processing?
Moderator: Felipe A Medeiros MD*
Roundtable B110
Fine Tuning Glaucoma Surgery for Optimal Results
Moderator: Jody R Piltz-Seymour MD*
Global Ophthalmology
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Global Education and Outreach Committee
Roundtable B111
How to Develop a Partnership with an Institution in a Developing 
Country
Moderator: David S Friedman MD MPH PhD*
Intraocular Inflammation, Uveitis
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Uveitis Society (AUS)
Roundtable B112
Biologic Warfare: Targeted Systemic Treatments for Uveitis
Moderator: Eric B Suhler MD*
Roundtable B113
How OCT, Fluorescein and ICG Angiography, and Ultrasonography 
Can Help You Manage Uveitis
Moderator: Sunir J Garg MD*
Neuro-Ophthalmology
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the North American Neuro-Ophthalmology Society (NANOS)
Roundtable B114
I Think My Patient has AION: What Do I Do Next?
Moderator: Neil R Miller MD*
Roundtable B115
Visual Loss With A Normal Eye Exam
Moderator: Michael S Vaphiades DO
Roundtable B116
Diplopia
Moderator: Stacy L Pineles MD
Orbit, Lacrimal, Plastic Surgery
Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Society of Ophthalmic Plastic and Reconstructive Surgery 
(ASOPRS)
Roundtable B117
Management of the Tearing Patient
Moderator: Parag D Gandhi MD
Roundtable B118
Ptosis Repair: How to Achieve the Best Results
Moderator: Cameron Nabavi MD
Pediatric Ophthalmology, Strabismus
Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Association for Pediatric Ophthalmology and Strabismus 
(AAPOS)
Roundtable B119
Refractive Surgery in Children
Moderator: Amy K Hutchinson MD
Roundtable B120
Optic Nerve Hypoplasia
Moderator: Mark S Borchert MD
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Sunday, Nov. 17 (cont.)
Practice Management/AAOE
Sponsored by the American Academy of Ophthalmic Executives (AAOE)
Business Operations & Finance
Roundtable B121
Management Reporting
Moderator: Ron Rosenberg PA MPH*
Roundtable B122
Not Full Time: Contracting Profitability with Part-Timers, Contractors, 
and Senior Physicians
Moderator: Daniel M Bernick JD*
Roundtable B195
Personal Financial Management For The Eye Care Professional
Moderator: Richard M Palmer MD
 Electronic Health Records
Roundtable B123
Big Data - Leveraging Analytics to Improve Your Bottom Line
Moderator: Jeffery Daigrepont
 Professional Growth
Roundtable B124
Productive Partner Meetings - The Art of Making Decisions Stick
Moderator: Maureen Waddle MBA*
Roundtable B125
Open Your Eyes to New Opportunities: A Guide to the Student Loan 
System
Moderator: Donna W Howell JD
Roundtable B126
Performance Indicators
Moderator: Jeff Grant*
Roundtable B127
Let’s Make A Practice Deal
Moderator: Michael J Parshall*
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the Senior Ophthalmologist Committee (SO)
Roundtable B128
Stopping Surgery - When, Why, and What It Means To Your Practice
Moderator: Michael W Brennan MD
Refractive Surgery
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the International Society of Refractive Surgery (ISRS) Executive 
Committee
Roundtable B129
Pearls of Correction of Astigmatism During Cataract Surgery
Moderator: Noel A Alpins MD FACS*
Retina, Vitreous
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Society of Retina Specialists (ASRS)
Roundtable B131
Which Angiogenesis Agent to Use for Choroidal Neovascularization
Moderator: Jeffrey S Heier MD*
Roundtable B132
Spectral Domain OCT Imaging
Moderator: Srinivas R Sadda MD*
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Macula Society
Roundtable B133
Integrating Spectral Domain OCT Into a Busy Clinical Practice: 
Pearls and Pitfalls
Moderator: Srinivas R Sadda MD*
Roundtable B134
Wide Angle Retina Imaging
Moderator: Jennifer K Sun MD*
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Retina Society
Roundtable B135
Pharmacologic Treatment of Vitreomacular Traction Syndromes
Moderator: Baruch D Kuppermann MD PhD*
Roundtable B136
Treatment of Complicated Retinal Detachment and the Role of 
Intravitreal Steroids in the Management of Recalcitrant Macular 
Edema
Moderator: Dennis P Han MD*
Vision Rehabilitation
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Vision Rehabilitation Committee
Roundtable B137
Microperimetry and Clinical Practice
Moderator: Samuel N Markowitz MD
Monday, Nov. 18
Cataract
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Society of Cataract and Refractive Surgery (ASCRS)
Roundtable B140
Surgical Management of Cataract and Glaucoma
Moderator: Reay Brown MD*
Roundtable B141
Limbal Relaxing Incisions/Presbyopia IOLs
Moderator: Jonathan B Rubenstein MD*
Roundtable B142
Femtosecond Laser Cataract Surgery
Moderator: Samuel Masket MD*
Roundtable B143
Strategies for Efficient Cataract Surgery
Moderator: Gary J Foster MD*
Roundtable B144
Clinical Pearls for Improving Outcomes with Presbyopia-Correcting 
IOLs
Moderator: Kevin M Miller MD*
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Monday, Nov. 18 (cont.)
Cornea, External Disease
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Cornea Society
Roundtable B145
Pterygium Treatments
Moderator: Stephen C Kaufman MD PhD
Roundtable B146
Acanthamoeba Keratitis
Moderator: Kristin Hammersmith MD
Ethics
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Ethics Committee
Roundtable B147
Ethical Dilemmas in Emergency Ophthalmic Care
Moderator: Gregory J McCormick MD
Glaucoma
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Glaucoma Society (AGS)
Roundtable B148
Optic Nerve and RNFL Imaging: Is This Patient Progressing?
Moderator: Kouros Nouri-Mahdavi MD*
Roundtable B149
Fine Tuning Glaucoma Surgery for Optimal Results
Moderator: Steven Gedde MD*
Global Ophthalmology
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Global Education and Outreach Committee
Roundtable B150
Global Ophthalmology: How To Start Volunteering Now!
Moderator: Grace Sun MD*
Intraocular Inflammation, Uveitis
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Uveitis Society (AUS)
Roundtable B151
Is the Uveitis Infectious? Bugs and Drugs
Moderator: Ramana S Moorthy MD
Neuro-Ophthalmology
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the North American Neuro-Ophthalmology Society (NANOS)
Roundtable B152
What Should I Do With the Patient with Elevated ONH?
Moderator: Rosa A Tang MD*
Roundtable B153
Neuro-Ophthalmic Emergencies
Moderator: Howard R Krauss MD*
Roundtable B154
Optic Neuritis
Moderator: Valerie A Purvin MD*
Orbit, Lacrimal, Plastic Surgery
Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Society of Ophthalmic Plastic and Reconstructive Surgery 
(ASOPRS)
Roundtable B155
Fillers and Neurotoxins for Facial Rejuvenation
Moderator: Wendy W Lee MD*
Roundtable B156
Blepharoplasty How to Create an Aesthetically Pleasing Eyelid
Moderator: Rona Z Silkiss MD FACS
Pediatric Ophthalmology, Strabismus
Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Association for Pediatric Ophthalmology and Strabismus 
(AAPOS)
Roundtable B157
ROP
Moderator: Graham E Quinn MD*
Roundtable B158
Pediatric Cataracts
Moderator: M Edward Wilson Jr MD*
Practice Management /AAOE
Sponsored by the American Academy of Ophthalmic Executives (AAOE)
Business Operations & Finance
Roundtable B159
Analyzing Medical Legal Tools: The Key to Lawsuit Prevention and 
Tax Reduction
Moderator: Carol Foster*
Roundtable B160
Bringing in a New Asscociate: Friend or Foe?
Moderator: Debra L Phairas
Roundtable B161
Buy-Ins and Pay-Outs
Moderator: Mark E Kropiewnicki JD LLM*
Roundtable B162
Partial Retirement in a Group Practice
Moderator: Robert J Landau JD
Electronic Health Records
Roundtable B163
Big Data - Leveraging Analytics to Improve Your Bottom Line
Moderator: Jeffery Daigrepont
Information Technology
Roundtable B164
Practice Management Computer Systems
Moderator: Ron Rosenberg PA MPH*
Professional Growth
Roundtable B165
Seeking Shelter Under the Hospital Umbrella: From Employment 
Agreements to Professional Services Agreements
Moderator: Lawrence Geller MBA*
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Monday, Nov. 18 (cont.)
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Senior Ophthalmologist Committee (SO) 
Roundtable B166
Transitions in Practice Slowing Down and Its Implications
Moderator: Paul N Orloff MD
Refractive Surgery
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the International Society of Refractive Surgery (ISRS) Executive 
Committee
Roundtable B130
Modern Presbyopia Correcting Options: Corneal and Lenticular
Moderator: Ronald R Krueger MD*
Roundtable B167
Femtosecond Technology in Corneal and Lenticular Refractive 
Surgery - The Versatile Tool
Moderator: Erik L Mertens MD FRACOPHTH*
Roundtable B168
Collagen Cross Linking and Combination Therapies in Keratoconus
Moderator: Arthur B Cummings MD*
Retina, Vitreous
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Society of Retina Specialists (ASRS)
Roundtable B169
AREDS 2 and the Role of Supplements for Macular Degeneration
Moderator: Emily Y Chew MD
Roundtable B170
Pharmacologic Treatment of Vitreomacular Traction Syndrome
Moderator: Pravin U Dugel MD*
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Macula Society
Roundtable B171
Wide Angle Retina Imaging
Moderator: Jennifer Irene Lim MD*
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Retina Society
Roundtable B173
Which Anti-Angiogenic Agent to Use for Choroidal 
Neovascularization
Moderator: Andrew A Moshfeghi MD*
Roundtable B174
Treatment of Venous Occlusive Disease
Moderator: David Brown MD FACS*
Vision Rehabilitation
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the Vision Rehabilitation Committee
Roundtable B175
Incorporating Low Vision Rehabilitation Into Your General 
Ophthalmology or Retina Practice
Moderator: Paul Homer MD
Tuesday, Nov. 19
Cataract
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Society of Cataract and Refractive Surgery (ASCRS)
Roundtable B176
Limbal Relaxing Incisions/Presbyopia IOLs
Moderator: R Bruce Wallace MD*
Roundtable B177
Financial Considerations in Purchasing a Femtosecond Laser for 
Refractive Cataract Surgery
Moderator: Steven D Vold MD*
Roundtable B178
Femtosecond Laser Cataract Surgery
Moderator: Bradley C Black MD*
Roundtable B179
Incorporation of High-Tech IOLs
Moderator: Sumit Garg MD*
Roundtable B180
Fuchs Endothelial Dystrophy: Preoperative Considerations for 
Cataract Surgery
Moderator: Clara C Chan MD*
Cornea, External Disease
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Cornea Society
Roundtable B181
Herpes Simplex Keratitis
Moderator: Erich Bryan Groos MD*
Roundtable B182
Boston Keratoprosthesis: Technique and Outcomes
Moderator: Peter Zloty MD
Ethics
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the Ethics Committee
Roundtable B183
Ethical Aspects of Practicing Internationally
Moderator: R V Paul Chan MD
Glaucoma
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Glaucoma Society (AGS)
Roundtable B184
Slit-Lamp Procedures 2 - Transconjunctival Suturing of the Over-
Filtering Bleb
Moderator: Steven R Sarkisian MD*
Roundtable B185
Pearls and Pitfalls of Glaucoma Drainage Devices
Moderator: Robert Feldman MD*
Intraocular Inflammation, Uveitis
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Uveitis Society (AUS)
Roundtable B186
Work-up for the Patient with Uveitis: What To Order and What Not 
to Order!
Moderator: Debra A Goldstein MD*
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Tuesday, Nov. 19 (cont.)
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Retina Society
Roundtable B187
Use of Biologics in the Treatment of Non-infectious Uveitis
Moderator: Janet Louise Davis MD*
Neuro-Ophthalmology
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the North American Neuro- Ophthalmology Society (NANOS)
Roundtable B188
Orbital Disease “Top Ten” Pearls (and Pitfalls)
Moderator: Marc H Levy MD
Roundtable B189
Eye Pain Pearls
Moderator: Paul W Brazis MD
Ocular Tumors and Pathology
Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Society of Ophthalmic Plastic and Reconstructive Surgery 
(ASOPRS)
Roundtable B190
Intraocular and Periocular Tumors: What We Know
Moderator: Hakan Demirci MD
Orbit, Lacrimal, Plastic Surgery
Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Society of Ophthalmic Plastic and Reconstructive Surgery 
(ASOPRS)
Roundtable B191
Brow Ptosis: How to Diagnose Brow Ptosis and Browplasty 
Technique to Correct
Moderator: John Joseph Martin MD*
Pediatric Ophthalmology, Strabismus
Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Association for Pediatric Ophthalmology and Strabismus 
(AAPOS)
Roundtable B192
Tips for Examining Children’s Eyes
Moderator: Daniel J Karr MD
Roundtable B193
Prescribing Glasses in Preverbal Children
Moderator: Daniel E Neely MD
Practice Management/AAOE
Sponsored by the American Academy of Ophthalmic Executives (AAOE)
Business Operations & Finance
Roundtable B194
Practice Valuations: What a Practice Worth Today?
Moderator: Mark D Abruzzo JD
Roundtable B196
Three Areas of Succession Planning for Senior Physicians
Moderator: Michael D Brown*
Professional Growth
Roundtable B197
Exit Strategies for the Solo Ophthalmologist
Moderator: Lawrence Geller MBA*
Roundtable B198
Mid-Career Planning - It’s Not Too Early to Plan for the Next 50 Years
Moderator: Frank J Weinstock MD
Refractive Surgery
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the International Society of Refractive Surgery (ISRS) Executive 
Committee
Roundtable B199
Laser Vision Correction After Refractive IOL Surgery
Moderator: Elizabeth Yeu MD*
Retina, Vitreous
 Jointly sponsored by the Academy’s Annual Meeting Program Committee 
and the American Society of Retina Specialists (ASRS)
Roundtable B200
Compounding Pharmacy Regulations and the Effect on Compounded 
Medication Supply
Moderator: Suber S Huang MD*
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the Macula Society
Roundtable B201
Treatment of Diabetic Macular Edema
Moderator: Judy E Kim MD
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
the American Society of Retina Specialists (ASRS)
Roundtable B204
Ultra Widefield Fluorescein Angiography
Moderator: Szilard Kiss MD*
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Cataract
Advanced Refractive Cataract Surgery and Anterior Segment 
Reconstruction
Course: 102 Sunday
Room: 211 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course is designed for surgeons who (1) want to achieve a higher level 
of emmetropic results by addressing toricity through the use of limbal relaxing incisions, 
toric IOLs, and bioptics, and (2) want to expand their armamentarium for dealing with 
difficult cataract cases, dislocated IOLs, and traumatized eyes.
Objective: This course will cover iris and scleral suture fixation techniques for IOLs, 
chopping techniques, capsular tension rings, artificial iris vs. primary closure for iris de-
fects, pars plana vitrectomy, introduction to femtosecond cataract surgery, and strategies 
for dealing with challenging cases. These techniques will be presented in the didactic 
course and will be practiced in the Skills Transfer lab.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Brock K Bakewell MD*
Instructor(s): Louis D Skip Nichamin MD*, William J Fishkind MD FACS*, Samuel Masket 
MD*, Warren E Hill MD*, Steven H Dewey MD*, Lisa B Arbisser MD*, Garry P Condon 
MD*, Alan S Crandall MD*, Richard S Hoffman MD*, Robert P Liss MD, Mark K Walsh 
MD
Management of Vitreous for the Anterior Segment Surgeon
Course: 106 Sunday
Room: R04 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will review the anatomy, physiology, and pathophysiology of the 
vitreous and will present vitrectomy techniques for challenging anterior segment surgery 
scenarios. Topics will include management of vitreous loss from the anterior and poste-
rior approach, utilizing the vitrector for decompression in challenging cataract cases, and 
visualizing the vitreous with triamcinolone acetonide (Kenalog).
Objective: This course is designed to enhance the anterior segment surgeon’s familiar-
ity with anterior and posterior vitrectomy techniques for challenging anterior segment 
cases. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Natalie A Afshari MD
Instructor(s): Iqbal K Ahmed MD*, Rosa Braga-Mele MD*, Ron Afshari Adelman MD 
MPH, Keith A Warren MD*, Baseer U Khan MD*, Thomas A Oetting MD
 h  Code Red: Mastering Phaco Nightmares and Worst-Case 
Scenarios — A Video-Based Course
Course: 152 Sunday
Room: 218 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: “Code red” signifies danger, and it’s best to be prepared for such cases. 
Endocapsular rings for subluxated cataracts, prosthetic irides, and pupil expanders are 
secrets for mastering phaco surgery’s worst-case scenarios. Intraoperative floppy iris 
syndrome, IOL implantation in eyes with deficient capsules, and glued IOLs will all be 
explained. Vitreous loss, torn rrhexis management, and other complication management 
will also be covered. Management of dropped lenses, hard cataracts, posterior capsular 
ruptures, and the like will all be explained with excellent videos. From basic compli-
cations to nightmare situations, all will be covered in this course. Questions from the 
audience will be discussed so that attendees will be able go back to their practices and 
manage any situation.
Objective: At the conclusion of this course, the attendee will be able to master difficult 
phaco cases and manage various complications without developing a heart attack.
Senior Instructor(s): Amar Agarwal MD*
Instructor(s): David F Chang MD*, Robert H Osher MD*, Athiya Agarwal MD*, Iqbal K 
Ahmed MD*, Brian C Little MD*
 h   YO  Conquering Capsule Complications: A Video Primer
Course: 154 Sunday
Room: R06 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMP
Synopsis: Video cases will illustrate a spectrum of techniques for anterior and posterior 
capsule complications: trypan blue dye, vitreous tap for crowded anterior chamber, torn 
continuous curvilinear capsulorrhexis (CCC) options, secondary CCC enlargement, flap 
tear-out rescue technique, posterior CCC, rrhexis capture of the optic, early recognition 
of posterior chamber rupture, conversion from top/clear corneal incision to extracapsular 
cataract extraction, posterior polar cataracts, IOL fixation with torn anterior or posterior 
capsule, capsular tension ring and capsule hooks for weak zonules, small pupil / floppy 
iris strategies (hooks, Malyugin and other expansion rings, epinephrine, Healon 5), pars 
plana bimanual anterior vitrectomy (± triamcinolone), and Viscoat posterior-assisted levi-
tation (PAL) + trap for descending nuclei.
Objective: To use video cases to systematically review techniques of preventing, rec-
ognizing, and handling complications with either the capsulorrhexis or posterior capsule.
Senior Instructor(s): David F Chang MD*
Instructor(s): Robert H Osher MD*
 NEW  Fundamentals of Anterior Segment Reconstruction
Course: 162 Sunday
Room: 210 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will consist of didactic lecture, surgical video, and panel discus-
sion highlighting various current topics in anterior segment surgery. Topics will include 
iris repair, IOL exchange, sutured IOLs, anterior vitrectomy, use of iris and capsule support 
devices, and complex cataract surgery. Instructive surgical video intertwined with didac-
tic slides will be used as the building blocks for this instructional course. Each case will 
focus on a common anterior segment situation and a technique or techniques for proper 
management and/or repair of that scenario.
Objective: Attendees will learn several surgical techniques for the repair of the ante-
rior segment and how to apply these techniques in their own clinical practice, thereby 
improving patient care.
Senior Instructor(s): Brandon Ayres MD*
Instructor(s): William Barry Lee MD*, George O Waring IV MD*, Elizabeth Yeu MD*, John 
P Berdahl MD*, Jai G Parekh MD MBA**
IOL Power Calculation: Problems With LASIK Eyes
Course: 183 Sunday
Room: 211 2:00 - 3:00 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will present the latest in IOL power calculation, from biometric 
measurements for axial length, corneal power, and anterior chamber depth, including the 
IOLMaster, LenStar, Galilei G6, Aladdin, Nidek, and Tomey, to formula usage and clinical 
decision making. The new Hoffer H5 formula will be explained. Special attention will 
be paid to improving the accuracy of these parameters in clinical practice. Means for 
dealing with special cases, such as staphyloma, piggyback lenses, pediatric eyes, LASIK 
eyes, and silicone oil eyes, will be covered based on the presenter’s 38 years of experi-
ence in the field. How to handle power errors will also be presented.
Objective: By the end of this course, attendees should have obtained all the latest in-
formation to improve the accuracy of IOL power prediction for all patients receiving IOLs, 
either aphakic or phakic. They also should be able to handle especially difficult situations 
and to choose effective means to correct postoperative problems that occur.
Senior Instructor(s): Kenneth J Hoffer MD FACS*
 h  Cataract Surgery in the Setting of Ocular Comorbidities 
and High-Risk Features for Intraoperative and Postoperative 
Complications
Course: 185 Sunday
Room: 218 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Ocular comorbidities and high-risk characteristics for intraoperative and 
postoperative complications occur with surprising regularity in cataract surgery patients. 
Ocular comorbidities often reduce visual potential. Systemic comorbidities and other 
characteristics of the eye or patient are often associated with a high risk of intraopera-
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tive and postoperative complications. In this course, a faculty of internationally recog-
nized experts in cataract surgery will discuss a variety of common comorbidities and 
high-risk characteristics, the unique problems they present, and strategies for achieving 
successful visual and surgical outcomes.
Objective: At the conclusion of this course, the attendee will be able to identify a va-
riety of ocular comorbidities and high-risk eye and patient characteristics for surgical 
complications at the time of cataract surgery. The attendee will also be able to describe 
strategies for obtaining optimal outcomes under these conditions.
Senior Instructor(s): Kevin M Miller MD*
Instructor(s): Iqbal K Ahmed MD*, David S Boyer MD*, Arup Chakrabarti MBBS, Michael 
Colvard MD*, Alan S Crandall MD*, James Philip Dunn Jr MD, Bonnie A Henderson 
MD*, Terry Kim MD*, Douglas D Koch MD*, Nick Mamalis MD*, Samuel Masket MD*, 
Thomas A Oetting MD, Randall J Olson MD, Robert H Osher MD*, Mark Packer MD*, 
Walter J Stark MD*, Abhay Raghukant Vasavada MBBS FRCS*
Phacoemulsification and Advanced Techniques: The Core 
Curriculum
Course: 120 Sunday
Room: 211 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: In this course, a faculty of experienced surgeons will present the latest pha-
co techniques and technologies that are applicable to ophthalmologists at every level 
of experience. This comprehensive course will cover the steps of phacoemulsification, 
including incisions, capsulorrhexis, hydrodissection, and phaco techniques with an em-
phasis chop. Safe cortex removal and IOL implantation will be demonstrated. Capsular 
tension rings, pupil expanders, hooks, capsular staining, and related techniques will also 
be presented. This course will teach the most up-to-date phacoemulsification techniques 
to both individuals with little or no experience with the method and those wishing to 
refine or update their technique or transitioning from other cataract surgery methods.
Objective: This course is designed to teach participants the principals and skills nec-
essary to understand and perform state-of-the-art phacoemulsification safely and effi-
ciently.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Steven H Dewey MD*
Instructor(s): Anita Nevyas-Wallace MD*, Ricardo G Glikin MD, Nick Mamalis MD*, 
Helen K Wu MD*, Mark H Blecher MD, Thomas A Oetting MD
Manual Extracapsular Cataract Extraction Surgery: Indications 
and Techniques
Course: 123 Sunday
Room: 346 3:15 - 5:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: Although extracapsular cataract extractions by large incision (ECCE) and 
small incision (SICS) are still performed routinely throughout the world, phacoemulsifica-
tion surgery has become the standard of care in many countries, and therefore ECCE/
SICS is no longer being taught. However, understanding how to perform this surgery 
competently is still crucial when faced with complications during phacoemulsification 
surgery, or when an ECCE approach may be a better choice for the patient.
Objective: By the conclusion of this course, the attendee will (1) have learned and be 
able to practice primary ECCE and SICS surgery, (2) have learned and be able to practice 
how to convert from a clear corneal phacoemulsification to either a ECCE or a SICS ap-
proach, and (3) better understand how to deal with complications of ECCE surgery.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Bonnie A Henderson MD*
Instructor(s): Geoffrey C Tabin MD, Maria Mendicino Aaron MD, Jeff H Pettey MD*
Tackling Weak Zonules and Using Capsular Tension Devices
Course: 206 Sunday
Room: R08 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover techniques, indications, and pitfalls for the use of 
capsular tension devices (rings and segments), capsular retractors, and other surgical 
techniques in patients with capsular-zonular complex pathology. A strategy for preopera-
tive evaluation and intraoperative clues to unstable or potentially unstable zonules will 
be presented, and surgical approach and selection of capsular device(s) and techniques 
for implantation will be discussed. Strategies for avoidance and management of compli-
cations will also be presented.
Objective: Participants will gain an understanding of the premise of and indications for 
capsular tension devices, the use of adjunctive devices, specific techniques in implanta-
tion, and potential complications.
Senior Instructor(s): Iqbal K Ahmed MD*
Instructor(s): Robert J Cionni MD*, Alan S Crandall MD*, Samuel Masket MD*, Robert H 
Osher MD*, Kenneth J Rosenthal MD FACS**
 NEW  Pearls for Evaluating Corneal Topography in Patients 
Scheduled for Cataract Surgery
Course: 217 Sunday
Room: 218 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Patients scheduled for cataract surgery can have surprisingly abnormal cor-
neal topography. This course will be led by a team of topography experts who will help 
attendees identify and interpret corneal topographies in patients scheduled for cataract 
surgery, and help optimize a treatment plan. Both virgin corneas, as well as corneas 
with previous PRK, LASIK, and radial keratotomy, will be discussed and analyzed by the 
faculty.
Objective: At the conclusion of the course, attendees will be able to analyze and iden-
tify normal vs. abnormal corneal topographies in patients scheduled for cataract surgery 
and to determine whether patients are eligible for toric or presbyopic IOLs, or for limbal 
relaxing incisions. Attendees will also be able to determine whether their patients would 
be eligible for PRK or LASIK following cataract surgery, or would potentially benefit from 
crosslinking.
Senior Instructor(s): William B Trattler MD*
Instructor(s): George O Waring IV MD*, Karolinne M Rocha MD, Renato Ambrosio Jr 
MD*, Jodi Luchs MD*
 NEW  Artificial Iris Implantation
Course: 229 Sunday
Room: 210 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will provide an overview of artificial iris devices available from 
Morcher, Ophtec, and HumanOptics. Indications, device availability in different markets, 
preoperative planning, implantation tips, and outcomes will be discussed. The effect of 
ocular comorbidities on the decision-making process will be reviewed. The didactic dis-
cussion will be supplemented by surgical video. Devices to be discussed include modified 
capsule tension rings, iris reconstruction lenses, and foldable silicone wafers.
Objective: At the conclusion of the course, attendees will be able to describe the artifi-
cial irises available commercially and understand their directions for use. They will know 
which devices are suitable for capsular bag implantation and which devices are suitable 
for the sulcus. They will be able to discuss how ocular comorbidities affect the choice of 
implant to be used. They will also be able to describe common intraoperative problems 
and their solutions.
Senior Instructor(s): Kevin M Miller MD*
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 NEW  Toric IOL Implantation: How to Improve Results and 
Manage Complications
Course: 235 Sunday
Room: 225 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Toric IOLs have rapidly changed the management of corneal astigmatism in 
cataract patients. For excellent results either with monofocal or multifocal IOLs, this 
course will present a structured approach to patient selection, evaluation and limbal 
imaging, IOL choice, proper centration, new alignment devices, and management of in-
traoperative complications, such as ballooning and bleeding. Understanding of misalign-
ment through vector analysis and new techniques as well as correction of residual errors 
will be discussed.
Objective: At the end of the course, participants will be able to exploit toric IOLs advan-
tages, reduce alignment errors, and manage possible unwanted results.
Senior Instructor(s): Fabrizio I Camesasca MD*
Instructor(s): Paolo Vinciguerra MD*, Jack T Holladay MD MSEE FACS*, Michael C Knorz 
MD*
 NEW  Anterior Segment Surgery in 3-D
Course: 240 Sunday
Room: R06 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will be video based, showing surgical video of new and innova-
tive anterior segment procedures in high-definition 3-D. After each video there will be a 
panel discussion and time for audience questions and answers. Techniques to be covered 
will include Descemet-stripping endothelial keratoplasty, Descemet membrane endothe-
lial keratoplasty, cataract removal, femtosecond laser cataract surgery, trabeculectomy, 
tube shunt placement, canaloplasty, and others. By observing the surgical procedures in 
3-D, participants in the course will gain a better understanding of how to perform these 
procedures. Viewing the procedures in 3-D will also highlight how 3-D viewing systems 
can enhance surgeon education, both in the operating room and in remote locations.
Objective: Attendees will experience and learn by watching through the surgeon’s eyes 
a variety of advanced anterior segment surgical procedures. Visualizing the procedures 
will enhance the attendees’ experience and add to their comfort level in performing 
these surgical procedure on their own patients.
Senior Instructor(s): Brandon Ayres MD*
Instructor(s): Scott J Fudemberg MD*, Anand V Mantravadi MD*, Michael J Pro MD*, 
Irving M Raber MD*, Sadeer B Hannush MD, Robert S Bailey MD
Intraoperative Floppy Iris Syndrome: Pearls for Management 
and Prevention
Course: 241 Sunday
Room: 228 4:30 - 5:30 PM
Education Level: INT Target Audience: COMP
Synopsis: Intraoperative floppy iris syndrome (IFIS) continues to challenge cataract 
surgeons. Multiple different surgical methods will be discussed in detail, with the goal 
of arming surgeons with a range of complimentary strategies. These include intracam-
eral alpha agonists, ophthalmic viscosurgical device strategies, phaco techniques, iris 
retractors, and pupil expansion devices, including the Malyugin ring. This course will also 
review what is known about the pharmacologic basis and mechanism of IFIS.
Objective: To update anterior segment surgeons on the latest clinical information about 
benign hyperstatic hypertrophy pharmacology, and the preoperative and intraoperative 
management of IFIS.
Senior Instructor(s): David F Chang MD*
Instructor(s): Steve A Arshinoff MD*, Allan J Flach MD
Advanced IOL Power Calculations for the Cataract and 
Refractive Surgeon
Course: 301 Monday
Room: R06 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: The indications for an IOL implantation following cataract or clear lensec-
tomy have significantly increased. Techniques for determining the proper IOL and power 
will be presented.
Objective: This course will provide clear methods and techniques for determining the 
proper IOL and power for complicated cases and will familiarize the clinician with indica-
tions and limitations of specialty lenses, such as multifocal and toric IOLs.
Senior Instructor(s): Jack T Holladay MD MSEE FACS*
 NEW  Phacoemulsification in Eyes With Complex Corneal 
Situations
Course: 305 Monday
Room: 355 9:00 - 10:00 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Phacoemulsification in cases with corneal problems poses difficulty in sur-
gery and suboptimal visual outcome. This course will include specific surgical steps and 
planning to improve the outcome in cases with these complex corneal problems. Ap-
propriate evaluation and surgical technique to achieve optimal outcome will be demon-
strated in eyes with endothelial corneal dystrophy / compromised endothelial function, 
as well as in cases with corneal opacity and haze due to corneal dystrophies / healed 
keratitis or traumatic scars. The course will also include phacoemulsification surgery in 
cases following refractive surgery and keratoplasty.
Objective: At the end of the course, the attendee will be well versed in the exact meth-
od of successfully completing phacoemulsification surgery in cases with complex corneal 
problems and achieving good postoperative outcome.
Senior Instructor(s): Jeewan S Titiyal MD
Instructor(s): Rajesh Sinha, Abhay Raghukant Vasavada MBBS FRCS*, Arup Chakrabarti 
MBBS, Sana Ilyas MD
 NEW  Implanting the Add-On Mirror Telescopic Intraocular 
Implant in AMD Eyes: Patient Selection, Surgical Technique 
and Clinical Results
Course: 309 Monday
Room: 225 9:00 - 10:00 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: The mirror telescopic implant is adapted to be used in phakic and pseudo-
phakic AMD eyes at any stages of the disease in combination with any IOL. The central 
field is magnified x2.5 while enabling some normal peripheral vision. A unique patient 
selection program will be discussed, along with surgical technique, clinical results, and 
possible complications.
Objective: At the conclusion of this course, the attendee will be able to select patients 
suitable for implantation, learn how to use the special program for patient selection, 
understand the design and optical performance of the device, be able to demonstrate to 
patients the expected postop results, be familiar with the surgical technique, evaluate 
the clinical results that will be presented by 3 leading surgeons, and learn how to avoid 
possible complications.
Senior Instructor(s): Isaac Lipshitz MD*
Instructor(s): Amar Agarwal MD*, Juan-Carlos Abad MD, Nada Jiraskova MD**
Understanding Ophthalmic Viscosurgical Devices to Optimize 
Their Use in Cataract Surgery and Complications
Course: 323 Monday
Room: 224 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will consist of a slide and video presentation of rheologic proper-
ties, classification, and varied utilization techniques for different ophthalmic viscosurgi-
cal device (OVD) types. New OVDs, recent discoveries, and principles and techniques to 
prevent and manage complications and postoperative IOP will be covered. Ample op-
portunity for discussion will be available.
Objective: At the conclusion of this course, attendees will have gained (1) insight into 
the rheologic properties and surgical behavior of different OVDs and (2) understanding 
about choice and optimal use of OVDs. This will enhance attendees’ skills in surgery and 
complication management.
Senior Instructor(s): Steve A Arshinoff MD*
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 NEW   YO  From Cadaver Eyes to Virtual Reality: Surgical 
Simulators 101
Course: 330 Monday
Room: 335 9:00 - 10:00 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Many tools are available to simulate cataract surgery, from traditional 
wet lab experience to virtual reality computer simulation. Effective surgery simulation 
is essential for training; however, the time and cost of establishing a surgical simula-
tion program is significant. This course will discuss the spectrum of phacoemulsification 
simulation tools and their respective strengths and weaknesses. Three distinct examples 
of surgical training through integration of surgical simulation will be presented from the 
Flaum, Wilmer, and Moran Eye Institutes. Simulation systems discussed will include the 
Kitaro wet and dry lab system, the EYESi VR Magic simulator, and the ImmersiveTouch 
Microvis simulator.
Objective: At the conclusion of this course, the attendee will (1) know the spectrum of 
surgical simulation tools available, (2) understand the respective strengths and weak-
nesses of available tools, and (3) know how to implement a systematic, structured, surgi-
cal simulation curriculum for training.
Senior Instructor(s): Jeff H Pettey MD*
Instructor(s): Yousuf M Khalifa MD*, Shameema Sikder MD*
 YO  Astigmatism in the Cataract Patient
Course: 130 Monday
Room: 355 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover management techniques for pre-existing astigmatism, 
specifically at the time of implant surgery, with focus upon intralimbal relaxing incisions, 
toric IOLs, and laser (femto / excimer) treatment modalities.
Objective: At the conclusion of this course, participants will be able to plan and per-
form the techniques necessary to control postcataract astigmatism.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Louis D Skip Nichamin MD*
Instructor(s): Jonathan B Rubenstein MD*
Cataract Surgery and Uveitis: Controlling Inflammation, Difficult 
Pupils, and Distorted Anatomy
Course: 360 Monday
Room: R06 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMP
Synopsis: This course will teach the management of difficult and potentially compli-
cated cataract surgery in uveitis using surgical videos (including 3-D videos) highlighting 
unique uveitic anatomy. The focus will be on preoperative immunosuppression and pa-
tient selection, intraoperative management of distorted uveitic anatomy, and postopera-
tive considerations. Both surgical and medical guidelines for the ophthalmologist will be 
given, with an emphasis on immunosuppression.
Objective: At the conclusion of this course, attendees will understand preoperative 
planning and immunosuppression for cataract surgery in uveitis patients. They will learn 
intraoperative management of uveitic anatomy via surgical videos and the management 
of postoperative inflammation.
Senior Instructor(s): Michael Saidel MD*
Instructor(s): David M Hinkle MD, Donald Stone MD, Debra A Goldstein MD*
 h  Learning Phaco Chop: Pearls and Pitfalls
Course: 368 Monday
Room: R06 2:00 - 4:15 PM
Education Level: INT Target Audience: COMP
Synopsis: Phaco chop minimizes ultrasound time and zonular stress. Pearls and strate-
gies for learning this technique will be presented, based upon the instructors’ experience 
in teaching residents. Using a special projection system, the audience will don stereo 
glasses to view 3-D high-definition videos that uniquely illustrate the angle and depth of 
the instrument tips for both horizontal (Nagahara) and vertical (quick chop) methods of 
chopping. A stepwise game plan for converting to phaco chop will be presented, along 
with phacodynamics principles for selecting machine parameters and instrumentation.
Objective: This course will present both variations of the phaco chop technique, their 
advantages in complicated cases, the instrumentation, machine parameters, and transi-
tion steps involved, and common mistakes.
Senior Instructor(s): David F Chang MD*
Instructor(s): Randall J Olson MD, Louis D Skip Nichamin MD*, Barry S Seibel MD*
 NEW  Cataract Surgery in Patients With Retinal Disease
Course: 371 Monday
Room: 210 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Recent advances including the advent of anti-VEGF therapy have changed 
our perspective on the management of common retinal disorders as well as coexist-
ing cataract in these patients. This course will include lectures, images, and interactive 
discussions about many issues that arise when cataract surgery is being considered in 
patients with retinal disorders such as exudative AMD and diabetic macular edema.
Objective: At the conclusion of this course, attendees will be able to recognize diag-
nostic and management issues involved when considering cataract surgery for patients 
with retinal diseases such as AMD and diabetic macular edema.
Senior Instructor(s): Homayoun Tabandeh MD MS FRCP FRCOphth*
Instructor(s): David S Boyer MD*, Kourous Rezaei MD*, Pouya N Dayani MD**, John D 
Hofbauer MD*
 NEW  Advancing Technology and Technique With 
Femtosecond Lasers in Refractive Cataract Surgery: A Video 
Review
Course: 375 Monday
Room: 209 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Participants will learn how to create and manage a laser-created capsuloto-
my to avoid complications, and how to optimize reduced cumulated dissipated energy as 
well as its clinical significance. The course will also define and illustrate the latest inte-
grated software guidance systems designed for surgical planning, especially as related 
to the correction of pre-existing astigmatism. The utilization of multipurpose femtosec-
ond laser platforms will also be presented, as will discussions regarding the incorpora-
tion and practicality of such systems in the cataract and refractive surgery practice.
Objective: At the conclusion of the course, participants should be able to avoid or man-
age surgical complications associated with femtosecond lasers in refractive cataract 
surgery and to evaluate the effectiveness of incorporation into a surgical practice.
Senior Instructor(s): Zoltan Nagy MD*
Instructor(s): Michael C Knorz MD*, Kerry D Solomon MD*, Stephen G Slade MD FACS*, 
Vance Michael Thompson MD*
 NEW  Achieving Proper Centration and Alignment for Vision 
Correction in Keratorefractive and Intraocular Surgery
Course: 379 Monday
Room: 220 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This lecture and video-based course will demonstrate how to center and 
align keratorefractive and intraocular devices and procedures for vision correction. Pearls 
on interpreting diagnostic testing, including corneal topography and pupil imaging, will 
be presented. Techniques for achieving good alignment and centration of diffractive 
multifocal and toric IOLs, limbal relaxing incisions, and corneal inlays—including the 
importance angle kappa—will be demonstrated and discussed.
Objective: At the conclusion of this course, attendees will be able to apply practical 
techniques, including the use of common imaging studies, to achieve good centration 
and alignment in keratorefractive and intraocular surgery.
Senior Instructor(s): Daniel H Chang MD*
Instructor(s): George O Waring IV MD*, John J DeStefano MD
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Cliffhanger: Vitrectomy by the Anterior Segment Surgeon for 
the Broken Posterior Capsule, the Sinking Nucleus, and the 
Dangling IOL
Course: 388 Monday
Room: R03 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Every anterior segment surgeon faces the problem of a broken posterior cap-
sule at some time or another and should know how to perform vitrectomy. One should 
also know how to manage a dropped nucleus or sinking fragments. Various techniques 
like the posterior-assisted levitation technique (PAL) and others will be taught, including 
how to perform bimanual vitrectomy. The dangling IOL and fixation of a posterior cham-
ber IOL in eyes without capsule using the glued IOL technique will also be taught. The 
management of various challenges will be explained through videos.
Objective: At the end of the course, the attendee will be able to fix an IOL in eyes 
without capsules, retrieve sinking lens fragments, and also do a thorough vitrectomy 
when required.
Senior Instructor(s): Amar Agarwal MD*
Instructor(s): David F Chang MD*, William F Mieler MD*
Techniques and Devices for Surgical Reconstruction of 
Traumatic and Developmental Iris Defects
Course: 396 Monday
Room: 209 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Iris reconstruction is required in cases of partial defects or total aniridia. This 
course will review all the currently available artificial iris implants in Europe and North 
America, including techniques and tips on implantation. Topics include (1) preoperative 
assessment and surgical planning, (2) systematic approach to iris reconstruction, (3) re-
view of currently available artificial iris devices, (4) indications, (5) detailed surgical tech-
niques of each type (demonstrated with videos), and (6) complications and management. 
Surgical videos will be used extensively to demonstrate the techniques of each modality 
and the management of complications.
Objective: After the course, the attendee will have gained a greater insight into the 
assessment, indications, and surgical strategies available for reconstructing the iris, to-
gether with management of complications in iris reconstruction.
Senior Instructor(s): Sathish Srinivasan MBBS*
Instructor(s): Michael E Snyder MD*
A Video Bouquet of Phaco Complications That Should Never 
Have Occurred, With Tips on Damage Control and Prevention to 
Optimize Postoperative Outcome
Course: 408 Monday
Room: R08 3:15 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This video course deals with the genesis, management, and prevention of 
unexpected surgeon- or technique-related complications in phacoemulsification in un-
complicated cataracts. The course will demonstrate complications that may be encoun-
tered during all steps of phaco (both uncomplicated and difficult cataracts) and will offer 
a stepwise strategy to prevent and manage them. Complications and remedial measures 
demonstrated include wound burns, wound length anomalies, capsulorrhexis extension 
and retrieval, two-stage rrhexis, use of microrrhexis forceps / scissors in tricky cases, 
incomplete / difficult hydrodissection, hurdles in phaco chop, misplaced capsular tension 
ring, inappropriately used iris hook, how to convert to a safer nonphaco technique in 
problem situations, and more.
Objective: At the end of the course, the attendee will have learned how to avoid and 
successfully manage certain intraoperative phaco complications that can not only mar 
the postoperative outcome but can also lead to sight-threatening sequelae.
Senior Instructor(s): Arup Chakrabarti MBBS
Instructor(s): Thomas A Oetting MD, Amar Agarwal MD*, Kevin M Miller MD*, Abhay 
Raghukant Vasavada MBBS FRCS*, Samuel Masket MD*, Khiun F Tjia MD*, Meena 
Chakrabarti MBBS
Clinical Decisions in the Management of Complications of 
Cataract and IOL Surgery
Course: 410 Monday
Room: 355 3:15 - 5:30 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This program brings together 12 experts in cataract and IOL surgery to dis-
cuss common and rare problems. First, the most unusual complication of the year will be 
presented by expert ophthalmologists, who will describe it up to the point of the clinical 
decision. Then the panel and/or audience will discuss the problem, and finally the pre-
senter will reveal the chosen management and resolution of the problem.
Senior Instructor(s): Manus C Kraff MD*
Instructor(s): Lisa B Arbisser MD*, Alan S Crandall MD*, Kenneth J Hoffer MD FACS*, 
Sheri Rowen MD*, Geoffrey C Tabin MD, James P Gills MD*, Marc A Michelson MD*, 
Louis D Skip Nichamin MD*, Luther Fry MD FACS*, James A Davison MD*, Kenneth J 
Rosenthal MD FACS**
 NEW  Temporal, Manual, Small- Incision Cataract Surgery: A 
Technique for the Developing and Developed World
Course: 420 Monday
Room: R03 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will teach participants an effective temporal, manual, small-
incision cataract surgery (SICS) for cost-effective, high-volume surgeries in the devel-
oping world and how to adapt it to difficult phacoemulsification cases3/4an important 
technique for those who are proficient in phacoemulsification. The course will be taught 
by surgeons with many years of experience with SICS, and early recognition of potential 
problems and how to avoid and manage them will be discussed.
Objective: At the end of the course, the attendees will be able to understand and per-
form the steps of temporal, manual SICS and how to adapt it to their difficult phacoemul-
sification cases to achieve high-quality visual outcomes.
Senior Instructor(s): Vadrevu K Raju MD FRCS FACS
Instructor(s): Madhavi Ghanta MD DNB**, Leela V Raju MD
A Video Symposium of Challenging Cases and the Management 
of Intraoperative Complications During Cataract Surgery
Course: 513 Tuesday
Room: R06 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover a spectrum of difficult cataract cases as well as a 
potpourri of intraoperative complications. The video content, which is updated yearly, 
will be discussed by the panel.
Objective: This course will expose the surgeon to principles and techniques useful in 
operating difficult cases and in managing serious intraoperative complications.
Senior Instructor(s): Robert H Osher MD*
 NEW  Advanced Techniques With Laser Cataract Surgery
Course: 517 Tuesday
Room: 228 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Basic certification in the use of a particular femtosecond laser confers only 
a degree of facility with the technology. This course will provide a wide range of real-
world, experience-driven pearls and tips to enhance efficiency, safety, and efficacy when 
using the femtosecond laser.
Objective: At the conclusion of the course, the surgeon will have a better understand-
ing of optimal patient selection, preoperative preparation, surgical planning, surgical 
execution, and unexpected event management than prior to this educational event.
Senior Instructor(s): Mark H Blecher MD
Instructor(s): William W Culbertson MD*, Jonathan H Talamo MD*, Burkhard Dick MD*, 
Lisa B Arbisser MD*
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 YO  Phaco Pearls for the Beginner
Course: 518 Tuesday
Room: 333 9:00 - 11:15 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This video course will teach surgical pearls and recommend guidelines to 
fine-tune all steps in routine phaco for uncomplicated cataracts in a comprehensive man-
ner. The course will highlight proper techniques and demonstrate specific strategies and 
maneuvers to optimize outcomes and to avoid iatrogenic complications. Adjunctive de-
vices to stabilize the capsular bag and ensure pupillary dilatation will also be discussed. 
The technique of converting to a safer nonphaco small-incision cataract surgery (SICS) 
in problematic situations like posterior chamber tear and impending nucleus drop will 
also be demonstrated.
Objective: Attendees will be able to fine tune their surgical strategy and optimize out-
comes of all steps of phacoemulsification in uncomplicated scenarios on a consistent 
basis, and will learn how to prevent common complications and successfully manage 
them should they still occur.
Senior Instructor(s): Arup Chakrabarti MBBS
Instructor(s): Thomas A Oetting MD, Kevin M Miller MD*, Abhay Raghukant Vasavada 
MBBS FRCS*, Warren E Hill MD*, Richard B Packard MD*, Samar K Basak MD DNB 
MBBS*, Jeewan S Titiyal MD
 NEW  Management of Malpositioned IOLs
Course: 520 Tuesday
Room: R04 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Early and late decentration / dislocation of IOLs represent significant com-
plications of current cataract surgery. This instruction course will consider the etiology, 
possible prevention, and, primarily, the surgical management of malpositioned IOLs.
Objective: To (2) recognize the causes of IOL dislocation / decentration, (2) consider 
prevention of malpositioned IOLs, (3) through use of video presentations, demonstrate 
various surgical techniques for correction of IOL decentration / dislocation.
Senior Instructor(s): Samuel Masket MD*
Instructor(s): Amar Agarwal MD*, Nicole R Fram MD*, Sadeer B Hannush MD, Thomas 
A Oetting MD
 h   YO  Multifocal and Accommodative IOLs: Face the 
Challenge
Course: 527 Tuesday
Room: 218 9:00 - 11:15 AM
Education Level: ADV Target Audience: COMPSUB
Synopsis: We will review the state-of-the-art knowledge on presently available multi-
focal and accommodative IOLs (MAI). Their features, indications and contraindications, 
matching possibilities, and clinical results, pursuing highly satisfactory uncorrected dis-
tance, intermediate, and near vision, will be examined. New multifocal IOLs (ie, torics) 
will be discussed.
Objective: Attendees will receive information on how to use MAI. A structured ap-
proach on patient and IOL selection based on accurate matching of IOL features with 
patient needs will be provided. Discussion will include IOL performance in terms of con-
trast sensitivity, light distribution and loss, and management of complications and visual 
complaints, with available solutions. The importance of achieving plano results will be 
well supported. At the end of this course, the attendee will be able to improve surgical 
center organization, choose the best IOLs for each specific patient, and manage possible 
postop complications.
Senior Instructor(s): Matteo Piovella MD*
Instructor(s): David F Chang MD*, Richard L Lindstrom MD*, Jack T Holladay MD MSEE 
FACS*, Jay Stuart Pepose MD PhD*, Richard Tipperman MD*, Claudio Carbonara MD*, 
Barbara Kusa MD
Microsurgical Suturing Techniques
Course: 144 Tuesday
Room: 340 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will cover basic microsurgical suturing techniques. In addition, 
principles, theories, and practical instruction in corneal-scleral laceration and corneal 
wound repair, management of cataract wound problems, including wound burns, and 
extension of clear corneal incisions will be offered.
Objective: This course offers basic microsurgical suturing training that is applicable in 
the management of penetrating keratoplasty suturing, corneal lacerations, and cataract 
wound problems. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Marian Sue Macsai-Kaplan MD*
Instructor(s): Woodford S Van Meter MD FACS
 NEW  Refractive and Cataract Surgery Nightmares: 
Management and Prevention of Most Common Complications
Course: 533 Tuesday
Room: 252 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will present intraoperative and postoperative complications 
of refractive and cataract IOLs surgery, showing possible and different strategies for 
managing sudden complicated and dangerous events in standard and difficult cases . 
The faculty will discuss pathogenesis, technical caveats, planned approach, prevention, 
diagnostic workup, management, and long-term follow-up of complicated cases. Special 
sections will be dedicated to post-refractive surgery ectasia, crosslinking, premium IOLs, 
and glare and halos management.
Objective: To provide state-of-the-art knowledge about prevention, management, and 
follow-up of the possible complications of refractive and cataract surgery, with a series 
of nightmare cases.
Senior Instructor(s): Donald N Serafano MD*
Instructor(s): Matteo Piovella MD*, David F Chang MD*, Daniel Epstein MD PhD, Roberto 
Zaldivar MD*, Richard L Lindstrom MD*, Marguerite B McDonald MD*, Robert H Osher 
MD*, Mounir A Khalifa MD*, Mohamed Shafik Shaheen MD PhD
 NEW  Better Surgery Through Chemicals
Course: 543 Tuesday
Room: 220 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will review the relevant pharmacology and physiology of intra-
camerally and intravitreally applied agents that include mydriatics, anesthetics, stains, 
ophthalmic viscosurgical devices, antioxidants, gas, steroids, antibiotics, and anti-VEGF 
agents. Potential risks of these agents and compounding as well as regulatory issues 
will be discussed. A panel discussion and questions from the audience will conclude 
the presentation.
Objective: Attendees will learn current options for intraocular administration of intra-
ocular medications and other agents for prophylaxis of intraoperative floppy iris syn-
drome and endophthalmitis and management of intraocular complications in intraocular 
surgery.
Senior Instructor(s): William G Myers MD*
Instructor(s): Minas T Coroneo MD MS*, Samuel Masket MD*, David B Glasser MD, 
Steve A Arshinoff MD*, William F Mieler MD*, Harry W Flynn MD*, James P Gills MD*, 
Ramon Lorente MD, Charles Leiter*
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Surgical Management of Astigmatism in Cataract and 
Refractive Surgery
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and the 
International Society of Refractive Surgery (ISRS)
Course: 550 Tuesday
Room: 208 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will teach strategies for minimizing surgically induced astigma-
tism, discuss surgical options for treating astigmatism during cataract and refractive sur-
gery (including wound construction approaches, limbal relaxing incisions, toric IOLs, and 
corneal refractive surgical techniques), and demonstrate methods to treat postoperative 
astigmatism occurring after cataract and refractive surgery.
Objective: By the conclusion of this course, the participants will be able to (1) identify 
regular and irregular astigmatism, (2) understand surgical strategies to minimize surgi-
cally induced astigmatism and determine treatment strategies for astigmatism, including 
complex refractive errors and eyes not amenable to surgical treatment, and (3) employ 
practical strategies for determining patient goals and desires for astigmatism correction.
Senior Instructor(s): J Bradley Randleman MD
Instructor(s): David T Vroman MD*
The Art of Achieving Success With Presbyopia-Correcting 
Intraocular Implants: The Consultation, the IOLs, and Correcting 
Residual Refractive Errors
Course: 551 Tuesday
Room: R08 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMP
Synopsis: This course will explore the three critical factors for producing happy pa-
tients with presbyopia-correcting IOLs (PC-IOLs): (1) strategies for conducting the preop-
erative consultation, (2) understanding the uniqueness of each PC-IOL, and (3) numerous 
strategies for correcting residual refractive errors. Both laser and incisional techniques 
for treating residual refractive errors will be discussed in detail.
Objective: Upon completion of this course, attendees will gain a better understanding 
of key issues for maximizing patient outcomes and patient satisfaction when correcting 
presbyopia with IOLs.
Senior Instructor(s): Frank A Bucci MD*
 NEW  Scleral Fixation of IOL With Fibrin Glue
Course: 571 Tuesday
Room: 208 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: IOL implantation is difficult in patients with absent or deficient capsular 
support. Sutured scleral-fixated IOLs and iris-fixated lenses suffer from inherent disad-
vantages and are not suitable for all cases. This course will introduce a technique of 
posterior chamber IOL fixation in patients with absent / deficient capsular support by 
tucking the haptics in scleral tunnels and using fibrin glue to reinforce the flap, ensuring 
IOL stability and centration with reduced surgical time and minimal complications. IOL 
fixation with fibrin glue is suitable for all patients, including those with multifocal IOLs. 
Various surgeons will share their experience with glued IOLs and discuss the merits and 
demerits of this exciting new technique of IOL fixation.
Objective: At the conclusion of this course, the attendee will be familiar with the tech-
nique of glued IOL and should be able to perform it.
Senior Instructor(s): George Beiko MD*
Instructor(s): Gabor Bernd Scharioth MD*, Amar Agarwal MD*, Kenneth J Rosenthal MD 
FACS**, Avnindra Gupta SR, David T Vroman MD*
Best of the Best : An Update in Cataract Surgery
Course: 572 Tuesday
Room: R06 12:45 - 3:00 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will discuss how advances in technology, IOLs, phaco machines, 
femtolasers, hydrogel bandages and indications are making cataract surgery extremely 
similar to refractive surgery. The cataract surgeon must not only provide restoration of 
vision but also optimal vision quality; the ideal, and increasingly demanded, result of 
cataract surgery is plano correction. This requires accurate customization of IOL choice, 
obsessively accurate biometry, adoption of new technologies (microincision and premium 
IOLs: multifocal, toric, multifocal + toric, aspheric).
Objective: This course is designed to provide attendees with key information in apply-
ing a refractive surgery approach to exploiting recent technological, surgical, organiza-
tional, and patient management advances.
Senior Instructor(s): Matteo Piovella MD*
Instructor(s): Fabrizio I Camesasca MD*, David F Chang MD*, Steven J Dell MD*, 
Stephen S Lane MD*, Richard L Lindstrom MD*, Steven C Schallhorn MD*, Roger F 
Steinert MD*
 NEW   YO  Cataract Surgery Crisis Management 101
Course: 583 Tuesday
Room: 338 12:45 - 3:00 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: Present-day cataract management requires a surgeon not only to incorporate 
newer technologies but also to update skills in managing complications. This course 
aims to identify complicated situations that every surgeon may encounter during or after 
cataract surgery and provides pearls to effectively manage such crises. It will illustrate 
critical management of issues such as posterior capsule rupture, phacoemulsification in 
challenging ocular environments, and dissatisfied premium IOL patients.
Objective: To provide trouble-shooting pearls for successful management of different 
intraoperative and postoperative complications during cataract surgery. The attendees 
shall learn from the instructors’ video case demonstrations and interactive discussion.
Senior Instructor(s): Abhay Raghukant Vasavada MBBS FRCS*
Instructor(s): Robert H Osher MD*, Alan S Crandall MD*, Nick Mamalis MD*, Kevin M 
Miller MD*, Samuel Masket MD*
Comprehensive Strategy for Unplanned Vitrectomy Technique 
for the Anterior Segment Surgeon
Course: 587 Tuesday
Room: 220 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will propose a strategy for prevention, early recognition, damage 
control, and specific plans for action to achieve an optimal outcome in cataract surgery 
complicated by vitreous presentation. Anterior and pars plana approaches will be de-
tailed with ample video. The panel includes a retina-vitreous subspecialist.
Objective: By the conclusion of this course, cataract surgeons of all levels of expertise 
will be able to describe a strategy for choosing the method and the timing for removal 
of residual lens material and for undertaking appropriate vitreous management, incision, 
and choice of IOL to achieve optimal outcomes in cataract surgery involving vitreous 
presentation.
Senior Instructor(s): Lisa B Arbisser MD*
Instructor(s): Michael J Howcroft MD*
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Abandoned Phaco: Convert to No-Stitch Manual Small-Incision 
Cataract Surgery
Course: 592 Tuesday
Room: 335 12:45 - 1:45 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Complications do occur in phacoemulsification surgery, for many reasons. 
Sometimes, the surgeons convert phaco to extracapsular cataract extraction (ECCE) for 
the patient’s safety. The closed chamber situation is then compromised, and problems of 
suturing are also there. But if the surgeon converts it to no-stitch manual small-incision 
cataract surgery (SICS), the wound integrity will remain and rehabilitation will be much 
faster. This course will teach the basics of an effective no-stitch manual SICS, which is 
crucial when complications are faced during phacoemulsification surgery.
Objective: At the conclusion of this video-based course, the cataract surgeon will be 
able to understand (1) the indications of primary no-stitch manual SICS technique in 
the most difficult situations, (2) how to perform no-stitch manual SICS, step by step, 
(3) conversion of abandoned phaco to no-stitch manual SICS, and (4) how to deal with 
complications of no-stitch manual SICS if they occur.
Senior Instructor(s): Samar K Basak MD DNB MBBS*
Instructor(s): Santanu Mitra MBBS, Arup Chakrabarti MBBS
Secure Posterior Chamber IOL Placement Without Adequate 
Capsular or Zonular Support
Course: 598 Tuesday
Room: 215 2:00 - 4:15 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: Loss of capsular support is often managed by placing an anterior chamber 
or iris-supported IOL. This is not always the best option, especially in eyes with compro-
mised endothelium or angle damage. Video demonstration will be used to show a spec-
trum of techniques to securely place posterior chamber lenses when there is inadequate 
capsular support or decentered bag due to zonular inadequacy. Use in a “hot” setting, 
when unanticipated capsule loss occurs, and in a “cold” setting, when capsule or zonular 
deficiency are known preoperatively, will be covered. Techniques such as optic capture, 
scleral sutured rings and segments, scleral sutured IOLs, haptics glued under scleral 
flaps, and haptics placed in scleral tunnels will be shown in a step-by-step manner.
Objective: At the end of the course, the attendee will have become familiar with a 
range of available techniques to allow secure posterior chamber IOL placement, even 
when there is inadequate capsular support or extensive zonular deficiency.
Senior Instructor(s): Kenneth J Rosenthal MD FACS**
Instructor(s): Amar Agarwal MD*, Michael E Snyder MD*, Suven Bhattacharjee MBBS 
MS
Computers, Information Technology
 NEW   SO  Breakthrough to Social Media
Course: 167 Sunday
Room: 340 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Social media is the preferred form of communication for hundreds of millions 
of consumers, which makes social media an important tool to build physician-patient 
rapport, expand patient knowledge of eye conditions and diseases, and react appropri-
ately to consumer media reports about eye health and vision. Yet many practices are not 
engaged in social media, or underutilize this important tool. What is holding ophthalmol-
ogy back?
Objective: To provide the attendee with a clear understanding of how social media can 
and should be used, and its connection with mobile technology. To remove the barriers 
to social media adoption, including time management concerns. The attendee will leave 
the course with an effective plan to implement social media in ophthalmology practice.
Senior Instructor(s): Vinay A Shah MD*
Instructor(s): Judith Lee*, Rohit Krishna MD*, Ron K Lord MD*
Cornea, External Disease
Surgery for Severe Corneal and Ocular Surface Disease
Course: 104 Sunday
Room: 214 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course is intended for ophthalmologists who plan to expand their surgi-
cal skills in the management of severe corneal and ocular surface disease. The topics 
will include amniotic membrane transplantation, limbal stem cell transplantations, and 
keratoprosthesis.
Objective: At the conclusion of this course, the attendee will be able to (1) describe 
the indications and apply the surgical techniques for amniotic membrane transplanta-
tion, (2) recognize limbal stem cell deficiency and effectively apply the various surgical 
techniques for limbal stem cell transplantation, (3) recognize and successfully prevent / 
treat limbal allograft rejection using systemic immunosuppression, and (4) describe the 
patient selection, surgical techniques, and postoperative management of patients with 
keratoprosthesis. 
Note: This is the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Ali R Djalilian MD
Instructor(s): Gunther Grabner MD*, Edward J Holland MD*, Scheffer C G Tseng MD 
PhD*, James Chodosh MD MPH*, Ahmad Kheirkhah MD, Maria S Cortina MD, Victor L 
Perez MD*
The Boston Keratoprosthesis: Case-Based Presentations 
Highlighting the Essentials for Beginning and Experienced 
Surgeons
Course: 151 Sunday
Room: 209 10:15 AM - 12:30 PM
Education Level: INT Target Audience: SUB
Synopsis: While traditionally considered a procedure of last resort, keratoprosthe-
sis (KPro) implantation is being performed with increasing frequency for an expanding 
variety of indications, including repeat corneal graft failure and corneal opacification 
combined with limbal stem cell failure. The design, indications and contraindications, 
surgical technique, and postoperative management of the Boston KPro will be presented.
Objective: Attendees will learn to recognize patients in their practices who are good 
candidates for KPro implantation. Presentation of surgical videos and a detailed discus-
sion of the postoperative management will familiarize attendees with KPro implantation, 
as well as with avoidance and management of postoperative complications.
Senior Instructor(s): Anthony J Aldave MD*
Instructor(s): Esen K Akpek MD*, James Aquavella MD*, Michael W Belin MD*, James 
Chodosh MD MPH*, Kathryn A Colby MD PhD*, Claes H Dohlman MD PhD*, Sadeer B 
Hannush MD
Endothelial Keratoplasty (DSEK/DSAEK/DMEK/DMAEK): 
Current Strategies to Improve Results and Avoid Complications
Course: 155 Sunday
Room: R05 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will feature a video and slide presentation of the current 
surgical technique, instrumentation, and complications of endothelial keratoplasty 
(EK)3/4Descemet-stripping automated EK (DSAEK) and Descemet membrane EK 
(DMEK)3/4from the largest prospective series in the world (> 1800 cases). Easier and 
faster DSAEK and DMEK techniques will be emphasized. Current modifications of EK that 
avoid complications will be stressed. Various techniques for DSAEK insertion (forceps, 
Busin glide, “pull through,” injectors) will be shown and correlated with their induced 
endothelial damage. EK combined with vitrectomy, secondary IOL, and cataract surgery 
will be presented, including special care using “precut” and “prestripped” tissue. The 
course will emphasize an ethical, prospective approach to this new surgery and methods 
on how to avoid common surgical and postoperative pitfalls.
Objective: At the conclusion of the course, the attendees will recognize the principles 
of EK surgical technique that produce low complications and excellent vision.
Senior Instructor(s): Mark A Terry MD*
Instructor(s): Michael D Straiko MD*, Paul M Phillips MD
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Extreme Corneal Ectasia: Battle of the Bulge
Course: 163 Sunday
Room: R01 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Advanced-stage ectatic disorders of the cornea may be associated with 
extreme thinning and forward protrusion of the cornea. Surgical intervention is often 
necessary to restore tectonic integrity and corneal anatomy, besides improving eyesight. 
Customized grafts —D-shaped, banana or crescent shaped, large diameter corneoscleral 
grafts, epikeratoplasty, lamellar grafts, wedge excision, and other techniques—are used 
in such situations. This course will discuss indications, preoperative evaluation, inves-
tigations, surgical planning and stepwise execution, managing intra- and postoperative 
complications, and postoperative care. A variety of clinical cases will be presented, 
along with videos, to enable discussion and audience interaction.
Objective: At the end of the course, the attendee will have a clear understanding of 
the various surgical options available in the management of extreme corneal ectasia. 
Application of appropriate surgical techniques will help improve vision as well as corneal 
anatomy and shape.
Senior Instructor(s): Rajesh Fogla MD FRCS*
Instructor(s): Sheraz M Daya MD*, Rasik B Vajpayee MD, Pravin Vaddavalli MD, Rishi 
Swarup MBBS FRCS, Vincenzo Sarnicola MD, Donald Tan MD FRCS FRCOphth*
Current Topics in Cornea/External Disease: Highlights of the 
Basic and Clinical Science Course 8
Course: 174 Sunday
Room: 223 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course is presented by the authors of Section 8 Basic and Clinical Sci-
ence Course series on the latest in diagnosis and treatment in cornea and external dis-
ease.
Objective: At the conclusion of this course the participant should be able to diagnose 
and manage the patient with tear dysfunction. They should be able to recognize common 
infectious, neoplastic, and immune-related diseases and prescribe appropriate treat-
ment. They should be able to differentiate the common corneal dystrophies. They should 
understand the role of collagen crosslinking, Descemet-stripping automated endothelial 
keratoplasty, Descemet membrane endothelial keratoplasty, deep anterior lamellar kera-
toplasty, and penetrating keratoplasty for the treatment of corneal disease.
Senior Instructor(s): Robert W Weisenthal MD
Instructor(s): Charles S Bouchard MD, Stephen E Orlin MD, Kathryn A Colby MD PhD*, 
Elmer Tu MD*, Natalie A Afshari MD, Denise de Freitas MD
 NEW  Cell-Based Therapy for Ocular Surface Reconstruction
Course: 179 Sunday
Room: 340 2:00 - 3:00 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: Ocular surface integrity is dependent on the intricate homeostatic loop that 
is governed by stem cells residing in the limbal niche. In this course, we will discuss (1) 
the role of stem cells in ocular surface health and disease, (2) stem cell-based therapy to 
manage them, (3) identification and quantification of stem cell deficiency using clinical 
signs, cell markers, and impression cytology, (4) preoperative assessment to chose ap-
propriate procedures, (5) techniques of stem cell retrieval and transplantation, (6) ex vivo 
expansion techniques, (7) direct stem cell transplantation and in vivo expansion, (8) the 
role of other stem cells sources (oral mucosa, dental pulp, hair follicle), (9) postoperative 
assessment, and (10) maintenance of stem cell health and outcomes of various forms of 
therapies for ocular surface disorders.
Objective: At the end of the course, attendees will be able to identify candidates for 
stem cell therapy, use appropriate techniques for stem cell retrieval, expansion, and 
transplantation, and effectively manage them postoperatively.
Senior Instructor(s): Somasheila I Murthy MD
Instructor(s): Shigeru Kinoshita MD*, Scheffer C G Tseng MD PhD*, Sayan Basu 
MBBS**, Jatin Naresh Ashar MD, Anurag Mathur MBBS
Ocular Surface Disease Management: Moving From Adequate 
to Expert
Course: 198 Sunday
Room: 338 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Ocular surface disease encompasses several entities, including keratocon-
junctivitis sicca and meibomian gland dysfunction, that share a common denominator: 
an inflamed and desiccated ocular surface. In this course, the pathogenesis, signs and 
symptoms, and diagnosis of specific ocular surface disease entities will be discussed. 
Case presentations will be used to help guide discussion of management and treatment 
options.
Objective: This course will help the clinician understand the pathophysiology and 
management of ocular surface disease. Attendees will (1) improve the diagnostic skills 
and therapeutic techniques used with keratoconjunctivitis sicca, blepharitis / meibomian 
gland dysfunction, and atypical conjunctival diseases, (2) understand the pathophysiol-
ogy of ocular surface disease, (3) increase their knowledge of drugs available to treat 
ocular surface disease, and (4) have a working differential diagnosis of the irritated and 
red eye.
Senior Instructor(s): Gregg J Berdy MD*
Instructor(s): Joseph Tauber MD*
 h  Help! A Corneal Ulcer Just Walked In! What Do I Do Next?
Course: 203 Sunday
Room: 210 2:00 - 4:15 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: Ophthalmologists invariably encounter corneal ulcers in practice. The knee-
jerk response is to treat with fourth-generation fluoroquinolones. However, this may be 
ineffective and could actually be detrimental in autoimmune or noninfectious keratitis. 
Features to identify in diagnosing and differentiating between the various types of cor-
neal ulceration (infectious and noninfectious) will be presented. The various established 
and experimental medical and surgical therapies to treat corneal ulceration will be de-
scribed, along with an explanation of which therapies may be useful for which types of 
ulcers. A flow chart for formulating a therapy plan for corneal ulceration will also be 
presented.
Objective: At the conclusion of this course, the attendees will be able to (1) differenti-
ate the various types of corneal ulceration, (2) determine which ulcers need emergent, 
urgent, or routine therapy, and (3) formulate a logical and stepwise treatment plan and 
decide when referral to a tertiary center is necessary.
Senior Instructor(s): Sonal S Tuli MD
Endothelial Keratoplasty Techniques
Course: 121 Sunday
Room: 342 3:15 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will explore the various surgical techniques used for endothelial 
keratoplasty (EK): Descemet-stripping EK, Descemet-stripping automated EK, and Des-
cemet membrane EK. Emphasis will be placed on basic techniques that minimize compli-
cations and maximize donor endothelial survival. Methods of donor tissue preparation, 
insertion, unfolding, and positioning will be discussed. Benefits and problems with tissue 
injectors will be presented. Techniques to promote donor tissue adhesion and to avoid 
primary graft failure will be emphasized. Detailed videos and discussion of EK in complex 
and combined cases will be presented.
Objective: At the conclusion of the course, participants will understand the safest 
methods of EK to avoid dislocation, primary graft failure, and pupillary block, and how to 
enhance faster visual rehabilitation. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Mark A Terry MD*
Instructor(s): Kenneth M Goins MD, George O D Rosenwasser MD*
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Endothelial Keratoplasty Surgery: Comprehensive Overview 
and Surgical Pearls
Course: 122 Sunday
Room: 208 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Endothelial keratoplasty (EK) has become the standard of care for the surgi-
cal treatment of endothelial diseases of the cornea. This course will utilize international 
corneal experts to teach a comprehensive overview of a variety of surgical techniques for 
Descemet-stripping EK (DSEK), including donor tissue preparation, various tissue inser-
tion techniques, and intraoperative surgical pearls. The course will also provide a review 
of the various potential complications of DSEK and their associated management strate-
gies. Finally, tips for starting Descemet membrane EK (DMEK) will be reviewed, along 
with various surgical pearls and outcomes of DMEK techniques.
Objective: At the conclusion of the course, the attendee will understand indications, 
surgical techniques, surgical pearls, and potential complications of DSEK and DMEK.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Edward J Holland MD*
Instructor(s): Francis W Price Jr MD*, Donald Tan MD FRCS FRCOphth*, Massimo Busin 
MD*, Mark J Mannis MD, David T Vroman MD*, William Barry Lee MD*, Keith A Walter 
MD*
Allergic Eye Disease: An Enigma for Physicians
Course: 207 Sunday
Room: 215 3:15 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Ocular allergy is a common disorder, affecting up to 20% of the population. 
Allergic eye diseases affect overall quality of life. Because of their varied presentations, 
they are often missed or may mimic other ocular surface pathologies and sometimes 
even infection. This may delay their diagnosis and management. We will present a se-
ries of cases that depict the various common and uncommon manifestations of allergic 
eye diseases. Topics include seasonal, perennial, vernal, atopic, and toxic keratocon-
junctivitis and their complications and sequelae. A stepwise algorithm approach will 
describe management for each, including the role of topical steroidal and nonsteroidal 
formulations, cyclosporine, mast cell stabilizers and antihistaminics, topical and oral 
anti-inflammatory and immunosuppressive drugs, and prevention and management of 
complications.
Objective: At the end of the course, attendee will be able to differentiate various forms 
of ocular allergies and formulate a logical stepwise treatment plan for them.
Senior Instructor(s): Neal P Barney MD
Instructor(s): Jatin Naresh Ashar MD, Somasheila I Murthy MD, Victor L Perez MD*, 
Anurag Mathur MBBS
Anterior Segment Imaging: A Practical Guide for 
Ophthalmologists
Course: 214 Sunday
Room: 333 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will provide a comprehensive review of established and newer 
anterior segment imaging instruments and their practical clinical uses for evaluation of 
pathology of the cornea and angle. Instructors will cover anterior segment OCT, ultra-
sound biomicroscopy, in vivo confocal microscopy, and corneal topography. The course 
will emphasize a case-based approach to choosing when to use each imaging modality, 
what it adds to clinical practice, and how to interpret the images.
Objective: This course will provide a practical and comprehensive review of anterior 
segment imaging techniques for comprehensive ophthalmologists and anterior segment 
specialists. At the end of the course, attendees will be able to choose the appropriate 
imaging modality to use for individual patients in the clinical setting.
Senior Instructor(s): Roni M Shtein MD*
Instructor(s): Shahzad I Mian MD*, Sayoko E Moroi MD PhD*, Maria A Woodward MD
How to Successfully Accomplish Endothelial Keratoplasty in 
the Presence of Significant Ocular Comorbidities
Course: 218 Sunday
Room: 221 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will outline successful surgical strategies for accomplishing en-
dothelial keratoplasty (EK) in the presence of comorbidities that make successful comple-
tion of surgery more challenging. The instructors will offer pearls for EK in phakic eyes; in 
the presence of cataract, aphakia, iris coloboma or zonular dehiscence, aniridia, anterior 
chamber IOLs, iris or scleral fixated posterior chamber IOLs; in unicameral eyes; and with 
failed penetrating or endothelial keratoplasty, and trabeculectomy or tube shunt. Clini-
cal examples will illustrate points where appropriate steps may help avoid unwanted 
complications. Slides and videos of case studies will be shown, emphasizing dangers 
and solutions.
Objective: This course is designed to enable participants to learn from our experience 
and avoid complications while shortening their learning curve for EK in the presence of 
ocular comorbidities.
Senior Instructor(s): Kathryn A Colby MD PhD*
Instructor(s): Alan Sugar MD, Jayne Weiss MD*, Christopher Rapuano MD*
Diagnosis And Management of Corneal Perforation
Course: 226 Sunday
Room: R05 4:30 - 5:30 PM
Education Level: INT Target Audience: COMP
Synopsis: Corneal perforation is an ophthalmic emergency that requires prompt diag-
nosis and treatment. Although infectious keratitis is a common cause, other causes such 
as corneal xerosis and collagen vascular diseases are also important differential diagno-
ses, especially in cases that do not respond to conventional medical therapy. Based on 
the size and location of the corneal perforation, various treatment options are applicable 
that include medical therapy, corneal gluing, amniotic membrane transplantation, and 
corneal transplantation.
Objective: At the end of the course the attendee will have a clear understanding of the 
concepts of stepwise management of corneal perforation.
Senior Instructor(s): Vishal Jhanji MD
Instructor(s): Rasik B Vajpayee MD, Sujata Das MBBS, Namrata Sharma MD MBBS, 
Jodhbir S Mehta FRCS FRCOPHTH*
 h  Recent Developments in the Diagnosis and Management of 
Conjunctival Tumors
Course: 314 Monday
Room: 215 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Conjunctival tumors have a varied spectrum of clinical presentation. These 
are often misdiagnosed as simulating conditions, often resulting in inappropriate man-
agement and tumor recurrence. The aim of this course is to provide a systematic over-
view of clinical manifestations of conjunctival tumors and to discuss recent concepts 
in diagnosis, management, and prognosis. Clinical evaluation of a case of conjunctival 
tumors and typical and atypical manifestations will be demonstrated with well-docu-
mented clinical cases. Systemic associations will be discussed. Advantages of anterior 
segment imaging techniques will be highlighted. Evidence-based treatment protocols, 
and indications and outcome of newer treatment modalities such as topical chemother-
apy and plaque brachytherapy will be discussed. Standard surgical procedures will be 
demonstrated with video films.
Objective: This course is designed to enable participants to accurately diagnose and 
appropriately manage common conjunctival tumors.
Senior Instructor(s): Santosh G Honavar MD
Instructor(s): Carol L Shields MD, Carol L Karp MD, Jerry A Shields MD
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 NEW  Pediatric Corneal Infections: A Systematic Approach to 
Diagnosis and Management
Course: 320 Monday
Room: 221 9:00 - 10:00 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Infectious keratitis is a common cause of childhood blindness. This course 
will describe the etiology of keratitis at various pediatric ages (neonatal, infantile, and 
later); the clinical features; the differentiating features of noninfective keratitis; risk fac-
tors, detailed protocol for microbiological workup; and treatment, including the role of 
systemic therapy and surgical therapy. A logical, stepwise approach preserves vision. 
The course will end with an interactive discussion on a number of difficult, commonly 
encountered clinical scenarios, with pearls for management for each one.
Objective: The course is designed to highlight the etiology, clinical profile, and system-
atic approach to the management of pediatric microbial keratitis.
Senior Instructor(s): Sunita Chaurasia MD
Instructor(s): Muralidhar Ramappa MBBS, Rasik B Vajpayee MD, Kathryn A Colby MD 
PhD*, Jatin Naresh Ashar MD
 h  Pterygium: The Outcome Measure Is Now Cosmesis, Not 
Recurrence
Course: 322 Monday
Room: 214 9:00 - 11:15 AM
Education Level: BAS Target Audience: COMP
Synopsis: PERFECT for Pterygium (pterygium extended removal followed by extended 
conjunctival transplantation) not only results in minimal recurrences (1 recurrence in 
1000 patients with 99% follow-up of more than 1 year) but also provides an excellent 
cosmetic result.
Objective: Attendees will understand the differences between the PERFECT for Pte-
rygium surgical procedure and routine autoconjunctival surgery for pterygium. They will 
be prepared to treat pterygium as a significant disease, with “serious surgery” designed 
to achieve a low recurrence rate and a cosmetic appearance at 1 year, with the site of 
the pterygium undetectable. Attendees will be able to incorporate into their pterygium 
surgery any components of PERFECT for Pterygium that they do not already use. They will 
understand the expected postoperative course and therapy and the complications of this 
surgery. Above all else, they will learn a new respect for this disease, which has so often 
been trivialized in the past.
Senior Instructor(s): Lawrence W Hirst MD MBBS MPH DO FRACO FRACS*
Instructor(s): Ivan R Schwab MD FACS, Linda Rose MD PhD*
How to Successfully Accomplish Endothelial Keratoplasty in 
the Presence of Significant Ocular Comorbidities
Course: 326 Monday
Room: 346 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will outline successful surgical strategies for accomplishing en-
dothelial keratoplasty (EK) in the presence of comorbidities that make successful comple-
tion of surgery more challenging. The instructors will offer pearls for EK in phakic eyes; in 
the presence of cataract, aphakia, iris coloboma or zonular dehiscence, aniridia, anterior 
chamber IOLs, iris or scleral fixated posterior chamber IOLs; in unicameral eyes; and with 
failed penetrating or endothelial keratoplasty, and trabeculectomy or tube shunt. Clini-
cal examples will illustrate points where appropriate steps may help avoid unwanted 
complications. Slides and videos of case studies will be shown, emphasizing dangers 
and solutions.
Objective: This course is designed to enable participants to learn from our experience 
and avoid complications while shortening their learning curve for EK in the presence of 
ocular comorbidities.
Senior Instructor(s): Sadeer B Hannush MD
Instructor(s): Anthony J Aldave MD*, Henry D Perry MD*
Anterior Lamellar Keratoplasty: Principles and Practice
Course: 131 Monday
Room: 342 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: This course will cover current and evolving practice in anterior lamellar 
keratoplasty. Topics include evolving lamellar techniques, including the “big bubble,” 
modified Melles, viscodissection, Ferrara, and automated and femtosecond lamellar 
techniques. A series of didactic lectures will be provided, with technique pearls (and 
complications), supported by video presentations and handouts. The lecture portion is a 
prerequisite for the wet lab, where candidates will be guided through many techniques.
Objective: The participant should leave the course with an understanding of various 
options for performing anterior lamellar keratoplasty. The participant will have a thor-
ough understanding of the indications, advantages, and disadvantages of each of these 
techniques. Additional hands-on training on the use of some of these procedures will be 
provided in the associated laboratory. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Sheraz M Daya MD*
Instructor(s): Sadeer B Hannush MD, Woodford S Van Meter MD FACS, William W 
Culbertson MD*, Luigi Fontana MD PhD, Shigeto Shimmura MD, Donald Tan MD FRCS 
FRCOphth*
Extreme Cornea: Diagnostic and Management Dilemmas in 
Your Practice
Course: 335 Monday
Room: 218 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: The faculty of the Massachusetts Eye and Ear Infirmary Cornea Service will 
present challenging clinical and surgical cases of corneal conditions that often pose a di-
lemma in both diagnostic and treatment decision making. The topics will include optimal 
management of corneal melting disorders, early and end-stage autoimmune diseases, ir-
regular corneal astigmatism, and anterior segment trauma. Recognition of sentinel signs 
of ocular surface tumors, innovative uses of scleral lenses and keratoprostheses, and 
novel techniques of measuring IOP in severe corneal disease with alternative devices 
will be discussed.
Objective: At the conclusion of this course, attendees will be able to recognize and 
use innovative strategies to manage commonly encountered yet complicated corneal and 
external disease conditions.
Senior Instructor(s): Ula Jurkunas MD*
Instructor(s): Kathryn A Colby MD PhD*, James Chodosh MD MPH*, Roberto Pineda II 
MD*, Deborah S Jacobs MD*, Samir A Melki MD PhD*
Failed Graft: Never Say Die!
Course: 367 Monday
Room: 225 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will describe the selection of appropriate surgical procedure for 
the high-risk failed grafts, such as repeat penetrating keratoplasty (PK), Descemet-strip-
ping endothelial keratoplasty (DSEK), or keratoprosthesis. Even DSEK and deep anterior 
lamellar keratoplasty (DALK) may fail over time and repeat surgery may be required. 
Keratoprosthesis may be the answer to multiple failed grafts. Surgical techniques and 
modifications required for performing DSEK for failed PK, repeat DSEK, repeat DALK, 
postoperative immunosuppressive regimen, and outcomes of such surgeries will be 
discussed. A panel discussion on expert consensus on controversial issues regarding 
Descemet scoring, graft sizing for DSEK for failed PK, and multiple repeat PK / kerato-
prosthesis will conclude the course.
Objective: At the conclusion of this course, attendees will be familiar with the indica-
tions and patient selection for regrafts, surgical techniques and modifications, follow-up, 
and risks of repeat graft (PK, DSEK, DALK, and keratoprosthesis) for failed grafts.
Senior Instructor(s): Jatin Naresh Ashar MD
Instructor(s): Sonia H Yoo MD*, David S Rootman MD*, Anthony J Aldave MD*, Mark A 
Terry MD*, Pravin Vaddavalli MD
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Next-Generation Technologies for the Diagnosis and Treatment 
of Dry Eye and Meibomian Gland Dysfunction
Course: 374 Monday
Room: R05 2:00 - 4:15 PM
Education Level: INT Target Audience: COMP
Synopsis: While diagnostics and treatments for dry eye are advancing, the majority of 
practitioners limit their interventions to giving out artificial tears. The panel of experts 
in this course will engage members of the audience to share their experiences with 
the presented technologies. The panel will discuss new diagnostic devices such as the 
InflammaDry Detector, the LipiView Interferometer, and tear osmolarity measurement, 
as well as the use of existing devices such as high-resolution OCT and topography to 
evaluate dry eye. Newer, as yet not widely used therapeutic strategies will be discussed 
including LipiFlow, intense pulsed light lasers, and Maskin Meibomian Probes. Finally, 
emerging therapeutics on the horizon will be discussed.
Objective: Attendees will collaborate with faculty to both summarize and disseminate 
our growing intuitions about how to approach and successfully treat one of the most 
common problems seen in the office daily.
Senior Instructor(s): Linda Rose MD PhD*
Instructor(s): William B Trattler MD*, Parag A Majmudar MD*, Marguerite B McDonald 
MD*, Penny Asbell MD FACS*, Mina Massaro-Giordano MD*
Herpes Simplex Keratitis: When Herpes Isn’t a Dendrite, and 
Vice Versa
Course: 386 Monday
Room: 218 2:00 - 4:15 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: Herpes simplex keratitis (HSK) is the most common cause of corneal blind-
ness in developed nations. Many cases are missed because ophthalmologists are un-
aware of the nondendritic manifestations of HSK, such as geographic, marginal, necrotiz-
ing, endotheliitis, and interstitial keratitis. Features and pathophysiology of the different 
forms of HSK and clues to their diagnosis will be presented. A logical plan for treatment 
will be presented, including when and how to use antivirals, steroids, and surgery. Major 
literature on herpes simplex keratitis will also be briefly discussed.
Objective: At the conclusion of this course, attendees will be able to (1) diagnose com-
mon as well as unusual forms of HSV keratitis, (2) formulate a logical treatment plan 
based on their understanding of the pathophysiology of the different manifestations of 
herpes, and (3) get a general understanding of the newer treatment modalities on the 
horizon.
Senior Instructor(s): Sonal S Tuli MD
Innovative Uses of Adhesives in Anterior Segment Surgery
Course: 395 Monday
Room: 220 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will present the use of cyanoacrylate, fibrin-based, and other 
new adhesives for corneal wounds, cataract surgery, pterygium surgery, LASIK complica-
tions, dislocated IOLs, limbal stem cell transplants, and glaucoma surgery.
Objective: At the conclusion of this course, the attendee will be able to identify and de-
scribe the use of various adhesives for corneal disorders, cataract / corneal procedures, 
dislocated IOL procedures, LASIK complications, and glaucoma procedures.
Senior Instructor(s): Terry Kim MD*
Instructor(s): Amar Agarwal MD*, Sadeer B Hannush MD, David R Hardten MD*, Robert 
J Noecker MD*, Christopher Rapuano MD*, David C Ritterband MD*, Jonathan B 
Rubenstein MD*
Keratoconus 360°
Course: 399 Monday
Room: 215 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will provide an overview of the current modalities of diagnos-
ing subclinical and clinical keratoconus and strategies for its management. Topics will 
include features of keratoconus, identifying subclinical keratoconus on corneal topogra-
phy, corneal biomechanics in ectasia, use of intracorneal ring segments for the surgical 
management of keratoconus, collagen crosslinking and photorefractive keratectomy for 
progressive keratoconus, management of acute hydrops, and keratoplasty (penetrating, 
femtosecond laser-assisted, anterior, and deep lamellar) in keratoconus. The course will 
end with a series of case discussions and clinical scenarios.
Objective: Attendees will be able to apply diagnostic techniques accurately to diag-
nose subclinical and clinical keratoconus and choose appropriate treatment alternatives 
in its management. At the end of the course, attendees will also be familiar with the 
approach to managing various complications in the surgical management of keratoconus.
Senior Instructor(s): Pravin Vaddavalli MD
Instructor(s): Michael W Belin MD*, A John Kanellopoulos MD*, Sonia H Yoo MD*, 
Damien Gatinel MD*, Donald Tan MD FRCS FRCOphth*, Ana Hofling-Lima MD MBA
 NEW  Peripheral Ulcerative Keratitis: Diagnosis and 
Management
Course: 401 Monday
Room: 210 3:15 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Peripheral ulcerative keratitis (PUK) is a difficult entity to treat as it usually 
has systemic associations. The epidemiology, immunopathogenesis, and comprehen-
sive workup of a case of PUK (clinical examination, ocular and systemic investigations), 
including Mooren ulcer, will be discussed. A treatment algorithm will be highlighted, 
focusing on the indications, duration, and strategies of topical and systemic immunosup-
pressive therapy as well as surgical modes of therapy such as glue, amniotic membrane 
transplants, and keratoplasty.
Objective: By the end of the course, the attendee will be well versed in the logical 
workup and treatment therapy of a case of PUK.
Senior Instructor(s): Namrata Sharma MD MBBS
Instructor(s): Rasik B Vajpayee MD, Somasheila I Murthy MD, Tushar Agarwal MD
 NEW  Meibomian Gland Dysfunction and Chronic Blepharitis
Course: 411 Monday
Room: R05 4:30 - 5:30 PM
Education Level: INT Target Audience: COMP
Synopsis: The role of meibomian gland dysfunction (MGD) in chronic blepharitis and 
ocular surface disease is rapidly evolving. MGD is a form of chronic blepharitis and is 
recognized as a cause of ocular surface disease. Subgroups of MGD will be discussed 
along with pathophysiological mechanisms, including the role of bacteria and lipolytic 
exoenzymes, meibum changes, and tear evaporation. Acute and chronic phase therapy 
will be presented. The role of topical therapies as well as systemic therapies will be 
discussed as they relate to both lid and ocular surface abnormalities.
Objective: At the conclusion of this course, attendees will be able to diagnose and 
treat MGD and associated ocular surface disease.
Senior Instructor(s): James P McCulley MD FACS FRCOphth*
 NEW  Management of Ocular Chemical Injuries
Course: 414 Monday
Room: 210 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Acute ocular chemical burn is an emergency and needs immediate manage-
ment, which includes copious irrigation, topical steroids, autologous and cord serum , 
amniotic membrane transplantation, and even tissue adhesives and tectonic keratoplasty 
in severe cases. In chronic chemical burns, a stepwise approach in the management of 
ocular surface reconstruction that depends on the laterality and the severity of limbal 
stem cell deficiency, including the limbal transplantation (direct and cultivated), will be 
discussed. Visual rehabilitative approaches that include keratoplasty and keratoprosthe-
sis will also be discussed.
Objective: At the end of the course, the attendee will be well versed in the acute and 
emergency management of ocular chemical burns (as should be every ophthalmologist) 
and will be aware of ocular surface transplantation techniques. This course will give a 
holistic overview of the management of ocular chemical burns.
Senior Instructor(s): Namrata Sharma MD MBBS
Instructor(s): Rasik B Vajpayee MD, Vishal Jhanji MD, Tushar Agarwal MD
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Follow the Cornea: Do You Know Where Your Corneal 
Transplant Tissue Comes From?
Course: 417 Monday
Room: R01 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: The first steps of corneal transplant surgery take place in the eye bank. 
Through a combination of brief talks and expert panel discussions, we will inform the 
corneal surgeon about the process of eye tissue banking. We will (1) follow the path 
of tissue through recovery to distribution for corneal transplantation, (2) provide the 
evidence-based standards for surgical tissue selection, (3) discuss trends in eye banking, 
and (4) inform corneal surgeons on ways to get involved in the process.
Objective: At the conclusion of this course, the attendee will understand the intricacies 
of corneal donation and tissue processing, will know the results of the Cornea Donor 
Study, will appreciate the complexity of the eye banks’ work, and will know ways to 
become involved with eye banks. The goal is to educate corneal surgeons in order to 
promote sustainability, to maintain availability of corneal tissue, and to broaden the sur-
geon’s knowledge of the vital resource of eye banking.
Senior Instructor(s): Kristiana D Neff MD*
Instructor(s): Maria A Woodward MD, Bennie H Jeng MD, Roni M Shtein MD*, Mark J 
Mannis MD, Marian Sue Macsai-Kaplan MD*, David B Glasser MD, Monty Montoya**, 
Kevin P Corcoran CAE
Anterior Segment Reconstruction Following Trauma
Course: 507 Tuesday
Room: 208 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover the presentation and the primary and secondary man-
agement of chemical and mechanical injury of the anterior segment including all aspects 
of anterior segment reconstruction. Topics will include etiology and acute management 
of chemical injuries and penetrating trauma, primary and secondary repair of corneal 
injuries, secondary IOLs, and corneal transplantation.
Objective: At the conclusion of this course, the attendee will be able to understand 
the key concepts in relation to the presentation and the contemporary management of 
anterior segment repair following severe trauma.
Senior Instructor(s): Charles McGhee PhD FRCOphth FRANZCO*
Instructor(s): Peter Zloty MD, Alexandra Crawford MD, Edward J Holland MD*, Michael 
W Belin MD*, Helen V Danesh-Meyer MD MBChB**, Donald Tan MD FRCS FRCOphth*, 
Noor Ali MBCHB
Surgical Strategies for Recurrent Pterygium With or Without 
Motility Restriction
Course: 514 Tuesday
Room: 346 9:00 - 11:15 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Although surgeries for primary pterygium have been successfully practiced 
by many general ophthalmologists, pterygium recurrence with or without motility restric-
tion presents a great challenge.
Objective: At the conclusion of this course, through interactive discussion, surgical 
video demonstration, and case presentation, the attendee will have learned the pathol-
ogy and risk factors that explain how recurrence occurs, as well as the most up-to-date 
published surgical strategies to prevent recurrence and restore ocular motility: cicatrix 
lysis, amniotic membrane transplantation, intraoperative application of mitomycin C, 
muscle sheath recreation, and sealing the gap between conjunctiva and Tenon with an-
choring sutures with or without additional conjunctival autograft or oral mucosal graft. 
Furthermore, this new information can be used to correct other ocular surface diseases 
manifesting cicatricial complications due to primary diseases or following surgeries for 
glaucoma, strabismus, and retinal problems.
Senior Instructor(s): Scheffer C G Tseng MD PhD*
Big Bubble Technique of Deep Anterior Lamellar Keratoplasty: 
A Simplified Approach to Successful Surgery
Course: 515 Tuesday
Room: 211 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: The big bubble technique for deep anterior lamellar keratoplasty (DALK) al-
lows successful baring of the host Descemet membrane (DM). Visual results are com-
parable to penetrating keratoplasty, with no risk of endothelial rejection. This course 
will deal with basic surgical technique in a detailed, stepwise manner, using surgical 
videos, and will also cover instrumentation, patient selection, preoperative workup and 
investigations, and postoperative management. Both intraoperative and postoperative 
complications, along with their management, will be discussed. The role of the femto-
second laser will also be presented.
Objective: At the end of the course, the attendee will have a clear understanding of 
case selection, surgical technique, postoperative care, and appropriate management of 
complications using the big bubble technique of DALK surgery.
Senior Instructor(s): Rajesh Fogla MD FRCS*
Instructor(s): Mark A Terry MD*, David S Rootman MD*, Luigi Fontana MD PhD
Atypical Keratitis
Course: 521 Tuesday
Room: 340 9:00 - 10:00 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Since many patients with corneal ulcer are managed empirically based on 
clinical features, it is important to be familiar with not only the classical but also the 
atypical clinical features. This course will present atypical features of common patho-
gens as well as clinical features of uncommon pathogens using representative cases. 
The course will also provide pearls for establishing diagnosis of such atypical cases, 
including the role of newer diagnostic modalities such as confocal microscopy and mo-
lecular methods.
Objective: To make participants familiar with atypical keratitis cases and provide 
pearls for early diagnosis.
Senior Instructor(s): Prashant Garg MD*
Instructor(s): Yoshitsugu Inoue MD PhD, Terrence P O’Brien MD*, Elmer Tu MD*
Descemet Membrane Endothelial Keratoplasty (DMEK and Thin 
Cut DSAEK) and Related Advanced Endothelial Keratoplasty 
Techniques
Course: 525 Tuesday
Room: R05 9:00 - 11:15 AM
Education Level: ADV Target Audience: COMP
Synopsis: Descemet-stripping automated endothelial keratoplasty (DSAEK) is the 
treatment of choice for endothelial dysfunction, yet a significant proportion of patients 
without ocular comorbidity fail to achieve maximal visual potential. Transplantation of 
only the Descemet membrane and endothelium, a procedure known as Descemet mem-
brane endothelial keratoplasty (DMEK), allows a significantly higher proportion of pa-
tients to achieve 20/25 or better vision. In addition, DMEK significantly reduces the risk 
of immunologic graft refection.
Objective: This course will cover indications and contraindications for DMEK, related 
techniques like Descemet membrane automated endothelial keratoplasty, and thin cut 
DSAEK; describe the surgical techniques in detail; discuss intra- and postoperative com-
plications and management; present visual and refractive outcomes and endothelial cell 
losses.
Senior Instructor(s): Francis W Price Jr MD*
Endothelial Keratoplasty in Challenging Cases
Course: 556 Tuesday
Room: 217 11:30 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: The indications for endothelial keratoplasty have rapidly expanded, to the 
point that this surgery is now appropriate for endothelial failure of almost any etiology. 
In this course the instructors will use video and case presentations to explain the various 
techniques for challenging cases, such as post-penetrating keratoplasty, phakia, apha-
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kia, buphthalmos, patients with anterior chamber IOLs, patients with filtering glaucoma 
procedures / devices, patients with long-standing / severe corneal edema, situations in 
which visualization is particularly poor, or in patients of pediatric age. Visual outcomes 
and complications will also be discussed in detail.
Objective: Attendees will gain information that is instrumental in choosing the type of 
surgery appropriate for patients with endothelial failure and complicating ocular factors.
Senior Instructor(s): Jacqueline E Beltz MBBS
Instructor(s): Massimo Busin MD*, Vincenzo Scorcia MD, Robert C Arffa MD, Silvana A 
Madi MD
Ocular Surface Diseases in Cancer Patients: Update on Clinical 
Spectrum and Treatment
Course: 561 Tuesday
Room: R04 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: In this course the clinical spectrum and management of ocular surface dis-
eases due to cancer treatment will be summarized. Update of new cancer treatments 
and their ocular side effects will be covered. Special surgical considerations in cancer 
patients will be discussed in an interactive format.
Objective: This course is designed to provide an overview and update of ocular surface 
diseases that result from modern cancer treatments. At the conclusion of the course, the 
attendees will be able to recognize and treat the spectrum of the ocular surface diseases 
in cancer patients.
Senior Instructor(s): Stella K Kim MD*
Instructor(s): Kimberly C Sippel MD*
Complications in Collagen Crosslinking : Diagnosis, 
Management, and Prevention
Course: 562 Tuesday
Room: 221 11:30 AM - 12:30 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will present a didactic approach to the clinical experience of 
complications encountered with several collagen crosslinking (CXL) treatments for indi-
cations such as (1) keratoconus, (2) ectasia following refractive surgery, (3) prophylactic 
CXL in LASIK and PRK, and (4) CXL in bullous keratopathy. Cornea scarring, infectious 
keratitis, delayed epithelial healing, regression, and endothelial decompensation were 
the most common complications encountered. Medical and surgical and treatment tech-
niques of the above will be presented and discussed in detail.
Objective: The participants will share our vast experience in CXL and the potential 
complications encountered in managing progressive keratoconus, post-LASIK ectasia, 
bullous keratopathy, prophylactic CXL in LASIK and PRK, and lamellar grafts in order to 
stabilize and potentially visually rehabilitate these patients.
Senior Instructor(s): A John Kanellopoulos MD*
Instructor(s): Gregory Pamel MD**, Henry D Perry MD*, R Doyle Stulting MD PhD*, Eric 
D Donnenfeld MD*, Soosan Jacob FRCS
 NEW  Mastering Transepithelial and Epithelial-Off Corneal 
Collagen Crosslinking for Keratoconus and Post-LASIK Ectasia
Course: 580 Tuesday
Room: 211 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will identify appropriate candidates for corneal collagen cross-
linking (CXL) and methods to optimize epithelial-on and epithelial-off CXL, as well as 
when to use higher UV energy levels. Additional treatment options, such as topo-guided 
PRK and Intacs will be reviewed. Techniques to reduce the risk of CXL will be described.
Objective: Attendees will learn from U.S. and international experts, who will share 
pearls for performing either epithelial-on or epithelial-off CXL. Additional uses of CXL, 
such as for corneal infections, stabilization of patients with a history of radial keratotomy 
and visual fluctuations, and pseudophakic corneal edema, will be reviewed.
Senior Instructor(s): Roy Scott Rubinfeld MD*
Instructor(s): William B Trattler MD*, A John Kanellopoulos MD*, Aleksandar Stojanovic 
MD, Parag A Majmudar MD*, George O Waring IV MD*, Jonathan H Talamo MD*
Descemet-Stripping Automated Endothelial Keratoplasty 
Cliffhangers
Course: 581 Tuesday
Room: R04 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will be comprised of video- and case-based presentations of 
difficult situations that may arise during Descemet-stripping automated endothelial 
keratoplasty (DSAEK), both during the learning curve and in experienced hands. Case 
scenarios will include surgical challenges such as floppy iris, inverted graft, identifying 
orientation of the lenticule, managing synechiae, and dealing with a shallow anterior 
chamber. The course will also focus on overcoming poor visualization, post-keratoplasty 
DSAEK, DSAEK following trabeculectomy and tube shunts, DSAEK in phakic and aphakic 
eyes, and DSAEK in children. Management of postoperative complications including dis-
located lenticules and repeat DSAEK will also be dealt with. The course will end with an 
introduction to Descemet membrane endothelial keratoplasty (DMEK) and will identify 
common problems faced by surgeons converting to DMEK.
Objective: At the end of the course, attendees will be familiar with challenging situa-
tions that may arise during DSAEK and maneuvers to manage and prevent them.
Senior Instructor(s): Pravin Vaddavalli MD
Instructor(s): Sonia H Yoo MD*, Mark A Terry MD*, Anthony J Aldave MD*, David S 
Rootman MD*, Jatin Naresh Ashar MD
 NEW  Descemet Membrane Endothelial Keratoplasty
Course: 597 Tuesday
Room: 224 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course intends to provide a full description of the Descemet membrane 
endothelial keratoplasty (DMEK) surgical technique, emphasizing the key steps neces-
sary to make DMEK feasible in various conditions. The course will present the results and 
the lessons learned after more than 500 DMEK surgeries with a maximum follow-up of 6 
years. Descemet membrane graft harvesting and preparation will be shown, indications 
and limitations of DMEK will be discussed, the standardized surgical technique will be 
explained, and additional alternative techniques and surgical considerations for chal-
lenging cases will be presented.
Objective: At the conclusion of this course, the attendee will be able to recognize the 
special characteristics of this lamellar keratoplasty technique, appreciate its advantages, 
and distinguish its limitations. The course intends to offer a stepwise approach to less 
experienced DMEK surgeons and useful surgical pearls to the more experienced.
Senior Instructor(s): Gerrit RJ Melles MD PhD*
Instructor(s): Vasilios S Liarakos MD, Isabel Dapena, Lisanne Ham PhD, Jack S Parker 
MD, Marina Rodriguez Calvo De Mora MD, Lamis Baydoun MD 
Advances in Treatment of Severe Ocular Surface Disease: 
Views From Experts on the Front Lines
Course: 599 Tuesday
Room: 209 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Exciting new treatment approaches to severe ocular surface diseases 
(Stevens-Johnson syndrome, graft versus host disease, chemical injuries, and others) 
have emerged in the past few years. In this course, leading experts in the field will 
present their own innovations as well as their perspectives on the latest developments. 
In Stevens-Johnson syndrome, for example, interventions in the acute disease phase, 
including topical and systemic medications, specialty contact lenses, and amniotic mem-
brane application, have shown great promise in limiting devastating long-term ocular 
sequelae. For patients with chronic ocular findings, treatment with mucous membrane 
grafts, specialty devices such as prosthetic replacement of the ocular surface ecosystem 
(PROSE), and keratoprostheses constitute potential sight-restoring interventions.
Objective: This course is designed to update general and subspecialty ophthalmolo-
gists on sophisticated novel treatment approaches to severe ocular surface disease.
Senior Instructor(s): Jessica B Ciralsky MD*
Instructor(s): C Stephen Foster MD*, Stella K Kim MD*, Darren G Gregory MD*, Esen K 
Akpek MD*, Kimberly C Sippel MD*, Peter A D Rubin MD, Deborah S Jacobs MD*
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Top 10 Hot Corneal Surgical Tips for 2013
Course: 601 Tuesday
Room: 210 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: An expert panel of experienced corneal surgeons presents their annual sur-
vey of the hottest corneal surgical tips for 2013. Each surgical tip has been carefully 
selected for novelty and maximum potential impact on clinical practice. Annually updated 
topics include time-saving office techniques (eg, rebubbling, amniotic membrane graft-
ing), refinements of common operations (eg, Descemet-stripping automated endothelial 
keratoplasty, pterygium), and pearls for cutting-edge surgical procedures (eg, Descemet 
membrane endothelial keratoplasty, deep anterior lamellar keratoplasty, femtosecond 
keratoplasty, keratoprosthesis, stem cell grafts). A rapid-fire format with expert panel 
commentary and audience Q&A will promote lively discussion, and annual refreshing 
of topics and a rotating faculty ensure that material is fresh and of interest to repeat 
attendees.
Objective: Through step-by-step instructions, surgical video, and detailed handouts, 
the practitioner will gain practical, specific, and immediately applicable knowledge of 
improved techniques and approaches for common and challenging corneal surgical prob-
lems.
Senior Instructor(s): David G Hwang MD
Instructor(s): Eduardo C Alfonso MD*, Sadeer B Hannush MD, Allan Slomovic MD*, 
Geoffrey C Tabin MD, Mark A Terry MD*
Electronic Health Records
 EHR  An Approach to Selecting and Implementing Electronic 
Health Records in Your Practice
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
Medical Information Technology Committee
Course: 197 Sunday
Room: 215 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will present a framework for implementing an electronic health 
record (EHR) system in an ophthalmic practice. We will discuss methods for assessing 
practice needs, creating a request for proposals (RPF), assessing vendors, and planning 
deployment of a system. These issues will all be discussed in the context of federal 
incentives to use EHR in your practice. Attendees will also be made aware of relevant 
resources available from the Academy.
Objective: At the conclusion of this course, attendees will be able to (1) design a strate-
gy for assessing the needs of their practices in terms of an EHR system, (2) create an RFP 
to be sent to vendors of appropriate EHR systems, (3) evaluate responses to RFPs and the 
vendors that provide them, and (4) design an implementation strategy for an EHR system.
Senior Instructor(s): Michael V Boland MD PhD
Instructor(s): Michael F Chiang MD*, Flora Lum MD, Linda L Wedemeyer MD, Michele C 
Lim MD, Brittney Wachter CPC OCS, Paulette Hottle
 NEW   EHR  Electronic Health Record and Image Data 
Management Implementation: Rapid-Fire Presentations and 
Panel Discussion
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
Medical Information Technology Committee
Course: 223 Sunday
Room: 222 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Electronic health record (EHR) systems are slated to become commonplace 
in medicine over the next few years regardless of practice setting, geographic location, 
or subspecialty focus. Ophthalmology faces significant obstacles to this progression due 
to the unique features of its practice with regards to clinical workflow and data manage-
ment. These obstacles, among others, explain why adoption of EHR systems within oph-
thalmology practices has been poor. This course will be presented in a rapid-fire format 
to allow for a wider overview than the traditional EHR courses.
Objective: To (1) describe the clinical and economic impact of EHR conversion, (2) 
discuss the methods for receiving a return on investment for your EHR conversion, (3) 
provide details on how data management in the EHR era has changed, (4) highlight the 
compliance issues involved when using EHR systems, and (5) discuss using EHR for re-
search and administrative tasks.
Senior Instructor(s): Rishi P Singh MD*
Instructor(s): Michael V Boland MD PhD, David E Silverstone MD, K David Epley MD*
 EHR  Electronic Health Records: Compliance and Medicolegal 
Issues
Jointly sponsored by the Academy’s Annual Meeting Program Committee and 
Medical Information Technology Committee and the American Academy of 
Ophthalmic Executives’ EHR Subcommittee
Course: 302 Monday
Room: 333 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will demonstrate how electronic health records (EHRs), while 
improving the quality of medical records, can also create problems that can trigger seri-
ous medicolegal and compliance issues. This course will explore how EHRs can be used 
wisely or foolishly. Case studies will be presented to illustrate problems created by the 
use of EHRs.
Objective: By the conclusion of this course, attendees will be able to (1) describe 
some strengths of EHR systems that can improve compliance with chart documentation 
requirements, (2) describe some “tricks” that could hurt documentation reliability and 
compliance, (3) identify features in EHRs that pose the greatest threats, and (4) modify 
EHR utilization to improve documentation reliability and compliance.
Senior Instructor(s): David E Silverstone MD
Instructor(s): Kevin J Corcoran*, Michele C Lim MD
 NEW   EHR  Maximizing Your Electronic Health Records 
System’s Productivity and Financial Benefits
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
Medical Information Technology Committee
Course: 537 Tuesday
Room: 355 10:15 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course is intended to familiarize attendees with the possible productiv-
ity gains and financial advantages of using an electronic health records (EHR) system 
in their practices. Information presented will include overall preconceptions and myths 
about productivity in an electronic environment, and will explain how these myths are 
not entirely true. Using examples and institutional data, scenarios and examples will be 
shared to demonstrate the vast benefits of EHRs, and to explain how the return on invest-
ment goes far beyond any meaningful use payments the government provides.
Objective: At the end of this course, participants will be familiar with some of the 
basic impacts an EHR system might have on practice productivity and financial health. 
The attendees will also learn actionable items to maximize their return on investment.
Senior Instructor(s): Colin McCannel MD*
Instructor(s): Rishi P Singh MD*, Michael F Chiang MD*, Michele C Lim MD
Ethics
The Institutional Review Board Submission Process: Why 
Should I Care, and What If I Don’t?
Course: 220 Sunday
Room: 217 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will define research, how/what to submit to IRBs, and applicabil-
ity of research rules/regulations. Discussion will include existing guidelines / regulations 
for all research, types of IRB review (full, expedited, exempt), institutional vs. private 
review boards, statutory authority of the Office for Human Research Protections (OHRP), 
regulations impacting prospective and retrospective human research, and special in-
formed consent required by research. Via case studies, participants will discuss real-life 
obstacles, multiple submissions requiring different reviewing bodies, and the potential 
consequences of not following ethical practices in IRB submission.
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Objective: At the conclusion of this course, attendees will be able to identify ethical 
dilemmas in human research and the OHRP’s specific regulations, describe the special 
nature of research-based informed consent, resolve the identified ethical dilemmas, and 
ethically manage IRB interactions.
Senior Instructor(s): Christie L Morse MD*
Instructor(s): Anthony J Aldave MD*, Keith D Carter MD FACS, Roberto Pineda II MD*, R 
V Paul Chan MD, Carla J Siegfried MD*
 NEW   EHR  Digital Devices & Patient Care: Confidentiality, 
Encryption, HIPAA and Ethical Considerations
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
the Ethics Committee
Course: 510 Tuesday
Room: 220 9:00 - 10:00 AM
Education Level: BAS Target Audience: COMP
Synopsis: This course will explain the HIPAA Privacy and Security Rules which protect 
the privacy of individually identifiable health information. Also discussed will be attend-
ees’ responsibilities under federal law, proper use of various mobile devices, encryption 
strategies, the multiple password conundrum, e-mail authorizations, patient use of social 
media for communication of health issues, and the relevant ethical issues.
Objective: At the conclusion of the course, attendees will be able to identify key com-
ponents of secure electronic communication and data storage practices, the HIPAA Pri-
vacy and Security Rules, the HITECH Breach Notification Rule, and safeguards needed to 
ensure the protection of private health information.
Senior Instructor(s): Christie L Morse MD*
Instructor(s): Anthony J Aldave MD*, R V Paul Chan MD, Keith D Carter MD FACS, Nadia 
Martyn JD
General Medical Care
 NEW   SO  Defending the Ophthalmologist in a Medical 
Malpractice Lawsuit
Course: 389 Monday
Room: R02 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course will provide an overview of medical malpractice cases specific to 
ophthalmology. Topics include malpractice litigation statistics and terms important to an 
understanding of malpractice, a review of the malpractice lawsuit process, and common 
theories of liability against ophthalmologists. Informed consent, the role of the expert 
witness, and the importance of preparation will be highlighted.
Objective: The current medical malpractice crisis presents ever-increasing challenges 
to the ophthalmologist. At the conclusion of this course, the physician will be both edu-
cated in and presented with effective approaches to minimize liability and maximize an 
effective defense.
Senior Instructor(s): Robert Ritch MD FACS*
Instructor(s): Kenneth R Larywon JD, Thomas A Mobilia JD
Drug-Related Adverse Effects of Clinical Importance to the 
Ophthalmologist
Course: 590 Tuesday
Room: 355 12:45 - 1:45 PM
Education Level: INT Target Audience: COMP
Synopsis: This course will describe adverse ocular reactions from topical ocular and 
systemic medications, with a focus on recently reported adverse events identified by the 
National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon) and applying 
the WHO classification system.
Objective: At the conclusion of this course, attendees will be able to recognize drug-
related adverse ocular and systemic side effects when they occur in association with 
drugs commonly used by clinicians. Only those medications of clinical importance to 
ophthalmologists will be discussed.
Senior Instructor(s): Rick W Fraunfelder MD*
Glaucoma
Computerized Scanning Imaging of the Optic Nerve and Retinal 
Nerve Fiber Layer
Course: 103 Sunday
Room: 225 9:00 - 11:15 AM
Education Level: BAS Target Audience: COMP
Synopsis: This lecture, required for the hands-on workshop, introduces the participant 
to the principles of computerized scanning imaging. This is a basic course featuring cur-
rent technologies. The main emphasis in this course will be spectral (Fourier) domain 
OCT, although some discussion of scanning laser polarimetry and topography (Heidelberg 
Retinal Tomography) will be included.
Objective: By the conclusion of this course, participants will be able to (1) understand 
the scientific basis for imaging, (2) understand how scanning imaging may be used in 
clinical practice, (3) learn how imaging can be applied to the optic nerve head, retinal 
nerve fiber layer, and macula, with emphasis on glaucoma, (4) understand the relation-
ship between structure and function, and (5) differentiate normal from abnormal scans 
through appropriate clinical examples. A question-and-answer session will be held at the 
end of the presentations, during which time questions will be entertained by the faculty.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Neil T Choplin MD
Instructor(s): E Randy Craven MD*, Howard Barnebey MD*
Glaucoma Laser Therapy: Innovations and Advice From the 
Experts
Course: 105 Sunday
Room: R03 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will provide a comprehensive review of laser procedures used to 
treat glaucoma. Topics discussed will include argon laser trabeculoplasty (ALT), selective 
laser trabeculoplasty (SLT), micropulse laser trabeculoplasty (MLT), cyclophotocoagula-
tion (both endoscopic and transscleral), iridotomy (Nd:YAG, argon, and diode), iridoplasty, 
and laser suture lysis. Indications, treatment techniques, and postoperative care will be 
discussed in detail during the didactic portion of the course. During the laboratory sec-
tion, participants will have the opportunity to perform endoscopic cyclophotocoagulation, 
transscleral cyclophotocoagulation, SLT, ALT, MLT, and iridotomies under the supervision 
of the course instructors.
Objective: At the conclusion of this course, attendees will be able to understand the 
indications and techniques for the various laser therapies used in the treatment of glau-
coma. After the laboratory section, they will have hands-on experience using these mo-
dalities on animal eyes.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Lisa S Gamell MD
Instructor(s): Robert J Noecker MD*, Joel S Schuman MD*, Jorge A Alvarado MD, Mark 
A Latina MD*, Malik Y Kahook MD*, Brian E Flowers MD*
Managing Angle-Closure Glaucoma With Crystalline Lens 
Removal and Adjunctive Procedures
Course: 158 Sunday
Room: 224 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMP
Synopsis: Preoperative diagnostics and ample surgical video will be used to demon-
strate a unified approach and specific techniques to safely perform phacoemulsification 
as a definitive treatment for angle-closure glaucoma. In addition, adjunctive procedures 
such as goniosynechialysis, endoscoplasty, pars plana vitreous tap, irido-zonulo-hyaloid-
ectomy, and pupilloplasty will be demonstrated. Tools such as capsular tension rings, 
pupillary rings, iris hooks, and microinstrumentation to enhance surgical success will 
be presented.
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Objective: This course is designed to provide surgeons with an approach and tools for 
safely performing phacoemulsification in the management of angle-closure glaucoma 
and to introduce adjunctive procedures to further enhance outcomes in these cases.
Senior Instructor(s): Devesh K Varma MD*
Instructor(s): Iqbal K Ahmed MD*, Garry P Condon MD*, Sebastien Gagne MD**, 
Diamond Y Tam MD
Cell Biology, Genetics, and Outflow Biochemistry of Glaucoma 
in 2013 and Beyond
Course: 169 Sunday
Room: 214 11:30 AM - 12:30 PM
Education Level: INT Target Audience: SUB
Synopsis: An overview of cell biology-based theories relevant to glaucoma will be pre-
sented. A very brief clinical summary of the discussions of the Trabecular Meshwork 
Society meeting in December 2012 will be presented, along with other recent biological 
advances pertaining to glaucoma. Uniquely, we emphasizes the substantial relevance of 
these findings and theories to clinical practice.
Objective: This course will give the attendee the tools to discuss the pros and cons of 
future genetic testing. The attendee will understand how specific concepts in cell biol-
ogy, such as the cytokine-modulated responses to trabeculoplasty, impact clinical care 
of the glaucoma patient. After the session, many attendees will engage in an ongoing 
scientific dialog about specific aspects of glaucoma, conducted through email. Handouts 
consist of numerous articles disseminated through a large file email service (Yousendit) 
and will serve as a partial basis for these ongoing discussions about the biology of the 
meshwork.
Senior Instructor(s): John R Samples MD*
Instructor(s): Murray A Johnstone MD*
 SO  Normal-Tension Glaucoma: Evaluation and Treatment
Course: 170 Sunday
Room: 225 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: A neuro-ophthalmologist will review neurologic conditions misdiagnosed as 
normal-tension glaucoma (NTG) and present the appropriate diagnostic evaluation. A 
glaucoma specialist will discuss the pathophysiology of NTG and appropriate medical 
and surgical therapies.
Objective: This course will enable participants to identify NTG patients who deserve 
further neurologic evaluation and to become familiar with the appropriate treatment of 
patients with glaucoma and normal IOP.
Senior Instructor(s): Mark L Moster MD*
Instructor(s): Marlene R Moster MD*
Glaucoma Filtration Device Mini-shunt: Friend or Foe?
Course: 172 Sunday
Room: 346 2:00 - 3:00 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will provide practical tips in the use of Ex-PRESS shunts, includ-
ing videos to demonstrate surgery to insert and remove the shunt if necessary. The man-
agement pearls for treatment of complications will be highlighted with illustrative cases.
Objective: This course will review indications and contraindications for the use of Ex-
PRESS shunts and practical tips for insertion. The course will also discuss prevention of 
complications and management of these, if they should occur.
Senior Instructor(s): Annapurna Singh MD
Instructor(s): Richard A Lehrer MD*
Continuous 24-Hour IOP Monitoring for Glaucoma
Course: 177 Sunday
Room: 355 2:00 - 3:00 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Intraocular pressure (IOP), the only modifiable risk factor for glaucoma, is a 
dynamic parameter. Peak IOPs occurring outside clinic hours remain undetected in many 
glaucoma patients. Recent availability of telemetric devices for continuous 24-hour IOP 
monitoring has the potential to improve glaucoma care.
Objective: This course will review (1) the nature of 24-hour IOP and its clinical signifi-
cance and (2) the role of 24-hour IOP monitoring technologies in clinical practice. At the 
conclusion of this course, the attendees will understand the complexities of 24-hour IOP 
patterns and how to integrate current technologies for monitoring IOP into the clinical 
management of glaucoma patients.
Senior Instructor(s): Kaweh Mansouri MD*
Instructor(s): Syril Dorairaj MD, Christopher Kai-shun Leung MD MBChB*, Arthur J Sit 
MD*, Robert N Weinreb MD*
Glaucoma Postop Care in the Office: A Video Compendium of 
Techniques—When and How to Intervene
Course: 184 Sunday
Room: R02 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will demonstrate strategies and techniques used during the 
postoperative period of trabeculectomy and glaucoma drainage implant procedures to 
increase surgical success.
Objective: At the conclusion of this course, the attendee will be able to identify 
causes of surgical failure and early postoperative complications that require interven-
tion. The strategies, timing, and techniques used to deal effectively with postoperative 
management of trabeculectomy and glaucoma implants will be discussed in detail and 
demonstrated with the use of slitlamp video footage to allow attendees to utilize these 
procedures in their own offices. The instructors, who have diverse training backgrounds, 
will show variations in technique that will allow even the seasoned glaucoma surgeon 
an opportunity for learning.
Senior Instructor(s): Cynthia Mattox MD FACS*
Instructor(s): Chandrasekharan Krishnan MD, Susan S Liang MD, Alan E Lowinger MD
The Management of Neovascular Glaucoma in 2013
Course: 201 Sunday
Room: 214 2:00 - 3:00 PM
Education Level: ADV Target Audience: SUB
Synopsis: This course will present cases and data on various etiologies of neovascu-
lar glaucoma and will discuss different methods to eradicate or reduce rubeosis iridis / 
angle neovascularization and different management options, including the use of trab-
eculectomy with mitomycin C, glaucoma drainage implants, and various cycloablative 
procedures. The role of intravitreal bevacizumab in the management of neovascular glau-
coma will be stressed, and audience participation will be encouraged.
Objective: At the conclusion of the course, the attendees will have gained confidence 
in managing patients with neovascular glaucoma of varied etiology.
Senior Instructor(s): Anil K Mandal MD
Instructor(s): Peter Andreas Netland MD PhD*, K V Chalam MD PhD, Scott D Lawrence 
MD*
Trabeculotomy by Internal Approach Surgery for Adult Open-
Angle Glaucoma
Course: 119 Sunday
Room: 340 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover the Trabectome, an FDA-cleared instrument for angle-
based surgery for open-angle glaucoma via an internal approach. The didactic part of the 
course will describe accumulated data from an ongoing case series (over 5000 eyes), 
published data, and comparative trials with cataract surgery alone, trabeculectomy, and 
aqueous tube shunt. Indications, surgical technique, IOP outcomes, and complications 
will be described during a one-hour didactic course. Surgical tips including proper iden-
tification of angle structures using the gonioscopic approach will be emphasized. This 
may also be followed by a hands-on lab session using inverted corneal donor rings for 
practice.
Objective: At the conclusion of the course, attendees will understand the indications, 
surgical technique, IOP outcomes, and complications associated with this device. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Brian A Francis MD*
Instructor(s): Sameh Mosaed MD*, Nils A Loewen MD*
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Glaucoma Filtration Surgery
Course: 124 Sunday
Room: 335 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course provides a comprehensive review of the techniques and compli-
cations of glaucoma filtration surgery. Glaucoma surgical technique will be stressed in 
this update of filtration surgery, with a heavy emphasis on surgical video presentations. 
The course will also discuss novel surgical techniques used in filtration surgery, such as 
Ex-PRESS shunts, as compared to conventional surgery. A panel discussion with ques-
tions and answers will conclude the session.
Objective: This course will review surgical anatomy, basic trabeculectomy techniques, 
antimetabolites (including 5-fluorouracil and mitomycin C), and postoperative manage-
ment and complications. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Steven L Mansberger MD*
Instructor(s): George A Cioffi MD, Jeffrey M Liebmann MD*, F Jane Durcan MD, Robert D 
Fechtner MD FACS*, Kuldev Singh MD MPH*, George A Cioffi MD, Celso Tello MD*
Schlemm Canal Surgery
Course: 125 Sunday
Room: 214 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Early results of nonpenetrating glaucoma surgery, an alternative approach in 
glaucoma filtering surgery, have shown comparable results to other methods, with a re-
duction in overall complications. Yet this technique has a learning curve, with its own set 
of unique challenges. This course will present a systematic, multimedia, video-assisted 
review of the anatomy, rationale, explanation, and illustration of canaloplasty.
Objective: This course will explain (1) the procedure’s method of re-establishing aque-
ous outflow, (2) the procedure’s advantages, disadvantages, risks, and benefits, and (3) 
the identification of glaucomas where the procedure would have highest probability of 
success. Recent clinical results and innovations to enhance the procedure will also be 
discussed. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Richard A Lehrer MD*
Instructor(s): Iqbal K Ahmed MD*, Alan S Crandall MD*, Robert Stegmann MD**, Clive O 
Peckar MD*, Howard Barnebey MD*, John R Kearney MD
Canal, Trab, or Tube: What Should I Do?
Course: 219 Sunday
Room: R04 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Surgical options for glaucoma today include filtering surgeries and newer 
minimally invasive technologies that increase outflow through physiologic channels. 
How does a glaucoma surgeon choose from all these available options? A case pre-
sentation format will highlight optimal clinical scenarios to help a surgeon pick cases 
appropriate for Schlemm canal surgery or traditional filtering surgery. Presentations will 
emphasize case selection, surgical pearls, potential pitfalls, and postop management.
Objective: On completion of this course, the attendees will be able to tailor glaucoma 
surgery to their individual patient, offering a customized approach and integrating newer 
minimally invasive procedures into their surgical practices.
Senior Instructor(s): Arvind Neelakantan MD*
Instructor(s): Ronald Leigh Fellman MD OCS*, Quang H Nguyen MD*, Keith Barton MD*
 NEW  Canal-Based Glaucoma Surgery: Canaloplasty vs. 
Microstent Implantation: Everything You Want to Know
Course: 221 Sunday
Room: 223 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: In this course the anatomy and pathophysiology of the Schlemm canal and 
its role in glaucoma, ultrasound studies of the canal, canal surgery (canaloplasty and 
microstent) indications, surgical techniques, outcomes, and management of complica-
tions will be discussed using surgical video footage and clinical pictures. Techniques for 
performing combination cataract and canal surgery and variations in difficult cases will 
be addressed. Future strategies for improving the surgical outcomes, including in the 
design and antifibrosis agents, will be discussed.
Objective: At the conclusion of this course, the attendee will be able to understand the 
basic anatomy, pathophysiology, indications, surgical techniques (including combination 
surgeries), and management of intra- and postoperative complications of canal based 
surgeries (canaloplasty and microstent implantation).
Senior Instructor(s): Ramesh S Ayyala MD FRCS*
Instructor(s): Thomas W Samuelson MD*
 h  Improving Success in Filtration Surgery: Intraoperative 
Surgical Techniques and Postoperative Management of the 
Failing Filter
Course: 319 Monday
Room: 338 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will describe techniques for successful performance of trabecu-
lectomy, nonpenetrating glaucoma procedures, and micro-incisional glaucoma (MIGS) 
procedures and will comprehensively review postoperative management of the failing 
glaucoma operation.
Objective: At the end of this course, attendees will understand the available tech-
niques for enhancing glaucoma surgery success, including antimetabolite administration, 
and will understand postoperative adjuncts for dealing with failing filtration character-
ized by either high IOP or low IOP.
Senior Instructor(s): Husam Ansari MD PhD*
Instructor(s): Bradford J Shingleton MD*
Computerized Perimetry Lecture: Visual Field Testing and 
Interpretation, Emphasizing Glaucoma
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and the 
American Glaucoma Society
Course: 132 Monday
Room: 335 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: This lecture reviews computerized perimetry, emphasizing glaucoma and 
the Humphrey field analyzer. Topics will include the stepwise interpretation of individual 
visual fields (VFs), the significance of each portion of the VF printout, determining if the 
VF is reliable and if it is normal or abnormal, tips for obtaining a more reliable VF and for 
selecting the appropriate test, SITA, SWAP, frequency doubling perimetry, and the analy-
sis of a series of VFs for progression. Numerous, mostly glaucomatous, case examples 
will be used. Note: Octopus perimetry will be covered in the lab.
Objective: This course will provide participants with the background knowledge neces-
sary to be more comfortable with visual field interpretation and to be prepared for the 
separate laboratory session. 
Note: This is the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Julia Whiteside-de Vos MD MPH*
Instructor(s): Todd W Perkins MD*
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 h  Update Your Anterior Chamber Angle Skills: How to Best 
Examine, Grade, and Treat
Course: 336 Monday
Room: 220 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMP
Synopsis: Studies show we look at the chamber angle in less than half of all initial 
glaucoma patient visits. Why? This course is about improving your chamber angle orga-
nizational skills to overcome chamber angle neglect. It will put everything together for 
the comprehensive ophthalmologist: how to best look at the angle, distinguish normal 
from abnormal angles, indent crowded angles, record your findings, and treat the iris 
and angle with laser therapy. In addition, important landmarks for up and coming canal 
procedures will be emphasized.
Objective: At the conclusion of the course, attendees will be able to better view the 
angle, improve their treatment of the angle, know when to perform and better record 
their gonioscopic findings, and be updated on the risks and benefits of laser peripheral 
iridotomy, selective laser trabeculoplasty, argon laser trabeculoplasty, and iridoplasty.
Senior Instructor(s): Ronald Leigh Fellman MD OCS*
Instructor(s): Ronald L Gross MD*, Silvia D Orengo-Nania MD*, Thomas W Samuelson 
MD*, Mark B Sherwood MD*, Steven T Simmons MD, George L Spaeth MD FACS*, 
Arvind Neelakantan MD*
What’s Your Next Step? Case Studies in Glaucoma 
Management
Course: 348 Monday
Room: 338 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: Both challenging and everyday glaucoma cases will be presented and dis-
cussed in a panel format. Visual fields and OCT, among other ancillary tests, will be 
used to demonstrate the case presentations. Audience participation will be encouraged.
Objective: At the conclusion of the course, the participants will have a better under-
standing of common glaucoma cases with diagnostic or interventional dilemmas.
Senior Instructor(s): Prithvi S Sankar MD
Instructor(s): Eydie G Miller MD*, Cynthia L Grosskreutz MD PhD*, Sarwat Salim MD*
 h  Top 10 Pitfalls, Problem Solving, and Interpretive Strategy 
for Automated Threshold Perimetry
Course: 350 Monday
Room: 222 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMP
Synopsis: This course presents a step-by-step interpretive strategy for automated 
threshold perimetry. This course will also teach recognition of the most common pit-
falls encountered and problem solving to avoid misinterpretation, underdiagnosis, and 
overdiagnosis.
Objective: Participants will learn to (1) systematically interpret central threshold visual 
fields, (2) recognize common pitfalls, including testing “legally blind” eyes, low reliability 
message, testing children, normal gray scale display in the presence of early scotomas, 
isolated peripheral nasal steps, severe visual field loss, limitations of computerized in-
terpretation, SITA variability, and pseudo-scotomas or pseudo-progression due to artifact 
(miosis, ptosis, lens rim), and (3) problem solve using nonstandard parameters (eg, size V 
stimulus) or alternate strategies (eg, central 10-degree or peripheral 30/60 degree field). 
This course was designed to optimize automated perimetry evaluation and monitoring 
and to eliminate common interpretational errors.
Senior Instructor(s): Alan H Zalta MD
Instructor(s): John S Cohen MD*
 NEW  The Art and Science of Glaucoma Drainage Devices: 
How to Optimize Your Surgical Results
Course: 353 Monday
Room: R01 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: The basic differences among the different glaucoma drainage devices 
(GDDs)3/4including design, size, biomaterial, the pathophysiology of the resulting blebs, 
indications, surgical techniques, outcomes, and management of complications3/4will 
be discussed using surgical video footage and clinical pictures. Techniques to perform 
different surgeries such as Descemet-stripping automated endothelial keratoplasty, pen-
etrating keratoplasty, phaco / posterior chamber IOL, and pupilloplasty in the presence 
of or combined with GDD will be discussed. Future strategies for improving the surgical 
outcomes, including in the design and antifibrosis agents, will be discussed.
Objective: At the conclusion of this course, the attendee will be able to understand the 
basic differences among the different GDDs, the pathophysiology of the resulting blebs, 
the indications, surgical techniques (including combination surgeries), and management 
of intra- and postoperative complications.
Senior Instructor(s): Ramesh S Ayyala MD FRCS*
Instructor(s): Steven Gedde MD*
Argon Laser Peripheral Iridoplasty: All You Need to Know
Course: 355 Monday
Room: 214 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover all you need to know about argon laser peripheral 
iridoplasty (ALPI)—from indications, contraindications, techniques, and pearls to results 
to complications and their management. Slitlamp photographs and videos will be exten-
sively used in the course, the handout, and the course DVD-ROM to illustrate the critical 
techniques.
Objective: At the conclusion of this course, the attendee will be able to safely, effec-
tively, and confidently perform ALPI in the appropriate patients.
Senior Instructor(s): Clement C Y Tham MBBS*
Instructor(s): Robert Ritch MD FACS*
Medical Therapy for Open-Angle Glaucoma: A Complete 
Review of the Pharmacodynamics, Pharmacokinetics, and 
Toxicity of All Potentially Useful Drugs
Course: 362 Monday
Room: 346 11:30 AM - 12:30 PM
Education Level: ADV Target Audience: COMP
Synopsis: This course will present the pharmacodynamics, pharmacokinetics, and 
toxicity of drugs potentially useful for open-angle glaucoma (OAG) treatment, including 
parasympathomimetics, sympathomimetics, sympatholytics, carbonic anhydrase inhibi-
tors, prostaglandin analogs, osmotics, neuroprotectors, blood flow enhancers, marijuana, 
Ginkgo biloba, and other alternative therapies.
Objective: Participants will be able to treat OAG more effectively by enhancing compli-
ance and risk-benefit ratios.
Senior Instructor(s): Allan J Flach MD
Complications Following Glaucoma Filtering Surgery: Face 
Them Boldly, Manage Them Efficiently
Course: 366 Monday
Room: R05 11:30 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: This course will review the early detection, prevention, and specific man-
agement strategy of the common complications that may be associated with glaucoma 
filtering surgery, such as hyphema, shallow to flat anterior chamber, early or late leaking 
bleb, encapsulated blebs, hypotony, the “wipeout” phenomenon, blebitis, bleb infection, 
and endophthalmitis.
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Objective: At the conclusion of the course, attendees will be able to face complica-
tions following glaucoma filtering surgery more boldly and manage them more efficiently.
Senior Instructor(s): Anil K Mandal MD
Instructor(s): Peter Andreas Netland MD PhD*, Dale K Heuer MD*, Eve J Higginbotham 
MD, Sriram Sonty MD FACS*
Implantation of Glaucoma Drainage Devices
Course: 137 Monday
Room: 342 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: The first part of this course is didactic, covering the indications, pathophysi-
ology, surgical technique, postoperative management, and complications of drainage 
devices (from anterior chamber tube to extraocular reservoir). The second part is hands-
on, with implantation of Molteno, Krupin, Baerveldt, Ahmed, and Schocket devices on 
porcine eyes. Ex-PRESS shunt, Trabectome, and canaloplasty will not be covered.
Objective: At the conclusion of this course, the attendee will be aware of principles 
and techniques of glaucoma drainage device implantation. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Richard P Mills MD MPH
Instructor(s): Ronald Leigh Fellman MD OCS*, George Baerveldt MD*, Anne Louise 
Coleman MD PhD*, Frederick M Kapetansky MD, Donald L Budenz MD MPH*, Paul A 
Sidoti MD, Angelo P Tanna MD*
 h  Tubes, Ties, and Videotape: Surgical Video of Baerveldt 
Glaucoma Implants and Managing Complications
Course: 390 Monday
Room: 211 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will present clinical photos, patient history, and edited surgical 
videos of several challenging glaucoma cases and will demonstrate efficient techniques 
for tube insertion and how to manage postoperative complications. The instructor will 
demonstrate how to reposition, extend, trim, cover, revise, and tie-off problematic tubes 
and will discuss how tubes are used in conjunction with surgery for cataracts, corneal 
failure, and retinal detachment.
Objective: At the conclusion of this course, the attendee will be able to formulate an 
appropriate surgical plan for a glaucoma drainage implant and be better prepared to 
avoid and manage potential complications.
Senior Instructor(s): Herbert P Fechter MD
Evidence-Based Guidelines in the Management of Glaucoma
Course: 393 Monday
Room: 214 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Early detection and treatment of glaucoma are of paramount importance to 
reduce the burden of blindness and its economic impact on society. Two important ques-
tions often confront a glaucoma specialist when initiating therapy: Who needs to be 
treated? And how should a patient be treated? This course will address the evidence-
based guidelines for treating glaucoma and review the invaluable information from major 
clinical trials (Glaucoma Laser Trial, Selective Laser Trabeculoplasty vs. Medical Therapy 
study, Ocular Hypertension Treatment Study, European Glaucoma Prevention Study, Early 
Manifest Glaucoma Trial, Collaborative Initial Glaucoma Treatment Study, Advanced 
Glaucoma Intervention Study, etc.) that have enhanced our understanding of the risk 
factors and treatment strategies at various stages of the disease.
Objective: At the conclusion of the course, the attendee will be knowledgeable about 
when and how to treat glaucoma patients based on evidence, including many of the 
major clinical trials that have guided clinical decision making in glaucoma practice.
Senior Instructor(s): Sarwat Salim MD*
Instructor(s): Malik Y Kahook MD*, Shan C Lin MD*, Raghu Mudumbai MD, Peter 
Andreas Netland MD PhD*, Joel S Schuman MD*, Quang H Nguyen MD*, Jody R Piltz-
Seymour MD*
 NEW  Managing Uveitic Glaucoma
Course: 406 Monday
Room: 338 3:15 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover the examination, monitoring, and management of 
uveitic glaucoma. Case presentations will be used to identify characteristic phenotypic 
features that help identify specific uveitic conditions, as well as the mechanism of IOP 
elevation. An algorithm for medically managing such patients will be discussed. Particu-
lar emphasis will be placed on defining the important features indicating when surgical 
intervention is required. Surgical options will be discussed, and video presentations will 
be used to demonstrate techniques to avoid complications in these patients.
Objective: At the conclusion of this course, attendees will have gained confidence in 
managing glaucoma / refractory ocular hypertension in uveitic patients. The attendee 
will be able to recognize different mechanisms of IOP elevation and instigate appropriate 
medical management and monitoring. They will appreciate the indications and options 
for surgery and understand the associated risks in this patient group.
Senior Instructor(s): Nicholas Strouthidis FRCOPHTH MBBS MD*
Instructor(s): Keith Barton MD*, Emmett T Cunningham Jr MD PhD MPH
 NEW  Lifestyle Intervention for the Treatment/Prevention of 
Age-related Eye Disorders: Practical Application
Course: 413 Monday
Room: R04 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Ocular disorders such as cataract / presbyopia, Fuchs endothelial corneal 
dystrophy, dry eye, AMD, and glaucoma are related to aging. Recent advances in un-
derstanding the mechanism of aging have provided the opportunity to interfere with the 
aging process to prevent and/or treat ocular diseases. This course will detail how age-
related changes in the immune system and mitochondrial dysfunction with attendant 
oxidative stress can contribute to the pathogenesis of eye disease. Specific interventions 
using diet, exercise, supplementation with vitamins and minerals, antioxidant interven-
tion, and stress reduction techniques target these pathologies.
Objective: At the end of this course, the attendee will understand the major aging hy-
potheses and learn their practical application through lifestyle intervention. The attendee 
will be able to incorporate the new knowledge and skills for themselves and in clinical 
practice for preventive and therapeutic management of age-related eye disorders.
Senior Instructor(s): Kazuo Tsubota MD*
Instructor(s): Jonathan Crowston MBBS PhD*, Ula Jurkunas MD*, Scott M MacRae MD*
3-D Optic Disc Viewing: Top 10 Pitfalls in Identifying Glaucoma 
Damage and Progression
Course: 421 Monday
Room: 222 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Participants will wear red-blue glasses to view 3-D PowerPoint projections 
of stereoscopic optic disc images. The most common pitfalls in identifying glaucomatous 
disc damage (including optic disc anomalies, swelling, and atrophy) will be viewed, dis-
cussed, and correlated with visual field loss. Characteristic glaucomatous disc changes 
will be highlighted, including vertical elongation of cupping and pallor, cup-to-disc asym-
metry, focal excavation, nerve fiber layer defects, and splinter hemorrhages. Special 
emphasis will be placed on simultaneous viewing of serial stereoscopic images that 
demonstrate progressive glaucomatous disc damage over time, including the evolution 
of rim notching, circumlinear vessel baring, laminar dot sign, and vessel course changes.
Objective: While viewing stereoscopic optic disc images, physicians will learn to iden-
tify 1) glaucomatous disc damage and progression and 2) the most common optic disc 
anomalies and pathologies that may confound this assessment.
Senior Instructor(s): Alan H Zalta MD
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Angle Closure and Angle-Closure Glaucoma
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
the Asia Pacific Glaucoma Society
Course: 531 Tuesday
Room: 215 9:00 - 11:15 AM
Education Level: ADV Target Audience: COMPSUB
Synopsis: Practically and logically, our course will define and classify these glauco-
mas, outline their prevalence and incidence, outline methods of assessment, and discuss 
pathophysiological mechanisms before covering medical, laser, and surgical strategies 
of prevention and treatment and current approaches to management of the acute angle-
closure crisis.
Objective: After the course, participants will have a deeper and broader understanding 
of the burden and current classification of angle closure and angle-closure glaucoma, an 
awareness of pathophysiological principles underlying choices of new treatment strate-
gies, and a detailed update on how best to prevent and to manage this spectrum of the 
glaucomas.
Senior Instructor(s): Tetsuya Yamamoto MD*
Instructor(s): Clement C Y Tham MBBS*, Paul T K Chew MD*, Tin Aung FRCS PhD*, Ki Ho 
Park MD*, Prin Rojanapongpun MD*, Ning Li Wang MD, Ching Lin Ho FRCS MBBS*
Combined Cataract Surgery With Glaucoma Surgery: 
Guidelines, Indications, Methods, Techniques, and 
Postoperative Management
Course: 540 Tuesday
Room: 225 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: COMP
Synopsis: This course will provide a comprehensive review of guidelines and indica-
tions for combined cataract / glaucoma filtering surgery based on glaucoma severity, 
IOP control, extent of optic nerve damage, level of visual field loss, and type of glau-
coma. Preoperative considerations from determination of surgical site, antimetabolite 
use, poorly dilating pupil, shallow anterior chamber, and posterior synechiae will be dis-
cussed. Surgical methods, anesthesia, one or two-site surgery, and surgical techniques 
will be explained. Glaucoma filtering surgery methods from conjunctival dissection and 
wound architecture to antimetabolite use will be stressed. Anticipation, avoidance, man-
agement of surgical and postsurgical complications, and postoperative management of 
glaucoma will be explained.
Objective: At the conclusion of this course, attendees will be able to proceed with com-
bined cataract / glaucoma surgery, determine best surgical method, avoid complications, 
and manage postoperative glaucoma course.
Senior Instructor(s): Leon G Partamian MD*
Instructor(s): Eve J Higginbotham MD, Cynthia Mattox MD FACS*, David Lee MD*, 
Marlene R Moster MD*, Anastasios P Costarides MD PhD*, Thomas W Samuelson MD*
Needling for Failed Blebs: All You Need to Know
Course: 549 Tuesday
Room: 228 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Needling appears to be a simple procedure, but its success is very technique-
dependent. This course will revisit the procedure in a step-by-step manner and with a lot 
of video illustrations (based on the first-prize winning video of the fourth World Glaucoma 
Congress), showing the proper way to perform each step of the procedure. The course 
will cover all you need to know about needling, from indications, contraindications, tech-
niques and pearls, choosing the right adjunct, and results to complications and their 
management. Slitlamp photographs and videos will be extensively used in the course, 
the handout, and the course DVD-ROM to illustrate the critical techniques.
Objective: At the conclusion of this course, participants will be able to safely, effective-
ly, and confidently perform needling, select the right adjunct, and achieve good results.
Senior Instructor(s): Dennis S C Lam MD
Instructor(s): Mingguang He MD PhD, Christopher Kai-shun Leung MD MBChB, Clement 
C Y Tham MBBS*
What’s New in Normal-Tension Glaucoma?
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
the Asia Pacific Glaucoma Society
Course: 555 Tuesday
Room: 333 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover recent advances in the pathogenesis, early diagnosis, 
risk factors, and treatment of normal-tension glaucoma (NTG). Based on rich clinical ex-
perience and proven study results, the authors will provide current and new information 
on NTG. The recent advances in the structural and functional diagnostic technology, risk 
factors for the development and progression of NTG, neuroimaging issues, and current 
strategies for treating NTG will be shared with attendees.
Objective: At the conclusion of this course, attendees will be able to assess and man-
age NTG patients with greater knowledge and confidence.
Senior Instructor(s): Ki Ho Park MD*
Instructor(s): Kazuhisa Sugiyama MD PhD, Makoto Aihara MD PhD*, Dexter Yu-Lung 
Leung DRCOPHTH FRCS, Tae-Woo Kim MD PhD*
Ophthalmoscopic Evaluation of the Optic Disc and Retinal 
Nerve Fiber Layer
Course: 560 Tuesday
Room: 338 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course covers the ophthalmoscopic evaluation of optic disc, cup, neuro-
retinal rim, parapapillary atrophy, disc hemorrhages, retinal nerve fiber layer, and retinal 
vessel width.
Objective: The course will help participants to (1) understand pseudoglaucomatous 
macrocupping and pseudonormal minicupping, (2) detect early glaucomatous changes, 
(3) differentiate glaucoma types by disc morphology, (4) distinguish glaucomatous optic 
neuropathy from nonglaucomatous optic nerve atrophy, (5) consider ethnic differences 
in the disc appearance, (6) discuss pathogenic implications of the disc morphology for 
glaucoma, (7) perform the dynamic optic disc assessment using modified ophthalmo-
dynamometry for estimation of central retinal artery and vein pressure, orbital tissue 
pressure, and brain pressure, (8) understand the presence of cerebrospinal fluid pressure, 
and (9) differentiate alpha, beta, gamma, and delta zones of parapapillary atrophy by OCT 
and histology.
Senior Instructor(s): Jost B Jonas MD*
Top 10 Essentials of Gonioscopy: 3-D Viewing and 
Interpretation
Course: 566 Tuesday
Room: 222 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Participants will wear red-blue glasses to view 3-D PowerPoint projections 
of stereoscopic gonioscopy and slitlamp images. Identifying traditional gonioscopic 
anatomy may be confounded by a variety of anterior chamber angle pathologies. The 
use of different gonioprisms and indispensable gonioscopy techniques (dynamic indenta-
tion and termination of the corneal light wedge) will be discussed. Special emphasis 
will be placed on the evaluation of narrow angles, decision making for laser iridotomy, 
and laser treatment of the angle and iris. Pathologic variations in overly deep anterior 
chambers, angle blood vessels, increased trabecular meshwork pigment, peripheral an-
terior synechiae due to anterior mechanisms with or without membranes and posterior 
mechanisms with or without pupillary block, and anterior chamber angle clefts will be 
presented.
Objective: While viewing stereoscopic images, the attendee will learn essential gonio-
scopic anatomy, examination techniques, and categorization with variations in pathology.
Senior Instructor(s): Alan H Zalta MD
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Understanding and Utilizing Glaucoma Imaging
Course: 576 Tuesday
Room: 209 12:45 - 1:45 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Recent advances in imaging have led the way to better understanding of a 
variety of pathological mechanisms in glaucoma. We are now able to obtain high-reso-
lution images of the anterior segment, iridocorneal angle, retinal nerve fiber layer, and 
optic nerve head. This has enabled us to use various types of imaging for the detection 
and monitoring of glaucoma progression, as well as aiding our diagnostic skills in as-
sessing prognosis for interventions and when to intervene. This course will concentrate 
on the modalities of ultrasound biomicroscopy, anterior segment OCT, and a new angle 
imaging technique, RetCam. Optic nerve head evaluation techniques such as Heidelberg 
Retinal Tomography and retinal nerve fiber layer assessment by time domain OCT and 
spectral domain (high-definition) OCT will also be discussed.
Objective: At the conclusion of this course, the attendee will be able to incorporate 
these insights into the diagnosis and management of glaucoma patients.
Senior Instructor(s): Shamira Perera MBBS*
Instructor(s): David Goh MBBS
Global Ophthalmology
 NEW   GO  Global Initiatives for Cataract Surgery Efficiency 
and Sustainability
Course: 552 Tuesday
Room: 355 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: Developed countries have excellent service models that enable access for 
patients and also interventions like manual sutureless small-incision cataract surgery 
(SICS) that offer cost-effective outcomes. However, eye care services in developing 
countries often lack management capacity to function at full potential and with finan-
cial sustainability. This course shares proven strategies that helped build clinical and 
organizational capacity to create sustainable and quality eye surgery programs. A panel 
presentation, followed by audience discussion, will explore the building blocks of an 
effective service, including the use of various cataract surgical procedures such as SICS 
and phacoemulsification.
Objective: Upon completion of this course, participants will be able to (1) understand 
the components of a viable, organizationally and financially sustainable eye care service, 
(2) recognize how a team approach leads to enhanced efficiency and effectiveness, even 
in the short-term, and (3) influence constructive changes for sustainable eye hospitals.
Senior Instructor(s): Susan Lewallen MD
Intraocular Inflammation, Uveitis
Medical and Surgical Therapy and Diagnosis of Uveitis
Course: 189 Sunday
Room: 220 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Recent advances have increased our ability to identify a specific etiology for 
many cases of uveitis. Medical and surgical therapeutic advances have also produced 
dramatic improvements in our ability to care for patients with uveitis. This course will 
present our system.
Objective: This course will enable participants to recognize, investigate, and treat pa-
tients with uveitis.
Senior Instructor(s): C Stephen Foster MD*
Instructor(s): Emil Mitchel Opremcak MD, Albert T Vitale MD*
How to Evaluate a Patient With Uveitis
Sociedad Panamericana de Enfermedades Inflamatorias Oculares of the Pan 
American
Course: 318 Monday
Room: R08 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will focus on the step-by-step evaluation of patients with uveitis 
by using case presentations to illustrate specific uveitis entities. Each course instructor 
will present interesting cases as unknowns for discussion by the panel of instructors. 
Course attendees will also be invited to present their own mystery cases by submitting 
the cases in advance. The rationale for ordering laboratory evaluations / ancillary tests 
and for the treatment plan will be explained in detail.
Objective: Attendees will have ample opportunity to participate in this interactive 
course and will experience how a uveitis specialist analyzes each patient. Presentations 
will include both infectious and noninfectious entities in patients with anterior, interme-
diate, posterior, and pan-uveitis. Special emphasis will be given to the newest treatment 
modalities. At the completion of this course, the attendee will be able to formulate a 
tailored laboratory evaluation for the entities presented.
Senior Instructor(s): Careen Yen Lowder MD PhD*
Instructor(s): Emilio M Dodds MD, Janet Louise Davis MD*, James Philip Dunn Jr MD, 
Debra A Goldstein MD*, Sunil K Srivastava MD*
 h  Decoding the Uveitis Workup: Why, When, and What to 
Order
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Uveitis Society (AUS)
Course: 506 Tuesday
Room: 223 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will primarily focus on the stepwise, cost-effective uveitis 
workup utilizing the history and clinical presentation. Uveitis entities will be classified 
in a fashion that simplifies and optimizes the workup and reduces unnecessary testing. 
Clinical cases will highlight important features.
Objective: Upon completion of this course, participants will be able to (1) selectively 
order appropriate diagnostic tests based on the clinical presentation of various uveitis 
entities in a cost-effective fashion and (2) interpret the results of diagnostic tests.
Senior Instructor(s): Sarkis H Soukiasian MD
Instructor(s): Michael E Zegans MD*, Russell N Van Gelder MD PhD*
International (Dis)Agreement on Infectious Uveitis
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Uveitis Society (AUS)
Course: 575 Tuesday
Room: R01 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Infectious uveitis is estimated to be responsible for 10%-30% of all uveitis 
cases. In some parts of the world toxoplasmosis alone is responsible for up to 50% 
of all posterior uveitis. Infectious uveitis poses unique diagnostic and therapeutic chal-
lenges. Uveitis resulting from infections can masquerade as noninfectious uveitis. The 
diagnosis may require an anterior chamber or vitreous tap. While autoimmune uveitis 
requires long-term immunosuppressive therapy, most infectious uveitides can be treated 
with short-term antimicrobial therapy. It is therefore highly desirable to identify possible 
infectious etiology in idiopathic uveitis. The instructors will present a variety of challeng-
ing cases from around the world, with interactive discussion sessions.
Objective: At the end of this course, the audience will be able to develop a stepwise 
approach to diagnosing and managing infectious uveitis entities.
Senior Instructor(s): Rubens Belfort Jr MD PhD*
Instructor(s): Hatice N Sen MD, Robert B Nussenblatt MD, Gary N Holland MD, Emilio 
M Dodds MD, Narsing A Rao MD, Khalid F Tabbara MD*, Careen Yen Lowder MD PhD*, 
Bahram Bodaghi MD PhD*, Cristina Muccioli MD, Ronald E Smith MD*, Thomas A Albini 
MD*, Heloisa Nascimento MD
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Medical Education
 NEW  Keys to Successful Publication in the Good 
Ophthalmology Journal
Course: 356 Monday
Room: R02 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: The editors-in-chief of the three major general ophthalmology journals will 
offer suggestions on preparing research for publication, including the initial steps in re-
search, construction of manuscripts, and expectations of the peer review process. Help-
ful do’s and don’ts will be offered to aspiring authors. Audience members may recount 
their expectations, experiences, and concerns to the editors.
Objective: At the conclusion of the course, the attendee will be able to understand how 
to select a journal to match a specific research study, the essential elements of a manu-
script, and how the manuscript will be handled during the peer review process. Audience 
interaction with the editors is anticipated to alleviate apprehensions about the process 
and encourage properly focused energy in offering new research to the peer reviewed 
literature. Audience members may introduce related topics during a panel discussion.
Senior Instructor(s): Thomas J Liesegang MD
Instructor(s): Daniel M Albert MD FACS*, George B Bartley MD
 NEW  Strategy and Statistics in Clinical Research: A 
Nonstatistician’s Guide to Thinking, Designing, and Executing
Course: 418 Monday
Room: R02 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will provide clear, nontechnical explanations of the statistics in 
clinical trials and outcomes-based technique / surgical studies, from hypothesis formula-
tion through analysis. The instructors will provide easy-to-follow study design and sta-
tistics templates for common studies performed in ophthalmic research for attendees to 
use outside of the course setting.
Objective: At the conclusion of this course, the attendee will be able to properly design 
and execute a clinical research study.
Senior Instructor(s): Craig N Czyz DO
Instructor(s): Jill Annette Foster MD FACS*, James J Jenkins II PhD
 NEW  Surgical Education: Improving Upon and Going Beyond 
the Apprentice Model
Course: 557 Tuesday
Room: R01 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Presenters will cover a wide variety of surgical education techniques, includ-
ing traditional surgery, wet lab, cognitive computer modeling, and simulation. They will 
focus on how to improve traditional teaching techniques and how to incorporate new 
techniques and technologies. The course will include strategies to optimize the use of ex-
isting resources and will give attendees a look at modalities to incorporate in the future.
Objective: To review and critique existing and new techniques in surgical education.
Senior Instructor(s): Andrew J Hendershot MD
Instructor(s): Andrew G Lee MD*, Karl C Golnik MD, Thomas A Oetting MD, Bonnie A 
Henderson MD*, Tiago Bisol MD
Neuro-Ophthalmology
 h  Understanding Nystagmus: A Practical Approach for the 
Clinician
Course: 190 Sunday
Room: R04 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course reviews the clinical features of different types of nystagmus. By 
using a systematic pathophysiologic approach, clinicians will develop a rational decision-
making process in the diagnosis and management of nystagmus. Numerous videos will 
be presented.
Objective: To impart an understanding of nystagmus using a practical approach. At the 
conclusion of this course, the attendees will be able to identify the salient features of 
different types of nystagmus, including their etiology and pathophysiology, as well as 
important diagnostic and treatment issues. This course will aid attendees in improving 
their clinical management of nystagmus.
Senior Instructor(s): Agnes M Wong MD*
 SO  Diagnostic and Therapeutic Dilemmas in Neuro-
Ophthalmology
Course: 191 Sunday
Room: 333 2:00 - 4:15 PM
Education Level: ADV Target Audience: SUB
Synopsis: In this course, actual diagnostic and therapeutic clinical dilemmas will be 
presented by a panel of university-based neuro-ophthalmologists, with members of the 
audience participating in the generation of differential diagnoses and therapeutic strate-
gies.
Objective: At the conclusion of the course, the attendee will be able to address difficult 
problems in the diagnosis and management of neuro-ophthalmic cases.
Senior Instructor(s): Nancy J Newman MD*
Instructor(s): Neil R Miller MD*, Valerie Biousse MD*, Mark L Moster MD*, Andrew G 
Lee MD*
 h  Diagnosis, Optic Neuropathy: Now What?
Course: 222 Sunday
Room: 224 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: Optic neuropathies demonstrate characteristic clinical features regardless of 
the underlying etiology. In this course, illustrative cases and discussion will identify spe-
cific features of common optic neuropathies, including optic neuritis, arteritic and non-
arteritic anterior ischemic optic neuropathy (AION and NAION), and compressive optic 
neuropathies. Current recommendations for evaluation and treatment will be presented.
Objective: At the conclusion of this course, the attendee will be able to diagnose com-
mon optic neuropathies and distinguish them from less common etiologies. The attendee 
will know when and what studies, treatments, and referrals to initiate for distinct diag-
noses.
Senior Instructor(s): Kenneth S Shindler MD PhD
Instructor(s): Gabrielle R Bonhomme MD, Madhura A Tamhankar MD, Nicholas J Volpe 
MD*
Visual Fields in Neuro-Ophthalmology
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
North American Neuro-Ophthalmology Society (NANOS)
Course: 224 Sunday
Room: R02 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will provide an overview of visual fields, with an emphasis on 
neuro-ophthalmic conditions. The role of visual fields in neuro-ophthalmology will be 
put in perspective. Guidelines will be suggested for choosing the best field technique. 
Some of the newest field techniques will be discussed. Anatomic correlations with vi-
sual fields will be comprehensively detailed. Reliability and artifacts in visual fields will 
be reviewed. Case examples of visual field defects will be presented, with audience 
participation.
Objective: At the end of this course, participants should be able to maximize their 
use of visual fields as a component of the complete evaluation in assessment of neuro-
ophthalmology patients.
Senior Instructor(s): Susan M Pepin MD
Instructor(s): Jacqueline A Leavitt MD, Steven A Newman MD
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 P   h  Case-Based Approach to Isolated Eye Pain
Course: 359 Monday
Room: R04 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Patients with eye pain and a normal ophthalmologic examination often 
present to the ophthalmologist. In this course, differential diagnosis, pathophysiology, 
management, and cases of isolated eye pain will be discussed in an interactive fashion.
Objective: The attendee will be able to identify common causes of isolated eye pain 
and summarize current treatment options.
Senior Instructor(s): Michael S Lee MD*
Instructor(s): Gregory S Kosmorsky DO
The Vertical Diplopia Dilemma, Made Simple
Course: 365 Monday
Room: 211 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: In the majority of patients, the etiology of vertical diplopia can be established 
by careful history taking and clinical examination. In this course, illustrative cases and 
discussion will identify specific features of common causes of vertical diplopia such as 
cranial nerve palsy, thyroid orbitopathy, myasthenia gravis, and orbital and head trauma. 
A systematic approach toward evaluation and critical management pathways will be 
presented.
Objective: At the conclusion of the course, the attendee will be able to diagnose com-
mon causes of vertical diplopia. A systematic approach toward management will aid the 
attendee in ordering appropriate tests, identifying patients requiring emergent manage-
ment, and making appropriate referrals to specialists.
Senior Instructor(s): Madhura A Tamhankar MD
Instructor(s): Kenneth S Shindler MD PhD, Nicholas J Volpe MD*, Collin M McClelland 
MD
Emergency Neuro-Ophthalmology: Diagnosis and Management
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
North American Neuro-Ophthalmology Society (NANOS)
Course: 369 Monday
Room: 228 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course will present a case-based review of the emergency management 
of acute and transient vision loss, optic nerve swelling, pupillary disorders, and ocular 
motility defects.
Objective: To teach participants to identify and manage patients with true neuro-oph-
thalmic emergencies, and to review the differential diagnosis and management of acute 
vision loss, anisocoria, and ophthalmoplegia.
Senior Instructor(s): Nicholas J Volpe MD*
Instructor(s): Mark L Moster MD*
 P  What You Need to Know About Headache: A Pain for the 
Patient and a Pain for the Doctor
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
North American Neuro-Ophthalmology Society (NANOS)
Course: 523 Tuesday
Room: 338 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Patients are often seen by or referred to the ophthalmologist because of 
headache or eye pain. These patients present a diagnostic and therapeutic challenge, as 
many will have no apparent ocular etiology for their pain. The purpose of this course is 
to present a simplified framework for diagnosis and management of these patients that 
will both streamline their evaluation and provide guidelines for potentially beneficial 
therapeutic interventions. This course will use a case-based approach to discuss various 
headache syndromes with ocular manifestations.
Objective: At the conclusion of this course, the attendees will be able to identify the 
major categories of underlying diagnoses for headache and eye pain, develop a succinct 
strategy for history and clinical examination to confirm the suspected diagnosis, and 
develop treatment goals in order to help their patients.
Senior Instructor(s): Peter A Quiros MD
Instructor(s): Lynn K Gordon MD PhD*
Swollen Disks, Headache, and Vision Loss: A Case-Based 
Approach to Pseudotumor Cerebri
Course: 559 Tuesday
Room: 223 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: What do you do when a patient with bilateral disc swelling presents? How 
do you determine the urgency of evaluation and make the right diagnosis? Using a case-
based approach, we will emphasize the workup that every patient needs and will show 
how to use technology (CT, MRI/MR venography, spectral domain OCT, visual fields) to 
help recognize the warning signs of sight-threatening disease. We will also discuss new 
treatment options, including venous sinus stenting, and the long-term consequences of 
pseudotumor cerebri.
Objective: At the conclusion of this course, the attendee will be able to identify fea-
tures of optic disc swelling that suggest sight-threatening disease and will understand 
the evaluation and referral process. Attendees will be able to interpret the results of 
diagnostic imaging techniques and recognize critical findings of venous sinus disease. 
They will become familiar with current strategies for the treatment of patients with id-
iopathic intracranial hypertension and describe the indications for medical and surgical 
or interventional treatments.
Senior Instructor(s): Prem S Subramanian MD PhD*
Instructor(s): Vivek R Patel MD
 h   YO  Curbside Consultation in Neuro-Ophthalmology
Course: 570 Tuesday
Room: R08 12:45 - 3:00 PM
Education Level: INT Target Audience: COMP
Synopsis: This course offers brief, concise, and practical answers to those questions 
that are often left unanswered by traditional texts and references in neuro-ophthalmolo-
gy. The presenters will use a case-based format to pose and answer questions of neuro-
ophthalmic interest to the general ophthalmologist. The presentations will be given in a 
“curbside consult” format that will be educational and entertaining.
Objective: At the conclusion of this course, attendees will be able to provide manage-
ment solutions to common neuro-ophthalmic presentations, including papilledema, optic 
neuritis, neuroretinitis, anterior ischemic optic neuropathy, optic atrophy, common visual 
field defects, and ocular motor cranial neuropathies.
Senior Instructor(s): Andrew G Lee MD*
Instructor(s): Lanning B Kline MD, Paul W Brazis MD
Ocular Tumors and Pathology
How to Get the Most Out of Your Pathologist
Course: 239 Sunday
Room: R01 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover biopsy and excision techniques for intraocular, con-
junctival, eyelid, and orbital lesions. Fine-needle aspiration biopsy techniques will be 
reviewed. The handling and submission of specimens to the pathology laboratory will be 
discussed. The common mistakes during biopsy and excision of lesions and how to avoid 
them will be pointed out. Pitfalls in pathologic processing and assessment of specimens 
will be reviewed. This will be an interactive course with audio-visual demonstration of 
biopsy and excision techniques.
Objective: The attendee will learn (1) the approaches to biopsy and excision of intra-
ocular, conjunctival, eyelid, and orbital lesions and (2) fine-needle biopsy techniques, 
including fresh tissue harvesting, as well as their pathological processing.
Senior Instructor(s): Hakan Demirci MD
Instructor(s): Irina V Koreen MD PhD**, Victor M Elner Ph D MD*
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Practical Ocular Oncology for the Comprehensive 
Ophthalmologist: What You Should Know
Course: 505 Tuesday
Room: R03 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will consist of presentations and discussions of the topics in 
ophthalmic oncology most important for comprehensive ophthalmologists. These include 
classic but distinctive fundus lesions, including choroidal melanoma, retinoblastoma, 
metastatic carcinoma, intraocular lymphoma, and other neoplastic lesions both benign 
and malignant. The presenters will emphasize the clinical diagnosis and current man-
agement as well as “hot topics” in ocular oncology. Current and future management in 
cancer and how it can affect the eye will also be discussed (eg, target therapy in systemic 
cancer has shown ocular side effects). Participation of the audience will be encouraged 
with representative cases.
Objective: At the end of this course, attendees will be able to identify the most com-
mon intraocular tumors as well as to understand current management and how patients 
can present at a general ophthalmology practice. This course will help comprehensive 
ophthalmologist to counsel oncology patients.
Senior Instructor(s): Miguel A Materin MD
Instructor(s): James Augsburger MD, Zelia M Correa MD, Hakan Demirci MD, Dan S 
Gombos MD, J William Harbour MD*, Brian P Marr MD, Prithvi Mruthyunjaya MD*, Jose 
S Pulido MD MS
Pediatric Ocular Tumors
Course: 530 Tuesday
Room: 217 9:00 - 10:00 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover the important ocular tumors affecting children. An or-
ganized presentation will be given on the recognition and management of tumors of the 
eyelid, conjunctiva, intraocular structures, and orbit. Retinoblastoma management will 
be summarized. Various cases will be presented, along with discussion of management.
Objective: At the conclusion of this course, the attendee should be able to identify 
the most common ocular tumors of childhood and understand management strategies.
Senior Instructor(s): Carol L Shields MD
Instructor(s): Jerry A Shields MD
Uveal Melanoma Therapies: Protons, Plaques, and Eyewall 
Resection
Course: 565 Tuesday
Room: R02 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: The course will overview the indications, contraindications, complications, 
and results with various therapies for uveal melanoma using an illustrative case ap-
proach with audience participation. The data set for the course is approximately 4000 
cases managed by the author and others. Iris, ciliary body, and uveal tumors will be 
discussed, and the advantages and disadvantages of various treatment modalities will 
be delineated, along with an approach for the surgeon on how to optimize results.
Objective: At the conclusion of the course, the participant should be able to select 
optimum therapy for each type of patient, determine the relative risks and successes of 
each procedure, and determine how to minimize treatment complications.
Senior Instructor(s): Devron H Char MD
Instructor(s): Devron H Char MD
Ophthalmic History
 SO  Evolution’s Witness: How Eyes Evolved
Course: 181 Sunday
Room: 208 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Although the journey to spatial vision actually began billions of years ago, 
the Cambrian explosion (543-490 million years ago) saw the first known eye. The Cambri-
an was a crucible of evolution and spawned nearly all ocular designs. This was followed 
by descent over millions of years, providing an unimaginable variety of eyes with at least 
10 different models. Some eyes display spectacular creativity, with mirror, scanning, or 
telephoto optics. From initial photoreception 3.75 billion years ago to early spatial recog-
nition in the first cupped eyespot in Euglena to fully formed camera-style eyes the size of 
beach balls in ichthyosaurs, animals have processed light to compete and survive in their 
respective niches. Vision is evolution’s greatest gift and its greatest triumph. This course 
will present the story of the evolution of eyes.
Objective: To stimulate curiosity about the novelties and the triumphs of the evolution 
of the eye.
Senior Instructor(s): Ivan R Schwab MD FACS
 SO  Vision and the Artist
Course: 582 Tuesday
Room: 215 12:45 - 1:45 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course fuses ophthalmology and art. We will demonstrate how art 
teaches ophthalmology3/4and how ophthalmology enhances the appreciation of art. 
We will discuss how light, dark, and contrast underlie vision and make representation 
in art possible. We will also discuss how art may reflect eye disease in the artist and 
demonstrate the functional effects of failing vision. Art from all ages will be shown, with 
special attention to the question of eye disease in Rembrandt, Cassatt, Degas, Monet 
and O’Keeffe. Simulations of the artists’ own view of their work will illustrate how dif-
ferent disabilities have affected different artists.
Objective: Attendees should gain understanding of how visual processes and eye dis-
ease affect their patients3/4and gain new appreciation of art.
Senior Instructor(s): Michael F Marmor MD*
Instructor(s): James G Ravin MD
Optics, Refraction, Contact Lenses
Review of Clinical Optics
Course: 157 Sunday
Room: 217 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: This review of clinical optics will prepare ophthalmology residents to take 
the Ophthalmic Knowledge Assessment Program examination and graduates of residen-
cy training programs to take the written qualifying examination of the American Board of 
Ophthalmology. It will also serve as a refresher course for those in practice. The course 
will be taught in a question-and-answer format, focusing on problem solving. Content 
and illustrations will be drawn from the American Academy of Ophthalmology’s Basic 
and Clinical Science Course book on clinical optics.
Objective: At the conclusion of the course, participants will be better prepared to an-
swer multiple-choice optics questions on written examinations.
Senior Instructor(s): Kevin M Miller MD*
Contact Lens in Ophthalmology Practice
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and the 
Contact Lens Association of Ophthalmologists (CLAO)
Course: 227 Sunday
Room: 209 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: In this course, the incentives, scope-of-practice options, and resource re-
quirements for contact lens practice will be presented. Practitioners from various prac-
tice settings, including comprehensive solo practice, academic practice, cornea practice, 
and multispecialty practice, will present their experiences in offering contact lens ser-
vices to their patients. Both private and institutional practices will be represented. Useful 
resources will be reviewed.
Objective: At the completion of this program, the participant will understand (1) the 
incentives for offering contact lens as part of comprehensive eye care, (2) options for 
offering a limited scope or full range of contact lens services, (3) resource requirements 
for a range of contact lens services and practice models, and (4) availability of resources 
for reference.
Senior Instructor(s): Deborah S Jacobs MD*
Instructor(s): S Lance Forstot MD FACS*, Bruce Koffler MD*, Thomas L Steinemann MD*
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Orbit, Lacrimal, Plastic Surgery
Cosmetic Botulinum Toxin and Facial Fillers: An Introductory 
Course
Course: 111 Sunday
Room: 338 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Principles of aesthetic facial injection of botulinum toxin and facial fillers will 
be presented in a didactic format.
Objective: At the conclusion of this course, the attendee will better understand the 
salient anatomy, clinical techniques (including complication avoidance), and pharmaco-
logical principles pertaining to aesthetic injection of these substances. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Kathleen M Duerksen MD
Instructor(s): Michael S McCracken MD, Deborah D Sherman MD*, John Joseph Martin 
MD*
Fundamental Facelifting Techniques
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and the 
American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS)
Course: 112 Sunday
Room: 215 10:15 AM - 12:30 PM
Education Level: INT Target Audience: SUB
Synopsis: This basic course will consist of a step-by-step slide and video presentation 
of a preoperative assessment, surgical facial anatomy, fundamental facelifting tech-
niques, postoperative care, and potential complications. A downloadable course manual 
will be available to participants.
Objective: Participants will acquire the ability to select appropriate patients, develop 
hands-on familiarity with facial surgical anatomy, perform safe surgical dissection, pro-
vide appropriate postoperative care, and integrate facelifting into their aesthetic oculo-
facial practice. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Brett S Kotlus MD
Instructor(s): Tanuj Nakra MD, Robert M Schwarcz MD*, Bobby S Korn MD PhD FACS*
Periocular Tumors and Techniques of Eyelid Reconstruction
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS)
Course: 150 Sunday
Room: 335 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will give an overview of the most common benign and malignant 
skin lesions that involve the periocular region, will highlight the general features of ma-
lignancy, will provide a detailed description of the most common eyelid neoplasms, will 
describe the different biopsy techniques, and will provide the requisites to reconstruct 
the upper and lower eyelid under any circumstance.
Objective: At the conclusion of this course, the attendee will be able to recognize 
malignant and benign tumors, differentiate among the various types of malignant le-
sions, safely diagnose every suspicious periocular tumor, and master the most useful 
techniques for upper and lower eyelid reconstruction.
Senior Instructor(s): Jeffrey A Nerad MD
Instructor(s): Francesco P Bernardini MD, Martin H Devoto MD, Robert C Kersten MD, 
Carlo de Conciliis MD
Facial Fracture Repair: Better Outcomes and Improved 
Technique
Course: 153 Sunday
Room: 223 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: This course will provide a detailed discussion of valuable pearls for the 
reconstruction of common facial fractures that are often seen within the scope of an 
oculofacial practice, but not commonly taught during fellowship training. The content 
will include valuable insight regarding the management of zygomatic complex, naso-
orbital-ethmoidal complex, and extensive multiple wall fractures of the orbit and roof 
and frontal sinus fractures.
Objective: This course is designed to provide participants with a high-level understand-
ing of the preoperative planning, nuances, and pitfalls of the most recent management 
and repair techniques of facial fractures from an orbitocentric perspective. In addition, 
participants should gain sufficient knowledge to improve surgical outcomes through the 
application of these techniques.
Senior Instructor(s): Eli L Chang MD
Instructor(s): Peter A D Rubin MD, Jeremiah P Tao MD, Vikram D Durairaj MD*, Hui Bae 
Harold Lee MD, William R Nunery MD
Stereo Anatomy of the Orbit, Eyelid, and Lacrimal System: A 
Surgeon’s Perspective
Course: 164 Sunday
Room: 333 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will provide a comprehensive review of orbital, eyelid, and lacri-
mal system anatomy using projected stereo images of meticulous cadaveric dissections. 
Surgical approaches and complications will be emphasized.
Objective: This course will reacquaint participants with the anatomy of the orbit / ocu-
lar adnexa and increase their confidence when operating in these areas.
Senior Instructor(s): Asa Dan Morton III MD*
Instructor(s): David B Lyon MD FACS, Victor M Elner Ph D MD*, Kimberly Cockerham MD 
FACS*
Basic Browlift: Principles and Techniques
Course: 165 Sunday
Room: 220 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: There are many brow elevation techniques, and in general the procedure 
should be tailored to the specific patient. This course will review the anatomical foun-
dations, evaluation, patient selection, and treatment of brow ptosis. The techniques 
reviewed will include direct, mid-forehead, pretrichial, coronal, limited incision, and 
browpexy.
Objective: At the conclusion of the course, the attendee will be able to describe the 
anatomical foundations of brow ptosis, evaluate the patient with brow ptosis, list the 
different techniques available for brow elevation, and select which procedure is most 
appropriate for the particular patient.
Senior Instructor(s): Richard C Allen MD PhD
Instructor(s): Jill S Melicher Larson MD, Keith D Carter MD FACS
Tips for Cosmetic Eyelid Surgery in Asian Patients
Course: 168 Sunday
Room: 211 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Asian people have different anatomic characteristics from non-Asian people, 
and different beauty standards as well. To obtain a satisfactory surgical outcome, it is 
important to understand the distinct points in anatomy and surgical techniques. This 
course will present detailed anatomic differences, as well as surgical pearls on cosmetic 
eyelid surgery such as double eyelid operation, upper lid blepharoplasty, and epicantho-
plasty for Asian patients.
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Objective: At the conclusion of this course, the attendee will be familiar with differ-
ent approaches and unique surgical techniques for performing various cosmetic eyelid 
procedures in Asian patients.
Senior Instructor(s): Yoon-Duck Kim MD
Instructor(s): Don Kikkawa MD*, Randal Pham MD FACS, Kyung In Woo MD
 NEW  Fat Grafting and Volume Restoration
Course: 115 Sunday
Room: 335 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: The purpose of this prerequisite didactic course is to present facial fat graft-
ing as a technique for volume restoration. Indications for surgery, patient selection, al-
ternatives to surgery, surgical techniques and instrumentation, and postoperative details 
will be reviewed. An interactive case presentation will allow attendees to participate.
Objective: At the conclusion of this course, the attendee will be acquainted with facial 
fat grafting techniques and appropriate patient selection, as well as addressing potential 
postoperative complications. The course will enable the attendee to formulate a custom-
ized approach to a patient’s needs and goals.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): David Khoramian Isaacs MD
Instructor(s): Robert M Schwarcz MD*, Tanuj Nakra MD, Norman Shorr MD, Robert A 
Goldberg MD*
Blepharoplasty
Course: 116 Sunday
Room: 225 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover the latest techniques in upper and lower eyelid bleph-
aroplasty. Basic and advanced surgical techniques, eyelid anatomy, patient selection, 
preoperative evaluation, and avoidance of complications will be discussed. A course 
handbook with illustrations outlining the surgical techniques will be provided.
Objective: This course will provide participants with the techniques required to perform 
successful upper and lower eyelid blepharoplasties. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Keith D Carter MD FACS
Instructor(s): Mark A Alford MD, Richard C Allen MD PhD, Richard L Anderson MD 
FACS*, Adam G de la Garza MD, Robert C Kersten MD, Jill S Melicher Larson MD, 
Jeffrey A Nerad MD
Where Neuro-Ophthalmology and Oculoplastics Collide: 
Challenging Cases and Topics
Course: 234 Sunday
Room: 338 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Many oculoplastic conditions are straightforward and require routine sur-
gical interventions. Occasionally, however, seemingly benign signs or symptoms may 
represent other life- and/or vision-threatening neurologic conditions. This course will 
emphasize detection of these potentially dangerous pathologies that could result in dev-
astating results without cooperation between two subspecialties for appropriate patient 
care. This interactive panel-fashion course aims to provide a detailed understanding of 
certain hard-to-diagnose disorders of oculoplastics that overlap with the neuro-ophthal-
mology field.
Objective: At the end of this course, the participant will be able to (1) recognize which 
ptosis patient may require additional workup, (2) list and describe diagnostic criteria of 
myasthenia gravis, CN III palsy, chronic progressive external ophthalmoplegia, Horner 
syndrome, and muscular dystrophies, (3) recognize common and subtle symptoms and 
signs of giant cell arteritis, and (4) outline the indications for optic nerve sheath fenestra-
tion.
Senior Instructor(s): Altug Cetinkaya MD
Instructor(s): Karl C Golnik MD
Thyroid Eye Disease
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
International Thyroid Eye Disease Society (ITEDS)
Course: 304 Monday
Room: 211 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Thyroid eye disease (TED) can be challenging to manage. This course pro-
vides a practical update to help the ophthalmologist care for the patient with TED. The 
International Thyroid Eye Disease Society (ITEDS) “VISA” standardized evaluation form 
will be utilized in the discussion of the clinical evaluation and management of this disor-
der. An overview of favored approaches for surgical management will also be provided.
Objective: By the conclusion of this course, participants should understand (1) disease 
activity, progress, and severity, (2) the ITEDS-VISA classification, (3) the use of the ITEDS-
VISA classification for management, (4) management during the active phase, including 
conservative therapy, medical therapy, radiotherapy, and urgent surgery, and (5) manage-
ment during the quiescent phase, including conservative therapy and surgical interven-
tion.
Senior Instructor(s): Mark J Lucarelli MD FACS
Instructor(s): Kenneth V Cahill MD FACS, Peter J Dolman MD, Raymond Douglas MD 
PhD*, Jonathan J Dutton MD PhD, Victor M Elner Ph D MD*, Steven E Feldon MD*, 
Michael Kazim MD, Don Kikkawa MD*, Jennifer A Sivak-Callcott MD, Jimmy M Uddin 
MD
 NEW  Evaluation and Treatment of Lower Lid Ectropion, 
Entropion, and Retraction
Course: 310 Monday
Room: 210 9:00 - 10:00 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Lower eyelid malpositions are common and include entropion, ectropion, and 
retraction. Etiologies of entropion include involutional, cicatricial, and spastic; etiologies 
of ectropion include involutional, cicatricial, paralytic, and mechanical; and etiologies of 
retraction include involutional, cicatricial, and paralytic. Surgical management is based 
upon the underlying etiology.
Objective: At the conclusion of the course, the attendee will be able to identify and 
classify each of the lower lid malpositions by their etiologies. In addition, the participant 
will be able to develop an appropriate surgical plan for each of the malpositions.
Senior Instructor(s): Richard C Allen MD PhD
Instructor(s): Erin Shriver MD, Jill S Melicher Larson MD
Evaluation and Management of Orbital Cellulitis
Course: 313 Monday
Room: 340 9:00 - 10:00 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Orbital cellulitis is a condition that may be associated with vision- and life-
threatening complications. Despite numerous medical advances in antimicrobial therapy, 
radiographic imaging, and surgical technique, the treatment of orbital cellulitis remains 
challenging. Successful management requires prompt diagnosis, aggressive medical 
therapy, and in some cases, timely surgical intervention. Through lectures, video, and 
panel discussions, participants will learn to manage these patients confidently.
Objective: This course will familiarize participants with the clinical features, radio-
graphic presentation, and current medical and surgical treatment options for orbital 
cellulitis.
Senior Instructor(s): Michael T Yen MD*
Instructor(s): Thomas Edward Johnson MD
Inflammatory Orbital Disorders and Their Differential 
Diagnoses
Course: 351 Monday
Room: 215 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will cover the inflammatory orbital disorders and their differen-
tial diagnosis. The systemic manifestations of inflammatory disorders, including infec-
tions, Graves eye disease, inflammatory pseudotumor and IgG-4 variant, Sjögren disease, 
sarcoidosis, Wegener granulomatosis, adult xanthogranulomatous disease, and fungal 
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infections, will be discussed. The clinical and imaging characteristics, the differential 
diagnosis from orbital malignancy, and current management options for orbital inflam-
mations will be reviewed. This will be an interactive course with case presentations and 
discussions.
Objective: The attendee will learn how to evaluate, provide a differential diagnosis for, 
and manage patients with inflammatory orbital diseases.
Senior Instructor(s): Hakan Demirci MD
Instructor(s): Victor M Elner Ph D MD*, Christine C Nelson MD, Alon Kahana MD PhD, 
Raymond Douglas MD PhD*, Terry A Smith**
Controversies and Advances in Pediatric Oculoplastic Surgery
Course: 358 Monday
Room: 333 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: A panel of experienced oculoplastic, pediatric, and pediatric oculoplastic sur-
geons will combine (1) short lectures on controversial topics, presented by pediatric and 
oculoplastics for differing views and (2) challenging case discussions. Topics include con-
genital ptosis with poor levator function, timing of surgery, uni- vs. bilateral repair, tech-
nique (frontalis sling, levator / tarsal resection), material choice, and whether bilateral 
surgery and levator extirpation are needed in Marcus-Gunn ptosis. Other topics include 
congenital nasolacrimal duct obstruction, timing / order of repair, Pediatric Eye Disease 
Investigator Group recommendations, balloon dacryoplasty, anophthalmia management 
with dermis fat, static and hydrogel expanders, periorbital hemangioma treatment, and 
advanced techniques.
Objective: The attendee should be better equipped to make treatment recommenda-
tions that incorporate the expertise of both specialties for these difficult pediatric ocu-
loplastic issues.
Senior Instructor(s): Cat Burkat MD
Instructor(s): Francesco P Bernardini MD, Martin H Devoto MD, William R Katowitz MD, 
Morris E Hartstein MD, Monte D Mills MD, Michael C Struck MD*, Shubhra Goel MD
Endoscopic Transnasal Lacrimal Surgery: Principles and 
Practice
Course: 135 Monday
Room: 340 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: The transnasal diagnosis and treatment of lacrimal outflow disorders will be 
presented. Endoscopic nasal anatomy, transnasal dacryocystorhinostomy surgical tech-
niques, endoscopic Jones tubes placement, and endoscopic diagnosis and management 
of lacrimal disorders will be covered.
Objective: At the conclusion of this course, participants will understand transnasal 
endoscopic diagnosis and treatment of lacrimal outflow disorders. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Francois Codere MD
Instructor(s): Bruce M Massaro MD, Jennifer A Sivak-Callcott MD
Introduction to Aesthetic Facial Surgery by Fractional Lasers, 
Intense Pulsed Light, Radiofrequency, and Ultrasound Devices
Course: 138 Monday
Room: 335 3:15 - 5:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will focus primarily on ablative fractional and nonfractional laser 
resurfacing and incisional blepharoplasty because this is the only rejuvenating technol-
ogy limited to physicians. Preoperative, intraoperative, and postoperative care, manage-
ment of complications, and marketing will be covered. There will also be introductions 
to the latest in nonablative fractional resurfacing, radiofrequency, and microfocused 
ultrasound.
Objective: By the conclusion of this course, attendees will be able to (1) compare and 
contrast the many different devices on the market, (2) have introductory knowledge of 
how to incorporate such new technologies into their practices, and (3) recognize and 
manage complications of these devices.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Julie A Woodward MD*
Instructor(s): Erin Holloman MD**, Raminder K Saluja MD**, Usha P Reddy MD, Randal 
Pham MD FACS, Adam J Scheiner MD*, John Joseph Martin MD*, Ioannis P Glavas MD
Endoscopic Forehead and Eyebrow Elevation
Course: 140 Monday
Room: 340 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: The aesthetic evaluation of the patient with eyebrow ptosis, the anatomy 
of the eyebrow and forehead, and a description of the endoscopic brow and forehead 
elevation procedure will be discussed. A course handbook will be provided, detailing the 
surgical technique.
Objective: This course is designed to provide an understanding of the preoperative 
patient evaluation, pertinent surgical anatomy, and technique of endoscopic brow and 
forehead elevation. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Stuart R Seiff MD
Instructor(s): Louis Savar MD, Susan R Carter MD
Avoiding and Managing Blepharoplasty Complications
Course: 427 Monday
Room: 211 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will discuss the management of upper and lower blepharoplasty 
complications, with particular emphasis on avoiding complications. Instead of presenting 
a list of complications and their remedies, this course will present a methodology that 
places complications in different categories. By understanding that complications can 
arise from technique errors or judgment errors, the blepharoplasty surgeon can better 
plan and execute more successful surgery. This course will teach the surgeon how to 
avoid common trouble spots and how to manage complications when they do arise.
Objective: At the conclusion of this course, participants will understand why complica-
tions occur and will learn how to plan for successful procedures and how to manage 
blepharoplasty complications, including orbital hemorrhage, asymmetric lid creases, 
webbing, too much fat removed, lower lid retraction, rounded lateral canthus, and the 
unhappy blepharoplasty patient.
Senior Instructor(s): Morris E Hartstein MD
Instructor(s): Don Kikkawa MD*
Management of Orbital Tumors: Case Presentation and 
Discussion
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS)
Course: 508 Tuesday
Room: R08 9:00 - 11:15 AM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will focus on management of orbital tumors through representa-
tive cases from the instructors’ orbital practices. Emphasis will be on clinical pictures 
showing initial presentation, imaging characteristics of orbital lesions, surgical ap-
proach, and the role of ancillary treatment options such as radiotherapy and/or systemic 
chemotherapy.
Objective: This course is designed to enable the orbital and oculoplastic specialist to 
appropriately diagnose orbital tumors and become familiar with the multidisciplinary 
management of orbital tumors using illustrative cases and the collective experience of 
the course instructors.
Senior Instructor(s): Bita Esmaeli MD FACS
Instructor(s): Geoffrey E Rose FRCOphth, Timothy J Sullivan MBBS, Dale R Meyer MD 
FACS, Jonathan J Dutton MD PhD
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 h  Optimizing Outcomes and Minimizing Complications in 
Oculofacial Plastic Procedures: A Case-Based Approach
Course: 524 Tuesday
Room: 221 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will present a practical, case-based guide for the evaluation, 
planning, and surgical management of common oculofacial plastic procedures. The 
course will feature high-definition surgical videos of selected cases, including blepha-
roplasty, eyelid and brow ptosis repair, and nonsurgical procedures such as botulinum 
toxin and subcutaneous filler injections. Emphasis will be placed on optimizing surgical 
outcomes and minimizing and managing complications, using case-based vignettes.
Objective: At the conclusion of this course, the attendee will be able to evaluate and 
manage common outpatient oculofacial plastic procedures in an efficient manner with 
optimal outcomes.
Senior Instructor(s): Bobby S Korn MD PhD FACS*
Instructor(s): Don Kikkawa MD*, Karim G Punja MD, Richard L Scawn MD, Nattawut 
Wanumkarng MD
Advanced Techniques in Orbital Decompression and Expansion
Course: 145 Tuesday
Room: 342 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: This course is designed to foster creative thinking in orbital decompression. 
Staging, planning, and techniques for orbital decompression will be reviewed, includ-
ing deep lateral, fat removal, transcaruncular, and endoscopic. Surgical versatility and 
creative decision making will be stressed.
Objective: This course is designed to acquaint participants with a variety of techniques 
for orbital decompression and to enable them to design an individualized approach based 
on the patient’s needs and goals. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Robert A Goldberg MD*
Instructor(s): Raymond Douglas MD PhD*, Norman Shorr MD, Catherine Hwang MD, 
Mehryar Taban MD, Joseph L Lin MD**, Daniel B Rootman MD MSc, Alice Siew Ching 
Goh MD
Lotions, Potions, Botulinum Toxin, and Fillers: Nonlaser 
Rejuvenation for the Ophthalmologist
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS)
Course: 534 Tuesday
Room: 209 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Cosmeceuticals, botulinum toxin, chemical peels, and soft tissue fillers all 
provide nonlaser options for minimally invasive facial rejuvenation. This course will 
review facial skin analysis and therapeutic options available to patients. Assessment, 
indications, and techniques for use of botulinum toxin, chemical peels, and soft tissue 
fillers will be discussed.
Objective: At the end of this course, attendees will be familiar with cosmeceutical 
categories and applications and will understand the indications, techniques, and compli-
cations (management and avoidance) for botulinum toxin, soft tissue fillers, and chemical 
peels.
Senior Instructor(s): Femida Kherani MD
Instructor(s): Christopher M DeBacker MD, Jill Annette Foster MD FACS*, Scott M 
Goldstein MD*, Wendy W Lee MD*
 h  Complete Guide to the Evaluation and Management of 
Ptosis
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS)
Course: 539 Tuesday
Room: 210 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will provide a comprehensive understanding of ptosis syndromes 
and surgical treatments. Surgical techniques, including Müller muscle resection and le-
vator and frontalis sling surgery, will be presented in detail.
Objective: Upon completion of this course, participants will gain a thorough under-
standing of ptosis syndromes and their evaluation and management. Participants will 
evaluate, categorize, and surgically plan for the ptosis patient.
Senior Instructor(s): Morris E Hartstein MD
Instructor(s): Adam G Buchanan MD, Gabriela Espinoza MD, Steven M Couch MD
Facial Nerve Palsy: Anatomy, Etiology, Evaluation, and 
Management
Course: 547 Tuesday
Room: 346 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will present the facial nerve anatomy, etiology, ocular complica-
tions, and treatment of facial nerve palsy.
Objective: At the conclusion of the course, the attendee will be able to evaluate and 
provide comprehensive management for patients with facial nerve palsy. In addition, 
theoretical knowledge of surgical techniques will be obtained.
Senior Instructor(s): Ioannis Mavrikakis MD PhD
Instructor(s): Efstathios T Detorakis MD PhD, Konstadinos Boboridis MD*, George C 
Charonis MD**
Enucleation, Evisceration, and Care of the Anophthalmic 
Socket
Course: 563 Tuesday
Room: 218 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Enucleation and evisceration techniques will be reviewed, along with the 
available implant materials. The indications and contraindications of each of the tech-
niques and care of the subsequent anophthalmic socket will be discussed.
Objective: At the conclusion of this course, the attendee will be able to discuss the ap-
propriate circumstance when either an enucleation or evisceration would be performed, 
recite the surgical procedure for each of the techniques, and differentiate between the 
available implants and indicate when each would be appropriately used. The attendee 
will also be able to formulate a plan for any early and late postoperative sequelae.
Senior Instructor(s): Richard C Allen MD PhD
Instructor(s): Erin Shriver MD, Jeffrey A Nerad MD
 h  Oculoplastic Office Procedures: Video Clips
Course: 578 Tuesday
Room: R05 12:45 - 1:45 PM
Education Level: INT Target Audience: COMP
Synopsis: Detailed instruction with emphasis on pearls of office eyelid and lacrimal 
surgeries will be presented with the use of video clips. The following procedures will 
be discussed: incision and drainage of a chalazion, lesion biopsy, lesion excisions, tar-
sorrhaphy (chemical and surgical), lacrimal probing and irrigation, punctoplasty, punctal 
cauterization, canaliculotomy, entropion repair, ectropion repair, and upper eyelid blepha-
roplasty.
Objective: Participants will be shown the relevant anatomy and surgical steps in per-
forming office eyelid and lacrimal procedures.
Senior Instructor(s): Susan M Tucker MD
Instructor(s): Nancy A Tucker MD
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 h  Oculoplastic Procedures for the General Ophthalmologist
Course: 586 Tuesday
Room: 223 12:45 - 1:45 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course will describe basic and effective procedures for the treatment of 
involutional ectropion and entropion, tarsorrhaphy, marginal eyelid lesions, dermatocha-
lasis, and aponeurogenic involutional ptosis.
Objective: At the conclusion of this course, the attendee will be able to select and 
perform the appropriate surgical technique for the treatment of common eyelid problems 
encountered in a general ophthalmology practice.
Senior Instructor(s): Robert C Kersten MD
Instructor(s): Francesco P Bernardini MD, Carlo de Conciliis MD, Martin H Devoto MD, 
Jose R Montes MD
Diagnosis and Management of Essential Blepharospasm and 
Hemifacial Spasm
Course: 594 Tuesday
Room: 222 12:45 - 1:45 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Patients with eyelid and facial spasms frequently present to ophthalmolo-
gists. The diagnosis and treatment of essential blepharospasm and hemifacial spasm is 
straightforward and gratifying. Through lectures, video, and panel discussions, partici-
pants will learn to manage these patients confidently.
Objective: This course will familiarize participants with the diagnostic features and 
current treatment options for blepharospasm, hemifacial spasm, and related facial dys-
tonias.
Senior Instructor(s): Richard L Anderson MD FACS*
Instructor(s): Michael T Yen MD*
Pediatric Ophthalmology, Strabismus
Management of Pediatric Cataracts
Course: 156 Sunday
Room: 222 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course highlights the paradigms for management of pediatric cataracts. 
Adhering to these paradigms will enhance intraoperative performance and ensure a good 
technical and functional outcome.
Objective: At the conclusion of this course, the attendee will understand the clinical 
pearls and tips for enhancing outcomes following pediatric cataract surgery.
Senior Instructor(s): Abhay Raghukant Vasavada MBBS FRCS*
Instructor(s): Rupal H Trivedi MBBS MS*, Kanwal K Nischal MBBS*, Michael O’Keeffe 
MD, Deborah K VanderVeen MD*, Bharti Kishore Nihalani Gangwani MD
ROP Screening and Treatment: What You Wanted to Know but 
Were Afraid to Ask (Intermediate/Advanced)
Course: 166 Sunday
Room: 208 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Retinopathy of prematurity (ROP) can be a difficult and challenging disease 
to manage. This course is intended for established screeners / treaters familiar with ROP 
management who would like to enhance their proficiency. This course will provide practi-
cal advice on how to safely and effectively screen and treat children, with an emphasis 
on clinical pearls designed to improve the approach to this condition. Topics include 
updated findings of the Early Treatment for ROP study (ETROP), the accurate diagnosis 
of plus disease, pitfalls in managing aggressive posterior ROP, the impact of oxygen on 
ROP, the appropriate time to refer for vitreoretinal surgery, medicolegal issues, the role 
of telemedicine and photodocumentation, and the use of anti-VEGF therapy. This will be 
followed by a presentation of challenging cases and how they were managed.
Objective: At the conclusion of this course, the attendee will be better able to recog-
nize children progressing to treatment-requiring ROP and to more effectively deal with 
the challenges of laser treatment.
Senior Instructor(s): Thomas Lee MD*
Instructor(s): Michael F Chiang MD*, William V Good MD, Kenneth W Wright MD*, G 
Baker Hubbard MD, R V Paul Chan MD, Anne M Menke RN PhD, Maria Ana Martinez-
Castellanos MD
New Techniques for Strabismus Surgery
Course: 117 Sunday
Room: 217 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Over the past several years, important surgical innovations have made 
strabismus surgery safer and more effective. This course will teach the use of novel 
strabismus surgical techniques, including grooved hook for suturing the muscle inser-
tion, minimally invasive techniques (rectus central tenotomy and plication), and use of 
amniotic membrane transplant for restrictive strabismus. Video will be presented to help 
teach the techniques. Outcome studies of surgical procedures will be presented.
Objective: At the conclusion of this course, the attendee will be able to use new stra-
bismus surgical techniques to improve surgical outcomes and reduce complications.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Kenneth W Wright MD*
Instructor(s): Yi Ning Strube MD, Luke W Deitz MD
Approach to Genetic Eye Diseases for the Comprehensive 
Ophthalmologist
Course: 216 Sunday
Room: R03 4:30 - 5:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course will focus on the comprehensive ophthalmologist’s role in the 
diagnosis and treatment of genetic eye diseases. The course will review the pertinent 
medical background, review the availability of diagnostic testing, including how to obtain 
it, and discuss nondirective counseling. Illustrative cases will be used to highlight perti-
nent aspects of the management of these patients.
Objective: By the end of this course, participants will be able to understand (1) how to 
approach and evaluate a patient and family with a genetic eye disorder, (2) the principles 
of inheritance patterns, (3) where to find reliable information and laboratory diagnostics, 
including the NIH eyeGENE network on genetic disorders, (4) guidelines on genetic coun-
seling, and (5) complexities of the process.
Senior Instructor(s): Johnny Tang MD
Instructor(s): J Bronwyn Bateman MD, Wadih M Zein MD, Pamela C Sieving MA MS 
AHIP
 NEW  Diplopia After Cataract and Refractive Surgery
Course: 237 Sunday
Room: 215 4:30 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Diplopia after cataract or refractive surgery is frustrating for the anterior 
segment surgeon and can be challenging for the strabismus specialist. We will provide 
a case-based approach to the evaluation and management of patients with diplopia af-
ter cataract or refractive surgery. Case presentations will illustrate how some problems 
can be avoided prior to anterior segment surgery, and other cases will illustrate how to 
manage the patient when problems occur. Specific topics to be covered will include mon-
ocular vs. binocular diplopia, pre-existing strabismus, need for a specific refractive state, 
need for a specific fixation pattern, longstanding optical blur, myotoxicity, and technical 
or optical problems. Audience participation and discussion will be encouraged
Objective: At the completion of this course, the attendee should have a greater under-
standing of how to avoid diplopia after cataract and refractive surgery, and if diplopia 
occurs, how to evaluate and manage the patient.
Senior Instructor(s): Jonathan M Holmes MD*
Instructor(s): Rosanne Superstein MD
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 h  Difficult Strabismus Problems: Diagnosis and Management 
2013
Course: 300 Monday
Room: 223 9:00 - 11:15 AM
Education Level: ADV Target Audience: SUB
Synopsis: Case presentations of complex strabismus will form the basis for panel dis-
cussion and audience participation in this course on proper diagnosis and management. 
Diagnostic techniques such as orbital imaging, forced ductions, saccadic velocity, and 
active force generation testing will be discussed as they apply to specific cases. Reop-
erations, cranial nerve palsies, trauma, Duane syndrome, Brown syndrome, and thyroid 
ophthalmopathy are representative topics.
Objective: This course is intended to enhance participants’ ability to accurately diag-
nose and treat complicated strabismus patients. Surgical and nonsurgical options will 
be elaborated.
Senior Instructor(s): Burton J Kushner MD
Instructor(s): Edward G Buckley MD, David G Hunter MD PhD*
 NEW  The Developmental Glaucomas: Diagnosis and 
Management in 2013
Course: 321 Monday
Room: R05 9:00 - 11:15 AM
Education Level: ADV Target Audience: SUB
Synopsis: This course will present the diagnostic evaluation, differential diagnosis, and 
management of the pediatric glaucomas. Recent advances in medical and surgical thera-
pies, including antifibrotic therapy (mitomycin C and 5-fluorouracil), glaucoma drainage 
devices, and cycloablative procedures, will be discussed.
Objective: At the conclusion of the course, the attendees will be familiar with the holis-
tic treatment of the pediatric glaucomas using medical, surgical, genetic, and rehabilita-
tion approaches in an integrated manner.
Senior Instructor(s): Anil K Mandal MD
Instructor(s): Peter Andreas Netland MD PhD*, David S Walton MD**, Dale K Heuer 
MD*, Eve J Higginbotham MD
Nightmares in Pediatric Cataract Surgery
Course: 333 Monday
Room: 221 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: In this video- and case-based presentation, cataract surgery in children with 
association of anterior segment trauma, anterior segment dysgenesis, microcornea, sub-
luxation, posterior lenticonus, persistent fetal vasculature, coloboma, after keratoplasty 
(penetrating / endothelial), after glaucoma filtering surgery, uveitis, and extended ante-
rior capsulorrhexis will be discussed. These cases are prone to develop intraoperative 
complications. Modifications in standard surgical technique will be discussed.
Objective: At the end of this course, the attendee will be able to identify challeng-
ing situations that arise in complicated pediatric cataract surgery, including the surgical 
modifications required and the optimal outcomes of surgery.
Senior Instructor(s): Ramesh Kekunnaya MBBS MD
Instructor(s): Pravin Vaddavalli MD, Muralidhar Ramappa MBBS, Kanwal K Nischal 
MBBS*, Jatin Naresh Ashar MD
Strabismus Surgery: A Comprehensive Approach
Course: 377 Monday
Room: 222 2:00 - 3:00 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: There are many techniques for performing any particular strabismus surgery. 
This course will consist of video-based, step-by-step strabismus surgery, ranging from 
basic surgeries to advanced. The techniques will be explained along with the logic be-
hind each step of the surgery, including a few tips on the possible complications.
Objective: Knowing, understanding, and seeing of all the techniques is helpful for sur-
geons who perform strabismus surgery. The intention of this course is to give a broader 
view of surgical concepts for all strabismus surgeries and to clarify any doubts at the end 
with case presentations and a question-and-answer session.
Senior Instructor(s): Venkateshwar Bhoompally MD
Instructor(s): Ramesh Kekunnaya MBBS MD, Sherwin Isenberg MD*, Federico G Velez 
MD, Stacy L Pineles MD, Inez B Y Wong MBBCHIR
 NEW  Diplopia Made Ridiculously Simple: Management of 
Diplopia for the Comprehensive Ophthalmologist
Course: 407 Monday
Room: R03 3:15 - 4:15 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course will use diplopia case examples to illustrate important clinical 
management concerns, including when to consider medical workup, surgery, and non-
surgical methods of alleviating diplopia. This course will demonstrate how press-on 
(Fresnel) prisms, ground-in prisms, and occlusive methods can be used to treat diplopia.
Objective: At the conclusion of this course, the attendee will be able to (1) identify 
diplopic patients who need further evaluation for medical issues, (2) understand which 
diplopic patients should be managed surgically vs. nonsurgically, (3) clinically evaluate 
for and appropriately prescribe press-on and ground-in prisms, and (4) understand the 
indications for occlusive devices (eg, spot patch, occlusive contact lens, and frosted tape) 
for diplopia.
Senior Instructor(s): Laura B Enyedi MD*
Instructor(s): Michelle J Cabrera MD
Management of Strabismus in Thyroid Eye Disease
Course: 425 Monday
Room: 224 4:30 - 5:30 PM
Education Level: INT Target Audience: SUB
Synopsis: Strabismus associated with thyroid eye disease (TED) is one of the more 
challenging types of ocular misalignments to correct. A variety of techniques have been 
described using adjustable as well as fixed sutures. This course will review the steps 
in the preoperative examination of the patient in the office, the gathering of necessary 
information to determine the muscles to be operated on, and the operative technique 
used by the instructors. Video clips will be used to partly transfer the necessary skills. A 
summary of the literature on the topic will also be given.
Objective: Upon completion of the course, participants will be able to (1) list the clinical 
data necessary for management of the patient with TED and strabismus, (2) describe the 
operative steps involved in the surgical technique used to correct the ocular misalign-
ment, and (3) understand the differences between the different surgical techniques for 
the correction of strabismus in TED and the pros and cons for each.
Senior Instructor(s): Elias I Traboulsi MD*
Instructor(s): Paul Joseph Rychwalski MD, Natalie Kerr MD
Pediatric Uveitis: What You Need to Know
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Uveitis Society
Course: 512 Tuesday
Room: 209 9:00 - 10:00 AM
Education Level: INT Target Audience: SUB
Synopsis: This course will cover the challenging issue of pediatric uveitis through case 
presentation and interactive discussion with the audience. More than 10% of blindness 
due to uveitic conditions occurs in the pediatric population. Among etiologic entities, 
juvenile idiopathic arthritis, infectious diseases, and pars planitis remain predominant.
Objective: At the conclusion of this course, the attendee will be able to diagnose com-
mon intraocular inflammatory conditions in children, evaluate the severity of disease, and 
propose a tailored workup. Therefore it will be possible to select the best therapeutic 
strategy in each situation and propose systemic immunosuppressors, when necessary.
Senior Instructor(s): Janet Louise Davis MD*
Instructor(s): Bahram Bodaghi MD PhD*, Debra A Goldstein MD*
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What’s New and Important in Pediatric Ophthalmology and 
Strabismus for 2013
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and the 
American Association for Pediatric Ophthalmology and Strabismus (AAPOS)
Course: 569 Tuesday
Room: 221 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will provide a stimulating overview of important publications 
from a variety of peer-reviewed journals from 20012/2013 in the field of pediatric oph-
thalmology and strabismus.
Objective: At the conclusion of this workshop, attendees will be able to (1) understand 
the latest research in retinopathy of prematurity prevention and treatment, (2) under-
stand the causes of various forms of strabismus, as elucidated by the most recent re-
search, (3) be aware of the resources available for genetic testing and how to more 
wisely implement genetic testing into their practices, (4) understand trends in pediatric 
cataract and refractive surgery and implement this new information into their practices, 
and (5) understand the latest information on therapeutic treatment options for amblyopia.
Senior Instructor(s): Jitka L Zobal-Ratner MD
Instructor(s): Darron A Bacal MD, Arlene V Drack MD*, Patrick J Droste MD, Majida A 
Gaffar MD, Ramesh Kekunnaya MBBS MD, Stacy L Pineles MD, Terri L Young MD*
Imaging Studies in Strabismus
Course: 577 Tuesday
Room: 346 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: In order to recognize the mechanism of eye movement disorders, imaging 
studies of brain and orbit are essential. The most recent imaging studies show not only 
anatomical abnormalities but also functional abnormalities of extraocular muscles. Vari-
ous types of strabismus cases are associated with abnormal findings on images, such as 
thyroid ophthalmopathy, esotropia with high myopia, strabismus reoperation, rupture of 
extraocular muscle after trauma, and special types of congenital strabismus. It is impor-
tant for comprehensive ophthalmologists and strabismus specialists to be familiar with 
recent advances in imaging studies of strabismus.
Objective: This course will show the findings of orbital and brain CT/MRI and present 
strategies for the treatment of special types of strabismus. At the conclusion of this 
course, the attendee will be able to recognize the importance of imaging studies and 
understand how their findings instruct the management of strabismus.
Senior Instructor(s): Miho Sato MD PhD
Instructor(s): Joseph L Demer MD PhD*, Tsuranu Yokoyama, Jeong-Min Hwang MD, 
Sonal R Farzavandi FRCS, Jonathan M Holmes MD*
Refractive Surgery
The Surgical Correction of Astigmatism
Course: 108 Sunday
Room: 355 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMP
Synopsis: This course will supply participants with the necessary principles, theories, 
and practical instruction in the various forms of astigmatic keratotomy (PRI, limbal relax-
ing incisions) and nonincisional astigmatism correction (LASIK, toric IOLs).
Objective: Attendees will gain an understanding of techniques used to evaluate and 
manage astigmatism as a primary procedure and as an adjunct to lens surgery. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Jean-Luc Febbraro MD*
Instructor(s): Hamza N Khan MD FACS*, Kurt A Buzard MD, Miles H Friedlander MD, 
Ronald N Gaster MD FACS*, David H Haight MD, Jack T Holladay MD MSEE FACS*, 
Douglas D Koch MD*, R Bruce Wallace MD*
Phakic IOLs
Course: 109 Sunday
Room: R02 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will educate the participant on the use of phakic IOLs in refrac-
tive surgery. Topics of discussion will include patient selection and preoperative test-
ing, IOL power calculations, postoperative care, complication management, surgical 
technique, and managing residual refractive error. Phakic IOLs currently available in the 
United States will be emphasized.
Objective: At the course conclusion, the participant will understand indications for the 
use of phakic IOLs and key management aspects of phakic IOL candidates. 
Note: This is the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Thomas M Harvey MD*
Instructor(s): Sherman W Reeves MD MPH*, David R Hardten MD*, Stephen S Lane 
MD*, Jack T Holladay MD MSEE FACS*, Scott D Barnes MD*, Paul J Harton Jr MD*, 
Gregory Parkhurst MD*, Elizabeth A Davis MD*
Femto Laser:Diagnosis and Management of Intraoperative and 
Postoperative Complications With the Use of a Femtosecond 
Laser for LASIK Surgery
Course: 171 Sunday
Room: R03 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: We will discuss the surgical complications that occur with femtosecond la-
ser flap creation: data entry errors, centration difficulties, suction loss, interface entry 
issues, vertical gas breakthrough, and flap tears. Also covered will be the diagnosis and 
management of postoperative complications: flap slippage, interface inflammation, how 
to distinguish these from diffuse lamellar keratitis, interface haze, transient light sen-
sitivity, rainbow glare, etc. This course is recommended for those surgeons who have 
recently purchased or already use a femtosecond laser.
Objective: This course will educate users of the potential risks associated with fem-
toLASIK flap creation.
Senior Instructor(s): Christopher L Blanton MD*
Instructor(s): Perry S Binder MD*, Jonathan H Talamo MD*, Ronald R Krueger MD*, 
Sonia H Yoo MD*
 YO  A Step-by-Step Primer to Starting LASIK in 2013
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and the 
International Society of Refractive Surgery (ISRS)
Course: 178 Sunday
Room: 209 2:00 - 4:15 PM
Education Level: BAS Target Audience: SUB
Synopsis: This course will provide an overview of the principles underlying the safe 
modern practice of LASIK, as well as pearls of surgical technique to benefit the begin-
ning LASIK surgeon. Technology overview will include wavefront sensing, excimer laser, 
microkeratome, femtosecond, and modern topographic technologies. Prevention and 
management of complications will be covered.
Objective: The attendee will acquire a broad understanding of the scientific principles 
underlying the various technologies involved in the practice of LASIK. The course will 
provide the foundations for patient selection, surgical planning, and operating technique, 
as well as an overview of complication avoidance and management.
Senior Instructor(s): Dan Z Reinstein MD*
Instructor(s): Daniel S Durrie MD*, David R Hardten MD*, Jack T Holladay MD MSEE 
FACS*, Stephen G Slade MD FACS*, Gustavo E Tamayo MD*
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Danger Zone: Refractive Surgery Nightmares and Worst-Case 
Scenarios: A Video-Based Course
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and the 
International Society of Refractive Surgery (ISRS)
Course: 187 Sunday
Room: 222 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Refractive surgery has its own danger zones. Various refractive surgery 
techniques, from surface ablation to LASIK and phakic IOLs, can have disasters that 
have to be handled with care. In this course, collagen crosslinking for ectasia and other 
conditions will be taught. Viscocannula-assisted reinversion of an implantable contact 
lens will be shown. Topics like flap complications, decentered ablations, and iatrogenic 
ectasia will be explained in detail. Attendees will be taught how to manage eyes with 
previous LASIK flaps and how to address problems with Kerarings and other intrastromal 
ring segments.
Objective: At the conclusion of this course, the attendee will know how to manage 
refractive surgery catastrophes, perform crosslinking, and treat iatrogenic keratectasia, 
flap complications, and femtosecond problems.
Senior Instructor(s): Amar Agarwal MD*
Instructor(s): Ronald R Krueger MD*, Athiya Agarwal MD*, Alaa M Eldanasoury MD*, 
Marguerite B McDonald MD*, Sonia H Yoo MD*, A John Kanellopoulos MD*, Soosan 
Jacob FRCS, Theo Seiler MD PhD*, Agarwal Ashvin MBBS
 NEW  Femtosecond Laser for Cornea Surgery: The Actual 
Options
Course: 312 Monday
Room: R02 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: The use of femtosecond laser for cornea and refractive surgery has rapidly 
expanded, to the point that this technology is now the gold standard, state-of-the-art 
procedure for cornea and refractive treatments. In this course instructors will use video 
and case presentations to explain the five different femtosecond laser platforms used 
for most techniques in routine cases such as flap creation, intrastromal ring segment im-
plantation, penetrating, anterior lamellar, and endothelial keratoplasties, and refractive 
lenticule extraction. The panel will discuss the benefits and advantages of the different 
laser platforms. Clinical outcomes and complications will also be discussed in detail.
Objective: Attendees will gain information about the similarities and differences 
among the most popular femtosecond lasers and their use in all the cornea and refrac-
tive techniques.
Senior Instructor(s): Arturo J Ramirez-Miranda MD*
Instructor(s): Arturo S Chayet MD*, Ramon Naranjo-Tackman MD*, Alejandro Navas 
MD*, Marco A Cantero MD, Luis Izquierdo Jr MD, Tito Ramirez-Luquin MD, Enrique O 
Graue Hernandez MD
Advanced Corneal Topographic Analysis
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and the 
International Society of Refractive Surgery (ISRS)
Course: 349 Monday
Room: 228 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will discuss advanced topographic analysis in the patient evalu-
ation process for the comprehensive clinician and refractive surgeon, focusing on under-
standing and recognizing normal and abnormal topographic patterns generated by mul-
tiple technologies, including standard Placido imaging, slitbeam-based imaging (Orbscan 
II), Scheimpflug imaging (Pentacam), and wavefront imaging.
Objective: By the conclusion of this course, the participants will be able to (1) identify 
subtle abnormal topographic patterns that place patients at increased risk for postop-
erative complications, including ectasia, (2) differentiate truly abnormal preoperative 
topographies from artifactual images, and (3) effectively utilize topographic imaging 
techniques to demonstrate corneal pathology before keratorefractive refractive surgery.
Senior Instructor(s): J Bradley Randleman MD
Instructor(s): William J Dupps MD PhD*
Anterior Segment OCT
Course: 376 Monday
Room: 338 2:00 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Optical coherence tomography (OCT) can measure corneal and anterior seg-
ment anatomy with micron-level precision. Recent advances in speed and software for 
corneal power and pachymetry / epithelial thickness mapping makes this technology 
increasingly useful in a wide variety of diagnostic and surgical planning applications.
Objective: By the conclusion of this course, the participants will be able to use OCT for 
(1) planning of LASIK and other laser refractive and therapeutic procedures, (2) calculat-
ing and selecting IOL power for cataract surgery after previous laser vision correction, (3) 
detecting forme fruste keratoconus, (4) fitting phakic IOL implants and following postop-
erative results, and (5) assessing risk for angle closure.
Senior Instructor(s): David Huang MD PhD*
Instructor(s): Georges D Baikoff MD*, Douglas D Koch MD*
State-of-the-Art Use of the Femtosecond Laser for Keratoplasty, 
Cataract Surgery, and Astigmatic Incisions
Course: 381 Monday
Room: R08 2:00 - 3:00 PM
Education Level: ADV Target Audience: COMP
Synopsis: This course will present worldwide experts to discuss their femtosecond 
laser surgery experiences.
Objective: Femtosecond laser surgery is a dramatic change from standard methods. 
Advantages, disadvantages, revolutionary changes in techniques, and different femto-
second laser surgery platforms will be presented.
Senior Instructor(s): Francis W Price Jr MD*
ISRS Laser Refractive Surgery Course
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and the 
International Society of Refractive Surgery (ISRS)
Course: 141 Monday
Room: 346 3:15 - 5:30 PM
Education Level: INT Target Audience: SUB
Synopsis: This course will start with the basics of how conventional and laser micro-
keratomes work and what one needs to know before performing LASIK and surface abla-
tion. It will move on to cover tips, step by step, with presentations discussing the newest 
applications and developments in LASIK and surface ablation. The prevention and treat-
ment of complications will be covered in detail.
Objective: This course is designed to give participants the information and skills need-
ed for LASIK and surface ablation, including patient selection, basic principles, postop-
erative care, and management of complications. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Michael C Knorz MD*
Instructor(s): Jason E Stahl MD, Richard L Lindstrom MD*, Jack T Holladay MD MSEE 
FACS*
Corneal Topographic Analysis and Anterior Segment Imaging: 
Pearls for Your Clinical Practice
Course: 403 Monday
Room: 217 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will present a systematic approach to the interpretation of 
corneal topographies and anterior segment imaging studies using didactic instruction 
combined with numerous clinical examples. The course will highlight several imaging 
systems and technologies, including Placido-based topography, single and dual Scheimp-
flug imaging, OCT, and scanning slit beam imaging.
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Objective: At the conclusion of this course, the attendee will understand the different 
technologies used to image the anterior segment, be able to use the different maps and 
displays available on multiple devices, know the advantages and disadvantages of the 
most common topographers and imaging devices, and use the study results to manage 
common clinical situations in corneal, cataract, and refractive surgery.
Senior Instructor(s): Mitchell P Weikert MD*
Instructor(s): Douglas D Koch MD*, Thomas Kohnen MD*, Cynthia Roberts PhD*, 
Surendra Basti MBBS*, William J Dupps MD PhD*, Li Wang MD
Refractive Lensectomy: Indications, Lenses, Formulas, 
Outcomes
Course: 574 Tuesday
Room: 342 12:45 - 1:45 PM
Education Level: ADV Target Audience: COMP
Synopsis: This course will present different approaches using refractive lensectomy as 
a refractive surgical procedure to achieve spectacle independence for far and near. The 
indications, contraindications, IOL calculation and selection (monofocal, multifocal, ac-
commodative), and patient selection criteria for successful outcomes will be shown and 
discussed in a didactic format.
Objective: At the conclusion of this course, the attendee will be able to define the best 
indications and most frequent contraindications of refractive lens exchange, identify the 
best IOL calculation method, know how to manage astigmatism, select the best choice 
for a multifocal IOL and the best cases for accommodative IOLs, and understand practical 
tips to achieve a high patient satisfaction rate with refractive lens exchange.
Senior Instructor(s): Jorge L Alio MD PhD*
Instructor(s): Warren E Hill MD*, Michael C Knorz MD*, Mark Packer MD*, Eric D 
Donnenfeld MD*, Andrzej Grzybowski MD*
Secrets of Highly Successful Refractive Cataract Surgery 
Practices
Course: 585 Tuesday
Room: 218 12:45 - 1:45 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Newly redesigned from last year to include femtosecond surgery, toric IOLs, 
limbal relaxing incisions, and aspheric monovision, this course is given by experienced 
surgeons and practice management experts who will review marketing, patient selec-
tion and education, staff organization, biometry / lens selection, and pearls for success.
Objective: Participants will be able to describe the following aspects of successful 
refractive cataract surgical practices: (1) steps toward successful marketing and patient 
communication, (2) regulatory, billing, and legal aspects of using premium technology 
and techniques, and (3) clinical pearls for achieving optimal outcomes.
Senior Instructor(s): John A Hovanesian MD*
Instructor(s): David R Hardten MD*, Kevin J Corcoran*
Solving the High Myopia Problem With Phakic IOLs
Course: 600 Tuesday
Room: 335 3:15 - 5:30 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will present a review of state-of-the-art knowledge on anterior 
and posterior chamber phakic IOLs, with information on patient, eye, and IOL selection, 
surgical techniques, and management of intra- and postoperative complications. Special 
attention will be dedicated to diagnostic instruments for patient selection and follow-up.
Objective: Participants will be able to assess phakic IOLs as a valuable tool in refrac-
tive surgery. Experience, imaging, and long-term follow-up will provide a safer approach 
to phakic IOLs. At the conclusion of this course, attendees will be able to understand the 
phakic IOL’s potential and possible weak points in order to decide whether to add phakic 
IOL’s advanced technology to their practices.
Senior Instructor(s): Matteo Piovella MD*
Instructor(s): Georges D Baikoff MD*, Dimitri Dementiev MD*, Luca Gualdi MD, David R 
Hardten MD*, Gregory Parkhurst MD*
Retina, Vitreous
Macular OCT: Mastering the Basics
Course: 110 Sunday
Room: R08 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course provides basic instruction on accurate interpretation of OCTs of 
common macular pathologies, as well as instruction on how to identify and prevent com-
mon OCT artifacts. The course also provides a clinically meaningful review of indications 
and limitations of OCT in the diagnosis and management of common macular diseases 
such as AMD, diabetic maculopathy, epiretinal membrane, macular holes, vitreomacu-
lar traction, central serous retinopathy, vascular occlusions, and postoperative cystoid 
macular edema.
Objective: Upon completion of this course, participants should be able to (1) accurately 
interpret OCTs of common macular pathologies, (2) describe the indications for and limi-
tations of OCT in the diagnosis and management of macular diseases, and (3) identify, 
interpret, and correct common OCT artifacts.
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): John S Pollack MD*
Instructor(s): John S Pollack MD*, Cynthia A Toth MD*, Anat Loewenstein MD*, Dante 
Pieramici MD*, Nadia Khalida Waheed MD
Retinaws: A Comprehensive Video-Oriented Course on 
Challenging Retinal Cases in the Operating Room
Course: 159 Sunday
Room: 221 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Retina specialists often work in a “shark-infested” world. Unexpected events 
are a fact of life, and learning how not to get bitten is an effective way to practice 
safely and efficiently. This course consists of video presentations describing challenging 
cases and unexpected events during retinal surgery. Faculty will share their experience in 
predicting, treating, and preventing unexpected outcomes during retinal detachment sur-
gery, diabetic vitrectomy surgery, small-gauge surgery, and complex vitreoretinal surgery.
Objective: At the conclusion of this course, attendees will be able to predict, treat, and 
prevent unexpected events during and after vitreoretinal surgery.
Senior Instructor(s): Kourous Rezaei MD*
Instructor(s): Kirk H Packo MD*, Francesco Boscia MD*, Virgilio Morales-Canton MD*, 
Marco Mura MD*, Sundaram Natarajan MD, Hiroko Terasaki MD*
 h  Mystery Retina 2013: Interactive Discussion of Challenging 
Cases
Course: 160 Sunday
Room: 346 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: The instructors will present 20 to 25 diagnostically challenging “mystery 
retina” cases. The majority of the presentations will include interpretation of color 
photographs, fluorescein angiography, and OCT imaging studies. When indicated, in-
docyanine green angiography, echography, autofluorescence, enhanced depth imaging, 
infrared images, electrophysiologic studies, microperimetry, CT, MRI, cytology, and/or 
histopathology will also be shown. The cases will be presented as unknowns, and au-
dience participation will be encouraged. At the completion of the case presentations, 
the attendees will receive a handout summarizing the cases, complete with pertinent 
references and images.
Objective: At the conclusion of this course, attendees will be better able to assess and 
evaluate a variety of diagnostically challenging “mystery retina” cases. They should also 
be able to establish a more complete differential diagnosis, know how to make the best 
use of ancillary diagnostic tests, and formulate a definitive treatment plan.
Senior Instructor(s): William F Mieler MD*
Instructor(s): Lee M Jampol MD*, Jerry A Shields MD, Richard F Spaide MD*, Lawrence 
A Yannuzzi MD
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Visual Electrophysiology Testing: Principles and Clinical 
Applications
Course: 161 Sunday
Room: 340 10:15 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Visual electrophysiologic tests are diagnostic tools that are helpful or es-
sential in a variety of retinal and visual disorders. This course, approved by the Interna-
tional Society for Clinical Electrophysiology of Vision (ISCEV), provides a comprehensive 
overview of clinical electrophysiologic tests with a focus on basic principles (including 
ISCEV standards) and clinical applications. A variety of clinical cases will be presented to 
illustrate the appropriateness and utility of visual electrophysiology testing.
Objective: At the conclusion of this course, the attendee will understand the basic 
principles and clinical applications of full-field electroretinogram (ERG), multifocal ERG, 
electro-oculogram, and pattern visual evoked potential, enabling the attendee to incor-
porate these tests effectively in clinical practice.
Senior Instructor(s): Byron L Lam MD*
Instructor(s): Michael F Marmor MD*, Mitchell Brigell PhD*
Diagnosis and Treatment of Polypoidal Choroidal Vasculopathy
Course: 175 Sunday
Room: R03 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Polypoidal choroidal vasculopathy (PCV) is a condition characterized by 
multiple, recurrent, serosanguineous pigment epithelial detachment and neurosensory 
retinal detachment due to abnormal choroidal polypoidal, aneurysmal lesions. PCV is 
particularly prevalent in Asians and occurs in up to 40% of cases presenting as neo-
vascular AMD; it may pose a diagnostic challenge to ophthalmologists. This instruction 
course aims to provide a comprehensive overview of the diagnosis and treatment of 
PCV through review of the currently available literature, illustrative case examples, and 
interactive panel discussion.
Objective: By the completion of this course, participants will understand the epidemiol-
ogy of PCV, the differences between PCV and AMD, the use of various diagnostic tools 
for PCV, the available treatment options for PCV, and the overall management strategy 
for PCV.
Senior Instructor(s): Timothy Y Lai MBBS*
Instructor(s): Fumi Gomi MD PhD*, Gregg T Kokame MD*, Adrian H Koh MD*, Won Ki 
Lee MD*
Update on Treatments for Diabetic Retinopathy: Clinically 
Relevant Results from the Diabetic Retinopathy Clinical 
Research Network
Course: 186 Sunday
Room: R05 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will present clinically relevant results of recently completed 
Diabetic Retinopathy Clinical Research Network (DRCRnet) protocols and through case 
examples will demonstrate implementation of these results into clinical practice.
Objective: At the conclusion of this course, the attendee will be able to describe the re-
sults of recently completed DRCRnet protocols. Specifically, the attendee will learn what 
role topical NSAIDS can play in the progression of noncentral diabetic macular edema 
(DME) to center-involved DME. The attendee will learn whether intravitreal ranibizumab 
is beneficial in decreasing the number of vitrectomies in eyes with vitreous hemorrhage 
secondary to proliferative diabetic retinopathy (PDR). The course will also include a 
review of the ongoing DRCRnet protocols, including the trial comparing ranibizumab, 
bevacizumab, and aflibercept for DME and the ranibizumab for PDR trials. Finally, the at-
tendee will be able to apply these results to clinically relevant situations in daily practice.
Senior Instructor(s): Carl W Baker MD*
Instructor(s): Abdhish R Bhavsar MD*, Neil M Bressler MD*, Susan B Bressler MD*, 
Scott M Friedman MD*, Lee M Jampol MD*, Jennifer K Sun MD*, John A Wells III MD*
Spectral Domain OCT Interpretation for the General 
Ophthalmologist
Course: 192 Sunday
Room: 228 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: The purpose of this course is to provide general ophthalmologists with basic 
knowledge for incorporating spectral domain OCT (SD-OCT) into clinical practice. Attend-
ees will be given an overview of scanning protocols on various SD-OCT systems on the 
market today. Lecturers will present an organized method for analysis of images and 
identification of pathology in the anterior segment, optic nerve, vitreous, macula, and 
choroid. The course will have a special focus on use of SD-OCT in patients with glaucoma 
and/or retinal disease.
Objective: At the conclusion of this course, the attendee will be able select appropriate 
SD-OCT scanning protocols and analyze pathology in SD-OCTs of the anterior segment, 
optic nerve, and posterior segment, especially to detect preparametric glaucoma, pro-
gression of glaucoma, and the most common retinal pathology.
Senior Instructor(s): Purnima S Patel MD
Instructor(s): Vikas Chopra MD*, Rajeev Kumar R Pappuru MBBS MD, Srinivas R Sadda 
MD*, Alexander C Walsh MD*
Retinal and Choroidal Manifestations of Selected Systemic 
Diseases 2013
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and Pan-
American Retina and Vitreous Society
Course: 196 Sunday
Room: R06 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will discuss the current state of retinal and choroidal manifesta-
tions of selected systemic diseases, including uveitis in selected diseases (toxoplasmo-
sis, tuberculosis, Lyme, dengue fever, Bartonella / catscratch disease, Toxocara), changes 
in pregnancy, vascular tumors, syphilis, paraneoplastic syndromes, atypical uveal me-
tastasis, systemic hypertension, Vogt-Koyanagi-Harada syndrome, and fungal diseases. 
Experts from the United States, Asia, and South America will discuss the impact that 
systemic diseases have had in the posterior pole of the eye worldwide. Topics are rotated 
every year to cover a wider variety of diseases.
Objective: At the conclusion of this course, participants will understand the variety of 
retinal and choroidal manifestations of selected systemic diseases in and outside the 
United States.
Senior Instructor(s): J Fernando Arevalo MD FACS*
Instructor(s): Rubens Belfort Jr MD PhD*, Carol L Shields MD, Jerry A Shields MD, 
William F Mieler MD*, Careen Yen Lowder MD PhD*, Lihteh Wu MD*, Francisco J 
Rodriguez MD*, Alay S Banker MD
Retinal OCT Interpretation 101
Course: 199 Sunday
Room: R08 2:00 - 3:00 PM
Education Level: BAS Target Audience: COMP
Synopsis: OCT is increasingly being used to diagnose and manage retinal diseases. 
This is an introductory, basic-level course for those who are not retinal specialists and 
are interested in learning about OCT and interpretation of OCT images of retinal condi-
tions. In this course, we will review the fundamentals of OCT, with emphasis on inter-
preting and recognizing OCT images obtained from various retinal conditions, through 
examples, to become more proficient at differentiating normal from pathologic findings.
Objective: At the conclusion of this course, the participants will be able to (1) discuss 
how OCT works and list differences between time domain and spectral domain OCT, (2) 
understand potential sources of artifacts, (3) recognize OCT images of common retinal 
diseases, and (4) learn to incorporate OCT into a practice.
Senior Instructor(s): Judy E Kim MD
Instructor(s): Jennifer Irene Lim MD*
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Simplifying Treatment of Diabetic Retinopathy for the 
Comprehensive Ophthalmologist: What You Really Need to 
Know in 2013
Course: 208 Sunday
Room: 217 3:15 - 4:15 PM
Education Level: INT Target Audience: COMP
Synopsis: A review of recent publications and clinical trials involving diabetic retinopa-
thy (DR), including Diabetes Control and Complications Trial, Early Treatment Diabetic 
Retinopathy Study, Diabetic Retinopathy Study, etc. Indications / techniques of laser, 
control of systemic disease, anti-VEGF intravitreal injections and steroid treatment in 
the management of DR will be discussed. Actual patient cases and management with 
panel discussion / audience participation will include every DR scenario seen in clinical 
practice.
Objective: To present management and treatment approaches for DR, enabling partici-
pants to understand (1) focal and panretinal photocoagulation, (2) anti-VEGF intravitreal 
injections, and (3) other pharmacotherapy. At the conclusion of this course, attendees 
will be confident about when and how to use laser based on current 2013 DR literature 
(DRCRnet articles on laser, ranibizumab, and steroids) and proficient in determining when 
and how often to implement intravitreal injections as an adjunct to laser.
Senior Instructor(s): John O Mason MD
Instructor(s): Richard M Feist MD, Michael A Albert MD, Thomas A Finley MD, Jacob 
Yunker MD
How to Interpret Fundus Fluorescein Angiography and 
Autofluorescence
Course: 306 Monday
Room: 228 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will teach how to interpret fundus fluorescein angiography (FA) 
and fundus autofluorescence images (FAF). A step-by-step guide will be used, support-
ed by (1) targeted review of the retinochoroidal anatomy, (2) illustrations to acquire a 
“visual” understanding of fluorescence patterns, and (3) numerous FA and FAF images 
correlating these patterns with fundus findings. The majority of vascular, degenerative, 
inflammatory, hereditary, and tumoral chorioretinal pathologies will be reviewed, and the 
audience will be taught how to recognize these diseases based on the imagery.
Objective: The attendee will be empowered with the know-how to recognize and in-
terpret the angiographic and autofluorescent features of the majority of chorioretinal 
pathologies and to recognize these disease entities based on the angiographic and au-
tofluorescence findings.
Senior Instructor(s): Sawsan R Nowilaty MD
Instructor(s): Hardeep S Dhindsa MD, Albert T Vitale MD*
 NEW  Challenging Cases in Neovascular AMD
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
The Retina Society
Course: 308 Monday
Room: R04 9:00 - 11:15 AM
Education Level: INT Target Audience: COMPSUB
Synopsis: Recently, several mechanisms have been proposed for neovascular AMD, 
and new frontiers in genetics have been referred to. Currently, the treatment of neovas-
cular AMD with pharmacologic agents has been well established, and novel drugs have 
been developed to control the disease. Nevertheless, the precise mechanism of disease 
and the reasons for treatment failure in some cases remain unknown. This course will 
offer an interactive discussion of unresponsive, atypical, and recalcitrant cases of neo-
vascular AMD by international experts in this field.
Objective: This session will provide an outline of some intricate neovascular AMD 
cases, propose a rationale for their complexity, and present appropriate treatment strat-
egies. Anti-VEGF agents will be discussed, as well as other pharmacologic drugs and 
nonpharmacologic treatment. At the conclusion, the attendee will be able to understand 
possible mechanisms for such cases of neovascular AMD with poor prognosis and sug-
gest a suitable treatment strategy for each presented case.
Senior Instructor(s): Luiz Lima MD
Instructor(s): William F Mieler MD*, Philip J Rosenfeld MD PhD*, Pravin U Dugel MD*, 
Frank G Holz MD*, Lihteh Wu MD*, Michel Eid Farah MD, Eduardo B Rodrigues MD*
Management of High-Risk ROP in the 21st Century: Thermal-
Destructive vs. Pharmacologic Treatment
Course: 311 Monday
Room: 217 9:00 - 11:15 AM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will describe the identification of high-risk ROP eyes and will 
present the rationale for both thermal and pharmacologic treatment.
Objective: By the conclusion of this course, attendees will be better able to (1) identify 
aggressive posterior ROP, (2) distinguish typical stage 3 ROP from flat stage 3 ROP, (3) 
understand the rationale for both thermal (laser) and pharmacologic (anti-VEGF) treat-
ment, (4) be familiar with the technique of current thermal laser treatment for posterior 
retinal disease, specifically dealing with flat neovascularization, and (5) be familiar with 
the technique of off-label pharmacologic management using available FDA-approved 
anti-VEGF drugs.
Senior Instructor(s): Michael T Trese MD*
Instructor(s): Antonio Capone Jr MD*, Kimberly A Drenser MD PhD*, Lois E H Smith MD 
PhD*
 NEW  Vitreoretinal Surgery: Video Presentation and 
Discussion
Jointly Sponsored by the Academy’s s Annual Meeting Program Committee and 
the European Vitreo-Retinal Society
Course: 316 Monday
Room: R03 9:00 - 11:15 AM
Education Level: INT Target Audience: SUB
Synopsis: This course will present a large number of surgical videos from around the 
world that highlight advances in vitreoretinal surgery. The course will update vitreoreti-
nal surgeons on the newest surgical techniques and their advantages and disadvantages. 
The indications for various surgical approaches will be discussed, along with surgical 
tips and specific approaches for a variety of clinical scenarios.
Objective: At the conclusion of this course, the attendee will be familiar with advances 
in vitreoretinal surgical techniques and will have a better understanding of newest tech-
niques.
Senior Instructor(s): Ron Afshari Adelman MD MPH
Instructor(s): Colin McCannel MD*, Frank H Koch MD*, Jerzy Nawrocki MD PhD, Gaurav 
K Shah MD*, Cesare Forlini MD, Antonia M Joussen MD PhD, Hassan Aly Mortada 
MD**, Giampaolo Gini MD, Grazia Pertile MD, Ihab S Othman MD, Ivan Fiser MD PhD, 
Barbara Parolini MD**, Sengul C Ozdek MD*
Diabetic Macular Edema: 2013 Update on Management
Course: 339 Monday
Room: 225 10:15 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will summarize the molecular mechanisms, imaging studies, con-
trol of systemic factors, laser therapies, new pharmacotherapies, and surgical strategies 
in the management of diabetic macular edema (DME). Major clinical trials (Diabetes 
Control and Complications Trial, Epidemiology of Diabetes Interventions and Complica-
tions, UK Prospective Diabetes Study, Action to Control Cardiovascular Risk in Diabetes, 
Early Treatment Diabetic Retinopathy Study, Diabetic Retinopathy Study, and Diabetic 
Retinopathy Clinical Research) will be reviewed. There will be case presentations / dis-
cussion by a panel.
Objective: At the conclusion of this course, the attendees will be able to (1) recognize 
the molecular mechanisms of DME, (2) review major clinical trials on DME, (3) under-
stand the role of imaging studies, and (4) manage DME patients based on a combination 
approach of control of systemic factors, laser therapy, pharmacotherapy (anti-VEGF and 
steroids), and surgical therapies.
Senior Instructor(s): Arup Das MD PhD*
Instructor(s): Thomas R Friberg MD*, Robert N Frank MD, Lloyd P Aiello MD PhD*, 
Michael S Ip MD*, George A Williams MD*, Andre J Witkin MD
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 NEW  Your First 20 Dates With the Internal Limiting Membrane: 
Tips on Macular Surgery Techniques for Beginners
Course: 344 Monday
Room: 210 10:15 - 11:15 AM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will outline principles of macular surgery, management of com-
plications, and an approach to extended indications of internal limiting membrane (ILM) 
peel. A practical and interactive way to achieve successful ILM peel for the beginner 
will be discussed, with interesting videos. Specific topics will include instrumentation, 
imaging modalities in evaluation of the vitreomacular interface, vital dyes and safety 
considerations, techniques of ILM peel, tips for avoiding complications, and the role of 
ILM peel in cases other than macular holes. Audience participation will be encouraged, 
and a comprehensive handout will be provided.
Objective: Upon completion of the course, the attendee will have gained greater in-
sight into safe and efficient ways of performing macular surgery. The course will provide 
beginners with a foundation for developing ILM peel skills and understanding of how to 
manage complications during macular surgery.
Senior Instructor(s): Malhar Soni MD MS DNB FRCS*
Instructor(s): David R Chow MD*, Peter W Stalmans MD PhD*, Paul E Tornambe MD*
Diabetic Vitrectomy
Course: 357 Monday
Room: R08 11:30 AM - 12:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: This course will use video and panel discussions, along with some didactic 
lecturing, to review the current indications, techniques, and results of vitrectomy for 
complications of proliferative diabetic retinopathy and diabetic macular edema. The 
merit of preoperative and postoperative adjunctive treatments (such as preoperative in-
travitreous bevacizumab or postoperative tamponade) will also be discussed. Emphasis 
will be placed on highlighting the advantages of each technique, particularly in situations 
shown on the video presentations.
Objective: At the completion of the course, attendees will be familiar with several 
intraoperative techniques and maneuvers that can be employed to increase anatomic 
and visual success. Moreover, attendees will be able to judiciously employ preopera-
tive, intraoperative, and postoperative adjunctive treatments that will benefit the patient.
Senior Instructor(s): Petros Carvounis MD FRCSC*
Instructor(s): Andrew J Barkmeier MD, Jorge A Fortun MD*
 h  Diagnostic Ophthalmic Ultrasonography
Course: 372 Monday
Room: R04 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will present a slide and video demonstration of diagnostic 
ophthalmic ultrasonographic techniques. Several case presentations will be included 
to highlight the evaluation, interpretation, and differentiation of a wide variety of oph-
thalmic disorders. Ultrasonographic findings will be correlated with fundus photography, 
OCT, computed tomography, MRI, indocyanine green angiography, fluorescein angiogra-
phy, and histopathology.
Objective: This course will review techniques of diagnostic ophthalmic ultrasonogra-
phy, including B-scan, diagnostic A-scan, and ultrasound biomicroscopy. The course will 
highlight the interpretation and diagnostic features of ultrasonographic images using 
well-illustrated cases. Correlation with ancillary diagnostic tests will also be presented.
Senior Instructor(s): Brandy C Hayden BS
Instructor(s): Arun D Singh MD
Diabetes 2013: Course on Diabetic Retinopathy
Course: 139 Monday
Room: 333 3:15 - 5:30 PM
Education Level: INT Target Audience: COMP
Synopsis: This course will present a rational approach to the diagnosis and treatment 
of diabetic retinopathy based on first understanding results and recommendations of the 
Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study and subse-
quently reviewing DRCRnet publications that may modify some of those recommenda-
tions. Case presentations made to a panel of experts will illustrate the role of OCT and 
pharmacotherapy relative to laser therapy.
Objective: By the conclusion of this course, participants will be able to understand 
(1) the clinical indications for laser treatment of diabetic retinopathy and (2) the role of 
pharmacotherapy and OCT in current management of diabetic retinopathy. 
Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, see the 
Skills Transfer section.
Senior Instructor(s): Keye Luc Wong MD*
Instructor(s): Abdhish R Bhavsar MD*, Alexander J Brucker MD*, Emily Y Chew MD, 
Harry W Flynn MD*, Arthur D Fu MD, Justin L Gottlieb MD, Sam Edward Mansour MD*
Advanced Vitreoretinal Surgical Techniques and 
Instrumentation
Course: 392 Monday
Room: 221 3:15 - 5:30 PM
Education Level: ADV Target Audience: SUB
Synopsis: This interactive, case-based course will highlight the latest developments 
in vitreoretinal surgery. The panel will make extensive use of videos to discuss the most 
advanced approaches to vitreoretinal surgery, including the advantages of newer instru-
mentation.
Objective: At the end of this course, attendees will be familiar with the latest advances 
in surgical instrumentation and techniques used for the treatment of macular diseases, 
retinal detachment, ocular trauma, retained lens material, and diabetic retinopathy.
Senior Instructor(s): Sunir J Garg MD*
Instructor(s): Julia A Haller MD*, Tarek S Hassan MD*, Allen C Ho MD*, Mark W 
Johnson MD*, Carl D Regillo MD FACS*, George A Williams MD*
Retinal Pharmacotherapy
Course: 402 Monday
Room: 225 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: The management of retinal diseases has changed in recent years, as the 
focus has moved into pharmacologic treatments. Several currently existing and upcom-
ing drugs are being used to treat various retinal diseases. This course will provide an 
in-depth knowledge of the drugs in retinal pharmacotherapy.
Objective: This course will serve as an overview of how various drugs may work in 
the retina. The session will present cutting-edge results of clinical trials, such as the 
Comparison of AMD Treatment Trial (CATT), as well as an overview of the techniques 
and complications in retinal pharmacotherapy. The most important drugs available in 
clinical practice, ranibizumab (Lucentis), bevacizumab (Avastin), aflibercept (Eylea), and 
dexamethasone intravitreal implant (Ozurdex), will be presented in detail. At the conclu-
sion, the attendee will be able to understand the indications, applications, and status of 
drugs available in retinal pharmacotherapy.
Senior Instructor(s): Eduardo B Rodrigues MD*
Instructor(s): Andrew P Schachat MD*, Michel Eid Farah MD, Quan Dong Nguyen MD*, 
Carsten H Meyer MD**, Philip J Rosenfeld MD PhD*, William F Mieler MD*, Fernando 
M Penha MD*
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 NEW  Vitreoretinal Surgical Rounds, Unleashed!
Course: 424 Monday
Room: 338 4:30 - 5:30 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will feature an interactive panel discussion with debate about 
different surgical approaches to a wide spectrum of vitreoretinal pathology and man-
agement of complications during vitreoretinal surgery and in the postoperative period. 
Challenging cases will be presented, with drawings, intraoperative photos, and high-
definition videos simulating the Saturday morning Duke vitreoretinal surgical rounds.
Objective: At the conclusion of this course, the attendee will be able to (1) determine 
the differences between and proper selection of 20-, 23-, 25-, and 27-gauge vitrectomy 
instrumentation, (2) identify and manage complications associated with different surgi-
cal approaches, (3) differentiate between the available light options with a better selec-
tion of diffusion light pipes, lighted picks, and chandeliers, according to the selected 
approach, and (4) recognize the evolving value of intraoperative OCT in vitreoretinal 
surgical techniques.
Senior Instructor(s): Tamer H Mahmoud MD
Instructor(s): Glenn J Jaffe MD*, Cynthia A Toth MD*, Carl C Awh MD*, Dean Eliott 
MD*, Eric A Postel MD, Sharon Fekrat MD, Prithvi Mruthyunjaya MD*, Paul Hahn MD 
PhD, Eric W Schneider MD, Glenn C Yiu MD
Engineering and Physics Principles: A Primer for the 
Vitreoretinal Surgeon
Course: 501 Tuesday
Room: 214 9:00 - 11:15 AM
Education Level: BAS Target Audience: SUB
Synopsis: A firm grasp of engineering and physics is necessary to develop solid vit-
reoretinal surgical skills regardless of the specific surgical equipment being used. This 
course will provide a practical, clinically relevant treatment of the basic physical prin-
ciples at play in vitrectomy surgery, as well as why and how these principles can be 
leveraged to benefit the patient. Specific topics may include fluid statics, fluid dynamics, 
impingement pressure, duty cycle, vitreous dynamics, slug flow, vitrectomy circuit, and 
dynamic IOP. These intimidating-sounding concepts are really quite intuitive, and they 
can be easily applied for the benefit of the retinal patient.
Objective: At the conclusion of this course, the attendee will understand the basic 
engineering principles outlined above and how they relate to performing safe and ef-
ficient vitreoretinal surgery.
Senior Instructor(s): Christopher D Riemann MD*
Instructor(s): Kirk H Packo MD*
Evaluation of Early-Onset Hereditary Retinal Degeneration in 
Infants and Children
Course: 509 Tuesday
Room: 342 9:00 - 10:00 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Infants and children with inherited retinal degenerations can present with 
typical retinal findings. However, sometimes they may present with normal or near nor-
mal retinal appearance. Although retinal function testing is sometimes required for a 
definitive diagnosis, the diagnosis is often suspected or confirmed by ocular history, fam-
ily history, and clinical examination. This course will provide a step-by-step approach to 
the diagnosis of early-onset retinal degenerations, with discussion of when to utilize 
electrophysiological testing, OCT, and genetic testing. This course will also discuss re-
sources available at various levels for parents of affected children and ophthalmologists.
Objective: At the conclusion of the course, the pediatric and comprehensive ophthal-
mologist will be able to better diagnose and differentiate among the early-onset inher-
ited retinal degenerations.
Senior Instructor(s): Sandeep Grover MD*
Instructor(s): Byron L Lam MD*, Craig A McKeown MD
Intraocular Foreign Body Injuries: An Update
Jointly sponsored by the Academy’s Annual Meeting Program Committee and the 
American Society of Ocular Trauma and the International Society of Ocular Trauma
Course: 522 Tuesday
Room: R01 9:00 - 10:00 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: Using intraoperative videotapes, this course will review all aspects of man-
aging patients with intraocular foreign bodies: history, epidemiology, pathophysiology, 
evaluation, instrumentation, timing, management principles and practice, complications, 
prognosis and outcome, and controversies.
Objective: To provide ophthalmologists with the necessary information for optimal 
treatment of patients with intraocular foreign body injuries.
Senior Instructor(s): Ferenc P Kuhn MD PhD
Instructor(s): Jose Dalma MD
Practical Considerations for Telemedicine Diabetic 
Retinopathy Screening
Jointly Sponsored by the Academy’s Annual Meeting Program Committee and the 
American Telemedicine Association
Course: 553 Tuesday
Room: R05 11:30 AM - 12:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Evidence-based recommendations for diabetes eye care are highly effective 
in reducing the risk for vision loss. However, poor compliance with recommendations 
for retinal examinations to ensure early detection of diabetic retinopathy (DR) remains a 
major unresolved challenge in ophthalmology. Telemedicine programs based on remote 
digital retinal imaging have demonstrated the potential to complement current DR sur-
veillance methods and increase the rate of DR assessment. Clinical recommendations, 
technical requirements for hardware, software and personnel, and operational consider-
ations will be discussed. Successful business models and financial and reimbursement 
factors will be presented.
Objective: At the conclusion of this course, the attendee will understand the rationale 
for telemedicine DR assessment and have a framework for implementation of a remote 
program for evaluation of DR.
Senior Instructor(s): Ingrid E Zimmer-Galler MD*
Instructor(s): Mark B Horton MD, Paolo Antonio S Silva MD
Epiretinal Membranes: Etiologies, Perioperative Management, 
Surgical Techniques, and Case Discussions
Course: 564 Tuesday
Room: 214 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course is organized into three presentations on the etiologies, perioper-
ative management, and surgical techniques for epiretinal membranes (ERMs): (1) etiolo-
gies of ERMs (eg, vitreoschisis), (2) indications for surgery (eg, functional and anatomical 
impairment); pre-, intra-, and postoperative management concerns (including avoiding 
operating on clinically insignificant ERMs and management of cataract, vitreous, periph-
eral retina); and recognition of specific problems that put patients at risk for less optimal 
outcomes, and (3) optimal surgical approaches and avoidance of complications. These 
three presentations will be followed by a question-and-answer session and then case 
presentations.
Objective: At the conclusion of this course, the attendee will know the etiologies and 
management implications of different types of ERMs, understand how to recognize and 
surgically manage the different symptoms caused by ERMs, and gain insight into surgical 
approaches to improve visual outcomes and reduce complications.
Senior Instructor(s): Albert O Edwards MD PhD
Instructor(s): Colin McCannel MD*, Mark W Johnson MD*
OCT: Interpretation and Clinical Applications
Course: 568 Tuesday
Room: 228 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Through a series of lectures and case presentations, participants will become 
familiar with the use of OCT for a large variety of posterior pole disorders / pathologies.
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Objective: At the conclusion of the course, the attendee will be able to interpret OCT 
images for the diagnosis and/or management of patients with posterior pole disorders.
Senior Instructor(s): Caroline R Baumal MD
Instructor(s): Carmen A Puliafito MD MBA*, Joel S Schuman MD*, Cynthia A Toth MD*, 
Michael S Ip MD*, Brandon J Lujan MD
 h  Controversies in the Management of Open-Globe Injuries 
Involving the Posterior Segment
Course: 573 Tuesday
Room: R02 12:45 - 1:45 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Controversies in the management of open-globe injuries will be presented 
and thoroughly discussed. An overview of the problem will be provided, followed by a de-
tailed breakdown of the controversies for which controlled clinical data regarding man-
agement are incomplete. These areas include the timing of vitrectomy, use of prophylac-
tic antibiotics, placement of prophylactic cryotherapy and/or scleral buckle, management 
of intraocular foreign bodies, use of silicone oil, concurrent placement of primary IOLs, 
management of hypotony, and surgery on NLP eyes. Guidelines for treatment will be 
provided based on clinical data and the experience of the presenters. Several videos will 
be presented, documenting select procedures and techniques.
Objective: This course is designed to provide an update on the clinical management 
of controversial issues in the setting of open-globe injuries through the use of slide pre-
sentations, videotapes, and interactive panel discussions. A comprehensive handout will 
be provided.
Senior Instructor(s): William F Mieler MD*
Instructor(s): Ferenc P Kuhn MD PhD
Retinoblastoma 2013: They Live and See!
Course: 579 Tuesday
Room: 210 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Recent advances in the diagnosis and management of retinoblastoma have 
contributed to improved outcome. The new staging and grouping systems are now 
clinically validated. Modern diagnostic and management strategies such as wide-field 
imaging, transpupillary thermotherapy, chemoreduction, and intravitreal and periocular 
chemotherapy are effective in improving eye and vision salvage. Selective intra-arterial 
chemotherapy is an exciting new development. Minimal manipulation enucleation has 
been optimized. Adjuvant therapy for histopathologic high-risk factors identified follow-
ing enucleation has reduced the risk of systemic metastasis. A multimodal protocol is 
effective in orbital retinoblastoma. Genetic studies now help in prenatal diagnosis and 
screening of siblings. The course will highlight the practical aspects in the current stan-
dard of care for retinoblastoma.
Objective: To enable the participants to incorporate recent advances in the diagnosis 
and management of retinoblastoma into their practices.
Senior Instructor(s): Santosh G Honavar MD
Instructor(s): Ralph Eagle MD*, Brenda L Gallie MD*, Ashwin C Mallipatna MBBS, Carol 
L Shields MD, Jerry A Shields MD, Arun D Singh MD
Endoscopic-Assisted Ophthalmic Surgery: Anterior and 
Posterior Segment Techniques
Course: 588 Tuesday
Room: R03 12:45 - 3:00 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will introduce the concept of endoscope-assisted intraocular 
surgery and will showcase video-based presentations of a wide range of anterior and 
posterior segment procedures. Pearls for rapid attainment of endoscopic proficiency will 
be discussed. Anterior segment surgery will include cataract/IOL, trauma and glaucoma 
(including goniosynechiolysis, cyclodialysis cleft repair, plateau iris treatment, and en-
doscopic cyclophotocoagulation). Posterior segment surgery will include management 
of blunt and penetrating trauma, safe sutured IOL removal, sclerotomy site pathology, 
cyclitic membranes, rhegmatogenous retinal detachment (RD) and traction RD in reti-
nopathy of prematurity, familial exudative vitreoretinopathy and persistent fetal vascula-
ture syndrome. The presenters are experienced anterior and posterior segment surgeons 
familiar with endoscopy.
Objective: To educate anterior and posterior segment surgeons on how intraocular en-
doscopy can assist them in complex surgical procedures.
Senior Instructor(s): S Chien Wong MBBS FRCS*
Instructor(s): Brian A Francis MD*, Robert J Noecker MD*, Thomas Lee MD*
Ocular Ultrasound
Course: 589 Tuesday
Room: 214 12:45 - 3:00 PM
Education Level: BAS Target Audience: COMP
Synopsis: This course will present the examination techniques and diagnostic findings 
of ocular ultrasound utilizing standardized A- and B-scan technology as applied in the 
clinical setting.
Objective: Upon the completion of the course, the attendee will be able to explain the 
basic principles and examination techniques of ocular ultrasound as applied to pathologi-
cal conditions in the eye.
Senior Instructor(s): Roger P Harrie MD
Instructor(s): Ronald L Green MD
 h  State-of-the-Art Techniques and Technologies for 
Microincision Vitrectomy Surgery to Treat Complex 
Vitreoretinal Diseases
Course: 591 Tuesday
Room: 225 12:45 - 3:00 PM
Education Level: ADV Target Audience: SUB
Synopsis: This interactive course will highlight state-of-the-art surgical techniques 
and technologies for small-gauge vitrectomy. The topics include 23-gauge endoscopic 
vitrectomy, and 25- and 27-gauge sutureless vitrectomy to treat challenging vitreoretinal 
pathologies, such as advanced retinal detachment, proliferative vitreoretinopathy, prolif-
erative diabetic retinopathy, subretinal hemorrhage, ocular trauma, and pediatric cases. 
The instructors will make extensive use of videos to engage the attendees in the discus-
sion of the most advanced techniques, newer instrumentation, and surgical adjuncts to 
facilitate safe and efficient approaches with minimizing surgical complications.
Objective: At the end of this course, the attendees will not only be familiar with state-
of-the-art microincision vitrectomy surgery but will also get a glimpse of future techno-
logical advances.
Senior Instructor(s): Yusuke Oshima MD*
Instructor(s): Carl C Claes MD*, Pravin U Dugel MD*, Jeffrey S Heier MD*, Shunsuke 
Osawa MD*, Ehab N El Rayes MD PhD, Fabio Patelli MD
Surgery of Retinal Detachment
Course: 593 Tuesday
Room: 333 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will review the principles involved in managing rhegmatogenous 
retinal detachment. We will provide a detailed, comprehensive, state-of-the-art ap-
proach to techniques of scleral buckling, primary vitrectomy, and pneumatic retinopexy 
for the management of selected detachments. Principles of buckle placement, selection 
of elements, drainage, and use of gases and other adjutants will be described.
Objective: At the conclusion of this course, the attendee will be able to (1) discuss the 
advantages and disadvantages of scleral buckling, vitrectomy, and pneumatic retinopexy, 
(2) identify the indications and contraindications and technique of drainage of subretinal 
fluid, (3) select the appropriate gas for intraocular injections, (4) discuss postoperative 
management of retinal detachment patients, and (5) recognize alternate techniques for 
the management of different types of retinal detachments.
Senior Instructor(s): Daniel P Joseph MD PhD
Instructor(s): Harry W Flynn MD*, George A Williams MD*, Edwin Hurlbut Ryan MD*
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 h  Principles of Pediatric Vitreoretinal Surgery in Retinopathy 
of Prematurity
Course: 595 Tuesday
Room: 340 12:45 - 3:00 PM
Education Level: ADV Target Audience: COMPSUB
Synopsis: This course will deal with the management of retinopathy of prematurity 
(ROP) retinal detachment. It will also touch on early treatment of peripheral retinal abla-
tion and possible pharmacologic therapy and its relationship to management of retinal 
detachment therapy. We will primarily deal with techniques of vitreoretinal surgery for 
ROP, including video presentations for stage 4A, 4B, and 5 ROP with and without enzy-
matic manipulation of the vitreoretinal juncture and core vitreous.
Objective: The attendee will be knowledgeable about the management of ROP vitreo-
retinal surgery techniques including enzymatic as well as nonenzymatic approaches.
Senior Instructor(s): Michael T Trese MD*
Instructor(s): Philip J Ferrone MD*, Antonio Capone Jr MD*, Kimberly A Drenser MD 
PhD*
 NEW  Peering to the Periphery: Applications of Wide-Angle 
Retinal Imaging
Course: 596 Tuesday
Room: 217 12:45 - 3:00 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: Wide-angle retinal imaging platforms have gained increased popularity. Nu-
merous applications have been demonstrated, including disease documentation, diag-
nosis, and targeted treatment of retinal diseases. Utilizing wide-angle angiography and 
autofluorescence provides insights into retinal and choroidal conditions such as macular 
degeneration, diabetic retinopathy, retinal vascular disease, and ocular tumors. Pitfalls 
with these technologies include artifact registration and false color processing, which 
may result in inaccurate diagnosis. Cases will be presented to highlight the clinical ap-
plications of wide-angle imaging.
Objective: After completing this course, the attendee will be able to identify imaging 
options for retinal peripheral diseases, understand the role of wide-angle angiography in 
retinal vascular disease, identify critical imaging artifacts, and understand applications 
of these technologies in pediatric and ocular oncology patients.
Senior Instructor(s): Prithvi Mruthyunjaya MD*
Instructor(s): Szilard Kiss MD*, Seenu M Hariprasad MD*, R V Paul Chan MD, Michael P 
Kelly FOPS, Sunil K Srivastava MD*
Systemic Therapeutic Agents and Retinal Toxicity
Course: 602 Tuesday
Room: 338 3:15 - 5:30 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: This course will provide a thorough review of systemic (and select intravitre-
al) medications that are capable of causing various patterns of retinal toxicity. Examples 
of all of these types and patterns of toxicity will be presented, including disruption of the 
retinal pigment epithelium, retinal vascular occlusion, cystoid macular edema / retinal 
edema, crystalline deposition, uveitis, miscellaneous, and subjective visual symptoms. 
The mechanism of action will be discussed. Numerous examples of all conditions will be 
shown, and time will be allotted for questions and answers. A comprehensive referenced 
handout will be provided to all attendees.
Objective: At the conclusion of the course, the attendee will be able to (1) recognize 
the various patterns of toxicity induced by a variety of systemic, topical, and intravitreal 
medications, (2) recognize medications capable of causing subjective visual symptoms, 
and (3) better understand the clinical setting in which toxicity is most likely to occur.
Senior Instructor(s): William F Mieler MD*
Instructor(s): George A Williams MD*, David F Williams MD*, Scott R Sneed MD, David 
Sarraf MD*
Vision Rehabilitation
 SO  Low Vision Rehabilitation for Ophthalmologists
Course: 176 Sunday
Room: R01 2:00 - 4:15 PM
Education Level: INT Target Audience: COMPSUB
Synopsis: As an ophthalmologist, you have the skills necessary to help low vision pa-
tients with vision rehabilitation. These basic, informative low vision testing tools will 
help your patients achieve their visual potential.
Objective: After completion of this course, you will know how to use the necessary 
tools as a resident, comprehensive ophthalmologist, or retinal specialist to incorporate 
low vision rehabilitation into your practice.
Senior Instructor(s): Robert M Christiansen MD FACS
Instructor(s): Paul Homer MD, Gwen K Sterns MD
 NEW   SO  Should My Visually Impaired Patient Be Driving?
Course: 325 Monday
Room: 209 9:00 - 10:00 AM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will cover the current evidence-based information on visual risk 
factors for motor vehicle collision involvement and impaired driving performance, ethi-
cal and legal issues for managing visually impaired patients who want to drive, where 
ophthalmologists can refer patients for driving assessments and what these services are, 
case studies presented by specialists in this area, and the increasingly common cases 
of older drivers who are likely to have medical comorbidities in addition to visual impair-
ment. A nationally recognized expert panel will lead the course.
Objective: At the conclusion of this course, participants will be familiar with visual 
characteristics that elevate crash risk, methods for managing and referring to driving as-
sessment specialists those visually impaired patients who want to drive, the ophthalmol-
ogist’s important role in having a dialogue about vision and driving with visually impaired 
patients, and practical information from case studies that facilitate clinical practice.
Senior Instructor(s): Cynthia Owsley MSPH PhD*
Instructor(s): David B Carr MD*, Lylas G Mogk MD*, Jennifer Elgin
•   Online & mobile viewing from your iPad, iPhone  
and Android devices
•   Over 200 hours of synchronized presenter  
slides and audio
•   Special Attendee Discounts!
•   USB for convenient offline access to select products
Choose One or More
AAO Subspecialty Day On Demand includes content presented in 
the following programs:
Cornea 2013:
Through the Looking Glass: Where We Are, Where We’re Headed
Glaucoma 2013:
The Future is Now! #Glaucoma2013 
Neuro-Ophthalmology 2013:
What to Make of This? Recognizing the Distinctive Neuro-Ophthalmic Symptom, 
Sign, or Test
Oculofacial Plastic Surgery 2013:
Blues, Blephs, and Blowouts
Pediatric Ophthalmology 2013:
Preparing for the Next Generation
Refractive Surgery 2013:
Perfecting Vision
Retina 2013:
Let the Good Times Roll
AAO Annual Meeting On Demand includes over  
150 hours of content from the 2013 Annual Meeting
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 Main Booth: Lobby G ( Fri-Tues)
 Satellite Booth: Great Hall Lobby ( Fri-Mon)
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Sample more than 30 new print and 
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a practice management expert
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CELEBRATE THE IRIS™ REGISTRY LAUNCH
Sunday, Nov. 17, 3:00 – 5:00 p.m.
Enjoy coffee and a snack while you demo the nation’s 
fi rst comprehensive, EHR-based eye disease clinical 
registry. Learn how you can use clinical data to 
improve care delivery and patient outcomes.
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 NEW  New course
 R Lab is available to Residents only
 EQUIP Participants are required to bring specific equipment to the course
 W Participants are required to sign an infectious disease transmission waiver/release form
These hands-on courses offer intensive training in surgical and diagnostic techniques, with direct super-
vision and a low participant-to-instructor ratio.  Attendance is limited to physicians only, except where 
noted in the course description.  (The term physician refers to the definition in the Federal Register: 
“those individuals licensed to practice medicine and surgery or osteopathy.”)
Skills Transfer courses are intended to provide instruction leading to new knowledge and/or skills.  The 
Academy does not certify competence upon completion of Academy courses.  Academy courses are not 
intended to serve as a basis for requesting new or expanded privileges.
Tickets and The Academy Plus Course Pass
Skills Transfer Labs are ticketed events - they are not included in the Academy Plus course pass 
and must be purchased separately.
If you are registering for a Skills Transfer lab (LAB), and a prerequisite lecture (LEC) is indicated, you 
must attend both courses. The lecture is included with the lab - you do not need to purchase the Acad-
emy Plus course pass to attend the lecture. 
Members in Training automatically receive a 50% discount on all Skills Transfer labs, except where 
noted. For labs available to Residents only, the Member in Training discount has already been applied.
Skills Transfer Didactic courses/lectures are included in the Academy Plus course pass. By pur-
chasing Academy Plus you may attend the lecture without purchasing the lab.
Note: Due to Fire Marshal regulations, seating capacities in courses/lectures are limited. Seating is 
available on a first-come basis, so please plan accordingly.
Selection Committee
The Skills Transfer Advisory Committee selected all Skills Transfer Courses and Labs.
Skills Transfer Program
Committee Members
Iqbal K Ahmed MD
Susan R Carter MD
Jack A Cohen MD FACS
William Barry Lee MD
Kevin M Miller MD
David D Verdier MD
Associate Secretary
Thomas W Samuelson MD
Skills Transfer Program
Skills Transfer Program General Information
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The Academy gratefully acknowledges the following companies for their generous support of equipment and supplies used during 
the Skills Transfer Course Program:
We would also like to thank the following companies for their contributions in the Cataract, Refractive Surgery/Cornea, Glaucoma, 
Retina and Plastics Skills Transfer Labs:
Durable Equipment / Instruments:
Abbott Medical Optics
Accurate Surgical & Scientific Instruments Corporation 
Accutome, Inc.
Alcon Laboratories, Inc.
Anodyne Surgical
Bausch & Lomb
Black & Black Surgical
Buffalo Filter
Carl Zeiss Meditec
Crestpoint Management
Dutch Ophthalmic, USA
Ellman International Inc.
Endo Optiks, Inc.
Epsilon Eye Care
IRIDEX
JEDMED Instrument Company
Katena Products Inc.
Lasering USA
Lumenis, Inc.
Mastel Inc.
Microaire Surgical Instruments
MST (MicroSurgical Technology)
NeoMedix
New World Medical, Inc.
Ophtec
Rhein Medical
Rumex International Co.
Sciton, Inc.
Stryker Medical
Syneron
Ziemer Group
Disposables:
Beaver-Visitec International Inc
Ethicon, Inc
FCI Ophthalmics
IOP Inc.
Medicis
Merz Aesthetics
STAAR Surgical Company
Tissue:
Bio-Tissue Inc.
Vision Share Eyebank Network
Medical Optics
Skills Transfer Course Contributors
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Cataract
Advanced Refractive Cataract Surgery and Anterior 
Segment Reconstruction
Course Director(s): Brock K Bakewell MD*
Prerequisite Didactic
Course: LEC102 Sunday, 9:00 - 11:15 AM
Room: 211 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course is designed for surgeons who (1) want to achieve a higher 
level of emmetropic results by addressing toricity through the use of limbal relaxing 
incisions, toric IOLs, and bioptics, and (2) want to expand their armamentarium for 
dealing with difficult cataract cases, dislocated IOLs, and traumatized eyes.
Objective: This course will cover iris and scleral suture fixation techniques for 
IOLs, chopping techniques, capsular tension rings, artificial iris vs. primary closure 
for iris defects, pars plana vitrectomy, introduction to femtosecond cataract sur-
gery, and strategies for dealing with challenging cases. These techniques will be 
presented in the didactic course and will be practiced in the Skills Transfer lab.
Instructor(s): Brock K Bakewell MD*, Louis D Skip Nichamin MD*, William J 
Fishkind MD FACS*, Samuel Masket MD*, Warren E Hill MD*, Steven H Dewey 
MD*, Lisa B Arbisser MD*, Garry P Condon MD*, Alan S Crandall MD*, Richard S 
Hoffman MD*, Robert P Liss MD, Mark K Walsh MD
Labs
Synopsis: This course is designed for surgeons who (1) want to achieve a higher 
level of emmetropic results by addressing toricity through the use of limbal relaxing 
incisions, toric IOLs, and bioptics, and (2) want to expand their armamentarium for 
dealing with difficult cataract cases, dislocated IOLs, and traumatized eyes.
Objective: This course will cover iris and scleral suture and sutureless fixation 
techniques for IOLs, chopping techniques, capsular tension rings, artificial iris vs. 
primary closure for iris defects, pars plana vitrectomy, introduction to femtosecond 
cataract surgery, and strategies for dealing with challenging cases.
Select one of the following
Course: LAB102A Sunday, 3:30 - 5:30 PM
Room: 356 Target Audience: COMPSUB
Fee: $320 EduLevel: INT
Instructor(s): Robert P Liss MD, Louis D Skip Nichamin MD*, Warren E Hill MD*, 
Bonnie A Henderson MD*, Ayman Naseri MD*, Garry P Condon MD*, James A 
Bryan III MD, Michael G Orr MD, Richard S Hoffman MD*, Roger C Furlong MD, 
Michele M Bloomer MD, Steven H Dewey MD*, Jeff S Maltzman MD, Corey A 
Miller MD, Bruce David Nichols MD, Lynn Polonski MD**, Kevin Lee Waltz MD*, 
Christine S Ament MD, M Todd Brown MD**, Cynthia S Chiu MD*
Course: LAB102B Monday, 3:30 - 5:30 PM
Room: 356 Target Audience: COMP
Fee: $320 EduLevel: INT
Senior Instructor(s): Roger C Furlong MD,
Instructor(s): , Steven H Dewey MD*, George Beiko MD*, William S Clifford MD*, 
Kenneth J Rosenthal MD FACS**,  Douglas Katsev MD*, Robert A Kaufer MD*, 
Jeff H Pettey MD*, Richard S Davidson MD*, James T Banta MD, Pablo Miguel 
Arregui MD*, Saman Garg**, Charles S Ahn MD*, Donald Stone MD,  Robert J 
Weinstock MD*, Helen K Wu MD*, Susan M MacDonald MD
 YO  Management of Vitreous for the Anterior Segment 
Surgeon
Course Director(s): Natalie A Afshari MD
Prerequisite Didactic
Course: LEC106 Sunday, 9:00 - 11:15 AM
Room: R04 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course will review the anatomy, physiology, and pathophysiology 
of the vitreous and will present vitrectomy techniques for challenging anterior seg-
ment surgery scenarios. Topics will include management of vitreous loss from the 
anterior and posterior approach, utilizing the vitrector for decompression in chal-
lenging cataract cases, and visualizing the vitreous with triamcinolone acetonide 
(Kenalog).
Objective: This course is designed to enhance the anterior segment surgeon’s fa-
miliarity with anterior and posterior vitrectomy techniques for challenging anterior 
segment cases.
Instructor(s): Iqbal K Ahmed MD*, Rosa Braga-Mele MD*, Ron Afshari Adelman 
MD MPH, Keith A Warren MD*, Baseer U Khan MD*, Thomas A Oetting MD
Labs
Synopsis: This Skills Transfer course will present management of vitreous during 
complicated anterior segment surgery. A variety of vitrectomy techniques will be 
discussed. Topics will include anterior vitrectomy, pars plana access to the anterior 
vitreous, and effective use of small-gauge instrumentation.
Objective: This course is designed to enhance participants’ technical skills in han-
dling vitreous during complicated anterior segment surgery.
Select one of the following
Course: LAB106A Sunday, 11:30 AM - 1:00 PM
Room: 356 Target Audience: COMPSUB
Fee: $280 EduLevel: INT
Instructor(s): Ron Afshari Adelman MD MPH, Sherleen Huang Chen MD, Baseer U 
Khan MD*, Gary S Schwartz MD, Roberto Pineda II MD*, Jack A Cohen MD FACS, 
Ali R Djalilian MD, Aryan Shayegani MD, Jerzy Nawrocki MD PhD, Francesco 
Boscia MD*, Shameema Sikder MD*, Robert B Bhisitkul MD*, Thomas A Oetting 
MD, Shahzad I Mian MD*, Joung Y Kim MD, William Barry Lee MD*
Course: LAB106B Monday, 1:00 - 2:30 PM
Room: 356 Target Audience: COMPSUB
Fee: $280 EduLevel: INT
Instructor(s): Ron Afshari Adelman MD MPH, Bonnie A Henderson MD*, Maria 
Mendicino Aaron MD, Sherleen Huang Chen MD, Baseer U Khan MD*, Gary S 
Schwartz MD, Ivan J Suner MD*, Roberto Pineda II MD*, Jack A Cohen MD FACS, 
Neda Shamie MD*, Ali R Djalilian MD, Aryan Shayegani MD, Jerzy Nawrocki MD 
PhD, Francesco Boscia MD*, Brad H Feldman MD*, Shameema Sikder MD*, Robert 
B Bhisitkul MD*, Majid Moshirfar MD**, Thomas A Oetting MD, Kenneth M Goins 
MD
Phacoemulsification and Advanced Techniques: The Core 
Curriculum
Course Director(s): Steven H Dewey MD*
Prerequisite Didactic
Course: LEC120 Sunday, 3:15 - 5:30 PM
Room: 211 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: In this course, a faculty of experienced surgeons will present the lat-
est phaco techniques and technologies that are applicable to ophthalmologists 
at every level of experience. This comprehensive course will cover the steps of 
phacoemulsification, including incisions, capsulorrhexis, hydrodissection, and 
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phaco techniques with an emphasis chop. Safe cortex removal and IOL implanta-
tion will be demonstrated. Capsular tension rings, pupil expanders, hooks, capsular 
staining, and related techniques will also be presented. This course will teach the 
most up-to-date phacoemulsification techniques to both individuals with little or no 
experience with the method and those wishing to refine or update their technique 
or transitioning from other cataract surgery methods.
Objective: This course is designed to teach participants the principals and skills 
necessary to understand and perform state-of-the-art phacoemulsification safely 
and efficiently.
Instructor(s): Anita Nevyas-Wallace MD*, Ricardo G Glikin MD, Nick Mamalis 
MD*, Helen K Wu MD*, Mark H Blecher MD, Thomas A Oetting MD
Labs
Synopsis: In the past few years, noteworthy new phaco technologies have altered 
the way surgeons execute and analyze the procedure. In this course, the latest 
phaco techniques and technologies will be presented. The most topical techniques 
will be taught, including wound construction, capsulorrhexis, capsular staining, 
phaco chop techniques, techniques for operating the mature cataract, astigma-
tism management, capsular tension rings, and pupil expanders and hooks. New 
machine principles, including micropulse phaco and torsional phaco, will be as-
sessed. Training will be one on one, allowing for customization of the techniques 
emphasized for each surgeon attendee.
Objective: By the conclusion of this course, the surgeon attendee should under-
stand the concepts influencing the latest phaco machine technologies and phaco 
techniques and attain the skills necessary for undertaking them.
Select one of the following
Course: LAB120A Monday, 8:00 - 9:30 AM
Room: 356 Target Audience: COMPSUB
Fee: $280 EduLevel: INT
Senior Instructor(s): Anita Nevyas-Wallace MD*, Gerald Roper MD*
Instructor(s): Boris Malyugin MD PhD*, Randall J Olson MD, Chi-Wah (Rudy) Yung 
MD, Donald J Doughman MD, Linda M Tsai MD, Steven R Sarkisian MD*, Marc A 
Michelson MD*, Audrey R Talley-Rostov MD*, Herbert J Ingraham MD, Nan Wang 
MD PhD, Surendra Basti MBBS*, Frank W Bowden III MD FACS, Stephen E Orlin 
MD, Michael Sulewski MD, William Wiley MD*, Robert W Weisenthal MD, Steven 
D Vold MD*, R Bruce Wallace MD*, Stephen V Scoper MD*, Deepinder K Dhaliwal 
MD*, Luther Fry MD FACS*, Kristiana D Neff MD*
Course: LAB120B Tuesday, 8:00 - 9:30 AM
Room: 356 Target Audience: COMPSUB
Fee: $280 EduLevel: INT
Senior Instructor(s): Gerald Roper MD*, Anita Nevyas-Wallace MD*
Instructor(s): David R Hardten MD*, Warren E Hill MD*, Alan N Carlson MD*, 
Jeffrey Whitman MD OCS*, Bennett Chotiner MD*, Erik A Chotiner MD, Ricardo G 
Glikin MD, Michael Hater MD**, Herbert J Nevyas MD, Florentino E Palmon MD, 
Clark L Springs MD*, P Dee G Stephenson MD FACS*, Linda M Tsai MD, James 
F Freeman MD*, Kevin M Miller MD*, Asim R Piracha MD*, Maria Cirone Scott 
MD*, Cathleen McCabe MD*, Tom Coffman MD**, James A Katz MD*, Dan B Tran 
MD*
 R  Phacoemulsification and Advanced Techniques Lab for 
Ophthalmology Residents
Course: LAB120C Tuesday, 1:00 - 3:00 PM
Room: 356 Target Audience: COMP
Fee: $175 EduLevel: BAS
Note: MIT discount already applied.
Senior Instructor(s): Maria Mendicino Aaron MD
Instructor(s): Natalie A Afshari MD, Ron Afshari Adelman MD MPH, David B Krebs 
MD, Nina A Goyal MD, Raj K Goyal MD MPH*, Hilary A Beaver MD*, Michael H 
Goldstein MD*, Bonnie A Henderson MD*, Robert S Bailey MD, Chi-Wah (Rudy) 
Yung MD, C Diane Song MD, Thomas A Oetting MD, Nan Wang MD PhD, Rahul T 
Pandit MD*, Jill R Wells MD, Joung Y Kim MD, Amy Grossman Coburn MD, Paul 
B Pruett MD, Maria A Woodward MD, Clark L Springs MD*, Preston H Blomquist 
MD, Daniel H Chang MD*
Manual Extracapsular Cataract Extraction Surgery: 
Indications and Techniques
Course Director(s): Bonnie A Henderson MD*
Prerequisite Didactic
Course: LEC123 Sunday, 3:15 - 5:30 PM
Room: 346 Target Audience: COMP
 EduLevel: BAS
Synopsis: Although extracapsular cataract extractions by large incision (ECCE) 
and small incision (SICS) are still performed routinely throughout the world, phaco-
emulsification surgery has become the standard of care in many countries, and 
therefore ECCE/SICS is no longer being taught. However, understanding how to 
perform this surgery competently is still crucial when faced with complications 
during phacoemulsification surgery, or when an ECCE approach may be a better 
choice for the patient.
Objective: By the conclusion of this course, the attendee will (1) have learned and 
be able to practice primary ECCE and SICS surgery, (2) have learned and be able to 
practice how to convert from a clear corneal phacoemulsification to either a ECCE 
or a SICS approach, and (3) better understand how to deal with complications of 
ECCE surgery.
Instructor(s): Geoffrey C Tabin MD, Maria Mendicino Aaron MD, Jeff H Pettey MD*
Labs
Synopsis: Although extracapsular cataract extractions by large incision (ECCE) 
and small incision (SICS) are still performed routinely throughout the world, phaco-
emulsification surgery has become the standard of care in many countries, and 
therefore ECCE/SICS is no longer being taught. However, understanding how to 
perform this surgery competently is still crucial when faced with complications 
during phacoemulsification surgery or when an ECCE approach may be a better 
choice for the patient.
Objective: By the conclusion of this course, the attendee will (1) have learned and 
be able to practice primary ECCE and SICS surgery, (2) have learned and be able to 
practice how to convert from a clear corneal phacoemulsification to either a ECCE 
or a SICS approach, and (3) better understand how to deal with complications of 
ECCE surgery.
Select one of the following
Course: LAB123A Monday, 10:30 AM - 12:00 PM
Room: 356 Target Audience: COMP
Fee: $280 EduLevel: BAS
Instructor(s): Bonnie A Henderson MD*, Eduardo C Alfonso MD*, Maria Mendicino 
Aaron MD, Geoffrey C Tabin MD, Preston H Blomquist MD, Jeff H Pettey MD*, 
Abhay Raghukant Vasavada MBBS FRCS*, Francisco J Gutierrez-Carmona MD PhD, 
Soosan Jacob FRCS, Amar Agarwal MD*, Dianna L Bordewick MD, Neera Kanjani, 
Surendra Basti MBBS*, Samar K Basak MD DNB MBBS*, Arup Chakrabarti MBBS, 
Nilesh Kanwarram Kanjani BMBS, Joung Y Kim MD, Zaiba Malik MD
Course: LAB123B Tuesday, 10:30 AM - 12:00 PM
Room: 356 Target Audience: COMP
Fee: $280 EduLevel: BAS
Instructor(s): Bonnie A Henderson MD*, Eduardo C Alfonso MD*, Maria Mendicino 
Aaron MD, Geoffrey C Tabin MD, Preston H Blomquist MD, Francisco J Gutierrez-
Carmona MD PhD, Abhay Raghukant Vasavada MBBS FRCS*, Jeff H Pettey MD*, 
Soosan Jacob FRCS, Amar Agarwal MD*, Dianna L Bordewick MD, Neera Kanjani, 
Surendra Basti MBBS*, Samar K Basak MD DNB MBBS*, Nilesh Kanwarram 
Kanjani BMBS, Arup Chakrabarti MBBS, Joung Y Kim MD, Zaiba Malik MD
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 YO  Astigmatism in the Cataract Patient
Course Director(s): Louis D Skip Nichamin MD*
Prerequisite Didactic
Course: LEC130 Monday, 10:15 AM - 12:30 PM
Room: 355 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course will cover management techniques for pre-existing astig-
matism, specifically at the time of implant surgery, with focus upon intralimbal 
relaxing incisions, toric IOLs, and laser (femto / excimer) treatment modalities.
Objective: At the conclusion of this course, participants will be able to plan and 
perform the techniques necessary to control postcataract astigmatism.
Instructor(s): Louis D Skip Nichamin MD*, Jonathan B Rubenstein MD*
Lab
Synopsis: This course will cover management techniques for pre-existing astig-
matism, specifically at the time of implant surgery, with focus upon intralimbal 
relaxing incisions, toric IOLs, and laser (femto / excimer) treatment modalities.
Objective: At the conclusion of this course, participants will be able to plan and 
perform the techniques necessary to control postcataract astigmatism.
Course: LAB130A Monday, 1:30 - 3:00 PM
Room: 345 Target Audience: COMPSUB
Fee: $230 EduLevel: INT
Instructor(s): Louis D Skip Nichamin MD*, Brock K Bakewell MD*, Rosa Braga-
Mele MD*, Y Ralph Chu MD*, Jonathan Davidorf MD*, Steven J Dell MD*, Randy 
J Epstein MD*, Leslie Grosinger MD, James C Hays MD*, Warren E Hill MD*, 
Richard S Hoffman MD*, Terry Kim MD*, Nick Mamalis MD*, Kevin M Miller MD*, 
Parag D Parekh MD MPA*, Gerald Roper MD*, Kenneth J Rosenthal MD FACS**, 
Alan Victor Spigelman MD, David T Vroman MD*, R Bruce Wallace MD*
An Innovative Approach to Iris Fixation of an IOL Without 
Capsular Support: Hands-on and Practical
Course Director(s): Paul R Rosenberg MD FACS
Course: LAB142 Monday, 4:00 - 5:00 PM
Room: 349 Target Audience: COMP
Fee: $65 EduLevel: INT
Synopsis: This course will present an innovative variation of a McCannel / Siep-
ser small-incision retrievable suture technique for peripheral iris fixation in the 
absence of capsule support for secondary foldable IOLs and dislocated IOLs. This 
technique will be demonstrated with video, animation, and hands-on practice with 
a model.
Objective: Surgeons will learn the rationale for iris fixation of a foldable implant 
and will add this technique to their arsenal of management options for IOL disloca-
tion and aphakia. Their understanding of the practical method of suturing will be 
cemented by a hands-on approach.
Instructor(s): Elana S Rosenberg MD
Microsurgical Suturing Techniques
Course Director(s): Marian Sue Macsai-Kaplan MD*
Prerequisite Didactic
Course: LEC144 Tuesday, 10:15 AM - 12:30 PM
Room: 340 Target Audience: COMPSUB
 EduLevel: BAS
Synopsis: This course will cover basic microsurgical suturing techniques. In addi-
tion, principles, theories, and practical instruction in corneal-scleral laceration and 
corneal wound repair, management of cataract wound problems, including wound 
burns, and extension of clear corneal incisions will be offered.
Objective: This course offers basic microsurgical suturing training that is appli-
cable in the management of penetrating keratoplasty suturing, corneal lacerations, 
and cataract wound problems.
Instructor(s): Marian Sue Macsai-Kaplan MD*, Woodford S Van Meter MD FACS
Lab
Synopsis: This course will cover basic microsurgical suturing techniques. In addi-
tion, principles, theories, and practical instruction in corneal-scleral laceration and 
corneal wound repair, management of cataract wound problems, including wound 
burns, and extension of clear corneal incisions will be offered.
Objective: This course will offer basic microsurgical suturing training that is appli-
cable in the management of penetrating keratoplasty suturing, corneal lacerations, 
and cataract wound problems.
Course: LAB144A Tuesday, 1:30 - 3:30 PM
Room: 345 Target Audience: COMPSUB
Fee: $210 EduLevel: BAS
Instructor(s): Marian Sue Macsai-Kaplan MD*, Woodford S Van Meter MD FACS, 
Andrew J W Huang MD MPH*, Carol L Karp MD, Anthony J Lubniewski MD*, Joel 
Sugar MD, Angelo P Tanna MD*, R Doyle Stulting MD PhD*, Anthony J Johnson 
MD, William Barry Lee MD*, Charles S Bouchard MD, David B Glasser MD, Aaleya 
F Koreishi MD*, Michael W Belin MD*, Andrea Kara-Jose MD, Ali R Djalilian MD, 
Bruno M Fontes MD*, Anat Galor MD*, Michael Saidel MD*, Satya Reddy MD, 
Julie H Tsai MD, Jennifer Y Li MD, Robert S Feder MD, Denise de Freitas MD,  
Jeanine Bagai MD
Computers, Information Technology
Computer Courses are open to all registrants. 
Note: Each participant must bring their own devices.
 EQUIP  The iPhone for Ophthalmologists (Basic)
Course Director(s): Vinay A Shah MD*
Course: LAB114 Sunday, 1:30 - 3:30 PM
Room: 350 Target Audience: COMPSUB
Fee: $120 EduLevel: BAS
Synopsis: Eighty percent of physicians utilize smartphones, and this number is 
expected to rise. Recently, the iPhone has covered about 50% of the smartphone 
market. This course will introduce the user to more intermediate applications of 
the iPhone and iPad in the following areas: (1) office management: calendar, ICD-9, 
schedules, (2) patient care tools: near vision card, Amsler grid, color plates, op-
tokinetic nystagmus drum, pupil gauge, patient consents, and external, slitlamp, 
and fundus photos, (3) patient education material: diagrams / videos, (4) physician 
education / reference material: eye atlas, study guides, pharmacopoeia, and board 
review material, (5) marketing of one’s practice through social media and a Person-
alized Doctor app, (6) use of the iPhone for personal use, from making a conference 
call to using various handy apps.
Objective: After the course, the attendees will understand and be able to use the 
iPhone for patient care, as a reference guide, for their own education, and to be 
more efficient.
Instructor(s): Ron K Lord MD*, Hemang K Pandya MD, Rohit Krishna MD*, Michael 
A Cassell MD**, Theodore Leng MD*, Robert T Chang MD*, Alex W Cohen MD
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 EQUIP  The iPhone for Ophthalmologists (Advanced)
Course Director(s): Vinay A Shah MD*
Course: LAB129 Monday, 9:00 - 11:00 AM
Room: 350 Target Audience: COMPSUB
Fee: $120 EduLevel: ADV
Synopsis: Eighty percent of physicians utilize smartphones, and this number is 
expected to rise. Recently, the iPhone has covered about 50% of the smartphone 
market. This course will introduce the user to intermediate to advanced applica-
tions of the iPhone & iPad in following areas: (1) office management: calendar, 
ICD-9, schedules, (2) patient care tools: near vision card, Amsler grid, color plates, 
optokinetic nystagmus drum, pupil gauge, patient consents, and external, slitlamp, 
and fundus photos, (3) patient education material: diagrams / videos, (4) physician 
education / reference material: eye atlas, study guides, pharmacopoeia, and board 
review material, (5) marketing of one’s practice through social media and a Person-
alized Doctor app, (6) use of the iPhone for personal use, from making a conference 
call to using various handy apps.
Objective: After the course, the attendees will have an advanced platform under-
standing and be able to use the iPhone for patient care, as a reference guide, for 
their own education, and to be more efficient.
Instructor(s): Ron K Lord MD*, Hemang K Pandya MD, Rohit Krishna MD*, Robert T 
Chang MD*, Michael A Cassell MD**, Theodore Leng MD*
 EQUIP   YO  Enhancing Your Presentation Using Keynote by 
Apple, Inc. for the Intermediate User
Course Director(s): Robert F Melendez MD MBA
Course: LAB133 Monday, 1:00 - 2:30 PM
Room: 350 Target Audience: COMPSUB
Fee: $95 EduLevel: INT
Synopsis: The purpose of this Skills Transfer course is to help enhance your key-
note presentations. This course is intended for intermediate users who already 
know how to use Keynote software (Apple, Inc.).
Objective: At the conclusion of this course, attendees will be able to incorporate 
video, audio, and special graphics into their slide presentations. They will learn 
how to build 3-D graphs and tables with special graphics, and how to build transi-
tion slides that flow nicely. We will also provide a list of third-party apps to en-
hance your presentations.
Instructor(s): Robert F Melendez MD MBA, John W Kitchens MD*, Andrew A 
Moshfeghi MD*
Cornea, External Disease
 W  Surgery for Severe Corneal and Ocular Surface Disease
Course Director(s): Ali R Djalilian MD, Gunther Grabner MD*
Prerequisite Didactic
Course: LEC104 Sunday, 9:00 - 11:15 AM
Room: 214 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course is intended for ophthalmologists who plan to expand their 
surgical skills in the management of severe corneal and ocular surface disease. 
The topics will include amniotic membrane transplantation, limbal stem cell trans-
plantations, and keratoprosthesis.
Objective: At the conclusion of this course, the attendee will be able to (1) de-
scribe the indications and apply the surgical techniques for amniotic membrane 
transplantation, (2) recognize limbal stem cell deficiency and effectively apply the 
various surgical techniques for limbal stem cell transplantation, (3) recognize and 
successfully prevent / treat limbal allograft rejection using systemic immunosup-
pression, and (4) describe the patient selection, surgical techniques, and postop-
erative management of patients with keratoprosthesis.
Instructor(s): Edward J Holland MD*, Scheffer C G Tseng MD PhD*, James Chodosh 
MD MPH*, Ahmad Kheirkhah MD, Maria S Cortina MD, Victor L Perez MD*
Lab
Synopsis: This course is intended for ophthalmologists who plan to expand their 
surgical skills in the management of severe corneal and ocular surface disease. 
The topics will include amniotic membrane transplantation, limbal stem cell trans-
plantations, and keratoprosthesis.
Objective: At the conclusion of this course, the attendee will be able to (1) de-
scribe the indications and apply the surgical techniques for amniotic membrane 
transplantation, (2) recognize limbal stem cell deficiency and effectively apply the 
various surgical techniques for limbal stem cell transplantation, (3) recognize and 
successfully prevent / treat limbal allograft rejection with the use of systemic im-
munosuppression, and (4) describe the patient selection, surgical techniques, and 
postoperative management of patients with keratoprosthesis.
Course: LAB104A Sunday, 3:30 - 5:30 PM
Room: 345 Target Audience: COMPSUB
Fee: $240 EduLevel: INT
Instructor(s): Ali R Djalilian MD, Andrew J W Huang MD MPH*, Jose Gomes MD*, 
Jose J de la Cruz Napoli MD*, Joung Y Kim MD, David D Verdier MD, Daniel H 
Scorsetti MD, Julie H Tsai MD, Heather M Skeens MD**, Pedram Hamrah MD*, 
Vadrevu K Raju MD FRCS FACS, Anthony J Lubniewski MD*, Ahmad Kheirkhah 
MD, Kristiana D Neff MD*, Clara C Chan MD*, Maria S Cortina MD, Aisha S Traish 
MD**, Andrea Y Ang MBBS, Guillermo Amescua MD, Leela V Raju MD, Victor L 
Perez MD*
Endothelial Keratoplasty Techniques
Course Director(s): Mark A Terry MD*
Prerequisite Didactic
Course: LEC121 Sunday, 3:15 - 5:30 PM
Room: 342 Target Audience: COMPSUB
 EduLevel: BAS
Synopsis: This course will explore the various surgical techniques used for en-
dothelial keratoplasty (EK): Descemet-stripping EK, Descemet-stripping automated 
EK, and Descemet membrane EK. Emphasis will be placed on basic techniques that 
minimize complications and maximize donor endothelial survival. Methods of donor 
tissue preparation, insertion, unfolding, and positioning will be discussed. Benefits 
and problems with tissue injectors will be presented. Techniques to promote donor 
tissue adhesion and to avoid primary graft failure will be emphasized. Detailed 
videos and discussion of EK in complex and combined cases will be presented.
Objective: At the conclusion of the course, participants will understand the safest 
methods of EK to avoid dislocation, primary graft failure, and pupillary block, and 
how to enhance faster visual rehabilitation.
Instructor(s): Mark A Terry MD*, Kenneth M Goins MD, George O D Rosenwasser 
MD*
Lab
Synopsis: This laboratory course will allow participants to become familiar with 
the instrumentation and surgical techniques involved with various forms of en-
dothelial keratoplasty (EK): Descemet-stripping EK, Descemet-stripping automated 
EK, and Descemet membrane EK. Use of the femtosecond laser for donor prepara-
tion may be available. Safe methods of donor insertion, unfolding, and positioning 
will be stressed. Techniques of promoting donor adherence and avoiding primary 
graft failure will be practiced.
Objective: At the conclusion of this course, the participants will understand the 
complexity and required instrumentation for these various techniques of endothe-
103
 Skills Transfer Program
Skills Transfer Program
 NEW  New Course.   R  Lab for Residents only.   SO  = Endorsed by Senior Ophthalmologist Committee.   YO  = Endorsed by Young Ophthalmologist Committee.  EQUIP  = Participants are 
required to bring specific equipment to the course.  W  = Participants are required to sign an infectious disease transmission waiver/release form.  Education Level Key: BAS = Basic, INT = 
Intermediate, ADV = Advanced. Target Audience: COMP = Comprehensive Ophthalmologist, SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist. 
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date. No asterisk indicates that the presenter has no financial interest.
lial keratoplasty. Techniques to avoid complications and preserve donor endothelial 
cells will be understood. 
Note: Participants will be sharing equipment.
Course: LAB121A Monday, 8:00 - 10:00 AM
Room: 345 Target Audience: COMPSUB
Fee: $240 EduLevel: BAS
Instructor(s): Mark A Terry MD*, George O D Rosenwasser MD*, Kenneth M Goins 
MD, Neda Shamie MD*, Anand K Shah MD, Irving M Raber MD*, Paul M Phillips 
MD, David D Verdier MD, Mark S Gorovoy MD, Edwin S Chen MD, Thomas John 
MD*, Ann McColgin MD, Robert L Schultze MD*, Michael D Straiko MD*, Mark 
Greiner MD, Jeffrey M Goshe MD, Julia C Talajic MD, Peter B Veldman MD, Col-
leen C Grace MD, Jennifer Y Li MD, Rajesh Fogla MD FRCS*, Luciene Sousa MD*, 
Karen L Hoar MD**, Ashraf F Amayem MD, Anita Panda MD FAMS FICS FICO 
MRCOPHTH**, Alexandre S Marcon MD, Vincenzo Sarnicola MD
 W  Endothelial Keratoplasty Surgery: Comprehensive 
Overview and Surgical Pearls
Course Director(s): Edward J Holland MD*
Prerequisite Didactic
Course: LEC122 Sunday, 3:15 - 5:30 PM
Room: 208 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: Endothelial keratoplasty (EK) has become the standard of care for the 
surgical treatment of endothelial diseases of the cornea. This course will utilize 
international corneal experts to teach a comprehensive overview of a variety of 
surgical techniques for Descemet-stripping EK (DSEK), including donor tissue prep-
aration, various tissue insertion techniques, and intraoperative surgical pearls. The 
course will also provide a review of the various potential complications of DSEK 
and their associated management strategies. Finally, tips for starting Descemet 
membrane EK (DMEK) will be reviewed, along with various surgical pearls and 
outcomes of DMEK techniques.
Objective: At the conclusion of the course, the attendee will understand indica-
tions, surgical techniques, surgical pearls, and potential complications of DSEK 
and DMEK.
Instructor(s): Francis W Price Jr MD*, Donald Tan MD FRCS FRCOphth*, Massimo 
Busin MD*, Mark J Mannis MD, David T Vroman MD*, William Barry Lee MD*, 
Keith A Walter MD*
Lab
Synopsis: Endothelial keratoplasty (EK) has become the standard of care for the 
surgical treatment of endothelial diseases of the cornea. This course will utilize 
international corneal experts to teach the various steps of Descemet-stripping EK 
(DSEK), including donor tissue preparation and specific surgical steps, with indi-
vidual stations to practice various tissue insertion techniques. Surgical videos of 
DSEK insertion techniques and surgical pearls will be reviewed during the course 
to enhance performance of various steps. Attendees will receive hands-on experi-
ence with all steps of DSEK, including donor tissue preparation steps with Des-
cemet membrane EK (DMEK).
Objective: At the end of this course, participants will understand all steps of 
DSEK and have hands-on experience with donor tissue preparation and surgical 
steps of DSEK and DMEK.
Course: LAB122A Monday, 11:00 AM - 1:00 PM
Room: 345 Target Audience: COMPSUB
Fee: $240 EduLevel: INT
Instructor(s): Francis W Price Jr MD*, Friedrich E Kruse MD, Donald Tan MD FRCS 
FRCOphth*, David B Glasser MD, Massimo Busin MD*, Mark J Mannis MD, David 
T Vroman MD*, William Barry Lee MD*, Keith A Walter MD*, David D Verdier MD, 
Shahzad I Mian MD*, Richard S Davidson MD*, Clara C Chan MD*, Andrea Y Ang 
MBBS, Kristiana D Neff MD*, Heather M Skeens MD**, Mahshad Darvish-Zargar 
MD, Jennifer Y Li MD, J Brian Foster MD**, Kenneth C Mathys MD, Joseph S Tims 
MD, Florentino E Palmon MD, Michael J Taravella MD*, Vipul C Shah MD, Charles 
L Thompson MD
Anterior Lamellar Keratoplasty: Principles and Practice
Course Director(s): Sheraz M Daya MD*, Sadeer B Hannush MD
Prerequisite Didactic
Course: LEC131 Monday, 10:15 AM - 12:30 PM
Room: 342 Target Audience: SUB
 EduLevel: ADV
Synopsis: This course will cover current and evolving practice in anterior lamellar 
keratoplasty. Topics include evolving lamellar techniques, including the “big bub-
ble,” modified Melles, viscodissection, Ferrara, and automated and femtosecond 
lamellar techniques. A series of didactic lectures will be provided, with technique 
pearls (and complications), supported by video presentations and handouts. The 
lecture portion is a prerequisite for the wet lab, where candidates will be guided 
through many techniques.
Objective: The participant should leave the course with an understanding of vari-
ous options for performing anterior lamellar keratoplasty. The participant will have 
a thorough understanding of the indications, advantages, and disadvantages of 
each of these techniques. Additional hands-on training on the use of some of these 
procedures will be provided in the associated laboratory.
Instructor(s): Woodford S Van Meter MD FACS, William W Culbertson MD*, Luigi 
Fontana MD PhD, Shigeto Shimmura MD, Donald Tan MD FRCS FRCOphth*
Lab
Synopsis: This wet-lab course will cover current and evolving practice in anterior 
lamellar keratoplasty. An international faculty will cover different lamellar dissec-
tion techniques and will include the “big bubble,” viscodissection, modified Melles, 
and automated and femtosecond lamellar deep anterior lamellar keratoplasty. 
Avoiding and managing complications will also be discussed. Candidates will be 
personally guided through these techniques by expert and experienced faculty, and 
there will be opportunity for in-depth discussion.
Objective: The participant should leave the course with an understanding of vari-
ous options for performing anterior lamellar keratoplasty. The participant will have 
a thorough understanding of the indications, advantages, and disadvantages of 
each of these techniques. Additional hands-on training on the use of some of these 
procedures will be provided in the associated laboratory.
Course: LAB131A Monday, 3:30 - 5:30 PM
Room: 345 Target Audience: SUB
Fee: $240 EduLevel: ADV
Instructor(s): Sadeer B Hannush MD, Sheraz M Daya MD*, Woodford S Van Meter 
MD FACS, William W Culbertson MD*, Luigi Fontana MD PhD, Shigeto Shimmura 
MD, Donald Tan MD FRCS FRCOphth*, Brandon Ayres MD*, Deepinder K Dhaliwal 
MD*, Jose Gomes MD*, Nabil E Habib FRCOphth*, Samer Hamada MD, Damian 
Lake MBChB, Mayank A Nanavaty MD, Rebecca Papadopoulos MD, Irving M Raber 
MD*, Konstantinos Samaras MD, Vincenzo Sarnicola MD, Mike Tappin FRCOphth**, 
Elmer Tu MD*, Federico Badala MD, Rajesh Fogla MD FRCS*, Hamed Mofeez 
Anwar MD, Francesca Harman MBBS**
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Glaucoma
Is It Time to Replace Gonioscopy by Anterior Segment 
Imaging in the Diagnosis and Management of Angle-
Closure Glaucoma?
Course Director(s): Syril Dorairaj MD
Course: LAB101 Sunday, 9:00 - 11:00 AM
Room: 343 Target Audience: COMPSUB
Fee: $130 EduLevel: BAS
Synopsis: Angle-closure glaucomas (ACGs) are a group of disorders characterized 
by mechanical blockage of the trabecular meshwork by the peripheral iris, result-
ing from interactions between the structures and hydrodynamics inside the eye. 
Imaging of the anterior segment (AS) is an essential tool aiding the diagnosis and 
understanding the mechanism and management of ACG. Various imaging devices 
are now available, each one representing particular technical advantages / dis-
advantages over the others. Anterior segment imaging cannot replace the direct 
visualization of angle structures, but it can overcome some of the limitations of 
gonioscopy by providing a more objective means of obtaining a qualitative and 
quantitative evaluation of the angle. These imaging techniques are enlightening 
clinicians and researchers about the importance of making an early diagnosis, es-
tablishing underlying causal mechanisms, and evaluating treatments.
Objective: The participant should leave the course with an understanding of im-
aging techniques, the importance of making an early diagnosis, establishing under-
lying causal mechanisms, and evaluating treatments.
Instructor(s): Christopher Kai-shun Leung MD MBChB*, Vishal Jhanji MBBS, Paul F 
Palmberg MD PhD*, Clement C Y Tham MBBS*, Tin Aung FRCS PhD*
Computerized Scanning Imaging of the Optic Nerve and 
Retinal Nerve Fiber Layer
Course Director(s): Neil T Choplin MD
Prerequisite Didactic
Course: LEC103 Sunday, 9:00 - 11:15 AM
Room: 225 Target Audience: COMP
 EduLevel: BAS
Synopsis: This lecture, required for the hands-on workshop, introduces the par-
ticipant to the principles of computerized scanning imaging. This is a basic course 
featuring current technologies. The main emphasis in this course will be spectral 
(Fourier) domain OCT, although some discussion of scanning laser polarimetry and 
topography (Heidelberg Retinal Tomography) will be included.
Objective: By the conclusion of this course, participants will be able to (1) un-
derstand the scientific basis for imaging, (2) understand how scanning imaging 
may be used in clinical practice, (3) learn how imaging can be applied to the optic 
nerve head, retinal nerve fiber layer, and macula, with emphasis on glaucoma, (4) 
understand the relationship between structure and function, and (5) differentiate 
normal from abnormal scans through appropriate clinical examples. A question-
and-answer session will be held at the end of the presentations, during which time 
questions will be entertained by the faculty.
Instructor(s): Neil T Choplin MD, E Randy Craven MD*, Howard Barnebey MD*
Labs
Synopsis: This workshop will familiarize participants with the clinical uses of 
computerized scanning imaging of the retina and optic nerve, with emphasis on 
spectral (Fourier) domain OCT. The main focus of the workshop will be interpreta-
tion of representative printouts from clinical examples. Instructors will be available 
to discuss scanning laser polarimetry (GDx) and confocal scanning tomography 
(Heidelberg Retinal Tomography) for interested participants.
Objective: By the conclusion of this course, participants will be able to (1) under-
stand image quality control and the indications for repeating images, (2) become 
familiar with the analysis software, and (3) practice interpretation of representa-
tive cases.
Select one of the following
Course: LAB103A Sunday, 12:00 - 2:00 PM
Room: 343 Target Audience: COMP
Fee: $130 EduLevel: BAS
Instructor(s): Neil T Choplin MD, E Randy Craven MD*, Howard Barnebey MD*
Course: LAB103B Monday, 11:00 AM - 1:00 PM
Room: 343 Target Audience: COMP
Fee: $130 EduLevel: BAS
Instructor(s): Neil T Choplin MD, E Randy Craven MD*, Howard Barnebey MD*
Glaucoma Laser Therapy: Innovations and Advice From 
the Experts
Course Director(s): Lisa S Gamell MD
Prerequisite Didactic
Course: LEC105 Sunday, 9:00 - 11:15 AM
Room: R03 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course will provide a comprehensive review of laser procedures 
used to treat glaucoma. Topics discussed will include argon laser trabeculoplasty 
(ALT), selective laser trabeculoplasty (SLT), micropulse laser trabeculoplasty (MLT), 
cyclophotocoagulation (both endoscopic and transscleral), iridotomy (Nd:YAG, 
argon, and diode), iridoplasty, and laser suture lysis. Indications, treatment tech-
niques, and postoperative care will be discussed in detail during the didactic por-
tion of the course. During the laboratory section, participants will have the opportu-
nity to perform endoscopic cyclophotocoagulation, transscleral cyclophotocoagula-
tion, SLT, ALT, MLT, and iridotomies under the supervision of the course instructors.
Objective: At the conclusion of this course, attendees will be able to understand 
the indications and techniques for the various laser therapies used in the treatment 
of glaucoma. After the laboratory section, they will have hands-on experience us-
ing these modalities on animal eyes.
Instructor(s): Robert J Noecker MD*, Joel S Schuman MD*, Jorge A Alvarado MD, 
Mark A Latina MD*, Malik Y Kahook MD*, Brian E Flowers MD*
Lab
Synopsis: This course will provide a comprehensive review of laser procedures 
used in the treatment of glaucoma. Topics discussed will include argon laser tra-
beculoplasty (ALT), selective laser trabeculoplasty (SLT), micropulse laser trabecu-
loplasty (MLT), cyclophotocoagulation (both endoscopic and transscleral), iridotomy 
(Nd:YAG, argon, diode, and krypton), and iridoplasty. Laser enhancement of filtering 
procedures will be covered as well, including laser suture lysis and bleb revision. 
During the laboratory section, participants will have the opportunity to perform 
endoscopic cyclophotocoagulation, transscleral cyclophotocoagulation, SLT, ALT, 
MLT, and iridotomies under the supervision of the course instructors.
Objective: At the conclusion of this course, attendees will be able to understand 
the indications and techniques for the various laser therapies used in the treatment 
of glaucoma. After the laboratory section, they will have hands-on experience us-
ing these modalities on animal eyes. 
Note: Participants will be sharing equipment.
Course: LAB105A Sunday, 12:30 - 2:30 PM
Room: 354 Target Audience: COMPSUB
Fee: $240 EduLevel: INT
Instructor(s): Robert J Noecker MD*, Joel S Schuman MD*, Jorge A Alvarado MD, 
Mark A Latina MD*, Malik Y Kahook MD*, Brian E Flowers MD*, Martin Uram 
MD*
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 W  Trabeculotomy by Internal Approach Surgery for Adult 
Open-Angle Glaucoma
Course Director(s): Brian A Francis MD*
Prerequisite Didactic
Course: LEC119 Sunday, 3:15 - 5:30 PM
Room: 340 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course will cover the Trabectome, an FDA-cleared instrument for 
angle-based surgery for open-angle glaucoma via an internal approach. The didac-
tic part of the course will describe accumulated data from an ongoing case series 
(over 5000 eyes), published data, and comparative trials with cataract surgery 
alone, trabeculectomy, and aqueous tube shunt. Indications, surgical technique, 
IOP outcomes, and complications will be described during a one-hour didactic 
course. Surgical tips including proper identification of angle structures using the 
gonioscopic approach will be emphasized. This may also be followed by a hands-on 
lab session using inverted corneal donor rings for practice.
Objective: At the conclusion of the course, attendees will understand the indica-
tions, surgical technique, IOP outcomes, and complications associated with this 
device.
Instructor(s): Sameh Mosaed MD*, Nils A Loewen MD*
Labs
Synopsis: During a one-hour lab session, attendees will practice with a Trabec-
tome console and handpiece, with adjustable power level and foot-pedal control, 
and a tissue model consisting of an inverted human corneal ring, including the 
trabecular meshwork. The corneal donor ring will be pin-fixated to a rubber holding 
device and submerged in BSS. Practice surgery will be done via an operating micro-
scope, enabling a realistic view of the instrument effects as the Schlemm canal is 
unroofed by electroablation. Simultaneous video illustrating the gonioscopic view 
and live surgeries will also be presented.
Objective: At the course conclusion, attendees will have had a realistic exposure 
to the surgical technique and one-on-one discussion of the advantages and disad-
vantages of the Trabectome procedure.
Select one of the following
Course: LAB119A Monday, 7:30 - 8:30 AM
Room: 354 Target Audience: COMPSUB
Fee: $165 EduLevel: INT
Instructor(s): Donald S Minckler MD*, Sameh Mosaed MD*, Quang H Nguyen 
MD*, Douglas J Rhee MD*, Paul A Sidoti MD, George Baerveldt MD*, Arthur J Sit 
MD*, Michael C Stiles MD*, Steven D Vold MD*, Martha Motuz Leen MD*, Ma-
rina A Ramirez MD**, Edward M Barnett MD PhD**, Troy M Tanji MD, Mitsunori 
Watanabe MD**, Masahiro Maeda MD
Course: LAB119B Monday, 9:00 - 10:00 AM
Room: 354 Target Audience: COMPSUB
Fee: $165 EduLevel: INT
Instructor(s): George Baerveldt MD*, Carla J Siegfried MD*, Douglas J Rhee MD*, 
Martha Motuz Leen MD*, Donald S Minckler MD*, Paul A Sidoti MD, Quang H 
Nguyen MD*, Sameh Mosaed MD*, Arthur J Sit MD*, Masahiro Maeda MD
Glaucoma Filtration Surgery
Course Director(s): Steven L Mansberger MD*
Prerequisite Didactic
Course: LEC124 Sunday, 3:15 - 5:30 PM
Room: 335 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course provides a comprehensive review of the techniques and 
complications of glaucoma filtration surgery. Glaucoma surgical technique will be 
stressed in this update of filtration surgery, with a heavy emphasis on surgical 
video presentations. The course will also discuss novel surgical techniques used in 
filtration surgery, such as Ex-PRESS shunts, as compared to conventional surgery. A 
panel discussion with questions and answers will conclude the session.
Objective: This course will review surgical anatomy, basic trabeculectomy tech-
niques, antimetabolites (including 5-fluorouracil and mitomycin C), and postopera-
tive management and complications.
Instructor(s): George A Cioffi MD, Jeffrey M Liebmann MD*, F Jane Durcan MD, 
Robert D Fechtner MD FACS*, Kuldev Singh MD MPH*, George A Cioffi MD, Celso 
Tello MD*
Labs
Synopsis: This Skills Transfer course will offer hands-on instruction on glaucoma 
filtration surgery, specifically for the general ophthalmologist. The lab session will 
provide experience with the techniques of trabeculectomy.
Objective: Using porcine eyes and dissection microscopes (one per student), glau-
coma surgical techniques will be performed. Surgical anatomy, scleral flap dissec-
tion, fistula creation, iridectomy, and closure techniques will be performed.
Select one of the following
Course: LAB124A Monday, 11:00 AM - 12:30 PM
Room: 354 Target Audience: COMPSUB
Fee: $190 EduLevel: INT
Senior Instructor(s): John C Morrison MD
Instructor(s): Young H Kwon MD PhD*, Paul A Sidoti MD, Frank J Mares MD, 
Michael R Banitt MD*, Christopher J Engelman MD, Steven D Vold MD*, Tak Yee 
Tania Tai MD, George A Cioffi MD, Mansi Parikh MD
 R   W  Glaucoma Surgical Lab for Ophthalmology Residents
Course: LAB124B Monday, 4:00 - 5:30 PM
Room: 354 Target Audience: COMP
Fee: $100 EduLevel: BAS
Note: MIT discount already applied.
Senior Instructor(s): Thomas W Samuelson MD*
Instructor(s): Thomas W Samuelson MD*, Iqbal K Ahmed MD*, George L Spaeth 
MD FACS*, Mark B Sherwood MD*, Michael C Stiles MD*, Leslie S Jones MD*, 
Jonathan S Myers MD*, James D Brandt MD*, Martha M Wright MD, Garry P 
Condon MD*, Julia Whiteside-de Vos MD MPH*, Richard Lee MD*, Steven Gedde 
MD*, J Brent Bond MD*, Robert P Liss MD, Husam Ansari MD PhD*, Amy W Gem-
perli MD, Davinder S Grover MD*, Christine L Larsen MD, Nathan M Radcliffe MD*
 W  Schlemm Canal Surgery
Course Director(s): Richard A Lehrer MD*
Prerequisite Didactic
Course: LEC125 Sunday, 3:15 - 5:30 PM
Room: 214 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: Early results of nonpenetrating glaucoma surgery, an alternative ap-
proach in glaucoma filtering surgery, have shown comparable results to other 
methods, with a reduction in overall complications. Yet this technique has a learn-
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ing curve, with its own set of unique challenges. This course will present a system-
atic, multimedia, video-assisted review of the anatomy, rationale, explanation, and 
illustration of canaloplasty.
Objective: This course will explain (1) the procedure’s method of re-establishing 
aqueous outflow, (2) the procedure’s advantages, disadvantages, risks, and ben-
efits, and (3) the identification of glaucomas where the procedure would have high-
est probability of success. Recent clinical results and innovations to enhance the 
procedure will also be discussed.
Instructor(s): Richard A Lehrer MD*, Iqbal K Ahmed MD*, Alan S Crandall MD*, 
Robert Stegmann MD**, Clive O Peckar MD*, Howard Barnebey MD*, John R 
Kearney MD
Lab
Synopsis: This course will demonstrate and train attendees in the procedure of 
viscodilation of the Schlemm canal. Attendees will be mentored in the procedure, 
with microscopic dissection and catheter and tension suture placement in the Sch-
lemm canal.
Objective: At the conclusion of this course, the attendees should have a good 
understanding of and hands-on ability to perform this procedure, from the insertion 
of the microcatheter through placement of the suture invaginating the trabecular 
meshwork. 
Note: Attendees should have experience with nonpenetrating glaucoma 
surgery.
Course: LAB125A Monday, 1:30 - 3:30 PM
Room: 354 Target Audience: COMPSUB
Fee: $240 EduLevel: INT
Senior Instructor(s): Richard A Lehrer MD*, Iqbal K Ahmed MD*
Instructor(s): Alan S Crandall MD*, Clive O Peckar MD*, Robert Stegmann MD**, 
Howard Barnebey MD*, John R Kearney MD, Robert P Liss MD, Baseer U Khan 
MD*, Sebastien Gagne MD**
Computerized Perimetry Lecture: Visual Field Testing and 
Interpretation, Emphasizing Glaucoma
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and 
the American Glaucoma Society (AGS)
Course Director(s): Julia Whiteside-de Vos MD MPH*
Prerequisite Didactic
Course: LEC132 Monday, 10:15 AM - 12:30 PM
Room: 335 Target Audience: COMP
 EduLevel: BAS
Synopsis: This lecture reviews computerized perimetry, emphasizing glaucoma 
and the Humphrey field analyzer. Topics will include the stepwise interpretation 
of individual visual fields (VFs), the significance of each portion of the VF printout, 
determining if the VF is reliable and if it is normal or abnormal, tips for obtaining 
a more reliable VF and for selecting the appropriate test, SITA, SWAP, frequency 
doubling perimetry, and the analysis of a series of VFs for progression. Numerous, 
mostly glaucomatous, case examples will be used.
Objective: This course will provide participants with the background knowledge 
necessary to be more comfortable with visual field interpretation and to be pre-
pared for the separate laboratory session.
Instructor(s): Julia Whiteside-de Vos MD MPH*, Todd W Perkins MD* 
Lab
Synopsis: This lab will prepare clinicians to interpret computerized visual fields 
(VFs) and use them more effectively in the diagnosis and management of glaucoma 
patients. The first 30 minutes of the lab will be devoted to a lecture regarding Oc-
topus perimetry. Subsequently, participants will practice interpreting Humphrey or 
Octopus unknown VFs under the guidance of an experienced instructor. Examples 
will include individual VFs and series of VFs for progression evaluation, using event 
and trend progression analysis methods corresponding to the type of perimeter the 
participant has chosen for concentration.
Objective: This course is designed to enable participants to master the skills nec-
essary for interpreting automated VFs and for using them in the management of 
glaucoma patients.
Course: LAB132A Monday, 2:00 - 4:00 PM
Room: 343 Target Audience: COMP
Fee: $130 EduLevel: BAS
Instructor(s): Jonathan S Myers MD*, E Randy Craven MD*, Anand V Mantravadi 
MD*, Todd W Perkins MD*, Jeffrey S Schultz MD*, David E Silverstone MD, 
Martha M Wright MD
Implantation of Glaucoma Drainage Devices
Course Director(s): Richard P Mills MD MPH
Prerequisite Didactic
Course: LEC137 Monday, 2:00 - 4:15 PM
Room: 342 Target Audience: COMPSUB
 EduLevel: BAS
Synopsis: The first part of this course is didactic, covering the indications, patho-
physiology, surgical technique, postoperative management, and complications of 
drainage devices (from anterior chamber tube to extraocular reservoir). The second 
part is hands-on, with implantation of Molteno, Krupin, Baerveldt, Ahmed, and 
Schocket devices on porcine eyes. Ex-PRESS shunt, Trabectome, and canaloplasty 
will not be covered.
Objective: At the conclusion of this course, the attendee will be aware of prin-
ciples and techniques of glaucoma drainage device implantation.
Instructor(s): Ronald Leigh Fellman MD OCS*, George Baerveldt MD*, Anne Louise 
Coleman MD PhD*, Frederick M Kapetansky MD, Donald L Budenz MD MPH*, Paul 
A Sidoti MD, Angelo P Tanna MD*
Lab
Synopsis: The first part of this course is didactic, covering the indications, patho-
physiology, surgical technique, postoperative management, and complications of 
drainage devices (from anterior chamber tube to extraocular reservoir). The second 
part is hands-on, with implantation of Molteno, Krupin, Baerveldt, Ahmed, and 
Schocket devices on porcine eyes. Ex-PRESS shunt, Trabectome, and canaloplasty 
will not be covered.
Objective: By the conclusion of this course, attendees will be able to complete a 
drainage device implantation in a fresh tissue eye.
Course: LAB137A Tuesday, 8:00 - 10:00 AM
Room: 354 Target Audience: COMPSUB
Fee: $240 EduLevel: BAS
Instructor(s): Ronald Leigh Fellman MD OCS*, Mark S Juzych MD**, Paul A Sidoti 
MD, Martha Motuz Leen MD*, Alfred M Solish MD*, Keith Barton MD*, Frederick 
M Kapetansky MD, Howard Barnebey MD*, Eugenio J Maul MD, Margaret Sophia 
Spencer MD, Marianne E Feitl MD, Simon K Law MD*, Joern B Soltau MD*, 
Steven Gedde MD*, Sameh Mosaed MD*, JoAnn A Giaconi MD*
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Neuro-Ophthalmology
Neuroimaging in Ophthalmology
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and 
the North American Neuro-Ophthalmology Society (NANOS)
Course Director(s): Christopher C Glisson DO*
Course: LAB127 Monday, 8:00 - 10:00 AM
Room: 343 Target Audience: COMPSUB
Fee: $130 EduLevel: INT
Synopsis: This review of CT and MRI scans of the head and orbit will improve par-
ticipants’ knowledge of anatomy and imaging analysis using illustrative cases. The 
course will be supervised by experienced neuro-ophthalmologists and will employ 
a hands-on format. Through detailed discussion and review of cases and related 
films, participants will gain knowledge to enhance skills used when ordering and 
interpreting imaging.
Objective: Participants will recognize normal and pathologic structures on CT and 
MRI scans, and become proficient at reviewing neuroimaging studies and recogniz-
ing the indications for ordering various types of imaging.
Instructor(s): Michael S Vaphiades DO, Eric Eggenberger DO*, Eric L Berman MD, 
Jade Schiffman MD, Larry P Frohman MD*, Jacqueline A Leavitt MD, Michael C 
Brodsky MD**, Nicholas J Volpe MD*, Rosa A Tang MD*, Julie Falardeau MD, 
John Pula MD**, Melissa W Ko MD**, Roger E Turbin MD, Fiona E Costello MD*
Optics, Refraction, Contact Lenses
 EQUIP  Soft Contact Lens Fitting for the Practicing 
Ophthalmologist
Contact Lens Association of Ophthalmologists (CLAO)
Course Director(s): Peter C Donshik MD*, William H Ehlers MD
Course: LAB107 Sunday, 9:30 AM - 12:00 PM
Room: 350 Target Audience: COMP
Fee: $120 EduLevel: BAS
Synopsis: To appropriately utilize contact lenses in practice, the Eye M.D. needs 
to recognize suitable candidates, select the most appropriate lens, and know how 
to fit and evaluate the contact lens. This course is for Eye M.D.s who want to add 
or expand soft contact lens fitting in their practices. The learning format includes 
PowerPoint presentations, videos, and interactive computer simulations to demon-
strate and teach soft contact lens fitting skills. The attendee will utilize computer 
simulation to place and evaluate multiple soft contact lens fittings. Individual as-
sistance will be available to attendees during the computer simulation training.
Objective: This course will teach the practitioner (1) recognition of suitable can-
didates, (2) appropriate soft lens selection, (3) soft spherical and toric lens fitting, 
and (4) patient and practice management.
Note: Each participant is required to bring their own PC laptop or MAC com-
puter to the course, and computers must be able to load CDs. Windows XP, 
Windows Vista, or Windows 7 is required.
Instructor(s): Melvin I Freeman MD FACS*, William T Driebe MD, Zoraida Fiol-Silva 
MD*, Michael H Goldstein MD*, Jeanine Suchecki MD, Bruce Koffler MD*, Peter R 
Kastl MD PhD, John S Massare PhD, William H Ehlers MD
Orbit, Lacrimal, Plastic Surgery
 YO  Basic Oculoplastic Surgery
Course Director(s): Eve E Moscato MD
Course: LAB100 Sunday, 8:00 - 10:30 AM
Room: 349 Target Audience: COMP
Fee: $245 EduLevel: BAS
Synopsis: This course is designed to refresh the ophthalmologist’s basic oculo-
plastics skills in a laboratory setting (employing porcine specimens), while simul-
taneously reviewing the fundamentals of ophthalmic plastic and reconstructive 
surgery knowledge. The basic principles involved in choosing suture materials 
and types of suture needle for various oculoplastics procedures will be reviewed. 
Surgical positioning and instrumentation will be touched upon as the course par-
ticipants perform various surgical techniques employed in ophthalmic plastic and 
reconstructive surgery, with instructor assistance.
Objective: To provide participants with an opportunity to hone surgical skills that 
are employed in basic oculoplastics procedures such as eyelid lesion removal, eye-
lid margin lesion resection and reconstruction, eyelid laceration repair, ectropion 
repair, and blepharoplasty. A very basic introduction to ptosis repair will also be 
presented.
Instructor(s): Christopher I Zoumalan MD, Raymond I Cho MD, Parag D Gandhi 
MD, Alice Song MD, Julia Song MD, Jennifer Trew Scruggs MD, Edward Wladis 
MD*, Harmeet S Gill MD, Keshini C Parbhu MD, Bryan J Winn MD, Sarit M Patel 
MD, Carrie L Morris MD, Amy M Fowler MD, Louis Savar MD, Ami Ashvin Shah 
MD, Michael Kangwhi Yoon MD, Lyndon B Lee MD**, Jill S Melicher Larson MD, 
Elizabeth M Palkovacs MD
 EQUIP   W  Cosmetic Botulinum Toxin and Facial Fillers: An 
Introductory Course
Course Director(s): Kathleen M Duerksen MD
Prerequisite Didactic
Course: LEC111 Sunday, 10:15 AM - 12:30 PM
Room: 338 Target Audience: COMPSUB
 EduLevel: BAS
Synopsis: Principles of aesthetic facial injection of botulinum toxin and facial fill-
ers will be presented in a didactic format.
Objective: At the conclusion of this course, the attendee will better understand 
the salient anatomy, clinical techniques (including complication avoidance), and 
pharmacological principles pertaining to aesthetic injection of these substances.
Instructor(s): Michael S McCracken MD, Deborah D Sherman MD*, John Joseph 
Martin MD*
Lab
Synopsis: Taught by experienced instructors, the lab provides hands-on, personal-
ized instruction in the basics of botulinum toxin and facial filler injections utilizing 
cadaver heads.
Objective: At the completion of the lab, the participant will be able to identify 
the proper sites, doses, and indications for injection of botulinum toxin and facial 
fillers. The participant will demonstrate proper injection technique with the goal of 
avoiding technique-related complications.
Note: Participants are required to bring surgical loupes.
Course: LAB111A Sunday, 1:30 - 3:00 PM
Room: 352 Target Audience: COMPSUB
Fee: $305 EduLevel: BAS
Instructor(s): Michael S McCracken MD, Deborah D Sherman MD*, Cat Burkat 
MD, Christopher M DeBacker MD, Jeffrey P Edelstein MD*, Craig Erwin Geist MD, 
Ioannis P Glavas MD, Morris E Hartstein MD, Ronald W Kristan MD, John Joseph 
Martin MD*, Dale R Meyer MD FACS, Gary Borodic MD*, Rona Z Silkiss MD FACS, 
108
 Skills Transfer Program
Sk
ill
s 
Tr
an
sf
er
 P
ro
gr
am
 NEW  New Course.   R  Lab for Residents only.   SO  = Endorsed by Senior Ophthalmologist Committee.   YO  = Endorsed by Young Ophthalmologist Committee.  EQUIP  = Participants are required 
to bring specific equipment to the course.  W  = Participants are required to sign an infectious disease transmission waiver/release form.  Education Level Key: BAS = Basic, INT = Intermediate, 
ADV = Advanced. Target Audience: COMP = Comprehensive Ophthalmologist, SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist. 
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date. No asterisk indicates that the presenter has no financial interest.
Charles B Slonim MD FACS*, Julie A Woodward MD*, Jane J Olson MD, Dawn C 
Buckingham MD, Kenneth David Steinsapir MD*, Asa Dan Morton III MD*, Fred S 
Bodker MD
 EQUIP   W  Fundamental Facelifting Techniques
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee 
and the American Society of Ophthalmic Plastic & Reconstructive Surgery 
(ASOPRS)
Course Director(s): Brett S Kotlus MD
Prerequisite Didactic
Course: LEC112 Sunday, 10:15 AM - 12:30 PM
Room: 215 Target Audience: SUB
 EduLevel: INT
Synopsis: This basic course will consist of a step-by-step slide and video presen-
tation of a preoperative assessment, surgical facial anatomy, fundamental facelift-
ing techniques, postoperative care, and potential complications. A downloadable 
course manual will be available to participants.
Objective: Participants will acquire the ability to select appropriate patients, de-
velop hands-on familiarity with facial surgical anatomy, perform safe surgical dis-
section, provide appropriate postoperative care, and integrate facelifting into their 
aesthetic oculofacial practice.
Instructor(s): Tanuj Nakra MD, Robert M Schwarcz MD*, Bobby S Korn MD PhD 
FACS*
Lab
Synopsis: Step-by-step cadaver dissection will demonstrate surgical anatomy, 
safe surgical planes, and fundamental facelifting techniques, including cervical-
mental restoration, flap and skin redraping, drain placement, and skin closure.
Objective: Participants will acquire hands-on familiarity with the surgical anato-
my and basic facelifting techniques so they will be able to incorporate facelifting 
procedures into their aesthetic practices.
Note: Participants are required to bring surgical loupes.
Course: LAB112A Monday, 11:00 AM - 1:00 PM
Room: 352 Target Audience: SUB
Fee: $410 EduLevel: INT
Instructor(s): Bobby S Korn MD PhD FACS*, Robert M Schwarcz MD*, Tanuj Nakra 
MD, David E Holck MD, Joel Kopelman MD**, Stuart R Seiff MD, Allan E Wulc 
MD FACS*, Roger A Dailey MD*, Kevin Ira Perman MD, Kenneth David Steinsapir 
MD*, Susan M Hughes MD FACS**, Kathleen M Duerksen MD, William R Nunery 
MD, Jill Annette Foster MD FACS*, Mikel W Lo MD, John D Ng MD*, Asa Dan 
Morton III MD*, Christopher M DeBacker MD, John Joseph Martin MD*, Kenneth E 
Morgenstern MD**, Adam S Hassan MD, Janet M Neigel MD*, Scott M Goldstein 
MD*, Geva E Mannor MD MPH, Dustin M Heringer MD, David Khoramian Isaacs 
MD
Enucleation and Evisceration: Theory and Practice
Course Director(s): Parag D Gandhi MD
Course: LAB113 Sunday, 11:30 AM - 2:00 PM
Room: 349 Target Audience: COMPSUB
Fee: $245 EduLevel: INT
Synopsis: This course will cover the theory and practice of enucleation and evis-
ceration surgery with detailed surgical steps, hands-on practical training, and video 
demonstrations. Implants will be available for attendees to use on porcine orbits.
Objective: By the conclusion of this course, participants will be able to (1) un-
derstand preoperative evaluation and imaging, (2) develop an instrument set and 
implant options before surgery, (3) understand and anticipate anesthesia require-
ments, (4) understand and perform steps of enucleation and evisceration surgeries, 
(5) develop and implement a framework for deciding which procedure to choose 
and when, (6) understand the history of orbital implants and gain facility with im-
plants currently available and identify their advantages, (7) understand the advan-
tages and disadvantages of wrapping and pegging implants, (8) gain familiarity 
with management of early postoperative complications, and (9) describe how to 
manage late complications and the postenucleation socket syndrome.
Instructor(s): Mauricio Chavez MD**, Maria Kirzhner MD, Gary J Lelli MD, Marcus 
M Marcet MD, Eve E Moscato MD, Andrew Munro MD, Sarit M Patel MD, Erin 
Shriver MD, Manoj M Thakker MD, M Reza Vagefi MD
 NEW   EQUIP   W  Fat Grafting and Volume Restoration
Course Director(s): David Khoramian Isaacs MD
Prerequisite Didactic
Course: LEC115 Sunday, 2:00 - 3:00 PM
Room: 335 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: The purpose of this prerequisite didactic course is to present facial 
fat grafting as a technique for volume restoration. Indications for surgery, patient 
selection, alternatives to surgery, surgical techniques and instrumentation, and 
postoperative details will be reviewed. An interactive case presentation will allow 
attendees to participate.
Objective: At the conclusion of this course, the attendee will be acquainted with 
facial fat grafting techniques and appropriate patient selection, as well as address-
ing potential postoperative complications. The course will enable the attendee to 
formulate a customized approach to a patient’s needs and goals.
Instructor(s): Robert M Schwarcz MD*, Tanuj Nakra MD, Norman Shorr MD, Robert 
A Goldberg MD*
Lab
Synopsis: The purpose of this course is to allow attendees to have a hands-on 
cadaver learning module in fat grafting. Lectures, video presentations, and labora-
tory demonstrations on cadavers will teach tumescent anesthesia, fat harvesting, 
and fat grafting techniques.
Objective: At the conclusion of this course, the attendee will be familiar with safe 
and effective fat grafting techniques and addressing potential postoperative com-
plications. The course will enable the attendee to formulate a customized approach 
to a patient’s needs and goals.
Note: Participants are required to bring surgical loupes.
Course: LAB115A Monday, 8:00 - 10:00 AM
Room: 352 Target Audience: COMPSUB
Fee: $410 EduLevel: BAS
Instructor(s): Robert A Goldberg MD*, Norman Shorr MD, Robert M Schwarcz MD*, 
Mehryar Taban MD, Catherine Hwang MD, Joseph L Lin MD**, Daniel B Rootman 
MD MSc, Tanuj Nakra MD
 EQUIP   W  Blepharoplasty
Course Director(s): Keith D Carter MD FACS
Prerequisite Didactic
Course: LEC116 Sunday, 2:00 - 4:15 PM
Room: 225 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course will cover the latest techniques in upper and lower eyelid 
blepharoplasty. Basic and advanced surgical techniques, eyelid anatomy, patient 
selection, preoperative evaluation, and avoidance of complications will be dis-
cussed. A course handbook with illustrations outlining the surgical techniques will 
be provided.
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Objective: This course will provide participants with the techniques required to 
perform successful upper and lower eyelid blepharoplasties.
Instructor(s): Keith D Carter MD FACS, Mark A Alford MD, Richard C Allen MD PhD, 
Richard L Anderson MD FACS*, Adam G de la Garza MD, Robert C Kersten MD, Jill 
S Melicher Larson MD, Jeffrey A Nerad MD
Lab
Synopsis: This course is designed to provide hands-on laboratory experience with 
the techniques used in upper and lower eyelid blepharoplasty. Videos of tech-
niques will be presented, along with personal assistance with cadaver dissection.
Objective: Participants will be shown the clinically relevant anatomy as it relates 
to performing upper and lower eyelid blepharoplasties.
Note: Participants are required to bring surgical loupes.
Course: LAB116A Monday, 2:00 - 4:00 PM
Room: 352 Target Audience: COMPSUB
Fee: $410 EduLevel: INT
Instructor(s): Keith D Carter MD FACS, Mark A Alford MD, Richard C Allen MD PhD, 
Richard L Anderson MD FACS*, Francesco P Bernardini MD, Carlo de Conciliis MD, 
Adam G de la Garza MD, Martin H Devoto MD, Jill S Melicher Larson MD, Robert C 
Kersten MD, Jose R Montes MD, Jeffrey A Nerad MD, Rachel K Sobel MD
 W  Oculoplastic Surgery: Anatomic Foundations, Surgical 
Techniques, and Enhanced Results
Course Director(s): Cat Burkat MD
Course: LAB118 Sunday, 3:00 - 5:30 PM
Room: 349 Target Audience: COMPSUB
Fee: $155 EduLevel: INT
Synopsis: Anatomic principles provide the cornerstone of successful oculofacial 
surgery. This course will cover the anatomic foundations to be considered when 
performing surgical procedures of the eyebrow, forehead, upper and lower eyelids, 
midface, and lacrimal system. A series of short lectures will be followed by interac-
tive demonstration of clinically relevant anatomy on various cadaver prosections.
Objective: This course is designed to provide knowledge of anatomic foundations 
on which participants can build successful oculofacial surgical procedures.
Instructor(s): Mark J Lucarelli MD FACS, Arash Jian-Amadi MD, Richard Angrist 
MD, Christina H Choe MD, Alon Kahana MD PhD, Don Kikkawa MD*, Bobby S Korn 
MD PhD FACS*, Jan W Kronish MD, David B Lyon MD FACS, Marcus M Marcet 
MD, John J McGetrick MD FACS, Karim G Punja MD, Nicholas A Ramey MD, John 
G Rose Jr MD, Joseph P Shovlin MD, Manoj M Thakker MD, Katherine M Whipple 
MD, Edward Wladis MD*, Roberta Gausas MD**
 EQUIP   W  Workshop in Techniques of Lacrimal Intubation
Course Director(s): Arthur Perry MD*
Course: LAB126 Sunday, 4:00 - 5:30 PM
Room: 352 Target Audience: COMPSUB
Fee: $305 EduLevel: INT
Synopsis: This course will review indications for silicone intubation and will show 
different intubation systems and techniques. Participants will spend most of the 
course time actually performing the intubation procedure on cadavers.
Objective: Participants should leave the course feeling confident that they can 
successfully intubate the lacrimal system and understand both the indications for 
this procedure and possible complications.
Note: Participants are required to bring surgical loupes.
Instructor(s): Bruce B Becker MD*, Jeffrey P Edelstein MD*, Arthur Perry MD*, 
Melissa L Meldrum-Aaberg MD, Bert Bowden MD, Karim G Punja MD, Scott M 
Goldstein MD*, Adam S Hassan MD, Asa Dan Morton III MD*
Orbitofacial Fracture Repair: Plating Workshop
Course Director(s): Jeremiah P Tao MD, Eli L Chang MD
Course: LAB128 Monday, 8:00 - 11:00 AM
Room: 349 Target Audience: SUB
Fee: $180 EduLevel: INT
Synopsis: We will introduce the orbitocentric approach to facial fracture repair, 
including anatomy, principals of rigid internal fixation, and best surgical approach-
es. A series of lectures will be followed by a lab that introduces fixation systems 
and plating concepts. Model skulls, facial plating hardware, and instrumentation 
will be provided.
Objective: At the conclusion of the course, the attendee will be able to understand 
the benefits of an orbitocentric approach to orbitofacial bone repair. In addition, 
participants will gain practical experience with facial plating and instrumentation.
Instructor(s): William R Nunery MD, Hui Bae Harold Lee MD, Peter J Timoney 
MBBCh, Mithra O Gonzalez MD
Workshop in Flap Techniques in Oculoplastic Surgery
Course Director(s): Dawn C Buckingham MD
Course: LAB134 Monday, 1:00 - 3:00 PM
Room: 349 Target Audience: COMPSUB
Fee: $130 EduLevel: INT
Synopsis: This course will begin with a discussion of various suturing materials 
and techniques. Basic flap techniques will then be discussed, including advance-
ment, rotation, and bilobe and rhomboid flaps. Additionally, Z-plasty, Y-V plasty, 
and the management of dog ears will be covered. These techniques are crucial 
in achieving the best possible cosmetic result in periorbital reconstruction. The 
majority of the course will be a hands-on practicum, during which participants may 
perform these procedures under the supervision of experienced course instructors, 
utilizing pig’s feet.
Objective: At the conclusion of this course, the participant will be more familiar 
with various suturing techniques useful in periorbital wound closure and will have 
a better understanding of the indications for and techniques utilized in flap recon-
struction of periorbital cutaneous defects.
Instructor(s): George O Stasior MD, Suzanne K Freitag MD, Morris E Hartstein MD, 
Junhee Lee MD, Sang H Hong MD, Cat Burkat MD, Nicholas A Ramey MD, Alice 
Song MD, Renzo Zaldivar MD
 EQUIP   W  Endoscopic Transnasal Lacrimal Surgery: 
Principles and Practice
Course Director(s): Francois Codere MD
Prerequisite Didactic
Course: LEC135 Monday, 2:00 - 3:00 PM
Room: 340 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: The transnasal diagnosis and treatment of lacrimal outflow disorders 
will be presented. Endoscopic nasal anatomy, transnasal dacryocystorhinostomy 
surgical techniques, endoscopic Jones tubes placement, and endoscopic diagnosis 
and management of lacrimal disorders will be covered.
Objective: At the conclusion of this course, participants will understand transna-
sal endoscopic diagnosis and treatment of lacrimal outflow disorders.
Instructor(s): Francois Codere MD, Bruce M Massaro MD, Jennifer A Sivak-Callcott 
MD
Lab
Synopsis: This course will present the transnasal diagnosis and treatment of 
lacrimal outflow disorders. Endoscopic nasal anatomy, transnasal dacryocystorhi-
nostomy surgical techniques, endoscopic placement of Jones tubes, endoscope-
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assisted intubation, and use of the endoscope for diagnosis and management of 
lacrimal disorders will be covered.
Objective: At the conclusion of this course, participants will understand transna-
sal endoscopic diagnosis and treatment of lacrimal outflow disorders.
Note: Participants are required to bring surgical loupes.
Course: LAB135A Tuesday, 11:00 AM - 1:30 PM
Room: 352 Target Audience: COMPSUB
Fee: $460 EduLevel: INT
Instructor(s): Francois Codere MD, Bruce M Massaro MD, Jennifer A Sivak-Callcott 
MD, Jorge Corona MD, Steven C Dresner MD, Angela M Dolmetsch MD, James H 
Merritt MD, Jamie Wong MD**, John T Harvey MD, Liat Attas-Fox MD, Patrick R 
Boulos MD*
Introduction to Aesthetic Facial Surgery by Fractional 
Lasers, Intense Pulsed Light, Radiofrequency, and 
Ultrasound Devices
Course Director(s): Julie A Woodward MD*
Prerequisite Didactic
Course: LEC138 Monday, 3:15 - 5:30 PM
Room: 335 Target Audience: COMPSUB
 EduLevel: BAS
Synopsis: This course will focus primarily on ablative fractional and nonfractional 
laser resurfacing and incisional blepharoplasty because this is the only rejuvenat-
ing technology limited to physicians. Preoperative, intraoperative, and postopera-
tive care, management of complications, and marketing will be covered. There will 
also be introductions to the latest in nonablative fractional resurfacing, radiofre-
quency, and microfocused ultrasound.
Objective: By the conclusion of this course, attendees will be able to (1) com-
pare and contrast the many different devices on the market, (2) have introductory 
knowledge of how to incorporate such new technologies into their practices, and 
(3) recognize and manage complications of these devices.
Instructor(s): Julie A Woodward MD*, Erin Holloman MD**, Raminder K Saluja 
MD**, Usha P Reddy MD, Randal Pham MD FACS, Adam J Scheiner MD*, John 
Joseph Martin MD*, Ioannis P Glavas MD
Lab
Synopsis: This course will focus primarily on ablative traditional laser skin resur-
facing, ablative fractional resurfacing, and incisional laser surgery because these 
procedures naturally compliment blepharoplasty and are the only rejuvenating 
technologies limited to physicians. Preoperative, intraoperative, and postoperative 
care as well as management of complications will be covered. There will also be 
information presented on Intense Pulsed Light since this is a very multifunctional 
device. Instructors with in depth knowledge about a variety of other energy based 
devices will be available for questions.
Objective: At the completion of this course, participants will (1) understand safe 
application of rejuvenation technology, (2) learn how to manage complications, and 
(3) start to choose which devices and procedures to incorporate into their current 
practices. 
Note: Participants will be sharing equipment.
Course: LAB138A Tuesday, 11:00 AM - 1:00 PM
Room: 354 Target Audience: COMPSUB
Fee: $240 EduLevel: BAS
Instructor(s): Julie A Woodward MD*, John Joseph Martin MD*, Randal Pham MD 
FACS, Adam J Scheiner MD*, Michael Richard MD, Ioannis P Glavas MD, Wendy 
W Lee MD*, Usha P Reddy MD, Amina Husain MD, Kristina M Price MD, Sara T 
Wester MD
 EQUIP   W  Endoscopic Forehead and Eyebrow Elevation
Course Director(s): Stuart R Seiff MD
Prerequisite Didactic
Course: LEC140 Monday, 3:15 - 5:30 PM
Room: 340 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: The aesthetic evaluation of the patient with eyebrow ptosis, the anat-
omy of the eyebrow and forehead, and a description of the endoscopic brow and 
forehead elevation procedure will be discussed. A course handbook will be pro-
vided, detailing the surgical technique.
Objective: This course is designed to provide an understanding of the preopera-
tive patient evaluation, pertinent surgical anatomy, and technique of endoscopic 
brow and forehead elevation.
Instructor(s): Louis Savar MD, Susan R Carter MD
Lab
Synopsis: A brief lecture outlining the steps in endoscopic forehead and eyebrow 
elevation will be followed by step-by-step cadaver dissections for hands-on experi-
ence with the equipment and surgical technique.
Objective: Participants will obtain a familiarity with the surgical anatomy of the 
brow and forehead, instrumentation, planes of dissection, and closure techniques 
in endoscopic forehead and eyebrow elevation.
Note: Participants are required to bring surgical loupes. 
Course: LAB140A Tuesday, 7:30 - 10:00 AM
Room: 352 Target Audience: SUB
Fee: $460 EduLevel: INT
Senior Instructor(s): Susan R Carter MD
Instructor(s): Kimberly Cockerham MD FACS*, Kathleen M Duerksen MD, Jill 
Annette Foster MD FACS*, David E Holck MD, John Bryan Holds MD*, Asa Dan 
Morton III MD*, Eve E Moscato MD, Harmeet S Gill MD, Morris E Hartstein MD, 
Craig N Czyz DO, Louis Savar MD, Rona Z Silkiss MD FACS
 W  Surgical Anatomy of the Eyelids: Cadaver 
Demonstration
Course Director(s): Edward H Bedrossian MD FACS
Course: LAB143 Tuesday, 8:00 - 10:30 AM
Room: 349 Target Audience: COMPSUB
Fee: $155 EduLevel: INT
Synopsis: Using slides, video, and cadaver prosections, this course will demon-
strate landmarks important in the correction of brow ptosis, blepharoptosis, ectro-
pion, entropion, and retraction. Included will be a precourse quiz and participant 
interaction.
Objective: This course is designed to (1) review eyelid anatomy, (2) show struc-
tures in prosected cadavers, and (3) improve surgical technique.
Instructor(s): Edward H Bedrossian MD FACS, Robert C Della Rocca MD**, Bryan 
Arthurs MD FRCSC
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 EQUIP   W  Advanced Techniques in Orbital Decompression 
and Expansion
Course Director(s): Robert A Goldberg MD*
Prerequisite Didactic
Course: LEC145 Tuesday, 10:15 AM - 12:30 PM
Room: 342 Target Audience: SUB
 EduLevel: ADV
Synopsis: This course is designed to foster creative thinking in orbital decompres-
sion. Staging, planning, and techniques for orbital decompression will be reviewed, 
including deep lateral, fat removal, transcaruncular, and endoscopic. Surgical ver-
satility and creative decision making will be stressed.
Objective: This course is designed to acquaint participants with a variety of tech-
niques for orbital decompression and to enable them to design an individualized 
approach based on the patient’s needs and goals.
Instructor(s): Raymond Douglas MD PhD*, Norman Shorr MD, Catherine Hwang 
MD, Mehryar Taban MD, Joseph L Lin MD**, Daniel B Rootman MD MSc, Alice 
Siew Ching Goh MD
Lab
Synopsis: Through lectures, video presentations, and laboratory dissection, vari-
ous techniques for orbital decompression will be reviewed, including deep lateral, 
fat removal, transcaruncular, and endoscopic. Surgical versatility and creative deci-
sion making will be stressed.
Objective: This course is designed to acquaint participants with a variety of tech-
niques for orbital decompression and to enable them to design an individualized 
approach based on the patient’s needs and goals.
Note: Participants are required to bring surgical loupes and headlamps.
Course: LAB145A Tuesday, 2:30 - 5:00 PM
Room: 352 Target Audience: SUB
Fee: $460 EduLevel: ADV
Instructor(s): Norman Shorr MD, Jonathan W Kim MD, Raymond Douglas MD PhD*, 
Tanuj Nakra MD, Ronald Mancini MD, Mehryar Taban MD, Catherine Hwang MD, 
Joseph L Lin MD**, Daniel B Rootman MD MSc, Alice Siew Ching Goh MD, Raman 
Malhotra MBChB FRCOphth, Aline Pimentel MD, Payam Vali Morgan MD**
 W  Surgical Anatomy of the Orbit and Lacrimal System: 
Cadaver Demonstration
Course Director(s): Robert C Della Rocca MD**
Course: LAB146 Tuesday, 12:00 - 2:00 PM
Room: 349 Target Audience: COMPSUB
Fee: $130 EduLevel: INT
Synopsis: In this course, instructors will address small groups of attendees (4 to 
5 persons). Surgical anatomy and clinical correlation will be emphasized. Several 
short didactic lectures with slide demonstrations will present nasolacrimal surgery, 
orbital fracture repair, and anterior and medial orbitotomy. Associated neuroanato-
my correlation will be included.
Objective: This course is designed to familiarize participants with surgical ana-
tomical landmarks encountered in orbital and lacrimal surgery. Specific surgical 
techniques will be demonstrated.
Instructor(s): Robert C Della Rocca MD**, Edward H Bedrossian MD FACS, 
Meredith A Abbott MD, David A Della Rocca MD**, Harsha S Reddy MD, Chaneve 
Jeanniton MD
Pediatric Ophthalmology, Strabismus
 W  New Techniques for Strabismus Surgery
Course Director(s): Kenneth W Wright MD*
Prerequisite Didactic
Course: LEC117 Sunday, 2:00 - 3:00 PM
Room: 217 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: Over the past several years, important surgical innovations have made 
strabismus surgery safer and more effective. This course will teach the use of novel 
strabismus surgical techniques, including grooved hook for suturing the muscle 
insertion, minimally invasive techniques (rectus central tenotomy and plication), 
and use of amniotic membrane transplant for restrictive strabismus. Video will be 
presented to help teach the techniques. Outcome studies of surgical procedures 
will be presented.
Objective: At the conclusion of this course, the attendee will be able to use new 
strabismus surgical techniques to improve surgical outcomes and reduce complica-
tions.
Instructor(s): Yi Ning Strube MD, Luke W Deitz MD
Lab
Synopsis: This hands-on lab will transfer the surgical skills required for the use 
of new strabismus techniques. Attendees will actually perform the procedures. 
Specific techniques will include use of the grooved hook for safe suturing of tight 
muscles and suturing of muscles during topical anesthesia surgery. Techniques for 
amniotic membrane transplant useful in the treatment of restrictive strabismus will 
be taught. Minimally invasive techniques of partial rectus tenotomy and plication 
will be presented. The minimally invasive procedures have utility for the treatment 
of small-angle strabismus.
Objective: At the conclusion of the course, the attendee will be able to perform 
new strabismus surgical techniques that will improve patient care and clinical out-
comes.
Course: LAB117A Sunday, 3:30 - 5:30 PM
Room: 354 Target Audience: COMPSUB
Fee: $180 EduLevel: INT
Instructor(s): Yi Ning Strube MD, Lisa S Thompson MD, Luke W Deitz MD, Rebecca 
S Leenheer MD
Refractive Surgery
The Surgical Correction of Astigmatism
Course Director(s): Jean-Luc Febbraro MD*, Hamza N Khan MD FACS*
Prerequisite Didactic
Course: LEC108 Sunday, 10:15 AM - 12:30 PM
Room: 355 Target Audience: COMP
 EduLevel: INT
Synopsis: This course will supply participants with the necessary principles, theo-
ries, and practical instruction in the various forms of astigmatic keratotomy (PRI, 
limbal relaxing incisions) and nonincisional astigmatism correction (LASIK, toric 
IOLs).
Objective: Attendees will gain an understanding of techniques used to evaluate 
and manage astigmatism as a primary procedure and as an adjunct to lens surgery.
Instructor(s): Kurt A Buzard MD, Miles H Friedlander MD, Ronald N Gaster MD 
FACS*, David H Haight MD, Jack T Holladay MD MSEE FACS*, Douglas D Koch 
MD*, R Bruce Wallace MD*
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Lab
Synopsis: This practical hands-on wet lab- and video-based course allows par-
ticipants to improve their management of astigmatism, identify appropriate surgi-
cal candidates for astigmatism correction, and select the best techniques for each 
case, either combined with lens surgery or alone. Participants will learn to mark ap-
propriately for toric IOLs and perform corneal incisions (peripheral corneal relaxing 
incisions or limbal relaxing incisions), and will learn pearls and common pitfalls of 
each. The impact of various cataract incisions on astigmatism (surgically induced 
astigmatism) and laser vision correction will be discussed.
Objective: Attendees will gain an understanding of techniques used to evaluate 
and manage astigmatism as a primary procedure and as an adjunct to lens surgery.
Course: LAB108A Sunday, 1:00 - 2:30 PM
Room: 345 Target Audience: COMPSUB
Fee: $190 EduLevel: INT
Instructor(s): Jean-Luc Febbraro MD*, Hamza N Khan MD FACS*, Jean-Luc 
Febbraro MD*, Kurt A Buzard MD, Miles H Friedlander MD, Ronald N Gaster MD 
FACS*, Paul Gilwit MD FACS, David H Haight MD, R Bruce Wallace MD*, Douglas 
D Koch MD*, Baseer U Khan MD*
Phakic IOLs
Course Director(s): Thomas M Harvey MD*
Prerequisite Didactic
Course: LEC109 Sunday, 10:15 AM - 12:30 PM
Room: R02 Target Audience: COMPSUB
 EduLevel: INT
Synopsis: This course will educate the participant on the use of phakic IOLs in 
refractive surgery. Topics of discussion will include patient selection and preop-
erative testing, IOL power calculations, postoperative care, complication manage-
ment, surgical technique, and managing residual refractive error. Phakic IOLs cur-
rently available in the United States will be emphasized.
Objective: At the course conclusion, the participant will understand indications 
for the use of phakic IOLs and key management aspects of phakic IOL candidates.
Instructor(s): Sherman W Reeves MD MPH*, David R Hardten MD*, Stephen S 
Lane MD*, Jack T Holladay MD MSEE FACS*, Scott D Barnes MD*, Paul J Harton 
Jr MD*, Gregory Parkhurst MD*, Elizabeth A Davis MD*
Lab
Synopsis: Using pig eyes, the participant will have the opportunity to practice the 
insertion of phakic IOLs. Instructors will be available to assist and answer ques-
tions. FDA-approved phakic IOLs will be emphasized and available for implantation.
Objective: This wet lab will enable the participant to practice the surgical tech-
nique of inserting phakic IOLs.
Course: LAB109A Sunday, 1:30 - 3:00 PM
Room: 356 Target Audience: COMPSUB
Fee: $280 EduLevel: INT
Instructor(s): David R Hardten MD*, D Rex Hamilton MD*, Scott D Barnes MD*, 
Thomas M Harvey MD*, Andrew J Velazquez MD, John P Berdahl MD*, Anthony J 
Lombardo MD PhD, William Wiley MD*, Sherman W Reeves MD MPH*, Preeya K 
Gupta MD*, George O Waring MD*, Gregory Pamel MD**, Andrew C Shatz MD*, 
Asim R Piracha MD*, Michael Vrabec MD*, Paul J Dougherty MD*, Lisa Nijm MD, 
Paul J Harton Jr MD*, Gregory Parkhurst MD*, Scott M MacRae MD*
ISRS Laser Refractive Surgery Course
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and 
the International Society of Refractive Surgery (ISRS)
Course Director(s): Michael C Knorz MD*
Prerequisite Didactic
Course: LEC141 Monday, 3:15 - 5:30 PM
Room: 346 Target Audience: SUB
 EduLevel: INT
Synopsis: This course will start with the basics of how conventional and laser 
microkeratomes work and what one needs to know before performing LASIK and 
surface ablation. It will move on to cover tips, step by step, with presentations dis-
cussing the newest applications and developments in LASIK and surface ablation. 
The prevention and treatment of complications will be covered in detail.
Objective: This course is designed to give participants the information and skills 
needed for LASIK and surface ablation, including patient selection, basic princi-
ples, postoperative care, and management of complications.
Instructor(s): Jason E Stahl MD, Richard L Lindstrom MD*, Jack T Holladay MD 
MSEE FACS*
Labs
Synopsis: The wet lab is designed for those interested in learning techniques in 
laser refractive surgery. Mechanical microkeratomes, femtosecond lasers, excimer 
lasers, and corneal inlays will be available in the lab, with experienced surgeons 
on hand to assist with questions and to demonstrate techniques.
Objective: Participants will become acquainted with a broad array of both me-
chanical and laser microkeratomes and how they work with excimer lasers.
Select one of the following
Course: LAB141A Tuesday, 8:00 - 10:00 AM
Room: 345 Target Audience: COMPSUB
Fee: $240 EduLevel: BAS
Note: Participants will be sharing equipment.
Senior Instructor(s): George O Waring IV MD*
Instructor(s): Jason E Stahl MD, David R Hardten MD*, Vance Michael Thomp-
son MD*, Wallace Chamon MD*, Minoru Tomita MD PhD*, Parag A Majmudar 
MD*, Karolinne M Rocha MD, Sherman W Reeves MD MPH*, Mihai Pop MD**, 
Elizabeth Yeu MD*, Calvin G Eshbaugh MD**, Duane A Wiggins MD, Raj K Goyal 
MD MPH*, Paul C Kang MD*, William Wiley MD*, John J DeStafeno MD, Thomas 
M Harvey MD*, John P Berdahl MD*, Brandon Ayres MD*, Jodhbir S Mehta FRCS 
FRCOPHTH*, Suphi Taneri MD*, Ashvin Agarwal
Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and 
the International Society of Refractive Surgery (ISRS
 R   YO  Laser Refractive Surgery for Ophthalmology 
Residents
Course: LAB141B Tuesday, 10:30 AM - 12:30 PM
Room: 345 Target Audience: COMPSUB
Fee: $140 EduLevel: BAS
Note: MIT discount already applied. Participants will be sharing equipment.
Senior Instructor(s): George O Waring MD*
Instructor(s): Jason E Stahl MD, Daniel S Durrie MD*, Shachar Tauber MD*, Scott 
D Barnes MD*, Renato Ambrosio Jr MD*, John A Hovanesian MD*, David A Gold-
man MD*, Michael Vrabec MD*, Erin D Stahl MD*, James C Loden MD*, Allen 
Boghossian DO, Michael J Collins MD FACS, Ryan T Smith MD, Lisa Nijm MD, Erik 
Letko MD, Jeremy Z Kieval MD*, Jessica B Ciralsky MD*, Aylin Kilic MD, Jason P 
Brinton MD
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 Skills Transfer Program
                
Skills Transfer Program
 NEW  New Course.   R  Lab for Residents only.   SO  = Endorsed by Senior Ophthalmologist Committee.   YO  = Endorsed by Young Ophthalmologist Committee.  EQUIP  = Participants are 
required to bring specific equipment to the course.  W  = Participants are required to sign an infectious disease transmission waiver/release form.  Education Level Key: BAS = Basic, INT = 
Intermediate, ADV = Advanced. Target Audience: COMP = Comprehensive Ophthalmologist, SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist. 
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date. No asterisk indicates that the presenter has no financial interest.
Retina, Vitreous
Macular OCT: Mastering the Basics
Course Director(s): John S Pollack MD*
Prerequisite Didactic
Course: LEC110 Sunday, 10:15 AM - 12:30 PM
Room: R08 Target Audience: COMP
 EduLevel: BAS
Synopsis: This course provides basic instruction on accurate interpretation of 
OCTs of common macular pathologies, as well as instruction on how to identify and 
prevent common OCT artifacts. The course also provides a clinically meaningful 
review of indications and limitations of OCT in the diagnosis and management of 
common macular diseases such as AMD, diabetic maculopathy, epiretinal mem-
brane, macular holes, vitreomacular traction, central serous retinopathy, vascular 
occlusions, and postoperative cystoid macular edema.
Objective: Upon completion of this course, participants should be able to (1) accu-
rately interpret OCTs of common macular pathologies, (2) describe the indications 
for and limitations of OCT in the diagnosis and management of macular diseases, 
and (3) identify, interpret, and correct common OCT artifacts.
Instructor(s): John S Pollack MD*, Cynthia A Toth MD*, Anat Loewenstein MD*, 
Dante Pieramici MD*, Nadia Khalida Waheed MD
Lab
Synopsis: This course will provide attendees with a small-group interactive for-
mat (5-6 attendees per instructor) for hands-on experience reviewing and evaluat-
ing OCTs covering a wide range of common macular diseases, with emphasis on 
sharpening the OCT-interpretation skills of the attendees. Attendees will rotate 
with all instructors, covering a variety of topics, including but not limited to AMD, 
vascular occlusions, epiretinal membrane, vitreomacular traction, macular holes, 
diabetic retinopathy, and postoperative cystoid macular edema. Attendees are 
invited to bring one challenging case for discussion at the end of the lab, time 
permitting.
Objective: Upon completion of this course, participants should be able to (1) iden-
tify the OCT features of normal and abnormal macular anatomy, (2) diagnose com-
mon macular pathologies based on specific OCT characteristics, and (3) identify, 
correct, and prevent common OCT artifacts.
Course: LAB110A Sunday, 3:00 - 5:00 PM
Room: 343 Target Audience: COMP
Fee: $130 EduLevel: BAS
Instructor(s): John S Pollack MD*, Jack A Cohen MD FACS, Dafna Goldenberg 
MD*, Brandon G Busbee MD*, Sanford F Chen MD, Justis Ehlers MD
Diabetes 2013: Course on Diabetic Retinopathy
Course Director(s): Keye Luc Wong MD*
Prerequisite Didactic
Course: LEC139 Monday, 3:15 - 5:30 PM
Room: 333 Target Audience: COMP
 EduLevel: INT
Synopsis: This course will present a rational approach to the diagnosis and treat-
ment of diabetic retinopathy based on first understanding results and recommen-
dations of the Diabetic Retinopathy Study and Early Treatment Diabetic Retinopa-
thy Study and subsequently reviewing DRCRnet publications that may modify some 
of those recommendations. Case presentations made to a panel of experts will 
illustrate the role of OCT and pharmacotherapy relative to laser therapy.
Objective: By the conclusion of this course, participants will be able to understand 
(1) the clinical indications for laser treatment of diabetic retinopathy and (2) the role 
of pharmacotherapy and OCT in current management of diabetic retinopathy.
Instructor(s): Keye Luc Wong MD*, Abdhish R Bhavsar MD*, Alexander J Brucker 
MD*, Emily Y Chew MD, Harry W Flynn MD*, Arthur D Fu MD, Justin L Gottlieb 
MD, Sam Edward Mansour MD*
Lab
Synopsis: The latest in diagnostic methods and treatment techniques will be 
reviewed in small groups using case presentations. Panel discussions with an ex-
tensive faculty will highlight current treatment controversies in which DRCRnet 
results may modify Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic 
Retinopathy Study (ETDRS) recommendations.
Objective: By the conclusion of this course, participants will be able to under-
stand the clinical indications for pharmacotherapy and laser treatment of diabetic 
retinopathy and to know the best treatment techniques based on DRS, ETDRS, and 
DRCRnet clinical trial results.
Course: LAB139A Tuesday, 8:00 - 10:30 AM
Room: 343 Target Audience: COMP
Fee: $150 EduLevel: INT
Instructor(s): Keye Luc Wong MD*, Justin L Gottlieb MD, Gary W Abrams MD*, 
Michael M Altaweel MD*, Neal H Atebara MD, Maria H Berrocal MD*, Robert A 
Braunstein MD, David J Browning MD PhD*, Alexander J Brucker MD*, Clement K 
Chan MD*, Suresh R Chandra MD, John H Drouilhet MD FACS*, Michael S Ip MD*, 
Richard H Johnston MD, James L Kinyoun MD
ISRS is a global society catering to our needs as  
refractive, cataract and corneal surgeons by  
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                                   — Amar Agarwal, MD
To become a member,  
visit the Membership Booth in  
the Academy Resource Center,  
Booth #3239.
I Invite You to Become  
an ISRS Member
International Society of Refractive Surgery
     A Partner of the American Academy of Ophthalmology
www.isrs.org 
ISRS is a global society catering to our needs as  
refractive, cataract and corneal surgeons by  
providing us with educational opportunities  
through the Multimedia Library, Journal of  
Refractive Surgery, international conferences  
and online forum. ISRS will connect you to  
the who’s who in ophthalmology.
                                   — Amar Agarwal, MD
To become a member,  
visit the Membership Booth in  
the Academy Resource Center,  
Booth #3239.
I Invite You to Become  
an ISRS Member
International Society of Refractive Surgery
     A Partner of the American Academy of Ophthalmology
www.isrs.org 
Who benefits from Academy Foundation funding?
a.  Ophthalmologists 
b.  An infant with retinopathy of prematurity
c.  Residents in Nairobi
d.  A grandmother in Warner, Oklahoma
e.  All of the above
For more than 30 years, the Foundation has supported the Academy’s educational, quality of care research and 
service programs, which benefit ophthalmologists and their patients worldwide.
The ONE® Network gives us cutting-edge knowledge to provide better patient care. The Hoskins Center for 
Quality Eye Care ensures best practices and accurate benchmarking.  The International Outreach Program 
helps educate our colleagues in the developing world. EyeCare America® changes the lives of the medically  
underserved across the U.S.  And the Museum of Vision shares the history of sight with the world. 
Your tax-deductible contributions make these and many other innovative programs possible. Help us  
continue to impact your continuing education, improve patient care and prevent avoidable blindness.
Make a gift today!  www.faao.org
Questions? Contact Karen Duke at kduke@aao.org or 415.447.0356
JOIN!
The American Academy of Ophthalmology (AAO), 
an internationally recognized medical organization,  
offers a wide variety of valuable benefits designed  
to give you the advantages needed to support you  
throughout your training and your career.
AAO Member Benefits
•  No registration fee for the Academy’s  
Annual Meeting
• Print subscription to Ophthalmology
•  Access to the Ophthalmic News &  
Education (ONE®) Network
• Discounts on Academy products and services
• Access to the Academy Online Community
AND MUCH MORE…For an application and a complete  
list of benefits, visit www.aao.org/member.
THE ACADEMY  
IS ALWAYS  
AT YOUR SERVICE.
Web: www.aao.org/member
Email: member_services@aao.org
Cover more ground 
 in less time.
The Integrated WaveLight® Refractive Suite 
The world’s fastest refractive platform features:
 
• Unrivaled 500 Hz Excimer Laser ablation times at just 1.4 seconds per diopter*
• Precise 200 kHz Femtosecond Laser custom flap creation in 6 seconds*
• A 1050 Hz-type Eye Tracker, synchronized at 500 Hz, with 2 millisecond latency time
• A broad range of customized, patient-specific treatments available
 
Ask your Alcon Sales Representative for more information.
*Based on typical treatment parameters for myopia.
For important safety information about this product, please refer to the adjacent page. 
WaveLight® FS200 
Femtosecond  Laser   
WaveLight® EX500 
Excimer  Laser        
Leaping over 50 times its own length, 
the rocket frog can accelerate up to twice 
the speed of gravity.{
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Important Safety Information about the 
WaveLight® Excimer Laser Systems
This information pertains to all WaveLight® Excimer Laser Systems, 
including the WaveLight® ALLEGRETTO WAVE®, the ALLEGRETTO 
WAVE® Eye-Q , and the WaveLight® EX500.  
Caution:  Federal (U.S.) law restricts the WaveLight® Excimer Laser 
Systems to sale by or on the order of a physician.  Only practitioners 
who are experienced in the medical mangement and surgical 
treatment of the cornea, who have been trained in laser refractive 
surgery (including laser calibration and operation) should use a 
WaveLight® Excimer Laser System.  
Indications:  FDA has approved the WaveLight® Excimer Laser for 
use in laser-assisted in situ keratomileusis (LASIK) treatments for:  
• the reduction or elimination of myopia of up to - 12.0 DS and 
up to 6.0 D of astigmatism at the spectacle plane;
• the reduction or elimination of hyperopia up to + 6.0 DS with 
and without astigmatic refractive errors up to 5.0 D at the 
spectacle plane, with a maximum manifest refraction spherical 
equivalent of + 6.0 D;
• the reduction or elimination of naturally occurring mixed 
astigmatism of up to 6.0 D at the spectacle plane; and
• the wavefront-guided reduction or elimination of myopia of 
up to -7.0 DS and up to 3.0 D of astigmatism at the spectacle 
plane.
The WaveLight® Excimer Laser Systems are only indicated for use in 
patients who are 18 years of age or older (21 years of age or older 
for mixed astigmatism) with documentation of a stable manifest 
refraction defined as ≤ 0.50 D of preoperative spherical equivalent 
shift over one year prior to surgery, exclusive of changes due to 
unmasking latent hyperopia.
Contraindications:  The WaveLight® Excimer Laser Systems are 
contraindicated for use with patients who:  
• are pregnant or nursing; 
• have a diagnosed collagen vascular, autoimmune or 
immunodeficiency disease; 
• have been diagnosed keratoconus or if there are any clinical 
pictures suggestive of keratoconus; or 
• are taking isotretinoin (Accutane*) and/or amiodarone 
hydrochloride (Cordarone*).
Warnings: The WaveLight® Excimer Laser Systems are not 
recommended for use with patients who have: 
• systemic diseases likely to affect wound healing, such as 
connective tissue disease, insulin dependent diabetes, severe 
atopic disease or an immunocompromised status; 
• a history of Herpes simplex or Herpes zoster keratitis; 
• significant dry eye that is unresponsive to treatment; 
• severe allergies; or 
• an unreliable preoperative wavefront examination that 
precludes wavefront-guided treatment. 
The wavefront-guided LASIK procedure requires accurate and reliable 
data from the wavefront examination. Every step of every wavefront 
measurement that may be used as the basis for a wavefront-guided 
LASIK procedure must be validated by the user. Inaccurate or 
unreliable data from the wavefront examination will lead to an 
inaccurate treatment.
Precautions:  The safety and effectiveness of the WaveLight® 
Excimer Laser Systems have not been established for patients with:
• progressive myopia, hyperopia, astigmatism and/or mixed 
astigmatism, ocular disease, previous corneal or intraocular 
surgery, or trauma in the ablation zone;
• corneal abnormalities including, but not limited to, scars, 
irregular astigmatism and corneal warpage;
• residual corneal thickness after ablation of less than 250 
microns due to the increased risk for corneal ectasia;
• pupil size below 7.0 mm after mydriatics where applied for 
wavefront-guided ablation planning;
• history of glaucoma or ocular hypertension of > 23 mmHg;
• taking the medication sumatriptan succinate (Imitrex*);
• corneal, lens and/or vitreous opacities including, but not 
limited to cataract;
• iris problems including , but not limited to, coloboma and 
previous iris surgery compromising proper eye tracking; or
• taking medications likely to affect wound healing including 
(but not limited to) antimetabolites.  
 In addition, safety and effectiveness of the WaveLight® Excimer Laser 
Systems have not been established for:  
• treatments with an optical zone < 6.0 mm or > 6.5 mm in 
diameter, or an ablation zone > 9.0 mm in diameter; or
• wavefront-guided treatment targets different from 
emmetropia (plano) in which the wavefront calculated defocus 
(spherical term) has been adjusted;
In the WaveLight® Excimer Laser System clinical studies, there 
were few subjects with cylinder amounts > 4 D and ≤ 6 D.  Not all 
complications, adverse events, and levels of effectiveness may have 
been determined for this population.
Pupil sizes should be evaluated under mesopic illumination 
conditions.  Effects of treatment on vision under poor illumination 
cannot be predicted prior to surgery.  
Adverse Events and Complications
Myopia:  In the myopia clinical study, 0.2% (2/876) of the eyes 
had a lost, misplaced, or misaligned flap reported at the 1 month 
examination.  
The following complications were reported 6 months after LASIK:  
0.9% (7/818) had ghosting or double images in the operative eye; 
0.1% (1/818) of the eyes had a corneal epithelial defect.
Hyperopia:  In the hyperopia clinical study, 0.4% (1/276) of the eyes 
had a retinal detachment or retinal vascular accident reported at the 
3 month examination.  
The following complications were reported 6 months after LASIK: 
0.8% (2/262) of the eyes had a corneal epithelial defect and 0.8% 
(2/262) had any epithelium in the interface.
Mixed Astigmatism:  In the mixed astigmatism clinical study, two 
adverse events were reported.  The first event involved a patient who 
postoperatively was subject to blunt trauma to the treatment eye 
6 days after surgery. The patient was found to have an intact globe 
with no rupture, inflammation or any dislodgement of the flap. 
UCVA was decreased due to this event. The second event involved the 
treatment of an incorrect axis of astigmatism. The axis was treated at 
60 degrees instead of 160 degrees.
The following complications were reported 6 months after LASIK:  
1.8% (2/111) of the eyes had ghosting or double images in the 
operative eye.
Wavefront-Guided Myopia:  No adverse events occurred during the 
postoperative period of the wavefront-guided LASIK procedures.  
In the Control Cohort (traditional LASIK treatment) one subject 
undergoing traditional LASIK had the axis of astigmatism 
programmed as 115 degrees instead of the actual 155 degree axis. 
This led to cylinder in the left eye.
The following complications were reported 6 months after 
wavefront-guided LASIK in the Study Cohort: 1.2% (2/166) of the 
eyes had a corneal epithelial defect; 1.2% (2/166) had foreign body 
sensation; and 0.6% (1/166) had pain.  No complications were 
reported in the Control Cohort.  
Clinical Data
Myopia:  The myopia clinical study included 901 eyes treated, 
of which 813 of 866 eligible eyes were followed for 12 months.  
Accountability at 3 months was 93.8%, at 6 months was 91.9%, and 
at 12 months was 93.9%.  Of the 782 eyes eligible for the uncorrected 
visual acuity (UCVA) analysis of effectiveness at the 6-month stability 
time point, 98.3% were corrected to 20/40 or better, and 87.7% 
were corrected to 20/20 or better.  Subjects who responded to a 
patient satisfaction questionnaire before and after LASIK reported 
the following visual symptoms at a “moderate” or “severe” level at 
least 1% higher at 3 months post-treatment than at baseline:  visual 
fluctuations (28.6% vs. 12.8% at baseline).  
Long term risks of LASIK for myopia with and without astigmatism 
have not been studied beyond 12 months.
Hyperopia:  The hyperopia clinical study included 290 eyes treated, 
of which 100 of 290 eligible eyes were followed for 12 months.  
Accountability at 3 months was 95.2%, at 6 months was 93.9%, 
and at 12 months was 69.9%.  Of the 212 eyes eligible for the UCVA 
analysis of effectiveness at the 6-month stability time point, 95.3% 
were corrected to 20/40 or better, and 69.4% were corrected to 
20/20 or better.  Subjects who responded to a patient satisfaction 
questionnaire before and after LASIK reported the following visual 
symptoms as “much worse” at 6 months post-treatment:  halos 
(6.4%); visual fluctuations (6.1%); light sensitivity (4.9%); night 
driving glare (4.2%); and glare from bright lights (3.0%).  
Long term risks of LASIK for hyperopia with and without astigmatism 
have not been studied beyond 12 months.
Mixed Astigmatism:  The mixed astigmatism clinical study included 
162 eyes treated, of which 111 were eligible to be followed for 6 
months. Accountability at 1 month was 99.4%, at 3 months was 
96.0%, and at 6 months was 100.0%.  Of the 142 eyes eligible for the 
UCVA analysis of effectiveness at the 6-month stability time point, 
97.3% achieved acuity of 20/40 or better, and 69.4% achieved acuity 
of 20/20 or better.  Subjects who responded to a patient satisfaction 
questionnaire before and after LASIK reported the following visual 
symptoms at a “moderate” or “severe” level at least 1% higher at 3 
months post-treatment than at baseline:  sensitivity to light (52.9% 
vs. 43.3% at baseline); visual fluctuations (43.0% vs. 32.1% at 
baseline); and halos (42.3% vs. 37.0% at baseline).  
Long term risks of LASIK for mixed astigmatism have not been 
studied beyond 6 months. 
Wavefront-Guided Myopia:  The wavefront-guided myopia clinical 
study included 374 eyes treated; 188 with wavefront-guided LASIK 
(Study Cohort) and 186 with Wavefront Optimized® LASIK (Control 
Cohort).  166 of the Study Cohort and 166 of the Control Cohort 
were eligible to be followed at 6 months.  In the Study Cohort, 
accountability at 1 month was 96.8%, at 3 months was 96.8%, and 
at 6 months was 93.3%. In the Control Cohort, accountability at 1 
month was 94.6%, at 3 months was 94.6%, and at 6 months was 
92.2%.  
Of the 166 eyes in the Study Cohort that were eligible for the UCVA 
analysis of effectiveness at the 6-month stability time point, 99.4% 
were corrected to 20/40 or better, and 93.4% were corrected to 
20/20 or better. Of the 166 eyes in the Control Cohort eligible for the 
UCVA analysis of effectiveness at the 6-month stability time point, 
99.4% were corrected to 20/40 or better, and 92.8% were corrected 
to 20/20. 
In the Study Cohort, subjects who responded to a patient satisfaction 
questionnaire before and after LASIK reported the following visual 
symptoms at a “moderate” or “severe” level at least 1% higher at 3 
months post-treatment than at baseline:  light sensitivity (47.8% 
vs. 37.2% at baseline) and visual fluctuations (20.0% vs. 13.8% at 
baseline). In the Control Cohort, the following visual symptoms were 
reported at a “moderate” or “severe” level at least 1% higher at 3 
months post-treatment than at baseline:  halos (45.4% vs. 36.6% at 
baseline) and visual fluctuations (21.9% vs. 18.3% at baseline). 
Long term risks of wavefront-guided LASIK for myopia with and 
without astigmatism have not been studied beyond 6 months.
Information for Patients:  Prior to undergoing LASIK surgery 
with a WaveLight® Excimer Laser System, prospective patients must 
receive a copy of the relevant Patient Information Booklet, and must 
be informed of the alternatives for correcting their vision, including 
(but not limited to) eyeglasses, contact lenses, photorefractive 
keratectomy, and other refractive surgeries.  
Attention:  Please refer to a current WaveLight® Excimer Laser 
System Procedure Manual for a complete listing of the indications, 
complications, warnings, precautions, and side effects.  
* Trademarks are property of their respective owners.
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Opening Session
O
pening Session
Sunday, Nov. 17 
8:30 – 10:00 AM 
The Great Hall
Join your colleagues at the 2013 Opening Session. Hear from the 
Academy’s President and CEO, celebrate the leaders in the profession and 
learn about the latest innovation from AAO.
The IRIS™ Registry: Ophthalmology’s Moon Shot?
Panel Moderator: Michael X Repka MD, Medical Director, Government 
Affairs
Panelists: Michael F Chiang MD, Chair, Academy’s Committee on 
Medical Information Technology; Paul P Lee MD JD, Advisory Member, 
Hoskins Center for Quality Eye Care; David May MD PhD, Chair, Board 
of Governors American College of Cardiology; William L Rich III MD, 
Academy’s Medical Director, Health Policy
In 2014 the American Academy of Ophthalmology will launch the 
IRIS™ Registry. In many respects, this will be the most significant 
project the Academy has ever undertaken. If successful, it will usher 
in a new era wherein ophthalmologists will have the data to review 
their own processes and outcomes of care in their continual quest for 
excellence. The IRIS registry will generate powerful data in defining the 
impact and value of the care ophthalmologists provide. It may assist 
ophthalmologists in the American Board of Ophthalmology’s Maintenance 
of Certification process. And it will ignite a new vehicle for clinical 
research. But there is a lot to be done, and there remain challenges. 
Listen as some of the registry experts discuss the IRIS initiative, the 
important issues before all of us, and take questions from the audience. 
Sessions and Symposia
Opening Session
2013 Academy Awards
Guests of Honor
Thomas M Aaberg Sr MD, Andrew P Schachat MD, and William B Snyder MD
Distinguished Service Award
Public Trustees of the American Academy of Ophthalmology Board of Trustees 
Humphrey J F Taylor and Paul B Ginsburg PhD
Special Recognition Award
American Academy of Ophthalmology Leadership Development Program 
(LDP)
Outstanding Humanitarian Service Award
Mario R Angi MD and Gullapalli N Rao MD
Straatsma Award for Excellence in Resident Education
Andreas K Lauer MD
International Blindness Prevention Award
Mohammad Daud Khan MD
Outstanding Advocate Award
Michael W Brennan MD
2013 Laureate Award:  
Daniel M Albert MD 
Dr. Albert is a Professor at the University of Madison-
Wisconsin. His scientific and medical research has 
opened new pathways for the treatment of ocular 
tumors, specifically melanoma and retinoblastoma. 
His dedication and leadership in education has 
inspired many and helped shape the way we teach 
and learn. 
Jackson Memorial Lecture:  
Mark S Blumenkranz MD
Dr. Blumenkranz is the H.J. Smead Professor and 
Chairman of the Department of Ophthalmology 
at Stanford University. He is a noted vitreoretinal 
surgeon whose primary clinical interests center on 
the medical and surgical treatment of vitreoretinal 
diseases. He was instrumental in developing 
the successful laser vision correction program at 
Stanford. 
For a full description of all Academy Awards and award recipients, turn to Tab 1, Awards, page 1.
Time Topic Speaker
8:30 AM Opening Remarks Jonathan B Rubenstein MD
8:38 AM Academy President’s Address Paul Sternberg Jr MD 
8:44 AM Academy Awards  
8:56 AM Laureate Award:  Daniel Albert, MD, MS Paul R Lichter MD 
8:59 AM Academy’s Chief Executive Officer’s Address David W Parke II MD
9:05 AM Academy’s President-Elect’s Address Gregory L Skuta MD 
9:10 AM The IRIS™ Registry: Ophthalmology’s Moon Shot? Panel Moderator: Michael X Repka MD, Medical Director, Government Affairs
9:30 AM Introduction of the Jackson Memorial Lecture Jonathan B Rubenstein MD 
9:32 AM Jackson Memorial Lecture: The History and Evolution of Lasers in Ophthalmology:  A Review of the Interactions Between Physicians, Patients, and Photons Mark S Blumenkranz MD
9:57 AM Jackson Memorial Lecture Award Presentation Thomas J Liesegang MD
9:58 AM Concluding Remarks Jonathan B Rubenstein MD
10:00 AM End of Session 
118 Academy staff are available at the Academy Resource Center, Hall G, Booth 3239, to answer any questions you may have.
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WHERE ALL OF OPHTHALMOLOGY MEETS
Saturday — Tuesday, Nov. 16 - 19
Spotlight Sessions and Symposia are free of charge and open to all attendees.
 GO  Global Ophthalmology
 SO  Endorsed by Senior Ophthalmologist Committee
 YO  Endorsed by Young Ophthalmologist Committee
 EHR  Electronic Health Records
Selection Committee
The Special Projects Committee developed the Spotlight on Ophthalmic Office Emergencies; the 
Spotlight on OCT; The Great Debate: Retina; The Great Debate: Glaucoma; Best of Anterior Segment 
Specialty Meetings 2013; Best of Posterior Segment Specialty Meetings 2013; Grand Rounds; Late 
Breakers Symposium; and the Academy Cafés.
The Annual Meeting Program Committee selected all other spotlight sessions and symposia.
See page page 33 for committee details.
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Saturday, Nov. 16
 GO  What are the Opportunities and Resources for 
Working in Developing Countries?
Event No: SYM01 2:00 - 3:30 PM
Room: 255
Combined meeting with the Academy’s Global Education and Outreach Committee
Chair(s): David S Friedman MD MPH PhD*, Linda M Lawrence MD
This symposium will provide information to individuals interested in expanding 
their engagement with eye health providers in developing countries. The focus 
will be on providing information to the audience about resources available to 
them and to their partners overseas, introducing the audience to the major non-
profits working in this sphere, educating eye care providers about the needs of 
local institutions and reviewing key factors to consider when engaging in work 
in these locations.
2:00 PM The Academy’s Global Alliances
Richard L Abbott MD*
Resources Available
2:02 PM Where and How Ophthalmologists Can Contribute Most in 
Developing Countries
Bruce E Spivey MD FACS
2:07 PM International Council of Ophthalmology Educational Programs and 
Other Resources for Global Ophthalmologists
William C Felch JR
2:12 PM LAICO’s Organizational Capacity Building for Enhancing Eye Care
Srinivasan Kavitha MD
2:19 PM Resources Available through the AAO
Linda M Lawrence MD
2:24 PM ONE Network Resources
James C Tsai MD MBA*
2:29 PM Q&A
NGO Panel Discussion
2:40 PM Helen Keller Institute’s Ongoing Eye Health Activities
Nick Kourgialis MA
2:45 PM Orbis Overview
Brian C Leonard MD*
2:50 PM The Fred Hollows Fellowship Program
Richard T Le Mesurier MBChB
2:55 PM Bringing Added Value to the Mission
Victoria M Sheffield*
3:00 PM Q&A
3:10 PM Perspective of the Local Ophthalmologists
Kunle O Hassan MBBS
3:15 PM Q&A
3:30 PM End of Session
Sunday, Nov. 17
 YO  Introduction to Cornea and Lens-Based Refractive 
Surgery for Residents
Event No: SYM02 8:00 - 11:00 AM
Room: 228
Sponsored by the International Society of Refractive Surgery (ISRS)
Chair(s): Ronald R Krueger MD*, J Bradley Randleman MD
This session will provide an overview of the most relevant topics on corneal and 
lens-based refractive surgery, including patient evaluation, topographic evalua-
tion, a step-by-step surgical explanation of LASIK and surface ablation proce-
dures, discussion of surgical complication recognition and management, and 
decision trees for choosing appropriate premium IOL candidates and managing 
complications unique to these individuals. This will provide a basis upon which 
individuals in training may begin to grow their knowledge base and gain comfort 
in practicing independently after graduation. The session will be an interactive 
didactic led by recognized experts and international leaders in the field of refrac-
tive surgery, but will be specifically directed at the resident education level, as 
opposed to many of the courses at AAO directed towards specialists already 
in practice. This focus should allow the resident to gain the optimal learning 
experience.
8:00 AM Welcome and Opening Remarks
J Bradley Randleman MD, Ronald R Krueger MD*
8:02 AM Basic LASIK Patient Evaluation
Ronald R Krueger MD*
8:20 AM Topographic and Tomographic Evaluation
Renato Ambrosio Jr MD*
8:40 AM Step-by-Step PRK and LASIK
Sonia H Yoo MD*
9:00 AM LASIK and Cataract Surgery Nightmares: How to Avoid Them?
Amar Agarwal MD*
9:20 AM LASIK/PRK Complications and Management
David R Hardten MD*
9:40 AM Decision Tree: When PRK and When LASIK
Marguerite B McDonald MD*
10:00 AM Patient Selection for Refractive Lens Exchange
Jason E Stahl MD
10:20 AM Toric, Multifocal, and Accommodating IOLs
J Bradley Randleman MD
10:40 AM Management of the Dissatisfied Premium IOL Patient
Bonnie A Henderson MD*
10:58 AM Closing Remarks
Ronald R Krueger MD*, J Bradley Randleman MD
11:00 AM End of Session
Spotlight on Ophthalmic Office Emergencies: Things 
You Don’t Want to Miss
Event No: SPO3 10:30 AM - 12:00 PM
Room: La Nouvelle Orleans AB
Chair(s): Rolando Toyos MD*, Preeya K Gupta MD*
Ophthalmic emergencies are not always common but critical to recognize and manage 
with speed and efficiency.This case-based presentation will cover how to recognize, tri-
age, and manage a broad range of ophthalmic emergencies.
10:30 AM Introduction
Preeya K Gupta MD*
10:32 AM My Eye is Red After Cataract Surgery
Paul Hahn MD PhD
10:42 AM I Can’t See and Don’t Feel Well
M Tariq Bhatti MD*
10:52 AM I See Double and Have a Terrific Headache
Nicholas J Volpe MD*
11:02 AM Panel Discussion
11:08 AM I’m Feeling Nauseated
Nathan M Radcliffe MD*
11:18 AM I Got Poked in the Eye, and Now I Can’t See!
Derek W Del Monte MD
11:28 AM Panel Discussion
11:34 AM My Eye is Swollen Shut
Michael Richard MD
11:44 AM I Fell Asleep in my Contact Lenses
Jessica B Ciralsky MD*
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11:54 AM Panel Discussion
12:00 PM End of Session
Innovation in Ophthalmology: From Theory to Therapy
Event No: SYM03 10:30 AM - 12:00 PM
Room: New Orleans Theater C
Chair(s): Emmett T Cunningham Jr MD PhD MPH
This course is intended to give clinical ophthalmologists an improved understand-
ing of the factors driving and influencing innovation in ophthalmology. Following 
a brief welcome, six 10-minute presentations will be given, covering: 1) Funding 
innovation; 2) An investor’s view of innovating in the ophthalmic sector: winners, 
losers, lessons learned; 3) ForSight Labs: An experiment in Ophthalmic Innova-
tion; 4) The role of physician innovators; 5) Innovating from private practice; and 
6) Innovating from Academia. This will be followed by a 20-30 minute audience 
Q&A session with all participants. Participants should gain an improved under-
standing of the innovative process, including how to protect and advance their 
own innovations.
10:30 AM Welcome
Emmett T Cunningham Jr MD PhD MPH
10:35 AM Funding Innovation
Gilbert H Kliman MD*
10:45 AM An Investor’s View of Innovating in the Ophthalmic Sector: Winners, 
Losers, and Lessons Learned
William Link PhD*
10:55 AM ForSight Labs: An Experiment in Ophthalmic Innovation
Eugene De Juan Jr MD*
11:05 AM The Role of Physician Innovators
Daniel M Schwartz MD*
11:15 AM Innovating from Private Practice
Richard L Lindstrom MD*
11:25 AM Innovating from Academia
Mark S Blumenkranz MD*
11:35 AM Panel Discussion/Q&A
12:00 PM End of Session
Detection of Glaucomatous Progression
Event No: SYM04 10:30 AM - 12:00 PM
Room: La Nouvelle Orleans C
Combined meeting with  Prevent Blindness America (PBA)
Chair(s): Angelo P Tanna MD*, David S Friedman MD MPH PhD*
The symposium will address various aspects of glaucoma progression detection, 
including visual field progression, detection of progressive excavation of the op-
tic disc using stereoscopic photographs, and detection of progressive atrophy of 
the retinal nerve fiber layer and optic disc using advanced imaging technologies. 
Additionally, detection of changes in total retinal thickness or retinal ganglion 
cell complex thickness of the macula as measured with spectral domain OCT will 
be reviewed. Finally, important concepts including rates of change and combined 
measures of structural and functional change will be addressed.
10:30 AM Introduction
Angelo P Tanna MD*
10:32 AM Visual Fields Progression
Balwantray C Chauhan MD
10:41 AM Progression Detection With Optic Disc Photography
Jody R Piltz-Seymour MD*
10:50 AM Structural Progression Detection With Spectral Domain OCT: The 
Retinal Nerve Fiber Layer and Optic Disc
Joel S Schuman MD*
10:58 AM Structural Progression Detection With Spectral Domain OCT: The 
Macula
Donald L Budenz MD MPH*
11:07 AM Combined Structure-Function Analysis
Felipe A Medeiros MD*
11:16 AM Moving from Statistically Significant to Clinically Significant 
Progression
George A Cioffi MD
11:25 AM Conclusion
David S Friedman MD MPH PhD*
ROBERT N SHAFFER LECTURE 
11:29 AM Introduction of the Robert N Schaffer Lecturer
Steven M Litinsky MD
11:34 AM Robert N Schaffer Lecture: Glaucoma Changes—Reality Bites
Joel S Schuman MD*
12:00 PM End of Session
Evidence Base for Vision Rehabilitation
Event No: SYM05 10:30 AM - 12:00 PM
Room: 342
Combined meeting with the Vision Rehabilitation Committee
Chair(s): Joseph L Fontenot MD, Thomas J O’Donnell MD
The ultimate goal of vision rehabilitation is to improve the quality of life of our 
patients, many of whom are seniors and may live for 20 or 30 years with vision 
loss due to age related eye disease. Effective and efficient interventions are re-
quired for the increasing number of patients who have vision loss. Critique of 
interventions assists the practitioner to enhance clinical rehabilitation practice. 
This symposium will review research design and outcomes used in vision re-
habilitation research. Recently published systematic reviews will be presented.
10:30 AM Introduction
10:32 AM How to Measure and Interpret Outcomes of Goal-Directed Vision 
Rehabilitation
Robert W Massof PhD**
10:44 AM Design and Evaluation of a Customized Reading Rehabilitation 
Program for Patients With AMD
Miguel J Maldonado MD PhD
10:56 AM Rehabilitating Visual Field Loss: What Should We Be Addressing, and 
How Should We Measure Success?
Pradeep Y Ramulu MD PhD*
11:08 AM Preferred Practice Patterns for Vision Rehabilitation 2012
Mary Lou Jackson MD*
11:20 AM Systematic Reviews of Rehabilitation Interventions I
Joseph L Fontenot MD
11:32 AM Systematic Reviews of Rehabilitation Interventions II
Deepthi M Reddy MD
11:44 AM Discussion
12:00 PM End of Session
The Great Debate: Retina
Event No: SYM06 10:45 AM - 12:00 PM
Room: The Great Hall
Chair(s): Peter K Kaiser MD*
This symposium will be structured as a lively, old-fashioned debate. Four groups 
of debaters will argue the pros and cons of controversial topics. Speakers will 
have the opportunity to present prepared statements and then will have a chance 
to rebut those of their opponents. Audience voting will be used to determine 
which speakers were most effective in stating their arguments.
10:45 AM Introduction
Peter K Kaiser MD*
Sunday, Nov. 17 (cont.)
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Avastin is Safe
10:50 AM Introduction of Question and Audience Voting
10:51 AM Pro
Daniel F Martin MD
10:54 AM Con
Jason S Slakter MD*
10:57 AM Pro Rebuttal
Daniel F Martin MD
10:58 AM Con Rebuttal
Jason S Slakter MD*
10:59 AM Audience Voting
The Best Anti-VEGF Treatment for AMD is...
11:00 AM Introduction of Question and Audience Voting
11:01 AM Ranibizumab
Dante Pieramici MD*
11:04 AM Aflibercept
Jeffrey S Heier MD*
11:07 AM Bevacizumab
Philip J Rosenfeld MD PhD*
11:10 AM Pegaptanib
Victor H Gonzalez MD*
11:13 AM Ranibizumab Rebuttal
Dante Pieramici MD*
11:14 AM Aflibercept Rebuttal
Jeffrey S Heier MD*
11:15 AM Bevacizumab Rebuttal
Philip J Rosenfeld MD PhD*
11:16 AM Pegaptanib Rebuttal
Victor H Gonzalez MD*
11:17 AM Audience Voting
The Best Anti-VEGF Treatment Regimen is...
11:18 AM Introduction of Question and Audience Voting
11:19 AM Fixed
Darius M Moshfeghi MD**
11:22 AM PRN
David S Boyer MD*
11:25 AM Treat and Extend
K Bailey Freund MD*
11:28 AM Fixed Rebuttal
Darius M Moshfeghi MD**
11:29 AM PRN Rebuttal
David S Boyer MD*
11:30 AM Treat and Extend Rebuttal
K Bailey Freund MD*
11:31 AM Audience Voting
All I Need to Manage Retina is an OCT
11:32 AM Introduction of Question and Audience Voting
11:33 AM Pro
Carmen A Puliafito MD MBA*
11:36 AM Con
Susan B Bressler MD*
11:39 AM Pro Rebuttal
Carmen A Puliafito MD MBA*
11:40 AM Con Rebuttal
Susan B Bressler MD*
11:41 AM Audience Voting
11:42 AM Conclusions
Peter K Kaiser MD*
11:45 AM End of Session
Michael F Marmor MD Lecture in Ophthalmology and 
the Arts
Event No: SYM54 11:30 AM - 12:00 PM
Room: 255
Chair(s): Michael F Marmor MD*
11:30 AM Introduction
Michael F Marmor MD*
11:33 AM Degas, New Orleans, and “Eyes Greatly in Need of Care”
Richard Kendall, Curator-at-Large, Clark Art Institute
11:58 AM Conclusion
Michael F Marmor MD*
12:00 PM End of Session
Extreme Vision: Science Fiction or Truth
Event No: SYM07 12:15 - 1:45 PM
Room: 255
Combined meeting with the Museum of Vision®
Chair(s): Michael F Marmor MD*
This symposium will focus on exploring the truth (and the fiction) about what hu-
man vision can do and about efforts (wise or foolish) to make it do more. Topics 
will include the ‘normal’ limits of vision, ancient ideas of ocular power, visual 
abilities in science fiction, animal vision that exceeds ours, the vision of athletes, 
and the latest in real science to extend vision.
12:15 PM Welcome
Michael F Marmor MD*
12:20 PM Extreme Vision: Ancient Times to Classic Literature
James G Ravin MD
12:30 PM Extreme Vision: Pulp Fiction and Superheroes
Jenny Benjamin
12:45 PM What Is ‘Normal’ Vision?
Norman B Medow MD FACS
12:55 PM Extraordinary Vision in Animals
Ivan R Schwab MD FACS
1:10 PM Military Research and Applications
Robert W Enzenauer MD MPH*
1:20 PM Science Fiction Meets Real Science: Prosthetics
Joseph F Rizzo III MD
1:30 PM Did Ted Williams See the Seams on the Ball?
Michael F Marmor MD*
1:40 PM Closing Remarks/Questions
Michael F Marmor MD*
1:45 PM End of Session
Cataract Surgery: The Cutting Edge
Event No: SYM08 12:15 - 1:45 PM
Room: The Great Hall
Chair(s): Robert H Osher MD*
Panelists: Douglas D Koch MD*, Richard J Mackool MD*, Roger F Steinert MD*, David 
F Chang MD*, Richard B Packard MD*, Warren E Hill MD*, Ehud I Assia MD*, Richard 
L Lindstrom MD*, Edward J Holland MD*, Iqbal K Ahmed MD*, Michael E Snyder MD*
To stimulate a panel discussion, this symposium will present short videos of 
novel ideas, techniques, and devices from cataract surgeons around the world. 
Sunday, Nov. 17 (cont.)
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Expect controversy and spirited debate from the expert international panel. Guar-
anteed to keep you on the edge of your seats!
 SO  Seeing Patients Is What I Want to Do: Adjusting 
to the Challenge of Extending My Career in 
Ophthalmology
Event No: SYM25 12:45 - 1:45 PM
Room: 243
Combined meeting with the Committee on Aging and the Senior Ophthalmologist 
Committee
Chair(s): Gwen K Sterns MD, Harry Zink MD*
As older ophthalmologists face reductions in reimbursement, computerization, 
and accountable care organizations, they are asking new questions: Are there 
alternatives to my present practice arrangement that would allow me to continue 
the practice of ophthalmology as I have known it? Can I successfully adopt the 
new skills needed, adapting to a different practice style with an emphasis on 
medical ophthalmology or vision rehabilitation? Are there resources for me to 
retrain and to maintain my knowledge skills? And can I achieve a healthy life 
balance? Options, opportunities, and alternatives will be discussed in this COA/
SO joint symposium.
12:45 PM Introduction
Harry Zink MD*
12:48 PM You Are a Valued Asset: The Role of the Senior Ophthalmologist
Paul P Lee MD JD*
12:58 PM Maintaining the Machine: Sustaining Our Health for the Long Haul
Andrew G Lee MD*
1:08 PM Continuing Education for the Senior Ophthalmologist: What Is 
Available?
Louis B Cantor MD*
1:18 PM Adjusting to the Electronic Medical Record: Rebooting Your Practice
Andrew P Doan MD PhD*
1:28 PM Panel Discussion: Specific Options
1:28 PM Low Vision
David Parke MD
1:28 PM Medical Ophthalmology
Michael W Brennan MD
1:28 PM Volunteer Services
M Bruce Shields MD*
1:28 PM Teaching
Gwen K Sterns MD
1:42 PM Closing
Harry Zink MD*
1:45 PM End of Session
 EHR  Big Data Drives Better Outcomes: The Power and 
Benefits of the IRIS™ Registry
Event No: SYM57 12:45 - 1:45 PM
Room: La Nouvelle Orleans C
Chair(s): Anne Louise Coleman MD PhD*, William L Rich MD
Physicians are facing increasing pressures to report quality measures and dem-
onstrate value from several fronts. One is the increasing regulatory burden to 
comply with various reporting requirements, including the Physician Quality 
Reporting System (PQRS), Value-based Modifier (VBP), and Meaningful Use for 
electronic health record systems. The cumulative penalty for noncompliance with 
these requirements begins at 3.5 percent of Medicare payments and rises over 
time. Another is Maintenance of Certification which requires reviews of office 
records. Another demand is to manage the population as a whole, paying at-
tention to resource use and efficiency.This symposium will explore the vision of 
the IRIS Registry, how it can help ophthalmologists to comply with the changing 
regulatory landscape and enhance their ability to improve the outcomes of their 
patients, as well as showcase the ease of implementation, benefits and utility of 
data reports for individual members using the registry.
12:55 PM Alleviating Regulatory Burdens on Physicians
William L Rich MD
12:45 PM The Power of Big Data for Physicians
David May MD PhD
1:05 PM Ease of Implementation of IRIS
John M Haley OCS
1:15 PM Benefits of IRIS for the Subspecialist
Timothy G Murray MD MBA*
1:25 PM Q&A
1:45 PM End of Session
Best of NANOS 2013: Featuring Best Papers from the 
North American Neuro-Ophthalmology Society
Event No: SYM56 2:00 - 3:00 PM
Room: 255
Chair(s): Jacqueline A Leavitt MD
Panelists: Rudrani Banik MD*, Flora Levin MD, Roger E Turbin MD
2:00 PM NORDIC Idiopathic Intracranial Hypertension Treatment Trial, study 
director—IIHTT study update
Michael Wall MD*
2:10 PM Exploring the Temporal Evolution of Structural and Functional 
Changes after Acute Optic Neuritis
Fiona E Costello MD*
2:20 PM A Phase I Open Label, Dose Escalation Trial Of QPI-1007 Delivered 
By A Single Intravitreal (IVT) Injection To Subjects With Low Visual 
Acuity And Acute NAION
Bradley J Katz MD*
2:30 PM Enlargement of the Sella Turcica Partially Explains the Partially Empty 
Sella of Pseudotumor Cerebri
Sungeun Kyung MD
2:40 PM Acute Changes in Retinal Birefringence at Onset of NAION Reveals 
Axonal Injury Corresponding to Permanent Regional Visual Field Loss 
Mark J Kupersmith MD*
2:50 PM Subclinical Optic and Retinal Atrophy in Eyes with Papilledema 
Detected by OCT
Brian E Goldhagen MD
The Great Debate: Glaucoma
Event No: SYM09 2:00 - 3:15 PM
Room: The Great Hall
Chair(s): Kuldev Singh MD MPH*
This symposium will be structured as a lively, old-fashioned debate. Five pairs of 
debaters will argue the pros and cons of controversial topics. Speakers will have 
the opportunity to present prepared statements and then will have a chance to 
rebut those of their opponents. Audience voting will be used to determine which 
speakers were most effective in stating their arguments.
2:00 PM Introduction
Kuldev Singh MD MPH*
Is IOP Variability a Proven Risk Factor for Glaucoma?
2:04 PM Introduction of Question and Audience Voting
2:06 PM Yes
Anne Louise Coleman MD PhD*
Sunday, Nov. 17 (cont.)
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2:09 PM No
Anders H Heijl MD PhD*
2:11 PM Yes Rebuttal
Anne Louise Coleman MD PhD*
2:12 PM No Rebuttal
Anders H Heijl MD PhD*
2:13 PM Audience Voting
Genetic Testing for Glaucoma is...
2:14 PM Introduction of Question and Audience Voting
2:16 PM Useful Today
Janey Lee Wiggs MD PhD*
2:19 PM Not Ready for Prime Time
Wallace L M Alward MD
2:22 PM Useful Today Rebuttal
Janey Lee Wiggs MD PhD*
2:23 PM Not Ready for Prime Time Rebuttal
Wallace L M Alward MD
2:24 PM Audience Voting
For Cataract and Glaucoma Controlled on Medication, I Prefer 
Cataract Surgery... 
2:25 PM Introduction of Question and Audience Voting
2:27 PM Alone
Steven L Mansberger MD*
2:30 PM Combined with an Adjunctive Glaucoma Procedure
Thomas W Samuelson MD*
2:33 PM Alone Rebuttal
Steven L Mansberger MD*
2:34 PM Combined with an Adjunctive Glaucoma Procedure Rebuttal
Thomas W Samuelson MD*
2:35 PM Audience Voting
Has Treatment of Pre Perimetric Glaucoma Been Shown to Im-
prove Glaucoma Outcomes?
2:36 PM Introduction of Question and Audience Voting
2:38 PM Yes
Joel S Schuman MD*
2:41 PM No
George L Spaeth MD FACS*
2:44 PM Yes Rebuttal
Joel S Schuman MD*
2:45 PM No Rebuttal
George L Spaeth MD FACS*
2:46 PM Audience Voting
For Acute Angle Closure Glaucoma Relieved by Laser Iridotomy 
with Persistent High IOP and Cataract, I Prefer Cataract Surgery...
2:47 PM Introduction of Question and Audience Voting
2:49 PM Alone
Clement C Y Tham MBBS*
2:52 PM Combined with Trabeculectomy
Douglas J Rhee MD*
2:55 PM Alone Rebuttal
Clement C Y Tham MBBS*
2:56 PM Combined with Trabeculectomy Rebuttal
Douglas J Rhee MD*
2:57 PM Audience Voting
2:58 PM Conclusions
Kuldev Singh MD MPH*
3:00 PM End of Session
Innovations in Pediatric Eye Surgery
Event No: SYM10 2:00 - 3:30 PM
Room: La Nouvelle Orleans AB
Combined meeting with the American Association of Pediatric Ophthalmology and 
Strabismus (AAPOS)
Chair(s): Stephen P Christiansen MD, Sharon F Freedman MD*
Ocular surgery in children is often more challenging than in their adult counter-
parts. In the short term, congenital malformations, unique responses to surgical 
maneuvers, small ocular size, a more robust inflammatory response, and many 
other unique characteristics must all be taken into consideration when planning 
surgery. In the longer term, biologic changes in the eye, refractive growth of the 
eye, alterations in CNS efference, and amblyopia may adversely impact long-
term surgical success. It is not surprising, then, that newer surgical techniques 
are constantly being developed to overcome these challenges in hopes of improv-
ing both short- and long-term surgical outcomes in children. In this symposium, 
experts will discuss advances in surgical treatment for pediatric ocular disease.
2:00 PM Introduction
Stephen P Christiansen MD
Strabismus Surgery: Can We Improve Outcomes?
2:02 PM Minimally Invasive Surgery
Jon Peiter Saunte MD
2:08 PM Adjustable Sutures in Children
David L Guyton MD*
2:14 PM New Drugs and Devices
Stephen P Christiansen MD
2:20 PM New Devices for Pediatric Glaucoma
Sharon F Freedman MD*
2:30 PM Expanding the Micro-ophthalmic Orbit
Christopher B Chambers MD
Point—Counterpoint
2:40 PM Using Enzyme in Pediatric Vitreoretinal Surgery: Pro
Michael T Trese MD*
2:50 PM Using Enzyme in Pediatric Vitreoretinal Surgery: Con
Cynthia A Toth MD*
MARSHALL M PARKS LECTURE
3:00 PM Introduction of the Marshall M Parks Lecturer
Leon-Paul Noel MD
3:05 PM Marshall M Parks Lecture: Aphakia, Pseudophakia, and 
Polypseudophakia: Refractive Management of the Pediatric Lens
M Edward Wilson Jr MD*
3:28 PM Presentation Ceremony
Leon-Paul Noel MD
3:30 PM End of Session
Scientific Advancements in Ophthalmic Plastics: 
Implications for the Practicing Ophthalmologist
Event No: SYM11 2:00 - 3:30 PM
Room: La Nouvelle Orleans C
Combined meeting with the American Society of Ophthalmic Plastic and 
Reconstructive Surgery (ASOPRS)
Chair(s): Louise A Mawn MD*
This topic has implications regarding emerging treatment options in ophthalmol-
ogy. These treatments and insights into eye disease will be the result of the oph-
thalmic scientists dedicated to learning more about the underlying mechanism 
Sunday, Nov. 17 (cont.)
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of ocular and periocular pathology. Cell signaling is a common thread throughout 
the laboratory discoveries of the seemingly disparate investigations focusing on 
eye cancer, orbital inflammation, thyroid disease, and extra-ocular muscle de-
velopment.
2:00 PM Introduction
2:05 PM From Zebrafish to Ptosis: Why Signaling Impacts Time to Ptosis 
Repair
Alon Kahana MD PhD
2:17 PM Cytokines and Receptors in Idiopathic Orbital Inflammation
Edward Wladis MD*
2:29 PM Epigenetics and Eye Disease
Shannath Louise Merbs MD PhD*
2:41 PM Role of Insulin-like Growth Factor-1 in the Pathogenesis of Thyroid 
Eye Disease
Raymond Douglas MD PhD*
2:53 PM Conclusion and Q&A
WENDELL L HUGHES LECTURE
2:58 PM Introduction of the Wendell L Hughes Lecturer 
3:03 PM Wendell L Hughes Lecture: Orbital Foreign Bodies: Increased 
Incidence, Improved Analysis and Improved Management Through 
Technological Advances
James C Fleming MD*
3:28 PM Presentation of Award
3:30 PM End of Session
Keratoconus: Past, Present, and Future
Event No: SYM12 2:00 - 3:30 PM
Room: 243
Combined meeting with the Contact Lens Association of Ophthalmologists (CLAO)
Chair(s): Deborah S Jacobs MD*, Warren R Fagadau MD*, Michael H 
Goldstein MD*
This symposium will bring attendees up to date on keratoconus. Speakers will 
cover updated information on the natural history of keratoconus and advances in 
imaging and contact lenses over the last decade. Surgical outcomes of penetrat-
ing keratoplasty and innovations in penetrating and lamellar keratoplasty will be 
presented. Hot topics including genetics and corneal collagen crosslinking will 
be covered. The symposium concludes with the Whitney G Sampson MD lecture.
2:00 PM Introduction
Deborah S Jacobs MD*
2:02 PM Past and Present: Perspectives on Natural History from the 
Collaborative Longitudinal Evaluation of Keratoconus Studies
Michael W Belin MD*
2:10 PM Past and Present: Imaging and Diagnosis
Stephen D Klyce PhD*
2:18 PM Present: Contact Lens for Rehabilitation
Peter R Kastl MD PhD
2:26 PM Present: Penetrating Keratoplasty Outcomes
Sanjay V Patel MBBS*
2:34 PM Past, Present, and Future: Penetrating Keratoplasty
Sadeer B Hannush MD
2:42 PM Present and Future: Advances in Lamellar Keratoplasty
Sheraz M Daya MD*
2:50 PM Present and Future: Corneal Collagen Crosslinking
Penny Asbell MD FACS*
WHITNEY G SAMPSON LECTURE
2:58 PM Introduction of the Whitney G Sampson Lecturer
Michael H Goldstein MD*
3:01 PM Whitney G Sampson Lecture: The Genetics of Keratoconus: 
Implications for Future Treatment
Yaron S Rabinowitz MD
3:26 PM Award Presentation
Warren R Fagadau MD*
3:28 PM Concluding Remarks
Deborah S Jacobs MD*
3:30 PM End of Session
 YO  2013 Modern Technologies and Techniques for 
Young Ophthalmologists to Know
Event No: SYM55 3:00 - 4:30 PM
Room: 252
Combined meeting with the Young Ophthalmologist Committees of the Academy, 
Young Ophthalmologists from the European Society of Ophthalmology (SOE) and the 
Pan-American Association of Ophthalmology (PAAO)
Chair(s): Lauren Patty Daskivich MD, Anthony P Khawaja MBBS, Sandra 
Belalcazar-Rey MD*
The joint session with the young ophthalmologist (YO) committees of the Acad-
emy, the European Society of Ophthalmology, and the Pan-American Association 
of Ophthalmology will include discussions of new techniques, approaches, or 
therapies that are applied internationally, but not yet universally practiced. At-
tendees will learn about clinical and surgical techniques that may be useful in 
their future practices. If applicable, appropriate disclosures will be made when 
discussing available but non-US approved technologies or techniques.
3:00 PM Welcome
Lauren Patty Daskivich MD, Anthony P Khawaja MBBS, Sandra 
Belalcazar-Rey MD*
3:05 PM How are Femtosecond Lasers Going to Change Cataract Surgery?
Alexander C Day MBBCHIR
3:15 PM Q&A
Anthony P Khawaja MBBS
3:17 PM Artificial Vision With a Subretinal Implant
Katarina Stingl MD*
3:27 PM Q&A
Anthony P Khawaja MBBS
3:29 PM Experience With the Eyesi in Colombia for Training and Re-training 
Ophthalmologists in Phaco
Carlos A Restrepo Pelaez MD
3:39 PM Q&A
Sandra Belalcazar-Rey MD*
3:41 PM Multimodality Imaging of Macular Diseases
Lihteh Wu MD*
3:51 PM Q&A
Sandra Belalcazar-Rey MD*
3:53 PM The Present and Future of the Macular Disease Treatment
Francisco J Rodriguez MD*
4:03 PM Q&A
Sandra Belalcazar-Rey MD*
4:06 PM Adopting New Techniques in Surgery After Formal Training: Ethical 
Considerations
Roberto Pineda II MD*
4:16 PM Q&A
Lauren Patty Daskivich MD
4:18 PM Innovations 101
Kenneth L Lu MD
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4:28 PM Q&A
Lauren Patty Daskivich MD
4:28 PM Closing Remarks
4:30 PM End of Session
Best of the Anterior Segment Specialty Meetings 2013
Event No: SYM14 3:45 - 5:00 PM
Room: La Nouvelle Orleans C
Best Papers from the AAPOS, AGS, ASCRS, ASOPRS, Cornea Society, and ISRS 
Meetings
This symposium will feature 10 of the best papers from the major anterior seg-
ment specialty meetings of 2013. These papers will be in the major anterior seg-
ment specialty areas and are selected by the program committees of the respec-
tive societies from their annual specialty meetings. 
3:45 PM Introduction 
3:47 PM Combined Procedures in Fuchs Dystrophy and Cataract Surgery
Brandon Ayres MD*
3:54 PM Lens Selection Challenges We Face in Regular Astigmatism: The 
Baylor Nomogram
Mitchell P Weikert MD*
4:01 PM The Effects of Surgical Factors on Postoperative Astigmatism in 
Patients Enrolled in the Infant Aphakia Treatment Study (IATS)
Palak B Wall MD**
4:08 PM Effect of Posterior Corneal Astigmatism on Refractive Outcomes 
After Cataract Surgery With Toric IOL Implantation
D Rex Hamilton MD*
4:15 PM Decreased Postoperative Endophthalmitis Rate After Institution of 
Intracameral Antibiotics in a Northern California Eye Department
Neal H Shorstein MD**
4:22 PM Reflections on the Mechanics of Upper Eyelid Movement: Lessons for 
the Ptosis Surgeon
John W Shore MD*
4:29 PM A Comparison of Trabeculectomy Surgery Outcomes With 
Mitomycin-C Applied by Intra-Tenon Injection Versus Sponge Method
Michele C Lim MD
4:36 PM The Ocular Hypertension Treatment Study: Difference in the Effect of 
Long Term IOP Variability on the Risk of Developing POAG
Mae O Gordon PhD**
4:43 PM Intralenticular Laser Treatment--When Will It Be Available Clinically?
Ronald R Krueger MD*
4:50 PM Multifocal IOLs--How to Select the Ideal Patient?
George Beiko MD*
4:57 PM Conclusion 
5:00 PM End of Session
Spotlight on OCT
Event No: SPO1 3:45 - 5:15 PM
Room: The Great Hall
Chair(s): Joel S Schuman MD*, Anne Louise Coleman MD PhD*
OCT imaging has become integral to clinical practice in ophthalmology. From refractive 
surgery to glaucoma to retinal disease, OCT imaging helps to guide our practice. OCT 
frequently provides a clear picture of the pathologies affecting our patients, and gives 
ophthalmologists objective, quantitative measures on which to base treatment. OCT 
continues to evolve rapidly. This Spotlight session reviews the current state-of-the-art 
in clinical OCT imaging and looks ahead towards what the future might have in store.
3:45 PM Introduction
Joel S Schuman MD*
3:47 PM OCT Imaging — So What?
Robert N Weinreb MD*
3:55 PM Anterior Segment OCT — The Anterior Chamber Angle
Christopher Kai-shun Leung MD MBChB*
4:03 PM OCT Imaging in Glaucoma
Gadi Wollstein MD*
4:11 PM Lessons from OCT Imaging of the Lamina Cribrosa
Claude F Burgoyne MD*
4:19 PM Retinal OCT Imaging: Macular Degeneration
Richard F Spaide MD*
4:27 PM Retinal OCT Imaging: Diabetic Retinopathy
Jay S Duker MD*
4:35 PM Retinal OCT Imaging: The Pediatric Ophthalmology Story
Cynthia A Toth MD*
4:43 PM Retinal OCT Imaging in the Cataract Patient
Carmen A Puliafito MD MBA*
4:51 PM OCT Advances: the Next 5 Years
James Fujimoto PhD*
4:59 PM Questions and Answers
5:15 PM End of Session
A Sticky Problem: Evaluation and Management of 
Chronic Socket Discharge
Event No: SYM15 3:45 - 5:15 PM
Room: 243
Combined meeting with the American Society of Ocularists (ASO)
Chair(s): Doss K Tannehill BCO BADO, Timothy Francis McDevitt MD
Nearly every patient who wears an ocular prosthesis will suffer from socket 
discharge. The causes of this condition vary from those that are self-limiting 
and require solely supportive measures to those that are multifactorial and will 
improve only with surgical intervention. Symposium speakers will address the 
unique challenges encountered with the long-term use of a custom ocular pros-
thesis. This knowledge will be for the comprehensive ophthalmologist as well as 
the oculoplastics subspecialist.
3:45 PM Introduction
3:47 PM Evaluation and Treatment of Eyelid and Lacrimal Disorders Causing 
Chronic Discharge
Constance L Fry MD
3:55 PM The Ocularist’s Strategies for Treatment of the Chronically 
Discharging Socket
Jean G Thompson BCO
4:03 PM Evaluation and Management of Chronic Discharge Related to 
Coupling Devices
Jonathan W Kim MD
4:11 PM The Ocularist’s Approach to Coupling Devices and Chronic Socket 
Discharge
Marie-France Clermont BCO
4:19 PM Types of Conjunctivitis Unique to the Chronically Discharging Socket
Mehryar Taban MD
4:27 PM ‘Normal’ Socket Discharge and Patient Interpretation of Chronic 
Socket Discharge
John Stolpe BCO
4:35 PM Patient Home Remedies for Chronic Socket Discharge: What Not to 
Do
Donald W Kluge BCO
4:43 PM Q&A
RUEDEMANN LECTURE
4:51 PM Introduction of the Ruedemann Lecturer
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4:53 PM Ruedemann Lecture: Socket Reconstruction: Trials and Tribulations
Don Kikkawa MD*
5:13 PM Presentation of Award
5:15 PM End of Session
Mythbusters: Examining the Orthoptic and Surgical 
Management of the Most Puzzling Childhood 
Syndromes
Event No: SYM16 3:45 - 5:15 PM
Room: La Nouvelle Orleans AB
Combined meeting with the American Orthoptic Council and American Association 
of Certified Orthoptists (AACO)
Chair(s): A Melinda Rainey MD, Cheryl Lynn McCarus OSA CO COMT
The Internet has been an amazing boon for those seeking quick and easy access 
to information. However, much of its content is mostly unedited, and some of this 
information can leave parents and families of children afflicted with syndromes, 
including those with ocular pathology, confused as to how that pathology should 
be best treated. This symposium will discuss case examples that help define the 
currently preferred ocular treatments of several of the more common, contro-
versial, and puzzling syndromes from an orthoptic and ophthalmic perspective. 
These include Down syndrome, cerebral palsy, craniofacial syndromes, treat-
ment of high accommodative convergence-to-accommodation ratio esotropia in 
teens, and optic nerve hypoplasia. Some of the current controversial treatments 
will be examined in depth. This course will provide general ophthalmologists 
and pediatric ophthalmologists with practical information about current trends, 
controversies, and practices that will be useful when confronted with these 
questions.
3:45 PM Introduction
Cheryl Lynn McCarus OSA CO COMT
3:50 PM The Orthoptics of Down Syndrome
Emily Miyazaki CO
4:00 PM Ophthalmology in Cerebral Palsy: When and Why to Operate
Mary Louise Z Collins MD
4:10 PM Orthoptics in Craniofacial Syndromes
Bonita Schweinler CO COMT
4:20 PM Ophthalmology in Craniofacial Syndromes: When and Why to 
Operate
Kanwal K Nischal MBBS*
4:30 PM Orthoptic Treatment of Teenagers With High Accommodative 
Convergence-to-Accommodation Ratios
Marla J Shainberg CO
4:40 PM Surgical Treatment of Teenagers With High Accommodative 
Convergence-to-Accommodation Ratios
Burton J Kushner MD
4:50 PM What We Know About Optic Nerve Hypoplasia
Neil R Miller MD*
5:00 PM Conclusion and Q&A
A Melinda Rainey MD
5:15 PM End of Session
 GO   YO  International Opportunities for Young 
Ophthalmologists
Event No: SYM13 4:15 - 5:15 PM
Room: New Orleans Theater C
Combined meeting with the YO International Subcommittee
Chair(s): Grace Sun MD*, Brad H Feldman MD*
Today’s residents and young ophthalmologists (YOs) must become tomorrow’s 
leaders in the global fight against eye disease. This session will address the chal-
lenges of treating eye disease in underserved parts of the world and will identify 
the organizations working toward this goal and the opportunities available for 
resident and YO involvement. The session will also examine the unique chal-
lenges of incorporating volunteer service into one’s career by sharing the experi-
ences of those who have found ways to balance work abroad with family, clinical 
practice, and financial concerns at home. At the conclusion of the session, the 
attendee will have an understanding of the global burden of eye disease, the 
organizations and strategies employed to address this burden, the role residents 
and YOs play in this work, and the challenges of balancing domestic life with 
international service.
4:15 PM Overview on Ophthalmology and Global Health
Grace Sun MD*
4:18 PM Integrating Global Health Into an Academic Career
R V Paul Chan MD
4:28 PM YO Opportunities With the Himalayan Cataract Project
Matthew S Oliva MD
4:38 PM So You Want to Go Overseas? Things to Know Before You Go
David S Friedman MD MPH PhD*
4:48 PM The Resident’s Perspective on Global Health Work
Michael D Tibbetts MD
4:58 PM Q&A
5:13 PM Closing Remarks
5:15 PM End of Session
Monday, Nov. 18
Advances in Keratoplasty: Where We Are in 2013
Event No: SYM20 8:15 - 10:15 AM
Room: La Nouvelle Orleans C
Combined meeting with the Cornea Society
Chair(s): William Barry Lee MD*, James P McCulley MD FACS FRCOphth*
We have seen a variety of advances in keratoplasty for the surgical treatment of 
corneal blindness in all age groups, young to elderly. Understanding both kera-
toplasty trends and the adoption of new techniques, including lamellar surgery, 
artificial corneal transplants, and stem cell transplants, and new devices, such 
as implementation of femtosecond laser technology, is crucial for ophthalmology 
in the 21st century. This symposium will feature surgical management strategies 
for diverse forms of corneal blindness. The symposium will conclude with the 
Castroviejo Lecture by Dr. Edward Holland, discussing advances in limbal stem 
cell disease.
8:15 AM Introduction
William Barry Lee MD*
8:17 AM Keratoplasty Trends in the United States
Woodford S Van Meter MD FACS
8:27 AM Management of the Failed Graft: Counterpoint—Keratoprosthesis Is 
Better
Victor L Perez MD*
8:37 AM Endothelial Keratoplasty: What the Future Holds
Francis W Price Jr MD*
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8:47 AM Advances in Deep Anterior Lamellar Keratoplasty: Don’t Burst the 
Bubble
Rajesh Fogla MD FRCS*
8:57 AM Advances in Femtosecond-Assisted Keratoplasty: Is It Worthwhile?
Marjan Farid MD*
9:07 AM Therapeutic Keratoplasty: Tips for Success
Clara C Chan MD*
9:17 AM Management of the Failed Graft: Repeat Tissue Transplantation Is 
Better
Deepinder K Dhaliwal MD*
9:27 AM Update on Pediatric Keratoplasty: Success or Distress?
Gerald W Zaidman MD FACS
CASTR OVIEJO LECTURE
9:37 AM Introduction of the Castroviejo Lecturer
James P McCulley MD FACS FRCOphth*
9:39 AM Castroviejo Lecture: The Evolution of Lamellar Keratoplasty
Edward J Holland MD*
10:11 AM Conclusion
William Barry Lee MD*
10:15 AM End of Session
Spotlight on Cataract Complications: M&M Rounds—
Learning From My Mistakes
Event No: SPO2 8:15 AM - 12:15 PM
Room: The Great Hall
Chair(s): David F Chang MD*, William J Fishkind MD FACS*
This case-based video symposium will focus on cataract surgical complications. Every 
cataract surgeon makes mistakes and suffers complications, but it is how and what 
we learn from them that makes us better ophthalmologists. Eighteen different cataract 
experts will present a video case where something went wrong and a complication oc-
curred that taught them valuable lessons. Paired panelists will then comment on the 
cases and the ‘teaching points’. The audience will weigh in using response pads. The 
symposium will conclude with the 9th annual Kelman Lecture.
8:15 AM Introduction
David F Chang MD*,
8:17 AM  Panel
Robert J Cionni MD*, Audrey R Talley-Rostov MD*
8:17 AM From Champagne to Lemonade
Roger F Steinert MD*
8:28 AM Conundrum
Stephen S Lane MD*
8:39 AM Panel
Ehud I Assia MD*, Louis D Skip Nichamin MD*
8:39 AM Killing Me Softly
Brock K Bakewell MD*
8:50 AM The Donnenfeld Snap Technique
Eric D Donnenfeld MD*
9:01 AM Panel
Alan S Crandall MD*, Bonnie A Henderson MD*
9:01 AM Open or Closed?
Sonia H Yoo MD*
9:12 AM Complex Cases Gone Wild
Iqbal K Ahmed MD*
9:23 AM Panel
Michael E Snyder MD*, Walter J Stark MD*
9:23 AM Fool Me Twice, Shame on Me
Richard S Hoffman MD*
9:34 AM Threading a Needle
Terry Kim MD*
9:45 AM Panel
Steven H Dewey MD*, Timothy G Murray MD MBA*
9:45 AM When Surgeons Need More Support
Thomas A Oetting MD
9:59 AM Blame the Horse
Lisa B Arbisser MD*
10:07 AM Panel
Boris Malyugin MD PhD, Randall J Olson MD
10:07 AM The 100 Year Old Lens
Kevin M Miller MD*
10:18 AM The Longest Day (Part 2)
Amar Agarwal MD*
10:29 AM Panel
Thomas W Samuelson MD*, Rudy Nuijts MD*
10:29 AM High Pressure Comes in Small Packages
Douglas D Koch MD*
10:40 AM Don’t Cry for Me Argentina
Geoffrey C Tabin MD
10:51 AM Panel
Nick Mamalis MD*, R Bruce Wallace MD*
10:51 AM Unhappy Multifocal Patient — Unhappy Surgeon!
Matteo Piovella MD*
11:02 AM A Haptic, a Haptic — My Kingdom for a Haptic
Richard J Mackool MD*
11:13 AM Panel
Richard L Lindstrom MD*, Kirk H Packo MD*
11:13 AM Chamber Shallowing Can be a Bloody Worry
Brian C Little MD*
11:24 AM Pithing the Eye
Robert H Osher MD*
CHARLES D KELMAN LECTURE 
11:35 AM Introduction to the Kelman Lecture
William J Fishkind MD FACS*
11:40 AM Charles D Kelman Lecture: 25 Years of the JCRS Consultation Section
Samuel Masket MD*
12:15 PM End of Session
Quality Measures in Ophthalmology: The Future 
Landscape
Event No: SYM17 8:30 - 10:00 AM
Room: New Orleans Theater C
Combined meeting with the American Medical Association Ophthalmology Section 
Council (AMA)
Chair(s): Kevin Thomas Flaherty MD, Samuel Solish MD, Mathew W Mac-
Cumber MD PhD*, S William Clark MD
With the ongoing implementation of the Affordable Care Act, many changes to 
the U.S. health care system are under way. These changes are at the nexus of 
public policy, clinical care, and payment issues. In this symposium, experts in 
quality measures and payment will discuss the potential impact of these mea-
sures on patient outcomes, as well as the risks and opportunities for ophthalmol-
ogy practices as these measures are linked by payers to financial incentives.
8:30 AM Introduction
8:32 AM Reporting on Quality and Cost: Consequences for Reimbursement
Cynthia Mattox MD FACS*
8:42 AM Quality Measures and MOC
Paul P Lee MD JD*
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8:52 AM A Quality and Outcomes Program in Massachusetts
Teresa C Chen MD
9:02 AM An Ophthalmic Clinical Registry: A Pathway to Improved Quality and 
Outcomes
William L Rich MD
PARKER HEATH LECTURE
9:12 AM Parker Heath Lecture: If We Are Serious About Value-based 
Payments, Redesign Performance Measures!
Frank Opelka MD FACS
9:32 AM Q&A
10:00 AM End of Session
Changing Paradigms in the Management of Venous 
Occlusive Disease
Event No: SYM18 8:30 - 10:00 AM
Room: La Nouvelle Orleans AB
Combined meeting with American Society of Retina Specialists (ASRS)
Chair(s): G Baker Hubbard MD
Multiple treatment modalities are available for patients with retinal vein occlu-
sion (RVO), and decision making about the best treatment for any given patient 
has become more complex in recent years. This symposium will review the evolv-
ing treatment of RVO and the most recent data regarding emerging therapies. 
In addition, typical and atypical cases of RVO will be presented to a panel of 
experts for opinions about optimum regimens in various clinical scenarios. Topics 
to be covered will include management of branch RVO and central RVO, timing of 
intervention, combination therapy, tips on use of imaging modalities, and when 
to perform laboratory workup for systemic disease. The presentations will stress 
practical and useful information for clinicians caring for patients with RVO.
8:30 AM Introduction
G Baker Hubbard MD
8:32 AM Epidemiology of Retinal Vein Occlusion
Ingrid U Scott MD MPH*
8:42 AM BRVO/CRVO: Overview of Surgical Treatments and When (if Ever) to 
Use Them
Gary C Brown MD*
8:52 AM BRVO: Overview of Medical Treatments
Julia A Haller MD*
9:02 AM CRVO: Overview of Medical Treatments
Michael S Ip MD*
9:12 AM Systemic Treatment
Justis P Ehlers MD*
9:22 AM Case Presentations/Panel Discussion
9:57 AM Summary and Closing Remarks
G Baker Hubbard MD
10:00 AM End of Session
 SO  Fitness for Duty: What’s Age Have to Do With It?
Event No: SYM19 8:30 - 10:00 AM
Room: 243
Combined meeting with the Senior Ophthalmologist Committee (SO)
Chair(s): David Parke MD, M Bruce Shields MD*, C P Wilkinson MD*
Aging and its physical and neuropsychological effects are well known in health 
care, and ophthalmologists are not exempt from these realities. Studies have 
demonstrated a statistical decline in physicians’ quality of care linked to ad-
vanced age, and this has raised patient safety concerns in many quarters. And 
aging changes may be compounded by medical progress that has increased 
intellectual, technological, and practice demands upon all physicians. The im-
plications of older ophthalmologists continuing as essential elements of the 
physician workforce include the recognition that aging may affect both cogni-
tive and physical capabilities of the Eye M.D. Although physician expertise can 
be maintained into later life, optimal performance may require modifications of 
practice habits. This symposium will include a discussion of the effects of aging 
changes, including mild cognitive impairment, upon physician capabilities and 
also the experiences of the Academy’s Ethics Committee and the American Board 
of Ophthalmology in dealing with these issues.
8:30 AM Introduction
8:33 AM Mild Cognitive Impairment and Additional Aspects of Aging: 
Detection and Management
Charles A Cefalu MD
8:52 AM Q&A
9:02 AM Ethical Considerations Regarding the Performances of Aging 
Physicians 
Charles M Zacks MD
9:21 AM Q&A
9:31 AM The American Board of Ophthalmologists’ Experience Regarding 
Practice Performances of Aging Physicians
John G Clarkson MD
9:50 AM Q&A
10:00 AM End of Session
 GO  2013 Global Forum: A Kaleidoscope of Volunteering 
in Developing Countries — Global Ophthalmology, 
Making a Difference
Event No: SYM21 8:30 - 11:00 AM
Room: 252
Combined meeting with the Academy’s Global Education and Outreach Committee
Chair(s): Linda M Lawrence MD, Fernando Pena MD*, David H Cherwek 
MD*, Timothy P Page MD*, Victoria M Sheffield*
A panel of international experts will discuss topics relevant to volunteers who 
are making a difference in developing countries by their participation in programs 
both at home and abroad. The symposium will include an opportunity for audi-
ence participation in a question-and-answer session with the panelists, as well 
as a tea-and-cookies break for informal interaction.
8:30 AM Welcome
Linda M Lawrence MD
8:35 AM Panel I: The Volunteer’s Role in Primary Eye Care, Research, and NGO 
Liaisons Overseas
Fernando Pena MD*
8:35 AM Integrating Primary Eye Care Into Primary Health Care: Early 
Detection, Ocular Safety Awareness, and How to Have Real Impact
Ivo Kocur MD
8:45 AM Contributing to Research Initiatives
Nathan G Congdon MD
8:55 AM Designing a Global Residency Experience: Weighing Resident and 
Host Expectations
Brad H Feldman MD*
9:05 AM How to Coordinate With NGOs to Synergize Efforts
Suzanne Gilbert PhD MPH
9:15 AM Audience Questions & Answers
9:35 AM Panel II: The Volunteer’s Role in Strengthening Global Ophthalmology 
From Home
David H Cherwek MD*
9:35 AM What Has Been Achieved: Advocacy, Funding, and Investments in Eye 
Health
Gullapalli N Rao MD
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9:45 AM Advocacy and the Importance of Data in Influencing Decision Makers 
and Donors
Serge Resnikoff MD PhD
9:55 AM Strategies to Help Patients Accept Western Medicine
Kunle O Hassan MBBS
10:05 AM Audience Questions & Answers
10:25 AM Summary
Timothy P Page MD*
10:30 AM Networking
11:00 AM End of Session
Best of the Posterior Segment Specialty Meetings 2013
Event No: SYM22 10:15 - 11:30 AM
Room: La Nouvelle Orleans AB
Best Papers from the AAPOS, American Uveitis Society, ASOPRS, NANOS, ASRS, 
Macula Society, and Retina Society Meetings
This symposium will feature best papers focusing on the posterior segment from 
the major retina, neuro-ophthalmology, uveitis, oculoplastics, and pediatric oph-
thalmology specialty meetings of 2013.
10:15 AM Introduction 
10:16 AM Management of Congenital Anophthalmia and Microphthalmia: The 
CHOP Experience
James A Katowitz MD**
10:24 AM Length of Day During Early Gestation is an Independent Predictor of 
Risk for Severe Retinopathy of Prematurity
Michael B Yang MD
10:32 AM Comparison of Wide-Field Fluorescein Angiography and Nine-Field 
Montage Angiography in Uveitis
Benjamin P Nicholson MD **
10:40 AM Association Between Genetic Mutations and Clinical Outcomes in 
Uveal Melanoma
J William Harbour MD*
10:48 AM Life Cycle of Pseudodrusen
Richard F Spaide MD*
10:56 AM Retained Lens Fragments After Cataract Surgery: Outcomes of Same-
day vs Later Para Plana Vitrectomy
Harry W Flynn Jr MD
11:04 AM 2013 Update on DRCR.net Topical Antibiotic Use and Endophthalmitis 
Rates With Intravitreal Drug Injections
Abdhish R Bhavsar MD*
11:12 AM CFH and ARMS2 Genetic Polymorphisms Predict Response to 
Antioxidants and Zinc in Patients With Age-Related Macular 
Degeneration
Carl C Awh MD*
11:20 AM Systemic Safety Profile of Intravitreal Ranibizumab in Wet AMD, 
RVO, and DME: A Meta-Analysis of 14 Phase II/III Clinical Trials
Baruch D Kuppermann MD PhD*
11:28 AM Conclusion 
11:30 AM End of Session
Teaching and Learning in Ophthalmology—”Give Me 
Something to Make Me a Better Teacher!” Faculty 
Development Modules
Event No: SYM23 10:15 - 11:45 AM
Room: 243
Combined meeting with the Association for University Professors of Ophthalmology 
(AUPO)
Chair(s): Andreas Lauer MD*, Tara A Uhler MD
Competency-based education is the rubric currently used to help prepare to-
morrow’s physicians to practice, learn and teach in an ever-changing clinical 
environment where patient safety, improved communication, effective clinical 
outcomes, and practice efficiency are prized. Through participation in selected 
modules offered in this symposium, participants will gain an increased under-
standing of competency-based education and gain an enhanced teaching skill 
set as ophthalmic educators. Attendees will have the opportunity to pick 2-3 of 
7 possible modules to attend, and in which to participate. At the conclusion of 
the modules, all the participants gather in preparation for the Straatsma Lecture. 
Following the Straatsma Lecture, each module leader will briefly summarize the 
content of their module to the group and a final synthesis will conclude the sym-
posium. Instructional faculty development is an area of great need in academic 
training programs as we incorporate the ACGME Milestones in ophthalmic edu-
cation and meet the changes of the Next Accreditation System.
10:15 AM Introduction and Orientation
Andreas Lauer MD*
10:20 AM Module: Engaging Residents to Participate and Successfully 
Complete Research Projects
Shahzad I Mian MD*
10:20 AM Module: EQUIPP (Education, Quality Improvement, and Patient Care 
Projects) for Ophthalmology Training
Laura L Wayman MD
10:20 AM Module: Mentoring in Ophthalmology Training: Then, Now, Tomorrow
Natalie Kerr MD
10:20 AM Module: Just in Time—Electronic vs. Interpersonal Learning
Thomas A Oetting MD
10:20 AM Module: The Aces in Promoting Professionalism in Training
Richard A Harper MD
10:20 AM Module: iLearn: An Educational Experiment in Teaching Lifelong 
Learning
Timothy W Olsen MD*
10:20 AM Module: The ART of Giving Structured Feedback and the PEARLS for 
Building Relationships
Douglas R Fredrick MD
11:09 AM Confluence
STRAATSMA LECTURE
11:12 AM Introduction of the Straatsma Lecturer
11:17 AM Straatsma Lecture: Motivation and Engagement—When Perfect is 
Good Enough
Andreas Lauer MD**
11:37 AM Presentation of the Straatsma Award
11:38 AM Synthesis and Conclusion
11:45 AM End of Session
Monday, Nov. 18 (cont.)
130 * The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.  
No asterisk indicates that the presenter has no financial interest..
Spotlight Sessions & Symposia
 S
po
tli
gh
t S
es
si
on
s 
 &
 S
ym
po
si
a
The Affordable Care Act and Health Care Reform in 
2013: Pearls and Potential Perils
Event No: SYM24 10:15 - 11:45 AM
Room: New Orleans Theater C
Combined meeting with the National Medical Association (NMA)
Chair(s): Robert A Copeland MD, Everton L Arrindell MD*
The Affordable Care Act was signed into law on March 23, 2010, and was found 
constitutional by the Supreme Court by a 5-4 decision on June 28, 2012. The 
implementation of this law’s timeline for rollout is imminent and on schedule. 
Some 30 million poor and marginalized American citizens will receive insurance 
and preventive care. Recent analysis reports that there will be a physician short-
age of 90,000 at the end of the decade and 130,000 by 2025. In this symposium 
we will discuss the law, the impact on physician shortages, and the changing 
payment methods. Additionally we will look at innovative ways to treat our pa-
tients and be more productive.
10:15 AM Introductions and Welcome
Robert A Copeland MD
10:17 AM What Does the Affordable Care Act Mean for Ophthalmologists?
William L Rich MD
10:25 AM How Will Graduate Medical Education Be Paid for Under the 
Affordable Care Act?
Leonard Marquez
10:33 AM Does the Affordable Care Act Address Workforce Issues in 
Ophthalmology for the Baby Boomers and the Y Generation?
Keith D Carter MD FACS
10:41 AM How Will the Affordable Care Act Affect Ongoing and Future 
Ophthalmic Research?
Randall J Olson MD**
10:49 AM Eye Health Disparities: How Does the Affordable Care Act Ameliorate 
the Problem?
M Roy Wilson MD
10:57 AM Implications of Bundled Payment Systems in Health Care 
Reimbursement Reform
Michael X Repka MD MBA*
11:05 AM What Are the Tools Needed to Be Successful and Thrive in the 
Affordable Care Act Era?
Paul P Lee MD JD*
11:13 AM What Is the Future for Ophthalmology Under the Affordable Care 
Act?
John G Clarkson MD
11:21 AM Q&A and Panel Discussion
11:43 AM Closing Remarks
Everton L Arrindell MD*
Blast Eye Injuries: Lessons Learned from Boston, West, 
Texas, Iraq, and Afghanistan
Event No: SYM52 10:45 - 11:45 AM
Room: La Nouvelle Orleans C
Chair(s): Jorge G Arroyo MD, Mary Gilbert Lawrence MD MPH, Robert A 
Mazzoli MD
This presentation brings attendees together with nationally recognized medical 
experts on blast eye injuries, who will share lessons learned from the Boston 
Marathon bombing; the catastrophic explosion of the fertilizer plant in West, TX; 
Operation Enduring Freedom; and Operation Iraqi Freedom. Ocular injuries from 
explosions represent special cases due to the not yet well-understood physics of 
blasts, physiological differences between blast eye injuries and concussive eye 
injuries, and the emergency or combat conditions under which blast eye injuries 
are treated. The panelists will provide their perspectives on emergency response 
in urban, rural, and combat settings; discuss the physics behind blasts injuries 
(pressure wave, shrapnel wave, translocation and heat wave); and provide take-
home points to best prepare the ophthalmologist for the next mass casualty 
event. The session will include a question and answer session at conclusion.
10:45 AM Introduction
Mary Gilbert Lawrence MD MPH
10:46 AM The Physics of Blasts and the Physiology of Ocular Blast Injuries
Allen B Thach MD
10:51 AM Blast Injuries in the Urban Canyon (Boston Marathon)
Yoshihiro Yonekawa MD, Dean Eliott MD*, Jorge G Arroyo MD
11:06 AM Blast Exposure in Rural Areas (Plant Explosion)
Henry Hacker MD
11:16 AM Combat Blast Eye Injuries: The Military Experience
Raymond I Cho MD**
11:26 AM Closing Statement and Lessons Learned
Robert A Mazzoli MD
11:31 AM Panel Discussion
Peter B Veldman MD, Matthew F Gardiner MD, Ankoor S Shah MD*
11:45 AM End of Session
Ergonomics: Preventing Work-Related Injury in the 
Ophthalmologist
Event No: SYM26 12:15 - 1:45 PM
Room: 255
Combined meeting with the Women in Ophthalmology (WIO)
Chair(s): Susan M MacDonald MD*, Kimberly Cockerham MD FACS*
‘Physician heal thyself.’ During ophthalmologists’ daily routine, they will put their 
bodies into prolonged stretches or compressions to examine patient’s eyes and 
perform surgical procedures. These non-neutral postures and awkward positions 
put ophthalmologists at risk of developing acute and chronic work-related mus-
culoskeletal disorders. Understanding the risks and identifying modifications in 
the day’s routine can create safer habits. Developing an ergonomically safe work 
environment and exercise routine is an important step in protecting ophthalmolo-
gists’ body and future.
12:15 PM Introduction
Susan M MacDonald MD*
12:20 PM Definitions and Incidence, With Special Emphasis on Increased Risk 
in Females
Jeffrey L Marx MD*
12:30 PM Q&A
12:35 PM Ideal Posture, Ideal Form
Renee Ostertag MD
12:45 PM Protecting Yourself in the Operating Room
Ashish Nimbarte PhD
12:55 PM Modifying Your Postural Habits: Identifying Opportunities to Improve 
the Ergonomics of Your Clinic Environment
Keith Hugh Baratz MD*
1:05 PM Q&A
1:10 PM Panel Discussion: Exercises/Stretching to Reduce Risk
Jennifer A Sivak-Callcott MD, Renee Ostertag MD
1:20 PM Employer Responsibility and Disability
Martin Wand MD
1:30 PM Q&A
1:35 PM Closing Remarks
Kimberly Cockerham MD FACS*
1:45 PM End of Session
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 EHR  Stage 2 of Meaningful Use: What You Need to Do to 
Qualify for Payment
Event No: SYM27 12:45 - 1:45 PM
Room: New Orleans Theater C
Combined meeting with the Committee on Medical Information Technology (CMIT)
Chair(s): Michael F Chiang MD*
The Medicare and Medicaid EHR Incentive Programs provide incentive payments 
to eligible professionals and hospitals as they adopt, implement, upgrade, or 
demonstrate meaningful use of certified EHR technology. Eligible professionals 
can receive up to $44,000 through the Medicare EHR Incentive Program and up to 
$63,750 through the Medicaid EHR Incentive Program. Beginning in 2015, Medi-
care eligible professionals who do not successfully demonstrate meaningful use 
will be subject to a negative payment adjustment, which could go up to as much 
as -5% in 2019. Significant changes have also been made to the definition of 
certified EHR technology, which can affect the choice of EHRs and EHR modules. 
To help ophthalmologists qualify for Meaningful Use incentives, this symposia 
will address the timeline, updates, and criteria for Stage 2.
12:45 PM Timeline, Payment Adjustments, and Hardship Exemptions for 
Meaningful Use
Michael X Repka MD MBA*
12:55 PM Federal Perspective on Stage 2 of Meaningful Use: Benefits for 
Practitioners and Future Vision
1:05 PM Stage 2 Meaningful Use: What Changes Are Most Relevant for Your 
Practice?
Michael V Boland MD PhD
1:15 PM Beyond Stage 2: What Do Ophthalmologists Need?
Michael F Chiang MD*
1:25 PM Q&A and Panel Discussion
1:45 PM  End of Session
Management of Corneal Edema, Opacification, and 
Ectasia in the 21st Century: Diagnostic and Treatment 
Strategies From the New Preferred Practice Pattern® 
Guideline
Event No: SYM28 12:45 - 1:45 PM
Room: 215
Combined meeting with the Preferred Practice Patterns Committee (PPPC)
Chair(s): Robert S Feder MD
Corneal edema, opacification, and ectasia are the focus of a new Preferred Prac-
tice Pattern (PPP) guideline. The authors—PPP Cornea & External Disease com-
mittee members—will use the evidence-based recommendations from this PPP 
to provide the comprehensive ophthalmologist with a good understanding of how 
the latest diagnostic equipment and surgical techniques can provide the best 
care for an affected patient. The utility of advanced corneal topography instru-
mentation and anterior segment OCT will be discussed. The emphasis will be on 
teaching the comprehensive eye physician the basic indications and techniques, 
as well as the advantages and disadvantages of Descemet-stripping endothe-
lial keratoplasty, deep anterior lamellar keratoplasty, anterior lamellar surgery, 
intrastromal ring segment insertion, and collagen crosslinking. Through didactic 
lecture and case presentation, the goal is to provide the attendee with pearls and 
take-home points that can be used in clinical practice. A free CD-ROM containing 
all 20 PPP titles and Summary Benchmarks will be distributed to attendees.
12:45 PM What Is the PPP?
Stephen D McLeod MD
12:48 PM How Does the Corneal Specialist Manage Corneal Opacification?
Francis S Mah MD*
1:03 PM Corneal Edema Management in the 21st Century
Woodford S Van Meter MD FACS
1:18 PM A Modern Evaluation and Treatment Algorithm for Corneal Ectasia
Audrey R Talley-Rostov MD*
1:33 PM Panel Q&A
1:45 PM End of Session
Why Take the Risk? How to Create an Effective Risk 
Management Strategy With Patient Education and 
Informed Consent Documents
Event No: SYM29 12:45 - 1:45 PM
Room: 224
Combined meeting with the Patient Education Committee and the Ophthalmic 
Mutual Insurance Company (OMIC)
Chair(s): Philip R Rizzuto MD FACS
Through analysis of specific medicolegal cases and a survey of OMIC defense 
counsel, learn how to minimize your risk against malpractice lawsuits with the 
effective use of ophthalmic patient education and informed consent tools.
12:45 PM Introduction
Philip R Rizzuto MD FACS
12:50 PM A Medico-legal Case Presentation
Devin A Harrison MD
1:05 PM Discussion of OMIC Defense Counsel Survey Results and Points
John W Shore MD*
1:20 PM Academy and OMIC Resources for Education and Informed Consent
Philip R Rizzuto MD FACS
1:35 PM Conclusion and Q&A
1:45 PM End of Session
Advances in Glaucoma: Medical and Surgical Therapy
Event No: SYM30 2:00 - 3:30 PM
Room: La Nouvelle Orleans C
Combined meeting with the Association for Research in Vision and Ophthalmology 
(ARVO)
Chair(s): Rohit Varma MD MPH*, Dimitri T Azar MD*
This session will emphasize current and controversial issues in glaucoma that are 
relevant to both the comprehensive ophthalmologist and the glaucoma specialist. 
A translational and scientific-based approach will be used to discuss advances in 
the diagnosis and management of glaucoma. Topics to be presented include the 
following: imaging and functional assessment in diagnosing early glaucomatous 
damage and progression; IOP monitoring in glaucoma; practice patterns in the 
medical treatment of glaucoma; efficacy and side effects of novel and traditional 
topical ocular hypotensive therapy; surgical management of glaucoma, including 
novel minimally invasive procedures, traditional trabeculectomy and drainage de-
vices, and future long-term drug delivery and neuroregenerative therapies.
2:00 PM Who Should I Treat?
Jeffrey M Liebmann MD*
2:09 PM What’s New in Drug Treament? New Drugs, Combination Drops, 
Preservative-Free Drops
Anne Louise Coleman MD PhD*
2:18 PM Drug Treatment: Is There an Alternative to Drops?
Mark S Humayun MD PhD*
2:27 PM Selective Laser Trabeculoplasty: Is It Better Than Argon Laser 
Trabeculoplasty? Is It Repeatable?
Ahmad A Aref MD*
2:36 PM Have Tubes Won the Trabeculectomy vs. Tube Battle?
Dale K Heuer MD*
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2:45 PM Minimally Invasive Glaucoma Surgery: Improving Drainage Through 
the Schlemm Canal
Thomas W Samuelson MD*
2:54 PM Minimally Invasive Glaucoma Surgery: Improving Subconjunctival 
Drainage and Creating Suprachoroidal Drainage
Richard A Lewis MD*
3:03 PM Novel Glaucoma Surgeries: Case Presentations
Iqbal K Ahmed MD*
3:12 PM Neuroprotection or Neuroregeneration in Glaucoma: Tired Hype or 
Potential Reality?
Neeru Gupta MD PhD*
3:21 PM Panel Discussion: Putting It All Together
Robert N Weinreb MD*
3:30 PM End of Session
New Drug or New Delivery System? The Way Forward 
in Combating Infectious and Inflammatory Diseases
Event No: SYM31 2:00 - 3:30 PM
Room: 243
Combined meeting with the Ocular Microbiology and Immunology Group (OMIG)
Chair(s): Prashant Garg MD*, Bennie H Jeng MD
Infectious and inflammatory ocular diseases pose several challenges. Important 
among these are the development of antimicrobial resistance and toxicity. The 
traditional approach to overcoming these challenges is to develop new and more 
potent molecules. However, since the time of penicillin this approach has failed, 
with several of these antibiotics, including fluoroquinolones, losing potency 
within a few years of development. Several alternative approaches have been 
explored recently, including those that improve drug delivery to the site of ac-
tion. This approach not only prevents development of drug resistance, but also 
reduces toxicity. During this symposium we will be discussing some of these 
approaches that are in various phases of development and may be ready for use 
in clinical practice in the near future.
2:00 PM Biological Agents in the Management of Ocular Inflammation: A 
Case-based Update
Nisha Acharya MD*
2:10 PM Q&A
2:13 PM Corneal Transplant Rejection: Is There a Role for Biologic Agents?
Victor L Perez MD*
2:23 PM Q&A
2:26 PM Intraocular Implants as a Potential Approach to Reduce Postoperative 
Inflammation and Infection
Debra A Goldstein MD*
2:36 PM Q&A
2:39 PM Intraocular Implants for Posterior Segment Inflammation: Current 
Status and the Way Forward
Sunil K Srivastava MD*
2:49 PM Q&A
2:52 PM Application of Nano-technology for Ocular Inflammation and 
Infections
William R Freeman MD*
3:02 PM Q&A
3:05 PM Antimicrobial Peptides (AMPs) and Infections: Will They Replace 
Conventional Antibiotic Therapy for Treatment of Infectious 
Diseases?
Terrence P O’Brien MD*
3:15 PM Q&A
3:18 PM Current Strategies for Management of MRSA
Francis S Mah MD*
3:28 PM Q&A
3:30 PM End of Session
Advanced Retinal Imaging and Its Impact on 
Therapeutic Strategies
Event No: SYM32 2:00 - 3:30 PM
Room: La Nouvelle Orleans AB
Combined meeting with The Retina Society
Chair(s): Charles C Barr MD FACS*, Mark W Johnson MD*
Treatment options for various retina diseases currently involve both medical and 
surgical approaches. In the past, management of different retinal diseases re-
quired the practitioner to use clinical skills to determine the severity and extent 
of clinical pathology. In this symposium, speakers will discuss currently used and 
newer imaging techniques, including digital photography, fluorescein angiogra-
phy, OCT, and ultrasound, and their impact on how we now manage retinal dis-
ease. They will focus on not only the visual and anatomic benefits to the patient 
but also the impact of these newer imaging techniques on treatment strategies. 
Understanding the paradigm shift that has taken place in retinal imaging will be 
of value to both vitreoretinal specialists and comprehensive ophthalmologists.
2:00 PM Trends in the Interface Between Digital Images and the Electronic 
Medical Record
James P Bolling MD
2:08 PM Ultrasound in the Time of OCT
Yale L Fisher MD*
2:16 PM Spectral Domain OCT Correlates of Visual Acuity: Practical 
Applications
Glenn J Jaffe MD*
2:24 PM Imaging of Neovascular Subtypes in AMD: Implications for Treatment
K Bailey Freund MD*
2:32 PM Non-invasive Choroidal Imaging
Brian C Leonard MD*
2:40 PM Enhanced Depth Imaging OCT of Ocular Tumors: Key Features to 
Recognize
Carol L Shields MD
2:48 PM Imaging in Retina Vein Obstruction
David Brown MD FACS*
2:56 PM OCT and the Management of Vitreoretinal Disease
Cynthia A Toth MD*
3:04 PM Ultra-wide-field Angiography in Diabetic Retinopathy
Szilard Kiss MD*
3:12 PM The RetCam, Telemedicine, and ROP
Graham E Quinn MD*
3:20 PM Overview: The New Paradigm of Retinal Imaging
Charles C Barr MD FACS*
3:28 PM Conclusion
3:30 PM End of Session
The Management of Glaucoma in the Cataract Patient
Event No: SYM33 2:00 - 4:00 PM
Room: The Great Hall
Combined meeting with the American Society of Cataract and Refractive Surgery 
(ASCRS)
Chair(s): Edward J Holland MD*, Stephen S Lane MD*
This collaborative symposium utilizes cases in a debate style format to address 
the management of clinical scenarios involving patients with glaucoma that 
would be seen by both comprehensive ophthalmologists and glaucoma special-
ists alike. Traditional approaches and surgery along with newer technologies will 
be discussed. Several discussions regarding the optimization of the refractive 
status of patients with glaucoma surgery will provide current and detailed in-
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formation to help the practitioner obtain better results. Furthermore, platform 
presentations on the potential uses of femtosecond laser assisted cataract sur-
gery, small pupil management, and narrow angles will bring you up to date on 
these hot topics.
2:00 PM Welcome
Edward J Holland MD*
2:01 PM Introduction
Thomas W Samuelson MD*, Douglas J Rhee MD*
2:03 PM Presentation of Case #1: Mild Glaucoma With Cataract and Mildly 
Elevated IOP
Thomas W Samuelson MD*
2:03 PM My Approach: Cataract Alone
James C Tsai MD MBA*
2:08 PM My Approach: Cataract and Angle Surgery
Thomas D Patrianakos DO
2:13 PM My Approach: Cataract and ECP
Malik Y Kahook MD*
2:18 PM Judges Panel Comments
2:23 PM ARS Voting
2:25 PM Presentation of Case #2: Advanced Glaucoma With Cataract and Very 
High IOP; Patient Needs Filter, What Do You Add?
Douglas J Rhee MD*
2:28 PM My Approach: iStent
Iqbal K Ahmed MD*
2:33 PM My Approach: Trabectome
Sameh Mosaed MD*
2:38 PM My Approach: Trabeculectomy
Joseph Caprioli MD FACS*
2:43 PM Judges Panel Comments
2:48 PM ARS Voting
2:50 PM Presentation of Case #3: Bleb-induced Astigmatism and Now 
Develops a Cataract
Thomas W Samuelson MD*
2:53 PM My Approach: Cataract With Monofocal IOL
Steven Gedde MD*
2:58 PM My Approach: Cataract With Toric IOL
Steven D Vold MD*
3:03 PM My Approach: Cataract With AK/LRI Cuts
Barbara A Smit MD PhD*
3:08 PM Judges Panel Comments
3:13 PM ARS Voting
3:15 PM Potential Role of Femtosecond Laser for Cataract Extraction in PXF 
and Traumatic Cataract
Eric D Donnenfeld MD*
3:22 PM Managing the Small Pupil and Flomax Iris
Reay Brown MD*
3:29 PM Narrow Angle Glaucoma: Role of LPI and/or Phaco
Richard A Lewis MD*
3:36 PM Panel Discussion
Douglas J Rhee MD*
4:00 PM End of Session
Reading With Low Vision: Rehabilitation and 
Neuroplasticity
Event No: SYM34 3:45 - 4:45 PM
Room: 243
Combined meeting with the Vision Rehabilitation Committee
Chair(s): Mary Lou Jackson MD*, Lylas G Mogk MD*
Seniors who develop age-related eye disease and adults who develop other neu-
rological disorders are often surprised and extremely disappointed to discover 
that they cannot read with ease. We know that reading involves both visual and 
cognitive function, and insult to either system can impact reading performance. 
Reading is the most common goal that individuals with vision loss bring to vi-
sion rehabilitation. The ability to read is a key part of maintaining independence 
and healthy aging. The ultimate goal of reading rehabilitation is to improve the 
quality of life of our patients, many of whom are seniors who may live for 20 or 
30 years with vision loss due to age-related eye disease. Fortunately, patients 
with central scotomas can effectively “rewire” the system, so that they can use 
an eccentric locus for fixation in place of the blind macula. They can improve 
their visual acuity and their reading in this way despite a lack of improvement in 
their macular disease. This symposium will focus on reading and reading reha-
bilitation, bringing together clinicians and scientists from the areas of neurology, 
ophthalmology, visual science, and neuroimaging.
3:45 PM Introduction
Mary Lou Jackson MD*
3:47 PM How Visual Function Impacts Reading
Andrew G Lee MD*
3:58 PM Reading Impairments in Retinal Disease
Donald Calvin Fletcher MD
4:09 PM Reading Impairments in Neurological Disease
Dean M Cestari MD
4:20 PM Reading Rehabilitation: Approaches and Controversies
Gale R Watson**
4:31 PM Reading Rehabilitation and Neuroplasticity: True or False?
Janet S Sunness MD*
4:42 PM Conclusion
Lylas G Mogk MD*
4:45 PM End of Session
How Do We Maintain Quality, Improve Efficiency, and 
Sustain the Physician-Patient Relationship?
Event No: SYM35 3:45 - 4:45 PM
Room: New Orleans Theater C
Combined meeting with the Committee on Practice Improvement
Chair(s): Joseph Caprioli MD FACS*, Anne Louise Coleman MD PhD*
Amidst the increasing complexity of health care, payers are taking the driver’s 
seat in demanding value for their health-care purchases. Ophthalmologists will 
be asked to measure quality more carefully, evaluate their processes more close-
ly, and become more efficient. The Academy’s Committee on Practice Improve-
ment is developing activities to help members increase efficiency and enhance 
the quality of the care process. These shared learnings and best practices will 
help ophthalmologists to evaluate their own care processes and target improve-
ment efforts, while sustaining the keystone of care, the physician-patient rela-
tionship. In this symposium, speakers will describe quality improvement initia-
tives and lessons learned. The need for effective communication and teamwork 
for quality patient care will be addressed, as well as keeping focus on the patient 
in a busy practice. Speakers will address practice efficiency through appropriate 
delegation of tasks by the ophthalmologist. All participants will receive a CD-
ROM containing all of the Preferred Practice Patterns.
3:45 PM Introduction
Joseph Caprioli MD FACS*, Anne Louise Coleman MD PhD*
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3:47 PM Quality Improvement in an Ophthalmic Academic Center
Robert M Levine MD
3:57 PM Practice Efficiency in the Real World and How the Academy Can Help 
Members
Joseph Caprioli MD FACS*
4:07 PM Benchmarking Your Practice and Lessons Learned
Steven V L Brown MD*
4:17 PM Data on the Use of Physician Extenders to Increase Practice Efficiency
David A Durfee MD
4:27 PM Panel Discussion and Q&A
4:45 PM End of Session
The Optical Biopsy: Ocular Imaging Modalities and 
Correlation With Histopathology
Event No: SYM36 3:45 - 5:15 PM
Room: La Nouvelle Orleans C
Combined meeting with the American Association of Ophthalmic Oncologists and 
Pathologists (AAOOP)
Chair(s): Nasreen A Syed MD, Debra J Shetlar MD
Most practicing ophthalmologists are using some form of ocular imaging in their 
practices today. Imaging modalities such as OCT and echography are used fre-
quently to manage patients with conditions such as AMD and glaucoma. As the 
technology advances, these modalities are providing high-resolution images of 
many ocular structures. This symposium will review some of the newer imaging 
modalities, such as ultrahigh-resolution OCT, posterior segment spectral domain 
OCT (SD-OCT), anterior segment SD-OCT, contrast enhanced ultrasonography, 
and adaptive optics, and will correlate each imaging modality with its anatomic 
/ histologic counterparts in order to educate the clinician in the structures be-
ing imaged and, ultimately, the interpretation and limitations of these imaging 
studies.
3:45 PM Introduction
Nasreen A Syed MD
3:46 PM Contrast-Enhanced Ultrasonography: Clinical and Histopathological 
Correlates
Hans E Grossniklaus MD
3:54 PM Adaptive Optics of the Retina: Clinical Correlates
Jacque L Duncan MD
4:02 PM Ultra-high-Resolution OCT in Corneal and Conjunctival Disease
Sander Dubovy MD
4:10 PM SD-OCT Imaging for Glaucoma: Clinical and Histopathologic 
Correlates
Christopher A Girkin MD*
4:18 PM SD-OCT Imaging of the Macula: Clinical and Histopathologic 
Correlates
Alison H Skalet MD PhD
4:26 PM Photoacoustic In Vivo Retinal Imaging: Clinical and Histopathologic 
Correlates
Amani Fawzi MD
ZIMMERMAN LECTURE
4:34 PM Introduction of Zimmerman lecturer
Ralph Eagle MD*
4:39 PM Zimmerman Lecture: Intraocular Tumors in Children and Adults—
Passing the Torch
Carol L Shields MD
5:14 PM Presentation of Zimmerman Medal
Hans E Grossniklaus MD
5:15 PM End of Session
Advanced Applications of Femtosecond Lasers for 
Refractive Surgery
Event No: SYM37 3:45 - 5:15 PM
Room: La Nouvelle Orleans AB
Combined meeting with the International Society of Refractive Surgery (ISRS)
Chair(s): Renato Ambrosio Jr MD*, George O Waring IV MD*
Femtosecond lasers emerged by the end of the last century as one of the most 
important innovations in anterior segment surgery. With rapid development and 
evolution, femtosecond lasers have revolutionized corneal and refractive sur-
gery. Though LASIK flap creation is still the most common application, corneal 
channels, pockets, and incisions can also be achieved with an unprecedented 
accuracy and safety in a bladeless fashion. In addition, femtosecond-assisted 
cataract and crystalline lens applications hold great promise and may represent 
the future of IOL surgery. These new applications are introduced continuously, 
making it a true challenge for refractive surgeons to stay updated with this tech-
nology. Attendees will receive a comprehensive update on femtosecond lasers 
and will understand the benefits of such technology for both corneal and lens-
based refractive procedures.
3:45 PM Introduction
Renato Ambrosio Jr MD*
3:46 PM Overview
Perry S Binder MD*
3:49 PM Corneal Wound Healing After Femtosecond Laser Surgery
Steven E Wilson MD*
3:56 PM LASIK
Steven C Schallhorn MD*
4:03 PM Intracorneal Ring Segments
Mauro S Campos MD
4:10 PM Pocket
Minoru Tomita MD PhD*
4:17 PM Intracor®
Mike P Holzer MD*
4:24 PM Corneal Transplant
Luciene B Sousa MD**
4:31 PM Accommodation
Ronald R Krueger MD*
4:38 PM Cataract
George O Waring IV MD*
4:45 PM The Market of Femtosecond Lasers: Can We Afford It?
Richard L Lindstrom MD*
BARRAQUER LECTURE
4:52 PM Introduction of the Barraquer Lecture
4:57 PM Barraquer Lecture: Wound Healing and Biomechanical Changes After 
Wavefront-guided and Q-based Keratorefractive Surgery: Theoretical 
and Practical Applications
Dimitri T Azar MD*
5:12 PM Presentation of the Award
5:14 PM Conclusion
5:15 PM End of Session
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Tuesday, Nov. 19
Management of Vitreoretinal Interface Diseases
Event No: SYM38 8:30 - 10:00 AM
Room: La Nouvelle Orleans C
Combined meeting with the European Latin America Retina Specialist Society 
(Eurolam)
Chair(s): Stanley Chang MD*, Gisbert W Richard MD*, Borja F Corcostegui 
MD*
Using intraoperative videotapes and case presentations, a panel of internation-
ally recognized experts will demonstrate their approaches to various types of dis-
ease involving the vitreoretinal interface, including macular hole, macular pucker, 
traumatic macular hole, diabetic traccional macular edema, myopic macular hole, 
and others.
8:30 AM Anti-VEGF Therapy and Geographic Atrophy
Ursula M Schmidt-Erfurth MD*
8:38 AM Surgical Techniques for Special Cases
Marcio B Nehemy MD*
8:46 AM Myopic Macular Schisis and Hole
Borja F Corcostegui MD*
8:54 AM Internal Limiting Membrane Management in Surgery for Idiopathic 
Macular Hole
Federico A Graue-Wiechers MD
9:02 AM Enzymatic Management of Abnormalities of the Vitreomacular 
Interface
George A Williams MD*
9:10 AM Tractional Diabetic Macular Edema
Francesco M Bandello MD*
9:18 AM Controversies in the Treatment of the Traumatic Macular Hole
David E Pelayes MD*
9:26 AM Vitreomacular Interface in the Post radiation Maculopathy
Arun D Singh MD
9:34 AM Vitrectomy for Myopic Foveoschisis: Is It Better Without Tamponade?
Yannick Le Mer MD*
9:42 AM Discussion
10:00 AM End of Session
 SO   YO  So You Want to Be a Leader in Ophthalmology?
Event No: SYM39 8:30 - 10:00 AM
Room: 243
Combined meeting with the Young Ophthalmologist (YO) and Senior 
Ophthalmologist (SO) Committees
Chair(s): Susan H Day MD, H Dunbar Hoskins Jr MD FACS*, Robert F 
Melendez MD MBA, Purnima S Patel MD
The number of vacancies for leadership positions in the rapidly evolving field of 
health care is growing and will continue to do so. This symposium will identify 
key leadership positions in ophthalmology: department chair, residency program 
director, state and national leadership positions, as well as practice- and hospital-
based leadership roles. Furthermore, the various etiologies for these deficiencies 
will be discussed. The need for leadership roles to ensure the persistent vitality 
of the field of ophthalmology will be emphasized. More importantly, the panel 
of speakers will comment on mechanisms by which a continued foundation of 
strong leadership can be sustained, with a particular focus on methods for young 
ophthalmologists to begin developing, fostering, and sharpening the leadership 
skills required to fill these positions. The speakers will be young ophthalmolo-
gists who occupy current leadership roles and experienced ophthalmologists 
who have been in these positions for many years. This will be a joint symposium 
of the Young Ophthalmologist (YO) Committee and the Senior Ophthalmologist 
(SO) Committee.
8:30 AM Introduction
H Dunbar Hoskins Jr MD FACS*
8:35 AM Why Are Leaders Necessary?
Susan H Day MD
8:40 AM Defining the Ideal Characteristics of a Leader
Julia A Haller MD*
8:47 AM Leadership Styles
Morton F Goldberg MD FACS*
Pathway to Leadership Panel: Personal Perspectives
8:55 AM Employed Leadership
Keith D Carter MD FACS
9:03 AM Volunteer Leadership
Thomas A Oetting MD
9:12 AM Leadership at the State Level
Linda M Tsai MD
9:19 AM Leadership Across Medicine
Dimitri T Azar MD*
9:27 AM International Leadership Development Program
Michael W Brennan MD
9:35 AM Specific Resources Available for Future Leaders
Ruth D Williams MD
9:42 AM Q&A
9:57 AM Closing Remarks
H Dunbar Hoskins Jr MD FACS*
10:00 AM End of Session
A Multidisciplinary Approach to Emerging Therapies in 
Neuro-Ophthalmology
Event No: SYM40 8:30 - 10:30 AM
Room: La Nouvelle Orleans AB
Combined meeting with the North American Neuro-Ophthalmology Society (NANOS)
Chair(s): Madhu R Agarwal MD, Matthew Dean Kay MD
The spectrum of diseases and findings seen by ophthalmologists are often mani-
festations of significant systemic disease. This symposium provides an overview 
of several diseases and describes emerging methods of treatments for patients 
suffering from them. Topics include optic neuritis, thyroid eye disease, giant cell 
arteritis, pseudotumor cerebri, pituitary tumors, aneurysmal third nerve palsy, di-
abetic mononeuropathy, and metastatic breast cancer. The care of these complex 
patients requires a multidisciplinary approach. Attendees will be better informed 
about novel medical and surgical approaches to systemic diseases and will be 
better able to coordinate care of these patients among the different medical sub-
specialties.
8:30 AM Welcome
Madhu R Agarwal MD
8:32 AM Optic Neuritis Case: Fingolimod (Gilenya)
Fiona E Costello MD*
8:41 AM Proptosis/TED Case: Rituximab (Rituxan)
Todd A Goodglick MD
8:50 AM Giant Cell Arteritis Case: IV Methylprednisolone (Solumedrol)
Mark L Moster MD*
8:59 AM Pseudotumor Cerebri Case: Bariatric Surgery (Gastric Bypass/Lap-
Band)
Rudrani Banik MD*
9:08 AM Pituitary Tumor: Endoscopic Neurosurgery
Steven A Newman MD
9:17 AM Aneurysmal Third Nerve Palsy: Glue/Coils
Mark J Kupersmith MD*
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9:26 AM Diabetic Sixth Nerve Palsy: Exenatide (Byetta)
Susan M Pepin MD
9:35 AM Breast Cancer Metastasis to Orbit: Trastuzuamab, Lapatinib 
(Herceptin, Tykerb)
Marie D Acierno MD
9:44 AM Conclusion
Matthew Dean Kay MD
WILLIAM F HOYT LECTURE 
9:46 AM Introduction of the William F Hoyt Lecturer
9:51 AM William F Hoyt Lecture: Neuro-Ophthalmology in Review: Around the 
Brain with 50 Fellows
Nancy J Newman MD*
10:16 AM Presentation of Award
10:30 AM End of Session
Anterior Segment Reconstruction
Event No: SYM41 10:15 - 11:45 AM
Room: 243
Combined meeting with the American Society of Ocular Trauma (ASOT)
Chair(s): G Philip Matthews MD PhD, Ronald Peter Danis MD*
This year’s symposium will include a detailed discussion on anterior segment re-
construction. The program will focus on primary surgical decisions and complex 
secondary surgical management. Special consideration will be given to the treat-
ment approach to traumatic cataract and the role of the iris prosthesis. Finally, 
the seventh Helen Keller Lecture will be presented.
10:15 AM Introduction
G Philip Matthews MD PhD
10:17 AM Timing and Wound Closure Strategies
M Bowes Hamill MD*
10:27 AM What Else to Consider?
Jose Dalma MD
10:37 AM Diagnostic Work-up
Mark I Rosenblatt MD PhD*
10:47 AM Timing of Surgical Intervention
Gregorio F Gabela MD
10:57 AM Traumatic Cataract: What, When, and How
Ferenc P Kuhn MD PhD
11:07 AM The Role of the Iris Prosthesis
Michael E Snyder MD*
HELEN KELLER LECTURE
11:17 AM Introduction of the Helen Keller Lecture
Ferenc P Kuhn MD PhD
11:19 AM Helen Keller Lecture: “Pole to Pole” Approach in Severe Ocular 
Trauma: Focus on the “Middle Earth”—Iris Reconstruction and 
Beyond
Cesare Forlini MD
11:44 AM Presentation of Award
Ferenc P Kuhn MD PhD
11:45 AM End of Session
Late Breakers Symposium
Event No: SYM42 10:15 - 11:45 AM
Room: La Nouvelle Orleans C
Topics will cover new technology and therapies as well as important topics and 
controversies that have come up within the last six months in the field of oph-
thalmology.
10:15 AM Introduction 
Maria M Aaron MD
10:16 AM Ten Year Results of the Cornea Donor Study
Edward J Holland MD*
10:26 AM Posterior Corneal Astigmatism and the Revised Toric IOL 
Recommendations
Mitchell P Weikert MD*
10:36 AM Plaquenil Screening Recommendations
Michael F Marmor MD*
10:46 AM Cataract Extraction for Angle Closure Glaucoma
Christopher Kai-shun Leung MD MBChB*
10:56 AM FDA Approval of the iStent
Steven D Vold MD*
11:06 AM Orbital Lymphoproliferative Disease Spectrum, Pathologic Variation, 
Implication and Treatment
J Douglas Cameron MD
11:16 AM OCT Evaluation of Papilledema: Pilot Studies and Baseline 
Characteristics of Participants in the Idiopathic Intracranial 
Hypertension Treatment Trial
Mark J Kupersmith MD*
11:26 AM Results of AREDS2
Emily Y Chew MD
11:36 AM FDA Approval of the Argus II
Mark S Humayun MD PhD*
11:46 AM End of Session 
Grand Rounds: Cases and Experts From Across the 
Nation
Event No: SYM43 10:45 AM - 12:00 PM
Room: La Nouvelle Orleans AB
Chair(s): Nicholas J Volpe MD*
Panelists: Alfredo A Sadun MD PhD*, Lee M Jampol MD*, Alexander J Brucker 
MD*, Raymond S Douglas MD PhD*
Real residents present real cases from real department grand rounds. Residents 
chosen from different academic programs will present cases to a panel of ex-
perts followed by Q&A and discussion by the panel.
10:45 AM Introduction and Welcome Remarks
Nicholas J Volpe MD
10:47 AM Chronic Uveitis With Hypopyon
Maria E Lim MD
10:58 AM Another Case of Diplopia: Exhausting but Not Painful
Kimberly M Hsu MD
11:09 AM 33-Year-Old With Transient Vision Loss
Denise S Kim MD
11:20 AM Why Won’t This Eye Swelling Resolve
Meraf A Wolle MD**
11:31 AM Deep Knee in the Nerve
Paula E Pecen MD**
11:43 AM Retinal Tear With a Twist
Vaidehi S Dedania MD
11:55 AM Closing Remarks
Nicholas J Volpe MD
12:00 PM End of Session
Tuesday, Nov. 19 (cont.)
Smarter. Better. Faster.1
LenSx® Laser. There’s only one.
Delivering precision and consistency1, the LenSx® Laser remains 
the proven global leader in laser refractive cataract surgery. As 
part of the Cataract Refractive Suite by Alcon, the LenSx® Laser 
continues its legacy of innovation designed to improve patient 
outcomes. LenSxLasers.com
BETTER1
 -  Lens fragmentation patterns for efficient 
phacoemulsification time
 -  LenSx® SoftFit™ Patient interface for easy 
patient docking, secure fixation and low IOP
 -  Can be used with VERION™ Digital Marker for 
surgical planning and execution
SMARTER
 - Pre-population of patient and incision data 
 -  Advanced incision pre-positioning, centration 
and cyclorotation
 -  Platform design enables continued 
innovation and rapid enhancements
FASTER1
 -  Laser procedure efficiency with reduced 
programming and laser treatment time 
 -  Designed for maximum procedural flexibility 
and ease of patient flow and transfer
 -  No fixed bed, head immobilization, or messy 
liquid interface requirements
1. Alcon data on file.
THE CATARACT REFRACTIVE SUITE BY ALCON
For important safety information, please see adjacent page.
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important safety information
Caution: United States Federal Law restricts this device to sale and use by or on the order of a 
physician or licensed eye care practitioner.
indiCation: The LenSx® Laser is indicated for use in patients undergoing cataract surgery for 
removal of the crystalline lens.  Intended uses in cataract surgery include anterior capsulotomy, 
phacofragmentation, and the creation of single plane and multi-plane arc cuts/incisions in the 
cornea, each of which may be performed either individually or consecutively during the same 
procedure.
restriCtions:
• Patients must be able to lie flat and motionless in a supine position. 
• Patient must be able to understand and give an informed consent.  
• Patients must be able to tolerate local or topical anesthesia.  
• Patients with elevated IOP should use topical steroids only under close medical supervision.
Contraindications:
•  Corneal disease that precludes applanation of the cornea or transmission of laser light at 
1030 nm wavelength
• Descemetocele with impending corneal rupture
• Presence of blood or other material in the anterior chamber
• Poorly dilating pupil, such that the iris is not peripheral to the intended diameter for the 
capsulotomy
•  Conditions which would cause inadequate clearance between the intended capsulotomy 
depth and the endothelium (applicable to capsulotomy only)
•  Previous corneal incisions that might provide a potential space into which the gas produced 
by the procedure can escape
• Corneal thickness requirements that are beyond the range of the system
• Corneal opacity that would interfere with the laser beam
• Hypotony or the presence of a corneal implant
•  Residual, recurrent, active ocular or eyelid disease, including any corneal abnormality (for 
example, recurrent corneal erosion, severe basement membrane disease)
• History of lens or zonular instability
• Any contraindication to cataract or keratoplasty
• This device is not intended for use in pediatric surgery.
Warnings: The LenSx® Laser System should only be operated by a physician trained in its use.  
The LenSx® Laser delivery system employs one sterile disposable LenSx® Laser Patient Interface 
consisting of an applanation lens and suction ring.  The Patient Interface is intended for single 
use only.  The disposables used in conjunction with ALCON® instrument products constitute a 
complete surgical system.  Use of disposables other than those manufactured by Alcon may 
affect system performance and create potential hazards.
The physician should base patient selection criteria on professional experience, published 
literature, and educational courses.  Adult patients should be scheduled to undergo cataract 
extraction.
preCautions:
• Do not use cell phones or pagers of any kind in the same room as the LenSx® Laser.
• Discard used Patient Interfaces as medical waste.
aes/CompliCations:
• Capsulotomy, phacofragmentation, or cut or incision decentration
• Incomplete or interrupted capsulotomy, fragmentation, or corneal incision procedure
• Capsular tear
• Corneal abrasion or defect
• Pain
• Infection
• Bleeding
• Damage to intraocular structures
• Anterior chamber fluid leakage, anterior chamber collapse
• Elevated pressure to the eye
attention: Refer to the LenSx® Laser Operator’s Manual for a complete listing of indications, 
warnings and precautions.
THE CATARACT REFRACTIVE SUITE BY ALCON important safety information for the verion™ referenCe unit and verion™ 
digital marker
Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.  
intended uses: The VERION™ Reference Unit is a preoperative measurement device that captures 
and utilizes a high-resolution reference image of a patient’s eye in order to determine the radii and 
corneal curvature of steep and flat axes, limbal position and diameter, pupil position and diameter, 
and corneal reflex position. In addition, the VERION™ Reference Unit provides preoperative surgical 
planning functions that utilize the reference image and preoperative measurements to assist with 
planning cataract surgical procedures, including the number and location of incisions and the 
appropriate intraocular lens using existing formulas. The VERION™ Reference Unit also supports the 
export of the high-resolution reference image, preoperative measurement data, and surgical plans 
for use with the VERION™ Digital Marker and other compatible devices through the use of a USB 
memory stick.  
The VERION™ Digital Marker links to compatible surgical microscopes to display concurrently the 
reference and microscope images, allowing the surgeon to account for lateral and rotational eye 
movements. In addition, the planned capsulorhexis position and radius, IOL positioning, and 
implantation axis from the VERION™ Reference Unit surgical plan can be overlaid on a computer 
screen or the physician’s microscope view. 
ContraindiCations: The following conditions may affect the accuracy of surgical plans 
prepared with the VERION™ Reference Unit: a pseudophakic eye, eye fixation problems, a non-intact 
cornea, or an irregular cornea. In addition, patients should refrain from wearing contact lenses 
during the reference measurement as this may interfere with the accuracy of the measurements.
Only trained personnel familiar with the process of IOL power calculation and astigmatism 
correction planning should use the VERION™ Reference Unit. Poor quality or inadequate biometer 
measurements will affect the accuracy of surgical plans prepared with the VERION™ Reference Unit. 
The following contraindications may affect the proper functioning of the VERION™ Digital Marker: 
changes in a patient’s eye between preoperative measurement and surgery, an irregular elliptic 
limbus (e.g., due to eye fixation during surgery, and bleeding or bloated conjunctiva due to 
anesthesia). In addition, the use of eye drops that constrict sclera vessels before or during surgery 
should be avoided. 
Warnings: Only properly trained personnel should operate the VERION™ Reference Unit and 
VERION™ Digital Marker. 
Only use the provided medical power supplies and data communication cable. The power supplies 
for the VERION™ Reference Unit and the VERION™ Digital Marker must be uninterruptible. Do not use 
these devices in combination with an extension cord. Do not cover any of the component devices 
while turned on.
Only use a VERION™ USB stick to transfer data. The VERION™ USB stick should only be connected 
to the VERION™ Reference Unit, the VERION™ Digital Marker, and other compatible devices. Do 
not disconnect the VERION™ USB stick from the VERION™ Reference Unit during shutdown of the 
system.  
The VERION™ Reference Unit uses infrared light. Unless necessary, medical personnel and patients 
should avoid direct eye exposure to the emitted or reflected beam.  
preCautions: To ensure the accuracy of VERION™ Reference Unit measurements, device 
calibration and the reference measurement should be conducted in dimmed ambient 
light conditions. Only use the VERION™ Digital Marker in conjunction with compatible surgical 
microscopes.  
attention: Refer to the user manuals for the VERION™ Reference Unit and the VERION™ Digital 
Marker for a complete description of proper use and maintenance of these devices, as well as a 
complete list of contraindications, warnings and precautions. 
THE CATARACT REFRACTIVE SUITE BY ALCON
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WHERE ALL OF OPHTHALMOLOGY MEETS
Sunday – Tuesday, Nov. 17 - 19
A panel discussion, with time for audience questions, will follow each paper presentation. 
At the end of each session, the panel will select the best paper from that session. 
Selection Committee 
The Annual Meeting Program Committee selected all Original Papers.
See page 33 for committee details.
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Cataract
Sunday, Nov. 17
10:30 AM - 12:15 PM
Room: 243
Moderator: Mitchell P Weikert MD*
Panel: William J Fishkind MD FACS*, Nicole R Fram MD*, R Bruce Wallace MD*
PA001 10:30 AM
 NEW  First 5th-Generation Formula: The Hoffer H-5
Presenting Author: Kenneth J Hoffer MD FACS*
Purpose: To improve the accuracy of fourth generation formulas such as the 
Holladay 2 and Hoffer H so as to consider other patient factors in predicting 
the effective lens position. Methods: A world literature search was done on 
the biometric measurements of human eyes in large series. The data were col-
lated and analyzed to produce average values for different populations based 
on race and gender. Results: The values calculated were used to replace 
those in the Holladay 2 and Hoffer H formulas to individualize the calculation 
for the specific patient based on their race and gender. MedAE of prediction 
was 0.36 D in series of 90 mixed race and gender eyes.  Conclusion: The 
Hoffer H-5 formula uses the structure of the Hoffer H formula and takes into 
account the demographic specifics of the individual patient based on race and 
gender.
10:37 AM
Panel discussion of previous paper
PA002 10:42 AM
 NEW  Ultrasound Biomicroscopy of Lens/IOL Position 
Before and After Cataract Surgery
Presenting Author: Peter D Fedor MD*
Purpose: To evaluate the position of the ciliary body (CB) and the lens/IOL in 
myopic and hyperopic patients before and after cataract surgery using ultra-
sound biomicroscopy (UBM) and Lenstar interferometry. Methods: Quantel 
UBM of 20 eyes was analyzed, including the axial position of the plane of CB 
apex (CBD-ciliary body depth) before and after cataract surgery. The measure-
ments of lens/IOL position were compared to Lenstar interferometry. Results: 
The pre- and postoperative CBD in myopic patients was 4.85 mm and 4.96 mm; 
and in hyperopic patients, 4.22 mm and 4.61 mm, respectively. CB apex shifted 
posteriorly 0.39 mm with cataract surgery in hyperopic patients, as compared 
to the 0.11-mm axial shift in myopic eyes. Conclusion: UBM revealed larger 
posterior axial shift of apex of the ciliary body after cataract surgery in hyper-
opic eyes than in myopic eyes.
10:49 AM
Panel discussion of previous paper
PA003 10:54 AM
 NEW  Prevalence of Corneal Astigmatism, Changes With 
Age, and Fellow Eye Correlations in Patients Undergoing 
Cataract Surgery
Presenting Author: Douglas A M Lyall MBCHB
Co-Author(s): Jia Ng MBCHB, Sathish Srinivasan MBBS*
Purpose: To establish the prevalence, age-related changes, and fellow-eye 
correlation of corneal astigmatism in a cataract surgery population. Methods: 
Prospective study. Keratometric data, obtained with the IOLMaster of 2970 
eyes of 1550 patients undergoing cataract surgery, was analyzed. Results: 
Mean astigmatism was 1.05 D. 19.7% of eyes had astigmatism > 1.5 D. A 
positive increase in against-the-rule astigmatism (ATR) was found with age 
(p = .004). There was a strong fellow-eye correlation of astigmatism magni-
tude (P < .001). 22.5% of patients with astigmatism > 2.5 D in one eye had a 
similar magnitude in the fellow eye. Conclusion: Patients with high corneal 
astigmatism in one eye are more likely to have similar significant levels in the 
fellow eye. ATR increases with age, and this may need consideration when 
planning for toric IOL.
11:01 AM
Panel discussion of previous paper
PA004 11:06 AM
 NEW  Toric IOL Selection and Positioning With and 
Without Intraoperative Aberrometry
Presenting Author: Kathryn Masselam Hatch MD*
Co-Author(s): Jonathan H Talamo MD*, Emily C Woodcock
Purpose: To determine the value of intraoperative aberrometry in cases of 
toric IOL implantation. Methods: Retrospective analysis of personal results 
for toric IOL implantation with intraoperative aberrometry (aberrometry group) 
and without it (control group). Results: Mean preop keratometry was 1.87 D ± 
0.76 D in the aberrometry group and 1.79 D ± 0.75 D in the control group. The 
mean postoperative refractive astigmatism was 0.48 D ± 0.48 D in the aber-
rometry group vs. 0.68 D ± 0.42 D in the control group. Postoperative refractive 
astigmatism was ≤ 0.50 D in 78% of eyes in the aberrometry group vs. only 
35% of control eyes. Conclusion: The reduction of refractive astigmatism to 
0.50 D or less with a toric IOL is more than twice as likely when implantation 
is aided by intraoperative aberrometry.
11:13 AM
Panel discussion of previous paper
PA005 11:18 AM
 NEW  IOL Selection Based on OCT for Cataracts Following 
Laser Vision Correction
Presenting Author: Alex Harris
Co-Author(s): Robert W Weisenthal MD, Mark V White MD
Purpose: To compare OCT-based IOL selection to 4 modalities used in post-la-
ser vision correction (LVC) cataract patients . Methods: Retrospective review 
of 29 post-LVC cataract cases. Prediction error was based on postoperative 
manifest refraction for selections using OCT, Orbscan, American Society of 
Cataract and Refractive Surgery (ASCRS), clinical history (CH), and Haigis-L. 
Mean arithmetic error (ME), mean absolute error (MAE), and error distribu-
tions (ED) were compared. Results: ME using OCT was -0.26 D; ASCRS, -0.26; 
CH, -0.37; Orbscan, -0.42; Haigis-L, -0.50. MAE using OCT was 0.60; ASCRS, 
0.65; CH, 1.10; Orbscan, 0.67; Haigis-L, 0.68. (P > .05). Conclusion: Although 
unable to show superiority, it was demonstrated that IOL selections based on 
OCT have similar predictive utility as leading alternative methods without the 
need to rely on historical patient data.
11:25 AM
Panel discussion of previous paper
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PA006 11:30 AM
 NEW  Implantation of Secondary or Piggyback IOLs Guided 
by Intraoperative Aberrometry
Presenting Author: William Wiley MD*
Co-Author(s): Shamik Bafna MD*
Purpose: To determine the utility of intraoperative wavefront aberrometry in 
the selection of secondary or piggyback IOLs in cases of high refractive error 
or high residual error after primary IOL implantation. Methods: Intraoperative 
wavefront aberrometry (ORA System, WaveTec Vision) was used in 14 con-
secutive cases (8 hyperopic; 6 myopic) of piggyback IOL implantation (placed in 
the sulcus). Results: Eleven procedures were planned piggyback IOLs due to 
high refractive error. Three were post-refractive surgery eyes that underwent 
unplanned piggyback IOL surgery due to higher-than-expected residual error. 
Mean prediction error was 0.39 ± 0.26 D. Conclusion: Intraoperative aber-
rometry can help guide the selection and placement of primary and secondary 
IOLs in a piggyback formation.
11:37 AM
Panel discussion of previous paper
PA007 11:42 AM
 NEW  Comparison of Postoperative Refraction With 
Intraoperative Refraction Measured by an Intraoperative 
Wavefront Aberrometer During Cataract Surgery
Presenting Author: Ming X Wang MD PhD*
Co-Author(s): Bryce D Brown OD, Megan Lee Blemker OD
Purpose: To assess the predictability of refraction and cylinder using an intra-
operative wavefront aberrometer, by comparing intraoperative and postopera-
tive measurements. Methods: In a series of 134 eyes that underwent cataract 
extraction, the differences between intraoperative refraction and cylinder and 
that obtained at 1 month and 3 months postoperatively, defined as the set-
tling factor (SF), were measured. Results were also calculated for 3 different 
groups: all eyes, virgin eyes, and postrefractive eyes. Results: The average SE 
SF of all eyes was 0.27 ± 0.88 D at 1 month and 0.29 ± 0.89 D at 3 months. The 
average cylinder magnitude SF for all eyes was 0.70 ± 0.51 D at 1 month and 
0.72 ± 0.49 D at 3 months. Conclusion: The ORA intraoperative wavefront 
system provides a good prediction for postoperative refraction and cylinder.
11:49 AM
Panel discussion of previous paper
PA008 11:54 AM
 NEW  IOL Calculations in Post-Laser Vision Correction 
Eyes Undergoing Cataract Surgery Using Multiple 
Methods
Presenting Author: Samuel Masket MD*
Co-Author(s): Nicole R Fram MD*
Purpose: To compare predicted outcomes in post-laser vision correction (LVC) 
eyes undergoing cataract surgery using Haigis-L, OCT-based formula, intra-
operative aberrometry (ORA), and Masket formula. Methods: Patients with 
previous LVC undergoing cataract surgery were reviewed. IOLMaster 500 
was used to measure axial length, keratometry, and anterior chamber depth. 
Haigis-L, OCT based- formula, ORA, and Masket formula were compared. 
Two-week postoperative BCVA was recorded. Mean absolute refraction errors 
(MAEs) were compared for all methods. Results: Twenty-six eyes with previ-
ous LVC undergoing cataract surgery were evaluated. Range of LVC was +4.21 
D to -7.25 D. The MAE was 0.57 for Haigis-L, 0.41 for OCT-based, 0.43 for ORA, 
and 0.49 for Masket. Conclusion: Newer methods such as OCT-based IOL 
formula and ORA show promising results in post-LVC IOL calculations.
12:01 PM
Panel discussion of previous paper
PA009 12:06 PM
 NEW  OCT vs. Leading Published Methods for Post-Laser 
Vision Correction IOL Selection
Presenting Author: Alex Harris
Co-Author(s): Robert W Weisenthal MD, Mark V White MD
Purpose: To compare OCT-based IOL selection to popular modalities used 
in post-laser vision correction (LVC) cataract patients. Methods: Retrospec-
tive review of 29 cataract cases. Prediction error for OCT-based IOL selection 
based on postoperative manifest refraction. Mean arithmetic error (ME), mean 
absolute error (MAE), and error distributions (ED) compared to the top 5 accu-
rate methods published in a larger study (n = 173). Results: Best ME achieved 
with Shammas, -0.10 ± 1.02 D; OCT, -0.26 ± 0.73 D. Best MAE achieved with 
Masket, 0.59 ± 0.67 D; OCT, 0.60 ± 0.48 D. Best ED for -1 to 0 D was OCT 
(58.6%); ± 0.5 D was Masket with Hoffer-Q (58.8%); ± 1 D was OCT (86.2%) 
(P > .05). Conclusion: Although unable to show superiority, the OCT-based 
method was found comparable to leading
12:13 PM
Panel discussion of previous paper
Sunday, Nov. 17
3:30  - 5:10 PM
Room: 255
Moderator: Steven H Dewey MD*
Panel: Panel: George Beiko MD*, James A Davison MD*, Samuel Masket MD*
PA015 3:30 PM
 NEW  Localized Opacification of Hydrophilic Acrylic IOLs 
After Procedures Using Intracameral Injection of Air/Gas
Presenting Author: Liliana Werner MD PhD*
Co-Author(s): Nick Mamalis MD*
Purpose: To describe clinicopathological findings in cases of IOL opacifica-
tion after procedures involving intracameral injections of air/gas. Methods: 
Five hydrophilic acrylic IOLs (4 designs) were explanted 2-9 months after 
Descemet-stripping endothelial keratoplasty (DSEK) / Descemet-stripping 
automated endothelial keratoplasty (DSAEK) because of a localized central 
optic opacification associated with significant decrease in visual acuity. The 
lenses underwent pathological and histochemical evaluation. Results: Granu-
lar deposits were densely distributed in a round pattern within the margins 
of the capsulorrhexis or the pupil, on the anterior surface / subsurface of the 
IOLs. Granules stained positive for calcium. Conclusion: Surgeons should be 
aware of possible localized calcification following DSEK/DSAEK procedures in 
pseudophakic patients with hydrophilic acrylic IOLs.
3:37 PM
Panel discussion of previous paper
140
Original Papers
O
ri
gi
na
l P
ap
er
s
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.  
No asterisk indicates that the presenter has no financial interest.
PA016 3:42 PM
 NEW  Sutured Scleral-Fixated IOL vs. Glued Intrascleral 
Haptic-Fixated IOL: Randomized Comparative Study
Presenting Author: Mayank Bansal
Co-Author(s): Rajesh Sinha, Namrata Sharma MD MBBS, Tanuj Dada MD, 
Radhika Tandon MD, Jeewan S Titiyal MD
Purpose: To compare clinical outcomes between sutured scleral and glued 
intrascleral haptic fixated IOLs. Methods: Forty aphakic eyes were random-
ized into 2 groups of 20 each. Preoperative and postoperative UCVA, BCVA, 
IOP, specular count, keratometry, central macular thickness (CMT), IOL tilt, and 
pseudophakodonesis on ultrasound biomicroscopy were recorded. Surgery 
was performed by a single surgeon. Results: Mean postoperative UCVA and 
BCVA was more in the glued group (P < .05). Mean endothelial cell loss, CMT, 
and IOL tilt in the sutured and glued groups were 11.49 ± 4.23% and 8.95 ± 
4.17% (P = .08); 250.95 ± 23.98, and 225.85 ± 21.13 microns (P = .009); 2.23° ± 
0.98° and 1.78° ± 0.97° (P = .38), respectively. Vision CMT had an inverse cor-
relation (P = .01). Pseudophakodonesis and macular edema were more in the 
sutured group. Conclusion: Glued haptic fixated IOL had more stable fixation, 
better visual outcome, and fewer complications.
3:49 PM
Panel discussion of previous paper
PA017 3:54 PM
 NEW  Capsular Bag Opacification With a New Silicone 
Oil-Filled Accommodating IOL
Presenting Author: Nick Mamalis MD*
Co-Author(s): Liliana Werner MD PhD*, Anne Floyd, Erica Liu MD, Shannon 
Stallings MD
Purpose: To evaluate biocompatibility and capsular bag opacification (PCO) of 
a new accommodating IOL with large haptic elements filled with silicone oil to 
change the optic shape to allow accommodation. Methods: Implantation of 
the study IOL in rabbit eyes compared to a control IOL and evaluation weekly 
with slitlamp followed by histopathological evaluation. Results: PCO scores 
at 6 weeks were 0.5 ± 0.31 in the study group and 3.0 ± 0.89 in the control, 
with no anterior capsular opacification in the study group. Miyake-Apple gross 
posterior view showed virtually no central PCO in the study group compared 
to the control. Histopathology confirmed the relatively clean capsules in the 
study group. Conclusion: The study IOL haptic elements maintain an open, 
expanded capsular bag, which appears to prevent capsular bag opacification.
4:01 PM
Panel discussion of previous paper
PA018 4:06 PM
 NEW  Improving Refraction With the Light Adjustable Lens: 
Three-Year Experience
Presenting Author: Tobias H Neuhann MD
Purpose: Assessment of the efficacy and stability of the light adjustable lens 
(LAL). Methods: The LAL was implanted in 65 eyes scheduled for cataract 
surgery, of which 24 had previous LASIK, keratoconus, or lack of a reliable IOL-
Master measurement. Outcomes included uncorrected distance visual acuity 
(UDVA), uncorrected near visual acuity (UNVA), and refraction. Results: Mean 
SE was -1.75 D ± 4.52 D preoperatively and -0.56 D at 2 years. Two years 
postop, 94% were within ± 0.5 D of the intended refraction, 100% of patients 
had a UDVA of 20/32 or better, and 100% of patients achieved a UNVA of J8 
or better. There were no differences between virgin and complicated eyes. 
Conclusion: The LAL delivers very good visual results in both complicated 
and virgin eyes of cataract surgery patients.
4:13 PM
Panel discussion of previous paper
PA019 4:18 PM
 NEW  Comparison of Morphologic Features of Clear 
Corneal Incisions Created With the Femtosecond Cataract 
Laser vs. the Manual Keratome Using Anterior Segment 
OCT
Presenting Author: Dilraj Singh Grewal MBBS
Co-Author(s): Agnieszka Kielian, Surendra Basti MBBS*
Purpose: To compare the morphology of clear corneal incisions (CCI) created 
during cataract surgery with a femtosecond laser (FS) (Catalys, Optimedica) vs. 
a 2.65-mm steel keratome using OCT (Spectralis; Heidelberg). Methods: Us-
ing Image J software, CCI morphology on OCT was analyzed 1 month follow-
ing surgery in 20 FS eyes and 15 age-matched keratome (K) eyes. CCI length, 
endothelial gaping (EG), endothelial misalignment (EM), and Descemet mem-
brane detachment (DMD) were compared. Results: Mean CCI length was 2.01 
± 0.076 vs. 2.05 ± 0.23 mm (P= .38), EG was 0.136 ± 0.03 vs. 0.198 ± 0.09 mm 
(P = .01), and EM was 0.04 ± 0.03 vs. 0.075 ± 0.06 mm (P = .032) in the FS and 
K groups, respectively. Zero of 20 FS eyes had a DMD, compared to 3/15 K 
eyes (P = .037). Conclusion: CCI created using FS had significantly lower EG, 
EM, and DMD.
4:25 PM
Panel discussion of previous paper
PA020 4:30 PM
 NEW  Visual Acuity and Predictability in Femtosecond 
Laser Cataract Surgery With Intraoperative Aberrometry
Presenting Author: Bret L Fisher MD*
Purpose: To determine the impact of intraoperative aberrometry on visual 
acuity and predictability in femtosecond laser cataract surgery. Methods: A 
retrospective comparison of 114 eyes undergoing LenSx laser cataract surgery 
with IOL implantation with and without ORA (Optiwave Refractive Analysis) 
intraoperative aberrometry. Results: Uncorrected visual acuity was 20/20 or 
better postop in 33% of the ORA group and in 23% of the non-ORA group, 
and 20/25 or better in 61% of the ORA group vs. 51% of the non-ORA group. 
Mean absolute prediction error was 0.32 D ± 0.28 D in the ORA group (82% 
of eyes within 0.5 D of predicted refraction) and 0.44 D ± 0.42 D in the non-
ORA group (76% of eyes within 0.5 D). Conclusion: Initial analysis suggests 
that intraoperative aberrometry can improve results with femtosecond laser 
cataract surgery.
4:37 PM
Panel discussion of previous paper
PA021 4:42 PM
 NEW  Toward the Elimination of Ultrasound With 
Femtosecond Laser Cataract Surgery
Presenting Author: Burkhard Dick MD*
Co-Author(s): Tim Schultz MD*, Ina Conrad-Hengerer MD
Purpose: To compare the effect of femtosecond laser cataract surgery on 
effective phacoemulsification time (EPT) with various fragmentation patterns. 
Methods: EPT was assessed laser cataract pretreatment (Catalys; Sunny-
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vale, Calif., USA). A comparison of manual (n = 750) and laser (n = 750) was 
conducted. Preoperative nuclear opacity was determined by 1 surgeon. Both 
groups underwent phacoemulsification using pulsed ultrasound energy. Re-
sults: Ultrasound reduction was seen across all grades of cataract. 100% 
elimination of ultrasound was observed in grade 2, 98% reduction in grade 3, 
and 94% reduction in grade 4. Conclusion: The use of the femtosecond laser 
system to pretreat the nucleus led to > 99% reduction in EPT. 
4:49 PM
Panel discussion of previous paper
PA022 4:54 PM
 NEW  The Extraordinary Patient Value and Financial Value 
to Society Conferred by Cataract Surgery
Presenting Author: Melissa M Brown MD MBA*
Co-Author(s): Gary C Brown MD*, Brandon G Busbee MD*
Purpose: To show the comparative-effectiveness, cost-effectiveness, and 
macroeconomics associated with U.S. cataract surgery. Methods: Cost-utility 
analysis with patient utilities, 2012 US dollars, and societal costs. A cost 
comparison from prior years is included. Results: Unilateral cataract surgery 
confers a 20.8% quality-of-life gain; and bilateral surgery, a 36.2% gain. The 
societal $/QALY is -$74,759. A 1-year cohort of cataract surgery patients nets 
$123.7 billion to society over 13 years, a 4,567% financial return on invest-
ment. The 2012 direct medical cost is $2,653, 34% less than in 2000 and 85% 
less than in 1985. The surgeon fee is 10.1% that in 1985. Conclusion: Cata-
ract surgery gives great patient value, is very cost-effective, and returns large 
financial resources to society.
5:01 PM
Panel discussion of previous paper
Cornea, External Disease
Monday, Nov. 18
2:00 - 4:45 PM
Room: 271
Moderator: Bennie H Jeng MD
Panel: Anat Galor MD*, Sanjay V Patel MBBS*
PA038 2:00 PM
 NEW  Reducing Complications in Descemet Membrane 
Endothelial Keratoplasty Using Prestripped Tissue, 
Yoeruek Tap Technique, and SF6 Gas
Presenting Author: Mark A Terry MD*
Co-Author(s): Michael D Straiko MD*, Julia C Talajic MD, Cor Van Zyl 
MBChB, Peter B Veldman MD
Purpose: To report dramatically improved results in Descemet membrane en-
dothelial keratoplasty (DMEK) using SF6 gas and prestripped tissue Methods: 
Prospective study of DMEK in our first 15 consecutive Fuchs dystrophy cases 
using prestripped tissue, Yoeruek tap technique, and SF6 (20% concentration) 
for tissue support Results: There were no primary graft failures, no pupillary 
blocks, and no case required a rebubble postoperatively. All corneas are clear 
with excellent vision. Surgical time was less than Descemet-stripping auto-
mated endothelial keratoplasty. Conclusion: The use of SF6 gas for prolonged 
tissue support has dramatically reduced the rebubble rate in DMEK, with no 
acute toxic effect, pupillary block, or primary graft failure. Adoption of DMEK 
by surgeons can be enhanced by this easier and safer standardized technique.
2:07 PM
Panel discussion of previous paper
PA039 2:12 PM
 NEW  The Impact of Donor Characteristics on 2-Year 
Descemet-Stripping Endothelial Keratoplasty Outcomes
Presenting Author: Nadia Hesham MD
Co-Author(s): Robert L Schultze MD*, Robert A Eden MD*
Purpose: To determine relationship between donor cornea tissue character-
istics and 2-year endothelial cell mortality (ECM) after Descemet-stripping 
endothelial keratoplasty (DSEK). Methods: Retrospective chart review of 
149 eyes with 1-year follow-up and 103 eyes with 2-year follow-up who un-
derwent DSEK. Statistical analysis was performed using multiple linear re-
gression and stepwise regression. Results: Donor death to use and donor 
age were statistically significant predictors of ECM at 1 year and 2 years, 
respectively. Conclusion: Shorter death to use and younger donor age may 
be predictive of lower ECM after DSEK.
2:19 PM
Panel discussion of previous paper
PA040 2:24 PM
 NEW  Predictive value of OCT in Graft Attachment After 
Descemet Membrane Endothelial Keratoplasty
Presenting Author: Ru-Yin Yeh
Co-Author(s): Vasilios S Liarakos MD, Isabel Dapena, Gerrit RJ Melles MD 
PhD*
Purpose: To assess the predictive value of early anterior segment OCT (AS-
OCT) on graft adherence after Descemet membrane endothelial keratoplasty 
(DMEK). Methods: In 87 eyes, AS-OCT was performed 1 hour, 1 week, and 
1, 3, and 6 months after DMEK. For each exam, detachments were graded as 
‘none’, ≤ 1/3, > 1/3, or ‘complete’. No rebubblings were performed. Results: 
One hour AS-OCT was most accurate at predicting 6-month graft adherence 
status. Attached grafts or ≤ 1/3 detached at 1 hour remained stable or im-
proved in 73% at 1 week and in 90% at 6 months. Detachments of > 1/3 
at 1 hour showed persistent detachment. Conclusion: The 1-hour AS-OCT 
showed best predictive value on 6-month graft adherence. A combination of 
the 1-hour and 1-week AS-OCT may facilitate decision making for surgical 
reintervention.
2:31 PM
Panel discussion of previous paper
PA041 2:36 PM
 NEW  Causes of Incomplete Visual Rehabilitation after 
Descemet Membrane Endothelial Keratoplasty
Presenting Author: Isabel Dapena MD PhD
Co-Author(s): Ru-Yin Yeh, Vasilios S Liarakos MD, Gerrit RJ Melles MD PhD*
Purpose: To determine the causes of incomplete visual rehabilitation after 
DMEK. Methods: 200 consecutive DMEK surgeries were retrospectively 
reviewed for visual discomfort or unexpected subnormal visual acuity at 6 
months after DMEK. Results: A total of 69 eyes (38%) presented with incom-
plete visual rehabilitation, further categorized as ‘primarily patient-related’ 
in 40/69 (58%), ‘primarily graft-related’ in 21/69 (30%), and a combination 
of ‘patient/graft-related’ in 8/69 (12%). Unrecognized pre-existing ocular pa-
thology, corneal irregularities / scarring, and (partial) graft detachment were 
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the main causes of incomplete visual rehabilitation. Conclusion: Incomplete 
visual rehabilitation after DMEK may virtually always be explained by con-
comitant ocular pathology or evident graft failure.
2:43 PM
Panel discussion of previous paper
PA042 2:48 PM
 NEW  Midterm Results on Visual Acuity and Endothelial 
Cell Density After Descemet Membrane Endothelial 
Keratoplasty
Presenting Author: Kyros Moutsouris MD
Co-Author(s): Lisanne Ham PhD, Marina Rodriguez Calvo De Mora MD, Gerrit 
RJ Melles MD PhD*
Purpose: To report the visual outcome and endothelial cell density (ECD) 
up to 6 years after Descemet membrane endothelial keratoplasty (DMEK). 
Methods: In 300 consecutive eyes, DMEK was performed for endothelial 
dysfunction. BCVA and ECD were documented before and after DMEK at 1, 
3, 6, and 12 months and annually up to 6 years. Results: A BCVA of ≥ 20/40 
was reached by 97.4% of eyes within the first 6 months after DMEK, and 79% 
reached ≥ 20/25, which remained stable up to 6 years. At 6 months after 
DMEK, a 35% decrease in ECD was found, followed by an annual decrease of 
8.6%. Conclusion: DMEK provides a fast and often complete visual recovery 
up to 6 years after surgery. The decrease in ECD compares to earlier endothe-
lial keratoplasty techniques.
2:55 PM
Panel discussion of previous paper
PA043 3:00 PM
 NEW  Prospective, Randomized Comparison of Topical 
Prednisolone Acetate 1% vs. Fluorometholone After 
Endothelial Keratoplasty
Presenting Author: Marianne O Price PhD*
Co-Author(s): Francis W Price Jr MD*, Matthew T Feng MD, Yuri F McKee 
MD, Friedrich E Kruse MD, Bachmann Björn MD, Theofilos Tourtas MD
Purpose: To compare efficacy and side effects of prednisolone vs. fluorometh-
olone after Descemet membrane endothelial keratoplasty (DMEK). Methods: 
Subjects used prednisolone 4 times a day for 1 month and then were random-
ized to stay on it or switch to fluorometholone, dosing 4 times a day for 2 
months, 3 times a day for 1 month, twice a day for 1 month, and once a day 
to 1 year. Results: 325 DMEK cases were randomized. Rejection episode rate 
was < 1% in both groups (P = .49). The prednisolone group had a 3-fold higher 
rate of clinically significant IOP elevation (P = .017). Conclusion: The rate of 
rejection episodes after DMEK was < 1% with either prednisolone or fluoro-
metholone; IOP elevation was a greater concern with prednisolone.
3:07 PM
Panel discussion of previous paper
PA044 3:12 PM
 NEW  Multicenter Trial on Descemet Membrane 
Endothelial Keratoplasty: First Case Series of 18 Surgeons
Presenting Author: Vasilios S Liarakos MD
Co-Author(s): Claire Monnereau, Isabel Dapena, Gerrit RJ Melles MD PhD*
Purpose: To document the clinical outcome of standardized ‘no-touch’ Des-
cemet membrane endothelial keratoplasty (DMEK) and its complications dur-
ing surgeons’ learning curve. Methods: Eighteen surgeons in 11 different 
countries performed DMEK for endothelial dysfunction in 431 eyes. Endothe-
lial cell density (ECD), BCVA, and complications were documented. Results: 
Eighty-two percent of eyes reached a BCVA of ≥ 20/40; 44%, of ≥ 20/25; and 
19%, of ≥ 20/20. Average decrease in ECD was 47% at 6 months postop-
erative. The main postoperative complication was (partial) graft detachment 
(35%). Conclusion: DMEK proved feasible as a new technique. The learning 
curve may be shortened by using organ-cultured donor tissue and possibly by 
outsourcing DMEK graft preparation.
3:19 PM
Panel discussion of previous paper
Moderator: Shahzad I Mian MD*
Panel: Natalie A Afshari MD, Jessica B Ciralsky MD*, Kenneth R Kenyon MD
PA045 3:30 PM
 NEW  Evaluation of Epi-on Corneal Collagen Crosslinking 
at 6 Months and 1 Year Follow-up in Patients Diagnosed 
With Keratoconus
Presenting Author: William B Trattler MD*
Co-Author(s): Roy Scott Rubinfeld MD*, Rosane Oliveira Correa MD, Gabriela 
Perez**
Purpose: To determine the efficacy of transepithelial corneal collagen cross-
linking (CXL) in keratoconic eyes. Methods: Keratoconic eyes that underwent 
transepithelial CXL with slitlamp confirmation of adequate corneal riboflavin 
loading were analyzed. UCVA, best spectacle-corrected visual acuity (BSCVA), 
and K-max measurements were taken and evaluated against preop measure-
ments at both 6 months follow-up and 1-year follow-up post-CXL. Results: A 
total number of 390.229 eyes had a follow-up visit at 6 months. 49.7% and 
46.6% of eyes achieved an improvement of 1 or more lines in UCVA and BSC-
VA, respectively. change in K-max was -0.94 D at 6 months follow-up. Ninety-
nine eyes had a follow-up visit at 1 year. 57.6% and 49.4% of eyes achieved 
an improvement of 1 or more lines in UCVA and BSCVA, respectively. Conclu-
sion: In this study, transepithelial CXL appears to be both safe and effective.
3:37 PM
Panel discussion of previous paper
PA046 3:42 PM
 NEW  Comparison of In Vivo Delivery Methods of Riboflavin 
for Corneal Collagen Crosslinking
Presenting Author: Pierre R Fournie MD
Co-Author(s): Myriam Cassagne, Vincent José Soler MD*, Anne Galinier 
MD, Jose G Cunha-Vaz MD PhD*, Joaquim N Murta MD PhD**, Francois 
Malecaze MD**
Purpose: To compare 3 delivery methods of riboflavin for corneal collagen 
crosslinking using in vivo fluorophotometry. Methods: Corneal riboflavin fluo-
rescence was measured by fluorophotometry in 30 eyes of 30 patients after 
standard with disepithelialization (n = 10), transepithelial with bioenhancers 
(n = 10), and iontophoretic (n = 10) delivery of riboflavin. Results: Corneal 
riboflavin concentrations were, respectively, 339 ± 247 ng/ml, 1124 ± 451 ng/
ml (P < .05), and 3250 ± 662 ng/ml (P < .05) after transepithelial, iontophoretic, 
and standard delivery of riboflavin. Conclusion: In vivo corneal riboflavin con-
centrations were, respectively, almost 3 and 10 times greater with standard 
compared to iontophoretic and transepithelial delivery methods of riboflavin.
3:49 PM
Panel discussion of previous paper
143
Original Papers
O
riginal Papers
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.  
No asterisk indicates that the presenter has no financial interest.
PA047 3:54 PM
 NEW  Boston Type 1 Keratoprosthesis Removal
Presenting Author: Divya Srikumaran MD
Co-Author(s): James Aquavella MD*, Sadeer B Hannush MD, Robert L 
Schultze MD*, Anthony J Aldave MD*, Esen K Akpek MD*
Purpose: To determine the indications for and outcomes after Boston type 1 
keratoprosthesis (KPro) removal. Methods: Multicenter, retrospective review. 
Results: 143 adult eyes received KPro surgery between January 2003 and 
December 2006. Thirty-five eyes required removal of the device between 6 
weeks to 5 years following implantation. The most common indication for re-
moval was a sterile corneal melt (51%), followed by infection (17%). Fifty-four 
percent of the eyes underwent repeat KPro, 40% of the eyes received a donor 
corneal graft, and 6% required enucleation. Seventy-nine percent of the eyes 
(15/19) retained the repeat KPro over a mean of 27 months. A third of these 
(5/15) maintained their best ever postoperative acuity at last follow-up. Con-
clusion: The most common indication for KPro removal is a sterile corneal 
melt. A repeat KPro can be considered in select eyes.
4:01 PM
Panel discussion of previous paper
PA048 4:06 PM
 NEW  Outcome of Intraoperative Descemet Membrane 
Perforation in Deep Lamellar Keratoplasty
Presenting Author: Ali A AlRajhi MD
Co-Author(s): Mosa AlHarby MD
Purpose: To evaluate outcome of deep lamellar keratoplasty (DLKP) cases 
with intraoperative Descemet membrane (DM) perforation. Methods: Forty 
cases (17 done by fellows) of 613 DLKP, age range 14-36 years, had DM per-
foration (28 were peripheral and 7 were central) during air injection (12.5%), 
lamellar dissection (60%), suturing (25%, 70% done by fellows) and other 
(2.5%). Results: Management included injection of air (25), SF6 (6), C3F8 (3), 
gluing / suturing (1 each) or nothing (4). DM attached in 38, with visual acuity 
≥ 20/40 in 90% of cases, and 9 developed high IOP, with fixed dilated pupil 
(5). Conclusion: Effective management of perforated DM can have good out-
come in DLKP with increased complication frequency during suturing among 
fellows.
4:13 PM
Panel discussion of previous paper
PA049 4:18 PM
 NEW  Does Fuchs Endothelial Dystrophy Exist?
Presenting Author: Martin Dirisamer MD
Co-Author(s): Ru-Yin Yeh, Gerrit RJ Melles MD PhD*
Purpose: To define the role of recipient endothelium in re-endothelialization 
of the host stroma after Descemet membrane endothelial transferal (DMET), a 
‘free-floating’ Descemet-graft in the host anterior chamber after descemetor-
rhexis. Methods: Twelve eyes, 7 with Fuchs endothelial dystrophy (FED), 5 
with bullous keratopathy (BK), were observed for up to 6 months postopera-
tive. Results: Eyes operated on for FED showed corneal clearance at 6 months 
postoperative, whereas BK eyes showed no improvement. Conclusion: If cor-
neal clearance after DMET relates with the underlying pathology, this would 
indicate that in FED, the remaining rim of host endothelium is involved in re-
endothelialization. If so, the endothelium is not dystrophic and Fuchs endothe-
lial “dystrophy” may be a misnomer.
4:25 PM
Panel discussion of previous paper
PA050 4:30 PM
 NEW  Keratoconus in Patients With Fuchs Endothelial 
Dystrophy Unmasked by Descemet Membrane Endothelial 
Keratoplasty
Presenting Author: Michael D Straiko MD*
Co-Author(s): Cor Van Zyl MBChB, David Lee Davis-Boozer MPH*, Julia C 
Talajic MD
Purpose: To investigate the prevalence of comorbid keratoconus and Fuchs 
endothelial dystrophy (FED). Methods: Fifty patients with FED who had suc-
cessful Descemet membrane endothelial keratoplasty (DMEK) surgery were 
identified. Postop Pentacam images were analyzed for characteristic stigmata 
of keratoconus. Results: Localized steepening, posterior corneal changes, 
and pachymetric changes consistent with the diagnosis of keratoconus or form 
fruste keratoconus were found in 64% of patients. These findings were con-
firmed with the Belin / Ambrosio software on the Pentacam HR. Conclusion: 
DMEK restores the native corneal anatomy and pachymetry and reveals that 
many patients with FED have keratoconus as well. This finding was masked 
by their preoperative edema. Keratoconus and FED occur together much more 
frequently than previously reported.
4:37 PM
Panel discussion of previous paper
Glaucoma
Tuesday, Nov. 19
8:30 - 11:30 AM
Room: 255
Moderator: Julia Agapov DO*
Panel: Husam Ansari MD PhD*, Shan C Lin MD*
PA065 8:30 AM
 NEW  Two-Year Results of a Schlemm Canal Scaffold for 
IOP Reduction in Primary Open-Angle Glaucoma
Presenting Author: Thomas W Samuelson MD*
Co-Author(s): Clemens Vass MD*, Marina A Ramirez MD**, Manfred Tetz 
MD**, Norbert Pfeiffer MD*, Gabor Bernd Scharioth MD*, Swaantje Grisanti 
MD*
Purpose: To evaluate the ability of a dilating scaffold placed in the Schlim 
canal to lower IOP in mild to moderate primary open-angle glaucoma (POAG). 
Methods: Subjects diagnosed with open-angle glaucoma with visual field 
mean deviation ≥ -12 dB were recruited from 6 centers in a prospective, in-
ternational study. Follow-up was conducted through 2 years postoperatively. 
Results: In 40 treated subjects, mean (±SD) IOP and medication use were 
reduced from 21.6 ± 4.4 on 1.7 ± 1.4 medications at baseline to 18.3 ± 4.2 
mmHg on 0.4 ± 1.0 at 2 years (both IOP and medications P < .05). Conclusion: 
A Schlim canal scaffold may offer a continuous, durable alternative to medical 
therapy for IOP reduction.
8:37 AM
Panel discussion of previous paper
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PA066 8:42 AM
 NEW  Comparison of Combined Cataract Surgery With 
iStent vs. Trabectome
Presenting Author: Michelle Khan
Co-Author(s): Hady Saheb MD*, Paul J Harasymowycz MD*, Arvind 
Neelakantan MD*, Zachary D Vest MD, Ronald Leigh Fellman MD OCS*, 
Iqbal K Ahmed MD*
Purpose: To compare the IOP and medication reduction of iStent and Trabec-
tome when combined with cataract surgery in patients with open-angle glau-
coma. Methods: Forty-nine patients who underwent combined phaco and 2 
iStents (Group i) and 52 patients with combined phaco and Trabectome (Group 
t) with 12-month follow-up were included. Results: A significant decrease in 
both IOP and medication use occurred in both groups. Postoperative IOP (P = 
.008) and medication use (P < .01) were significantly lower in Group i than in 
Group t. Thirty-nine percent of patients in Group i and 14% in Group t had an 
IOP < 18 on no medications at 12 months (P = .03). Conclusion: This study 
shows a greater reduction in both IOP and medication use in Group i than in 
Group t.
8:49 AM
Panel discussion of previous paper
PA067 8:54 AM
 NEW  A Novel Stainless Steel Spiral Intracanalicular 
Device for Schlemm Canal Dilation to Treat Open-Angle 
Glaucoma
Presenting Author: Vinod Kumar MD PhD
Co-Author(s): Galina Dushina, Elena Bozhok, Galina Dushina
Purpose: To evaluate the efficacy of a novel intracanalicular device (ICD) in 
decreasing IOP in patients with open-angle glaucoma (OAG). Methods: Be-
tween October 2012 and December 2012, 10 eyes (10 patients) with OAG had 
implantation of ICD into the Schlemm canal (SC). Follow-up was 3 months. 
Efficacy measures were IOP changes, complication rate, and additional medi-
cation. Results: Complete success was achieved in 70% of cases; partial, in 
30% of cases. Mean IOP decrease was 10.6 mmHg (44.1%; P < .05). Decrease 
in mean number of medications was 2.2 (88%; P < .05). Conclusion: In eyes 
with OAG, ICD decreases IOP significantly by keeping the SC opened.
9:01 AM
Panel discussion of previous paper
PA068 9:06 AM
 NEW  360° Gonioscopy-Assisted Transluminal 
Trabeculotomy: A Novel, Ab Interno Method for 
Circumferential Opening of the Schlemm Canal
Presenting Author: Davinder S Grover MD*
Co-Author(s): David G Godfrey MD*, Ronald Leigh Fellman MD OCS*, 
Oluwatosin U Smith MD*
Purpose: To describe the results of a conjunctival-sparing ab interno 360-de-
gree trabeculotomy. Methods: A retrospective chart review of 176 consecu-
tive cases with > 3 months follow-up. Results: The average age was 64.3 
years. The mean pre- and postoperative IOP and glaucoma medications were 
24.7 mmHg and 3.0, respectively, reduced to 14 mmHg on 1.1 medications, at 
a mean follow-up of 5.8 months (range: 3-14). The cumulative proportion of 
failing with a preoperative IOP ≥ 18 mmHg was 10.0% and 19.1% at 6 and 12 
months, respectively. The cumulative percent requiring glaucoma reoperation 
at 6 and 12 months was 5.1% and 8.2%, respectively. Conclusion: Prelimi-
nary GATT results show excellent safety and efficacy in treating open-angle 
glaucomas, including eyes with prior failed glaucoma surgery.
9:13 AM
Panel discussion of previous paper
PA069 9:18 AM
 NEW  Outcomes of Open-Angle Glaucoma Treated by 
Canaloplasty: Two-Year Interim Results
Presenting Author: Angela N Baldwin MD
Co-Author(s): Jacob W Brubaker MD, Steven R Sarkisian MD*, Mahmoud A 
Khaimi MD*, Kai Ding PhD, John David Stephens
Purpose: To evaluate 2-year canaloplasty efficacy to treat open-angle glauco-
ma (OAG). Methods: This retrospective study comprised OAG patients treated 
with canaloplasty. Primary outcome measures were IOP and glaucoma medi-
cation use. Results: At 2 years all 177 eyes had a mean IOP of 17.0 mmHg ± 
5.0 (SD) and mean glaucoma medication use of 0.47 ± 0.72 (baseline values 
22.3 mmHg ± 6.3 and 1.8 ± 1.0 medications). At 1 month, eyes had a mean IOP 
of 15.1 mmHg ± 6.4 and mean medication use of 0.12 ± 0.4. At 1 year, eyes 
had a mean IOP of 16.3 mmHg ± 4.8 and mean medication use of 0.46 ± 0.7. 
IOP and medications were statistically significantly decreased at all postop 
time points vs. baseline (P < .001 both). Conclusion: Canaloplasty effectively 
reduces IOP and glaucoma medication use in patients with OAG .
9:25 AM
Panel discussion of previous paper
PA070 9:30 AM
 NEW  Ultrasonic Circular Cyclo-coagulation in Patients 
With Primary Open-Angle Glaucoma: A Multicenter 
Clinical Trial
Presenting Author: Florent Aptel MD PhD*
Co-Author(s): Philippe Denis MD*, Jean-Francois Rouland MD*, Yves 
Lachkar**, Jean-Paul Renard MD, Eric Sellem MD*, Christophe Baudouin 
MD PhD, Alain M Bron MD*
Purpose: To evaluate the efficacy and safety of the ultrasonic circular cyclo-
coagulation (UC3). Methods: Forty-two eyes with primary open-angle glau-
coma (POAG) were insonified. The 6 transducers of the probe were activated; 
18 patients (Group 1) were treated with a 4-second exposure time, and 24 
patients (Group 2) with a 6-second exposure time. Primary outcome was surgi-
cal success (IOP reduction ≥ 20%) at the last follow-up visit. Results: IOP was 
significantly reduced in both groups, from a mean value of 29.4 ± 4.7 mmHg 
in Group 1 and 29.1 ± 7.8 mmHg in Group 2 to 17.0 ± 4.2 mmHg in Group 1 
and 17.9 ± 4.1 mmHg in Group 2 at last follow-up. Success rates were 60% in 
Group 1 and 72% in Group 2. No major complications occurred. Conclusion: 
UC3 seems to be an effective and well-tolerated method to reduce IOP in 
patients with POAG.
9:37 AM
Panel discussion of previous paper
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PA071 9:42 AM
 NEW  Simultaneous Use of Amniotic Membrane and 
Mitomycin C in Trabeculectomy for Primary Glaucoma: A 
Pilot Study
Presenting Author: Kirti Jaisingh MBBS
Co-Author(s): Prolima Thacker MBBS**, Sonal Dangda MS, Usha Yadava MD 
MBBS, Monika Kapoor MBBS
Purpose: To study the role of amniotic mibrane transplantation (AMT) as an 
additional modulator in primary mitomycin C (MMC)-augmented trabeculec-
tomy. Methods: Twenty adult primary glaucoma eyes were divided into 2 
groups: 1 had trabeculectomy with MMC and the second had AMT in addition. 
IOP and blebs were assessed (Indiana Bleb Appearance Grading Scale) month-
ly for 6 months. Results: Difference among eyes achieving complete success 
(IOP < 16 mmHg on no medication), qualified success (IOP < 16 mmHg with 1 
medication), or failure (need for more than 1 medication, surgical intervention) 
was not statistically significant between the 2 groups; P = 0.13, 0.27, 0.15. 
AMT blebs had better extent (E3), P = .03 and height (H2 and H3), P = .03, on 
first day but comparable at 6 months. Conclusion: AMT improved early bleb 
morphology, requiring fewer needlings and predicting better IOP outcome.
9:49 AM
Panel discussion of previous paper
Moderator: Mark B Sherwood MD*
Panel: Barbara A Smythe MD**, Nathan M Radcliffe MD*
PA072 10:00 AM
 NEW  Pilot Study of OCT Angiography of Optic Disc 
Perfusion in Glaucoma
Presenting Author: David Huang MD PhD*
Co-Author(s): Yali Jia PhD*, Xiaogang Wang, John C Morrison MD, James 
Fujimoto PhD*, Joachim Hornegger PhD
Purpose: To detect optic disc perfusion changes in glaucoma using OCT an-
giography. Methods: One eye of each subject was scanned by a high-speed 
1050-nm wavelength swept-source OCT. The split-spectrum amplitude-decor-
relation angiography algorithm was used to compute 3-D optic disc angiogra-
phy. A disc flow index was computed from 4 registered scans. Results: Eleven 
early glaucoma patients and 24 normal subjects were compared. Disc flow 
index was reduced by 25% in the glaucoma group (P = .003). Sensitivity and 
specificity were both 100% using an optimized cutoff. The flow index was 
highly correlated with visual field pattern standard deviation (R2 = 0.767, P = 
.001). Conclusion: OCT disc angiography may be a useful new modality for 
glaucoma evaluation.
10:07 AM
Panel discussion of previous paper
PA073 10:12 AM
 NEW  Continuous Nyctohemeral IOP Pattern Discriminates 
Between Healthy Subjects and Glaucoma Patients
Presenting Author: Rene Goedkoop MO*
Co-Author(s): Jeanette Lindell*, Sonja C Simon-Zoula**, Kaweh Mansouri 
MD*, Yossi S Tal PhD MA
Background: The 24-hour IOP pattern may contain disease-specific informa-
tion. Methods: IOP patterns recorded with a contact lens sensor (Sensimed; 
Switzerland) were pooled to investigate the capability of discriminating be-
tween subjects with (n = 183) and without (n = 82) glaucoma. Results: Of the 
13 parameters derived from smoothed IOP patterns, 10 were statistically sig-
nificantly different between the two groups, with area under the curve ranging 
from 0.65 to 0.69 and sum of sensitivity and specificity ranging between 1.31 
and 1.35. Conclusion: Parameters derived from continuous 24-hour IOP pat-
terns may distinguish between healthy and glaucoma subjects, independent 
of absolute tonometry values.
10:19 AM
Panel discussion of previous paper
PA074 10:24 AM
 NEW  Risk Factors for Functional and Structural 
Progression in Preperimetric Open-Angle Glaucoma
Presenting Author: Ko Eun Kim MD
Co-Author(s): Jin Wook Jeoung MD, Dong Myung Kim MD, Ki Ho Park MD*, 
Young Kook Kim MD, Seok Hwan Kim MD
Purpose: To determine risk factors for the progression in preperimetric 
open-angle glaucoma (P-POAG). Methods: 137 patients with P-POAG were 
included. All patients had series of stereo disc photography, red-free pho-
tography, frequency doubling technology (FDT) perimetry, and standard auto-
mated perimetry, and they were evaluated for detecting progression. Results: 
Glaucoma progression was detected in 76 eyes. Between progressors and 
nonprogressors, significantly different factors were cold hands/feet (P = .019), 
disc hemorrhage (P = .037), and FDT abnormality (P = .007). FDT abnormality 
(P < .001) and disc hemorrhage (P = .037) were significantly associated with 
progression in P-POAG. Conclusion: Disc hemorrhage and FDT abnormality 
were significant risk factors for the glaucoma progression in P-POAG.
10:31 AM
Panel discussion of previous paper
PA075 10:36 AM
 NEW  Comparison of Online Perimetry and Humphrey 
Visual Field in Patients With Glaucoma
Presenting Author: Jing Hou MD PhD
Co-Author(s): Sean Ku Wang, Jeremy D Keenan MD MPH, Brian Chon, Nita 
Subramanian DOMS MBBS, Tsontcho Ianchulev MD*, Robert L Stamper 
MD*, Robert T Chang MD*, Ying Han MD PhD
Purpose: To compare a new online perimetry (Peristat) with Humphrey visual 
field (HVF) for patients with glaucoma. Methods: All subjects performed 24-2 
SITA-standard HVF and Peristat. Results: Fifty-nine glaucoma patients (78 
eyes) and 15 controls (15 eyes) obtained reliable HVF and Peristat. Cohen’s 
kappas between the two tests for mild, moderate, and severe glaucoma were 
0.30, 0.75, and 0.86, respectively. The sensitivity and specificity of Peristat to 
identify glaucomatous eyes were 82.4% and 93.3% for moderate glaucoma, 
and 92.9% and 93.3% for severe glaucoma, respectively. Conclusion: The 
Web-based Peristat has a good to very good agreement with HVF to identify 
eyes with moderate and severe glaucoma, has high sensitivity and specific-
ity to identify eyes with moderate to severe glaucoma, and could be a good 
glaucoma-screening tool.
10:43 AM
Panel discussion of previous paper
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PA076 10:48 AM
 NEW  Comparative-Effectiveness and Cost-Effectiveness of 
Glaucoma Therapy
Presenting Author: Gary C Brown MD*
Co-Author(s): Joshua D Stein MD MS*, Melissa M Brown MD MBA*, George 
L Spaeth MD FACS*, Richard Wilson MD
Purpose: To show the preference-based comparative / cost-effectiveness of 
glaucoma therapy since recent Agency for Healthcare Research and Quality 
(AHRQ) Comparative Effectiveness Reviews questioned glaucoma screening 
and therapy. Methods: Cost-utility analysis using patient utilities, 2012 US 
real dollars, direct medical costs expended, and societal costs saved. Results: 
Glaucoma therapy with timolol confers a mean 19% quality-of-life gain. The 
societal $/quality-adjusted life year (QALY) is -$183,631 and third party insurer 
$/QALY is $3,151. Therapy costs $7500 but has a net 21-year return-on-invest-
ment (ROI) of over $440,000 to patients and society, a 21-year 5,827 financial 
ROI, or 22.5% annual ROI. Conclusion: A widely applicable glaucoma therapy 
model dionstrates great patient value vs. interventions across medicine, is 
very cost-effective, and has a considerable financial ROI to society.
10:55 AM
Panel discussion of previous paper
PA077 11:00 AM
 NEW  Intraoperative IOP Changes During Victus 
Femtosecond Laser-Assisted Cataract Operation in 
Chinese Eyes
Presenting Author: Nafees Begum Baig MBBS FRCS
Co-Author(s): George P M Cheng MD, Clement C Y Tham MBBS*, Kelvin Kam 
Lung Chong MD, Vishal Jhanji MBBS
Purpose: To demonstrate IOP changes during femtosecond laser-assisted 
cataract surgery (FLACS) using Victus in Chinese eyes. Methods: Tono-Pen 
is used to measure IOP preoperatively, during suction-on and suction-off. Re-
sults: Among 20 subjects, the mean age is 70.6 ± 7.2. The mean IOPs preop-
eratively, during suction-on and suction-off, are 16.8 ± 3.5 mmHg (10-22), 42.4 
± 10.4 mmHg (24-55), and 14.0 ± 3.2 mmHg (9-20), respectively. The differ-
ences between preop IOP and suction-on as well as suction-on and suction-
off are statistically significant (P = 0.000 and P = .001). The mean treatment 
time is 60 seconds. Conclusion: A rise in IOP during FLACS is statistically 
significant. Caution should be taken in ocular conditions that are vulnerable 
to IOP fluctuation.
11:07 AM
Panel discussion of previous paper
PA078 11:12 AM
 NEW  Patient Acceptance of an Alternative Model of 
Glaucoma Delivery
Presenting Author: Ravi Pandit
Co-Author(s): David S Friedman MD MPH PhD*, Michael V Boland MD PhD
Purpose: To characterize patient acceptance of a tele-ophthalmological ap-
proach to glaucoma diagnosis and management. Methods: Ninety adult glau-
coma patients at the Wilmer Eye Institute were surveyed. Results: Fifty-five 
percent of patients reported a visit that yielded no change in management. 
Fifty-eight percent of patients favored this new model. Each additional visit 
per year decreased odds of acceptance by a factor of 0.5 (P = .038; 95% CI, 
0.26-0.96). Indicating “avoiding unnecessary visits” as a potential benefit was 
associated with a 7.6-fold increase in the odds of acceptance (P = .046; 95% 
CI, 1.04-55.61). Conclusion: Glaucoma care delivery must become more ef-
ficient. Perceived convenience is the most important factor driving patient ac-
ceptance of a new model of care. Notably, age did not predict acceptance of 
this technology-driven model.
11:19 AM
Panel discussion of previous paper
Intraocular Inflammation, Uveitis
Sunday, Nov. 17
10:15 - 11:15 AM
Room: 255
Moderator: Janet Louise Davis MD*
Panel: Lucia Sobrin MD**, Jennifer E Thorne MD PhD*
PA010 10:15 AM
 NEW  Analysis of Anterior Chamber Inflammation by 
Spectral Domain OCT
Presenting Author: Careen Yen Lowder MD PhD*
Co-Author(s): Sumit Sharma MD, Kimberly Marie Baynes COA, Peter K Kaiser 
MD*, Sunil K Srivastava MD*
Purpose: To determine the feasibility of anterior segment spectral domain 
OCT (AS-OCT) to grade anterior chamber (AC) inflammation. Methods: Pa-
tients with active AC inflammation were prospectively examined and clinically 
graded using the Standardization of Uveitis Nomenclature criteria. AS-OCT 
images consisting of 3-D volume scans were obtained. Images were manu-
ally graded to evaluate for the presence of cells and correlated to clinical 
exam. Results: Eighty-three eyes were enrolled. The range of cells seen on 
each individual AS-OCT line scan was 0-20. Pearson correlation coefficient 
comparing the clinical exam to AS-OCT grading was 0.92 (P < .0001). Conclu-
sion: AS-OCT is a useful tool to grade the degree of AC inflammation. Clinical 
exam grading strongly correlates with the number of cells seen on AS-OCT 
line scans.
10:22 AM
Panel discussion of previous paper
PA011 10:27 AM
 NEW  Wide-field Imaging Findings of Patients With Susac 
Syndrome
Presenting Author: Sunil K Srivastava MD*
Co-Author(s): Robert J Courtney MD, Kimberly Marie Baynes COA, Priyanka 
Kumar MD, Justis P Ehlers MD*, Careen Yen Lowder MD PhD*, Robert 
Martin Rennebohm MD
Purpose: This study evaluates ultrawide-field fluorescein angiography (FA) 
features in Susac syndrome and their relationship to systiic symptoms. 
Methods: Retrospective, observational, consecutive case series of patients 
referred to the Cleveland Clinic International Susac Clinic. All patients had 
complete eye and systiic exams with wide-field FA performed. Results: Thir-
teen patients were identified. Novel peripheral findings included fluorescein 
column segmentation, capillary nonperfusion, vessel wall leakage, and neo-
vascularization. Ten of 10 eyes had vascular changes visible only with wide-
field FA. Vascular leakage and column segmentation were associated with 
active neuro symptoms. Conclusion: Ultrawide-field FA dionstrates the pan-
retinal nature of the vasculopathy in Susac. These findings often correlated 
with systiic symptoms.
10:34 AM
Panel discussion of previous paper
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PA012 10:39 AM
 NEW  Pattern of Uveitis in Behçet Disease in a Tertiary 
Center Over 25 Years: The Results of a Uveitis Survey 
Study Group
Presenting Author: J Fernando Arevalo MD FACS*
Co-Author(s): Ammar M Al Mahmood MD, Sulaiman M Alsulaiman MD, 
Abdul Aziz Al Rushood MD, Andrés Francisco Lasave MD, Yahya Ahmad 
Alzahrani, Hassan A Al-Dhibi MD
Purpose: To describe the pattern of uveitis in Behçet disease in a tertiary cen-
ter over a 25-year period. Methods: Out of 888 consecutive uveitis patients 
(1409 eyes), 132 patients (232 eyes, 14.8%) with Behçet disease were retro-
spectively evaluated. Results: Panuveitis and posterior uveitis were the most 
common forms of presentation, affecting 104 (78.8%) and 13 (9.8%) patients, 
respectively. Retinal vasculitis was found in 61 eyes (26.3%), ischiic retinitis 
in 59 eyes (25.4%), and macular edia in 42 eyes (18.1%). 56.5% of patients 
maintained a visual acuity of 20/50 or better with immunosuppressive therapy 
and oral systiic corticosteroids. Conclusion: Behçet’s uveitis affects predomi-
nantly young men. Bilateral panuveitis associated with retinal vasculitis was 
the most common ocular manifestation.
10:46 AM
Panel discussion of previous paper
PA013 10:51 AM
 NEW  Prevalence of Spondyloarthritis in Anterior Uveitis 
Patients: The SENTINEL Study Group
Presenting Author: Miguel Cordero Coma MD*
Co-Author(s): Xavier Juanola MD
Purpose: To determine the true prevalence of seronegative spondyloarthri-
tis (SpA) among idiopathic anterior uveitis patients by using new diagnostic 
tools, such as magnetic resonance imaging (MRI), and new diagnostic criteria 
(Assessment of SpondyloArthritis international Society, ASAS). Methods: 
Prospective multicenter noncomparative cohort study. Results: A total of 231 
patients from 29 tertiary referral centers with anterior uveitis and no previ-
ous diagnosis of any associated immune-mediated condition were included 
in the study. After an initial systiatic clinical evaluation protocol, 148 patients 
(64.6%) were newly diagnosed with a type of SpA based on ASAS criteria. 
Conclusion: These preliminary results show that in a large prospective 
cohort, almost 65% of patients with idiopathic anterior uveitis have an as-
sociated underlying SpA, which significantly increases previously reported 
incidence.
10:58 AM
Panel discussion of previous paper
PA014 11:03 AM
 NEW  In Vivo Analysis of Choroidal Changes in Multifocal 
Choroiditis
Presenting Author: Ramya N Swamy MD
Co-Author(s): Muneeswar G Nittala, Hossein Nazari Khanamiri, Srinivas R 
Sadda MD*, Narsing A Rao MD
Purpose: To study in vivo characteristics of choroidal vasculature, volume, 
and thickness in multifocal choroiditis (MFC). Methods: Spectral domain OCT 
data were utilized to construct choroidal thickness and volume maps of 24 
eyes from 14 patients with chronic MFC and 17 eyes of normal controls. Re-
sults: Average choroidal thickness in the MFC group was measured at 149.83 
µm compared to 268.3 µm in controls (P < .001). Average choroidal volume 
was 5.39 µm3 in the MFC group and 7.51 µm3 in controls (P < .001). Analysis 
of B-scans revealed loss of medium and large choroidal vessels. Conclusion: 
Chronic MFC is associated with thinning of choroid and loss of choroidal vol-
ume, with changes affecting the Sattler and Haller layers.
11:10 AM
Panel discussion of previous paper
Neuro-Ophthalmology
Sunday, Nov. 17
2:00 - 3:00 PM
Room: 255
SYM56
Best of NANOS 2013: Featuring Best Papers from the 
North American Neuro-Ophthalmology Society
Ocular Tumors and Pathology
Monday, Nov. 18
8:30 - 9:10 AM
Room: 255
Moderator: H Culver Boldt MD**
Panel: Amy Schefler MD**, Arun D Singh MD
PA023 8:30 AM
 NEW  Overexpression of Nuclear Survivin and Androgen 
Receptor: Biomarker for Recurrence in Eyelid Sebaceous 
Gland Carcinoma
Presenting Author: Sneha Jay Shah MBBS MS
Co-Author(s): Kaustubh Bharat Mulay BMBS MD**, Valerie White MD
Purpose: To determine the expression of nuclear survivin and androgen re-
ceptor in eyelid sebaceous gland carcinoma (SGC) and to investigate their role 
as prognostic biomarkers for tumor recurrence. Methods: Histopathological 
specimens of all the patients diagnosed to have SGC from June 2000 to June 
2012 were processed and stained with nuclear survivin and androgen receptor, 
and correlated with outcome. Results: There were 56 patients with a mean 
age of 57 years and an average follow-up of 33 months. Of 8 patients who had 
local tumor recurrence, nuclear survivin and androgen receptor scores were 
high in 100% (46% in controls, P < .001) and 88% (33% in controls, P = .005), 
respectively. Conclusion: Nuclear expression of survivin and androgen recep-
tor have a high correlation with recurrence of eyelid SGC.
8:37 AM
Panel discussion of previous paper
PA024 8:42 AM
 NEW  Intravitreal Melphalan for Persistent or Recurrent 
Retinoblastoma Vitreous Seeds Provides Control With 
Minimal Complication
Presenting Author: Carol L Shields MD
Co-Author(s): Fairooz Puthiyapurayil Manjandavida MBBS, Swathi Kaliki MD, 
Rachel Schwendeman MA, Carlos G Bianciotto MD, Sara E Lally MD, Jerry A 
Shields MD
Purpose: To analyze intravitreal melphalan for viable vitreous seeds from 
retinoblastoma following systiic chiotherapy. Methods: Retrospective inter-
ventional case series. Results: The vitreous seeds occupied 35%-50% fundus 
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(n = 6) and 75%-100% fundus (n = 5). Intravitreal melphalan yielded vitreous 
seed control in 11 (100%) within 1 to 4 cycles, manifesting as disappearance 
or calcification of vitreous seeds. At mean 19 months follow-up, there was 
no tumor recurrence or extraocular tumor seeding. Conclusion: Intravitreal 
melphalan injection for vitreous seeds from retinoblastoma is effective for 
seed control with no tumor spread.
8:49 AM
Panel discussion of previous paper
PA025 8:54 AM
 NEW  Significance of Measuring Immune Mediators 
for Differentiating Malignant From Benign Pigmented 
Intraocular Tumors
Presenting Author: Yoshihiko Usui MD
Co-Author(s): Shunichiro Ueda MD, Yoko Okunuki MD, Takeshi Kezuka MD 
PhD, Hiroshi Goto MD
Purpose: To examine the usefulness of measuring immune mediators in aque-
ous humor samples (AH) to differentiate malignant from benign pigmented 
intraocular tumors. Methods: In 26 eyes (13 with benign pigmented tumor, 13 
with malignant melanoma), IFN-g, IL-1b, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, 
IL-12p70, VEGF, angiogenin, bFGF, Fas ligand, eotaxin, GM-CSF, RANTES, LT-a, 
Mig, IP-10, MIP-1a, MIP-1b, OSM, MCP-1, and TNF in AH were measured 
with a cytometric bead array. Results: AH levels of angiogenin and MCP-
1 were significantly (P < .05) higher in eyes with malignant melanoma than 
in those with benign tumor. Conclusion: Measuring angiogenin and MCP-1 
in AH is a useful adjunct in distinguishing malignant from benign intraocular 
tumors.
9:01 AM
Panel discussion of previous paper
Orbit, Lacrimal, Plastic Surgery
Monday, Nov. 18
9:10 - 10:00 AM
Room: 255
Moderator: Alon Kahana MD PhD
Panel: Flora Levin MD, Pete Setabutr MD
PA026 9:10 AM
 NEW  Are We There Yet? The Journey of Fluorine 
Deoxyglucose Positron Emission Tomography in the 
Staging of Ocular Adnexal Lymphoproliferative Disease
Presenting Author: James English BSMT MBBS
Co-Author(s): Timothy J Sullivan MBBS
Purpose: To further evaluate fluorine 18 deoxyglucose positron iission tomog-
raphy (FDG PET) in the initial staging of ocular adnexal lymphoproliferative 
disease (OALD). Methods: Retrospective nonrandomized case series with re-
view of clinical and imaging records including computed tomography (CT) and 
FDG PET (± PET/CT). Results: Thirty-four patients had FDG PET and CT scans 
at initial staging and were retrospectively reviewed. Of these, 17 (50%) had 
primary and 17 (50%) had secondary disease. Systiic disease was dionstrated 
by FDG PET (± CT) in 15 of 16 patients (94%) and 11 of 16 patients (69%) with 
CT. Conclusion: Our study suggests FDG-PET detects systiic disease more 
reliably than CT and significantly changes staging and treatment. FDG-PET 
riains an essential part of initial staging.
9:17 AM
Panel discussion of previous paper
PA027 9:22 AM
 NEW  The Effect of Preaponeurotic Fat Advancement 
in Levator Recession for the Treatment of Upper Lid 
Retraction in Asian Patients
Presenting Author: Juhyang Lee MD
Co-Author(s): Kyung In Woo MD, Yoon-Duck Kim MD
Purpose: To investigate the effectiveness of preaponeurotic fat advancient in 
levator recession for upper lid retraction in Asian patients. Methods: Forty-
three patients (58 eyelids) who underwent levator recession surgery with (n = 
29) or without (n = 29) the preaponeurotic fat advancient flap procedure were 
included. Results: There were no multiple lid creases in the fat advancient 
group, compared with 6 eyes (20.7%) without fat advancient. There were no 
differences between the two groups in achieving reliable eyelid lowering and 
eyelid symmetry (69.0% and 72.4%, respectively). Conclusion: Preaponeu-
rotic fat advancient flap is an effective method to prevent unintended multiple 
lid creases and provide satisfactory cosmetic outcomes in levator recession.
9:29 AM
Panel discussion of previous paper
PA028 9:34 AM
 NEW  Managing Orbital Vascular Lesions in the 
Endovascular Operating Room
Presenting Author: Emmy Yuen-Mei Li FRCS MPH
Co-Author(s): Kwok-lai Yuen MBCHB MRCSED, Kelvin Kam Lung Chong MD
Purpose: To describe hybrid procedure for orbital vascular lesions in endovas-
cular operating room (EVOR). Methods: Interventional case series. Results: 
Six patients with orbital vascular lesions received one-stage direct puncture 
venogram, image-guided glue injection, and surgical resection in the EVOR 
equipped with biplane digital subtraction angiography machine. Indications 
of treatment include enlargient mass with disfigurient, pain, and visual im-
pairment. Surgical resections were facilitated with reduced bleeding, and all 
patients have uneventful postoperative recovery. Conclusion: The one-stage 
hybrid approach by interventional radiologists and surgeons in the setting of 
EVOR appears to be safe and effective for orbital vascular lesions.
9:41 AM
Panel discussion of previous paper
PA029 9:46 AM
 NEW  Reduction of Thyroid-Stimulating Immunoglobulin 
After Orbital Fat Decompression in Patients With Graves 
Orbitopathy
Presenting Author: Jei Hun Jeon MD
Co-Author(s): Sun Young Jang MD, Tyler Hyung Taek Rim MD MBA, Eung 
Kweon Kim MD PhD, Jin S Yoon MD
Purpose: To investigate the change of thyroid-stimulating immunoglobulin 
(TSI) levels after orbital fat decompression in Graves orbitopathy patients. 
Methods: Retrospective, observational case series. Ophthalmic manifesta-
tions including NOSPECS, clinical activity score (CAS), and TSI level before 
and after the surgery were analyzed. Results: Data of 24 patients were eligi-
ble for analysis. Preoperative TSI levels significantly decreased after surgery. 
The decreased amount of TSI was significantly correlated with preoperative 
NOSPECS/CAS and with the change of NOSPECS/CAS after surgery. Conclu-
sion: Rioval of Graves orbital fat tissue, with its antigenic components, may 
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result in the reduction of serum level of functional antibodies to TSH receptor, 
thus supporting the concept that continued antibody production depends on 
the persistence of autoantigen in the body.
9:53 AM
Panel discussion of previous paper
Pediatric Ophthalmology, Strabismus
Monday, Nov. 18
2:00 - 3:30 PM
Room: 255
Moderator: Terri L Young MD*
Panel: Hilda Capo MD, Michael F Chiang MD*, Michelle T Cabrera MD
PA051 2:00 PM
 NEW  Pediatric Anterior Segment Pathology as Imaged by 
Intraoperative OCT
Presenting Author: Bibiana J Reiser MD*
Co-Author(s): Pho Nguyen MD, Daniel Sand MD, David Huang MD PhD*
Purpose: To evaluate high-resolution anterior segment OCT (AS-OCT) in ex-
amination and preoperative managient of pediatric corneal opacities. Meth-
ods: Twenty eyes of 15 consecutive patients (ages 1 day to 11 years of age) 
with corneal opacities were enrolled and examined by an iVue unit mounted 
on an iStand. Results: Peters anomaly, sclerocornea, corneal staphyloma, 
hydrops, idiopathic congenital central corneal opacity, shield ulcer, trauma, 
microbial colonization, lipid keratopathy. Seven patients underwent surgical 
intervention based on AS-OCT imaging. Conclusion: Anterior segment OCT 
is an important noninvasive imaging modality in confirming the diagnosis and 
guiding surgical managient of pediatric corneal opacities.
2:07 PM
Panel discussion of previous paper
PA052 2:12 PM
 NEW  Visual Acuity and Macular OCT Abnormalities in 
Children With History of Retinopathy of Prematurity
Presenting Author: Victor M Villegas MD
Co-Author(s): Kara M Cavuoto MD, Audina Berrocal MD*, Craig A McKeown 
MD, Hilda Capo MD
Purpose: To correlate visual acuity (VA) and macular OCT findings in retinopa-
thy of priaturity (ROP) patients with normal macular funduscopy. Methods: 
Retrospective study of ROP children with OCT in past 2 years. Eyes were ex-
cluded if abnormal macular funduscopy or surgery. Eyes divided by VA into 
Group 1 if ≥ 20/40, and Group 2 if < 20/40. Results: Forty-four patients (44 
eyes) in Group 1, 29 in Group 2. Mean values in groups 1 vs. 2: age (years), 9.7 
vs. 7.9, spherical equivalent (D), -5.6 vs. -10.2, gestational age (weeks), 24.9 
vs. 25.3, central foveal thickness (micrometers), 313 vs. 299, and retention 
inner retinal layers, 62 vs. 67%. Conclusion: Patients with ROP frequently 
have abnormal foveal morphology by OCT, but this does not necessarily imply 
poor VA.
2:19 PM
Panel discussion of previous paper
PA053 2:24 PM
 NEW  A Cost-Effectiveness Comparison of Bevacizumab 
(Avastin)and Laser for Treatment of Retinopathy of 
Prematurity
Presenting Author: Michael J Geske MD
Co-Author(s): Alejandra G de Alba-Campomanes MD*
Purpose: To evaluate the cost-effectiveness of bevacizumab (Avastin) and 
laser for the treatment of retinopathy of priaturity (ROP). Methods: A Markov 
model was created to estimate average cost per patient. Costs were obtained 
from the Centers for Medicare and Medicaid Services. Rates of recurrence, 
time to recurrence, and percentage of infants requiring retreatment were de-
rived from the Bevacizumab Eliminates the Angiogenic Threat of ROP (BEAT-
ROP) clinical trial. Results: Total estimated cost per patient for bevacizumab 
treatment was $1102.13 for Zone I ROP and $879.60 for Zone II ROP. Estimated 
costs for laser treatment averaged $2241.18 for Zone I ROP and $1749.46 for 
Zone II ROP. Conclusion: Bevacizumab is a cost-effective alternative to laser 
treatment for threshold ROP.
2:31 PM
Panel discussion of previous paper
PA054 2:36 PM
 NEW  Comparative Evaluation of Combined Trabeculotomy-
Trabeculectomy vs. Combined Trabeculotomy-
Trabeculectomy With Subconjunctival Implantation of 
Collagen Matrix Implant for Primary Congenital Glaucoma
Presenting Author: Nigar Hasanova-Makhmudova MD
Co-Author(s): Jamil V Hasanov MD
Purpose: To compare the outcomes of combined trabeculotomy-trabeculecto-
my (CTT) with those of CTT with subconjunctival collagen matrix implant (CMI) 
implantation in the treatment of primary congenital glaucoma (PCG). Meth-
ods: A total 20 eyes of 16 patients were involved. CTT was performed in 10 
eyes (Group 1), and CTT with subconjunctival CMI (Ologen) implantation was 
performed in 10 eyes (Group 2). Pre- and postoperative IOP, corneal clarity and 
diameters, visual acuity, and complications were evaluated. Results: Mean 
preop IOP was 41.0 ± 8.68 in Group 1, 40.4 ± 6.87 in Group 2, which reduced 
to 16.3 ± 1.89 and 13.6 ± 2.01, respectively. Eighty percent of cases in Group 1 
and 100% of cases in Group 2 showed IOP < 18 mmHg at the end of 6 months 
(P < .001). Conclusion: The results of both groups were comparable, and both 
procedures can be taken up as primary procedures in case of PCG.
2:43 PM
Panel discussion of previous paper
PA055 2:48 PM
 NEW  Normative Visual Acuity Values in Preschool 
Children
Presenting Author: Suzanne A Turner MBBS
Co-Author(s): Cathy Williams FRCOPHTH MBBS PhD, John M Sparrow 
FRCOphth
Purpose: To establish the normative visual acuity values for preschool chil-
dren and establish the minimum age at which monocular testing is possible. 
Methods: 1432 children were tested at 6-monthly intervals from the age of 
12 months until the age of 43 months. Age-appropriate tests were used, and 
at each visit both binocular and monocular testing were attipted. Results: 
Visual acuity and testability improved with increasing age. Monocular testing 
was not possible at all in the majority aged less than 2.5 years. Monocular Kay 
150
Original Papers
O
ri
gi
na
l P
ap
er
s
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.  
No asterisk indicates that the presenter has no financial interest.
picture values were possible in 62% of children aged 31 months. Monocular 
testing with a letter chart was possible in 53% of children aged 43 months. 
Conclusion: Mass screening with a test sensitive and specific in detecting 
amblyopia is not feasible below about 4 years of age.
2:55 PM
Panel discussion of previous paper
PA056 3:00 PM
 NEW  A Randomized Trial Comparing Part-time Patching 
With Observation for Children With Intermittent Exotropia
Presenting Author: Brian G Mohney MD
Co-Author(s): Susan A Cotter MS OD, Danielle Long Chandler MSPH*, 
Jonathan M Holmes MD*
Purpose: To determine the effectiveness of part-time patching for treatment 
of intermittent exotropia (IXT) in children. Methods: 358 children ages 3 to < 
11 years old with previously untreated IXT were randomly assigned to obser-
vation or 3 hours daily patching for 5 months. Results: Of 318 participants 
(89%) completing the 6-month primary outcome exam thus far, deterioration 
occurred in 6% (9 of 160) of the observation group and in 1% (1 of 158) of 
the patching group (difference = 5%, lower limit of one-sided exact 95% con-
fidence interval = 1%). Conclusion: Deterioration of previously untreated 
childhood IXT over a 6-month period is uncommon. Compared with observa-
tion alone, the treatment effect of part-time patching is statistically significant 
but not clinically meaningful.
3:07 PM
Panel discussion of previous paper
PA057 3:12 PM
 NEW  Occurrence of Intracranial Disease Among 40 
Children With Acute Acquired Comitant Esotropia
Presenting Author: Helena B Hesgaard MD
Co-Author(s): Troels Vinding
Purpose: To discriminate between acute acquired comitant esotropia (AACE) 
with and without intracranial pathology and to determine risk factors for in-
tracranial pathology and reclassify AACE accordingly. Methods: We reviewed 
medical records of 40 children referred with AACE during 2000-2012. Results: 
Six causes of AACE were identified. Intracranial pathology was present in 
10% of the children. Eleven risk factors for intracranial pathology were identi-
fied. The children with intracranial disease exhibited 4 or more of these risk 
factors. Conclusion: We propose a reclassification of AACE: AACE with intra-
cranial disease and AACE without intracranial disease. Furthermore, we sug-
gest neuroimaging in children with AACE, when neurologic signs or at least 4 
risk factors are observed.
3:19 PM
Panel discussion of previous paper
Refractive Surgery
Monday, Nov. 18
10:15 AM - 12:00 PM
Room: 255
Moderator: Sonia H Yoo MD*
Panel: Karl G Stonecipher MD*, John Allan Vukich MD*, Elizabeth Yeu MD*
PA030 10:15 AM
 NEW  Brain Plasticity Overcomes Presbyopia: Persistence 
Over Time
Presenting Author: Uri Polat PhD*
Co-Author(s): Oren Yehezkel PhD*, Anna Sterkin PhD**, Maria Lev MS**, 
Tova Ma-Naim MD
Purpose: In presbyopia, uncorrected near visual acuity (UCNVA) results in 
blurred images and progresses with age. We showed that perceptual train-
ing on PC and mobile devices improved the UCNVA by ~2.5 ETDRS lines and 
enabled glasses-free reading without optical changes. Here we tested the 
persistence of these training gains. Methods: Sixty presbyopes were trained 
at 40 cm for 15-30 min/session, 3 times/week. Results: The improvient of 
the UCNVA continued for 6.22 years (average: 2.45 years), despite the natural 
deterioration of ~0.5 D and 2 ETDRS lines expected during this time. Conclu-
sion: Perceptual training produces an effective solution that overcomes the 
continuous effect of natural deterioration of vision in presbyopia by enhancing 
image processing in the brain.
10:22 AM
Panel discussion of previous paper
PA031 10:27 AM
 NEW  Preliminary 1-Year Results of LASIK vs. Contact Lens 
Patient Satisfaction Survey
Presenting Author: Francis W Price Jr MD*
Co-Author(s): Marianne O Price PhD*
Purpose: To compare patient satisfaction with LASIK and contact lenses. 
Methods: In this prospective study patients were surveyed at baseline (be-
fore surgery for those in the LASIK group) and 1 year later to assess visual 
satisfaction and problis. Results: Twenty-one centers enrolled 1085 LASIK 
patients and 738 successful contact lens wearers. Median age was 34 years 
(range: 18-60), and median spherical equivalent was -3.5 D (range: -11 to +4). 
The LASIK group reported improved night vision (P = .0006) and increased feel-
ings of dryness at 1 year (P = .016), whereas contact lenses wearers reported 
no significant changes in those measures. Conclusion: LASIK significantly 
improved night vision but increased dryness at 1 year.
10:34 AM
Panel discussion of previous paper
PA032 10:39 AM
 NEW  Rapid Vision Recovery Beyond 20/20: Improving the 
Speed of Visual Recovery After PRK and LASIK
Presenting Author: Daniel S Durrie MD*
Co-Author(s): Stephen G Slade MD FACS*
Purpose: To evaluate visual recovery immediately after LASIK or PRK. Meth-
ods: Prospective trial of 199 eyes (103 patients) treated for myopia and 
astigmatism, evaluated at 30 minutes and 1, 2, 4, and 24 hours after surgery. 
Variables included different combinations of 5 lasers and the novel use of an 
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ocular shield after PRK and LASIK to accelerate recovery. Results: Binocular 
20/20 vision or better was reached within 4 hours in 99% of patients. The ocu-
lar shield significantly improved recovery. Conclusion: The speed of visual 
recovery after modern excimer surgery is rapid. Techniques achieving 20/20 
vision within minutes are within reach.
10:46 AM
Panel discussion of previous paper
PA033 10:51 AM
 NEW  Clinical Outcomes of Posterior Chamber Phakic IOL 
Implantation With Central Hole: One-Year Follow-up
Presenting Author: Erik L Mertens MD FRACOPHTH*
Purpose: The purpose of this study was to assess the visual outcomes at 
1 year on patients who received the Visian Implantable Collamer Lens V4C 
model. Methods: Seventy-five eyes underwent implantation of a myopic or 
toric implantable collamer lens (V4C model, Staar Surgical, Inc.). The new de-
sign shows a central hole that allows a more natural aqueous flow, eliminat-
ing the need to perform Nd:YAG iridotomy or peripheral iridectomy. Results: 
At 1 year the mean efficacy and safety index were 1.06 ± 0.11 and 1.07 ± 0.11, 
respectively. The mean UCVA and BCVA were 20/20 or better in 97.3% and 
98.6% of eyes, respectively. 97.3% and 100% of eyes were within ± 0.5 D and 
± 1.0 D of the expected correction. Conclusion: The results of the present 
study support the good outcomes of this design.
10:58 AM
Panel discussion of previous paper
PA034 11:03 AM
 NEW  Comparison of Epithelium-off and Transepithelial 
Corneal Collagen Crosslinking for Treatment of 
Keratoconus
Presenting Author: Mohammed Iqbal Hafez Ahmed Sleem MD
Purpose: To compare the efficiency of epithelium-off corneal crosslinking 
(CXL) and transepithelial crosslinking (TE-CXL) in keratoconus (KC) patients. 
Methods: Visual acuity, simulated keratometry, corneal topography, and 
pachymetry were evaluated at baseline and 1, 3, and 6 months. Fifteen KC 
patients were treated with TE-CXL, and 20 KC patients were treated with 
epithelium-off CXL. Results: In the epithelium-off CXL group a significant im-
provient at Month 12 was present for K-max (-1.11 D, P = .01), K-min (-3.2 D, P 
= .001), mean K (-1.47 D, P = .01. In the TE-CXL group a significant improvient 
at Month 12 was present for K-max (-1.14 D, P = .02), K-min (-2.04 D, P = .01), 
mean K (-1.63 D, P = .01), and surface asymmetry index (-0.86 D, P = .001). 
Conclusion: In KC patients, TE-CXL was less painful and provided similar 
effectiveness and fewer complications than epithelium-off CXL.
11:10 AM
Panel discussion of previous paper
PA035 11:15 AM
 NEW  Femtosecond Laser Intrastromal Astigmatic 
Keratotomy
Presenting Author: William W Culbertson MD*
Co-Author(s): Sonia H Yoo MD*, Vasilios F Diakonis MD
Purpose: To determine the efficacy and safety of using an OCT-guided fitosec-
ond laser to perform intrastromal astigmatic keratotomy to reduce naturally 
occurring astigmatism. Methods: The Optimedica Catalys fitosecond cataract 
laser was iployed to create paired intrastromal astigmatic keratotomies at 
a 7.0-mm optic zone, with an arc length of 70° at 80% of corneal depth in 
corneas with between 0.50 D and 2.0 D of naturally occurring regular corneal 
astigmatism. Results: In the 20 eyes studied, corneal astigmatism was re-
duced by an average of 0.70 D (range: 0.2-0.9 D). There were no significant 
complications. Conclusion: A clinical fitosecond cataract laser may be ip-
loyed to safely reduce low amounts of naturally occurring corneal astigmatism 
to an optically insignificant level.
11:22 AM
Panel discussion of previous paper
PA036 11:27 AM
 NEW  Corneal Inlay Implantation for the Treatment of 
Presbyopia: Over 10,000 Cases
Presenting Author: Minoru Tomita MD PhD*
Co-Author(s): Satoshi Yukawa MD, Toru Nakamura MD
Purpose: To evaluate outcomes of corneal inlay implantation for the treat-
ment of ametropic and post-LASIK presbyopes. Methods: A corneal inlay was 
implanted monocularly in over 10,000 patients either with simultaneous LASIK 
(CLK) or in pocket interface below prior LASIK flap for post-LASIK patients 
(PLK). Uncorrected distance and near visual acuities (UDVA/UNVA) were eval-
uated. Results: Mean UDVA and UNVA gained 8 lines to 20/20 and 3 lines 
gain to J2 for the CLK group, and lost 1 line to 20/20 and gained 3 lines to J2 
for the PLK group at 1 year. Conclusion: Implantation of a corneal inlay is an 
effective treatment option for ametropic and post-LASIK presbyopes.
11:34 AM
Panel discussion of previous paper
PA037 11:39 AM
 NEW  Outcome of Same Day Topographic-Guided PRK 
and Corneal Crosslinkage in Patients With Subclinical 
Keratoconus
Presenting Author: Talal A Althomali MD
Purpose: To compare outcomes of same-day topographic-guided PRK with 
those of corneal crosslinkage in patients with forme fruste keratoconus (FFKC). 
Method: Forty eyes with FFKC were treated with topographic-guided PRK and 
same-day corneal collagen crosslinkage with riboflavin. Results: Median pre-
operative spherical equivalent (SE) refraction was -2.25 D. At 1 year follow-up, 
SE was statistically significantly reduced to -0.25 D. BCVA was 0.60. Median 
postoperative UCVA was 0.90 . Median steepest K reading preop was 46.25 
D, and it was 43.62 D at final follow-up visit. Conclusion: Same-day top-
ographic-guided PRK and corneal crosslinkage is a safe treatment, offering 
good vision in subclinical cases of keratoconus.
11:46 AM
Panel discussion of previous paper
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Retina, Vitreous
Monday, Nov. 18
3:45 - 5:15 PM
Room: 255
Moderator: Srinivas R Sadda MD*
Panel: Neil M Bressler MD*, Pravin U Dugel MD*, William F Mieler MD*
PA058 3:45 PM
 NEW  Interim Results of a Phase 1 Clinical Study 
Evaluating the Safety and Clinical Response of Human 
Umbilical Tissue-Derived Cells Administered Subretinally 
in Subjects with Geographic Atrophy
Presenting Author: Michael A Samuel MD*
Co-Author(s): Tom S Chang MD, Allen C Ho MD*
Purpose: Phase 1/2a, multicenter, randomized, single dose, dose escalation, 
fellow-eye controlled study evaluating the safety and clinical response of a 
single subretinal administration of CNTO 2476 in subjects with visual acu-
ity impairment associated with geographic atrophy (GA) secondary to AMD. 
Methods: Nineteen subjects with advanced GA secondary to dry AMD have 
been enrolled in the Phase 1 study. Subjects were assessed for adverse 
events, clinical examinations, and clinical laboratory tests. Results: Clinical 
response at 6 months, 38% (6/16) of treated eyes achieved at least a 3-line 
improvient in BCVA, and 50% (8/16) of treated eyes achieved at least a 2-line 
improvient. Conclusion: Subretinal administration of CNTO 2476 may result 
in favorable clinical response in some subjects with vision loss from GA.
3:52 PM
Panel discussion of previous paper
PA059 3:57 PM
 NEW  Intravitreal VEGF Levels in Proliferative Vascular 
Retinopathies Strongly Correlate With the Extent 
of Capillary Nonperfusion Noted on Wide-angle 
Angiography
Presenting Author: K V Chalam MD PhD
Co-Author(s): Shailesh K Gupta MD**
Purpose: To report the correlation between intravitreal VEGF levels in prolif-
erative vascular retinopathies (PR) and compare thi to the degree of capillary 
nonperfusion (CNP) noted on wide-angle angiogram (WFA). Methods: In this 
retrospective study, in patients with PR (N = 34), WFA was performed and 
ratio of CNP was estimated. Cohort consisted of PDR (n = 20),RVO (n = 10), 
and sickle cell retinopathy (n = 4).VEGF levels obtained during surgery were 
measured with Luminex assay. Results: VEGF levels ranged from 182 to 1047. 
Degree of CNP ranged from 22% to 89% and correlated strongly (r = 0.89) with 
VEGF levels. Conclusion: Degree of capillary nonperfusion noted on WFA is 
a good predictor of intravitreal VEGF levels and may help in modulating anti-
VEGF therapy in proliferative vascular retinopathies.
4:04 PM
Panel discussion of previous paper
PA060 4:09 PM
 NEW  Safety and Performance Results of the Argus II 
Retinal Prosthesis System 3 Years Following Implant
Presenting Author: Allen C Ho MD*
Co-Author(s): Mark S Humayun MD PhD*, Lyndon daCruz FRANZO 
FRCOPHTH*, Gislin Dagnelie PhD*, Paulo E Stanga MD*, David G Birch 
PhD*, Jacque L Duncan MD, Jose A Sahel MD*
Purpose: The Argus II Systi is being studied in an ongoing clinical trial to 
determine its safety and probable benefit. Methods: Subjects had bare light 
perception or worse vision due to retinitis pigmentosa before implant. Ad-
verse events were monitored throughout. Visual function, functional vision, 
and well-being were assessed. Results: As of Deciber 1, 2012, 30 subjects 
have been implanted at 10 centers (over 125 patient-years of follow-up). Per-
formance was better with the Systi on than with it off in both visual function 
and functional vision tasks. Conclusion: This is the largest study of a vi-
sual prosthesis to date. The results confirm previous reports on the reliability, 
safety, and probable benefit of the Argus II. Commercial approval in the United 
States was granted by the FDA in 2013.
4:16 PM
Panel discussion of previous paper
PA061 4:21 PM
 NEW  The Natural History of Diabetic Retinopathy Is 
Modified by Long-term Treatment With Intravitreal 
Ranibizumab
Presenting Author: Michael S Ip MD*
Co-Author(s): Amitha Domalpally MBBS, Jason S Ehrlich MD*
Purpose: To analyze the long-term effect of ranibizumab (RBZ) on diabetic 
retinopathy (DR) severity. Methods: Exploratory analysis of ≥ 2 and ≥ 3-step 
change on the ETDRS severity scale in study eyes (N = 707) in the RISE and 
RIDE trials of monthly RBZ (0.3 or 0.5 mg) vs. sham eyes crossing over to 0.5 
mg at the end of 2 years. Cox regression identified baseline predictors for DR 
worsening. Results: More RBZ-treated eyes showed improvient in DR sever-
ity vs. eyes in the sham/0.5-mg group at Month 36. Baseline capillary loss 
was associated with DR worsening in eyes treated with 0.3- or 0.5-mg RBZ. 
Conclusion: RBZ can reverse the progression of DR. Delayed intervention of 
RBZ may limit its therapeutic effect. Progression to neovascularization in eyes 
undergoing monthly ranibizumab can occur infrequently and may be related to 
macular nonperfusion.
4:28 PM
Panel discussion of previous paper
PA062 4:33 PM
 NEW  Residual Edema Evaluation with 0.5-mg and 2.0-mg 
Ranibizumab Formulations: The REEF Study
Presenting Author: Dilsher S Dhoot MD*
Co-Author(s): Dante Pieramici MD*, Ma’an A Nasir MD, Alessandro A 
Castellarin MD*, Robert F See MD, Stephen S Couvillion MD**, Nathan C 
Steinle MD*, Melvin D Rabena MD*, Robert L Avery MD*
Purpose: To compare 0.5-mg and 2.0-mg ranibizumab (RZ) in patients with 
persistent diabetic macular edia (DME) previously treated with bevacizumab 
(BV). Methods: Forty-three patients received 3 monthly injections of 0.5-mg 
RZ. At Month 3, patients with persistent DME received 3 monthly injections 
of 2.0-mg RZ. Results: Visual acuity (VA) improved by +6.4 letters at 3 months 
and by +8.8 letters at 6 months. Central subfield thickness (CST) decreased 
by -114 µm at 3 months and -165µm at 6 months. Prior to enrollment, 29/43 
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patients (67.4%) showed < 10% reduction in CST following monthly BV. After 
3 monthly 0.5-mg RZ, 22/29 (75.9%) showed > 10% reduction in CST. Six pa-
tients showed < 10% reduction in CST after monthly BV and 0.5-mg RZ (x3). 
In these patients, 3/6 showed > 10% reduction in CST after 3 monthly 2.0-mg 
RZ. Conclusion: DME patients that show a partial or nonresponse to BV may 
improve following RZ therapy.
4:40 PM
Panel discussion of previous paper
PA063 4:45 PM
 NEW  Long-term Outcomes in Patients With Retinal Vein 
Occlusion Treated With Ranibizumab: The RETAIN Study
Presenting Author: Peter A Campochiaro MD*
Co-Author(s): Raafay Sophie MD, Joel A Pearlman MD*, David Brown MD 
FACS*, David S Boyer MD*, Jeffrey S Heier MD*, Dennis M Marcus MD*, 
Leonard Feiner MD*, Arun Patel MD
Purpose: To determine long-term outcomes of ranibizumab (RBZ)-treated reti-
nal vein occlusion (RVO) patients. Methods: Patients completing the Lucentis 
for Retinal Vein Occlusion (HORIZON) RVO trial were seen every month for 1 
year and at least every 3 months for a second year and treated with RBZ for in-
traretinal fluid. Results: Mean BCVA 48 months after entry into the BRAVO or 
CRUISE studies (Ranibizumab for Branch/Central Retinal Vein Occlusion) was 
74.1 (improvient D = 18) in all 28 BRVO patients, 75.6 (D = 19) in 18 that sta-
bilized, and 71.5 (D = 17) in 10 patients still requiring injections; mean BCVA 
was 64 (D = 15) in all 26 CRVO patients, 73.2 (D = 26) in 13 that stabilized, 
and 56.8 (D = 9) in the other 13. Conclusion: Within 4 years of starting RBZ, 
75% of BRVO and 50% of CRVO patients no longer needed injections. Patients 
with BRVO who still required injections had an excellent visual outcome, while 
those with CRVO did less well but still had mean improvient of 2 lines.
4:52 PM
Panel discussion of previous paper
PA064 4:57 PM
 NEW  Fundus Autofluorescence Patterns in Central Serous 
Chorioretinopathy
Presenting Author: Seung Young Yu MD
Co-Author(s): Ji-Ho Yang MD, Hyung Woo Kwak MD PhD
Purpose: To investigate the patterns and frequency of fundus autofluores-
cence (FAF) abnormalities in patients with central serous chorioretinopathy 
(CSC) and evaluate correlation with spectral domain OCT (SD-OCT) findings 
and BCVA. Methods: Cross-sectional observational study, in which 127 eyes 
of 119 patients with CSC underwent fundus photography, FAF imaging, fluo-
rescein angiography, indocyanine green angiography, and SD-OCT. Results: 
Alterations in FAF were classified into 5 patterns: blocked, mottled, hyper, 
hyper/hypo, and descending tract in order by the length of duration of symp-
tom (P = 0.000). The visual acuity was the best in the blocked AF group (P 
= .045). Intact inner/outer segment junction on SD-OCT were most common 
in the blocked AF group (P = 0.000). Conclusion: The FAF abnormalities in 
CSC showed multiple distinct patterns and sei to correlate with duration of 
symptom and BCVA.
5:04 PM
Panel discussion of previous paper
Tuesday, Nov. 19
10:00 AM - 12:00 PM
Room: 271
Moderator: John T Thompson MD*
Panel: Julia A Haller MD*, Baruch D Kuppermann MD PhD*,  
Phillip J Rosenfeld MD PhD*
PA079 10:00 AM
 NEW  Pilot Study of OCT Angiography in Neovascular AMD
Presenting Author: Steven T Bailey MD
Co-Author(s): Yali Jia PhD*, Christina J Flaxel MD, James Fujimoto PhD*, 
David Huang MD PhD*, Joachim Hornegger PhD
Purpose: To detect choroidal neovascularization (CNV) in AMD patients us-
ing OCT angiography. Methods: Eyes with neovascular AMD were scanned 
by a high-speed 1050-nm wavelength swept-source OCT. The split-spectrum 
amplitude-decorrelation angiography algorithm was used to compute 3-D 
macular angiography. En face angiograms of the outer retinal, inner retinal, 
and choroid layers were created by maximum flow projection. Results: Eight 
eyes were scanned. En face outer retinal angiograms revealed CNV in patterns 
that agreed with the fluorescein angiograms. CNV size and flow index were 
measured, and vascular patterns could be dionstrated. Conclusion: This is 
the first dionstration of OCT angiography to detect CNV.
10:07 AM
Panel discussion of previous paper
PA080 10:12 AM
 NEW  Integrin Peptide Therapy: The First Human Wet AMD 
Experience
Presenting Author: David S Boyer MD*
Co-Author(s): Peter A Campochiaro MD*, Jeffrey S Heier MD*, Julia Ann 
Kornfield PhD**, Baruch D Kuppermann MD PhD*, Hugo Quiroz-Mercado 
MD*, Shulamit Schwartz MD*, Vicken H Karageozian MD*, Hampar L 
Karageozian MBA MS PHARMD, Lisa Karageozian*, John Park*, Marc 
Kirshbaum JD*, Peter K Kaiser MD*
Purpose: ALG-1001 inhibits integrin receptors and arrests neovascularization 
meditated by avB3, avB5 and a5B1 integrin sites. The study objective was 
to evaluate the dose ranging safety and efficacy of ALG-1001 in humans with 
wet AMD. Methods: Fifteen wet AMD subjects received 3 monthly injections 
of 2.0-mg or 3.2-mg ALG-1001 in monotherapy with 4 months off treatment 
follow-up. Results: There were no serious adverse effects reported. In the 
3.2-mg group, the mean improvement in ETDRS BCVA was +8 letters at Day 
120 (60 days off all treatment), with a mean reduction in OCT central macular 
thickness of 30% at study day 150 (90 days off all treatment). Conclusion: 
ALG-1001 in monotherapy was very well tolerated and produced a clinically 
significant biologic effect in the 3.2-mg group with improvements in BCVA and 
lesion regression lasting at least 3 months off treatment. 
10:19 AM
Panel discussion of previous paper
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PA081 10:24 AM
 NEW  Phase 1 Two-Year Device Safety and Explantation 
Experience With an Intravitreal Ranibizumab Sustained 
Delivery Implant
Presenting Author: Carl C Awh MD*
Co-Author(s): Guna Laganovska MD, Signe R Erickson PhD*, Eugene De Juan 
Jr MD*
Purpose: To assess ongoing tolerability of a drug delivery implant. Methods: 
Twenty patients received a refillable implant and were treated for 12 months. 
At 12 months, 6 patients underwent surgical rioval of the device. The riaining 
14 patients continued to receive ophthalmic examinations for up to 24 months. 
Results: Excision of 6 devices revealed the presence of a thin fibrous capsule 
over the extrascleral portion of the implant. Following rioval of this layer, the 
device was rioved without enlargient of the original incision. The rioved device 
showed no signs of tissue involvient. Ocular examinations revealed integrity 
of the device and surrounding tissue in 14/14 patients. Conclusion: Ophthal-
mic observations indicate ongoing device tolerability and continued visibility 
of the refill target.
10:31 AM
Panel discussion of previous paper
PA082 10:36 AM
 NEW  Ranibizumab vs. Bevacizumab for Neovascular 
AMD: One-Year Results From the GEFAL Randomized Trial
Presenting Author: Laurent Kodjikian MD PhD*
Co-Author(s): Eric H Souied MD PhD*, Francine Behar-Cohen**, Laure Huot, 
Ggilles Aulagner PHARMD PhD**, Martine Mauget-Faysse MD*, Gerard 
Mimoun MD**
Purpose: To dionstrate the noninferiority in terms of clinical efficacy of beva-
cizumab vs. ranibizumab intravitreal injections for the treatment of subfoveal 
neovascular AMD. Methods: Groupe d’Evaluation Français Avastin vs. Lucen-
tis (GEFAL) is a noninferiority head-to-head double-masked randomized mul-
ticenter French clinical trial. The primary outcome was the change in visual 
acuity at 1 year. Results: 501 patients have been included. Statistical analy-
ses are ongoing. As the results about efficacy and safety have not been pub-
licly disclosed yet, they will be presented in their entirety at the 2013 Annual 
Meeting. Conclusion: The GEFAL trial is a reliable double-masked study that 
respects the posology set out in the IEA marketing authorization. GEFAL data 
will enhance the data currently available from head-to-head studies.
10:43 AM
Panel discussion of previous paper
PA083 10:48 AM
 NEW  Comparison of Systemic Pharmacokinetics 
Following Anti-VEGF Intravitreal Injections of 
Ranibizumab, Bevacizumab, and Aflibercept
Presenting Author: Robert L Avery MD*
Co-Author(s): Alessandro A Castellarin MD*, Nathan C Steinle MD*, Dilsher 
S Dhoot MD*, Dante Pieramici MD*, Robert F See MD, Stephen S Couvillion 
MD**, Ma’an A Nasir MD, Melvin D Rabena MD*, Kha N Le PhD*, Jennifer 
Visich PhD**
Purpose: To compare the systiic pharmacokinetics (PK) of intravitreal (IVT) 
bevacizumab (BEV), ranibizumab (RBZ), and aflibercept (AFB). Methods: Forty-
five neovascular AMD patients received 3 monthly IVT injections of RBZ 0.5 
mg, BEV 1.25 mg, or AFB 2.0 mg. ELISA assays measured serum anti-VEGF 
levels after the first and third doses. Results: The molar ratio of BEV to RBZ 
for median Cmax and AUC0-t was ~13- and 24-fold, respectively. Serum BEV 
levels prior to the third dose were 2-fold higher than the BEV IC50, whereas 
serum RBZ levels were 40-fold lower than the RBZ IC50. Complete PK of the 3 
anti-VEGF agents will be presented. Conclusion: Monthly IVT BEV results in 
meaningful systiic exposure and may provide a rationale for the differences in 
systiic serious adverse events observed in comparative studies.
10:55 AM
Panel discussion of previous paper
PA084 11:00 AM
 NEW  Early vs. Delayed 15-Letter Gainers With 
Ranibizumab Treatment in Year 1 of the HARBOR Study
Presenting Author: Glenn L Stoller MD*
Co-Author(s): Gregg T Kokame MD*, Richard Dreyer MD**, Howard Shapiro 
PhD* 
Purpose: To examine patterns of visual and anatomic response over time to 
ranibizumab (RBZ) 0.5 mg or 2.0 mg administered monthly or as needed after 3 
monthly loading doses in patients with subfoveal wet AMD. Methods: All pa-
tients from the High-Dose Ranibizumab for AMD Study (HARBOR) were evalu-
ated (N = 1097). Patients were characterized as early (n = 266) or delayed (n 
= 135) ≥ 15-letter gainers based on changes in BCVA from baseline. Results: 
Approximately 25% and 14% of patients were early and delayed gainers, re-
spectively. Roughly 82% of early gainers maintained their ≥ 15 letter gain 
at Month 12. There was no significant difference in the anatomic response 
between early and delayed gainers. Conclusion: A subset of patients who 
are not early gainers at Month 3 can achieve 3-line gains at Month 12 with 
continued RBZ treatment. The gradual functional recovery was not due to a 
delayed anatomic response.
11:07 AM
Panel discussion of previous paper
PA085 11:12 AM
 NEW  HARBOR 2-Year Results Support Less Frequent 
Dosing in Patients With Wet Age-Related Macular 
Degeneration
Presenting Author: Brad J Baker MD*
Co-Author(s): Zhengrong Li*, Phillip C Lai MD*
Purpose: To evaluate if p.r.n. treatment with ranibizumab (RBZ) can maintain 
vision gained in Year 1 of the HARBOR (High-Dose Ranibizumab for AMD)
study, and provide similar visual acuity gains as monthly dosing over 2 years, 
with comparable safety. Methods: Patients aged ≥ 50 years with subfoveal 
wet AMD (N = 1097) were randomized to receive RBZ 0.5 mg or 2.0 mg month-
ly or p.r.n. after 3 monthly loading doses. Results: For patients in the 0.5-mg 
p.r.n. group who completed Year 2 (n = 237), the average injection frequency 
was 9.9 weeks after 3 loading doses, and 93% of patients did not require 
monthly dosing. Mean BCVA gains at Year 2 were 7.9, 6.7, and 9.7 letters in 
patients receiving injections, on average, every 1 month, 1-2 months, or > 2 
months, respectively. Conclusion: An individualized treatment approach with 
RBZ 0.5 mg may be appropriate for most patients with wet AMD.
11:19 AM
Panel discussion of previous paper
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PA086 11:24 AM
 NEW  Identification of Clinically Relevant Parameters in 
OCT Over 2 Years in the VIEW2 Trial
Presenting Author: Ursula M Schmidt-Erfurth MD*
Co-Author(s): Christian Simader**, Sebastian M Waldstein MD, Michael 
Kundi MD PhD*, Todd A Katz MD*
Purpose: To evaluate correlation of OCT and BCVA data in the VEGF Trap-Eye: 
Investigation of Efficacy and Safety in Wet AMD Study (VIEW2). Methods: 
OCT analysis of 1202 patients treated with ranibizumab or aflibercept in a 
fixed (Week 0-52) and subsequent capped p.r.n. (Week 52-96) regimen. Re-
sults: At baseline (BL), 64% of eyes had intraretinal cysts (IRC), 80% had 
pigment epithelial detachment (PED), and 84% had subretinal fluid (SRF). BL 
IRCs were associated with lower initial BCVA (P < .0001). After 3 monthly 
doses, at Week 12, approximately 75% of SRF, 70% of IRC, and 25% of PED 
had resolved. At 96 weeks, BL-SRF-only achieved best outcomes (+12 letters). 
BL-IRC+PED performed worst (+6 letters). Capped p.r.n. regimen introduced 
BCVA loss associated with occurrence of new IRC. Conclusion: IRC is the 
most important parameter for vision loss, especially in p.r.n. regimens, and 
may reflect irreversible retinal degeneration.
11:31 AM
Panel discussion of previous paper
PA087 11:36 AM
 NEW  Effect of Early, Persistent Macular Fluid on Visual 
Acuity in Wet AMD: Subgroup Analyses of the VIEW 1, 
VIEW 2 Studies
Presenting Author: Peter K Kaiser MD*
Co-Author(s): Jason S Slakter MD*, Jeffrey S Heier MD*, Glenn J Jaffe 
MD*, Philip J Rosenfeld MD PhD*
Purpose: To determine if anti-VEGF drug and dosing influenced visual acu-
ity (VA) during the week 16-52 interval in eyes with early persistent fluid at 
weeks 0-12. Methods: Analyses of 1759 patients after 3 monthly injections: 
ranibizumab 0.5 mg every 4 weeks (Rq4), intravitreal aflibercept (IAI) 2 mg 
every 4 weeks (2q4), and IAI 2 mg every 8 weeks (2q8). Results: Eyes with 
persistent fluid were 19% (2q4), 21% (2q8), and 29% (Rq4). In these eyes, VA 
improved from baseline during the week 16-52 interval. VA was better in 2q4 
compared to 2q8 (P = .002) and Rq4 (P = .033), and did not differ in 2q8 and Rq4 
(P = .19). Overall mean VA letter gain was 11.7 (2q4), 6.7 (2q8), and 8.4 (Rq4). 
Conclusion: For a subgroup of patients with early persistent fluid during all 
first 4 visits, IAI 2q4 may provide additional clinical benefit over 2q8 and Rq4.
11:43 AM
Panel discussion of previous paper
PA088 11:48 AM
 NEW  Anti-VEGF Effect in Eyes With Retinal Pigment 
Epithelium Elevation in the VIEW 1 and VIEW 2 Studies of 
Wet AMD Patients
Presenting Author: Chirag P Shah MD*
Co-Author(s): Glenn J Jaffe MD*, Peter K Kaiser MD*, Jason S Slakter MD*, 
Jeffrey S Heier MD*, Giovanni Staurenghi MD*, Tien Yin Wong MBBS*, 
Andrew A Chang MBBS*
Purpose: To compare treatment effect of intravitreal aflibercept injection (IAI) 
and ranibizumab on retinal pigment epithelial (RPE) elevation. Methods: In-
cidences of flattening of RPE elevation were evaluated in 1349 patients with 
baseline (BL) RPE elevation: 435 [ranibizumab 0.5 mg every 4 weeks (Rq4)], 460 
[IAI 2 mg every 4 weeks (2q4)], 455 [IAI 2 mg every 8 weeks (2q8)]. Results: 
Cumulative incidences of flattening of RPE elevation at Week 52 were sig-
nificantly higher with IAI (2q4: 59.6%; 2q8: 52.6%) vs. Rq4 (45.7%). Over the 
52 weeks of follow-up, IAI2q4 and IAI2q8 were 1.50 (95% CI, 1.25-1.81) and 
1.23 (1.01-1.49) times more likely than Rq4 to have flattening of RPE elevation. 
Conclusion: IAI2q8 and IAI2q4 were 23%-50% more effective than Rq4 in 
flattening RPE elevation.
11:55 AM
Panel discussion of previous paper
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SESSION ONE
Scientific Poster 1
Clinical Results and Rotation Stability of Toric IOLs: Alcon 
AcrySof Toric IOL, Abbott Tecnis Toric IOL, and Bausch + 
Lomb enVista Toric IOL
Presenting Author: Mariana S Cardoso MD
Co-Author(s): Joana Pires MD, Sergio G Monteiro MD**, Rita Matos, Manuel S Mariano 
MD**
Purpose: To compare the efficacy and rotation stability of 3 IOLs: the Alcon AcrySof To-
ric, the Abbott Tecnis Toric, and the Bausch + Lomb enVista Toric IOLs. Methods: This 
prospective study enrolled 60 eyes with corneal astigmatism > 1.00 D, which underwent 
uncomplicated phacoemulsification with toric IOL implantation: 20 eyes with an Alcon Ac-
rySof, 20 eyes with an Abbott Tecnis, and 20 eyes with a Bausch + Lomb enVista toric IOLs. 
Rotational stability and UCVA were measured at 1 day and 1, 3, and 6 months after surgery. 
Results: Preliminary results showed an high success rate in terms of UCVA, with residual 
postoperative astigmatism and a mean toric IOL axis rotation < 5°. Conclusion: All toric 
IOLs were effective in reducing preexisting corneal astigmatism, with no significant differ-
ences being found between them.
Scientific Poster 2
Postoperative Spherical Equivalents for Toric Lenses
Presenting Author: David K Wang
Co-Author(s): Robert H Osher MD*
Purpose: To determine the postoperative refractive spherical equivalents for eyes under-
going toric lens implantation. Methods: This retrospective chart review collected the 3 
weeks postoperative refraction in 256 patients undergoing microcoaxial phacoemulsifica-
tion with AcrySof (Alcon) toric IOL implantation from September 2009 to December 2012 
and stratified by toric lens models. Results: The 3-week postoperative refraction had a 
spherical equivalent of 0.5 D or less in 83 eyes (87.3%) for T3 lenses, 70 eyes (86.4%) with 
T4 lenses, 66 eyes (92.8%) with T5 lenses, and 15 eyes (100%) with T6-9 lenses (T6: 8 
eyes, T7: 2 eyes, T8: 1 eye, T9: 3 eyes); 228 eyes (89%) overall. Conclusion: With thorough 
diagnostic testing and careful surgical technique toric IOL implantation can help patients 
with astigmatism achieve minimal residual refraction.
Scientific Poster 3
 h  Objective Reduction of Cylinder During Toric IOL 
Implantation Guided by Intraoperative Wavefront 
Aberrometry
Presenting Author: William Wiley MD*
Co-Author(s): Shamik Bafna MD*
Purpose: To evaluate the objective reduction of cylinder in eyes implanted with toric IOLs 
guided by intraoperative aberrometry. Methods: Retrospective analysis of 250 consecutive 
cases. Cylinder power and axis were determined by aphakic intraoperative aberrometry 
and confirmed with pseudophakic measurements, then compared to postop manifest re-
fraction. Results: In preliminary results (first 194 eyes), mean preop corneal cylinder was 
1.92 D. Intraoperative mean aphakic cylinder was 1.74 ± 0.78 D. Final mean pseudophakic 
intraoperative cylinder was 0.50 ± 0.42 D. Mean postoperative manifest cylinder was 0.45 
D. Conclusion: Intraoperative aberrometry-guided toric IOL selection, placement, and po-
sitioning objectively reduces cylinder.
Scientific Poster 4
Clinical Characteristics of Retained Lens Fragments in the 
Anterior Segment After Routine Phacoemulsification
Presenting Author: Manuj Kapur MD
Co-Author(s): Diana Chao MD, Alexander S Davis MD, Emma K Loucks MD*
Purpose: To study clinical characteristics and outcomes of patients with retained nuclear 
fragments (RNF) in the anterior segment (AS). Methods: Retrospective chart review of 
13 patients with RNF. Patient characteristics, intraoperative features, and clinical courses 
were compared. Results: Ten patients had at least the following: long axial length (AL), 
steep keratometry readings, or deep anterior chamber (AC). Five had intraoperative floppy 
iris syndrome (IFIS). All had AC inflammation on exam. Twelve were diagnosed via slitlamp 
exam and 1 by dilated gonioscopy; 12 required surgical removal of RNF, and 1 responded 
to topical steroids. Conclusion: RNF in the AS were associated with long AL, steep kera-
tometry, deep AC, and IFIS. Standard and dilated gonioscopy may be useful in diagnosing 
RNF in the AS.
Scientific Poster 5
 h  Refractive Error After Cataract Surgery: How to 
Resolve It? IOL Exchange, Piggyback or LASIK
Presenting Author: Pilar Casas de Llera MD
Co-Author(s): Roberto Fernandez Buenaga, Jorge L Alio MD PhD*, Laura PinillaCortes, 
Rafael I Barraquer Compte MD*
Purpose: To evaluate the efficacy, predictability, and safety of IOL explantation, piggy-
back, and LASIK to correct residual refractive error following cataract surgery. Methods: 
Retrospective study that comprised 65 eyes. Group 1 (IOL explantation: 17 eyes), Group 2 
(piggyback: 20 eyes), and Group 3 (LASIK: 28 eyes) were compared. Results: Group 3 had 
a reduction in spherical equivalence and refractive cylinder in comparison with Group 1 (P 
< .001) and also a significantly reduced cylinder in comparison with Group 2 (P = .002). In 
the efficacy index, significant differences were found between Groups 1 and 3 (P = .004) 
and Groups 2 and 3 (P = .003), favoring group 3. The highest predictability was achieved 
in Group 3. Conclusion: Group 3 (LASIK) had the best refractive outcomes, efficacy, and 
predictability.
Scientific Poster 6
Outcomes of the Posterior Chamber IOL Intrascleral Haptic 
Fixation (Glued IOL) Technique in a U.S. Referral Practice
Presenting Author: Yuri F McKee MD
Co-Author(s): Francis W Price Jr MD*, Marianne O Price PhD*
Purpose: To evaluate adoption of the intrascleral haptic posterior chamber IOL (PC-IOL) 
fixation technique. Methods: A retrospective review of the first 25 cases of this tech-
nique at a single center evaluated safety and efficacy with an emphasis on complications 
and outcomes. Results: Over a 4-month period, 25 PC-IOLs were successfully placed with 
intrascleral haptic fixation by 2 experienced surgeons. No IOL dislocated, decentered, or 
was unstable. Self-resolving hypotony occurred in 6 eyes. The reasons for PC-IOL scleral 
fixation were aphakia (32%), dislocated IOL with lens reposition (28%), and problematic IOL 
with lens exchange (40%). Two cases involved the successful placement of iris prostheses. 
Conclusion: This technique is effective and safe in treating a variety of IOL complications, 
aphakia, and aniridia in the absence of capsular support.
Scientific Poster 7
Unique Case of Toric IOL Repositioning in a Post-Radial 
Keratotomy Eye
Presenting Author: Jonathan D Solomon MD
A 53-year-old male with history of radial keratotomy underwent cataract surgery with toric 
IOL elsewhere 10 months prior to presenting for possible IOL rotation. Keratometry mea-
sured 5.3 D of oblique astigmatism, while elevation-based tomography demonstrated 3.8 
D of against-the-rule cylinder. Based on all preop measurements, an AcrySof SN6AT8 was 
placed at the steep axis according to vector analysis. Postoperatively, BCVA was 20/50. The 
ORA system showed that the patient had 4.0 D of astigmatism in the pseudophakic refrac-
tion, as a result of higher order aberration, including contributions from the posterior cornea 
surface. Guided by ORA, the IOL was repositioned. After repositioning, refractive cylinder 
was 0.73 D, BCVA was 20/25, and patient satisfaction was greatly improved.
Scientific Poster 8
 h  Evaluating Fragmentation Patterns by the Effective 
Phacoemulsification Time and Power in Laser Cataract 
Surgeries
Presenting Author: Minoru Tomita MD PhD*
Co-Author(s): Mariko Mita MD
Purpose: To compare the effects of lens fragmentation patterns by the effective phaco-
emulsification time (EPT) and power in laser cataract surgery. Methods: Using the Catalys, 
71 eyes underwent laser cataract surgery. Either the Quadrant or the Complete pattern 
was used for fragmentation. For each cutting pattern, the EPT and power were evaluated. 
Results: The EPT for the Quadrant and Complete groups was 29.47 and 16.31 seconds, 
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and the mean phaco power was 8.07% and 4.77%, respectively. Conclusion: By using the 
smaller (Complete) fragmentation pattern with Catalys, the EPT and power were reduced 
significantly.
Scientific Poster 9
Femtosecond Laser vs. Conventional Phaco Surgery: A 
Case Control Study
Presenting Author: Jeffrey C Chan MBCHB
Co-Author(s): John So-Min Chang MD*, Dorothy Shu P Fan MD, Agnes Tse MD, Alvin K 
H Kwok MD FRCS PhD, Kenneth K W Li MBCHB, Walton W Li MD, Siu-Ping Hui MD
Purpose: To compare the clinical outcome and the intraoperative complications between 
femtosecond laser cataract surgery (FLCS) and conventional phaco surgery (CPS). Meth-
ods: The outcome of the first 101 cases of FLCS performed at a tertiary eye center were 
compared with 100 cases of CPS performed during the same period. Results: No signifi-
cant differences were found between the 2 groups in radial anterior capsular tear (4.4% 
vs. 0%), posterior capsular tear (1.1% vs. 0%), and loose zonules (1.1% vs. 5%). Two cases 
of significant anterior capsular phimosis in the FLCS group required surgical intervention. 
No difference in visual outcome was observed. Conclusion: Our initial experience with 
FLCS is favorable, but the most common complication encountered in FLCS remains radial 
anterior capsular tear.
Scientific Poster 10
Single-center, Contralateral Evaluation of Femtosecond 
Laser Cataract Surgery Compared With Manual Cataract 
Surgery
Presenting Author: Mike P Holzer MD*
Co-Author(s): Florian Niklas Auerbach MD, Anna Fitting MS*, Ramin Khoramnia MD*, 
Florian T A Kretz MD*, Tanja M Rabsilber MD*, Gerd U Auffarth MD*
Purpose: To present a study on IOL overlap, effective lens position, and refractive out-
comes using femtosecond laser vs. a manual approach. Methods: In this contralateral, 
comparative, randomized, prospective study, 30 patients underwent capsulotomy and lens 
fragmentation with a femtosecond laser in one eye (Victus, Bausch + Lomb Technolas); the 
manual technique was used in the fellow eye. Six-month follow-up data include functional 
results, flare, biometry, endothelial cell count, and IOL photos. Results: Initial results find 
the femtosecond laser produces centered and precise capsulotomies. So far, results are 
comparable to manual surgery. Further data will be presented. Conclusion: Results in-
dicate femtosecond laser cataract surgery technique to be safe, effective, and precise.
Scientific Poster 11
Femtosecond Laser-Assisted Cataract Surgery and IOP 
Elevation on the First Postoperative Day
Presenting Author: Joshua Kim MD*
Co-Author(s): William L Soscia MD**, William J Lahners MD*, David W Shoemaker 
MD*, John P Fezza MD*
Purpose: It is known that leakage of lens material can cause trabecular meshwork outflow 
obstruction. The aim of this study is to investigate the incidence of IOP elevation after fem-
tosecond laser-assisted cataract surgery on the first postoperative day (POD1). Methods: 
This retrospective review comprised 148 eyes that underwent femtosecond laser-assisted 
cataract surgery (Lensar) between July and December 2012. Elevated IOP was defined as 
≥ 25 mmHg. Results: The incidence of IOP elevation ≥ 25 mmHg was 8.2% (15/148). This 
was not statistically different from conventional phacoemulsification, at 7.5% (3/40) (P = 
.22). Conclusion: The incidence of IOP elevation on POD1 in femtosecond laser-assisted 
cataract surgery was no different than that in conventional phacoemulsification.
Scientific Poster 12
Refractive Outcomes With a Monofocal IOL and 
Intraoperative Aberrometry-Guided Power Calculation
Presenting Author: Denise M Visco MD
Purpose: To assess the utility of intraoperative aberrometry in improving refractive out-
comes with a commonly implanted monofocal IOL. Methods: In 140 eyes implanted with 
AcrySof SN60WF IOLs, the Optiwave Refractive Analysis intraoperative aberrometry sys-
tem was used to determine IOL power selection and compared to results in 106 eyes in 
which preoperative biometry alone was used to select IOL power. All eyes were targeted 
for plano. Results: Nearly 80% of the group utilizing intraoperative aberrometry was within 
0.5 D of the predicted refraction, compared to 59% of the biometry-only group. Conclu-
sion: The addition of intraoperative aberrometry to preoperative biometry improves the 
accuracy of monofocal IOL power selection by approximately 20%.
Scientific Poster 13
Novel Concept of a Blue Light Filtering IOL With Light-
Adaptive Transmission and Evaluation of its Cytoprotective 
Effects Regarding Light-Induced Oxidative Stress and 
Growth Factor Expression in Human Retinal Pigment 
Epithelial Cells
Presenting Author: Marcus Kernt MD*
Co-Author(s): Aljoscha S Neubauer MD*, Christos Haritoglou MD*, Anselm Kampik MD, 
Hartwig Becker
Purpose: To introduce the concept of a blue light filtering IOL with light-adaptive transmis-
sion (TA-IOL) and in vitro compare its cytoprotective effects to an UV-absorbing IOL. Meth-
ods: An IOL with central blue light filtering zone, surrounding the transition zone and clear 
periphery, was designed. Retinal pigment epithelial cells were exposed to white light and 
either the TA-IOL or a UV-absorbing IOL was placed in the light beam. Cellular viability, ROS, 
and VEGF expression were evaluated. Results: Under bright light, the TA-IOL achieved a 
greater reduction in light-induced effects on viability, ROS, and VEGF expression, compared 
to the UV-absorbing IOL. Conclusion: A TA-IOL may help to reduce potential negative influ-
ences of blue light-filtering IOLs on vision quality under low light conditions and may protect 
better against light-induced retinal damage.
Scientific Poster 14
Properties of the Lens Material in a New, 1-Piece, 
Foldable, Hydrophobic Acrylic IOL
Presenting Author: Mark Packer MD*
Purpose: To describe the physical properties and clinical benefits of the lens material in a 
new hydrophobic acrylic IOL (enVista, Bausch + Lomb). Methods: Nanoindentation experi-
ments compared the surface hardness and elastic modulus of 4 hydrophobic IOLs. Results: 
Displacement after load was 6- to 10-fold less with the Xact IOL (containing the same 
lens material as the enVista IOL) compared with AcrySof, Hoya, and Sensar IOLs. Surface 
modulus was ≥ 6-fold greater with the Xact IOL than the other IOLs. Surface hardness was 
> 20 times greater with the Xact IOL than the other IOLs. Conclusion: The lens material in 
the enVista IOL is glistenings free and has an exceptionally hard surface, making the lens 
durable and resistant to scratching during lens insertion and unfolding.
Scientific Poster 15
Safety and Visual Outcomes in Cataract Patients Implanted 
With a Glistening-Free Hydrophobic Acrylic IOL
Presenting Author: Mark Packer MD*
Purpose: To evaluate safety and visual outcomes associated with implantation of the en-
Vista (Bausch + Lomb) model MX60 1-piece hydrophobic acrylic IOL during cataract surgery. 
Methods: Prospective, randomized, multicenter (6 sites) clinical study. Patients underwent 
cataract extraction by small-incision phacoemulsification and implantation of the IOL. Re-
sults: Safety and effectiveness data for the lens were superior to historical controls data in 
the FDA grids. At postoperative Day 150 (± 30 days), 118 patients (100%) achieved BCVA ≥ 
20/40 compared with 96.7% of historical controls. Incidence of posterior capsule opacifica-
tion was low. No glistenings developed. Conclusion: Safety and visual outcomes with the 
enVista MX60 IOL were excellent.
Scientific Poster 16
Visual Performance of a New Segmented Asymmetric 
Multifocal IOL
Presenting Author: Sunil Shah MD*
Purpose: To evaluate the visual performance of patients implanted with a new bi-aspheric, 
+3-D nonblended segment, multifocal IOL. Methods: Eleven patients (18 eyes) with cata-
racts were bilaterally implanted with the lens, and visual acuity (VA), contrast sensitivity, 
defocus curves, and halometry were assessed 3 months postsurgery. Results: Residual 
refractive error was 0.01 ± 0.47 D (89% within ± 0.5 D). Uncorrected distance VA was 0.11 
± 0.17 logMAR; 78% of eyes could read ≤ J3. Contrast sensitivity was good (1.67 ± 0.07 
log-units), and defocus showed a 1.5-2.5 D near-addition. Halometry showed < 1 degree of 
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debilitating light scatter, with an asymmetric profile reflecting the location of the IOL seg-
ment. Conclusion: This new aspheric, segmented IOL provides a good visual outcome at 
distance and near, with minimal dysphotopsia.
Scientific Poster 17
 h  Grooved and Nongrooved Clear Corneal Incisions in 
Phacoemulsification: Permeability Study
Presenting Author: Victor Dias Bergamasco MD
Co-Author(s): Victor Andrigheti Coronado Antunes Sr, Jose Ricardo A Reggi MD**, 
Richard Y Hida MD
Purpose: To detect the inflow of trypan blue through grooved and nongrooved sutureless 
self-sealing clear corneal incisions at the end of phacoemulsification. Methods: Prospec-
tive masked trial considered 52 eyes randomized into 3 groups (nongrooved incisions, 
grooved incisions, and control group). By the end of the phacoemulsification, trypan blue 
was instilled on the ocular surface. A sample of fluid from the anterior chamber was col-
lected and analyzed with high-performance liquid chromatography to quantify the trypan 
blue concentration. Results: There was a statistically significant difference between non-
grooved incisions and control groups (P = .0448). No significant difference was observed 
between grooved incision and control groups (P = .1800). Conclusion: There was no trypan 
blue detection in groups with grooved clear corneal main incision.
Scientific Poster 18
The Secular Changes in the Strength of Sutures Used in 
IOL Scleral Fixation
Presenting Author: Tsukasa Hanemoto MD
Co-Author(s): Hiroyuki Matsushima MD PhD, Tadahiko Kozawa MD PhD**
Purpose: To describe secular strength changes of the sutures used in IOL scleral fixation. 
Methods: Nylon, polypropylenes (PP), and polyvinylidene (PVDF) were prepared for each of 
the different suture materials. They were immersed into 75°C saline for 115 days in vitro, 
which means the equivalent to 5 years hydrolyzation in the eye. Then the hydrolyzed sutures 
with knot were pulled until they cut off. Suture toughness was analyzed as integrating the 
power and elonged suture. Results: Nylon was the weakest among the materials sub-
jected to 5 years of hydrolyzation, while PP and PVDF had almost the same strength.  Con-
clusion: PP and PVDF may be suitable for the use of IOL scleral fixation of at least 5 years.
Scientific Poster 19
 h  Accuracy of Predicted Refractive Outcomes in 
Combined Macula and Cataract Surgery and Cataract 
Surgery Alone: A Comparative Study
Presenting Author: Amilia Schrier MD
Co-Author(s): Elona Gavazi MD, Winston Lee MA, Aakriti Garg, Jessica Kerns, Emily 
Sarah Smith, Stanley Chang MD*
Purpose: To compare the accuracy of predicted refraction in combined phacoemulsification 
and vitrectomy for macular pucker or hole to that of predicted refraction in phacoemulsifica-
tion alone. Methods: Retrospective chart review of 230 consecutive eyes operated within 
8 years: 95 controls that underwent phacoemulsification and 135 study eyes that under-
went phacoemulsification / vitrectomy. Acceptable refractive outcomes: within ± 0.50 D of 
predicted refraction. Results: The mean difference in predicted vs. outcome refraction in 
controls was 0.05 ± 0.62 (range: -1.50 to 1.60); in the study group it was -0.13 ± 0.54 (range: 
-1.5 to 1.75). The difference in means is 0.18 [0.05 - (-0.13)]. Confidence interval, -0.02, 
0.33; P < .001. Conclusion: The combined surgery yields refractive results as reliable and 
predictable as those of phacoemulsification alone.
Scientific Poster 20
Retrodot-Opaque-Area and Visual Function
Presenting Author: Hiroshi Sasaki MD
Co-Author(s): Norihiro Mita BSMT, Natsuko Hatsusaka BSMT**, Eri Shibuya**, Mai 
Sasaki, Kazuyuki Sasaki, Eri Kubo MD PhD
Purpose: To correlate retrodot-opaque-area (RDoa), best corrected visual acuity (BCVA), re-
fractive error, and higher-order aberration (HOA). Methods: In 74 eyes with retrodot opacity 
(70.3 ± 6.5 years) but no other opacity ≥ grade 1 (WHO), RDoa, crystalline lens power (LP), 
ocular and internal total HOA, coma, and spherical aberration in 4-mm and 6-mm diameter 
pupils were correlated. Results: As RDoa increased, BCVA deteriorated (P < .01), LP de-
creased (P < .05), and spherical equivalent showed myopic shift (P < .01). RDoa correlated 
with internal total HOA (4 mm, P < .01; 6 mm, P < .01), coma aberration (4 mm, P < .05; 6 
mm, P < .01), and negative spherical aberration (4 mm, P < .01; 6 mm, P < .01). Conclusion: 
RDoa affects BCVA, myopic shift, and negative spherical aberration.
Scientific Poster 21
Dexamethasone-Loaded Punctum Plug for Treatment of 
Ocular Inflammation and Pain After Cataract Surgery
Presenting Author: Tom R Walters MD*
Purpose: To evaluate the safety and efficacy of a dexamethasone-loaded punctum plug 
(OTX-DP) for treatment of ocular inflammation and pain after cataract surgery. Methods: 
Fifty-nine subjects (59 eyes) were randomized 1:1 to receive OTX-DP or a vehicle control 
(nondrug-loaded punctum plug) after cataract surgery. Subjects were evaluated at postop-
erative Days 1, 4, 8, 11, 14, and 30. Results: Ninety-eight percent and 92% retention of 
the punctum plugs was achieved at Day 14 and Day 30, respectively. Forty-seven percent 
of subjects were placed on rescue medications when an increase in cell flare or pain was 
noted. No long-term IOP spikes occurred in either treatment group. Conclusion: Initial 
results demonstrate OTX-DP is safe and effective for treatment of ocular inflammation and 
pain in subjects who underwent cataract surgery.
Scientific Poster 22
Efficacy Comparison of Single Subtenon 20-mg 
Triamcinolone Injection With Dexamethasone 0.1% 
Eye Drop in Controlling Intraocular Inflammation After 
Phacoemulsification
Presenting Author: Pitipol Choopong MD
Co-Author(s): Nattaporn Tesavibul MD, Nuttawut Rodanant MD
Purpose: To quantitatively compare efficacy of subtenon 20-mg triamcinolone injection 
with dexamethasone 0.1% eye drop in controlling intraocular inflammation after phaco-
emulsification. Methods: In this controlled trial, a total of 29 patients were randomly 
treated with a single subtenon 20-mg triamcinolone injection (15 patients) or dexametha-
sone 0.1% eye drop 4 times daily for 1 month (14 patients) after an uneventful phacoemul-
sification. The patients were examined at postoperative Days 1, 7, 14, 28, and 90. The 
main outcomes were anterior chamber inflammatory (ACI) score and laser flare/cell meter. 
Results: No significant differences were observed in ACI score (P > .58) and laser flare (P > 
.16) at any visit. Conclusion: A single subtenon 20-mg triamcinolone injection is clinically 
equivalent to dexamethasone eye drop.
Scientific Poster 23
Identification of Possible Factors That Affect the Anterior 
Surface Flora During Anterior Segment Surgery
Presenting Author: Chryssa Terzidou MD
Co-Author(s): Georgios Dalianis MD, Stamatina Golegou MD, Ioulia Koubi MD**
Purpose: To investigate the possible factors that affect the microbial load at the begin-
ning and the end of anterior segment surgery. Methods: Prospective study including 98 
patients, subjected to anterior segment surgeries by a single surgeon. Two samples from 
the anterior surface were taken for cultivation: one at the beginning of the surgery and the 
second at the end, after the incision’s hydration with cefuroxime solution 1%. Different 
parameters were evaluated. Results: Out of 98 samples taken at the beginning of the 
surgery, 35 (35.7%) were found positive, while all 98 samples at the end of the surgery 
were negative (100%). Positive samples reduced from 44.9% to 13.8% when increased 
quantity of 10% betadine was used. Conclusion: Preoperative antisepsis proved safer 
when increased quantity of betadine solution was used.
Scientific Poster 24
Accommodative-Disaccommodative IOL With Zonular 
Capture Haptics
Presenting Author: Paul Beer MD*
Co-Author(s): Paul L Kaufman MD*, Gregg Heatley MD, Mary Ann Croft MS*, Jared 
McDonald**
Purpose: To demonstrate the range of axial shift and accommodative amplitude of accom-
modative-disaccommodative IOLs (AD-IOLs) using zonular capture haptics (ZCH). Methods: 
Prototypical AD-IOLs were implanted into surgically uniridic eyes of Rhesus monkeys. After 
an interoperative period of capsular fibrosis, the capsular bag was sectioned radially. Ac-
commodation was induced pharmacologically. The range of axial shift and amplitude of 
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accommodation were recorded. Results: The first prototype with Prolene ZCH showed a 
0.54-mm axial shift in response to 0.59-mm change in diameter of the capsular bag. This 
resulted in 4 D of accommodation, measured by a Hartinger refractor. Results for a second 
prototype with metallic ZCH are pending. Conclusion: ZCH-based AD-IOLs demonstrated 
effective axial shift and accommodation.
Scientific Poster 25
Effect of Distance Refractive Error on Intermediate Vision 
With the Tecnis Multifocal IOL
Presenting Author: Jehanya Jegatheeswaran
Co-Author(s): Alan Kosaric MD**, Narendra Armogan MD, David B Yan MD*
Purpose: To determine effect of refractive outcome on near, intermediate, and distance vi-
sion with the Tecnis multifocal IOL. Methods: Eyes were divided into 2 groups by spherical 
equivalent distance refraction: Group A = -0.25 D to -1.0 D (n = 18), Group B = -0.13 D to 
+0.63 D (n = 16). Uncorrected visual acuity (VA) was measured at 40 cm, 63 cm, 1 m, and 6 
m. Results: Mean refraction was -0.5 ± 0.1 D in Group A and +0.1 ± 0.2 D in Group B. No 
difference was found in logMAR VA between Groups A and B at 6 m (0.09 ± 0.10 vs. 0.12 
± 0.09, P = NS), 63 cm (0.33 ± 0.14 vs. 0.34 ± 0.17, P = NS), or 40 cm (0.11 ± 0.12 vs. 0.16 
± 0.12, P = NS); at 1 m, Group A had superior intermediate VA (0.24 ± 0.15 vs. 0.44 ± 0.13, 
P = .0003). Conclusion: Mild myopia improves multifocal IOL intermediate vision without 
affecting distance or near vision.
Scientific Poster 26
Method Development for Assessing Clear Corneal Wound 
Integrity
Presenting Author: Michael B Raizman MD*
Co-Author(s): John A Hovanesian MD*, Samuel Masket MD*
Purpose: To develop a quantitative method to simulate increases in IOP resulting from 
patient manipulation following cataract surgery. Methods: A calibrated force gauge (CFG) 
was developed to apply quantifiable forces to the eye (n = 30), and tested in healthy eyes 
to match IOP fluctuations in the literature. Stromally hydrated (Study 2) (n = 30) and sutured 
CCIs (Study 3) (n = 21) were challenged for leaks using this method. Results: Using 1.0-oz 
force, the CFG raised IOP to 43.4 mmHg, or 25.9 mmHg from baseline, consistent with light 
and firm digital forces on the eye (27 and 58 mmHg). Using this method, 66.7% of wounds 
leaked in Study 2, and 23.7% leaked in Study 3. Conclusion: 1.0 oz. of force appears to 
be a clinically relevant assessment of wound leaks resulting from patient manipulation.
Scientific Poster 27
Multicenter Evaluation of Wound Leakage From Sutured 
Clear Corneal Cataract Incisions
Presenting Author: John A Hovanesian MD*
Co-Author(s): William Flynn MD*, Michael J Endl MD*
Purpose: To evaluate wound leakage in sutured clear corneal incisions (CCIs) following 
cataract surgery. Methods: In this prospective multicenter clinical study, a calibrated force 
gauge (CFG) was used intraoperatively to apply up to 1 ounce of external force to assess 
wound leakage of CCIs that were closed using 10-0 nylon sutures. During follow-up, a 
Seidel test was performed without use of the CFG at 1, 3, 7, and 28 days post-procedure. 
Results: 204 eyes were enrolled at 23 U.S. centers. The intraoperative leak rate using up 
to 1 oz of force was 30%. Two of the 183 eyes (1%) evaluated for 28 days had a leak 7 days 
after surgery. Conclusion: CCIs are susceptible to leakage even after closure with suture 
when subject to external forces representative of eye touching or rubbing.
Scientific Poster 28
Comparison of 2 Combined Cohesive and Dispersive 
Ophthalmic Viscoelastic Devices During Cataract Surgery
Presenting Author: Mike P Holzer MD*
Co-Author(s): Florian Niklas Auerbach MD, Ramin Khoramnia MD*, Florian T A Kretz 
MD*, Tanja M Rabsilber MD*, Gerd U Auffarth MD*
Purpose: To compare two combined cohesive and dispersive ophthalmic viscoelastic de-
vices during cataract surgery. Methods: One eye of 54 patients was randomized to receive 
either Twinvisc (Carl Zeiss Meditec) or DuoVisc (Alcon) intraoperatively. Follow-up examina-
tions were performed up to 3 months postoperatively. Results: Median IOP 6 hours after 
surgery was 21 mmHg in both groups, and values ≥ 30 mmHg have been found in 7.7% 
(Twinvisc) and in 17.9% (DuoVisc) of eyes, respectively. A median endothelial cell count 
loss of 4% was seen in both groups 3 months postoperatively (P > .05). Conclusion: The 
Twinvisc application was as secure as DuoVisc during cataract surgery.
Scientific Poster 29
 h  Two Phase 3 Trials of OMS302 in Irrigation Solution for 
Maintenance of Mydriasis in IOL Replacement
Presenting Author: Steve Whitaker MD*
Co-Author(s): Alan S Crandall MD*, Gregory Demopulos MD*, Edmund Ng PhD*
Purpose: Two trials evaluated OMS302 (phenylephrine/ketorolac) for maintenance of in-
traoperative mydriasis as a primary endpoint. Methods: Each prospective, randomized, 
double-masked trial enrolled > 400 subjects, all receiving standard preoperative mydriatic 
and anesthetic agents. OMS302 was administered intracamerally in standard irrigation 
solution. Results: OMS302 maintained pupil diameter throughout the procedure, while 
the placebo group showed progressive constriction (P < .00001). Fewer OMS302-treated 
than placebo-treated patients experienced (1) ≥ 2.5-mm pupillary constriction, represent-
ing ~50% decrease in the operative field (≤ 3% vs. > 27%; P < .001), and (2) ≤ 6-mm pupil 
diameter (≤ 10% vs. ≥ 46%; P < .0001). Conclusion: OMS302 significantly maintained 
mydriasis and prevented miosis during IOL replacement.
Scientific Poster 30
Fibrin Glue-Assisted Intrascleral Fixation of Posterior 
Chamber IOLs in Children
Presenting Author: Rajesh Sinha
Co-Author(s): Himanshu Shekhar, Sudarshan K Khokhar MBBS
Purpose: To evaluate outcomes of intrascleral haptic fixation of posterior chamber IOL 
(PC-IOL) with fibrin glue in children with aphakia. Methods: Retrospective analysis of 23 
eyes of 15 children. Outcome measures included visual outcome, endothelial changes, and 
intraoperative and postoperative complications. Results: Mean age was 7.35 ± 2.41 years. 
Mean preoperative and postoperative BCVA was 0.40 logMAR ± 0.36 and 0.18 logMAR ± 
0.12, respectively (P < .001). No significant change in endothelial cell density occurred (P 
= .23). No postoperative retinal detachment, IOL dislocation, endophthalmitis, or glaucoma 
was noted during follow-up. Conclusion: Fibrin glue-assisted intrascleral fixation of PC-
IOL is a safe and effective method to manage aphakia with inadequate capsular support 
in children.
Scientific Poster 31
Randomized Controlled Study of an Ocular Sealant to 
Prevent Wound Leak After Cataract Surgery
Presenting Author: Terry Kim MD*
Co-Author(s): Farrell Tyson II MD*, Jeffrey H Levenson MD
Purpose: To evaluate an ocular sealant for preventing incisional leakage from clear corneal 
incisions (CCIs) within the first 7 days of cataract surgery. Methods: 488 eyes were treated 
in a prospective, randomized, parallel arm, controlled multicenter trial. Subjects with a 
demonstrated wound leak were treated with an ocular sealant or suture and evaluated for 
28 days post procedure. A Seidel test was performed intraoperatively and at 1, 3, 7, and 28 
days. Results: The ocular sealant was superior for preventing wound leaks compared to 
suture (P < .0001). No safety issues were raised. Conclusion: The ocular sealant is safe 
and effective for intraoperative management of CCIs with a wound leak and for prevention 
of postoperative fluid egress following cataract surgery.
SESSION TWO
Scientific Poster 256
Clinical Evaluation of a New Aspheric, Hydrophobic-
Acrylic, 1-Piece Toric IOL
Presenting Author: Farrell Tyson II MD*
Co-Author(s): Kevin Lee Waltz MD*, Donald Nixon MD*, Kristen Featherstone MS*, 
Sanjeev Kasthurirangan PhD*, Pamela J Smith MS*
Purpose: To evaluate a new toric IOL. Methods: Two-arm study: randomized control arm 
(RCA) compared eyes with planned preop Kcyl of 0.75-1.50 D corneal astigmatism (CA) 
implanted with ZCT150 toric IOL or ZCB00 standard IOL; open-label arm (OLA) compared 
eyes with ≥ 1.50 D CA to target values. Results: Greater mean percent reduction in cylin-
der (P < .0001) for ZCT150 (74.53% ± 72.25) than ZCB00 eyes (31.61% ± 78.73) in RCA; > 
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25% target in OLA (76.27 ± 33.09, P < .0001). RCA: 43.6% (44/101) of ZCT150 and 23.7% 
(22/93) of ZCB00 eyes had uncorrected distance visual acuity (UCDVA) ≥ 20/20 (P = .0026). 
OLA: 38.0% (27/71) had ≥ 20/20 compared to 6% target (P < .0001). Mean absolute change 
in axis between visits for toric eyes pooled < 3 °. Conclusion: The ZCT toric IOL achieved 
decreased ocular astigmatism and improved UCDVA, with great rotational stability.
Scientific Poster 257
Prevalence of Anterior and Posterior Astigmatism Patterns 
and Their Influence in the Amount of Total Corneal 
Astigmatism by Ray Tracing
Presenting Author: Carlos G Arce Arce MD*
Co-Author(s): Sathish Srinivasan MBBS*
Purpose: To study the anterior, posterior, and total corneal astigmatism (TCA) by ray trac-
ing. Methods: Value and axis of simulated keratometry (SimK), posterior axial and TCA 
cylinders were studied in 438 eyes with Galilei. Results: Anterior/posterior cylinder was 
parallel (1) with-the-rule (WTR): 69.4%, (2) WTR: 4.8%, (3) oblique: 3.9%, and crossed (4) 
against-the-rule (ATR)/WTR: 12.8%, (5) WTR/ATR: 0%, (6) oblique: 0.2%, (7) WTR/oblique: 
1.4%, (8) ATR/oblique: 4.6% (9) oblique/ATR: 2.5%, (10) oblique/ATR: 0.5%. More frequent 
at all ages was type 1. Types 4 and 8 increased with age. TCA was larger than anterior 
cylinder in types 1 (94%) and 3 (88%) and smaller in types 2 (71%), 8 (75%), and 4, 6, 7, and 
10 (100%). Conclusion: TCA tends to be larger than anterior cylinder if both had parallel 
axes and smaller if they were crossed. We propose to calculate toric IOLs using TCA and 
SimK average instead of anterior cylinder and fudge factors.
Scientific Poster 258
Postoperative Herpetic Endophthalmitis: A Case Report
Presenting Author: Ya-Yun Yang MD
Co-Author(s): Yuan-Chieh Lee MD*
We report a herpetic endophthalmitis following cataract surgery. A 65-year-old man un-
derwent uneventful phacoemulsification. Vision improved in the early postoperative days. 
However, visual loss with an anterior chamber reaction of ++++ and a ++ vitreous cell were 
noted in the fourth week. Repeated intravitreal injection of vancomycin and ceftriaxone, 
pars plana vitrectomy and Intraocular lens (IOL) with whole bag removal were performed 
sequentially for months but in vain. Bacterial, mycobacterial and fungal culture of the IOL 
with bag demonstrated negative findings. Pathological examination revealed no pathogen 
but lots of mononuclear cells and several multinuclear giant cells. Serology exam revealed 
positive HSV IgM and IgG. The intraocular inflammation resolved soon after changing an-
tibiotics into oral valcyclovir.
Scientific Poster 259
Outcomes of Patch Grafts in Patients With Burkholderia 
cepacia Tunnel Infection Following Cataract Surgery Due to 
Contaminated Topical Anesthetic Drops
Presenting Author: Pravin Vaddavalli MD
Co-Author(s): Virender S Sangwan MBBS, Swapna Reddy Motukupally, Muralidhar 
Ramappa MBBS, Prashant Garg MD*
Purpose: To report the manifestations and outcomes of cataract surgical site wound in-
fection due to contaminated topical proparacaine drops. Methods: Clinical, microbiology, 
genetic, and histology data from patients were collected prospectively. Results: Twenty-
two patients presenting with tunnel infiltrates following phacoemulsification under topical 
anesthesia underwent a patch graft. Therapeutic success was achieved in 14 patients. 
Multidrug resistant Burkholderia cepacia was isolated from all patients and from an un-
opened bottle of proparacaine drops. Conclusion: Contamination of topical drops used 
during cataract surgery could result in corneal tunnel infections. Burkholderia cepacia is 
a tenacious organism and may not respond to medical therapy even with antibiotics it is 
sensitive to.
Scientific Poster 260
Comparison of Capsular Breakage Using Dull vs. Sharp 
Phacoemulsification Needles
Presenting Author: Brian Zaugg MD
Co-Author(s): Jeff H Pettey MD*
Purpose: To compare the level at which capsular bag breakage occurs using dull vs. sharp 
phacoemulsification (phaco) tips at increasing levels of vacuum and phaco. Methods: 
Eighteen paired fresh cadaver eyes from 9 subjects were randomized to either the dull or 
sharp arm. The posterior capsule was exposed with usual techniques for cataract extrac-
tion. The capsule was then aspirated with increasing levels of vacuum and then phaco 
until breach occurred. Other settings on the phaco machine were equal in the two arms. 
Results: The capsular bag did not break at any level of vacuum alone with either tip. The 
dull tip caused breach of the capsule at higher levels of phaco (41.11%) compared to the 
sharp tip (23.33%); P = .015. Conclusion: The capsular bag is more resistant to breakage 
using a dull phaco tip than using a sharp tip.
Scientific Poster 261
Comparison of Surgical Outcomes of Trypan Blue Staining 
in Mature, Traumatic, Corneal Opacity-Associated, and 
Uncomplicated Cataracts: Results of the Ophthalmic 
Surgical Outcomes Data Project
Presenting Author: Nakul Shekhawat
Co-Author(s): Elizabeth F Baze MD, Mary K Daly MD, David E Vollman MD MBA*, Amy 
Chomsky MD, Mary Gilbert Lawrence MD MPH
Purpose: To assess association of trypan blue (TB) use and cataract complications. Meth-
ods: Retrospective review of outcomes in TB vs. non-TB cases. Results: Posterior capsular 
(PC) tear rates in mature (n = 168) vs. normal (n = 4619) cataracts were higher when TB was 
not used (P < .05). With TB use, mature cataracts had similar rates to normal cataracts (P 
= .127). Among mature cataracts, TB cases had less retained lens material (P < .05) and no 
increase in capsular damage (P = .248), vitreous prolapse (P = .893), conversion to large 
incision surgery (P = .711), or change in final IOL location (P = .929). Traumatic (n = 33) and 
corneal opacity-associated (n = 80) cataracts had similar TB risk profiles. Conclusion: TB 
use in complex cataracts is not associated with an increase in adverse events and may 
protect against PC rupture in mature cataracts.
Scientific Poster 262
The U.S. Army Teaching Small-Incision Cataract Surgery in 
West Africa: A Success Story
Presenting Author: Darrel K Carlton MD
Co-Author(s): Jean W Diallo MD, William R Wilson MD**, Brett A Nelson MD, 
Samantha B Rodgers MD**, Kevin Michael Czarkowski
Purpose: To report recent U.S. Army success in training a West African ophthalmologist as 
a manual small incision cataract surgery (SICS) surgeon and as a surgical mentor. Meth-
ods: N/A Results: An ophthalmologist from the Burkina Faso Army was trained by the U.S. 
Army at his facility, performing 25 SICS cases. Over the next 6 months he went on to per-
form over 200 SICS cases on his own. He then took part in a mission to Mauritania, perform-
ing 40 of the 108 total cases and serving as a primary surgical mentor. Conclusion: This 
training model may be used to improve adoption of SICS in the developing world, thereby 
improving patient outcomes and reducing cataract blindness. Future missions should focus 
primarily on training local surgical resources.
Scientific Poster 263
Intraindividual Anterior Capsule Healing in Standard and 
Laser Cataract Surgery
Presenting Author: Tim Schultz MD*
Co-Author(s): Ina Conrad-Hengerer MD, Burkhard Dick MD*
Purpose: To evaluate differences in capsular bag shrinkage between laser cataract surgery 
(LCS) and standard procedure. Methods: A prospective randomized intraindividual trial on 
53 patients (106 eyes) was conducted to compare capsular bag diameter (CBD) between 
standard and laser cataract surgery (Catalys; Sunnyvale, Calif., USA). Capsular measuring 
ring was implanted in all eyes following anterior capsulotomy of 5 mm. CBD was measured 
postoperatively. Results: Intraoperatively CBD was 10.5 mm in both groups. Median CBD 
at Week 8: laser 9.8 mm / standard 9.5 mm (P < .0005); at Week 12: laser 9.8 mm / standard 
9.4 mm (P < .0005). Conclusion: Significantly reduced capsular bag shrinkage up to 12 
weeks postoperatively was observed compared to the standard procedure.
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Scientific Poster 264
Therapeutic Laser-Assisted Cataract Surgery With Corneal 
Opacity From Graft-Host Junction Status-Post Penetrating 
Keratoplasty and Scleral Patch Graft
Presenting Author: Kathryn Masselam Hatch MD*
Co-Author(s): Jonathan H Talamo MD*
Purpose: To determine advantages/limitations of laser-assisted cataract surgery in chal-
lenging cases. Methods: A post-penetrating keratoplasty patient with corneal opacity and 
a scleral patch graft was treated with laser-assisted cataract surgery (Catalys; Sunnyvale, 
Calif., USA). The patient was docked with a liquid patient interface, and all ocular sur-
faces were mapped. Capsulotomy and lens fragmentation were also performed. Results: 
The case was completed with no complications. The nonapplanating liquid interface was 
sufficiently gentle to enable docking. 3-D OCT was used to map all ocular surfaces. Lens 
fragmentation improved ease of cataract removal. Conclusion: Therapeutic laser-assisted 
cataract surgery with a liquid interface in challenging cases is safe and simplifies lens 
removal.
Scientific Poster 265
Capsulotomy Centration: OCT-Scanned Capsule vs. Pupil-
Guided
Presenting Author: Shamik Bafna MD*
Co-Author(s): William Wiley MD*
Purpose: To compare capsulotomy centering techniques of OCT-guided scanned capsule 
vs. pupil centration created by a femtosecond laser. Methods: Retrospective analysis of 50 
consecutive femtosecond-assisted cataract surgeries. Both scanned capsule centration and 
pupil centration techniques were computed to display potential rhexis positions and cap-
sule-optic overlap. Results: In scanned capsule eyes, 79% were more nasal and 66% were 
more vertical. Scanned capsule showed better capsule-optic overlap in 78% eyes. Twenty-
five percent of the pupil-centered and 0% of the scanned capsule eyes had incomplete 
capsule optic coverage. Conclusion: Scanned capsule-guided femtosecond laser-created 
capsulotomy centration allows more complete and symmetric capsule optic-overlap.
Scientific Poster 266
Hydrophobic vs. Hydrophilic IOL: Effect on Posterior 
Capsule Opacification
Presenting Author: Keissy Sousa De Oliveira MD
Co-Author(s): Olga Marina Berens, Joao G Rosendo MD**, Paula Eduarda Bompastor 
Ramos, Augusto Candeias MD
Purpose: To determine the effect of IOL material posterior capsule opacification rate at 6, 
12, and 18 months. Methods: Forty-three eyes with cataract were prospectively random-
ized to receive a hydrophobic acrylic or hydrophilic acrylic square-edge single-piece IOL by 
the same surgeon. Posterior capsule opacification was assessed in miosis and mydriasis. 
Results: Eighteen hydrophobic and 25 hydrophilic IOLs showed a mean visual acuity of 
0.93 vs. 0.86 (P < .05) 6 months after surgery; 0.85 vs. 0.69 (P < .05) 18 months after sur-
gery. Twenty-five percent of hydrophilic IOLs required an Nd:YAG capsulotomy 12 months 
following surgery (P = .031); 40% of hydrophilic IOLs required a capsulotomy vs. 12.5% of 
hydrophobic IOLs (P = .067) 18 months after. Conclusion: Hydrophobic IOLs had superior 
visual acuity results and less Nd:YAG laser capsulotomy than hydrophilic IOLs.
Scientific Poster 267
Visual Outcomes and Patient Satisfaction After 
Implantation of a Trifocal IOL
Presenting Author: Luis Izquierdo Jr MD
Co-Author(s): Maria A Henriquez MD, Mauricio Rodriguez Sr
Purpose: To analyze visual outcomes after cataract surgery with trifocal IOL implantation. 
Methods: Thirty eyes of 15 patients (age 55-80 years) were included in this prospective 
study. All subjects underwent a bilateral cataract surgery with implantation of the new 
trifocal FineVision IOL (Physiol; Belgium). Distance (4 m), intermediate (70 cm), and near 
(40 cm) visual acuities (VA), defocus curve, and refractive outcomes were evaluated at 3 
months. Results: Mean uncorrected distance VA was 0.00 logMAR, mean uncorrected in-
termediate and near VA were 0.35 and 0.30 logMAR, respectively. Mean defocus at -3.00 D 
was 0.03 logMAR. Conclusion: The trifocal FineVision IOL is able to restore successfully 
distance, intermediate, and near visual acuity after cataract surgery.
Scientific Poster 268
One-Year Clinical Results and Quality of Vision After 
Implantation of a Preloaded Trifocal IOL
Presenting Author: Barbara Kusa MD
Co-Author(s): Matteo Piovella MD*
Purpose: To evaluate visual and optical performances of cataract eyes after phacoemul-
sification and trifocal IOL (AT LISA tri 839MP) implantation. Methods: Twenty cataract 
eyes received a preloaded trifocal IOL (AT LISA tri839MP). Follow-up examinations were 
performed up to 180 days after surgery. Results: Preoperative distance UCVA was 0.60 
± 0.30 logMAR. At 6 months, distance UCVA was 0.01 ± 0.02 logMAR, monocular near 
vision was 20/25, and binocular near vision was 20/18. Monocular intermediate vision 
was 20/33.75, binocular intermediate vision was 20/20.5 Conclusion: AT LISA tri 839MP 
provided satisfactory distance and near as well as intermediate visual acuity. This lens 
also improved quality of vision through remarkable diffraction efficiency while maintaining 
contrast sensitivity.
Scientific Poster 269
Hydrogel Ocular Bandages to Protect and Increase 
Watertight Properties of Corneal Incisions After Cataract 
Surgery
Presenting Author: Barbara Kusa MD
Co-Author(s): Matteo Piovella MD*
Purpose: To evaluate liquid hydrogel ocular bandages for clear corneal cataract surgical 
incisions. Methods: At the end of cataract surgery, we applied either OcuSeal liquid ban-
dage (247 eyes) or ReSure Adherent Ocular Bandage (52 eyes) to reinforce closure of clear 
corneal incisions. OcuSeal is made of a synthetic dentritic hydrogel. Resure is made of a 
polyethylene glycol-based hydrogel. Results: During the immediate postoperative period, 
all patients reported ocular comfort. Resure remained over the wound for at least 24 hours 
in 52 patients (100%), while Ocuseal disappeared within 12 hours. Conclusion: Liquid 
bandage applied at the end of cataract surgery may enhance wound closure and improve 
postoperative comfort. After refilling with BSS, these bandages increase anterior chamber 
stability by improving watertight properties.
Scientific Poster 270
American Society of Cataract and Refractive Surgery / 
European Society of Cataract and Refractive Surgeons 
Survey on Foldable IOLs Requiring Explantation or 
Secondary Intervention: 2012 Update
Presenting Author: Nick Mamalis MD*
Co-Author(s): Anne Floyd, Erica Liu MD, Shannon Stallings MD
Purpose: American Society of Cataract and Refractive Surgery / European Society of Cata-
ract and Refractive Surgeons survey regarding explantation of foldable IOLs . Methods: 
Type of IOL, materials, and complications requiring explantation were evaluated. Results: 
Dislocation/decentration was the most common complication associated with 1-piece and 
3-piece acrylic IOLs, as well as 3-piece silicone IOLs. The most common reason for explan-
tation of multifocal lenses was glare/optical aberrations. Toric IOLs were removed due to 
incorrect lens power. Conclusion: The most common complications with foldable IOLs 
were dislocation / decentration, glare/optical aberrations, and incorrect IOL power.
Scientific Poster 271
Optimization of the A Constant for the SRK/T Formula
Presenting Author: John C Merriam MD FACS
Co-Author(s): Eva Nong, Lei Zheng MD
Purpose: To optimize the A constant in the SRK/T formula using axial length (AL) and 
average preoperative keratometry (Kavg) and to improve the accuracy of predicted refrac-
tion. Methods: Using the postoperative manifest refraction from 635 eyes that underwent 
AcrySof SN60WF IOL implantation, we calculated the precise A constant for the postopera-
tive spherical equivalent refraction. To optimize the A constant, we used linear, quadratic, 
and categorical (based on AL groups) regression models to relate the precise A constants to 
AL and Kavg. Results: Compared to the manufacturer’s A constant, the regression models 
decreased postoperative hyperopia and reduced predicted mean absolute error from 0.50 D 
to 0.25 D (P < .001). Conclusion: Optimizing A constants based on the AL and Kavg in the 
SRK/T formula improves refractive outcomes.
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Scientific Poster 272
Vitreous Hyper-reflective Dots in OCT After Uneventful 
Phacoemulsification Cataract Surgery
Presenting Author: Choul Yong Park MD
Co-Author(s): Jonghyun Oh MD, Roy S Chuck MD PhD*
Purpose: To report the significance of vitreous hyper-reflective dots (VHDs) after phaco-
emulsification surgery. Methods: Medical records of 156 eyes of 120 patients who under-
went phacoemulsification surgery were reviewed. Spectral domain OCT was performed 
preoperatively and postoperatively at 1 month. The number of VHDs was counted in 5 OCT 
images of high-definition 5-line raster scan. Central subfield retinal thickness (CRT) and the 
development of cystoid macular edema (CME) 1 month after the surgery were assessed. 
Results: 31.3% of eyes had 3 or more VHDs (5.1 ± 2.27; range: 3 to 13). In eyes with 3 or 
more VHDs, CRT increased more (by 15.7 ± 4.75 µm; P = .001), and CME developed more 
often (in 30.6% vs. 6.3%, P < .001) than in eyes with 2 or fewer VHDs. Conclusion: The 
number of VHDs was associated with an increase in CRT and the development of CME.
Scientific Poster 273
 h  The Importance of Ambidexterity in Simulated Anterior 
Segment Surgery
Presenting Author: Sundeep Singh Uppal
Co-Author(s): Vikas Sharma MBBS
Purpose: To determine whether greater nondominant hand surgical proficiency is associ-
ated with better 2-handed surgical outcomes. Methods: The EYESi surgical simulator was 
used to measure surgical performance in 14 residents using their dominant/nondominant 
hands, and on a bimanual task. Results: Surgical performance was better in the dominant 
than the nondominant hand (mean score: 71.1 vs. 64.4; P = .034). There was no statistically 
significant difference between dominant hand and bimanual performance (mean score: 
71.1 vs. 74.6; P = .156), though bimanual performance was better than the use of non-
dominant hand (mean score: 74.6 vs. 64.4; P = .002). Conclusion: Two-handed surgical 
outcomes are directly related to dominant hand surgical performance and less so to the 
nondominant hand.
Scientific Poster 274
The Effect of Pseudoexfoliation on Intraoperative 
Procedures and Cataract Surgery Complications: Results 
of the Ophthalmic Surgical Outcomes Data Project
Presenting Author: Tulay Cakiner-Egilmez NP
Co-Author(s): Mary K Daly MD, Amy Chomsky MD, David E Vollman MD MBA*, 
Elizabeth F Baze MD, Mary Gilbert Lawrence MD MPH
Purpose: To analyze whether pseudoexfoliation (PXF) was associated with increased rates 
of complications of cataract surgery. Methods: 4923 cataract surgery cases were included 
in the study. Outcomes analyzed included small pupil, pseudoexfoliation, pupillary expan-
sion devices, and intraoperative complications. P-values were calculated using Fisher exact 
test. Results: Small pupils and the use of pupillary expansion devices and capsular tension 
rings were significantly higher in the PXF group than in the control group (P < .0001; P < 
.0001, and P = .0002, respectively). Conclusion: Operative events were not statistically 
significant in PXF and control groups, suggesting a protective effect of pupillary expansion 
devices in patients with PXF against intraoperative complications.
Scientific Poster 275
Correlation Between Objective and Subjective 
Measurements of Light Scattering and Light Distortion in 
Normal and Pseudophakic Eyes
Presenting Author: Jose Manuel Borges MD PhD
Co-Author(s): Helena Neves OD, Sofia Cláudia Peixoto-de-Matos MS, Jose Manuel 
Gonzalez-Meijome Sr*
Purpose: To correlate the index of light distortion surrounding an intense source of light 
measured with an experimental device with the ocular scattering index measured with a 
commercially available device in pseudophakic patients with monofocal IOL. Methods: 
Sixty-five cataractous patients (age 69 ± 7 years) implanted with monofocal IOL. Three 
measures of light distortion were conducted in the tested eye (always monocularly). Overall 
ocular scattering index was evaluated with the Optical Quality Analysis System (OQAS). 
Results: Intraocular light distortion measured with the OQAS was significantly correlated 
with light distortion (r = 0.511; P > .001). Conclusion: A significant part of the perception of 
light distortion can be explained by the scattering index in pseudophakic patients.
Scientific Poster 276
Long-term Evaluation of Posterior Capsule Opacification 
After Implantation of a Single-Piece Hydrophobic Acrylic 
IOL
Presenting Author: Abhay Raghukant Vasavada MBBS FRCS*
Co-Author(s): Mamidipudi Praveen DO**, Shetal Raj MD
Purpose: To evaluate long-term impact of AcrySof SN60AT IOL implantation on develop-
ment of posterior capsule opacification (PCO) up to 5 years. Methods: This was a prospec-
tive evaluation of 390 eyes for PCO and analyzed influence of anterior capsule (total and 
part-on) cover on IOL optic by evaluation of posterior capsule opacification (EPCO). Results: 
A significant increase in PCO was noticed up to 3 years (P < .001); no significant develop-
ment was found between 3 and 5 years. Increase in PCO was more in the part-on group 
(P < .001). Conclusion: PCO stabilized between 3 and 5 years. Less PCO was found with 
total-on cover of the anterior capsule on the IOL optic.
Scientific Poster 277
Safety and Effectiveness of Cyclosporine A 0.05% Emulsion 
After Cataract Surgery for Ocular Surface Problems and 
Corneal Sensation
Presenting Author: Samer Hamada MD
Co-Author(s): Tara Moore V PhD, Madonna Al Dreihi MD, Anas A Anbari MD, Sunil Shah 
MD*
Purpose: To assess efficacy and safety of cyclosporine-A (CsA) 0.05% ophthalmic emul-
sion after cataract surgery to improve ocular surface and corneal sensation. Methods: 
Patients were randomized to have topical CsA or polyvinyl alcohol (PVA) drops. Subjec-
tive and objective assessments were performed preoperatively, 1 week, and 1 month after 
surgery: osmolarity, tear breakup time, Schirmer’s type-I, ocular surface staining, corneal 
sensitivity, and ocular surface disease index. Results: None of the 60 eyes lost any best 
spectacle-corrected visual acuity. All results improved after CsA drops compared to PVA 
drops at 1 month following surgery (P < .05). CsA eyes tended to have higher recovery of 
corneal sensation. Conclusion: CsA is effective and safe in management of ocular surface 
problems after cataract surgery. CsA allows faster recovery of corneal sensation.
Scientific Poster 278
Endophthalmitis Rates After Cataract Surgery With 
Subconjunctival Antibiotic Prophylaxis: A Review of 
43,127 Eyes
Presenting Author: Suzanne A Turner MBBS
Co-Author(s): Robert Johnston MBBS FRCOphth**
Purpose: To establish the rate of endophthalmitis after cataract surgery for a single unit 
using subconjunctival antibiotics exclusively. Methods: Evaluation of 43,127 consecutive 
cataract operations in a UK district general hospital. Several audit cycles were carried out, 
and the overall rate of endophthalmitis was calculated. Results: There was a 0.046% rate 
of endophthalmitis during the study period. Conclusion: The rate of endophthalmitis is 
comparable in our unit to that in the group treated with intracameral cefuroxime in the 
landmark European Society of Cataract and Refractive Surgeons study (0.073%). We feel 
further direct comparison in the form of a randomized controlled trial is needed to ascer-
tain whether intracameral antibiotics confer any additional advantage in comparison to 
subconjunctival.
Scientific Poster 279
Evaluation of an Aberration Corrected, Pure Diffractive 
Multifocal IOL (MIOL) as a Toric and Nontoric Version
Presenting Author: Florian T A Kretz MD*
Co-Author(s): Anna Fitting MS*, Verena Friederich, Sarah Pramschiefer, Il-Joo Limberger 
MD**, Gerd U Auffarth MD*
Purpose: Comparison of a toric and a nontoric full diffractive, multifocal IOL (M-IOL). 
Methods: For cataract surgery either a M-IOL (ZMB00, AMO; USA) in patients with a cor-
neal astigmatism of less than 1 D or a toric M-IOL (ZMT--, AMO; USA) in patients with an 
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astigmatism over 1 D was implanted. Subjective refraction and visual acuity (VA; near in 
30 cm and distance) were evaluated. Results: Uncorrected distance VA was 0.1 in both 
M-IOL groups, with an uncorrected near VA of 0.2 in the toric and 0.1 in the nontoric M-
IOL group (logMAR). Conclusion: The aberration-corrected, diffractive multifocal IOL with 
and without astigmatism correction showed good refractive results for near and distance 
visual acuity.
Scientific Poster 280
A Prospective, Randomized, Multicentered Clinical Trial of 
the Trulign Toric Presbyopia-Correcting IOL
Presenting Author: Jay Stuart Pepose MD PhD*
Purpose: To assess safety and effectiveness of Trulign toric presbyopia-correcting IOL. 
Methods: Prospective, randomized trial. Results: Trulign Toric IOL showed 85.5% reduc-
tion in cylinder, greater reduction in cylinder of 1.25 D toric vs. spherical control, rotational 
stability of < 2 degrees, 96.9% ≤ 5 degrees rotation, and improvement in uncorrected dis-
tance visual acuity vs. spherical control. Mean UCVA was 20/25 distance, 20/22 interme-
diate, and 20/40 near. Conclusion: Trulign toric IOL reduces the effects of preoperative 
corneal astigmatism while preserving excellent intermediate and functional near.
Scientific Poster 281
Study of Accuracy of Manual Toric Reference Marking 
Using Cionnis Toric Marker
Presenting Author: Sourabh D Patwardhan MD
Co-Author(s): Nidhi Sourabh Patwardhan DOMS MD**
Purpose: To evaluate the accuracy of manual reference toric marking on slitlamp. Meth-
ods: 164 eyes of 164 patients were enrolled in the study. Patients were asked to sit upright 
and to fix on a distant object. Under topical anesthesia marking was done with Cionni toric 
marker with gentian violet color. Patients were then examined on the slitlamp. Accuracy of 
the marking was confirmed by slit beam with baseline axis at 180° by other observer. Any 
deviation was measured by rotating the axis of the slit. Results: The average axis-marking 
error was 3.37 ± 2.24° with manual marking. Twelve percent of patients had marking error 
of more than 5°. Conclusion: In 88% of eyes, manual toric reference marking was within 
5 degrees. But 12% of eyes had error of more than 5 degrees. Alternative methods should 
be explored for improving accuracy of marking.
Scientific Poster 282
Accuracy of Manual Continuous Curvilinear 
Capsulorrhexis Using Patwardhan Capsulorrhexis Marker
Presenting Author: Sourabh D Patwardhan MD
Co-Author(s): Nidhi Sourabh Patwardhan DOMS MD**
Purpose: To measure and compare sizing and positioning parameters of manual continu-
ous curvilinear capsulorrhexis (CCC) using Patwardhan capsulorrhexis marker with manual 
CCC without using marker. Methods: In Group 1 (n = 35), manual CCC was done without 
using marker. In Group 2 (n = 36), manual CCC was done assisted by Patwardhan capsulor-
rhexis marker. CCC size of 4.75 mm was aimed. Results: Minimum overlap of optic in 
Groups 1 and 2 was 0.15 ± 0.25 mm and 0.26 ± 0.13 mm, respectively (P = .02). Maximum 
overlap in Groups 1 and 2 was 1.1 ± 0.22 and 0.77 ± 0.22 mm, respectively (P < .001). Over-
lap coefficient in Groups 1 and 2 was 0.18 ± 0.24 and 0.36 ± 0.21 (P = .001), respectively. 
Conclusion: Manual CCC assisted by Patwardhan capsulorrhexis marker gives better cen-
tration and overlap than manual CCC without using marker.
Scientific Poster 283
Refractive Outcomes Using Intraoperative Aberrometry to 
Confirm Power Calculations in Multifocal IOL Surgery
Presenting Author: Maria Cirone Scott MD*
Purpose: To evaluate refractive outcomes following cataract surgery with implantation of 
Tecnis Multifocal IOLs (AMO) guided by intraoperative aberrometry with the ORA System 
(Optiwave Refractive Analysis, WaveTec Vision). Methods: A single surgeon performed 
cataract surgery on 131 eyes, using the ORA System to confirm or adjust IOL power calcula-
tions intraoperatively. Results: Of 131 eyes, 60% were within 0.25 D of predicted spherical 
equivalent and 89% were within 0.50 D. Without intraoperative aberrometry, only 83% 
of eyes would have been within 0.50 D Conclusion: Intraoperative aberrometry-assisted 
power calculation closely predicts refractive outcome.
Scientific Poster 284
Effect of the Open Ring Guider for Continuous Curvilinear 
Capsulorrhexis
Presenting Author: Choun-ki Joo MD
Co-Author(s): Jeong-Ah Shin MD**, Hae-ri Yum MD, Yong Eun Lee MD, Changrae Rho 
MD
Purpose: To describe an open ring-shaped caliper for optimal size, shape, and centration of 
capsulorrhexis and to report its efficiency. Methods: Phacoemulsification candidates were 
included and divided into either the open ring guider caliper (ORGC) group or the manual 
group. Open ring guider was inserted for continuous curvilinear capsulorrhexis (CCC). Pho-
toshop and ImageJ program were used for analysis of size, location, circularity, and decen-
tration of CCC during and after surgery. Results: Size of the CCC was larger in the ORGC 
group than in the manual group. CCC of the ORGC group was more regular. Deviation of the 
CCC was less in the ORGC group than in the manual group, and circularity was significantly 
better in the ORGC group than in the other group. Conclusion: ORGC helped surgeon to 
make uniform, well-centered, and circular CCC. There was no complication during our study.
Scientific Poster 285
“Haptic Lasso” Makes for Simplified Intrascleral Insertion 
of Haptics in Fixation of 3-Piece IOL
Presenting Author: Anala Maharaj
Co-Author(s): Gursumeet Sohanpal MBBS, Ryan R Ramoutar MBBS, Ronnie M Bhola 
MBBS, Nnilesh Persad MBBS
Purpose: To describe a simple technique of intrascleral haptic fixation. Methods: A 
25-gauge vitrectomy trocar (VT) was used to make scleral tunnels (ST) and left in situ; 8-0 
vicryl was used to ‘lasso’ the haptic near the tip and the needle was passed through the VT. 
The haptic was introduced into the VT, the suture was used to pull the haptic into the VT, 
and the VT was slowly removed, leaving the haptic in the ST. Results: Twenty eyes of 20 
patients were operated on with no complications in 6 to 9 months follow-up. Conclusion: 
This technique allows easier insertion of haptics into ST.
Scientific Poster 286
Accuracy of IOL Power Calculations Provided by 
Intraoperative Aberrometry With and Without Streaming 
Refractive Data
Presenting Author: Stephen S Lane MD*
Purpose: To compare global results of IOL power calculations provided by intraoperative 
aberrometry with and without the use of streaming refractive information. Methods: Ret-
rospective review of the mean absolute value of the prediction error (MAVPE) obtained 
with ORA (Optiwave Refractive Analysis) intraoperative aberrometry (n = 10,434 eyes) and 
the first 300 cases performed with the same system with VerifEye streaming refractive 
information. Results: MAVPE in the ORA group was 0.33 D ± 0.27 D, with 79% of eyes 
within 0.5 D of predicted postop outcome. MAVPE in the ORA with VerifEye group was 
0.29 D ± 0.20 D, with 84% of eyes within 0.5 D of predicted postop outcome. Conclusion: 
Early results demonstrate that streaming refractive information improves the accuracy of 
IOL power calculations.
Computers, Information Technology
SESSION TWO
Scientific Poster 287
Patient Satisfaction Within Online Reviews of 
Ophthalmologists Evaluated by Contextual Analysis
Presenting Author: Robert M Kinast MD
Co-Author(s): Gordon T Barker MS, Susan H Day MD, Steven L Mansberger MD*
Purpose: Doctor rating websites are a growing trend in ophthalmology, but little is known 
about the factors associated with positive and negative online reviews. Methods: We 
collected 595 ophthalmology online reviews and used contextual analysis to determine 
whether reviews were positive or negative, and whether they included comments regarding 
the physician (bedside manner, competence) or office factors (staff, wait time, access, en-
vironment, finances, location). Results: Physician factors were 54% of positive comments, 
but office factors were 73% of negative comments. Refractive surgeons had more reviews 
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(P < .007) and higher scores (P < .001) than nonrefractive surgeons. Conclusion: Office fac-
tors are as important as patient-physician interactions in determining patient satisfaction 
and may damage a physician’s online reputation.
Scientific Poster 288
 h  A Novel Tele-ophthalmology Diagnostic Screening 
Protocol: Detecting Disease and Improving Eye Care 
Access
Presenting Author: April Y Maa MD
Co-Author(s): Centrael Tyson Evans MD, William Richard Delaune PhD, Purnima S Patel 
MD, Mary Gerard Lynch MD
Purpose: A prospective pilot study comparing a tele-eye screening protocol with a face-to-
face exam. Methods: Fifty-two patients were evaluated with both the screening protocol 
and a face-to-face ophthalmic exam. Detection accuracy for common ocular conditions was 
measured. Results: The protocol had 92% agreement, 89% sensitivity, 94% specificity 
for normal eyes; 87% agreement with 64% sensitivity, 95% specificity for glaucoma; 96% 
agreement with 100% sensitivity, 96% specificity for AMD; 100% agreement, sensitivity, 
and specificity for surgical cataract. Conclusion: Initial data suggest that this remote tele-
eye screening protocol has ability to detect ocular disease and warrants a larger study to 
confirm validity.
Scientific Poster 289
Validity and Acceptance of Color Vision Testing on 
Smartphones
Presenting Author: Omar K Ozgur MD
Co-Author(s): Rudrani Banik MD*
Purpose: To assess the validity of smartphone-based color vision testing (CVT) by compar-
ing results using the Eye Handbook (EHB) color plate application to standard pseudoisochro-
matic Ishihara color plates (ICP). Methods: Prospective study of adults with acuity ≥ 20/60 
at 14 inches who underwent CVT under standardized illuminance with both modalities. A 
study group had congenital or acquired color deficit, while the control group had no known 
color deficit. Results: Eight-nine percent of patients had no difference between testing 
modalities, and 11% had a difference of 1 plate, performing better on EHB. Sixty-seven 
percent preferred EHB, 11% preferred ICP, and 22% had no preference. Conclusion: In 
our study, CVT results were similar between the EHB and ICP groups, though there was a 
patient preference for EHB testing.
Cornea, External Disease
SESSION ONE
Scientific Poster 33
Deep Anterior Lamellar Keratoplasty for Spheroidal 
Degeneration
Presenting Author: Ashish P Nagpal MBBS
Co-Author(s): Manish Nagpal MD*
Purpose: To evaluate visual outcomes, complications, and graft survival of patients under-
going deep anterior lamellar keratoplasty (DALK) to treat extensive spheroidal degenera-
tion. Methods: In this retrospective, noncomparative study, 12 eyes that underwent DALK 
were included. Preoperative characteristics, intraoperative complications, postoperative 
acuity, complications, and subsequent operations were analyzed. Results: Mean follow-up 
was 44 ± 18 months. Six eyes had delayed epithelialization and required temporary tarsor-
rhaphy. Three eyes experienced an episode of stromal graft rejection. 8 eyes underwent 
subsequent cataract surgery. Conclusion: DALK in eyes with spheroidal degeneration is a 
safe and effective option that preserves host endothelium with favorable results. DALK in 
these eyes is associated with delayed epithelialization.
Scientific Poster 34
Progression of Fellow Eye in Cases of Asymmetric Ocular 
Cicatricial Pemphigoid: Is Treatment Always Necessary?
Presenting Author: Fiorella K Saponara MD
Co-Author(s): Anne S Steiner MD, Carolyn Y Shih MD MBA MPH, Ira J Udell MD
Purpose: To determine if fellow eyes invariably achieve the same disease stage as more 
affected eyes in asymmetric ocular cicatricial pemphigoid (OCP). Methods: Retrospective 
chart review of 20 OCP cases. Using Foster clinical staging, eyes were staged, and treat-
ments and progression were analyzed. Results: Preliminary results show an average age 
of 82 and follow-up ranging from 2 to 20 years (average: 5.9). Sixty-five percent of all eyes 
progressed, 92% bilaterally. Thirty-five percent of patients had asymmetric presentation; 
71% of these had stage III disease, and 29% had stage IV disease in the more affected eye. 
Forty-three percent of fellow eyes had stage I, 29% had stage II, and 29% had stage III. 
Twenty-nine percent of fellow eyes did not progress and were maintained on doxycycline 
alone. Conclusion: Although the majority of asymmetric OCP cases lead to progression, 
not all fellow eyes progress.
Scientific Poster 35
Is It OK to Do PRK in Keratoconus? Long-term Results
Presenting Author: Gustavo E Tamayo MD*
 Purpose: Review 16 years of excimer laser ablation to restore vision in keratoconus. 
Methods: Retrospective review of eyes with keratoconus treated with PRK between 1995 
and 2009. Ninety-five eyes completed the follow-up. Through the years, several techniques 
have been used. Contoured ablation pattern technique, 6 years; wavefront, when intro-
duced; mitomycin C, since 2000. Results: Mean follow-up: 125 months (range: 49-160). 
Preoperative UCVA: 53.3%, CF; 40%, 20/200; 6.6%, 20/800. Postoperative UCVA: 67%, 
20/25; 24.6%, 20/70; 8.3%, CF. Mean BCVA: 52%, 20/25; 33%, 20/30; 6%, 20/40; and 
8.3%, CF. Conclusion: The use of surface ablation excimer in keratoconus can be safe and 
effective provided some guidelines are followed. The rate of corneal transplants after a 
long follow-up is normal and no larger than the disease natural course.
Scientific Poster 36
 h  Computer-Aided Diagnosis of Keratoconus Based on 
Ultrasound Layered Pachymetric Map Analysis
Presenting Author: Ronald H Silverman PhD*
Co-Author(s): Raksha Urs PhD*, Timothy J Archer MS, Marine Gobbe PhD, Arindam 
RoyChoudhury PhD*, Dan Z Reinstein MD*
Purpose: To determine if ultrasound-based layered corneal pachymetric maps can inde-
pendently differentiate normal from keratoconic (KC) corneas. Methods: We scanned 130 
normal and 74 KC subjects with the Artemis-1 ultrasound arc-scan system. We performed 
computer-analysis of epithelial and stromal thickness maps on one eye per subject. Linear 
discriminant (LDA) and neural network (NN) analyses were then performed. Results: A 
6-variable model provided complete separation of normal from KC corneas by LDA and NN. 
Validation analysis resulted in 99.2% specificity and 94.6% sensitivity by LDA and 99.5% 
specificity and 98.9% sensitivity by NN. Conclusion: Layered pachymetric maps offer an 
independent means for differentiation of normal from KC corneas. Detection of epithelial 
remodeling may provide an avenue toward early diagnosis.
Scientific Poster 37
Corneal Collagen Crosslinking Without Removing Corneal 
Epithelium
Presenting Author: Fook Chang Lam MBChB
Co-Author(s): Nashila Hirji, Samer Hamada MD, Damian Lake MBChB
Purpose: To assess the safety and efficacy of corneal collagen crosslinking in the treatment 
of progressive keratoconus using a technique where the corneal epithelium is physically 
disrupted but not removed. Methods: A retrospective analysis of the visual, refractive, and 
topographic outcomes of 147 consecutive patients with progressive keratoconus. Results: 
The mean K-max readings reduced by 0.4 D. 20.2% demonstrated continued progression at 
1 year (ie, K-max increased by 1 D or more). 2.2% of eyes lost 2 or more lines of vision, 2.7 
% developed sterile infiltrates, and 0.9% developed a central corneal scar. Conclusion: 
This technique of crosslinking after the mechanical disruption of corneal epithelium is an 
efficacious way of stabilizing keratoconus. This method is safer than currently published 
epithelium-off techniques.
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Scientific Poster 38
A Comparative Study of Collagen Crosslinking for 
Keratoconus in Thin vs. Thick Corneas
Presenting Author: Salina Teja MD
Co-Author(s): W Bruce Jackson MD FRCSC*, George Minstioulis FRCSC, Kashif Baig 
MD MBA*
Purpose: To compare the 1-year outcomes of collagen crosslinking (CXL) in keratoconus 
between thin and thick (< 400 µm vs. > 400 µm) corneas. Methods: Baseline and postop-
erative (up to 1 year) measures of keratometry, visual acuity, pachymetry, and refraction 
were compared between groups retrospectively (n = 107). A repeated measure regression 
was performed for each variable separately. Results: Preoperatively, the thin group had 
more severe keratoconus with all measures of disease (P < .05). At 1-year follow-up, the 
thin group showed no significant changes in any measures with a 30% failure rate, and 
the thick group showed significant reduction in K-max by 2.4 D (P < .001) with no failures. 
Conclusion: Our study shows that CXL halts progression of keratoconus in thin corneas; 
however, it does not cause significant regression of ectasia as seen in thick corneas.
Scientific Poster 39
Comparison of Fibrin Glue and Autologous Blood for 
Conjunctival Autograft Fixation in Pterygium Surgery
Presenting Author: Salina Teja MD
Co-Author(s): Sophie Boucher COMT, Kashif Baig MD MBA*
Purpose: To compare autologous blood (AB) and fibrin glue (FG) for conjunctival graft fixa-
tion in pterygium excision surgery. Methods: Data were collected up to 1 year postop-
eratively for 40 patients (20 AB, 20 FG), and outcomes were compared between groups. 
Results: There were no intraoperative complications, and the surgical costs differed due 
to cost of fibrin glue and extra time required with autologous blood. At 3 months postop-
eratively, 6 AB patients lost their graft compared to 0 FG patients, while 3 in each group 
had graft displacement. One FG patient had a recurrence, and 2 AB patients developed 
pyogenic granuloma. Visual acuity was stable. Conclusion: Our comparison of the efficacy 
and stability of conjunctival autografts between FG and AB will help to further establish the 
role of AB in pterygium surgery.
Scientific Poster 40
Bowman Layer Implantation: An Alternative to Penetrating 
/ Deep Anterior Lamellar Keratoplasty for Advanced 
Keratoconus
Presenting Author: Jack S Parker MD
Co-Author(s): Korine van Dijk OD, Gerrit RJ Melles MD PhD*
Purpose: To evaluate the efficacy of Bowman layer implantation in reducing and stabilizing 
corneal ectasia in patients with advanced keratoconus (AKC). Methods: Ten eyes of 9 pa-
tients with AKC and contact lens intolerance, who were not candidates for UV-crosslinking, 
underwent midstromal implantation of an isolated Bowman membrane and were followed 
for a mean of 16 months. Results: Maximum corneal power decreased on average from 
74.5 D (± 7.1 D) to 68.3 D (± 5.6 D) after surgery (P = 0.00). All surgeries were uncomplicated 
and uneventful, and contact lens tolerance was restored in all eyes. BCVA and pachymetry 
were not significantly affected (P = .77; P = .11). Conclusion: Bowman layer implantation 
may be safe and effective in treating ectasia in AKC.
Scientific Poster 41
High Fluence Iontophoretic Corneal Collagen Crosslinking: 
In Vivo OCT Imaging of Riboflavin Penetration
Presenting Author: Paolo Vinciguerra MD*
Co-Author(s): Miguel M Rechichi MD, Pietro Rosetta MD, Vincenzo Scorcia MD, Claudio 
Azzolini MD, Riccardo Vinciguerra MD
Purpose: To evaluate the effect of epi-off vs. iontophoresis (ION) on riboflavin penetration 
during collagen crosslinking (CXL) in vivo using HD-OCT. Methods: Twenty eyes undergoing 
CXL were acquired pre-, intra-, and postoperatively using HD-OCT. In 10 eyes, the standard 
epi-off protocol was used, whereas in 10 eyes riboflavin penetration was promoted by ION. 
Results: In the epi-off group, after 30 minutes a homogeneous hyper-reflective band was 
measured at a mean depth of 80 µm. In the ION group, a less homogeneous band with fad-
ing effect was measured at 200 µm. Conclusion: Intraoperative OCT could be an useful 
aid to evaluate in vivo penetration of riboflavin in the stroma. The in vivo OCT results of the 
ION group showed a lower but deeper concentration of riboflavin in the stroma compared 
to the epi-off technique.
Scientific Poster 42
Infectious Keratitis in Mexico: Ten-Year Experience in 
Corneal Scrapes
Presenting Author: Enrique O Graue Hernandez MD
Co-Author(s): Alejandro Navas MD*, Julio Hernandez Camarena MD, Arturo J Ramirez-
Miranda MD*
Purpose: To report the distribution, microbiologic trends, and antibiotic sensitivity of infec-
tious keratitis in Mexico City. Methods: Retrospective study. Samples were obtained from 
corneas with diagnosis of infectious keratitis from January 2002 to December 2011. Re-
sults: 1638 corneal scrapings were taken. A pathogen was recovered in 38% of samples, 
with bacterial keratitis for 88%. The most common isolated pathogen was Staphylococcus 
epidermidis, and the most common Gram-negative was Pseudomonas aeruginosa, whose 
resistance to ceftazidime increased from 11.1% in the first 5 years to 88.9% for the last 5 
years. Conclusion: The ceftazidime resistance of P aeruginosa increased during the 5 last 
years, suggesting that is not ideal for empiric treatment. Vancomycin resistance accounted 
for 9.9% of all Gram-positives, while 13.3% of all the bacterial isolates were resistant to 
quinolone.
Scientific Poster 43
Glaucoma in Herpetic Eye Diseases
Presenting Author: Sonal S Tuli MD
Co-Author(s): Delbert Benzenhafer, Anthony B Greer MD, Eric Calver Swanson, Trent M 
Talbot MD**, Anup A Kubal MD
Purpose: To evaluate the risk and outcomes of glaucoma in patients with herpetic eye dis-
ease. Methods: Retrospective review of 68 patients with herpes simplex and 52 patients 
with herpes zoster keratitis and keratouveitis. Patients were followed for up to 20 years 
following the onset of herpetic eye disease. Results: Glaucoma or ocular hypertension 
was noted in 22% of herpes simplex patients and 35% of zoster patients. This was highly 
statistically significant. Sixty percent of these patients in the herpes simplex group needed 
surgery, and 50% of those in the zoster group. Conclusion: Glaucoma is very prevalent in 
herpetic eye disease patients and follows a very aggressive course, with more than half 
of the patients needing surgical intervention. Patients with herpetic eye disease should be 
closely followed for development of glaucoma.
Scientific Poster 44
Polymerase Chain Reaction of Conjunctival Swab for the 
Diagnosis of Microsporidial Keratoconjunctivitis
Presenting Author: Yogesh Vamanrao Bhadange MD
Co-Author(s): Sujata Das MBBS, Praveen Kumar Balne, Batriti Shympliang Wallang DO, 
Savitri Sharma MD
Purpose: To evaluate the efficacy of polymerase chain reaction (PCR) of conjunctival swab 
in the diagnosis of microsporidial keratoconjunctivitis. Methods: Conjunctival swabs from 
42 clinically diagnosed cases of microsporidial keratoconjunctivitis were collected from in-
ferior fornix with the help of Rayon swabs. The swabs were immersed into phosphate buf-
fer saline and subjected to microsporidial PCR. Results: PCR was positive in 33 patients. 
DNA sequencing and blast analysis identified the organisms to be Vittaforma corneae in 12 
cases. The positivity of the PCR result was not related to the number of lesions and duration 
of symptoms. Conclusion: Collection of sample using conjunctival swab can be used as 
an alternative to corneal scraping in the diagnosis of microsporidial keratoconjunctivitis.
Scientific Poster 45
Newly Emerging Pathogens in Keratomycosis: A Study 
From India
Presenting Author: Anup K Ghosh PhD
Co-Author(s): Amit Gupta MBBS, Suruchi Gupta MBBS, Rituparna Bhattacharya**, 
Arunaloke Chakrabarti MD, Mangat R Dogra MBBS
Purpose: To study the newly emerging trend of keratomycosis at a tertiary hospital in 
India. Methods: Spectrum of fungal pathogen causing keratomycosis during 2005-2011 
was evaluated; DNA-based technology was used for identification of newer pathogen. Re-
sults: Incidence was high (37.3%) during crop harvesting season, with male predominance 
(78.3%). Fungi could be isolated from 383 of 757 cases of keratomycosis (50.59%). As-
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pergillus species were the most common 189 isolates (49.3%), followed by dematiaceous 
group, with 75 (19.5%). Ten isolates from keratitis and Papulospora equi causing human 
infection were isolated for the first time. Conclusion: Agriculture-related activity is the 
major risk factor; new species are emerging, and the dematiaceous group is a concern for 
keratomycosis.
Scientific Poster 46
Guidelines for the Use of Intracameral Amphotericin B 
in Recalcitrant Keratomycosis: Experience With a Large 
Case Series
Presenting Author: Amit Gupta MBBS
Co-Author(s): Suruchi Gupta MBBS, Manjari Tandon Sr MBBS MS**, Arunaloke 
Chakrabarti MD, Poooja Bansal MBBS
Purpose: To report outcomes of early vs. delayed intervention using intracameral ampho-
tericin B (ICAMB) in keratomycosis. Methods: Fifty eyes with nonresponding fungal kerati-
tis: Group I (25 eyes) receiving ICAMB at 2 weeks and Group II (25 eyes) at 4 weeks. Time to 
heal, type of corneal opacity, and complications were noted. Results: In Group I vs. Group 
II, mean number of injections was 4.08 vs. 4.64, healing time was 18.06 vs. 36.68 days, 
maculoleucomatous opacity was present in 12 vs. 4 eyes, vascularized opacity in 9 vs. 17 
eyes, cataract in 6 vs. 14 eyes, hyphema in 1 vs. 2 eyes, and corneal perforation in 0 vs. 10 
eyes. Conclusion: Early intracameral amphotericin B significantly hastens resolution and 
reduces ocular morbidity in keratomycosis.
Scientific Poster 47
Comparison of Voriconazole and Natamycin Eye Drops in 
the Treatment of Fungal Keratitis
Presenting Author: Savitri Sharma MD
Co-Author(s): Sujata Das MBBS, Ajoy S Virdi MBBS, Merle Fernandes MS, Srikant 
Kumar Sahu**, Prashant Garg MD*, Swapna Reddy Motukupally
Purpose: Randomized controlled trial to compare efficacy of 1% voriconazole (A) with 5% 
natamycin (B) eye drops in the treatment of fungal keratitis. Methods: Microscopy-proven 
118 fungal keratitis patients were treated with either A (58) or B (60) as inpatients for 
7 days and followed up for a mean duration of 35 days (7-400 days). Based on clinical 
response, patients were classified as healed / resolving / worsening / failure. Results: 
More patients on B (71%) healed / were resolving compared to A (55%). Initial infiltrate 
size and keratitis severity being comparable, final vision was better (P = .037) and infiltrate 
was smaller in the B group (P = .024). Conclusion: Compared to voriconazole, natamycin 
was more effective in the treatment of fungal keratitis.
Scientific Poster 48
Fusarium Keratitis in Brazil and the United States: 
Comparison of Laboratory Analysis and Clinical Outcomes
Presenting Author: Rafael A Oechsler MD
Co-Author(s): Ana Hofling-Lima MD MBA, Paulo Josç Martins Bispo MS, Michael R 
Feilmeier MD, Darlene Miller MPH, Tiago Massao Yamanaka, Juliana F Sartori MD**, 
Flavio Hirai MD, Maria CecÌia Zorat-Yu PhD, Eduardo C Alfonso MD*
Purpose: To compare genotyping, antifungal susceptibilities, and clinical outcomes from 
Fusarium keratitis in the United States and Brazil. Methods: Fifty-eight Fusarium spp iso-
lates were obtained at the Bascom Palmer Eye Institute (Miami, Flor., USA), and 41 isolates 
at the Federal University of São Paulo (Brazil). All isolates were genotyped and submitted 
to antifungal susceptibility testing and the respective patients’ records were reviewed. Re-
sults: F. solani was the main species identified by genotyping in Brazil (88% of isolates) 
and in United States (75%). Amphotericin B was the drug with the lowest MIC90 in both 
countries (2 µg/ml). Mean follow-up BCVA was 20/800 in Brazil and 20/90 in United States; 
therapeutic keratoplasties were necessary in 54% of patients in Brazil and in 14% in United 
States. Conclusion: Fusarium keratitis in Brazil had an overall worse clinical outcome than 
in the United States.
Scientific Poster 49
Comparison of Umbilical Cord Serum and Amniotic 
Membrane Transplantation in Acute Ocular Chemical 
Burns
Presenting Author: Namrata Sharma MD MBBS
Co-Author(s): Sri Vatsa Sehra, Rajesh Sinha, Jeewan S Titiyal MD, Thirumurthy 
Velpandian PhD, Radhika Tandon MD, Rasik B Vajpayee MD
Purpose: To compare efficacy of cord serum (CS) with amniotic membrane transplantation 
(AMT) in acute ocular chemical burns. Methods: Fifty-five eyes with grade III, IV, and V 
chemical burns within 3 weeks received medical therapy (MT; n = 20) or additional 20% CS; 
n = 17) or AMT (n = 18) retrospectively. Results: Mean time to healing was 57.7 ± 29.3, 27.4 
± 19, 41.1 ± 28.9 days in MT, AMT, and CM, respectively (P = .02). Significant decrease in 
epithelial defect diameter was seen earlier in CS group (P = .04). Mean tear breakup time at 
3 months was 8.6 ± 0.7, 10.3 ± 1.1, 9.4 ± 1.2 (P = .02), and mean Schirmer was 13.7 ± 1, 16.9 
± 3, 13.2 ± 1.5 mm in MT, CS, and AMT, respectively (P = .01). No difference was seen in vi-
sual outcomes, vascularization, and symblepharon. Conclusion: CS is a better alternative 
to AMT in moderate to severe ocular chemical burns as it avoids surgery in inflamed eyes.
Scientific Poster 50
Oral Mucosal Transplantation and “Wrap Around”? 
Amniotic Membrane Transplantation in Ankyloblepharon 
due to Chronic Stevens-Johnson Syndrome
Presenting Author: Namrata Sharma MD MBBS
Co-Author(s): Tushar Agarwal MD, Rasik B Vajpayee MD
Purpose: To evaluate results of oral mucosal transplantation (OMT) and “wrap around” 
amniotic membrane transplantation (AMT) in ankyloblepharon due to chronic Stevens-
Johnson syndrome (SJS). Methods: In this retrospective study, 22 eyes underwent OMT 
on both lids and AMT on cornea and bulbar conjunctiva. Edges of amniotic membrane 
were pulled from under the symblepharon ring over the tarsal conjunctiva and wrapped on 
the lids. Results: At 1 year, complete and partial anatomical success was seen in 81.8% 
(18/22) and 9.1% of eyes (2/22) and failure in 9.1% of eyes (2/22). Corrected distance 
visual acuity improved from hand motion close to face preoperatively to > 6/60 in 72.6% of 
eyes (16/22). Conclusion: In severe ankyloblepharon due to chronic SJS, OMT with “wrap 
around” AMT provides ambulatory visual acuity.
Scientific Poster 51
Conjunctival Autograft and Fibrin Glue for Primary 
Pterygium: Global Outcomes and Comparison Between 
Expert and Trainee Ophthalmologists
Presenting Author: Pedro Arriola-Villalobos MD
Co-Author(s): Pilar Cifuentes-Canorea MD, Jorge Peraza-Nieves Sr, David Diaz-Valle MD 
PhD*, Jose A Gegundez-Fernandez MD PhD*, Jose Manuel Benitez-del-Castillo
Purpose: To evaluate the outcomes of autoconjunctival graft attached with fibrin glue (FG) 
for primary pterygium, comparing expert and trainee ophthalmologists. Methods: A ret-
rospective, comparative, nonrandomized, interventional study was carried out in 249 eyes 
(210 patients, mean age 47.19 ± 13.29 years) with primary pterygium that were subjected 
to surgery (conjunctival autograft fixed using FG) by expert (131 eyes) or trainee ophthal-
mologists (117 eyes). Mean follow-up was 7.73 months. Results: Recurrence rate was 
7.7%, being 6.1% in the expert ophthalmologists group and 9.4% in the trainee group (P = 
.33). The reoperation rates were 1.2%, 0%, and 2.6% (P = .104), respectively. Conclusion: 
Autoconjunctival grafting and FG achieved good outcomes in primary pterygium surgery. 
The experience of the surgeon seems to influence success rates.
Scientific Poster 52
Environmental Factors and Dry Eye Syndrome: A Study 
Utilizing the National U.S. Veterans Affairs Administrative 
Database
Presenting Author: Anat Galor MD*
Co-Author(s): Hermes J Florez, Katherine Teresa McManus, David J Lee PhD, Naresh 
Kumar PhD, William J Feuer MS
Purpose: To evaluate the effect of environmental factors on dry eye syndrome (DES). 
Methods: Case-control study of patients seen in a Veterans Affairs (VA) eye clinic in the 
continental United States over a 5-year period. Cases carried a DES diagnosis and received 
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DES therapy. The main outcome measure was the effect of environmental conditions on 
the risk of having DES. Results: A total of 3.41 million patients were seen in a VA eye 
clinic; 606,708 had DES. Among all variables, air pollution (as measured by aerosol optical 
depth) was the most important risk factor, with an incidence rate ratio (IRR) of 1.4, P-value 
< .0005. Higher humidity (%) decreased that risk of DES (IRR 0.989, P < .0005). Conclusion: 
Increased air pollution and decreased humidity increase the risk of having DES.
Scientific Poster 53
Limbal Stem Cell Dysfunction From Superior Limbic 
Keratoconjunctivitis in Chronic Graft Versus Host Disease
Presenting Author: Kavitha R Sivaraman MD
Co-Author(s): Renu V Jivrajka MD, Ali R Djalilian MD
Purpose: To describe the presence of superior limbic keratoconjunctivitis (SLK) in patients 
with chronic graft versus host disease (cGVHD) leading to limbal stem cell dysfunction. 
Methods: Descriptive retrospective case series of 12 eyes of 6 patients with cGVHD with 
concomitant SLK and limbal stem cell dysfunction. Results: All 12 eyes showed evidence 
of both SLK and limbal stem cell dysfunction as evidenced by a combination of corneal pan-
nus, superior corneal punctate rose Bengal staining, and/or loss of the palisades of Vogt. 
All eyes responded to initiation of aggressive lubrication with or without punctual cautery 
and topical cyclosporine. Conclusion: SLK may be a comorbid condition in patients with 
cGVHD-related dry eye and may secondarily lead to limbal stem cell dysfunction.
Scientific Poster 54
Efficacy of 2% Rebamipide Ophthalmic Suspension for the 
Treatment of Blink-Related Ocular Surface Disorders
Presenting Author: Norihiko Yokoi MD PhD*
Co-Author(s): Hiroaki Kato MD, Aoi Komuro MD PhD, Yukiko Sonomura, Shigeru 
Kinoshita MD*
Purpose: To evaluate the efficacy of 2% rebamipide ophthalmic suspension (ROS) for treat-
ing blink-related ocular surface disorders (BROSD). Methods: Twenty eyes of 20 patients 
with at least either filamentary keratitis (FK), superior limbic keratoconjunctivitis (SLK), 
or lid-wiper epitheliopathy (LWE) were evaluated before and at 1, 2, and 3 months after 
treatment with ROS in relation to visual analog scale of symptoms, tear meniscus radius, 
tear-film breakup time, FK and corneal staining (scored with fluorescein), and conjunctival 
staining, SLK, and LWE (all using lissamine green). Results: By 3 months, significant im-
provement was seen in FK, SLK, and LWE (P < .01), and foreign body sensation, eye pain, 
and opening difficulty (P < .05). Conclusion: ROS is effective for treating BROSD.
Scientific Poster 55
Outcomes of Autologous Serum Tear Use for Corneal 
Neuropathy-Induced Severe Light Sensitivty
Presenting Author: Shruti Aggarwal MBBS
Co-Author(s): Ahmad Kheirkhah MD, Clara M Colon, Emma Sue Brown, Pedram Hamrah 
MD*, Bernardo Menelau Cavalcanti MD
Purpose: To evaluate the use of autologous serum tears (AST) treatment for severe light 
sensitivity in patients with corneal neuropathy. Methods: Sixteen cases with no ocular 
surface disease suffering from severe light sensitivity were treated with AST 8 times/day. 
Changes in severity of symptoms (0-10) and sub-basal corneal nerve density and morpholo-
gy by in vivo confocal microscopy (IVCM) were evaluated and compared to 16 age-matched 
controls. Results: Light sensitivity improved from 8.8 ± 1.1 at baseline to 1.6 ± 1.7 (P < 
.05) with ATS. Baseline IVCM showed significantly decreased density and altered nerve 
morphology compared to controls (all P < .001). After mean of 3.6 months of AST, all nerve 
parameters improved significantly (P < .05). Conclusion: AST-induced nerve regeneration 
may lead to improved patient-reported light sensitivity.
Scientific Poster 56
Should the Schirmer Score Remain a Gold Standard for 
Diagnosis of Ocular Graft Versus Host Disease?
Presenting Author: Hasanain T Shikari MD*
Co-Author(s): Ujwala Saboo MBBS, Francisco Amparo MD*, Reza Dana MD MSc MPH*
Purpose: To evaluate the reliability of the Schirmer score in establishing a diagnosis of 
ocular graft versus host disease (oGVHD). Methods: Retrospective review of 100 patients 
with oGVHD. Results: Current NIH criteria for oGVHD diagnosis exclude patients with a 
mean Schirmer score ≥ 10. Our data demonstrate that Schirmer scores moderately cor-
relate with corneal fluorescein staining (CFS) (R = -0.4, P < .001) and symptoms (OSDI) (R 
= -0.4, P < .01). Fifteen percent of patients with oGVHD presented with mean Schirmer 
scores ≥ 10, but significantly higher CFS (2 ± 0.3) than patients with Schirmer scores 6-10 
(1 ± 0.2, P = .03). Conclusion: Schirmer scores vary significantly and may falsely exclude 
patients with oGVHD.
Scientific Poster 57
The Pterygium Conjunctiva Autograft’s Adieu to Second 
Site Harvest
Presenting Author: Jasdeep S Sandhu DOMS MCHO
Co-Author(s): Arun Verma MBBS**
Purpose: To report the outcomes and safety of single-site surgery using pterygium con-
junctiva autograft. Methods: Prospective case series of 83 consecutive surgeries for pri-
mary pterygium. The pterygium conjunctiva was dissected from the underlying fibro vascu-
lar component, which was excised at the base. The thin clear free autograft was applied 
on bare sclera after 90° rotation and without sutures or glue. Results: Mean follow-up: 
14.4 ± 3.2 months, assessing complications, recurrence, and aesthetics. There was graft 
dislodgement in 3 eyes (3.6%), granuloma formation in 3 eyes (3.6%), graft edema in 2 
eyes (2.4%), recurrence in 1 eye (1.2%). Seventy-four patients (89.1%) expressed satisfac-
tion with cosmesis. Conclusion: This single-site technique can be useful in preserving 
extralesional conjunctiva.
Scientific Poster 58
A Comparative Analysis of 3 Methods of Graft Fixation 
Techniques in Conjunctival Autografting for Pterygium 
Surgery
Presenting Author: Santanu Mitra MBBS
Purpose: To compare the outcomes of 3 different methods of conjunctival graft fixation in 
pterygium surgery. Methods: Comparative, nonrandomized, interventional case series. 237 
nasal pterygium in 3 groups: Group A (n = 57): graft fixation with sutures; Group B (n = 94): 
with fibrin glue; and Group C (n = 86): with oozing blood. Mean surgical time, postoperative 
subjective symptoms, and recurrence rate were compared. Minimum follow-up: 6 months. 
Results: Surgical time and postoperative symptoms were least with Group A. Recurrence 
was significantly higher with sutures (P < .05). In Group C, 1 eye had early graft loss, but 
otherwise had similar results as with glue. Conclusion: Using patient’s oozing blood for 
graft fixation gives all benefits of synthetic glue and avoids postoperative suture-related 
problems.
Scientific Poster 59
Alcaftadine 0.25% vs. Olopatadine 0.2% in Prevention 
of Ocular Itching Due to Allergic Conjunctivitis in a 
Conjunctival Allergen Challenge Model
Presenting Author: Eugene B McLaurin MD FACS
Co-Author(s): Nicholas P Marsico MD, Joseph B Ciolino MD, Julia M Williams*, David 
Hollander MD*
Purpose: To evaluate q.d. dosed ocular antiallergics. Methods: A 3-arm (alcaftadine 
0.25%, olopatadine 0.2%, placebo) study utilizing the Conjunctival Allergen Challenge 
(CAC) model. The primary efficacy measure was subject-evaluated ocular itching 16 hours 
following dosing at 3 minutes following challenge. Results: 157 enrolled subjects. At 16 
hours after dosing, both actives exhibited significantly lower mean ocular itching than did 
placebo (P < .001). At 3 minutes following CAC, alcaftadine achieved significantly lower 
mean itching (P = .008) and a greater proportion of patients with mean itch scores < 1 (P = 
.040) and = 0 (P = .042) than did olopatadine. Conclusion: Both actives were effective at 16 
hours following challenge compared to placebo. Alcaftadine demonstrated greater efficacy 
compared to olopatadine measured in a CAC model.
Scientific Poster 60
Femto-Assisted Corneal Tattoo
Presenting Author: Keith A Walter MD*
Purpose: Demonstration of the benefit of femto-assisted corneal tattoo for iris defects 
and/or aniridia. Methods: Retrospective review of 10 cases of femtosecond laser-assisted 
corneal tattoo. The femtosecond laser (FS200, Alcon) was used to make a lamellar pocket 
in the cornea stroma at approximately 250 microns deep, using the Intacs ring software 
and/or a modified LASIK flap software. Appropriate titanium dioxide pigment was inserted 
into the lamellar pocket after blunt dissection. A bandage contact lens was placed after the 
procedure. Results: Complete resolution of glare / photophobia symptoms was achieved 
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in all cases. Procedure time and pain were drastically reduced in all cases compared to tra-
ditional corneal tattoo. Conclusion: Femto-assisted corneal tattoo is a safe and efficient 
method for resolution of iris defects.
Scientific Poster 61
Relationship Between the Corneal Guttae and Quality of 
Vision in Patients With Mild Fuchs Endothelial Corneal 
Dystrophy
Presenting Author: Shinya Watanabe MD
Co-Author(s): Yoshinori Oie MD PhD*, Hisataka Fujimoto MD PHD, Takeshi Soma MD*, 
Shizuka Koh MD*, Motokazu Tsujikawa**, Naoyuki Maeda MD*, Kohji Nishida MD
Purpose: To investigate whether the severity of corneal guttae affects the quality of vi-
sion (QOV) in patients with Fuchs endothelial corneal dystrophy (FECD). Methods: For the 
12 FECD eyes without edema, the area ratio of corneal guttae at the central cornea, cor-
rected distance visual acuity (CDVA), letter contrast sensitivity (LCS), and straylight were 
measured. Results: Multivariate stepwise logistic regression analysis showed that the 
area ratio of corneal guttae significantly correlated with CDVA, LCS, and straylight (P = 
.006, .02, and .006, respectively). Conclusion: The corneal guttae deteriorates the QOV 
in eyes with FECD.
Scientific Poster 62
Femtosecond Laser-Assisted Penetrating Keratoplasty: 
Analysis of Outcomes and Comparison of Incision 
Morphology
Presenting Author: Joshua C Teichman MD
Co-Author(s): Stephanie A Low MD, Raneen Shehadeh Mashor MD, Neera Singal MD, 
Allan Slomovic MD*, David S Rootman MD*
Purpose: To investigate femtosecond laser-assisted penetrating keratoplasty and com-
pare incision morphologies. Methods: Retrospective data analysis of patients who had 
femtosecond laser-assisted penetrating keratoplasty. Descriptive and inferential statistical 
analyses were performed. Results: Forty-five eyes of 43 patients were included. UCVA was 
1.3 preoperatively and improved to 0.48 postoperatively (P < .0001). Median follow-up was 
23 months. There was a statistically significant difference in postoperative UCVA between 
zig-zag and top-hat morphology (P = .008) and between zig-zag and mushroom morphology 
(P = .026), with zig-zag having better postoperative UCVA. Conclusion: There was statisti-
cally significantly better UCVA in those who had zig-zag incision morphology as compared 
with top-hat or mushroom.
Scientific Poster 63
 h  Visual Acuity Outcomes of the Boston Keratoprosthesis 
Type 1: Multicenter Study Results
Presenting Author: Christopher J Rudnisky MD*
Co-Author(s): Michael W Belin MD*, Joseph B Ciolino MD
Purpose: To report the visual outcomes of the Boston KPro Type 1. Methods: Forms re-
porting case parameters were prospectively collected and analyzed. Snellen acuity was 
converted to logMAR values; eyes with LP or NLP vision were recorded as categorical 
variables. Results: 300 eyes of 300 patients were included. Mean follow-up time was 
17.1 months. Visual acuity was 1.78 logMAR units (20/1205) preoperatively and improved 
significantly (P < .0001) to a mean final value of 0.89 (20/150). The mean time to 20/200 
acuity was 1 month, and ~75% retained that level for 4 years. Multivariate analysis demon-
strated 3 independent predictors of final visual outcome: chemical injury (P = .0017), aniridia 
(P = .04), and AMD (P < .0001). Conclusion: Keratoprostheses are an effective and stable 
option for severe surface disease.
Scientific Poster 64
Femtosecond Laser Zigzag Keratoplasty: Suture Out 
Results
Presenting Author: Matthew W Wade MD
Co-Author(s): Roger F Steinert MD*, Sumit Garg MD*, Marjan Farid MD*
Purpose: To report visual and astigmatism outcomes in patients who underwent zig-zag 
femtosecond laser-enabled keratoplasty (FLEK) with subsequent full suture removal. Meth-
ods: Retrospective study evaluating uncorrected and corrected visual acuity (UDVA, CDVA) 
and manifest (Mrx cyl) and topographical (Topo cyl) astigmatism. Eighty-three eyes with 
good visual potential (≥ 20/30) underwent full suture removal. Results: Full suture removal 
occurred on average 1.2 years (SD 0.7) after FLEK. The pre- vs. post-suture removal values 
were significant only for CDVA (showing improvement): UDVA from logMar 0.74 (0.45) to 
0.68 (0.45) (P = .687), CDVA from 0.28 (0.22) to 0.23 (0.19) (P = .024), Mrx cyl from 3.57 (1.83) 
to 3.48 (2.12) (P = .906), and Topo cyl from 5.33 (3.83) to 5.71 (5.41) (P = .547). Conclusion: 
The zig-zag FLEK incision results in good vision and astigmatism after suture removal.
Scientific Poster 65
Influence of Descemet-Stripping Automated Endothelial 
Keratoplasty Graft Diameter on Endothelial Cell Loss in 
Non-Fuchs Bullous Keratopathy
Presenting Author: Anshu Arundhati MD
Co-Author(s): Marianne O Price PhD*, Donald Tan MD FRCS FRCOphth*, Jodhbir S 
Mehta FRCS FRCOPHTH*, Francis W Price Jr MD*
Purpose: To correlate graft diameter and endothelial cell (EC) loss in Descemet-stripping 
automated endothelial keratoplasty (DSAEK) for non-Fuchs bullous keratopathy at Singa-
pore National Eye Centre, Singapore, and Price Vision Group, United States. Methods: 
Retrospective case series of 374 eyes with EC loss data and at least 6 months follow-up. 
Results: EC loss at 6 months and 2 years was 35% and 44% for 8-mm grafts, 34% and 40% 
for 8.5-mm grafts, 25% and 23% for 8.75-mm grafts, and 29% and 37% for 9.0-mm grafts, 
respectively. Multivariate analysis showed that at 1- and 2-year follow-up, respectively, 
graft diameter (P = .04 and .03), site (P < .0001 and .002), and prior glaucoma surgery (P 
= .05 and .02) had a significant influence on EC loss (R2, 0.10). Conclusion: Although a 
trend toward higher cell loss was noted with smaller graft diameters, the size of the effect 
was limited.
Scientific Poster 66
Graft Survival After Descemet-Stripping Automated 
Endothelial Keratoplasty in Eyes with Previous Glaucoma 
Surgery
Presenting Author: Cristina Bovone MD
Co-Author(s): Elena Albe MD, Stefano DeAngelis MD, Paolo Santorum MD, Massimo 
Busin MD*
Purpose: To evaluate the long-term survival of donor endothelium Descemet-stripping au-
tomated endothelial keratoplasty (DSAEK) in eyes with previous glaucoma surgery. Meth-
ods: Endothelial cell loss and survival probability (Kaplan-Meier) were evaluated every 6 
months up to 3 years after DSAEK, in 78 eyes with previous trabeculectomy (n = 56) or shunt 
(n = 22). Results: Endothelial cell loss was significantly (P = .03) higher at 6 and 12 months 
in eyes with prior shunt surgery. Graft failure occurred in 26% of post-trabeculectomy eyes 
and in 23% of post-shunt eyes. Conclusion: DSAEK graft survival in eyes with previous 
glaucoma surgery is reduced substantially.
Scientific Poster 67
 h  Refractive Stability After Descemet Membrane 
Endothelial Keratoplasty
Presenting Author: Marina Rodriguez Calvo De Mora MD
Co-Author(s): Lisanne Ham PhD, Gerrit RJ Melles MD PhD*
Purpose: To determine refractive change and stability at 2 years after Descemet mem-
brane endothelial keratoplasty (DMEK). Methods: From 149 DMEK eyes with complete 
follow-up data up to 2 years, complete subjective refractive and Pentacam data were ob-
tained. Results: A mean hyperopic shift in spherical equivalent of about +0.4 D, and a 
mean change in refractive cylinder of ± -0.3 D were found at 3 months postoperatively. After 
that, no significant change was observed up to 2 years. Pentacam showed a mean decrease 
in true net power of ± 1 D. Conclusion: DMEK may give a minimal refractive change and 
stabilization thereof at 3 months. Refraction remained stable up to 2 years after DMEK. The 
hyperopic shift may result from stromal deswelling.
Scientific Poster 68
Clinical Characteristics of IOL Opacification After 
Posterior Endothelial Keratoplasty Procedures
Presenting Author: Valery Bersudsky MD
Co-Author(s): Shimon Rumelt MD MPA
Purpose: To report the characteristics of opacification of IOLs in eyes after posterior endo-
thelial keratoplasty (EK) procedures. Methods: Clinical data of all cases with opacification 
of IOLs after EK procedures (Descemet-stripping automated EK, non-Descemet-stripping 
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automated EK, and Descemet membrane endothelial EK) were collected. Results: Seven 
out of 70 eyes (10%) had opacification of the IOL after EK. The only associated factors 
were hydrophilic lenses (17% vs. 0%, P = .037) and multiple air injections into the anterior 
chamber (mean ± SD: 2.0 ± 1.0 vs. 1.17 ± 0.52, P = .003). Conclusion: IOL opacification 
is frequently associated with EK. The process of opacification may be mediated by IOL 
interface properties.
Scientific Poster 69
 h  Periodic Endothelial Cell Loss in Descemet-Stripping 
Endothelial Keratoplasty in 550 Consecutive Cases Over 
the Last 5 Years
Presenting Author: Samar K Basak MD DNB MBBS*
Purpose: To evaluate the periodical endothelial cell loss (ECL) in Descemet-stripping endo-
thelial keratoplasty (DSEK) in a large series. Methods: Prospective, noncomparative inter-
ventional case series. 550 consecutive cases of DSEK performed by single surgeon by for-
ceps insertion technique were evaluated. Preoperative donor cell density was > 2400 cells/
mm2 in all cases. ECL was analyzed after 3 months and then yearly for 5 years. Results: 
After 3 months, median ECL was 17.9%. It was 37.4% (416 eyes), 40.2% (303), 44.6% (237), 
48.8% (107), and 55.2% (69) after 1 year and 2, 3, 4, and 5 years, respectively. Secondary 
graft failure occurred in 38 eyes (6.2%) during this period. Conclusion: Maximum endothe-
lial cell loss following DSEK happens at the first year, and then it is gradual over the years.
Scientific Poster 70
In Vitro Antimicrobial Efficacy of Riboflavin/UVA 
Irradiation Combination (365 nm) Against Bacterial, Fungal, 
and Protozoal Isolates
Presenting Author: Pravin Vaddavalli MD
Co-Author(s): Swapna Reddy Motukupally, Alok Sati MS, Prashant Garg MD*
Purpose: To assess the effect of ultraviolet A irradiation with riboflavin against various 
microorganisms in an in vitro model. Methods: Fifty-one isolates comprising MRSA (12), 
multiple drug resistant Pseudomonas aeruginosa (MDR-PA) (22), Nocardia (3), Fusarium 
(3), Aspergillus flavus (3), Curvularia (3), UID (3), and Acanthamoeba (3) were tested. Re-
sults: On exposure to UVA + riboflavin, all MRSA, 15/22 MRD-PA, and all Nocardia isolates 
showed significant inhibition of growth. None of the fungal or Acanthamoeba isolates 
tested showed any inhibition. Conclusion: Combined riboflavin/UVA treatment seems to 
significantly inhibit in vitro growth of bacterial isolates and Nocardia but had no effect on 
fungi or Acanthamoeba.
Scientific Poster 71
Bacterial Killing Rate After Corneal Collagen Crosslinking 
In Vitro
Presenting Author: David Tabibian MD
Co-Author(s): Florence Hoogewoud
Purpose: We investigated the antimicrobial efficacy of corneal crosslinking (CXL) in vitro 
using different treatment modalities. Methods: Solutions containing 0.1% riboflavin and 
106 of either MRSA or Pseudomonas aeruginosa were irradiated using different time and 
power settings, but providing the same total energy (5.4 mJ). Controls without riboflavin 
and with riboflavin but without irradiation were performed. Results: All power settings 
reduced the number of bacteria by 2 log(10) units. No significant differences were detected 
between the 3 protocols. Conclusion: CXL is an efficient bactericidal method in vitro, and 
the antimicrobial efficacy was comparable using the 3 protocols tested, suggesting that 
treatment duration might be reduced considerably in the future.
SESSION TWO
Scientific Poster 290
In Vivo Confocal Microscopy Morphological Comparison 
Between Different Laser-Assisted Lamellar Keratoplasty 
Procedures for Keratoconus
Presenting Author: Romina Fasciani MD
Co-Author(s): Luigi Mosca MD, Leopoldo Spadea MD, Aalice Caristia, Antonio Agresta 
MD, Emilio Balestrazzi MD
Purpose: In vivo confocal microscopy (IVCM) evaluation in patients with keratoconus who 
underwent corneal lamellar ablation for transplantation (CLAT), femtosecond anterior la-
mellar keratoplasty (FALK), and femtosecond deep anterior lamellar keratoplasty (Femto-
DALK). Methods: Thirty eyes underwent CLAT; 18, FALK; and 17, Femto-DALK. A mor-
phological tissues evaluation and a pachymetry study were obtained at 2 and 12 months. 
Results: Reduction of interface thickness and light-scattering intensity was demonstrated. 
Dark striae were inversely proportional to stromal bed thickness and symmetry, and de-
creased in follow-up. Conclusion: Using excimer laser we obtained less scarring reaction 
and inflammation. Interface quality was inversely proportional to compression of residual 
stromal bed. IVCM is useful to investigate morphological results between techniques.
Scientific Poster 291
Refractive and Visual Outcomes in Penetrating 
Keratoplasty vs. Deep Anterior Lamellar Keratoplasty in 
Keratoconus
Presenting Author: Mohammad Javadi MD
Co-Author(s): Sepehr Feizi, Fatemeh Javadi
Purpose: To compare the visual and refractive outcomes after penetrating keratoplasty 
(PK) with those after deep anterior lamellar keratoplasty (DALK) in patients with keratoco-
nus. Methods: In this retrospective study, conventional PK and big-bubble DALK between 
1994 and 2011 were evaluated, and postoperative refractive outcomes were compared. 
Results: 448 eyes received PK, and 241 eyes underwent DALK. Mean follow-up period was 
66.5 ± 47.9 months. Final BCVA was comparable between the study groups (P = .18). Astig-
matism after PK was significantly higher than after DALK (P = .04). However, DALK yielded a 
steeper graft (P = .01). Conclusion: Graft astigmatism is lower after DALK compared to PK; 
however, DALK yielded steeper keratometry and significantly myopic shift compared to PK.
Scientific Poster 292
 h  Penetrating Keratoplasty and/or Descemet-Stripping 
Endothelial Keratoplasty in Children With Congenital 
Hereditary Endothelial Dystrophy: Two Decades of Our 
Experience
Presenting Author: Muralidhar Ramappa MBBS
Co-Author(s): Sunita Chaurasia MD, Pravin Vaddavalli MD, Ashik Mohamed MBBS
Purpose: To determine the functional success of penetrating keratoplasty (PK) and Des-
cemet-stripping endothelial keratoplasty (DSEK) in children with congenital hereditary 
endothelial dystrophy (CHED). Methods: Retrospective case series of 260 eyes of 130 chil-
dren with CHED who underwent PK (246 eyes) and DSEK (14 eyes) between 1989 and 2012. 
Results: Median age at surgery was 8 years (interquartile range [IQR]: 4-14), M:F = 89:41; 
all cases of CHED underwent PK or DSEK. 89.91% had clear graft, with a median follow-up 
of 26 months (IQR: 13-36). Median BCVA improved from 2.00 (IQR: 2.00-3.00) preoperatively 
to 0.90 (IQR: 0.48-2.00) at last follow-up visit (P < .0001). Complications include graft rejec-
tion (18.22%), graft infection (18.3%), graft failure (11.91%), and graft host dehiscence 
(5.91%).  Conclusion: PK/DSEK seems to offer better graft outcomes and visual prognosis 
in children with CHED, even in the presence of nystagmus.
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Scientific Poster 293
Trends in In Vitro Antibiotic Susceptibility for 
Pseudomonas Species Corneal Infection at a Tertiary Eye 
Care Center in South India
Presenting Author: Muralidhar Ramappa MBBS
Co-Author(s): Muralidhar Ramappa MBBS, Prashant Garg MD*, Savitri Sharma MD, 
Harsha BL Rao MD*
Purpose: To report the changing trends in in-vitro susceptibility of Pseudomonas . Meth-
ods: 1618 cases of Ps keratitis between 1991 and 2012. Susceptibility was tested against 
multiple antibiotics by Kirby-Bauer disc diffusion. Results: Ciprofloxacin, gentamicin sus-
ceptibility declined in recent years, OR: 0.90 (95% CI, 0.88-0.93) and 0.96 (95% CI, 0.93-
0.98), respectively, compared to the 1980s and late 1990s. Moxifloxacin OR, 1.55 (95% CI, 
1.38-1.74),ofloxacin OR, 1.12 (95% CI, 1.05-1.19; P < .0001), piperacillin OR, 1.35 (95% CI, 
1.03-1.78; P 0.030), and tobramycin OR, 1.08 (95% CI, 1.00-1.16; P = 0.048), have shown 
increase in their susceptibility. Conclusion: Moxifloxacin, ofloxacin, amikacin, and tobra-
mycin remain a first choice against Ps Piperacillin and ticarcillin reserved for multiresistant 
Ps keratitis. Trends warrant continuous surveillance.
Scientific Poster 294
One-Year Results of Accelerated Corneal Crosslinking 
Procedure Applied to Keratoconus Patients
Presenting Author: Ahmet Demirok MD
Co-Author(s): Haci Ugur Celik, Engin Bilge Ozgurhan BSB, Alper Agca, Burcu Guleryuz 
BSB, Ilker Kadir Cankaya MD, Omer Faruk Yilmaz MD*
Purpose: To evaluate the 1-year results of accelerated corneal crosslinking (CXL) proce-
dure in keratoconus patients. Methods: This prospective study was performed with 50 
of 50 patients (30 M, 20 F, 10 to 40 years). In January 2012, patients received accelerated 
CXL treatment with Avedro KXL (Boston, USA) and were followed up for 12 months. Main 
outcome measures were BCVA, maximum K-values (Kmax), and endothelial cell count. Re-
sults: Preoperative and postoperative 12-month Kmax values were 57.6 ± 6.6 and 56.8 ± 
6.4, BCVAs were 0.49 ± 0.36 (logMAR) and 0.48 ± 0.40, and endothelial cell counts were 
2404.4 ± 12.3 and 2403.5 ± 18.03, respectively. Conclusion: Accelerated CXL appears to 
be a safe procedure in keratoconus patients.
Scientific Poster 295
Outcomes of Accelerated Corneal Collagen Crosslinking 
With Riboflavin Compared to Conventional Collagen 
Crosslinking
Presenting Author: Himanshu P Matalia MBBS
Co-Author(s): Ashwini Ranganath, Sharon D’Souza MBBS, Rohit Shetty MD MBBS
Purpose: To compare safety and effectiveness of accelerated (A-CXL) with those of con-
ventional (CXL) corneal crosslinking. Methods: CXL (n = 42) and A-CXL (n = 40) were stud-
ied for BCVA, simulated keratometry (SimK), corneal stromal haze (Pentacam), and endothe-
lial cell count up to 6 months. Results: BCVA and SimK remained stable in both groups up 
to 6 months. Corneal haze increased at 1 month, with greater haze in CXL, 40.21 (95% CI, 
35.1-45.3), than in ACXL, 39.43 (95%CI, 35.8-43.0). At 6 months, haze returned to preopera-
tive levels in A-CXL but remained higher in CXL. No endothelial cell changes were noted 
in A-CXL. Conclusion: A-CXL appears to be a safe and effective procedure. Postoperative 
corneal haze is less with A-CXL than CXL.
Scientific Poster 296
Comparison of Topographic and Tomographic Metrics 
for the Distinction Between Eyes With Keratoconus and 
Normal Eyes
Presenting Author: Jens Buehren MD*
Co-Author(s): Karl Hempel, Thomas Kohnen MD*
Purpose: To compare the ability of wavefront, keratometric, and pachymetric metrics to 
detect keratoconus (KC). Methods: Twenty-nine eyes with early KC and 97 normal eyes 
were examined with the Pentacam. The area under the receiver operating characteristics 
curve (Az ROC) was computed for Zernike coefficients from the anterior and posterior cor-
neal surface and keratometric, elevation, and pachymetric indices.  Results: Discriminant 
functions from anterior and posterior Zernike coefficients yielded the maximum Az ROC 
(0.998) followed by C3-1 (0.963), and the ARTmax pachymetry metric (0.955). Among eleva-
tion data the discriminant function Df reached an AzROC of 0.944. The highest keratometric 
index was the keratoconus index KI (0.928). Conclusion: The Zernike method yielded ex-
cellent results for the detection of early KC with the Pentacam.
Scientific Poster 297
A Systematic Review of Safety and Efficacy of Epithelium 
Removal and Transepithelial Corneal Collagen 
Crosslinking for Keratoconus
Presenting Author: Zaid Shalchi MBBS
Co-Author(s): Mayank A Nanavaty MD
Purpose: To review the safety and efficacy of epithelium removal (ER) and transepithelial 
(TE) corneal collagen crosslinking (CXL) for keratoconus. Methods: We used Medline to 
identify all ER and TE CXL studies performed on minimum groups of 20 eyes with at least 
12 months follow-up. Results: Thirty-one ER (2049 eyes) and 4 TE (185 eyes) studies were 
included. Unlike the TE groups, all ER studies showed improvement in corrected distance 
visual acuity (CDVA) (P = .01), maximum keratometry (Kmax) (P = .01), and myopic spherical 
equivalent refraction (P = .04). ER studies reported haze, scar formation, and loss of CDVA 
in up to 12.7%, 9.5%, and 18.9%, respectively. Haze occurred in up to 4% of TE patients 
without any other adverse event. Conclusion: ER has greater efficacy than TE CXL for 
treating keratoconus but shows higher adverse events.
Scientific Poster 298
Epithelial Mapping in Partial Topography-Guided Ablation 
Combined With Corneal Crosslinking (Athens Protocol) in 
Keratoconus
Presenting Author: George Asimellis PhD*
Co-Author(s): A John Kanellopoulos MD*
Purpose To assess efficacy, safety, and reproducibility of epithelial mapping (EM) with an-
terior segment OCT (aOCT) after Athens Protocol (AP) for keratoconus (KC). Methods: With 
6-18 months follow-up, we studied the EM with aOCT in 165 untreated KC cases (Group A) 
and 165 treated with AP (Group B). We also studied corrected distance visual acuity, refrac-
tion, keratometry, and topometric indices. Results: Mean thickness, Group A: 55.65 ± 1.22 
µm; Group B: 40.60 ± 1.22 µm. Thickness variability, Group A: ± 9.80 ± 0.41 µm, and Group 
B: ± 5.37 ± 0.40 µm. All differences were statistically different (P < .0002). Conclusion: EM 
with aOCT reveals thinning and less variability following AP for KCN.
Scientific Poster 299
Pulsed Accelerated Crosslinking for Keratoconus: OCT 
Imaging and Medium-term Clinical Results
Presenting Author: Miguel M Rechichi MD
Co-Author(s): Alessandro Meduri MD**
Purpose: To evaluate morphological and clinical effects of epi-off pulsed accelerated cor-
neal collagen crosslinking (PA-CXL) in a small group of patients affected by keratoconus. 
Methods: Twenty eyes of 20 patients underwent PA-CXL. Fellow eye was considered as 
control. Irradiation protocol was 30 Mw/cm2 for all the eyes. Ten eyes had pulsed CXL ratio 
of 2:1 (2 seconds on, 1 off); 10 eyes had 1:1. Follow-up was 6 months. Results: There was 
significant stabilization of keratometry, improvement in BCVA, and high-order aberration. 
No complications were reported. HD-OCT images showed an even corneal stromal hyper-
reflective about 280 micron depth in all eyes. In untreated eyes there was a trend toward 
worsening. Conclusion: Both protocol of PA-CXL appeared to produce corneal morphologi-
cal changes and halt keratoconus progression in the short-term period.
Scientific Poster 300
The Increase in Biomechanical Stiffness in Corneal 
Collagen Crosslinking Is Oxygen Dependent
Presenting Author: Arthur Hammer MD
Co-Author(s): Olivier Richoz MD*, David Tabibian MD, Zisis Gatzioufas MD PHD, Farhad 
Hafezi MD PhD*
Purpose: Recently, corneal collagen crosslinking (CXL) devices have implemented in-
creased UV-A fluence. Oxygen diffusion might become a limiting factor in high-fluence 
treatment. Here, we investigated the potential oxygen-dependency of CXL. Methods: We 
crosslinked 2 groups (n = 16 each) of fresh porcine corneas with a fluence of 9 mW/cm2 for 
10 minutes in two different environments, one containing 21% of oxygen and the other con-
taining less than 1% of oxygen. Results: We observed a statistically significant difference 
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(P = .004) in the increase in biomechanical stiffness measured between the normal oxygen 
environment and the low-oxygen-environment group. Conclusion: The biomechanical ef-
fect of CXL seems to be an oxygen-dependent process, raising concerns about the efficiency 
of high-fluence CXL and probably also about epithelium-on procedures.
Scientific Poster 301
The Influence of Preoperative Examination Data on the 
Outcome of Corneal Collagen Crosslinking
Presenting Author: Riccardo Vinciguerra MD
Co-Author(s): Emanuela Morenghi PHD, Paolo Vinciguerra MD*
Purpose: To evaluate the influence of preoperative curvature and minimum pachymetry 
in the outcome of standard epi-off corneal collagen crosslinking (CXL). Methods: Patients 
evaluated were divided into 3 groups basing on the preop corneal curvature (below 45 D, 
between 45 and 50 D, and more than 50 D) and pachymetry (below 400 µm, between 400 
and 450 µm, and more than 450 µm). Results: This long-term analysis included 400 of 
301 patients. The comparison between curvature subgroups indicated the subgroup > 50 
D as the best responder (P < .05). Comparative analysis based on pachymetry showed a 
better reaction to CXL in the subgroup < 400 µm (P < .05). Conclusion: Outcomes stratified 
by pachymetry and curvature indicated better functional and morphological results in the 
population with a preop pachymetry < 400 µm and a curvature of > 50 D.
Scientific Poster 302
Experimental Study of Iontophoretic Delivery of Riboflavin 
in Corneal Collagen Crosslinking
Presenting Author: Pierre R Fournie MD
Co-Author(s): Myriam Cassagne, Vincent José Soler MD*, Camille Laurent MD**, Anne 
Galinier MD, Stephane D Galiacy PHD, Francois Malecaze MD**
Purpose: To evaluate iontophoretic delivery of riboflavin for corneal collagen crosslinking 
(CXL). Methods: 108 eyes from New Zealand rabbits were investigated using high-perfor-
mance liquid chromatography and second harmonic generation imaging to compare corneal 
riboflavin concentration and stromal modifications after CXL using iontophoretic (I-CXL) vs. 
conventional (C-CXL) delivery of riboflavin. Results: Corneal concentrations of riboflavin 
were 936.2 ± 312.5 ng/ml after iontophoresis and 1708 ± 908.3 ng/ml after conventional 
delivery (P < .05). Collagen fibers were more strongly interlinked, with a higher lamellar 
organization, in the anterior stroma 14 days after I-CXL or C-CXL as compared to controls. 
Conclusion: I-CXL is a promising alternative method for riboflavin delivery.
Scientific Poster 303
An Unusual Pathogen in the Armamentarium of Keratitis: 
Corynebacterium
Presenting Author: Sujata Das MBBS
Co-Author(s): Aalladas Venkat Ssubba Rrao DO MBBS**, Savitri Sharma MD
Purpose: To report the clinical and microbiological profile of corynebacterial keratitis. 
Methods: Retrospective analysis of medical records of 25 patients (June 2009-December 
2012) with significant pure growth of Corynebacterium spp. from corneal scrapings. Re-
sults: The mean age of patients was 47 ± 22 years. Ocular trauma as a predisposing factor 
was found in 8 patients. Surgical intervention was required in 11 patients (44%). In vitro 
susceptibility (Kirby Bauer disc diffusion method) results of Corynebacterium spp. to van-
comycin (86.9%), cefazolin (86.9%), chloramphenicol (56.5%), ofloxacin (77.3%), and gati-
floxacin (60.8%) was variable. Conclusion: Trauma is a major risk factor in corynebacterial 
keratitis. Corynebacteria can cause severe corneal infection requiring surgical intervention.
Scientific Poster 304
Microbial Keratitis
Presenting Author: Daniel Sand MD
Co-Author(s): Rosemary She MD, Hugo Y Hsu MD*
Purpose: To evaluate the spectrum and antibiotic susceptibility panel of infectious keratitis 
at a major tertiary-care referral eye center in Southern California. Methods: Retrospective 
review of infectious keratitis cases from 7/1/08 to 12/31/12. Results: 598 cases were 
identified. 290 cases were cultured. 188 (65%) had a positive yield, and 44 cases (23%) 
were polymicrobial. 246 organisms were identified, of which 45 were unique. Coagulase-
negative staphylococci was the most commonly identified Gram-positive and Pseudomonas 
was the most commonly identified Gram-negative organism. Thirty-four percent of all iso-
lates were resistant to fluoroquinolones, and 11% were resistant to gentamicin. Thirty-
seven percent of Staphylococcus aureus were MRSA. Conclusion: Our series revealed 
that Gram-positive bacteria were the most common pathogen in infectious keratitis, with 
66% of all pathogens being sensitive to fluoroquinolones.
Scientific Poster 305
Evaluation of Ultraviolet A/Riboflavin Antimicrobials and 
Combined Treatment: Effect on Various Ocular Pathogens
Presenting Author: Verinder S Nirankari MD
Co-Author(s): Jagdish Chander MD, Ashok Sharma MD
Purpose: To evaluate effectiveness of ultraviolet A/riboflavin (UVA/R), antimicrobial 
agents (AM), and combined treatment on various ocular pathogens. Methods: Four groups 
of organisms were tested: (1) methicillin-sensitive Staphylococcus aureus (SA), (2) Strepto-
coccus pneumonae (SP), (3) Pseudomonas aeruginosa (PA), and (4) Candida albicans (CA). 
All groups were tested 12 times with UVA/R, AM, or combination treatment. Growth in-
hibition zone (GIZ) was measured. Results: GIZ values showed consistent combination 
therapy to be superior to UVA/R or AB alone in testing against SA, SP, and PA (P < .05) in all 
groups. There was no effect of all treatments against CA. Conclusion: Combined UVA/R / 
antimicrobial treatment was more effective against SA/SP and PA, but all treatments were 
ineffective against CA.
Scientific Poster 306
Biofilm Forming Ability of Bacterial Strains Isolated From 
the Surface of Implanted Boston Type 1 Keratoprosthesis
Presenting Author: Maria S Cortina MD
Co-Author(s): Assraa Hassan Jassim Jaboori, Sonal Gandhi, Sapna Tibrewal, Sarmad H 
Jassim MBChB
Purpose: To determine the biofilm forming capability of bacterial isolates in patients 
with implanted Boston type 1 keratoprosthesis (KPro). Methods: Twenty-four eyes were 
included. Conjunctival and KPro surface cultures were obtained. Isolates were tested for 
biofilm-producing capability with microplate adherence and polymerase chain reaction for 
ica and atle genes. Results: Twenty eyes showed positive growth of coagulase negative 
staphylococci (CNS) sensitive to vancomycin. Nine eyes showed positive growth from the 
KPro surface, and of these, 7 tested positive for biofilm formation. Five out the 7 were on 
vancomycin prophylaxis. Conclusion: Most CNS isolated demonstrated ability to form bio-
film, which may enhance their pathogenic potential and survival ability despite vancomycin 
prophylaxis in patients with implanted KPros.
Scientific Poster 307
 h  Association Between Susceptibility Testing and 
Clinical Outcomes in Fungal Keratitis
Presenting Author: Catherine Q Sun*
Co-Author(s): Lalitha Prajna MD, N Venkatesh Prajna MD**, Jeena MARIA 
Mascarenhas MS, Tiruvengada Krishnan, Rajaraman Revathi MD, Dr Meenakshi 
Ravindran, Anita Raghavan MD FRCS, Kieran Sunanda OBrien, Stephen D McLeod MD, 
Michael E Zegans MD*, Nisha Acharya MD*, Thomas M Lietman MD**
Purpose: To assess the association between minimum inhibitory concentration (MIC) and 
clinical outcomes. Methods: The Mycotic Ulcer Treatment Trial I (MUTT I) was a 323-pa-
tient randomized, double-masked clinical trial comparing topical natamycin and voricon-
azole for the treatment of fungal keratitis. Main outcomes included visual acuity, infiltrate/
scar size, corneal perforation, and time to re-epithelialization. Results: Of the 221 isolates 
with MIC values, Fusarium and Aspergillus species were the most common organisms. 
A higher MIC to natamycin was associated with larger 3-month infiltrate/scar size (0.29 
mm, 95% CI, 0.15-0.43, P < .001) and increased likelihood of perforation (OR 2.41, 95% CI, 
1.46-3.97, P = .001). Conclusion: A higher MIC to natamycin was associated with worse 
outcomes in filamentous fungal keratitis.
Scientific Poster 308
Superior or Inferior: Comparing Donor Graft Site in 
Pterygium Surgery
Presenting Author: Sabita Katoch MBBS MD
Co-Author(s): Debasish Bhattacharya MBBS
Purpose: To compare results of inferotemporal (IT) conjunctival grafts with conventional 
superotemporal (ST) grafts in pterygium surgery. Methods: Group A had 466 cases with ST 
grafts, and Group B had 456 cases with IT grafts done by 2 different surgeons. Follow-up 
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ranged from 4 to 48 months. Results: Recurrence rates were 3.58% in Group A and 3.07% 
in Group B, with comparable cosmesis and no statistical difference in mean surgical time 
between the groups. Conclusion: IT grafts have comparable outcomes to ST grafts. In 
patients where superior conjunctiva is scarred or has to be preserved, they are a viable 
alternative.
Scientific Poster 309
Meibomian Gland Dysfunction in Aqueous-Deficient Dry 
Eyes With Sjögren Syndrome
Presenting Author: Shizuka Koh MD*
Co-Author(s): Reiko Arita MD PhD*, Rika Shirakawa MD, Tohru Sakimoto MD PHD, 
Naoyuki Morishige**, Takashi Suzuki MD PHD, Kohji Nishida MD, Motoko Kawashima 
MD PHD
Purpose: To study meibomian gland (MG) changes in aqueous-deficient dry eyes (ADDEs) 
with Sjögren syndrome (SS). Methods: In 100 ADDEs (63 with SS; 37 with non-SS), non-
contact meibography showed MG dropout of the entire upper/lower lids. Ocular symptoms 
(0-14), lid margin abnormality (0-3), and MG dropout (0-6) were evaluated and scored. Re-
sults: The SS group had significant (P = .002) ocular dryness compared with the non-SS 
group. The non-SS group (2.8 ± 1.4) had significantly (P = .006) higher MG dropout than the 
SS group (2.0 ± 1.7). Ocular symptoms and lid margin abnormality did not differ significantly. 
No reported tendency for severe MG dropout was seen in SS compared with non-SS. Con-
clusion: In ADDE with SS, MG dropout is less than in ADDE with non-SS.
Scientific Poster 310
Observation of Meibomian Gland in Patients With Limbal 
Stem Cell Deficiency Using Noncontact Meibography
Presenting Author: Yoshinori Oie MD PhD*
Co-Author(s): Shizuka Koh MD*, Hisataka Fujimoto MD PHD, Takeshi Soma MD*, 
Motokazu Tsujikawa**, Naoyuki Maeda MD*, Kohji Nishida MD
Purpose: To observe meibomian gland in patients with limbal stem cell deficiency using 
noncontact meibography. Methods: Thirty-six eyes of 22 patients with limbal stem-cell 
deficiency (LSCD group) and 31 eyes of 31 normal cases (control group) were included. 
Grading of meibomian gland morphologic changes (meiboscore) was assessed with non-
contact meibography. The severity of ocular involvement was graded using Sotozono’s 
grading system in LSCD group. Results: Meiboscore in the LSCD group (4.9 ± 1.2) was 
significantly higher than that in the control group (1.7 ± 1.5) (P = .001). Meiboscore was 
positively correlated with the severity of ocular involvement in the LSCD group (r = 0.39, P 
= .019). Conclusion: The severity of LSCD is associated with a decrease in the number of 
functional meibomian glands.
Scientific Poster 311
Incidence of Pyogenic Granuloma Formation Following 
EagleVision Plug1 Insertion
Presenting Author: Joshua H Hou MD
Co-Author(s): Siri Mayakshi Hiremath, Aisha S Traish MD**, Maria S Cortina MD
Purpose: To evaluate the incidence of pyogenic granuloma formation following insertion 
of EagleVision 1-size-fits-all Plug1 punctal plugs. Methods: Retrospective review. Patients 
who underwent punctal occlusion with Plug1 plugs from June 2012 to March 2013 were 
identified and evaluated for subsequent punctal granuloma formation. Associated lot num-
bers were identified, and scanning electron microscopy (SEM) was performed to compare 
plugs from different lots. Results: Punctal granuloma formation was noted in 7.5% of 
identified cases (8/107) following Plug1 insertion. Granulomas occurred more frequently 
with lot #77308 plugs (10.4%). SEM showed no difference between plugs from different 
lots. Conclusion: Lot #77308 plugs, and Plug1 plugs overall, may have a high incidence of 
granuloma formation. Surface roughness on SEM is unlikely the cause.
Scientific Poster 312
Long-term (4 Years) Effects of a Thermal Pulsation System 
Treatment on Meibomian Gland Function and Dry Eye 
Symptoms
Presenting Author: Jack Volker Greiner DO PhD*
Purpose: To determine long-term effects of LipiFlow thermal pulsation system (TPS) treat-
ment on dry eye patients with meibomian gland dysfunction (MGD). Methods: Meibomian 
gland scores (MGS), tear breakup time (TBUT), Ocular Surface Disease Index (OSDI), and 
Standard Patient Evaluation for Eye Dryness (SPEED) questionnaires were measured in 17 
patients at baseline (BL), 1 month, and 1-4 years post-TPS treatment. Results: MGS in-
creased from BL (4.5 ± 3.6) to 1 month (10.8 ± 4.5; P < .001) and at 3 years (17.2 ± 5.4; P < 
.001), persisting unchanged at 4 years. SPEED decreased from BL (13.7 ± 4.3) to 1 month 
(7.4 ± 5.6; P < .001) and at 3 years (10.6 ± 6.8; P < .05), remaining unchanged at 4 years. 
TBUT and OSDI returned to BL values at 1 and 2 years, respectively. Conclusion: A single 
TPS treatment of MGD patients improves MGS and SPEED scores for up to 4 years, surpass-
ing all current MGD treatments.
Scientific Poster 313
 h  Amniotic Membrane Transplantation in Severe Ocular 
Chemical Burns: Does It Work?
Presenting Author: Hamidreza Hasani MD
Co-Author(s): Alireza Baradaran-Rafii MD, Roghiyeh Shamsoddinimotlagh MD
Purpose: To evaluate the effect of amniotic membrane transplantation (AMT) in the man-
agement of acute grade III and IV ocular chemical burns. Methods: Patients randomly re-
ceived conventional medical therapy (15 eyes) vs. combined medical therapy and AMT (15 
eyes). Results: Thirty eyes of 28 patients with a mean age of 25 ± 6.8 years were enrolled. 
Corneal epithelial defect healed within 74.41 ± 48.07 days in the AMT group vs. 99.67 ± 
36.8 days in controls (P = .163). Perilimbal ischemia improved in 76.41 ± 42.8 days in the 
AMT group vs. 89.16 ± 44.6 days in the control group (P = .482). Mean final visual acuity 
was 0.02 logMAR vs. -0.07 logMAR in the AMT and control groups, respectively (P = .6). 
Conclusion: Compared to conventional medical therapy, combined AMT does not improve 
perilimbal ischemia, accelerate corneal epithelialization, decrease corneal vascularization, 
or improve visual acuity.
Scientific Poster 314
Outcome of Autologous Serum Tears With Concurrent Anti-
inflammatory Treatment in Ocular Surface Disease
Presenting Author: Ahmad Kheirkhah MD
Co-Author(s): Andrea C Cruzat MD, Shruti Aggarwal MBBS, Candice Williams, Monique 
Trinidad, Reza Dana MD MSc MPH*, Pedram Hamrah MD*, Bernardo Menelau 
Cavalcanti MD
Purpose: To evaluate effects of anti-inflammatory treatment (AIT) on corneal nerve regen-
eration in cases with ocular surface disease (OSD) using autologous serum tears (AST). 
Methods: OSD patients received AST (6-8 times/day) with none to minimal (≤ 1 time/
day) topical steroids (Group 1, n = 27), or q.i.d. dose followed by a 6-12 weeks taper (Group 
2, n = 28). Sub-basal corneal nerve density was assessed by in vivo confocal microscopy 
retrospectively at baseline and final follow-up (at least 3 months), and compared to 52 age-
matched controls. Results: Patients with OSD had lower corneal nerve density compared 
to controls (P = .01). After AST treatment, corneal nerve density increased by 41% in Group 
2, but by 4% in Group 1 (P = .02). Conclusion: Concurrent AIT may be necessary for suc-
cessful regeneration of corneal nerves after treatment with AST in OSD.
Scientific Poster 315
The Use of Eye-Platelet Rich Plasma in the Treatment of 
Ocular Surface Disorders
Presenting Author: Pilar Casas de Llera MD
Co-Author(s): Jorge L Alio MD PhD*, Alejandra Rodriguez MS, Elias Eskandafi 
PHARMD**
Purpose: The objective of this work is to show the use of blood-derived product known as 
eye platelet-rich plasma (E-PRP) in ophthalmology and outline its current clinical applica-
tions. Methods: 1237 preparations of autologous E-PRP were used to treat patients with 
different ocular surface disorders in different formulations (eyedrops, clot, or fibrin mem-
brane). Results: Patients were suffering from dry eye (65%), ulcers (15%), ocular surface 
syndrome (9%), ocular perforations (4%), and another diagnosis (6%). The results were 
different for each patient, but about 88.3% of the patients improved in different degrees 
after using E-PRP. Conclusion: The use of E-PRP was found to be a safe and effective 
therapeutic tool to enhance epithelial wound healing in ocular surface disorders.
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Scientific Poster 316
Determining the Excimer Laser Ablation Rate in the 
Crosslinked Cornea
Presenting Author: Olivier Richoz MD*
Co-Author(s): Samuel Arba Mosquera*, Thomas Magnago**, Farhad Hafezi MD PhD*
Purpose: Currently, the ablation rate per pulse in a crosslinked cornea is unknown. Meth-
ods: The excimer ablation rate of porcine corneas was analyzed using optical coherence 
pachymetry. Conditions: (1) normal cornea, with 5 consecutive ablations of 50 µm each, 
(2) normal cornea, previously soaked with riboflavin 0.1 %, crosslinked (18 mW/cm2), and 
subjected to 5 consecutive ablations of 50 µm each, (3) normal cornea, previously soaked 
with riboflavin 0.1 %, crosslinked (3 mW/cm2), with 5 consecutive ablations of 50 µm each. 
Results: The following ablation rates were obtained: No CXL, 18 mW/cm2, 3 mW/cm2, 
1X50, 60, 53, 48, 2X50, 56, 44, 39. Conclusion: CXL seems to decrease the ablation rate of 
the cornea, and this decrease seems to be more pronounced in a low-fluence CXL.
Scientific Poster 317
Corneal Hypoesthesia but Normal Sub-basal Nerve 
Densities Following Trigeminal Neuralgia Surgery
Presenting Author: Virinder Kaur Dhillon MBBS MRCOPHTH MRSCED(OPHTH)
Co-Author(s): Mouhamed Ali Al-Aqaba MD, Surajit Basu FRCS(ED) MBBS MD*, 
Harminder S Dua MD MBBS PhD**
Purpose: We aimed to evaluate the effects of ganglionic / preganglionic intraoperative 
damage to the trigeminal nerve (V1) following trigeminal neuralgia surgery by studying 
corneal sensation (CS) and sub-basal nerve density (ND). Methods: Twenty-one patients; 
10 with microvascular decompression surgery (Group 1) and 11 with balloon compression 
(Group 2), were recruited. Postoperative CS was measured using Cochet-Bonnet esthesi-
ometry and ND using in vivo confocal microscopy. Results: Patients in Group 2 (but not 
Group 1) had significantly reduced CS on their operated sides (P = .001) without significant 
difference in ND on both sides (P = .98). Conclusion: This suggests the trigeminal ganglion 
has neurotrophic factors capable of sustaining distal axons. This function is preserved in 
preganglionic and incomplete ganglionic damage.
Scientific Poster 318
Long-term Visual Outcomes of Boston Type 1 
Keratoprosthesis (KPro) Through a Time Series Analysis
Presenting Author: Luca Zatreanu MD
Co-Author(s): James Aquavella MD*
Purpose: To evaluate long-term outcomes on visual acuity (VA) after KPro. Methods: Ret-
rospective chart review of KPros performed at a single institution from December 2003 to 
March 2007. Time series effects on VA of key factors were analyzed through event study 
regression analyses. Results: Seventy-five eyes with mean follow-up of 3.7 years. KPro 
was associated with 0.74 logMAR improvement from baseline VA. Postop glaucoma did 
not deteriorate vision (+0.19 VA), yet patients requiring postop glaucoma surgery did not do 
well (-0.68 VA). KPro removal was associated with decreased VA, yet KPro removal in the 
setting of KPro melt was associated with improved VA. Conclusion: KPro improves vision 
in the long term. Postop complications do not always worsen vision. Additional surgical 
procedures primarily do not improve VA.
Scientific Poster 319
Effect of Glaucoma Tube Position on Corneal Thickness 
and Endothelial Cell Density
Presenting Author: Euna B Koo MD
Co-Author(s): Jing Hou MD PhD, Ying Han MD PhD, Jeremy D Keenan MD MPH, Robert 
L Stamper MD*, Bennie H Jeng MD
Purpose: To investigate changes in corneal thickness and endothelial cell density (ECD) 
after glaucoma tube implantation. Methods: Twenty-eight eyes with superotemporal (ST) 
tubes were evaluated at the University of California, San Francisco, at 45 ± 40.4 months 
postop. ST, central, and inferonasal (IN) ECD and pachymetry were obtained. Angle of the 
tube from the cornea was obtained with anterior segment OCT. Linear regression analyses 
were used to assess the effect of tube position on the cornea. Results: ST ECD was lower 
than central (P = .0001) and IN ECD (P = .003). ST and IN cornea were thicker than central 
cornea (P < .0001). For each degree in angle away from the cornea, there were 21.6 more ST 
cells, though this difference was insignificant (P = .20). Conclusion: Tube shunts cause sig-
nificant local endothelial cell loss. These cells may be better preserved with tubes angled 
further away from the cornea.
Scientific Poster 320
Management of Failed Penetrating Keratoplasty: A New 
OCT-Based Protocol
Presenting Author: Jatin Naresh Ashar MD
Co-Author(s): Anurag Mathur MBBS
Purpose: To evaluate OCT-based protocol for management of failed penetrating kerato-
plasty (PK). Method: Fifty-five failed PKs were subjected to anterior segment OCT. 440 graft 
host junctions (GHJ) were analyzed for anterior /posterior malapposition: gape, step, ledge, 
protrusion hill/ tag, ACD, synechiae, and stromal hyper-reflectivity (SH). Result: Minimal/ 
no SH (18) due to scarring allowed Descemet-stripping endothelial keratoplasty (DSEK), 
cases with SH needed PK. Smooth posterior GHJ (12); larger/same sized PK (5)/DSEK (7); 
anterior malapposition (12); repeat PK, posterior malapposition (36); larger PK (25); smaller 
DSEK (11); > 180 degree synechiae (5); additional glaucoma surgery; lower ACD – glaucoma 
valve placement/ available space for DSEK. Conclusion: OCT-based protocol for failed PK 
improves planning for repeat PK/DSEK.
Scientific Poster 321
Trends in Eye Bank Corneal Tissue Utilization: 1991-2011
Presenting Author: Patricia A Ple-Plakon MD
Co-Author(s): Yan He MD**, Roni M Shtein MD*, Maria A Woodward MD, Shahzad I 
Mian MD*
Purpose: To analyze characteristics of donor corneal tissue distributed by Midwest Eye 
Bank. Methods: Retrospective review of donor records between 1991 and 2011. Cause of 
death, death-to-preservation interval, death-to-surgery interval, endothelial assessment, 
and tissue utilization were analyzed. Results: 115,491 corneas from 60,183 donors were 
evaluated, of which 71,878 (62.84%) were transplanted, with a mean donor age of 55.5 
years. The distribution of tissue increased 2.81 times, with 55.34% of the increase due to 
Descemet-stripping automated endothelial keratoplasty. Endothelial cell counts increased 
from 2331 mm 2 to 2714 mm 2 . The most common causes of donor death were cardio-
vascular disease (38%), cancer (22%), and trauma (9%). Conclusion: Evaluation of the 
data provides valuable information in correlation to corneal transplantation and eye bank 
improvements.
Scientific Poster 322
What Happens to the Corneal Transplant Endothelium After 
Surgery?
Presenting Author: Luiz F Regis-Pacheco MD
Co-Author(s): Perry S Binder MD*
Purpose: To examine transplant donor/host junction to determine endothelial fate. Meth-
ods: Dissecting microscopic and scanning electron microscopy studies were performed on 
clear transplant specimens obtained 1 month to 20 years after keratoplasty. Primary kera-
toplasty indications: keratoconus (10), Fuchs endothelial dystrophy (8), bullous keratopathy 
(5), other (5); 11 cases had no clinical data. Results: We performed morphologic analyses in 
12 of 39 eyes. Wounds were of 4 basic shapes. Cells migrated from the center of the donor 
across the wounds toward the host; the cells spread out, enlarged, and were ultimately 
lost in the host. Conclusion: Donor cells migrate from higher to lower density across the 
wounds. Wound configuration, donor and recipient endothelial health, and probable cell-to-
cell contact inhibition are involved.
Scientific Poster 323
Long-term Outcome of Large Keratoplasty “á Chaud” for 
Interface Infection After Descemet-Stripping Automated 
Endothelial Keratoplasty
Presenting Author: Cataldo Russo
Co-Author(s): Silvana A Madi MD, Benedetta Filipovic, Stefano DeAngelis MD, Massimo 
Busin MD*
Purpose: To evaluate the outcome of penetrating keratoplasty (PK) performed for post- 
Descemet-stripping automated endothelial keratoplasty (DSAEK) infection. Methods: Vi-
sual outcome and complications were evaluated after a 9-mm PK performed “á chaud” in 
6 post-DSAEK eyes with interface infection resistant to antibiotics; recipient cornea and 
DSAEK graft were removed en bloc and submitted for cultural and histologic examination. 
Results: Fungi were identified in 4 cases; bacteria, in 2. With an average follow-up of 29.5 
± 19.9 months, no recurrence of infection was seen; 4 of 6 grafts were clear, with vision ≤ 
20/25. Conclusion: Large PK “á chaud” eliminates post-DSAEK interface infection.
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Scientific Poster 324
Modified Descemet-Stripping Automated Endothelial 
Keratoplasty to Reduce Cataract Formation in Phakic Eyes
Presenting Author: Elena Albe MD
Co-Author(s): Stefano DeAngelis MD, Paolo Santorum MD, Vincenzo Scorcia MD, 
Massimo Busin MD*
Purpose: To evaluate a modified Descemet-stripping automated endothelial keratoplasty 
(DSAEK) performed in phakic eyes, aimed at reducing the incidence of postoperative cata-
ract. Methods: Lens clarity was evaluated up to 4 years in 62 post-DSAEK (graft delivery 
through clear cornea tunnel with Busin glide) phakic eyes assigned to Group 1 (incisions at 
3 and 9 o’clock, n = 33) or Group 2 (incisions at 2 and 10 o’clock, n = 30). Results: Surgically 
induced cataract developed in 7 eyes of Group 1 and no eyes of Group 2 (P < .001). Conclu-
sion: Modifying the incision site eliminates the risk of early cataract in phakic post-DSAEK 
eyes.
Scientific Poster 325
Outcomes of Eye Bank-Prepared Descemet Membrane 
Endothelial Keratoplasty Tissue
Presenting Author: Shahzad I Mian MD*
Co-Author(s): Michael S Titus, Maria A Woodward MD
Purpose: To evaluate initial outcomes of eye bank-prepared tissue for Descemet mem-
brane endothelial keratoplasty (DMEK) at one eye bank. Methods: Twenty-nine donor 
corneas were prepared for DMEK using manual dissection. Endothelial cell density (ECD) 
was evaluated. Successful outcome was defined as an intact 9-mm DM, measurable ECD, 
or slitlamp evaluation of ECD. Results: Overall success rate was 82% increasing to 85.7% 
in the second half of the group (14 eyes). Mean ECD before and after preparation was 2537 
± 384 and 2633 ± 452 cells/mm2, respectively. Donor age, death to processing, and ECD did 
not correlate with successful outcome (Rpb = 0.11, -0.24, 0.09, respectively). Conclusion: 
DMEK tissue can be successfully prepared at an eye bank. A learning curve is associated 
with improvement. Further studies are needed to evaluate predictive factors for success.
Scientific Poster 326
Sulfur Hexafluoride (SF6) in Descemet Membrane 
Endothelial Keratoplasty: A Safe, Effective Method to 
Reduce the Rebubble Rate in the Surgical Learning Curve
Presenting Author: Mark Greiner MD
Co-Author(s): Anna S Kitzmann MD, Matthew S Ward MD, Jordan J Rixen MD, Michael 
D Wagoner MD, Kenneth M Goins MD
Purpose: To report short-term complications after Descemet membrane endothelial kera-
toplasty (DMEK) with intraoperative use of SF6 20% air-gas tamponade. Methods: Retro-
spective review of 13 consecutive eyes with Fuchs dystrophy or posterior polymorphous 
dystrophy that underwent DMEK with the same technique using SF6 20%. Minimum fol-
low-up was 1 month after surgery to ensure bubble dissipation. Incidence of graft edge lift, 
rebubble procedure, pupillary block, IOP ≥ 30 mmHg, and primary graft failure (PGF) were 
tracked. Results: Edge lifts were noted in 3 eyes (23.1%). No eyes required a rebubble 
procedure or had IOP ≥ 30 mmHg. No cases of pupillary block or PGF occurred. Conclusion: 
Use of SF6 20% in DMEK is a safe and effective method to reduce the rebubble rate in the 
surgical learning curve.
Scientific Poster 327
Overview of Ocular Complications in Patients With 
Electrical Burns : An Analysis of 102 Cases Across a 7-Year 
Period
Purpose: Herein, we retrospectively analyzed records of patients with electrical injuries to 
summarize the ophthalmic characteristics and visual symptoms. Methods: We collected 
the medical records of patients; then ophthalmic, systemic, and demographic factors asso-
ciated with electrical burns were identified. Results: There were 53 eyes (29 patients) with 
ophthalmic complication. Corneal epithelial erosion was the most common ocular electrical 
injury and the primary reason for subjective visual symptoms. Electrical burns affecting 
head and neck were significantly related to subjective symptoms of visual disturbances. 
Conclusion: Earlier involvement of ophthalmologists in the case of any patient who has 
suffered a facial burn is advisable. Appropriate management is helpful to prevent complica-
tions and alleviate visual symptoms.
Electronic Health Records
SESSION TWO
Scientific Poster 328
Adapting Electronic Medical Records Tools to Improve 
Retinopathy of Prematurity Tracking Systems and 
Coordination of Care
Presenting Author: Alejandra G de Alba-Campomanes MD*
Co-Author(s): Peter Churgin MD
Purpose: To describe how electronic medical record (EMR) tools can be utilized to create 
an integrated care system for ROP that increases efficiency and minimizes lapses in care. 
Methods: An institution-wide EMR system (EPIC; Madison, Wisc., USA) was implemented 
in 2012. We adapted existing tools and designed new applications to implement a system 
appropriate to the challenges of ROP management. Results: These include (1) automatic 
list generation, (2) “do not change appointment” message, (3) automatic alert generation 
after missed exams, (4) reports, and (5) educational material for parents in discharge docu-
mentation. Conclusion: Non context-specific EMRs may be capable of adapting to prac-
tice-specific challenges. EMRs may be able to improve quality and increase the efficiency 
and safety of ROP screening programs.
Scientific Poster 329
 h  Making Clinical Guidelines Computer Actionable
Presenting Author: Ravi Pandit
Co-Author(s): Michael V Boland MD PhD
Purpose: To evaluate whether the American Academy of Ophthalmology Preferred Prac-
tice Pattern (PPP) for primary angle-closure glaucoma (PACG) can be adapted for use in an 
electronic health record (EHR). Methods: All graded recommendations in the PACG PPP 
were extracted and graded as to whether they could be represented in an EHR. Each recom-
mendation was then mapped to the General Eye Exam (GEE) Clinical Document Architecture 
(CDA) standard. Results: Twenty-nine recommendations were analyzed. Of those, 28 could 
be mapped to the GEE CDA. A total of 77 mappings were required (mean: 2.6 modules, 
range: 1-6). However, 31% of recommendations were vague and would require revision to 
be fully computer- actionable. Conclusion: The PPP can be mapped to the GEE CDA, but 
doing so is complex, and a complete implementation would require that the CDA be written 
with EHRs in mind.
Ethics
SESSION TWO
Scientific Poster 330
Truth-Telling and Non-organic Vision Loss
Presenting Author: George R Wandling MD
Co-Author(s): Lara Wandling MD**, Michael S Lee MD*
Purpose: We sought to examine neuro-ophthalmologists’ perspectives regarding diagno-
sis and the management of non-organic vision loss (NOVL) for adults and children with the 
goal of promoting discussion of the ethical implications for clinical practice. Methods: 500 
neuro-ophthalmologists were surveyed with multiple choice treatment options for clinical 
scenarios of NOVL. Results: Disclosure of a NOVL diagnosis was not favored in adults and 
children without a perceived secondary gain. In contrast, disclosure was favored in adults 
with a perceived secondary gain. Conclusion: Ophthalmologists adapt their disclosure of 
a diagnosis to their patients, which imposes some limits on truth-telling. The best method 
for communicating the diagnosis of NOVL will need to balance ethical considerations with 
therapeutic benefit.Cancel
ed
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General Medical Care
SESSION ONE
Scientific Poster 73
The Impact of a Teleretinal Screening Program on Patient 
Care and Medical Center Resources
Presenting Author: Joel Chasan MD
Co-Author(s): William Richard Delaune PhD, April Y Maa MD, Mary Gerard Lynch MD
Purpose: To evaluate the impact of teleretinal screening on patient care and resources. 
Methods: Clinical charts were reviewed for a 2-year period after patient referral from 
a teleretinal screening program. Results: 1935 patients underwent primary care-based 
diabetic teleretinal screening; 24% of patients were referred for an exam. Reasons for 
referral were diabetic retinopathy (43.2%), nerve (30.8%), lens/media (19.1%), macular 
degeneration (12.9%), and diabetic macular edema (5.6%). Percent agreement was above 
90%; total sensitivity was 73.6%. Diabetic macular edema resulted in the largest resource 
burden (visits and relative value units). Conclusion: Teleretinal screening is accurate and 
sensitive, allowing for timely, sight-saving treatment. Resource utilization ratios may help 
predict resource burden of implementing this technology.
Scientific Poster 74
Emergency Room Ocular Diagnostic Study III
Presenting Author: Daniel Ofori
Co-Author(s): Paul O Phelps MD, Richard M Ahuja MD
Purpose: To assess the pattern and accuracy of ocular disease diagnoses and manage-
ment in the emergency department (ED) in a U.S. Level 1 Trauma Center. Methods: Pro-
spective study of patients presenting to the ED with ocular complaints from 01/2013 to 
04/2013. Demographic, diagnostic, and management data were gathered. Only patients 
referred to the eye clinic and evaluated by an ophthalmologist were included in the study. 
Diagnoses were divided into vision-threatening cases (VTC) and non-VTC. Results: 256 col-
lected, 247 analyzed. Most common diagnosis categories were retina-vitreous, trauma, and 
inflammation / infection. 52% correct ED diagnosis, 43% appropriate ED treatment; 45% 
VTC, and 55% non-VTC. Correct diagnosis was less common in non-VTC (49%) than in VTC 
(53%). Conclusion: This suggests a need for improved ED physician exposure to current 
ophthalmic practice guidelines.
Glaucoma
SESSION ONE
Scientific Poster 76
International Pilot Survey of Childhood Glaucoma
Presenting Author: Elena Bitrian MD
Co-Author(s): Maria Papadopoulos MBBS, Sharon F Freedman MD*, Allen Dale Beck 
MD*, James D Brandt MD*, Peng T Khaw MD PhD, Alana Grajewski MD*
Purpose: To create an international database, the International Pilot Survey of Childhood 
Glaucoma (IPSOCG), to collect information on pediatric glaucoma. Methods: An Internet 
accessed database was designed to collect information on pediatric patients with glau-
coma, preserving confidentiality. Demographics, IOP, visual acuity, medical and surgical 
management, and complications were included. The patients fulfill the Childhood Glau-
coma Research Network (CGRN) definition of glaucoma. Results: This registry allows us 
to determine the types of childhood glaucoma managed at major centers, notice different 
approaches of care, create guidelines, design clinical trials, and improve the delivery of 
care. Conclusion: The IPSOCG is a tool and initiative aimed at improving quality of care 
in childhood glaucoma.
Scientific Poster 77
Pseudoexfoliation Syndrome at a Singapore Eye Clinic
Presenting Author: Jason K Lee MBBS
Co-Author(s): Su Ling Ho MBBch
Purpose: To study the demographics of pseudoexfoliation syndrome (PXF) in a Singapore 
hospital eye outpatient clinic. Methods: Patients aged 40 and above who were seen by 
a single ophthalmologist over a period of 37 months were included in the study. Results: 
Of the 3294 patients, 89 patients (2.7%) were found to have PXF. There was a significant 
association between PXF and race (P < .001), where there was a higher prevalence of PXF 
in Indians and lower prevalence of PXF in Chinese. No significant gender predisposition for 
PXF was noted. More males had pseudoexfoliative glaucoma (PXFG) compared to females 
(P = .001). There was no association between race and PXFG. Conclusion: PXF is not an 
infrequent encounter among elderly Singapore eye clinic patients, being more common in 
Indians and less common among Chinese.
Scientific Poster 78
Distribution of IOP, Central Corneal Thickness, and Vertical 
Cup-to-Disc Ratio in a Healthy Iranian Population: The 
Yazd Eye Study
Presenting Author: Mohammad Pakravan MD
Co-Author(s): Mohammad Javadi MD, Shahin Yazdani MD, Elham Ghahari**
Purpose: To determine the distribution of IOP, central corneal thickness (CCT), and vertical 
cup-to-disc ratio (VCDR) in a healthy Iranian population. Methods: In this cross-sectional 
epidemiologic study, eligible adults aged 40 to 80 years were selected using cluster random 
sampling. Results: 2262 eyes from 1159 subjects were evaluated. Mean values for IOP, 
CCT, and VCDR were 14.2 ± 2.5 mmHg, 543 ± 35 µm and 0.32 ± 0.14, respectively. Multiple 
regression analysis showed a significant correlation between IOP and age, CCT, diabetes 
mellitus, spherical equivalent refractive error, and smoking. Conclusion: The distribution 
of IOP, CCT, and VCDR in this Iranian population was different from most other studies.
Scientific Poster 79
Prevalence and Associated Factors of Glaucoma in Rural 
Central India: The Central India Eye and Medical Study
Presenting Author: Jost B Jonas MD*
Co-Author(s): Arshia Matin MD**, Krishna Bhojwani MD**, Maithili Ved Kulkarni 
DOMS, Anshu Khare DOMS MD**, Shubhra Agarwal MBBS*, Prabhat Nangia MBBS*, 
Karishma BHate MBBS*, Purna Nangia MBBS*, Songhomitra Panda-Jonas MD, Ajit 
Sinha MD**, Vinay Nangia FRCOPHTH FRCS MBBS*
Purpose: To assess glaucoma prevalence in rural Central India. Methods: The population-
based Central India Eye and Medical Study included 4711 subjects (aged 30+ years). Re-
sults: Glaucoma was detected in 122 subjects (2.67%). In multivariate analysis, glaucoma 
was (P < .05) associated with older age, lower body mass index, lower blood hemoglobin 
concentration, higher IOP, disc hemorrhages, myopic retinopathy, lower education level, 
longer axial length, smaller retinal nerve fiber layer cross section area, higher vertical cup/
disc ratios, and narrower anterior chamber angle. Ratio of open-angle glaucoma to angle-
closure glaucoma was 7.7:1. Conclusion: Glaucoma prevalence in remote rural Central 
India is comparable to that in other regions. The described risk factors may be of clinical 
interest.
Scientific Poster 80
Pseudoexfoliation: Normative Data and Associations —
The Central India Eye and Medical Study
Presenting Author: Jost B Jonas MD*
Co-Author(s): Arshia Matin MD**, Krishna Bhojwani MD**, Anshu Khare DOMS MD**, 
Shubhra Agarwal MBBS*, Karishma BHate MBBS*, Ajit Sinha MD**, Vinay Nangia 
FRCOPHTH FRCS MBBS*
Purpose: To assess the prevalence of pseudoexfoliation (PEX) in rural Central India. Meth-
ods: The population-based study included 4711 individuals. Results: PEX was detected in 
69 subjects (1.49 ± 0.18%). In multivariate analysis, PEX was (P < .05) associated with older 
age, lower body mass index, and higher diastolic blood pressure. PEX was not associated 
with retinal nerve fiber layer cross section area (P = .76), presence of open-angle glaucoma 
(P = .15), or any other major disorder. Conclusion: In rural Central India, PEX prevalence 
(1.49 ± 0.18%) was associated with age, body mass index, and blood pressure but not with 
refractive error, any ocular biometric parameter, nuclear cataract, early AMD and retinal 
vein occlusion, diabetes mellitus, smoking, or dyslipidemia.
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Scientific Poster 81
Evaluation of the Age-Related Speed of Anterior Chamber 
Reduction by 3-D Scheimpflug Camera in Japanese 
Normal Subjects
Presenting Author: Yoko Ikeda MD
Co-Author(s): Kazuhiko Mori MD*, Morio Ueno MD*, Haruna Yoshikawa MD, Yuko 
Maruyama MD, Shigeru Kinoshita MD*
Purpose: To evaluate age-related speed of anterior chamber reduction in normal Japanese 
subjects. Methods: We enrolled 1323 normal volunteers with bilateral phakic eyes (853 
females/470 males, mean age: 55.0 ± 14.2 years; range: 20-79 years), and in whom both 
eyes could be examined by 3-D Scheimpflug camera. Each sex was divided into 12 groups 
(5-year age range each), and the respective mean scores of anterior chamber depth (ACD), 
anterior chamber volume (ACV), and anterior chamber angle (ACA) were plotted, and reduc-
tion slopes were calculated. Results: The reduction slope of ACD, ACV, ACA was -0.1 cm/
year, -7.7 mm3/year, -1.1 °/year (males), and -0.1 cm/year , -9.6 mm3/year, -1.3 °/year 
(females), respectively. Conclusion: Age-related speed of anterior chamber reduction was 
faster in females than in males.
Scientific Poster 82
A Hierarchical Cluster Analysis of Progression Pattern in 
Open-Angle Glaucoma Patient With Medical Treatment
Presenting Author: Hyoungwon Bae MD
Co-Author(s): Seungsoo Rho MD, Hyesun Lee, Naeun Lee**, Samin Hong MD PhD, Gong 
Je Seong MD**, Yoo Kyung Song**, Kyung Rim Sung MD PhD, Chan Y Kim MD
Purpose: To classify open-angle glaucoma (OAG) by the pattern of progression and find the 
characteristics of progression by comparing between clusters. Methods: Ninety-five OAG 
patients who have undergone visual field (VF) tests for ≥ 5 years were retrospectively ana-
lyzed. We classified medically treated OAG into subgroups by using a hierarchical cluster 
analysis and compared other parameters between clusters. Results: Two clusters were 
made. Between the 2 clusters, there was no difference in age, gender, IOP, CCT, or axial 
length. However, Cluster 2 included more high-tension glaucoma (HTG) (P = .035) and had a 
greater number of antiglaucoma eyedrops (P = .001) than Cluster 1. Conclusion: OAG was 
divided into fast and slow progression groups. In the fast group, the portion of HTG was 
bigger and the number of antiglaucoma medications was greater than in the slow group.
Scientific Poster 83
Importance of Family Screening in Primary Angle-Closure 
Glaucoma
Presenting Author: Srinivasan Kavitha MD
Co-Author(s): Rengaraj Venkatesh MBBS, Pradeep Y Ramulu MD PhD*, Krishnamurthy 
Palaniswamy
Purpose: To assess and compare risk of angle closure among siblings of individuals with 
open angles (OA), primary angle closure suspects (PACS), and either primary angle closure 
or primary angle-closure glaucoma (PAC/PACG). Methods: We evaluated 304 sibling pairs, 
including 81 with OA, 146 with PACS, and 77 with PAC/PACG. Complete ophthalmic evalu-
ation, including refraction, biometry, applanation tonometry, gonioscopy, and anterior seg-
ment OCT, was done. Gonioscopy was done by masked grader and classified into different 
categories. Results: Angle closure (AC) was prevalent in 3.7% of OA siblings, 35.6% of 
PACS siblings, and 36.4% of PAC/PACG siblings. Conclusion: Siblings of angle closure 
have a greater than 1 in 3 risk of angle closure in at least one eye. The frequency of PAC/
PACG was higher among PAC/PACG siblings.
Scientific Poster 84
Longitudinal Evaluation of Frequency Doubling Technology 
Perimetry for Prediction of Progression in Glaucoma
Presenting Author: Daniel Meira Freitas MD PhD*
Co-Author(s): Andrew Tatham, Renato Lisboa MD, Robert N Weinreb MD*, Tung-Mei 
Kuang MD, Linda Zangwill PhD*, Christopher A Girkin MD*, Jeffrey M Liebmann MD*, 
Felipe A Medeiros MD*
Purpose: To evaluate the ability of longitudinal frequency doubling technology (FDT) to pre-
dict standard automated perimetry (SAP) loss in glaucoma suspects. Methods: 587 eyes 
of 367 glaucoma suspects were included. Joint longitudinal survival models were used to 
evaluate the ability of rates of FDT pattern standard deviation (PSD) change to predict re-
peatable SAP loss. Results: Sixty-three eyes developed SAP loss (progressors). Mean rate 
of FDT PSD change in progressors was 0.07 dB/year, vs. 0.02 dB/year in nonprogressors. 
Baseline and slopes of FDT PSD change were predictive of progression, with hazard ratios 
of 1.11 per 0.1 dB higher and 4.40 per 0.1 dB/year faster, respectively. Longitudinal model 
performed significantly better than baseline model. Conclusion: Rates of FDT change 
were highly predictive of SAP loss in glaucoma suspects.
Scientific Poster 85
Association Between Visual Field Defects and Quality of 
Life in a Population-Based Survey of the United States
Presenting Author: Mary Qiu
Co-Author(s): Sophia Ying Wang MD, Kuldev Singh MD MPH*, Shan C Lin MD*
Purpose: To examine the association between visual field defects (VFD) and quality of life. 
Methods: Cross-sectional study of 5186 subjects from the 2005-2008 National Health and 
Nutrition Examination Survey, age ≥ 40 years, who underwent frequency doubling technol-
ogy perimetry and self-reported visual and physical functional difficulty. Results: The mul-
tivariate analysis adjusting for confounders revealed an association between severe VFD 
and disability with reading newsprint (OR 3.53), close work (3.44), descending stairs (6.56), 
seeing to the side (7.71), finding things on crowded shelves (5.54), daytime driving (12.40), 
activities of daily living (ADLs) (2.45), instrumental ADLs (2.50), and social activities (3.29), 
all P-values < .05. Conclusion: VFD severity is associated with subjectively impaired visual 
and physical function.
Scientific Poster 86
Laser Scanning Tomography in a Population-Based Cohort 
Study: Principal Components and Associations
Presenting Author: Anthony P Khawaja MBBS
Co-Author(s): Michelle Chan, David C Broadway MD*, Shabina Hayat MS, Jennifer 
Lai Yee Yip MBBS MRCOPHTH PhD, Robert N Luben, David F Garway-Heath MD 
FRCOphth*, Kay-Tee Khaw*, Paul J Foster FRCS*
Purpose: To identify principal components (PCs) of and associations with Heidelberg Retina 
Tomograph (HRT) measures in a large population-based cohort. Methods: HRT2 measure-
ments were taken from 6430 subjects aged 48-90 years. Statistical analysis comprised PC 
analysis and multivariable linear regression. Results: Three PCs were identified and named 
Cup, Contour, and Rim, based on their correlated measures. Female sex, higher education 
level, and shorter axial length were associated with greater Contour (all P < .001), while 
lower body mass index and higher IOP were associated with greater Cup (both P < .001) and 
smaller Rim (both P < .001). Conclusion: HRT measures were largely explained by 3 PCs. 
Cup and Rim had different associations than Contour, suggesting distinct determinants.
Scientific Poster 87
In Vivo Imaging of Lamina Cribrosa Sheet by Novel High-
resolution, Broad-wavelength Laser OCT
Presenting Author: Takuhei Shoji MD
Co-Author(s): Shin Yoneya MD PhD, Motoyoshi Baba MS PhD, Hiroto Kuroda PhD
Purpose: To visualize and assess the structure of the lamina cribrosa (LC) using novel high-
sensitive, high-resolution OCT. Methods: This prototype OCT system was used on a 200-
nm bandwidth laser light source. A total of 300 optic nerve head B-scans were obtained by 
10-µm steps, and 3-D images were rendered from these image sequences. Results: Forty 
eyes of 21 patients were enrolled. Visual field mean deviation was -10.0 ± 9.5 dB. The 3-D 
images could provide multislice enface images of LC. The laminar pore size and location 
were changed, and the laminar pore shape was deformed within the LC layer. Each laminar 
sheet structure was identified in 36 eyes (90%). Conclusion: These 3-D constructed im-
ages were able to visualize each laminar sheet and detailed laminar pores within the LC.
Scientific Poster 88
Artifacts in Retinal Nerve Fiber Layer Thickness 
Measurement Using Spectral Domain OCT
Presenting Author: Ruojin Ren MD
Co-Author(s): Sung Chul Park MD, Tsung-Yu Ho MD, Yiyi Liu, Jeffrey M Liebmann MD*, 
Robert Ritch MD FACS*
Purpose: To determine the types of spectral domain OCT (SD-OCT) retinal nerve fiber layer 
(RNFL) thickness measurement artifacts. Methods: RNFL scan data (raw RNFL images, 
RNFL segmentation images, and RNFL thickness profiles) were reviewed for artifacts in 436 
eyes (218 glaucoma patients). Results: RNFL thickness was falsely overestimated in eyes 
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with retinoschisis / subretinal fluid (7 eyes), vitreous traction (16 eyes), epiretinal mem-
brane (14 eyes), or thick posterior hyaloid membrane (1 eye) and underestimated when the 
scan circle intersected beta-zone parapapillary atrophy (15 eyes). Scan circle misplacement 
(13 eyes), cut-off scans (7 eyes), upside-down scans (2 eyes), and poor-quality scans (43 
eyes) also caused erroneous RNFL thickness results. Conclusion: Raw RNFL data should 
routinely be analyzed to detect and correct for artifacts.
Scientific Poster 89
Regression Analysis of OCT Disc Variables for Glaucoma 
Diagnosis
Presenting Author: Grace Marie Richter MD MPH
Co-Author(s): Brian A Francis MD*, Vikas Chopra MD*, David S Greenfield MD*, Rohit 
Varma MD MPH*, Joel S Schuman MD*, David Huang MD PhD*
Purpose: To improve glaucoma diagnosis with Fourier-domain OCT (FD-OCT). Methods: 
Normal and perimetric glaucoma (PG) subjects from the Advanced Imaging for Glaucoma 
Study were randomly selected and age-, sex-, and ethnicity-matched. RTVue FD-OCT was 
used. Multiple logistic regression (MLR) determined the combination of axial length (AL) 
and optic disc size, rim, and cup variables that optimized diagnostic accuracy. Results: 180 
normal and 180 PG eyes were analyzed. The best single disc variable was vertical cup/disc 
ratio (V-CDR) with an area under the curve (AUC) of 0.874. The MLR index combining V-CDR 
and AL had an AUC of 0.881 (P = .05). Conclusion: V-CDR was the best diagnostic variable 
for glaucoma, and AL adjustment further improved diagnostic accuracy.
Scientific Poster 90
Long-term Effectiveness and Complications of Laser 
Peripheral Iridotomy in Acute Primary Angle Closure
Presenting Author: Sonya B Shah MD
Co-Author(s): Alicia Menezes MD, Victor Cvintal MD, Bruno M De Faria MD, L Jay Katz 
MD*
Purpose: To evaluate long-term outcomes of laser peripheral iridotomy (LPI) after primary 
angle closure (APAC) attack. Methods: Retrospective chart review. Sixty-seven patients 
presented with APAC; those with less than 6 months’ follow-up were excluded. Results: 
Twenty-two patients and 24 eyes were included: 15 female and 7 male, 10 (46%) were 
white. All were phakic. Mean follow-up was 44 months. Initial mean visual acuity (VA) was 
1.3 (logMAR), mean IOP was 46.6 mmHg. VA at last follow-up was 0.72 (P < .001), and IOP 
was 14.9 (P < .001). Mean deviation was -11.05 dB. Ten eyes (41.7%) needed glaucoma 
medication, 7 (29.1%) required cataract surgery, and 5 required trabeculectomy (20.8%). 
None developed retinal tear or glare. Conclusion: Although LPI is a safe treatment for 
APAC, many eyes require further surgery and have long-term sequelae.
Scientific Poster 91
Ultralow Fluence Laser Iridotomy With Pattern Scan Laser: 
An Efficacy and Safety Study
Presenting Author: Orlando Chan FRCS(ED) MBBS
Co-Author(s): Jeffrey C Chan MBCHB, NgaKwan Bonnie Choy MBBS MRSCED(OPHTH), 
Kenneth K W Li MBCHB
Purpose: To assess the efficacy and safety of ultralow fluence laser peripheral iridotomy 
(LPI). Methods: Twenty-two cases of primary angle closure suspects were recruited. All 
had ultralow fluence LPI using pattern scan laser followed by Nd:YAG laser. All cases were 
followed up for 6 months. Results: No cases had IOP spike at 1-hour following laser (post 
mean 12.6 ± 2.9 mmHg vs. baseline mean 15.6 ± 2.3 mmHg). Only 2 eyes had IOP increase 
of 0.5 mmHg on Day 1. There were no complications during or after the procedure. There 
was no significant corneal endothelial cell loss at 6 months (baseline: 2359 ± 298 vs. 6 
months: 2269 ± 455, P = .47). Conclusion: Ultralow fluence LPI has a very promising safety 
profile when compared with traditional sequential laser.
Scientific Poster 92
Association Between Single Nucleotide Polymorphisms 
of Metalloproteinase Genes and Latanoprost Response in 
Glaucoma
Presenting Author: Fernando Ussa-Herrera MD*
Co-Author(s): Lourdes Juan PhD, Maria Brion PhD, Angel Carracedo, Ana Sanchez-Jara 
MD, Itziar Fernandez, Soledad Jimenez-Carmona MD, Ramon Juberias MD, Jose Maria 
Martinez de La Casa MD*, Francisco Blazquez-Arauzo MD MS, J Carlos Pastor MD PhD
Purpose: To determine if single nucleotide polymorphisms (SNPs) of genes coding for 
prostaglandin F2a receptor gene (PTGFR) are related to latanoprost response in a Spanish 
population. Methods: Genotyping (Sequenom technology) was performed in 117 primary 
open-angle glaucoma patients with a minimum treatment duration of 4 weeks. Statistical 
multiple comparison tests were performed for the SNPs studied. Results: PTFGR SNPs 
were associated with positive (rs6686438, rs10786455) or negative (rs3753380, rs6672484, 
rs11578155) response to latanoprost. Conclusion: SNPs of the PTGFR and MMP-1 genes 
may determine latanoprost response in a white European Spanish population.
Scientific Poster 93
Effects of Benzalkonium Chloride-Preserved and SofZia-
Preserved Topical Prostaglandin Analogues on the Human 
Ocular Surface
Presenting Author: Yoshiaki Kiuchi MD*
Co-Author(s): Masaki Tanito*, Naoki Komatsu MD PhD, Tomoko Naito, Shiro Mizoue*, 
Tetsuya Baba MD
Purpose: To evaluate toxicity profiles of tafluprost with 0.001% benzalkonium chloride 
(BAK) and travoprost preserved with sofZia on the anterior segment of glaucomatous eyes. 
Methods: A crossover randomized multicenter prospective study was conducted in 170 
subjects, and evaluation was made on the IOP-lowering power, tear breakup time (TBUT), 
and grade levels of superficial punctual keratopathy (SPK) and conjunctival hyperemia. Re-
sults: Both of the ophthalmic solutions showed similar IOP-lowering effects, TBUT, and 
conjunctival hyperemia grade levels. BAK-preserved tafluprost demonstrated the SPK grade 
lower than sofZia-preserved travoprost. Conclusion: A BAK-preserved prostaglandin ana-
logue is not always harmful to the human ocular surface.
Scientific Poster 94
 h  Evaluation of a 60-Day Travoprost Punctum Plug for IOP 
Reduction
Presenting Author: Robert J Noecker MD*
Co-Author(s): Pierre Wassermann FRCOPHTH MBCHB, Malcolm James Carey
Purpose: To evaluate a novel sustained-release travoprost punctum plug (TP) for IOP reduc-
tion over 60 days in ocular hypertensive or glaucoma patients. Methods: Twenty patients 
(36 eyes) at 2 sites in South Africa were treated with TP (1 per eye) in either the superior 
or inferior puncta and prospectively followed over 60 days. Results: The mean IOP reduc-
tion at 60 days from a baseline average at 8 AM of 28.7 mmHg was 23.5% or 6.7 mmHg. 
Overall, the TP was easy to insert and well tolerated by patients. Conclusion: The TP 
provided therapeutic benefit for the targeted duration of 60 days. The TP shows promise as 
an alternative to topical drops, with the potential of overcoming noncompliance.
Scientific Poster 95
Ocular Hypotensive Effect of ONO-9054, a Novel FP/EP3 
Dual Receptor Agonist: Fourteen-Day Study in Subjects 
With Ocular Hypertension or Open-Angle Glaucoma
Presenting Author: Janet B Serle MD*
Co-Author(s): Cheryl l Rowe-Rendleman PhD*, Takafumi Ouchi**, Andrew Wood PhD*
Purpose: To evaluate IOP lowering after multiple doses of ONO-9054 in subjects with el-
evated IOP. Methods: A single-center, randomized, double-masked, dose escalation study 
of 3, 10, 20, or 30 µg/mL ONO-9054 in 48 subjects. Subjects received 1 drop of either 
placebo or 3, 10, 20, or 30 µg/mL ONO-9054 on Day 1 and Days 5-18 O.U. with follow-up on 
Day 25. Goldmann tonometry was performed at 0800, 1000, 1200, and 1600 h. Results: On 
Day 1, at 9 hours post dose, IOP reduction ranged from 5% to 25% for the 3-30 µg/mL dose 
cohorts and was proportionate with dose. On Day 18 the percentage change from baseline 
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ranged from 15% to 30% for the 3-30 µg/mL cohorts. After withdrawal of the drug on Day 
19, IOP remained below baseline for 33 hours for all but the 3-µg/mL dose cohort. Conclu-
sion: ONO-9054 reduces IOP after single and multiple dosing.
Scientific Poster 96
A New Implant for Schlemm Canal Surgery
Presenting Author: Matthias Christian Grieshaber MD*
Co-Author(s): Robert Stegmann MD**, Hans R Grieshaber*
Purpose: To assess the safety and efficacy of a new implant for Schlemm canal surgery 
in white patients with primary open-angle glaucoma (POAG). Methods: Schlemm canal 
surgery with the implantation of the Stegmann Canal Expander (Ophthalmos GmbH) in 22 
patients. Results: IOP dropped from 27.1 ± 5.3 mmHg preoperatively to 12.5 ± 1.5 mmHg 
at 1 month, and 13.1 ± 1.6 mmHg at 9 months (P < .001). Success rate of an IOP ≤ 21 mmHg 
was 95.5% (95% CI, 0.44-0.87), and ≤ 16 mmHg 90.9% (95% CI, 0.06-0.80) at 6 months. 
Complications were microhyphema (n = 2), peripheral Descemet membrane detachment (n 
= 2), and transient elevated IOP (n = 1). Conclusion: Implantation of the Stegmann Canal 
Expander was safe and effective in lowering IOP.
Scientific Poster 97
Outcome of Viscodilation and Tensioning of the Schlemm 
Canal for Uveitic Glaucoma
Presenting Author: Evan Kalin-Hajdu MD
Co-Author(s): Karim Hammamji MD, Sebastien Gagne MD**, Paul J Harasymowycz 
MD*
Purpose: To evaluate the safety and efficacy of canaloplasty in the treatment of uveitic 
glaucoma (UG). Methods: Canaloplasty was performed on 19 UG eyes without prior glau-
coma surgery. Results: Mean follow-up time from canaloplasty was 2.6 ± 1.1 years. Mean 
IOP decreased from 30.4 ± 8.4 mmHg preoperatively to 13.8 ± 5.0 mmHg at last follow-up 
(P < .001). The mean number of ocular hypotensive medications decreased from 3.7 ± 0.8 
preoperatively to 0.4 ± 1.0 at last follow-up (P < .001). At last follow-up, the complete 
success, qualified success, failure, and complete failure rates were 73.7%, 10.5%, 5.3%, 
and 10.5%, respectively. No canaloplasty-related permanent sight-reducing complications 
occurred. Conclusion: This study supports canaloplasty as a durable, safe, and effective 
primary surgical intervention in UG.
Scientific Poster 98
Long-term Outcomes of Trabeculectomy for Normal-
Tension Glaucoma: The Moorfields Experience
Presenting Author: Hari Jayaram BMBCh
Co-Author(s): Deborah Soraya Kamal**
Purpose: To evaluate long-term outcomes of trabeculectomy for normal-tension glaucoma 
(NTG) with contemporary surgical technique.Methods: Prospective and retrospective case 
note review of all 131 NTG cases undergoing trabeculectomy between 2007 and 2012 at 
Moorfields. Results: At 1, 2, 3, and 4 years the mean rate of IOP reduction was 42%, 38%, 
36%, and 40%. No glaucoma progression was seen using progressor visual field and HRT 
analyses in 90% of patients up to 4 years. No significant reduction in acuity was observed, 
with an 8.8% cumulative risk of requiring cataract surgery. Complications such as early 
(2%) and late (0.8%) hypotony were significantly lower than suggested in the literature. 
Conclusion: Trabeculectomy based upon the Moorfields Safer Surgery System is associ-
ated with safer and more successful long-term outcomes in NTG patients than the current 
available evidence suggests.
Scientific Poster 99
Surgical Outcome of Infantile Glaucoma Presented With 
Acute Corneal Hydrops
Presenting Author: Anil K Mandal MD
Purpose: To determine the long-term outcomes of surgery in infantile glaucoma presenting 
with acute hydrops. Methods: Retrospective analysis of 19 children (24 eyes) who under-
went combined trabeculotomy-trabeculectomy (CTT) between 1990 and 2010. Results: The 
mean IOP was reduced from 27.05 ± 5.27 to 11.17 ± 3.43 mmHg (P < .0001). Postoperatively, 
1 patient needed antiglaucoma medication and 1 underwent repeat trabeculectomy. All 
other patients (17/19) were controlled without medications. The mean follow-up was 40.03 
± 51.39 months. Postoperatively, all eyes had clear cornea with Haab striae. There were no 
sight-threatening complications. Conclusion: Primary CTT is safe and effective for infan-
tile glaucoma presenting with acute hydrops.
Scientific Poster 100
Outcome of Primary Trabeculectomy With Adjunctive 
Bevacizumab vs. 5-Fluorouracil
Presenting Author: Tomasz Zarnowski MD
Co-Author(s): Ewa Kosior-Jarecka
Purpose: To compare the effect of bevacizumab and 5-fluorouracil (5-FU) on the efficacy 
and safety of trabeculectomy. Methods: In Group 1 trabeculectomy with adjunctive 5-FU 
was performed. In Group 2 trabeculectomy enhanced by subconjunctival bevacizumab ap-
plication was done. Results: Mean IOP before 5-FU-augmented trabeculectomy was 28.0 
± 8.0 mmHg, and before bevacizumab-augmented trabeculectomy mean IOP was 27.8 ± 9.5 
mmHg (P = .96). After 36 months, mean IOP in the 5-FU group valued 13.8 ± 3.4 mmHg and 
in the bevacizumab group, 15.3 ± 3.0 mmHg (P = .2). No differences were noted with respect 
to corneal endothelial density, visual field indices, or postoperative complications. Conclu-
sion: Results at 36 months comparing the outcome of bevacizumab and 5-FU-augmented 
trabeculectomy did not show any significant difference. 
Scientific Poster 101
A Multicenter Retrospective Study on Gamma-Irradiated 
Sterile Cornea for Glaucoma Drainage Device Surgery
Presenting Author: Qing Pan MD
Co-Author(s): Rubamalar Gunatheesan MBA MBBS, Frank Cotter MD, Gail F Schwartz 
MD*, David L Cute DO, Henry D Jampel MD MHS*, Yassine J Daoud MD*, Pradeep Y 
Ramulu MD PhD*, Walter J Stark MD*, Walter J Stark MD*
Purpose: To evaluate the safety and efficacy of a new gamma-irradiated sterile cornea 
(GISC) as a graft in glaucoma drainage device (GDD) surgery. Methods: A multicenter ret-
rospective study of 319 eyes (295 patients) between April 2009 and October 2012 was con-
ducted. The primary outcome was graft-related tube erosion / exposure (GRTE). Results: 
The mean follow-up was 15.8 ± 10.0 (SD) months. Eight out of 319 eyes (2.5%) experienced 
GRTE, with a median time of 13.3 ± 7.2 (SD) months after surgery. All eyes tolerated the 
GISC graft well, with no clinical evidence of graft-related infection and inflammation. Con-
clusion: GISC appears to be an effective and safe alternative in GDD surgery. It offers ease 
of availability and sterility advantages, as well as improved cosmesis because of its clarity.
Scientific Poster 102
 h  Second Aqueous Tube Shunt vs. Endoscopic 
Cyclophotocoagulation after Failed Aqueous Tube Shunt in 
Glaucoma
Presenting Author: Brian A Francis MD*
Co-Author(s): Vikas Chopra MD*, Rohit Varma MD MPH*
Purpose: To compare the efficacy of a second tube shunt to that of endoscopic cyclopho-
tocoagulation (ECP) after failed tube shunt. Methods: Glaucoma patients who underwent 
second tube shunt (Group 1) or ECP (Group 2) due to failure of IOP control were retrospec-
tively analyzed. The primary outcome was reduction of IOP at 1 year. A subanalysis of 
matched pairs (IOP and age) was also performed. Results: Mean IOP in Group 1 (n = 49) 
was reduced from 23.7 ± 8.2 mmHg to 14.8 ± 4.0 at 1 year. Group 2 (n = 25) IOP was reduced 
from 24.0 ± 6.2 to 15.4 ± 3.8 at 1 year. Conclusion: After failed tube shunt, both second 
tube shunt and ECP significantly lowered IOP by a comparable amount.
Scientific Poster 103
 h  Phacoemulsification vs. Peripheral Iridotomy in the 
Management of Chronic Primary Angle Closure: Long-term 
Follow-up
Presenting Author: Arnaldo D Santos MD
Co-Author(s): Joana Patrícia Ferreira, Luís Pinto, Joao Paulo Cunha MHSA MD, Isabel 
Moraes Domingues II**, Jose Pedro R Pires Da Silva MD, Maria P Reina MD
Purpose: To compare the long-term efficacy of phacoemulsification to that of laser periph-
eral iridotomy (LPI) in the management of chronic primary angle closure (CPAC). Methods: 
Thirty eyes of 30 subjects with CPAC were randomized to receive either LPI or phacoemul-
sification. Examinations before and after the procedure included gonioscopy, Goldmann 
applanation tonometry, and anterior chamber evaluation using the Pentacam Scheimpflug 
camera. Results: The mean follow-up time was 31.1 ± 5.0 months. The IOP was signifi-
cantly lower in the phacoemulsification group, along with higher anterior chamber depth, 
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angle, and volume (P < .01). Conclusion: Phacoemulsification appears to be more effec-
tive in lowering IOP and preventing its long-term increase by improving anterior chamber 
morphology in CPAC.
Scientific Poster 104
Comparative Study of Phacotrabeculectomy vs. Small-
Incision Cataract Surgery With Trabeculectomy
Presenting Author: Kalyani Vijaya Kumari Sodimalla MBBS
Co-Author(s): Vidya J Chelerkar MBBS, Manthan Zaverilal Dedhia DOMS MBBS
Purpose: To compare the results of phacotrabeculectomy (phacotrab) and small-incision 
cataract surgery with trabeculectomy (SICS+trab). Methods: Cross-sectional retrospective 
study of 100 patients with primary open-angle glaucoma, primary angle-closure glaucoma, 
and pseudoexfoliation with cataract. Surgical decision was taken on affordability. Post-
operative vision (Snellen), IOP (applanation tonometer), and disc progression (90 D) were 
recorded at 1, 7, 30, 90, 180, and 365 days. Results: Early follow-up visual recovery was 
faster in phacotrab than in SICS+trab (P 0.038). In the later follow-ups, visual recovery was 
good in all patients (P 0.105). Mean IOP in phacotrab (11) and SICS+trab (13) was statisti-
cally not significant (P 0.087). No significant difference in disc progression was noted (P 
-0.615) in either of the groups. Conclusion: SICS with trab is as effective as phacotrab in 
long-term follow-up. So in patients with less affordability, SICS+trab can be a good surgical 
option. 
Scientific Poster 105
Structure and Function in Multifocal Pupillographic 
Objective Perimetry
Presenting Author: Ted Maddess PhD*
Co-Author(s): Allan Yao Hong Chain MBBS, Andrew Charles James PhD*, Maria Kolic*, 
Corinne Francis Carle PhD*
Purpose: To compare correlations between peripapillary retinal nerve fiber layer (RNFL) 
thicknesses and standard automated perimetry (SAP) and multifocal pupillographic objec-
tive perimetry (mfPOP) in glaucoma. Methods: Structure-function correlations from 25 
glaucoma and 25 normal subjects for SAP and fields from 3 mfPOP methods: yellow and 
2 red/green variants testing 44 / regions / eye in the central 60°. Results: The strongest 
correlations were observed in the superior-superotemporal sector in severe glaucoma eyes: 
r = 0.94 for yellow mfPOP r = 0.90 (n = 16, P < .05). Correlations across all test points in 
both SAP and mfPOP were strongest in eyes with severe glaucoma SAP r = 0.56, mfPOP (r 
= 0.55, 0.52, 0.41, all n = 192, P < .05). Scatterplots of mfPOP/RNFL deviations were quite 
linear while SAP/RNFL data saturated. Conclusion: AP and mfPOP and SAP showed simi-
lar structure/function relationships.
Scientific Poster 106
 h  Visual Field Factor Related to Collisions With 
Oncoming Right-Turning Car During the Driving Simulator 
in Advanced Glaucoma Patients
Presenting Author: Shiho Kunimatsu MD
Co-Author(s): Toru Nakazawa MD PhD, Yuki Aoki MD**, Sachiko Udagawa, Shinji 
Ohkubo MD PhD*, Aiko Iwase MD PhD*, Kazuhisa Sugiyama MD PhD, Takeo Fukuchi 
MD, Hiroshi Ono**, Makoto Araie MD*
Purpose: To examine factors related to visual field defects affecting motor vehicle colli-
sions (MVCs) with oncoming right-turning cars. Methods: 104 patients with mean devia-
tion < -12 dB in both eyes (Humphrey Field Analyzer 24-2 SITA-S program; HFA 24-2) used 
a driving simulator (DS; Honda Motor Co.; Tokyo). We compared HFA24-2 and the binocular 
integrated-visual field (IVF) in patients who did or did not have MVCs in 2 scenarios show-
ing oncoming right-turning cars. Results: Patients who had MVCs in both scenarios (80 of 
104) were older (P = .006), with worse visual acuity of the better eye (P < .0001), and lower 
IVF in the lower 10° hemifield (P = .03). Conclusion: Age, visual acuity of the better eye, 
and IVF in lower 10° hemifield were related to MVCs with oncoming right-turning cars in 
advanced glaucoma patients.
SESSION TWO
Scientific Poster 331
Set-fl Regulates Axon Growth and Regeneration of Retinal 
Ganglion Cells In Vivo
Presenting Author: Melina Isabel Morkin MD
Co-Author(s): Ephraim Feliks Trakhtenberg**, Yan Wang PhD**, Stephanie Fernandez**, 
Gregory Michael Mlacker**, Jeffrey L Goldberg MD PhD*
Purpose: To investigate the role of Set-b in axon growth of retinal ganglion cells (RGCs) 
in order to develop a regenerative therapy for glaucoma patients. Methods: Wild-type 
Set-b and its mutant variants were overexpressed in purified RGCs to test their effect in 
vitro. Myristoylated Set-b, which increases the cytoplasmic retention signal, was overex-
pressed after optic nerve crush in vivo. Results: Set-b overexpressed in RGCs localized 
to the nucleus and suppressed axon growth. In contrast, myristoylated Set-b and shRNA 
knockdown of Set-b promoted axon growth. Gene therapy with myristoylated-Set-b pro-
moted axon regeneration in vivo. Conclusion: Set-b inhibits or promotes axon growth in 
RGCs, depending on its subcellular localization and phosphorylation. Manipulation of Set-b 
in vivo provides a strategy to enhance regeneration.
Scientific Poster 332
Five-Year Incidence of Open-Angle Glaucoma in a Health-
Screened Population
Presenting Author: Young Kook Kim MD
Co-Author(s): Jin Wook Jeoung MD, Hyukjin Choi MD PhD, Ko Eun Kim MD, Ki Ho Park 
MD*, Dong Myung Kim MD
Purpose: To investigate the incidence of open-angle glaucoma (OAG) and its associated 
factors in a health-screened Korean population. Methods: The health-screened popula-
tion-based study (2010-2011) included 5076 subjects who were screened in 2005-2006. By 
using fundus photographs and automated perimetry, we determined the 5-year incidence 
of OAG. Results: The 5-year incidence of OAG was 1.49%. Incident OAG was significantly 
associated with older age (OR, 1.05; 95% CI, 1.02-1.09), higher body mass index (OR, 1.16; 
CI, 1.05-1.28), higher education level (OR, 1.65; CI, 1.09-2.19), and higher hematocrit (OR, 
1.36; CI, 1.26-1.82). Conclusion: In a health-screened Korean population, the 5-year inci-
dence of OAG was 1.49%. Age, body mass index, education level, and hematocrit were 
associated with incident OAG.
Scientific Poster 333
Systemic Comorbidities of Pseudoexfoliative Glaucoma in 
the Utah Population
Presenting Author: Steven M Christiansen MD
Co-Author(s): Barbara Marie Wirostko MD*, Karen Curtin PhD**, Gregory S Hageman 
PhD*
Purpose: To identify systemic comorbidities of pseudoexfoliative glaucoma (PEX) using 
the Utah Population Database. Methods: 1059 individuals with PEX were compared with 
118,871 individuals age 40 and over without glaucoma seen at the Moran Eye Center from 
1992 to 2012. Odds ratios (OR) were obtained from unconditional logistic regression mod-
els with adjustment for age, sex, race, BMI, tobacco/alcohol use, and diabetes. Results: 
Individuals with PEX have increased risk (P < .01) of hypertension (OR 1.4), ischemic heart 
disease (1.3), hyperlipidemia (1.4), and rheumatologic and collagen vascular disease (1.3), 
and decreased risk of diabetes (OR 0.81,P = .03) compared to those without glaucoma. 
Conclusion: Similar to non-PEX glaucoma, PEX is associated with a 30%-40% increased 
risk of vascular, collagen-vascular, and rheumatologic comorbidities.
Scientific Poster 334
The Association of Pseudoexfoliation Syndrome With 
Cardiovascular and Cerebrovascular Disease
Presenting Author: Helen Chung MD
Co-Author(s): Sourabh Arora MD*, Karim F Damji MD, Ezekiel Weis MD
Purpose: Meta-analysis of the association between pseudoexfoliation syndrome (PEX) and 
cardiovascular (CVD) and cerebrovascular (CVA) disease. Methods: English PubMed and 
Embase were searched for studies on CVD and/or CVA in PEX and control. Results: Odds 
ratio was 1.46 (1.13-1.89) for 12 CVD studies (P < .01), 2.16 (1.16-4.03) for 5 CVA studies 
(P = .02), and 1.58 (1.31-1.91) for 13 combined vascular events (CVE) studies (P < .0001). In 
CVD and CVE studies, there were no significant differences in patient age (P = .29, 0.13), 
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sex (P = .82, 0.56), and study design (P = .20, 0.16). CVA studies did not report these data. 
Publication bias was not significant for CVD, CVA, or CVE (P = .78, 0.07, 0.13). Conclusion: 
Strong associations exist between PEX and CVD/CVA.
Scientific Poster 335
Effect of Epiretinal Membrane on Retinal Nerve Fiber Layer 
Thickness in Eyes With Glaucoma
Presenting Author: Jong Jin Jung MD
Co-Author(s): Yong Ho Sohn MD, Young A Kwon
Purpose: To evaluate the effect of epiretinal membrane (ERM) on circumpapillary retinal 
nerve fiber layer (RNFL) thickness as determined by spectral domain OCT. Methods: Among 
the patients with open-angle glaucoma in both eyes and ERM in only 1 eye, those who 
underwent RNFL thickness measurement by OCT were enrolled. RNFL thicknesses in global 
area and quadrants were compared between glaucomatous eyes with ERM (G+E group) 
and glaucomatous eyes without ERM (G-only group). Results: Thirty-three patients with 
bilateral glaucoma and unilateral ERM were enrolled. In the inferior quadrant, RNFL of the 
G+E group was thinner than that of the G-only group (P = .044). In the temporal quadrant, 
RNFL of the G+E group was thicker than that of the G-only group (P < .001). Conclusion: 
This finding suggests that ERM may affect circumpapillary RNFL thickness profile in glau-
comatous eyes.
Scientific Poster 336
Proportion of Undetected Narrow Angles or Angle Closure 
in Cataract Surgery Referrals
Presenting Author: Stephanie N Kletke
Co-Author(s): Devesh K Varma MD*, Amandeep Singh Rai MD, Iqbal K Ahmed MD*
Purpose: To identify the proportion of patients referred for cataract surgery consultation 
that had undetected narrow angles (primary angle closure suspect (PACS), primary angle 
closure (PAC), or primary angle-closure glaucoma (PACG). Methods: 976 phakic patients 
referred by eye care providers for assessment and management of cataracts only were 
reviewed. Results: Of the sample population, the proportion of underlying PACS was 9.4%, 
PAC was 0.5%, and PACG was 0.2%. Overall, 10.1% of patients had missed narrow angles 
or angle closure. Conclusion: A significant number of patients referred for cataract surgery 
were found to have undetected narrow angles/angle closure. These results imply that goni-
oscopy may not be adequately performed in this patient population, and possibly in general.
Scientific Poster 337
Anterior Chamber Aqueous Flare, Pseudoexfoliation 
Syndrome, and Glaucoma
Presenting Author: Rim Kahloun MD
Co-Author(s): Bechir Jelliti MD, Salim Ben Yahia MD*, Moncef Khairallah MD
Purpose: To assess anterior chamber aqueous flare (ACAF) in patients with pseudoexfolia-
tion (PEX) syndrome. Methods: 101 patients with bilateral (n = 73) or unilateral (n = 28) PEX 
syndrome and 53 control subjects were examined by laser flare photometry. Results: ACAF 
was significantly higher in the PEX syndrome group in comparison with the control group (P 
= .0001), in patients with unilateral PEX syndrome in comparison with contralateral unaf-
fected eyes (P = .01), and in patients with pseudoexfoliation glaucoma compared to PEX 
syndrome without associated glaucoma (P = .001). Conclusion: A high ACAF value might 
be a predictor for the development of glaucoma in patients with PEX syndrome.
Scientific Poster 338
Prescheduled Appointments as a Strategy for Improving 
Follow-up Rates After Community-Based Glaucoma 
Screening
Presenting Author: Tave van Zyl MD
Co-Author(s): Elaine J Zhou, Zhuo Su, Ryan K Wong MD, Amir Mohsenin MD, Spencer 
W Rogers MD**, James C Tsai MD MBA*, Susan H Forster MD
Purpose: To determine if prescheduled appointments increase follow-up rates after 
community-based glaucoma screening. Methods: We screened individuals over age 40 
and randomized positive screenees to receive either a prescheduled follow-up appointment 
(intervention) or standard counseling (control). Chi-squared analysis was used to determine 
differences in follow-up. Results: While there was no difference in overall follow-up rate 
between intervention subjects (41%, n = 22) and controls (24%, n = 41, P = .17), subjects 
lacking insurance (67% vs. 5%, n = 28, P = .004) or access to car (47% vs. 7%, n = 30, P = 
.03) were significantly more likely to follow-up if provided with appointments. Conclusion: 
Prescheduled appointments improve follow-up rates among screenees lacking access to a 
car and/or health insurance.
Scientific Poster 339
Association Between Oral Contraceptive Use and 
Glaucoma in the United States
Presenting Author: Ye Elaine Wang
Co-Author(s): Diego Tebaldi de Queiroz Barbosa MD, Sophia Ying Wang MD, Shan C Lin 
MD*
Purpose: To investigate the association between oral contraceptives (OCs) use and preva-
lence of glaucoma. Methods: This cross-sectional study included female participants ≥ 
40 years from the 2005-2008 National Health and Nutrition Examination Survey, who com-
pleted vision/reproductive health questionnaire and underwent eye exams. The predictor 
was > 3 years OCs use, and outcome was self-reported glaucoma. Results: After adjusting 
for confounders, those with > 3 years OCs use had odds ratio of 1.94 of having self-reported 
glaucoma (CI = 1.21-3.10). Other factors associated with increased risk of glaucoma in-
cluded older age, African American race, and later age of menarche (all P < .01). Conclu-
sion: Greater than 3 years OCs use was associated with increased risk of glaucoma, further 
supporting the role of circulating estrogen in the pathogenesis of glaucoma.
Scientific Poster 340
Comparison of Factors Associated With Occludable Angle 
Between American Whites and Ethnic Chinese
Presenting Author: Ye Elaine Wang
Co-Author(s): Yingjie Li Jr, Dandan Wang**, Mingguang He MD PhD, Shan C Lin MD*
Purpose: To assess differences in factors associated with occludable angle among whites 
and ethnic Chinese. Method: 120 whites, 116 American Chinese, and 116 mainland Chi-
nese ≥ 40 years old were enrolled. Multivariate logistic regression was performed with 
presence of occludable angle (posterior trabecular meshwork not visible for ≥ 2 quadrants 
on gonioscopy) as the dependent variable, and anterior segment OCT and A-scan measured 
parameters as independent variables. Results: Occludable angle was significantly associ-
ated with lens vault, iris area, and gender (all P < .03) in Chinese, and with lens vault, 
anterior chamber depth, iris thickness, age, and gender (all P < .04) in whites. Conclusion: 
Factors associated with occludable angle differed between whites and Chinese. Lens vault 
and gender were the only 2 common factors shared by both ethnicities.
Scientific Poster 341
Intraocular Hypertension Is a Common and Significant 
Complication in Ocular Graft versus Host Disease
Presenting Author: Francisco Amparo MD*
Co-Author(s): Ujwala Saboo MBBS, Hasanain T Shikari MD*, Reza Dana MD MSc MPH*
Purpose: To evaluate the incidence of ocular hypertension (OHT) in patients diagnosed 
with ocular graft versus host disease (oGVHD). Methods: Retrospective review of IOP in 
patients with oGVHD. Results: We analyzed IOP patterns in 230 patients, with a median 
follow-up of 516 days from onset of oGVHD. A total of 64 patients (28%) developed intra-
ocular hypertension; 27 patients (10%) presented with IOP readings ≥ 24 mmHg, and 10 pa-
tients (4%) developed characteristic diagnostic signs of glaucoma. Length of corticosteroid 
treatment was not statistically associated with incidence of OHT (P = .20). Conclusion: 
Elevated IOP and glaucoma are relatively common significant complications in patients with 
oGVHD.
Scientific Poster 342
Spectral Domain OCT Analysis of Optic Disc Traction in 
Idiopathic Epiretinal Membrane
Presenting Author: Yong-Woo Kim MD
Co-Author(s): Jin Wook Jeoung MD, Hyeong G Yu MD*
Purpose: To investigate whether optic disc traction occurs and affects the visual function 
in idiopathic epiretinal membrane (ERM) patients. Methods: Optic discs of consecutive 
116 eyes with idiopathic ERM and 62 age-matched normal eyes were scanned by Cirrus 
HD-OCT; retinal nerve fiber layer (RNFL) thickness and optic nerve head (ONH) parameters 
were analyzed. Automated Humphrey visual fields (SITA 30-2) were evaluated. Results: 
Optic disc traction occurred in 52 eyes (44.8%) in ERM patients, which associated with 
increased average and temporal RNFL thicknesses, alteration of the rim architecture, and 
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decreased mean deviation values compared to ERM eyes without optic disc traction and 
normal control (P < .05). Conclusion: Optic disc traction occurred in idiopathic ERM pa-
tients and affected their visual function.
Scientific Poster 343
Peripapillary Tilting and Central Visual Field Loss in Early 
Normal-Tension Glaucoma Using OCT
Presenting Author: Shinichi Usui MD PhD
Co-Author(s): Yasushi Ikuno MD, Yukari Jo MD, Tomoko Asai MD, Masahiro Akiba PhD*
Purpose: To evaluate the relationship between the direction of peripapillary tilting and 
paracentral visual function in normal-tension glaucoma (NTG). Methods: We evaluated 
tilting in circle scan OCT images around the disc (tilting degree = ± degree between tilt line 
and horizontal line of the optic disc) and threshold values of 4 paracentral points within 5° 
of SITA30-2 test in 47 NTG eyes with early visual field defect (mean deviation < -6 db) . Re-
sults: The mean tilt was -9.4 ± 47.7° (15 eyes, -7.5°; 12 eyes, -22.5°; 8 eyes, +7.5°; 12 eyes, 
other). Of the -7.5°, -22.5°, +7.5° groups, the +7.5° threshold value was lowest (31.1 ± 1.5a 
vs. 29.7 ± 5.8b vs. 15.3 ± 14.2ab, a, P = .0001, b P = .0006) supratemporally. Conclusion: 
Most NTG eyes had inferotemporal tilting. Early NTG cases with slight supra-temporal tilt-
ing tend to have a paracentral defect supra-temporally.
Scientific Poster 344
Logistic Regression Analysis for Glaucoma Diagnosis 
Using Spectral Domain OCT
Presenting Author: Antonio Ferreras MD PhD*
Co-Author(s): Laura Gil MD, Beatriz Abadia MD PhD, Blanca Ferrandez MD, Mirian Ara 
MHSA, Sofia Otin MD, Ana Belen Pajarin MD PhD
Purpose: To develop and evaluate the diagnostic ability of a linear discriminant function 
(LDF) based on optic disc and retinal nerve fiber layer parameters measured with Cirrus OCT. 
Methods: Sixty-eight healthy controls and 60 patients with glaucoma comprised the teach-
ing set. Another independent sample of 85 normal eyes and 106 glaucomatous eyes was 
used to evaluate the diagnostic accuracy of the LDF. Results: In the validating set, the LDF 
and rim area had the best sensitivity-specificity balance 92.5%-97.6% and 84.0%-91.8%, 
respectively. The LDF had the largest area under the ROC curve (0.985 vs. 0.952; P < .001, 
DeLong method). Conclusion: The LDF increased the diagnostic ability of OCT-provided 
parameters.
Scientific Poster 345
Structure-Function Relationship of the Ganglion Cell-
Inner Plexiform Layer Thickness and the Macular Mean 
Sensitivity in Advanced Glaucoma
Presenting Author: Ko Eun Kim MD
Co-Author(s): Ki Ho Park MD*, Jin Wook Jeoung MD, Seok Hwan Kim MD, Dong Myung 
Kim MD
Purpose: To evaluate the structure-function relationship between the macular mean sen-
sitivity (mMS) and the ganglion cell-inner plexiform layer thickness (GCIPLT) compared to 
macular circumpapillary retinal nerve fiber layer thickness (mcpRNFLT) in advanced glau-
coma using Cirrus OCT. Methods: Eighty-six advanced open-angle glaucoma patients with 
mean deviation ≤ -12 dB were enrolled. The relationships between mMS and thickness 
of GCIPL or mcpRNFL were compared. Results: In advanced glaucoma, the association 
between mMS and GCIPLT were all significant (R2 of ave = 0.193, min = 0.149, suP = .242, 
and inf = 0.187; all P < .05). However, no significant association was found between MS and 
mcpRNFLT (R2 of ave = 0.011, suP = .061, and inf = 0.039; all P > .05). Conclusion: GCIPLT 
can demonstrate the functional damage better than mcpRNFLT in advanced glaucoma.
Scientific Poster 346
Corneal Biomechanical Parameters in Different Types of 
Glaucoma
Presenting Author: Goktug Seymenoglu MD
Co-Author(s): Esin Fatma Baser MD, Gulsum Irey**, Sibel Zorluozturk**
Purpose: To compare the corneal biomechanical parameters in different types of glau-
coma. Methods: Data from 400 patients for ocular hypertension (OHT), primary open-angle 
glaucoma (POAG), primary angle-closure glaucoma (PACG), pseudoexfoliative glaucoma 
(PXG), and normal-tension glaucoma (NTG) were reviewed. Corneal biomechanical param-
eters and central corneal thickness (CCT) were compared between groups. Results: The 
mean corneal resistance factor of the NTG and PXG groups were significantly lower than 
those of the POAG group (P: .001) . The mean corneal hysteresis measurements of NTG and 
PXG groups were significantly lower than those of other groups (P: .001). The mean CCT 
values of NTG and PXG groups were significantly thinner than those of the other groups 
(P: .001). Conclusion: These results may lead clinicians to measure IOP differently than 
actual in PXG, NTG, and OHT.
Scientific Poster 347
Twenty-Four-Hour Effects of IOP-Lowering Medications 
Using Continuous 24-Hour IOP Monitoring and Response to 
the Water Drinking Test
Presenting Author: Kaweh Mansouri MD*
Co-Author(s): Felipe A Medeiros MD*, Ali Tafreshi**, Robert N Weinreb MD*
Purpose: To study circadian IOP effects of glaucoma medications. Methods: Twenty-three 
glaucoma patients underwent 24-hour IOP recording using a contact lens sensor (CLS). Ses-
sion 1 (S1): untreated; S2: randomly assigned to 1 of 4 classes of glaucoma drops; S3: 
with a prostaglandin analog add-on. To evaluate response to water drinking test (WDT), 
linear regression slopes were constructed from pre-WDT IOP measurements to 2 hours af-
ter WDT. Results: Significant positive linear slopes were seen from wake/sitting to sleep/
supine at S1 (15.9 ± 15.0 arbitrary units [a.u.]) and S2 (1.2 ± 28.5 a.u.), but negative slopes at 
S3 (-7.5 ± 31.1 a.u.). Slopes from 30 minutes before WDT to 30 minutes after WDT were 5.0 
± 11.7 (P = .05) at S1, 3.7 ± 5.5 at S2 (P = .008), and 1.7 ± 12.6 at S3 (P = .657). Conclusion: 
A flattening of the IOP increase from wake/sitting to sleep/supine period was observed.
Scientific Poster 348
Power Settings for Selective Laser Trabeculoplasty 
and Argon Laser Trabeculoplasty in the Treatment of 
Open-Angle Glaucomas: A Systematic Review and Meta-
analysis
Presenting Author: Sourabh Arora MD*
Co-Author(s): Karim F Damji MD, Ezekiel Weis MD
Purpose: To study the relationship between treatment protocols for first-time selective 
laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT) in lowering IOP for open-
angle glaucoma (OAG). Methods: Prospective clinical studies involving SLT and/or ALT 
were included if they reported mean IOP reduction at 12 months. Results: There were 
26 eligible studies (1328 cases). The mean power setting reported was 0.79 (0.2-1.7) mJ 
for SLT and 725 (400-1500) mW for ALT. For SLT, there was no difference in 12-month IOP 
reduction based on minimum energy, maximum energy, or degrees treated. ALT led to better 
12-month IOP reduction if used to higher maximum power (P = .046), and with increased 
degrees treated (P = .025). Conclusion: SLT efficacy is not influenced by power settings, or 
180° vs. 360° application. Increased power settings and degrees treated using ALT resulted 
in larger IOP reduction.
Scientific Poster 349
The Diurnal and Nocturnal Effect of Travoprost With SofZia 
on IOP and Ocular Perfusion Pressure
Presenting Author: Leonard K Seibold MD*
Co-Author(s): Malik Y Kahook MD*
Purpose: To assess the 24-hour effect of travoprost with SofZia (TZ) on IOP and ocular 
perfusion pressure (OPP) and to assess durability of effect. Methods: Forty subjects with 
open-angle glaucoma or ocular hypertension underwent 24-hour monitoring sessions at 
baseline, on drug, and 72 hours after last dose. IOP and blood pressure were measured 
every 2 hours in the habitual position. Results: After 4 weeks of TZ therapy, mean IOP was 
significantly lower than baseline throughout the 24-hour cycle. Significant IOP reduction 
persisted 72 hours after last dose at all time points. OPP was increased from baseline 
during the diurnal, but not the nocturnal period. Conclusion: TZ significantly lowers IOP 
throughout the 24-hour cycle, with the effect enduring at least 72 hours. OPP is increased 
during the diurnal period.
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Scientific Poster 350
Phase 3 Study of Fixed Combination Brinzolamide / 
Brimonidine B.I.D. vs. Brinzolamide vs. Brimonidine in 
Open-Angle Glaucoma or Ocular Hypertension
Presenting Author: Tin Aung FRCS PhD*
Co-Author(s): Ivan Goldberg MBBS FRANZCO*
Purpose: To compare fixed combination (FC) brinzolamide 1%/brimonidine 0.2% (Brinz/
Brim) with brinzolamide 1% (Brinz) or brimonidine (Brim 0.2%) in open-angle glaucoma 
(OAG) or ocular hypertension (OHT). Methods: In this randomized double-blind study, pa-
tients (N = 560) received FC BrinzBrim, Brinz, or Brim 1 drop b.i.d. in affected eyes for 6 
months. Primary endpoint was mean IOP change at Month 3. Results: At Month 3, IOP 
was significantly reduced with FC BrinzBrim compared to Brinz or Brim (-7.9 vs. -6.5 vs. 
-6.4 mmHg; P < .0001). FC BrinzBrim b.i.d. showed similar trends at Weeks 2 and 6 and at 
Month 6. Discontinuations due to related adverse events with FC BrinzBrim, Brinz, and Brim 
were 10.4%, 0.5%, and 7.4 %, respectively. Conclusion: FC Brinz/Brim b.i.d. significantly 
lowered IOP compared to Brinz b.i.d. or Brim b.i.d. in patients with OAG and OHT.
Scientific Poster 351
Glaucoma Medication and Tear Film Osmolarity
Presenting Author: Ioannis S Halkiadakis MD**
Co-Author(s): Georgios Kontadakis MD, Stylianos A Kandarakis MD, Artemios 
Kandarakis MD
Purpose: Tear film osmolarity (TFO) evaluation in patients without ocular discomfort symp-
toms, treated with IOP-lowering medication. Methods: We measured TFO in 93 patients 
without subjective discomfort, either treated with preserved eye drops for glaucoma (medi-
cation group, 61 patients) or not treated (32 age-matched controls), and compared groups. 
Correlation of TFO with treatment time, number of medications, and number of instillations 
was assessed in the medication group. Results: No difference was detected between 
groups (medication group: 295.56 ± 12.54 mOsms/L, controls: 294.84 ± 14.73 mOsms/L , 
P = .807). Correlations were not significant. Conclusion: Patients treated with preserved 
IOP-lowering medication with no symptoms of ocular discomfort do not exhibit tear film 
hyperosmolarity.
Scientific Poster 352
Two-Year Clinical Experience After Combined Cataract 
Surgery and Supraciliary Microstent Implantation to Treat 
Glaucoma
Presenting Author: Brian E Flowers MD*
Co-Author(s): William Flynn MD*, Helmut R Hoeh MD*, Marek Rekas MD PhD, 
Pravoslava Ianchuleva MD PhD*, Salvatore Grisanti*, Swaantje Grisanti MD*, Tsontcho 
Ianchulev MD*
Purpose: To evaluate safety of microstent implantation in conjunction with cataract sur-
gery. Methods: The CyPass Micro-Stent was implanted into the supraciliary space through 
the phaco incision of 136 eyes. Results: IOP decreased from 25.5 ± 4.9 mmHg (baseline) 
to 15.8 ± 3.8 mmHg (24 months) in patients with IOP ≥ 21 mmHg at baseline (n = 23) and 
was maintained (16.4 ± 2.7 mmHg to 16.1 ± 3.2 mmHg) in patients with IOP < 21 mmHg at 
baseline (n = 59). Reduction in medication use was 52% and 48%, respectively. Conclu-
sion: Microstent implantation in conjunction with cataract surgery shows sustained IOP 
control for 2 years.
Scientific Poster 353
 h  Phaco-Trabectome vs. Phaco-iStent in Patients With 
Open-Angle Glaucoma
Presenting Author: Khaliq Kurji MD
Co-Author(s): Sourabh Arora MD*, Christopher J Rudnisky MD*, Jaspreet S Rayat MD, 
Michael W Dorey MD, Samer A Abuswider MD, Karim F Damji MD
Purpose: To investigate efficacy and safety of Phaco-Trabectome (PT) vs. Phaco-iStent (Pi) 
for IOP control in open-angle glaucoma (OAG). Methods: Retrospective case-control. Re-
sults: Thirty-six eyes of 30 patients had PT, and 34 eyes of 25 patients had Pi. Baseline IOP 
differed between groups (PT, 20.92 ± 5.07; and Pi, 17.47 ± 4.87; P = .026). At 6 months there 
was no significant change in mean IOP from baseline between groups (PT, -4.94 ± 5.64 vs. 
Pi, -3.85 ± 3.92; P = .39). PT had a significantly greater reduction in glaucoma medication 
use (PT, -0.97 ± 1.22 vs. Pi, -0.32 ± 0.59; P = .005). However, Pi had fewer complications (PT, 
10 vs. Pi, 1; P = .002). Conclusion: At 6 months, PT and Pi had equivalent IOP reduction 
from baseline. Eyes with PT were on fewer medications but had a higher complication rate.
Scientific Poster 354
Evaluation of the New Glaukos iStent With 
Phacoemulsification in Coexistent Open-Angle Glaucoma 
or Ocular Hypertension and Cataract
Presenting Author: Pedro Arriola-Villalobos MD
Co-Author(s): David Diaz-Valle MD PhD*, Cristina Fernandez-Perez PhD, Julian Garcia-
Feijoo MD PhD**, Jose Maria Martinez de La Casa MD*
Purpose: To evaluate Glaukos iStent GTS-400 combined with phacoemulsification in pa-
tients with cataract and open-angle glaucoma (OAG) or ocular hypertension (OHT). Meth-
ods: Prospective, noncomparative, interventional case series study. Twenty subjects with 
mild-moderate OAG or OHT and cataract underwent phacoemulsification along with im-
plantation of two GTS-400. Results: Mean follow-up was 31.2 ± 7.18 months. A significant 
IOP decrease (34.66%, or 9.21 ± 3.58 mmHg; P < .001) from baseline washout IOP and 
14.42% or 3.15 ± 3.9 mmHg (P = .002) from medicated baseline IOP was achieved, with a 
significant decrease in glaucoma medications. No complications of surgery were observed. 
Conclusion: Combined phacoemulsification and GTS-400 seems to be an effective and 
safe procedure to treat OAG or OHT and cataract.
Scientific Poster 355
Outcomes of Surgical Repair of Late Leaking Blebs
Presenting Author: Arpita Basia MBBS MS
Co-Author(s): Anil K Mandal MD
Purpose: To report outcomes of conjunctival procedures for the repair of late leaking blebs 
with hypotony. Methods: Retrospectively reviewed all cases of late leaking or cystic blebs 
with hypotony following surgical repair. Results: Fifty-six eyes of 54 patients had under-
gone surgical repair. IOP pre- and post-bleb repair surgery was 8.8 ± 4.6 and 15.1 ± 8.9 
mmHg in the conjunctival advancement group and 6.5 ± 4.1 and 12.2 ± 4.2 mmHg in the 
conjunctival autograft group (P < .001). Complete success rate was 90% at 6 months in 
both groups. Conclusion: Bleb repair with conjunctival procedures are safe and effective 
procedures.
Scientific Poster 356
Blebitis After ExPRESS Shunt
Presenting Author: Sunita Radhakrishnan MD*
Co-Author(s): Andrew George Iwach MD*, Terri-Diann Pickering MD*, Dmitry Yarovoy 
MD
Purpose: To describe the course and management of blebitis after Ex-Press shunt implan-
tation. Methods: Retrospective chart review, 2007 to 2013. Results: Five patients were 
identified. Median interval between Ex-Press shunt implantation and blebitis was 2.3 years 
(range: 1.4-3.3). Median follow-up was 7 months (range: 1-20). Two patients wore contact 
lenses, 3 had bleb leak along with blebitis. All patients were treated with topical antibiot-
ics; 3 also received oral antibiotics. Blebitis resolved in all cases; 1 patient had a recurrence 
1 year later which resolved with topical, oral, and intravitreal antibiotics. Conclusion: 
Blebitis after Ex-Press shunt implantation can resolve with antibiotic treatment without 
removal of the device.
Scientific Poster 357
Efficacy of the Baerveldt 250-mm2 Compared With the 
Baerveldt 350- mm2 Glaucoma Drainage Implant: Long-
term Results
Presenting Author: Evan J Allan MD
Co-Author(s): Joshua Martin Jones, Kai Ding PhD, Gregory L Skuta MD*, Mahmoud A 
Khaimi MD*
Purpose: To compare results of the Baerveldt 250 mm2 with those of 350 mm2 glaucoma 
drainage implants (GDI). Methods: Retrospective review of 89 consecutive eyes with up 
to 78 months of follow-up. The primary outcome measure was surgical success. Second-
ary outcome measures were visual acuity, IOP, number of medications, and complications. 
Results: There was no difference in surgical survivability (P = .98). No significant differ-
ences were observed in visual acuity, IOP, and number of medications (P = .09, 0.23, and 
0.82). Complication and failure rates were comparable (P = .82 and 0.92). Conclusion: No 
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differences were noted between Baerveldt 250 mm2 and 350 mm2 GDIs in surgical success, 
visual acuity, IOP, number of medications, complications, and failure rate. Size of GDI may 
not be associated with better IOP control.
Scientific Poster 358
Postoperative Course and Midterm Follow-up of FP8 
(Pediatric) Ahmed Glaucoma Valves in Advanced Age
Presenting Author: Adam Kiel Muzychuk MD
Co-Author(s): Jaspreet K Grewal COMT*, Andrew Crichton MD*
Purpose: To describe the safety and efficacy of FP8 (Pediatric) Ahmed valves in patients 
over the age of 85. Methods: Retrospective chart review. Outcome measures include IOP, 
number of glaucoma medications, visual acuity, and complications. Analysis was performed 
with the paired Student t-test. Results: Sixteen females and 3 males were included. Mean 
IOP at Day 1 was 9.5 ± 4.7 mmHg (r = 2-22); Day 2, 10.2 ± 5.2 mmHg (r = 4-22); and 1 week, 
9.2 ± 5.4 mmHg (r = 2-19). Significant decreases (P < .05) were seen in IOP at all visits up 
to 12 months and in medication use at the 3-, 6-, and 9-month visits. One patient suffered 
choroidal detachments and 1 patient required further surgical glaucoma intervention. Con-
clusion: The FP8 Ahmed valve appears to be a viable surgical modality in advanced age.
Scientific Poster 359
Amniotic Membrane Draping Technique for Leaky Cystic 
Blebs
Presenting Author: Pooja Sethi MD
Co-Author(s): Raj N Patel MD, Raquel Goldhardt MD, Ramesh S Ayyala MD FRCS*
Purpose: To describe the successful use of amniotic membrane graft for the repair of leak-
ing cystic blebs following trabeculectomy with mitomycin C. Methods: Nineteen eyes of 
20 patients that had undergone trabeculectomy with MMC and presented with leaky cystic 
blebs were treated with amniotic membrane graft over the leaking area with bleb retention. 
Results: Seventeen out of 20 eyes achieved nonleaking bleb with IOP controlled without 
further intervention. The last follow-up IOP was 11 mmHg. Nineteen eyes maintained or 
improved their visual acuity at last follow-up. No incidences of hypotony maculopathy were 
observed. Conclusion: Our technique of amniotic membrane draping decreases the risk of 
hypotony and its associated complications of maculopathy and endophthalmitis, while suc-
cessfully maintaining bleb function and stabilization of IOP and visual acuity.
Scientific Poster 360
Surgical Outcomes: Canaloplasty vs. Trabeculectomy With 
and Without Combined Phacoemulsification at 12 Months
Presenting Author: Evan Dreskin Schoenberg MD
Co-Author(s): David Zurakowski PhD, Ramesh S Ayyala MD FRCS*
Purpose: To compare outcomes following canaloplasty (canal) or trabeculectomy (trab), 
with or without combined phacoemulsification. Methods: Charts of 75 open-angle glau-
coma patients who underwent canal (48% with phaco) and 84 who underwent trab (49% 
with phaco) with 1 year of follow-up were reviewed. Results: All groups achieved signifi-
cant IOP reduction (P < .001). Trab achieved lower mean IOP than canal (11.9 ± 4.6 vs. 14.2 
± 5.4 mmHg, P < .01) with fewer glaucoma drops (P = .03). Multivariate regression found 
the odds of surgical failure were 5 times higher for canal than for phaco-canal (odds ratio 
5.1, 95% CI, 1.8-25.4, P = .02); the groups were otherwise similar. Conclusion: While both 
surgeries are effective, trab achieves lower IOP. Combined phaco-canal may have greater 
operative success than canal alone.
Scientific Poster 361
 h  In Vivo Visualization, Measurement, and Comparison of 
Novel Anterior Chamber Angle Metrics Using Heidelberg 
Spectralis Spectral Domain OCT vs. Zeiss Cirrus Spectral 
Domain OCT
Presenting Author: Vikas Chopra MD*
Co-Author(s): Xiaojing Pan MD, Alexander Ho, ZhouYuan Zhang MS, Brian A Francis 
MD*, Srinivas R Sadda MD*
Purpose: First-reported comparison of the Spectralis spectral domain OCT (SD-OCT) and 
Cirrus SD-OCT to identify and measure novel anterior chamber angle parameters using 
Schwalbe line (SL). Methods: The inferior angles of 42 normal eyes were imaged twice 
with each SD-OCT under light-meter controlled dark-conditions. Results: SL was identified 
in 100% of images with calculation of 2 new angle metrics, SL-angle opening distance 
(SL-AOD) and SL-trabecular iris surface area (SL-TISA), with excellent agreement in mea-
surements between the 2 SD-OCTs (SL-AOD, R 2 = 0.94, P < .001; and SL-TISA, R2 = 0.91, 
P < .001). Conclusion: Both SD-OCTs provided comparable measurements and permitted 
calculation of novel angle metrics based on location of SL instead of scleral spur, which may 
provide more meaningful clinical measurements for angle grading and screening.
Scientific Poster 362
Clinical Evidence for CNS Control of Visual Field Loss in 
Chronic Glaucoma: The Jigsaw Effect
Presenting Author: Sylvia Groth MD
Co-Author(s): William Eric Sponsel MD*, Matthew Aaron Reilly MS PhD, Nancy 
Satsangi, Stuart J McKinnon MD PhD*
Purpose: To determine whether chronic bilateral visual field degeneration is an indepen-
dent ocular pathologic phenomenon, or if the CNS helps direct the process. Methods: 
Forty-seven patients with bilateral severe glaucoma and reliable Humphrey 30-2 visual 
fields were evaluated. Each O.S. field locus was paired with (a), its directly comitant O.D. 
locus, or (b), a random coisopteric noncomitant O.D. locus (running 10,000 iterations for b). 
Results: Mean 30-2 threshold values were 14.7 dB O.S. and 15.8 dB O.D. (15.3 dB O.U.), ~5 
dB lower than a (20.6 dB; P < .000000001), which was also 0.5 dB greater than a (20.1 dB; 
P = .0002). Actual binocular HVF thresholds showed high correlation with a. Conclusion: 
The CNS appears to control bilateral chronic glaucomatous neurodegeneration to maximize 
the binocular field of vision.
Global Ophthalmology
SESSION ONE
Scientific Poster 107
Screening Eye Examination for School Children in 2 
Subdivisions of South India: Cost Analysis
Presenting Author: Leela V Raju MD
Co-Author(s): Madhavi Ghanta MD DNB**, Vadrevu K Raju MD FRCS FACS
Purpose: In this study, we estimated the cost incurred in training teachers to screen, 
performing the screening, and providing spectacles to needy children in 2 subdivisions in 
southern India. Methods: One teacher per 200 students was trained. Data were collected 
on the number of children screened, referred, examined by a medical team, and provided 
with spectacles. Results: The most affected age group was > 11 years old. Myopia was the 
most common refractive error observed. Screening cost was $0.09 per child, and the most 
cost-effective portion was the initial screening by teachers. Conclusion: Preliminary vision 
screening by teachers is the most cost-effective method to address uncorrected refractive 
errors in children. This kind of collaboration would ensure early identification and examina-
tion and would help ensure spectacle use.
Scientific Poster 108
Pattern of Eye Diseases in 3 Nigerian Rural Communities: 
Results of a Screening Study
Presenting Author: Magdalene N Ajani MBBS
Co-Author(s): Ibrahim Bashir MD, Fredrick Adizua Azogu BMBS, Jane E Ifechukwu 
MBBS, Olumuyiwa Joseph Olupona MBBS
Purpose: The study measured the prevalence of eye diseases and obtained data for appro-
priate interventions. Methods: A cross-sectional survey, over 9 months. Results: Of 2682 
respondents screened, 3.8% were blind and 6.3% visually impaired. Cataract (45.3%), glau-
coma (39.6%), and refractive errors (15.1%) were the leading causes of visual impairment. 
Leading causes of blindness were cataract (65.8%) and glaucoma (34.2%). Conclusion: 
The prevalence of the eye diseases is significant enough to justify regular eye screening 
programs.
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Scientific Poster 109
Clinical Activities of Mobile Eye Hospital in Elimination of 
Preventable Blindness in Armenia
Presenting Author: Roger V Ohanesian MD
Co-Author(s): Asatur N Hovsepyan MD
Purpose: To investigate the volume of surgical activity of the mobile eye hospital (MEH) 
in regard to outcomes and to summarize results to help make decisions for the future. 
Methods: 15,871 patients from 12 regions who had different types of ocular interventions 
through the MEH. All patients had undergone comprehensive ophthalmological examina-
tion, 4524 eyes were treated with lasers, 11347 eyes had surgery. The majority of cases 
were for cataract (9624). Results: On a repeat visit to one region, a special follow-up 
study was carried out in an example region: 94 cases of pure cataract surgeries showed 
85.1% good visual outcome; 8.5% borderline; and only 6.4% poor. Conclusion: The MEH 
outcomes are similar to international standards, showing that the MEH is an effective way 
of providing eye surgeries to patients in far regions.
SESSION TWO
Scientific Poster 363
Uptake of Free, High-quality Cataract Surgery Among 
Bilaterally Blind Patients in Ethiopia
Presenting Author: David S Sanders*
Co-Author(s): Matthew S Oliva MD, Mark Mark Orrs, Alemu Kerie Tesfaw, Sanduk Ruit 
MD**, Geoffrey C Tabin MD
Purpose: To determine factors associated with uptake of free cataract surgery in bilater-
ally blind patients. Methods: A prospective cohort study design was employed in northern 
Ethiopia. Free transport and surgery were offered to all patients (N = 535), and uptake 
of cataract surgery was documented 1 month after an initial vision screening.  Results: 
Decreased cataract surgery uptake was associated with female gender (OR = .41; 95% CI, 
0.259-0.662; P < .001), and increasing age (OR = .96; 95% CI, 0.937-0.983; P = .001). Severity 
of blindness (3/60 - 1/60 vs. < 1/60) was not associated with a difference in uptake (P = .9). 
Conclusions: Female gender and increasing age were associated with lower uptake of 
cataract surgery in bilaterally blind patients. Increased efforts should be made to improve 
access to surgery in these populations.
Scientific Poster 364
 h  Identifying the Prevalence of Ocular and Auditory 
Manifestations of Congenital Rubella Syndrome in School-
Aged Children From Cameroon
Presenting Author: Imran Jivraj MD
Co-Author(s): Christopher J Rudnisky MD*, Emmanuel A Tambe MD**, Matthew T 
Tennant MD*
Purpose: Congenital rubella syndrome (CRS) is a global cause of preventable hearing im-
pairment, blindness, and intellectual disability. We sought to identify the prevalence of 
CRS in school-aged children in Mbingo, Cameroon. Methods: Students at 2 schools were 
screened for evidence of CRS, including cataracts, congenital glaucoma, and pigmentary 
retinopathy. Evidence was integrated to form case definitions based on modified Centers 
for Disease Control guidelines. Results: Between September 2009 and May 2010, 320 
students from the 2 schools participated in this study. There were 28 probable cases of CRS 
(10.2%), 104 suspects (37.8%), and 143 unaffected (52.0%). Conclusion: We identified 28 
probable cases of CRS. Introduction of a rubella vaccination offers the potential of reducing 
the rates of CRS.
Scientific Poster 365
Seropositivity of the Donors: Hospital Cornea Retrieval 
Program Collection vs. Voluntary Collection From Home
Presenting Author: Soham Basak
Co-Author(s): Samar K Basak MD DNB MBBS*
Purpose: To compare the seropositivity profile of the donors from two different types of 
cornea collection in eye banking. Methods: Retrospective comparative case series. Blood 
samples of consecutive 1982 donors during 2008-2012 were tested for human immunode-
ficiency virus 1 and 2 (HIV), hepatitis B virus (HBV), hepatitis B virus (HCV), and syphilis by 
approved rapid screening tests. Results: 1543 donors (77.9%) from hospital and 22.1% 
from home death. Total 53 donors (2.67%) were seropositive, among which 49 (2.47%) 
from hospital and 4 (0.20%) in home death (P < .01). Seropositivity was significantly higher 
in HBV (P < .05). In all cases, prior medical history was negative. Conclusion: Seropositiv-
ity of the donors is important for safety issues, and it is higher in hospital cornea retrieval 
program collection.
Scientific Poster 366
Eye Care Services for the Populations of Remote Districts: 
A Practical Framework Using a Mobile Vision Van
Presenting Author: Nancy Chen MD
Co-Author(s): Min-Muh Sheu MD, Rong-Kung TSAI MD PhD
Purpose: We present the framework of the Mobile Vision Van to work as an eye health 
screening station in remote districts.  Methods:  A van, well equipped with ophthalmic 
examination instruments, was brought into remote areas of Eastern Taiwan to provide eye 
care services. The cost-effectiveness is analyzed and reported. Results: 600 eye care ser-
vices were delivered to 28 indigenous villages and remote townships in Eastern Taiwan 
within 6 years. We screened 32,048 inhabitants. 1961 patients were referred to second-
ary or tertiary centers. Spectacles were provided to 1644 participants. 244 educational 
programs were conducted.  Conclusion: The model proved to be highly feasible in rural 
communities with insufficient eye care services.
Health Policy
SESSION ONE
Scientific Poster 32
Waiting Times in Out Patient Departments: Lessons to 
Learn
Presenting Author: Himika Gupta
Co-Author(s): Ramesh Murthy MBBS**, Vidyashankar Balasubramaniam**
Purpose: To quantify and analyze waiting times of walk-in adult patients in a charitable 
eye hospital. Methods: Time of entry, refraction, examination, and exit of 188 consecu-
tive patients were recorded prospectively via a form attached at registration. Days were 
stratified (light, medium, and busy) as per workload and staff. Follow-ups, specialty refer-
rals, and inadequate forms were excluded. Total time (TT), entry to refraction (ER), entry to 
doctor (ED), and doctor to exit (DE) times were calculated, and factors affecting each were 
examined by univariate and multivariate analysis with Kaplan Meier and Cox regression.
Results: A 156-patient dataset gave mean values of TT: 77; ER: 27; ED: 45; DE: 35 minutes. 
Age > 60, station > 6, and diagnosed cataract significantly correlated with more TT. Con-
clusion: Older patients take extra time in refraction and reach doctors later. Special staff 
assisting their refraction is desirable.
Scientific Poster 72
 h  Do Visors Have an Impact on Eye Injuries? A 10-Year 
Review of the National Hockey League
Presenting Author: Jonathan A Micieli MD
Co-Author(s): Iqbal K Ahmed MD*
Purpose: To determine the incidence, mechanisms, and time/value lost of eye injuries and 
the effect of visors over the past 10 years in the National Hockey League (NHL). Methods: 
Eye and orbital injuries were extracted from The Sports Network (TSN), Pro Sports Transac-
tions, and the Sporting News Hockey Register. Visor data were obtained from The Hockey 
News annual survey. Results: 105 eye injuries over the past 10 years resulted in an overall 
incidence of 2.57 per 10,000 athlete exposures. The 883 missed games led to a lost value 
of over $26 million. There was a significantly increased risk of having an eye injury when 
a visor was not worn (OR = 2.19; 95%CI, 1.24-3.87). Most injuries were a result of being 
struck by a puck. Conclusion: Eye injuries are a significant risk, and cost to the NHL and its 
players and can be greatly minimized by the use of a visor.
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Scientific Poster 75
Controlled Ambient Surgery Cabin (ArcSterile) for 
Outpatient Ophthalmic Surgery
Presenting Author: Roberto Gallego-Pinazo MD*
Co-Author(s): Manuel Diaz Llopis MD PhD**, Maria Andreu-Fenoll NP, Rosa Dolz Marco 
MD, David Salom MD, M Dolores Pinazo-Duran MD**
Purpose: To evaluate the safety and profitability of the controlled ambient surgery cabin 
(ArcSterile) for minor ophthalmic surgery (MOS). Methods: Nonrandomized comparative 
observational retrospective study of MOS procedures performed in a conventional operat-
ing room (COR) and in the ArcSterile. Results: 1736 MOSs were performed in the COR, and 
1851 in the ArcSterile. The cost per hour of MOS was 142.5 a and 30.5 a respectively, and 
the calculated cost per procedure was 137.9 a and 27.8 a. The overall productivity increased 
by 49.34%, with an increase in the surgical specific productivity of 18.74%. No differences 
were observed with regards to the rate of ocular infections between both groups. Con-
clusion: The ArcSterile for outpatient ophthalmic minor surgery may be safe and better 
economically than the COR.
Intraocular Inflammation, Uveitis
SESSION ONE
Scientific Poster 110
Outcomes of Post-Cataract Surgery Endophthalmitis in 
Egypt: Twelve-Year Experience and 143 Patients
Presenting Author: Mohamed F Abou Shousha MBCHB*
Co-Author(s): Fadel F Abou Shousha MD
Purpose: To evaluate the 12-year outcomes of post-cataract endophthalmitis (PC-E) in a 
tertiary eye center in Egypt. Methods: Retrospective consecutive case series of 143 cases 
of PC-E treated between 2000 and 2012. Intracameral (ICAB) and intravitreal (IVAB) anti-
biotic injections were done. If visual acuity (VA) was light perception (LP), pars plana vit-
rectomy (PPV) was added. Results: Fifty-five percent of cases presented with LP VA. Treat-
ment delay was noted in 85% of cases. At 6 months, 45% and 75% of cases presenting 
with better than LP vision had VA better than 20/60 and 20/200, respectively, but only 8% 
and 36%, respectively, in the LP group. Conclusion: ICAB and IVAB with PPV are effective 
in managing PC-E. Poor outcomes might be due to treatment delay. Aggressive prophylaxis 
and changing practice in developing countries are warranted.
Scientific Poster 111
Cytomegalovirus Endotheliitis and Keratouveitis: A 
Singapore In Vivo Confocal Microscopy Study
Presenting Author: Annabel Chew MBBS
Co-Author(s): Han Nian Marcus Ang MBBS, Jay Siak MBBS, Soon-Phaik Chee MD*
Purpose: To evaluate the in vivo confocal microscopy (IVCM) findings in cytomegalovi-
rus (CMV) endotheliitis and keratouveitis. Methods: This is a prospective, single-center 
study. Twelve eyes of 12 patients with active CMV endotheliitis or keratouveitis underwent 
slitlamp examination and IVCM (HRT 2-RCM). Results: Slitlamp findings included mutton-
fat and medium-sized keratic precipitates (KPs), endothelial nodules with surrounding halo, 
and linear endothelial deposits. IVCM showed dendritiform and globular KPs, highly reflec-
tive round bodies, owl’s eye morphology in the endothelium, activated keratocytes, and ab-
normal nerve plexus. Conclusion: CMV endotheliitis and keratouveitis had characteristic 
features, and IVCM might be useful as an adjunct for diagnosis of the condition.
Scientific Poster 112
Fundus Autofluorescence in Management of Paradoxical 
Worsening in Presumed Tubercular Serpiginous-Like 
Choroiditis
Presenting Author: Garima Lakhotia MBBS
Co-Author(s): Padmamalini Mahendradas MBBS DO DNB, Rohit Shetty MD MBBS, Priya 
Srinivasan
Purpose To study fundus autofluorescent (FAF) changes in paradoxical worsening of pre-
sumed tubercular serpiginous-like choroiditis. Method: Prospective observational case 
series. Fundus photography and FAF in all visits, OCT, and fundus fluorescein angiography 
(FFA) in selected visits, treated with antitubercular therapy and systemic steroids with/
without immunosuppressants. Pattern and time taken for healing were noted. Results: Six 
out of 7 patients had unilateral disease. All 8 eyes showed hypo- with hyper-autofluores-
cence at presentation. Increased FAF at active edge in all cases noted between 7 to 34 days 
(mean: 21). During healing phase, hypo- mixed with hyper- autofluorescence started at 8 
weeks. Complete hypo- autofluorescence noticed after 7 months. Conclusion: FAF can be 
used as an additional investigational tool to titrate the treatment in presumed tubercular 
serpiginous-like choroiditis.
Scientific Poster 113
The Comparison of T-Cell Population in Uveitis Vitreous 
Fluid
Presenting Author: Kazuichi Maruyama MD PhD
Co-Author(s): Tohru Inaba, Manabu Mochizuki MD**, Shigeru Kinoshita MD*, Hiroshi 
Kunikata, Toru Nakazawa MD PhD
Purpose: CD4/CD8 ratio of vitreous T lymphocytes had high diagnostic value for ocular 
sarcoidosis. We investigated the vitreous lymphocyte subsets of uveitis to elucidate the 
immunological features of this disorder. Methods: This study involved 166 uveitis patients. 
Forty-four patients with sarcoidosis, 46 patients with suspected sarcoidosis (S-S), 11 pa-
tients with tumor, 10 patients with viral infection, 21 patients with other uveitis, and 34 
patients with idiopathic uveitis were enrolled in this study. Their vitreous samples were 
analyzed by flow cytometry. Results: CD4/CD8 ratios were higher in sarcoidosis/S-S than 
in nonsarcoidosis vitreous samples. CD8 population was higher in tumor or viral infection. 
Conclusion: Vitreous T lymphocytes subset has high diagnostic value for uveitis.
Scientific Poster 114
 h  Outcomes of the Boston Keratoprosthesis Type 1 in 
Uveitis and Advanced Ocular Surface Diseases
Presenting Author: Kittikamol Vongpaisarnsin MD
Co-Author(s): Gueorgui Tomov Markov MBCB, C Stephen Foster MD*
Purpose: To report the outcomes and complications of Boston Keratoprosthesis (KPro) type 
1 implantation in uveitis and advanced ocular surface diseases. Methods: A case series of 
20 eyes (17 patients) who had KPro at the Massachusetts Eye Research and Surgery Institu-
tion from July 2005 to October 2012. Mean follow-up was 32.1 months. Results: Ninety-
five percent (19/20 eyes) had a preoperative BCVA < 20/200. After surgery, all patients had 
BCVA improvement and 80% achieved ≥ 20/200. At last follow-up visit, 45% had retained 
BCVA of ≥ 20/200. KPro retention rate was 90%. Conclusion: KPro type 1 provides ef-
fective and long-term improvement of vision in patients with uveitis or advanced ocular 
surface diseases, with an excellent retention rate. Postoperative care remains challenging, 
especially in the setting of autoimmune diseases.
Scientific Poster 115
Morphologic Analysis of Kyrieleis Perivasculitis With 
Spectral-Domain OCT
Presenting Author: Rosa Dolz Marco MD
Co-Author(s): Ssarah Mmrejen MD, Jerome Giovinazzo MD**, Naomi R Goldberg MD, 
Emmett T Cunningham Jr MD PhD MPH, Lawrence A Yannuzzi MD, Manuel Diaz Llopis 
MD PhD**
Purpose: To analyze the morphologic characteristics of Kyrieleis perivasculitis by spectral 
domain OCT (SD-OCT). Methods: Retrospective review of cases with Kyrieleis perivascu-
litis by multimodal imaging analysis including color photographs, fluorescein angiography 
images, and SD-OCT scans. Results: Four cases of Kyrieleis perivasculitis were included. 
They all showed a spotted pattern with multiple small white deposits that did not induce 
any angiographic change, and corresponded to hyper-reflective humps anterior to the artery 
walls in the SD-OCT. Conclusion: the SD-OCT study of Kyrieleis perivasculitis revealed 
new morphologic insights, although the pathogenesis and anatomical correlation of these 
plaques are still controversial.
Scientific Poster 116
Anti-tumor Necrosis Factor Agents in Inflammatory Eye 
Disease
Presenting Author: Careen Yen Lowder MD PhD*
Co-Author(s): Maria M Choudhary MD, Rula Hajj-Ali MD, Sunil K Srivastava MD*
Purpose: To compare the effectiveness of anti-tumor necrosis factor agents in noninfec-
tious inflammatory eye disease. Methods: Chart review of patients with noninfectious 
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uveitis and scleritis treated with anti-TNF agents, 2003-2011. Primary outcomes: time to 
first and time to sustained remission. Results: We included (1) 94 adults, mean age: 45.1 
(range: 19-79 years), 69% women, 45.7% anterior uveitis, 3.2% intermediate uveitis, 9.6% 
posterior, 24.5% pan, and 17% scleritis; 41 patients were on infliximab; 31, etanercept; and 
22, adalimumab; (2) 38 children, mean age: 11.2 (range: 3-17), 76.3% females, 60.5% ante-
rior uveitis; 0.5%, intermediate; 7.9%, posterior; and 21.1%, pan; 5 patients were on etan-
ercept; 21, infliximab; and 12, adalimumab. Conclusion: Patients on infliximab achieve 
first remission earlier and have sustained remission longer.
Scientific Poster 117
Monitoring of Therapeutic Response by Spectral Domain 
OCT and Indocyanine Green Angiography in Vogt-
Koyanagi-Harada Disease
Presenting Author: Tsutomu Sakai MD
Purpose: To study choroidal thickness (CT) and circulation (CC) before and after immuno-
suppressive therapy in Vogt-Koyanagi-Harada disease (VKH). Methods: Spectral domain 
OCT (SD-OCT) and indocyanine green angiography (ICGA) were used to monitor the CT 
and CC in VKH. The CC was graded on the ordinal scales of 0-4 based on ICGA findings. 
Results: Fifty eyes of 25 patients with VKH were analyzed. After the treatment, the CT 
and CC were decreased 873 to 373 µm and 3.5 to 0.7, respectively, over time. The CT and 
CC had rebound or persistence in 20 (40%) and 6 eyes (12%), respectively, in the absence 
of other evidence of increased inflammation during the treatment (P < .01). Conclusion: 
Evaluation of the choroidal status by SD-OCT and ICGA was helpful to monitor the thera-
peutic response in VKH. ICGA was superior to SD-OCT in follow-up evaluation of this study.
SESSION TWO
Scientific Poster 367
Corneal Changes Following Cataract Extraction in 
Children With Endogenous Uveitis
Presenting Author: Ekaterina V Denisova MD
Co-Author(s): Juliya Shestova, Ludmila Katargina PhD**
Purpose: To evaluate corneal changes after cataract extraction (CE) in children with en-
dogenous uveitis (EU). Methods: CE was performed in 41 children with EU, in 34 eyes with 
posterior chamber IOL implantation and in 16 without implantation. Corneal morphology 
was assessed by ConfoScan 4 (Nidek; Japan). Results: Mild decrease in posterior stroma 
cell density and Descemet membrane tightening-up were found postoperatively. No statis-
tically significant difference was noted in mean endothelial cell loss at 12 months in pseu-
dophakic (15.5%) and aphakic (17.8%) eyes, as well as in endothelial cell density, which 
was in normal limits in 92% of cases. Conclusion: Corneal changes after CE in children 
with EU are within acceptable limits and do not differ in pseudophakic and aphakic eyes.
Scientific Poster 368
Ocular Syphilis: Case Series (2000-2009) From 2 Tertiary 
Care Centers in Montreal
Presenting Author: Kinda Najem MD
Co-Author(s): Laurence Jaworski MD, Annie-Claude Labbe, Claude Fortin**, Eric Fortin 
MD**, Marie-Lyne Belair MD**, Bouchra Serhir PhD**, Marie-Josee Aubin MD
Purpose: To review ocular syphilis cases treated between 2000 and 2009 at Maisonneuve-
Rosemont and Notre-Dame Hospitals, Montreal. To describe the demographics, clinical 
presentations, proportion of co-infection with HIV, treatment, and outcome. Methods: 
Medical records of patients with positive treponemic serologic testing who visited the 
ophthalmology department were retrospectively reviewed. Several data were compiled. 
Results: Ninety-one patients (80% males) were included. The majority of cases were found 
in men aged 51-60 years (26%). The most common ophthalmologic diagnosis was anterior 
uveitis (31%). Co-infection with HIV was found in 34% of patients. In about 85% of patients 
treated, no history of reinfection was noted. Conclusion: Syphilis is important to keep in 
mind, especially since the treatment has an excellent outcome.
Scientific Poster 369
Treatment of Chronic, Noninfectious, Nongranulomatous 
Uveitis in Patients With Juvenile Idiopathic Arthritis
Presenting Author: Anton Kolomeyer MD
Co-Author(s): Yufei Tu MD, Elisabetta Miserocchi MD*, David S Chu MD*
Purpose: To describe treatment of uveitis in juvenile idiopathic arthritis (JIA) patients. 
Methods: Eighty-two patients (147 eyes) treated for ≥ 2 months were included. Main out-
come measures were rates of inflammation control and medication discontinuation, visual 
acuity (VA), and side effects. Results: Mean age was 5.2 ± 4.0 years (78% female, 79% 
bilateral, 74% anterior uveitis). Mean VA did not significantly change. Thirty patients (37%) 
required surgeries (associated with older age, panuveitis, active inflammation, and lower 
VA at baseline (P < .05). Forty-one patients (50%) achieved inflammation control (more 
likely with adalimumab, infliximab, methotrexate (P < .05); less likely with cyclosporin A 
and steroids (P < .05). Nine patients (11%) experienced side effects. Conclusion: TNF-
alpha inhibitors and methotrexate should be strongly considered for ocular inflammation 
in JIA patients.
Scientific Poster 370
Retinal Detachment and Uveitis at a Tertiary Center Over 
25 Years: The Results of a Uveitis Survey Study Group
Presenting Author: Andrés Francisco Lasave MD
Co-Author(s): Ammar M Al Mahmood MD, Sulaiman M Alsulaiman MD, Abdul Aziz Al 
Rushood MD, Yaha Ahmad Alzahrani, Hassan A Al-Dhibi MD, J Fernando Arevalo MD 
FACS*
Purpose: To evaluate the frequency, visual prognosis, and treatment of retinal detachment 
(RD) in patients with uveitis. Methods: The authors retrospectively evaluated 888 consecu-
tive patients (1409 eyes) with uveitis of whom 173 patients (19.5%) (273 eyes) with RD 
were identified. Results: Exudative retinal detachment (ERD) was diagnosed in 177 eyes 
(64.8%), rhegmatogenous retinal detachment (RRD) in 96 eyes (35.1%), and tractional reti-
nal detachment (TRD) in 78 eyes (28.5%). Panuveitis was present in 125 patients (71.8%). 
Oral prednisone was the first line of treatment in 141 patients (81%). Immunosuppressive 
treatment was employed in 64 patients (36.8%). More than 70% of eyes maintained a 
visual acuity of 20/50 or better. Conclusion: RRD and TRD may be a late complication of 
eyes with uveitis.
Scientific Poster 371
Effect of Cataract Surgery on Eyes With Chronic Uveitis
Presenting Author: Merih Oray MD
Co-Author(s): Nilufer Gozum MD, Ilknur Tugal-Tutkun MD*, Ayse Yildiztas MD
Purpose: To evaluate the outcomes of phacoemulsification with IOL implantation in eyes 
with chronic uveitis. Methods: Review of clinical records of 55 patients (66 eyes) with 
chronic uveitis. Main outcome measures were BCVA, anterior chamber reaction, and quan-
titative measurement of inflammation with laser flare photometry. Results: BCVA improved 
in 60 eyes (91%), and 46 eyes (70%) had a final BCVA ≥ 0.5. No improvement was seen in 
6 eyes (9%). Visual loss did not occur in any eye. Laser flare photometry did not show major 
increases in inflammation. Conclusion: If the ocular inflammation is controlled before sur-
gery, phacoemulsification with IOL implantation is safe and efficient and does not increase 
inflammation further than the disease itself.
Scientific Poster 372
Does Intracameral Cefuroxime Reduce Postcataract 
Surgery Endophthalmitis?
Presenting Author: Savitri Sharma MD
Co-Author(s): Srikant Kumar Sahu**, Soumyava Basu MS, Sujata Das MBBS, 
Taraprasad Das MD, Tapas Padhi**
Purpose: To determine if intracameral injection of cefuroxime at the end of cataract sur-
gery decreases the incidence of endophthalmitis. Methods: Other factors remaining com-
parable, incidence of endophthalmitis was measured in patients with or without intracam-
eral cefuroxime. Results: Patients without cefuroxime (WOC) numbered 7756 (2006-2010); 
and with cefuroxime (WC), 7366 (2010-2012). The difference in rate of clinical endophthal-
mitis in WOC (12, 0.155%) and WC (8, 0.108%) was not significant (P = .13). The culture 
positivity rate, at 58.33% (7/12) for WOC and 37.5% (3/8) for WC, was also not statistically 
significantly different (P = .24). No immediate or delayed adverse reaction was reported. 
Conclusion: Intracameral cefuroxime did not significantly reduce the risk for developing 
acute endophthalmitis after cataract surgery.
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Scientific Poster 373
 h  Clinically Significant Distinct Fundus Autofluorescence 
Patterns in Posterior Uveitis
Presenting Author: Hossein Nazari Khanamiri
Co-Author(s): Narsing A Rao MD
Purpose: To determine fundus autofluorescence (FAF) alteration patterns in patients with 
posterior uveitis. Methods: Prospectively 182 eyes of 97 patients with various posterior/
panuveitis entities underwent FAF imaging and spectral domain OCT during a 2-year period. 
In patients with chronic Vogt-Koyanagi-Harada syndrome, multifocal choroiditis, tubercu-
losis, and autoimmune retinopathy, FAF alterations correlated with clinical features and 
corresponding color fundus image. Results: FAF revealed distinct retinal pigment epithelial 
damage patterns in the above-mentioned entities and early progression of the uveitis that 
were not apparent from clinical examination or fundus photography. Conclusion:  FAF 
imaging was found useful in diagnosis of posterior uveitis and recommended for monitoring 
of early progression and for timely medical intervention.
Scientific Poster 374
Incidence of Peripheral Vascular Leakage in Intermediate 
/ Posterior Uveitis With Ultrawide-field Fluorescein 
Angiography
Presenting Author: Robert M Beardsley MD
Co-Author(s): John P Campbell MD MPH, Wonchon Lin MD, Christina J Flaxel MD, 
James T Rosenbaum MD*, Eric B Suhler MD*, Phoebe Lin MD PhD
Purpose: To determine the incidence of peripheral vascular leakage in posterior and in-
termediate uveitis utilizing ultrawide-field fluorescein angiography (UWF-FA). Methods: 
A single center, retrospective FA image review of 60 eyes of 60 patients with posterior or 
intermediate uveitis compared to 25 patients without uveitis in whom UWF-FA was done. 
Vascular leakage was evaluated by masked graders.  Results: Sixty-five percent (39/60) of 
uveitic eyes displayed peripheral leakage, while none of the nonuveitic eyes did. Of uveitis 
eyes with expected leakage (active disease, intermediate, vasculitis, etc.), 94.8% (37 of 
39) did. Conclusions: UWF-FA is a useful adjunct for the management of posterior and 
intermediate uveitis, and peripheral leakage may serve as a surrogate for disease activity.
Scientific Poster 375
Efficacy and Safety of Infliximab Treatment for 
Inflammatory Lesions in BehÁet Disease
Presenting Author: Takeshi Kezuka MD PhD
Co-Author(s): Yoko Okunuki MD, Jun Suzuki MD PhD**, Yoshimichi Matsunaga MD, 
Yoshihiko Usui MD, Hiroshi Goto MD
Purpose: To evaluate the efficacy and safety of infliximab for refractory inflammatory le-
sions in Behçet disease (BD). Methods: We reviewed 36 BD patients with inflammatory le-
sions treated with infliximab and no other immunosuppressant at Tokyo Medical University. 
Results: Mean duration of follow-up was 3.2 years. Infliximab was effective in 26 of 36 
patients (72%) with uveoretinitis, and in 21 of 36 patients (58%) with extraocular diseases. 
Adverse events related to infusion reaction were encountered in 3 patients, including ana-
phylactic shock in 2, antiphospholipid antibody syndrome in 1, psoriasis-like exanthema 
in 1, and lower limb cellulitis in 1. Conclusion: Although strict monitoring is required, 
infliximab treatment is effective for inflammatory lesions in BD in the long term.
Medical Education
SESSION TWO
Scientific Poster 376
Validity of Ophthalmology Surgical Competency 
Assessment Rubric for Strabismus Surgery (OSCAR: 
Strabismus) in Resident Training
Presenting Author: W Walker Motley MD
Co-Author(s): Karl C Golnik MD, Irene I Anteby MD, Huban Atilla MD, Glen Anthony Gole 
MD FRANZCO, Claudia Elena Murillo-Correa, Scott E Olitsky MD, Rachel Pilling MB ChB, 
Aravind R Reddy MD MBBS**, Pradeep Sharma MD, R Michael Siatkowski MD*, Maria 
B Yadarola MD
Purpose: To validate the OSCAR:Strabismus assessment tool inter-rater reliability. Meth-
ods: Video recordings of strabismus surgeries performed by 5 ophthalmology residents 
were distributed to 10 experienced strabismus surgery mentors in 9 countries. Surgical 
skills were evaluated using the OSCAR:Strabismus assessment tool. Scored evaluations 
were analyzed for inter-rater agreement using the Cronbach alpha coefficient. Results: The 
OSCAR:Strabismus tool demonstrated excellent inter-rater agreement with a composite 
Cronbach alpha coefficient of 0.91. Analyzed individually, each OSCAR:Strabismus element 
demonstrated acceptable inter-rater agreement except for one pertaining to muscle disin-
sertion. Conclusion: The OSCAR:Strabismus is a valid tool for the evaluation of ophthal-
mology residents learning strabismus surgery.
Scientific Poster 377
Measuring Quality of Care: New High-throughput 
Automated Analysis of Compliance With Preferred 
Practice Patterns in Management of Glaucoma in a 
Resident-Run Ophthalmology Clinic
Presenting Author: Bozho Todorich MD PhD
Co-Author(s): Kenneth Goldberg MD, Kuruvilla P Kurian PhD, Pratap Challa MD*
Purpose: To develop novel, automated analysis of glaucoma practice patterns in a resi-
dent-run ophthalmology clinic. Method: Ophthalmology resident notes of 914 glaucoma 
patients were extracted from Durham VA CPRS record using programmed script and sub-
sequently analyzed for conformance with American Academy of Ophthalmology Preferred 
Practice Patterns utilizing a binary algorithm. Method was validated using manual analysis. 
Results: The study showed high concordance (> 80%) with manual analysis for all compo-
nents of clinic encounter except family history. Residents performed well in documenting 
history, exam, treatment, and follow-up, except for therapeutic counseling (< 0.2% notes). 
Conclusion: Automated analysis is a comprehensive method to evaluate practice pat-
terns, improve quality of patient care, and aid in ophthalmology resident education.
Scientific Poster 378
Quality Evaluation of Ophthalmology Web-Based Learning 
Resources for Trainees
Presenting Author: Sourabh Arora MD*
Co-Author(s): Feisal A Adatia MD*
Purpose: To identify and quantitatively evaluate ophthalmology educational websites. 
Methods: Quantitative evaluation involved the Michigan Website Evaluation Tool (MWET), 
Quality Component Scoring system (QCS), and the Technical Component Score System 
(TCS). Results: Fifty-two websites were included. The mean MWET score was 40.0 ± 16.3 
(maximum possible score [MPS]: 80). For a sample of websites, the mean QCS score was 
9.6 ± 1.7 (MPS: 13); while for TCS it was 10.6 ± 6.6 (MPS: 20), with a mean aggregated 
score of 20.2 ± 6.7 (MPS: 33). The dominant teaching styles used were text-based (39%), 
multimedia (24%), case-based (21%), research-based (12%), and quiz-based (3%). Con-
clusion: This study has provided a quality-ranked listing of online learning resources for 
ophthalmology trainees.
Scientific Poster 379
Strabismus Surgery Outcomes From Trainee vs. 
Experienced Staff as Primary Surgeon
Presenting Author: Viraj Jayesh Mehta MD
Co-Author(s): Virginia M Utz MD, Elias I Traboulsi MD*, Paul Joseph Rychwalski MD
Purpose: To compare strabismus surgery outcomes of trainees to that of staff surgeons. 
Methods: Charts of 607 patients (1025 eyes) undergoing surgery for horizontal deviation, 
thyroid eye disease (TED), or nystagmus were reviewed. Success was defined as horizontal 
deviation ≤ 10 PD, no diplopia or diplopia requiring correction of ≤ 10 PD, and residual 
head turn ≤ 10 degrees, respectively. Results: 552 patients (936 eyes) had surgery for 
horizontal deviation, 42 patients (64 eyes) for TED, and 13 patients (25 eyes) for nystagmus. 
No significant difference was seen in success rates between trainee and staff surgeon 
for strabismus (P = .54), TED (P = .84), or nystagmus (P = 1.0) after ≥ 8 weeks follow-up. 
Conclusion: Properly supervised trainees achieve strabismus surgery results comparable 
to an experienced staff surgeon.
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Scientific Poster 118
 h  Safety and Tolerability of QPI-1007 for Acute-Onset 
Nonarteritic Anterior Ischemic Optic Neuropathy
Presenting Author: Rishi P Singh MD*
Co-Author(s): Bradley J Katz MD*, Andrew N Antoszyk MD*, Rabia Gurses-Ozden MD*, 
Shai Erlich PhD**, Leonard A Levin MD PhD*, Neil R Miller MD*
Purpose: To determine the safety and tolerability of intravitreal QPI-1007, a siRNA against 
caspase 2, for acute-onset nonarteritic anterior ischemic optic neuropathy (NAION). Meth-
ods: A 12-month, 2-stratum, Phase 1, multicenter, open-label, dose-escalation (0.2-6 mg) 
study was performed in patients with retinal or optic nerve pathology (S1; n = 18) or acute-
onset NAION (S2; n = 30). Results: 261 of 273 adverse events (AEs) were of mild-to-mod-
erate severity. There were no serious AEs. One of 24 NAION subjects (4.2%) experienced 
a ≥ 3-line loss of visual acuity at Month 12, compared with 15.8% of Ischemic Optic Neu-
ropathy Decompression Trial historical controls. Conclusion: A single intravitreal injection 
of QPI-1007 was safe and well tolerated.
Scientific Poster 119
Nonvisual Responses Mediated by Intrinsically 
Photosensitive Retinal Ganglion Cells in Hereditary Optic 
Neuropathy
Presenting Author: Aki Kawasaki MD
Co-Author(s): Lorette Leon MD, Sylvie Collomb, Mirjam Munch PhD
Purpose: In this study, we examined and compared the functional integrity of conventional 
retinal ganglion cells and intrinsically photosensitive retinal ganglion cells in patients with 
hereditary optic neuropathy (HON). Methods: Eight patients with HON and 8 age-matched 
controls underwent a thorough ophthalmologic examination and chromatic pupillometry 
during the daytime. Study participants were then tested overnight with additional pupil 
testings and hourly salivary samples for melatonin, and were exposed for 2 hours to bright 
white light. Results: Patient with HON showed significant visual loss but did not demon-
strate any reduction of pupil responses and acute melatonin suppression by light. Conclu-
sion: This dissociation of visual and nonvisual function further supports a mechanism of 
selective ganglion cell damage occurring in HON.
Scientific Poster 120
The Effects of Topical Carbonic Anhydrase Inhibitor for 
Treatment of Nystagmus
Presenting Author: Birsen Gokyigit MD
Co-Author(s): Serpil Akar MD, Ebru Demet Aygt MD, Banu Satana MD, Ahmet Demirok 
MD
Purpose: To evaluate the effects of topical carbonic anhydrase inhibitor (CAI) brinzolamide 
(Azopt) for treatment of nystagmus patients Methods: Twenty-four patients who used 
brinzolamide for treatment of nystagmus were prospectively analyzed. Patients’ mean age 
was 9.5, and diagnosis were periodic alternate nystagmus in 8, infantile nystagmus syn-
drome in 9, and ocular albinism in 7. The mean follow-up was 24.7 months. SPSS 15.0 com-
puter program was used for evaluation of data. Results: We found reduction of amplitude 
in 6 of the patients, increase in vision in 10. In addition, reduced abnormal head position 
(AHP) was noted in 5 patients. There was no identified change in 7. Conclusion: The medi-
cal treatment of nystagmus with topical brinzolamide was found effective in our series, but 
wider series and longer follow-up studies are needed.
Scientific Poster 121
Hypoxic Night Blindness at High Altitude on Mount 
Everest
Presenting Author: Michael S Wiedman MD FACS
Purpose: Hypoxic at 25,000 feet, while night-time descending they froze and perished. Re-
search done to assess hypoxia effects on night vision and safety. Methods: Fifteen climb-
ers dark adapted, 4000 and 13,500 feet on Everest. Threshold testing with unique portable 
Goldman adaptometer neutral density filters, by one investigator. Results: All subjects lost 
significant rod sensitivity, threshold average .4 log change between base and high camps. 
Conclusion: Awareness of night blindness importance recommends appropriate lighting 
gear safety for nocturnal climbing.
SESSION TWO
Scientific Poster 380
Enhanced Depth Imaging OCT Features Distinguishing 
Papilledema and Anomalous Optic Nerves
Presenting Author: Peter Y Chang MD
Co-Author(s): Sung Chul Park MD, Rudrani Banik MD*
Purpose: To find features on enhanced-depth imaging OCT (EDI-OCT) that may distinguish 
pseudopapilledema (PP) and true papilledema (TP). Methods: We examined EDI-OCT im-
ages of 7 patients with PP, 7 patients with TP, and 7 controls with normal-appearing optic 
nerves. Results: In PP, retinal nerve fiber layer thickness is more likely to be within normal 
limits, whereas it is significantly increased in TP. In addition, in TP, the prelaminar neuroglial 
tissue bulges into the peripapillary region in all directions, whereas in PP and controls, it 
is more likely to bulge into the nasal aspect only. Finally, peripapillary intraretinal fluid 
pockets are more likely to be seen in TP but not in PP or controls. Conclusion: EDI-OCT 
may be a useful tool for distinguishing PP from TP, sparing the need for neuroimaging or 
lumbar puncture.
Scientific Poster 381
Erythropoietin: A Novel Treatment for Methanol-
Associated Optic Neuropathy
Presenting Author: Farzad Pakdel MD
Co-Author(s): Mostafa Soltan Sanjari**, Mehdi Modarres MD, Mohsen B Kashkouli 
MD**
Purpose: To report the results of intravenous erythropoietin in treatment of optic neuropa-
thy associated with recent methanol poisoning. Methods: In a prospective study, patients 
received intravenous recombinant erythropoietin 20,000 units for 3 successive days. BCVA, 
visual field, fundus and systemic evaluations were performed. Results: Sixteen consecu-
tive patients from November 2010 to January 2013 were included. Mean follow-up time 
was 5.2 (range: 1-19) months. The mean BCVA improved significantly in right (3.79 and 
0.710 logMAR units, before and after treatment) and left eye (3.36 and 0.82 logMAR units, 
before and after treatment) (P < .0001). No complication was detected. Conclusion: Intra-
venous erythropoietin can be regarded as a new and promising modality of treatment for 
methanol-associated optic neuropathy.
Scientific Poster 382
Practice Patterns Following Retinal Artery Occlusion
Presenting Author: Anne E Abel MD
Co-Author(s): Sandra R Montezuma MD, Adam Carpenter MD*, Michael S Lee MD*
Purpose: To assess retinal artery occlusion (RAO) workup by subspecialty training. Meth-
ods: Ophthalmologists (Ophs) and neurologists (Neuros) were invited to complete a web-
based survey. Results: 115 Ophs and 24 Neuros responded. For RAO < 12 hours, 35% of 
Ophs vs. 75% of Neuros perform emergent stroke workup. No Ophs and 13% of Neuros 
refer these patients for intra-arterial tissue plasminogen activator (tPA). For RAO present 
24-48 hours, the majority of Ophs (82%) and Neuros (71%) perform outpatient testing. Con-
clusion: Neuros recommend emergent stroke protocol for acute RAO, while most Ophs do 
not. Clear management differences exist when RAO presents under 12 hours. A common 
trend toward outpatient management was seen when RAO presents after 24 hours. Ophs 
should consider activating a stroke protocol in acute RAO. Intra-arterial tPA referral for 
RAO is uncommon.
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Scientific Poster 122
Primary and Secondary Intra-arterial Chemotherapy for 
Retinoblastoma
Presenting Author: Fairooz Puthiyapurayil Manjandavida MBBS
Co-Author(s): Carol L Shields MD, Giulia Pieretti MD, Sruthi Arepalli, Jerry A Shields MD
Purpose: To analyze the efficacy of primary and secondary intra-arterial chemotherapy 
(IAC) in retinoblastoma. Methods: Retrospective analysis of 69 consecutive eyes in 65 
patients undergoing intra-arterial chemotherapy over 4 years. Results: IAC, including mel-
phalan (51), melphalan plus topotecan (14), and melphalan plus carboplatin (4), was admin-
istered in 69 eyes using 193 catheterizations of ophthalmic artery. The mean age at first 
IAC was 30 months. Primary IAC in 35 eyes had 71% eye salvage overall (100% in Groups 
B and C, 94% in Group D, and 35% in Group E) at 17 months mean follow-up. Secondary 
IAC for 34 eyes demonstrated 65% globe salvage. Conclusion: IAC demonstrates remark-
able tumor control and globe salvage in the management of retinoblastoma, especially as 
primary treatment in Group B, C, and D eyes.
Scientific Poster 123
 h  American Joint Committee on Cancer (AJCC) Cancer 
Staging of Posterior Uveal Melanoma Is Predictive of 
Prognosis: Analysis of 7731 Patients
Presenting Author: Carol L Shields MD
Co-Author(s): Swathi Kaliki MD, Minoru Furuta MD, Carolina Alarcon MD, Jerry A 
Shields MD, Enzo M Fulco MD
Purpose: To analyze American Joint Committee on Cancer uveal melanoma staging. 
Methods: Retrospective series. Results: Of 7731 patients, melanoma was stage I (n = 
2767), stage II (n = 3735), stage III (n = 1220), and stage IV (n = 9). Kaplan-Meier metastasis 
at 5, 10, and 20 years were 5%, 12%, and 20% (stage I), 17%, 29%, and 44% (stage II), 
44%, 61%, and 73% (stage III), and 100% at 1 year (stage IV). Compared to stage I, hazard 
ratio for metastasis was 3.1 for stage II and 9.3 for stage III. Conclusion: Metastases 
increase 3-fold for stage II and 9-fold for stage III, compared to stage I.
Scientific Poster 124
Genome-Wide Analysis of Ocular Adnexal 
Lymphoproliferative Disorders Using High-resolution 
Single Nucleotide Polymorphism Array
Presenting Author: Yoshihiko Usui MD
Co-Author(s): Hiroki Takahashi DVM, Shunichiro Ueda MD, Aiko Sato-Otsubo MS, 
Hiroshi Goto MD
Purpose: To identify the genomic signature of ocular adnexal mucosa-associated lym-
phoid tissue lymphoma (MALT), IgG4-related ophthalmic disease (IgG4-ROD), and reactive 
lymphoid hyperplasia (RLH). Methods: Thirty-nine MALT (22 conjunctiva and 17 orbit), 13 
IgG4-ROD, and 4 cases of RLH were studied by using Affymetrix GeneChip Human Map-
ping arrays. Results: In MALT, chromosomal aberrations were detected at chromosomes 
3 (36%), 6 (20%), 18 (18%), and 21 (10%) and found in about 76% of orbital MALT, and the 
frequency was higher than in conjunctival MALT (40%). Uniparental disomy (UPD) in chro-
mosomes 3 and 6 were frequently found in MALT. No chromosomal aberrations were found 
in IgG4-ROD and RLH. Conclusion: We detected novel chromosomal aberrations in MALT. 
MALT lymphoma had different patterns of chromosomal aberrations.
Scientific Poster 125
Multispectral Imaging of Choroidal Tumors
Presenting Author: Charles J Pavlin MD FRCS
Co-Author(s): Hatem Krema FRCS, E Rand Simpson MD
Purpose: Multispectral imaging uses light-emitting diodes of different frequency (green to 
infrared) to illuminate retina and choroid. Longer wavelengths produce deeper penetration, 
providing a series of en face images at increasing depth. Methods: Thirteen choroidal 
tumors were imaged at all wavelengths. Results: Tumor margins were more clearly visual-
ized at the longer wavelengths (deep red and infrared) with increased visibility of tumor 
pigmentation and choroid. Lipofuscin was clearly imaged at longer wavelengths. Longer 
wavelengths allowed imaging of the peri-tumor choroidal vascular pattern . Conclusion: 
Multispectral imaging of choroidal tumors provides useful information without the use of 
injectable dyes. Tumor margins can be more clearly delineated, lipofuscin is clarified, and 
peri-tumor choroidal changes can be imaged.
Scientific Poster 126
Surgical vs. Medical Treatment of Ocular Surface 
Squamous Neoplasia: A Comparison of Recurrences and 
Complications
Presenting Author: Afshan A Nanji MD
Co-Author(s): Christina S Moon MD, Anat Galor MD*, Julia Sein MD, Patrick Rafael 
Oellers MD, Carol L Karp MD
Purpose: To compare recurrence and complication rates of surgical treatment to those of 
medical treatment of ocular surface squamous neoplasia (OSSN). Methods: A case control 
study of patients with OSSN treated with surgery (n = 49) vs. topical interferon therapy, 
either in drop or injection form (n = 49). Results: Mean patient age and gender were similar 
between the groups. Eyes in the medically treated group had higher American Joint Com-
mittee on Cancer stage tumors. Despite this, the recurrence rate was equal, at 3 recurrenc-
es per group. The 1- and 5-year recurrence rates in the surgical group were 5% and 11%, 
vs. 0% and 21% in the medical group (P = .73). Nonlimbal location was a risk for recurrence 
(hazard ratio: 9.72). Side effects between the groups were generally similar. Conclusion: 
Surgical and medical therapies were found to have similar recurrence rates for OSSN.
Scientific Poster 127
Association Between Regression Rate and Gene 
Expression Profile Class in Uveal Melanomas Undergoing 
I-125 Plaque Brachytherapy
Presenting Author: Rajesh C Rao MD
Co-Author(s): Shahed Nicolas Badiyan MD, J William Harbour MD*
Purpose: To determine whether gene expression profiling (GEP) is associated with rate 
of tumor regression following I-125 plaque brachytherapy (IPB) for uveal melanoma (UM). 
Methods: Retrospective review of 138 patients with posterior UM treated with IPB in 
which GEP class and 3-month post-radiation tumor thickness were available. Results: GEP 
class assignment was class 1 in 83 and class 2 in 55 of patients. Mean age was 60.9 years 
for class 1 and 68.1 years for class 2 tumors (P = .002). Mean reduction in tumor thickness 
at 3 months postradiation was 26.5% for class 1 and 13.0% for class 2 tumors (P = .01). 
Complete tumor regression with flat residual tumor at 3 months was observed for 4 class 1 
tumors and no class 2 tumors. Conclusion: Class 1 tumors exhibit more rapid early tumor 
regression than class 2 tumors following IPB.
Scientific Poster 128
Long-term Outcomes of Anti-VEGF Therapy for Choroidal 
Neovascularization Associated With Choroidal Osteoma
Presenting Author: Mohammed Ali Khan MD
Co-Author(s): Francis C DeCroos MD, Philip Storey MD, Jerry A Shields MD, Sunir J 
Garg MD*, Carol L Shields MD
Purpose: To investigate the efficacy of serial anti-VEGF injections for CNV associated with 
choroidal osteoma. Methods: Retrospective case series at the Wills Eye Institute, Philadel-
phia, Pennsylvania. Results: Eight tumors in 8 eyes were treated with a median of 8 anti-
VEGF injections (range: 1-19). Resolution of fluid on OCT was observed in 7 of 8 eyes (87%). 
The mean Snellen acuity improvement was 1 line (range: loss, 3 — gain, 7 lines) at a mean 
32.5 months follow-up. Four eyes (50%) had at least 1 recurrence. Four eyes (50%) received 
supplemental photodynamic therapy (PDT); of these, only 1 (25%) had a recurrence. Con-
clusion: Therapy with anti-VEGF can be effective for CNV due to choroidal osteoma, with 
preservation of visual acuity. Supplemental PDT may reduce the risk of CNV recurrence.
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Scientific Poster 129
RetCam Fluorescein Angiography Findings in Eyes With 
Advanced Retinoblastoma
Presenting Author: Jonathan W Kim MD
Co-Author(s): Srinivas R Sadda MD*, Yohko Murakami MD
Purpose: We propose that fluorescein angiography (FA) performed on the Retcam II can 
be important in the evaluation of retinoblastoma patients. Methods: A retrospective case 
series was performed on all new retinoblastoma patients evaluated with Retcam FA from 
2000 to 2012. FA images were analyzed, and a chart review was performed. Results: For 
the 100 Group D and E eyes, notable findings included iris neovascularization (54/100), 
intrinsic tumor vasculature (76/100), retinal or tumor nonperfusion (84/100), and retinal vein 
periphlebitis (20/47 Group D). Retcam FA was not clinically useful after 3 minutes. Conclu-
sion: Characteristic retinovascular findings on Retcam FA were described. Retcam FA adds 
minimal time to the exam and is useful in defining the extent of disease and distinguishing 
retinoblastoma from simulating conditions.
SESSION TWO
Scientific Poster 383
The Corneal Scar in Peters Anomaly and Primary 
Congenital Glaucoma: An Immunohistochemical Study
Presenting Author: Mohammed A Alshamrani MBBS
Co-Author(s): Mosa AlHarby MD, Hind M Alkatan MBBS, Sabah Jastaneiah MD, 
Jonathan Song MD, Deepak Paul Edward MD
Purpose: To compare immunopathology of the corneal scar in Peters anomaly (PA) and 
congenital glaucoma (CG). Method: Review of corneal pathology from PA and CG patients 
(n = 8 each); semiquantitative immunolabeling with antibodies against 5 extracellular ma-
trix proteins and smActin with appropriate controls. Results: PA and CG corneas showed 
significantly greater collagen I, III, heparan sulfate, and smActin stromal scar label and 
significantly decreased keratan sulfate label compared to normal age-matched control and/
or adult scarred corneas (P < .008). 1.5 to 2-fold more intense label was noted in PA corneas. 
PA and CG cornea immunolabel was comparable. Conclusion: The ECM protein and cel-
lular component in PA and CG corneal scars were distinctly different from normal and adult 
scarred corneas. The changes were more prominent in PA.
Scientific Poster 384
Wide-angle Optos Retinal Angiography Complements 
RetCam in Evaluation and Follow-up of Pediatric Age 
Group With Retinoblastoma
Presenting Author: Ihab S Othman MD
Co-Author(s): Shereen Hasan Sadek Mourad MD
Purpose: To evaluate Optos wide-angle fundus photography (OWAFF) in evaluation and 
further management of pediatric age group with retinoblastoma. Methods: Fifteen pa-
tients previously treated and managed at the EyeWorld Hospital were evaluated. Age 
ranged from 3 to 7 years. Fundus photos were taken with Optos 200Tx and compared to 
RetCam fundus imaging. Steering was performed whenever possible to get details of pe-
ripheral fundus. Results: OWAFF matched the RetCam fundus imaging in children over 4 
years old with steering. Images were high resolution and provided detailed description of 
the retina and tumors. Conclusion: OWAFF is a useful adjunct in children over 3 years 
old with retinoblastoma for follow-up of the central and peripheral lesions with no need 
of general anesthesia.
Scientific Poster 385
Acute Inflammatory Regression of Class 1 Posterior Uveal 
Melanomas Following I-125 Plaque Radiotherapy
Presenting Author: Royce W Chen MD
Co-Author(s): J William Harbour MD*
Purpose: To determine if acute inflammatory regression of posterior uveal melanoma 
(PUM) following I-125 brachytherapy is associated with a specific gene expression profile 
(GEP) molecular class. Methods: Retrospective study of 294 consecutive PUM patients 
who underwent GEP testing from fine needle aspiration biopsy prior to I-125 brachytherapy. 
Results: The GEP was Class 1 in 171 (58%) and Class 2 in 123 (42%) tumors. Rapid in-
flammatory regression to a flat scar within 3 months of brachytherapy occurred in 12 tu-
mors (4%). All 12 of these tumors were Class 1 (P < .01). Conclusion: Acute inflammatory 
regression may occur preferentially in Class 1 PUM. This finding suggests that radiated, 
necrotic Class 1 melanoma cells are more immunogenic than Class 2 cells and explains why 
immunotherapy is rarely effective in metastatic PUM from Class 2 tumors.
Scientific Poster 386
 h  Sebaceous Gland Carcinoma: Clinical Profile, 
Management, and Outcomes in 147 Patients
Presenting Author: Akshay Gopinathan Nair MD
Co-Author(s): Milind N Naik MBBS**, Swathi Kaliki MD
Purpose: To describe clinical profile, management, and outcomes of ocular adnexal se-
baceous gland carcinoma (SGC). Methods: Retrospective. Results: The median age at 
presentation was 55, and 89 (61%) were female. Based on American Joint Commission 
on Cancer classification, the tumors were classified as T2 (59%), T3 (39%), and T4 (1%). 
Primary treatment included wide excision biopsy (74%), exenteration (12%), neoadjuvant 
chemotherapy (8%), external beam radiotherapy (1%), topical mitomycin C (1%), and cryo-
therapy (< 1%). Overall, eyelid/globe salvage was achieved in 84% over a median follow-up 
period of 80 months. Local recurrence (14%), locoregional metastasis (18%), systemic me-
tastasis (14%), and death due to metastasis (11%) occurred. Conclusion: SGC is a disease 
of the elderly with predilection for women. Primary excision was possible in 74%, and 16% 
cases required exenteration.
Scientific Poster 387
Incidence of Radiation Maculopathy in Patients With 
Uveal Melanoma Treated With I-125 Plaque Brachytherapy
Presenting Author: Nisha V Shah MD
Co-Author(s): Samuel K Houston MD**, Arnold Michael Markoe MD, Timothy G Murray 
MD MBA*
Purpose: To report radiation maculopathy incidence and BCVA outcomes on 265 patients 
treated with I-125 plaque brachytherapy for uveal melanoma. Methods: Institutional re-
view board-approved, consecutive, retrospective study utilizing spectral domain OCT (SD-
OCT) at 2-4 month intervals, prompting commencement of bevacizumab. Results: BCVA 
at the time of SD-OCT radiation maculopathy detection improved from median of 20/70 
to 20/50 after 3 years of bevacizumab therapy. In patients with over 30 months follow-up, 
46.8% of radiation maculopathy eyes attained 20/40 or better BCVA. Conclusion: Up to 
70% of patients presented with radiation maculopathy following I-125 plaque brachyther-
apy. Intravitreal bevacizumab proves effective in preserving vision up to 4 years following 
plaque brachytherapy.
Scientific Poster 388
Chemoreduction for Infants Under 6 Months of Age With 
Retinoblastoma
Presenting Author: Jesse L Berry MD
Co-Author(s): Rima Jubran MD, Thomas Lee MD*, A Linn Murphree MD**
Purpose: To evaluate outcomes of infants diagnosed with retinoblastoma before 6 months 
of age. Methods: Retrospective review from 2000-2009. Ninety eyes of 53 infants were 
included. Systemic chemoreduction (CRD) was administered when local modalities failed. 
Primary outcome measure was globe salvage and CRD-related complications. Results: Of 
53 infants, 35 (66%) required CRD; 28 infants (53%) avoided CRD during the first 6 months 
of life. Globe salvage was achieved in 60% of eyes (54/90) and 93% (41/44) of Group A-C 
eyes. No patient was hospitalized for CRD-related illness. Bilateral disease and Group C-E 
classification was associated with need for CRD (P 0.005, P 0.02). Median follow-up was 
65.2 months. Conclusion: Bilateral disease and Group C-E classification in at least 1 eye 
at presentation increased the chance of an infant requiring CRD.
Scientific Poster 389
Palladium-103 Plaque Radiation Therapy for Large 
Choroidal Melanoma
Presenting Author: Ekaterina Semenova MD
Co-Author(s): Paul Finger MD*
Purpose: To evaluate outcomes after palladium-103 brachytherapy for American Joint 
Commission on Cancer (AJCC) T3- and T4-sized choroidal melanoma. Methods: Forty-sev-
en patients with the AJCC T3 and T4 choroidal melanoma were treated with palladium-103 
brachytherapy. Results: Mean radiation dose to the tumor apex was 68.9 Gy. At a mean 48 
months, local control was 91.5%; and eye retention, 89.4%. Treatment-related complica-
tions were radiation maculopathy (66%), radiation optic neuropathy (51.1%), secondary 
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cataract (36.4%) and secondary glaucoma (17%). Vision was better than or equal to 20/200 
in 53.2% of patients. Metastatic melanoma developed in 31.9% of patients. Conclusion: 
Palladium-103 ophthalmic plaque radiation therapy can be used as an eye- and vision-
preserving treatment for relatively large AJCC T3 or T4 choroidal melanomas.
Ophthalmic History
SESSION ONE
Scientific Poster 130
The Last Ride of Henry II: The Demise of the Sport of 
Jousting in France After an Organic Orbital Foreign Body
Presenting Author: Kian Eftekhari MD
Co-Author(s): Christina H Choe MD, M Reza Vagefi MD, Lauren A Eckstein MD PhD
The sport of jousting flourished during the Renaissance in Western Europe. However, the 
sport was not without its dangers, and traumatic eye injuries were common. In 1559, King 
Henry II of France was injured in a jousting match. During the king’s last ride of the day, he 
did not buckle his visor and was struck with a wooden lance in his right eye. His surgeons, 
Ambroise Pare and later Vesalius, described his injury as a splinter of wood that had en-
tered the right orbit. They did not intervene at the time to remove the organic material in 
the orbit. The king went on to develop a fulminant meningitis. Despite the best efforts of 
his famous physicians, King Henry II died of an organic orbital foreign body, and his death 
coincided with the demise of jousting in France.
Scientific Poster 131
Blindness and the Blues
Presenting Author: Nicholas K Wride MBChB*
Purpose: To analyze blind musicians from the Mississippi Delta region and how they came 
to influence Delta blues music. Methods: A retrospective search of print media, the Inter-
net, and music sources was performed to gather data on blind blues recording artists active 
pre-1950. Results: Thirty-one cases were identified for the purposes of this study. M:F, 
30:1. In 15 cases, the probable cause of blindness was documented: 6 were due to trauma, 
3 from glaucoma, and 3 from congenital cataract. The most common instrument was guitar 
(21 cases). Conclusion: Due to a unique combination of events, such as their disability and 
environmental and socioeconomic factors, blind blues musicians performed a crucial role 
in the development of blues music. This study assesses and celebrates their achievements.
Scientific Poster 132
Boleslaw Wicherkiewicz: An Interesting Contributor to 
European Ophthalmology
Presenting Author: Andrzej Grzybowski MD*
Co-Author(s): Dieter Schmidt Sr**
Purpose: Boleslaw Wicherkiewicz (1847-1915) published about 300 scientific reports in 
Polish, German, English, and French; however, both his interesting life and his scientific 
achievements were never studied in detail. The aim of this study is to fill this gap. Meth-
ods: The study is based on analysis of all papers written by Wicherkiewicz, mainly in Polish 
and German. The biographical details were verified in National Archives in Poznan and Cra-
cow, cities where he lived and worked. Results: His original contributions on oculoplastic 
surgery, cornea transplants, glaucoma surgery, cataract surgery, and clear lens surgery in 
myopia are presented. Conclusion: Wicherkiewicz was an important contributor to Euro-
pean ophthalmology.
Optics, Refraction, Contact Lenses
SESSION ONE
Scientific Poster 133
Scleral Contact Lens in Pellucid Marginal Degeneration
Presenting Author: Jagadesh C Reddy MD
Co-Author(s): Varsha M Rathi DO, Preeji Mandathara, Srikanth Dumpati**
Purpose: To assess the visual outcome of scleral contact lenses in patients with pellucid 
marginal degeneration (PMD). Methods: Nineteen patients underwent trial with scleral 
contact lens (PROSE; USA) for:00 PMD. Lenses with different front surface eccentricities 
were tried to improve the visual acuity. Results: Twenty eyes of 12 patients received the 
lenses. Mean age was 43.83 years. Two patients had superior PMD; 4 eyes had coexisting 
keratoconus and PMD. Visual acuity improved with scleral lens by more than 2 lines in all 
eyes. The front-surface eccentricity ordered was 0.6 in most of the eyes; 1 eye had 0.3 ec-
centricity. Two eyes had improved visual acuity, with 0.8. Two patients had hydrops during 
the wearing period. Conclusion: Scleral lenses improve visual acuity in PMD.
Scientific Poster 134
An Explanation for Over-emmetropization Among Chinese 
Children: Re-evaluation of 5757 Chinese Schoolchildren’s 
Refractive Error
Presenting Author: Yining Shi MD
Purpose: To observe the natural course of myopization in Chinese schoolchildren. Meth-
ods: 5757 students in 4 primary and middle schools underwent noncycloplegic refraction, 
VA, IOP, fundus evaluation, and the special designed questionnaire. Their data were input 
into a special computer program and statistically analyzed. Results: With no hyperotic 
buffering left for normal emmetropization, Chinese childrens’ myopization began at 7 years 
old in an average refractive error -0.78 D, instead of +2.5 D. Their myopic shift progressed 
to -3.75 D at 18 years old during normal emmetropization with the -0.22 D average increase 
per year to compensating 1-mm normal ocular axial length growing. Conclusion: The high 
prevalence of myopia in Chinese children may be due to an exhausted hyperotic buffering 
with normal speed emmetropization.
SESSION TWO
Scientific Poster 390
Scleral Contact Lens Fitting in Keratoconus
Presenting Author: Varsha M Rathi DO
Co-Author(s): Preeji Mandathara, Srikanth Dumpati**, Bhupesh Bagga DO MBBS
Purpose: To report success and failures in fitting scleral contact lens (PROSE; USA) in kera-
toconus (KC). Methods: 106 out of 941 patients seen in scleral lens clinic during 2009-2012 
had KC and were analyzed retrospectively. Results: Sixty-six patients wore and 40 patients 
did not order lenses. Reasons for poor candidates were no visual improvement (NVI), 13; 
mentally challenged, 1; lens insertion failure, 2; not comfortable, 2; and ghost images, 2. 
Among the good candidates: Did not order, 20; underwent keratoplasty, 4; not interested, 
7; undecided, 3; NVI, 2; training failure, 2; glaucoma, 1; monetary reasons, 1. Conclusion: 
Twenty of 106 KC patients were poor PROSE candidates.
Scientific Poster 391
Accuracy of the Retinomax K-Plus3 in Measuring 
Refractive Error Within a Pediatric Population
Presenting Author: Michelle Yun Peng
Co-Author(s): Noelle S Matta COT, David I Silbert MD*, Jing Tian MS, Eric L Singman 
MD PhD
Purpose: To evaluate the accuracy of the Retinomax K-plus3 handheld autorefractor (AR) 
as compared to a pediatric ophthalmologist in determining refractive error in cyclopleged 
children. Methods: We determined the sphere, cylinder power, and axis of 622 eyes in 311 
children, 5 months to 17 years. A paired t-test was performed for sphere, cylinder power, 
axis of astigmatism, and spherical equivalent, and a 1-sample t-test for vector dioptric 
distance. Results: Overall, the refractions were not significantly different with regard to 
cylinder power and axis. An age-group comparison showed inconsistency in statistically 
similar refractive error parameters among the different age groups. Conclusion: In chil-
dren ≤ 18 years old, the Retinomax AR provides a reasonable estimate of only cylinder 
axis and power.
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Orbit, Lacrimal, Plastic Surgery
SESSION ONE
Scientific Poster 135
Medial Epicanthoplasty for Epiblepharon and Entropion 
Patients With Combined Epicanthal Folds
Presenting Author: HyungChul Kim MD
Co-Author(s): Helen Lew MD PhD**
Purpose: To evaluate the clinical outcomes following modified epicanthoplasty to treat 
the epiblepharon and entropion in Korean patients. Methods: Between October 2010 and 
February 2013, epiblepharon and entropion were treated using modified epicanthoplasty 
in 40 patients. Prominent epicanthal folds were corrected, and horizontal tension from the 
lower eyelid to medial canthal angle was released by pericilliary V-Y plasty (n = 15) or modi-
fied z-plasty (n = 25). Results: The mean age of the patients was 21.8 ± 19.5 years, and the 
average follow-up period was 11.1 ± 5.1 months. Cilia touch and erosion of cornea were 
removed without recurrence and operative scars were acceptable in all patients. Conclu-
sion: Epiblepharon or entropion combined with epicanthal folds can be treated effectively 
and safely using modified epicanthoplasty.
Scientific Poster 136
Usefulness of Orbital Fat to Total Orbit Area Ratio in Mild 
to Moderate Thyroid-Associated Ophthalmopathy
Presenting Author: HyungChul Kim MD
Co-Author(s): Won Kyung Song MD, Helen Lew MD PhD**
Purpose: To find a useful predictor of orbital CT images in mild to moderate thyroid-as-
sociated ophthalmopathy (TAO). Methods: Between January 2012 and March 2013, 74 
subjects were divided into 49 TAO patients and 23 controls following ophthalmic examina-
tion and thyroid function test. The cross-sectional areas of extraocular muscles and total 
orbit area were calculated on coronal view 6 mm posterior from posterior pole of globe 
using Syngo (2007, Argus, Siemens) and analyzed according to the clinical manifestations. 
Results: Orbital fat to total orbit area ratio (OF/TOA) was increased in TAO with retraction 
(P = .009) and TAO with proptosis (P = .011). There was a positive correlation between 
proptosis and OF/TOA (P = .008). Conclusion: The OF/TOA ratio is a useful predictor in 
mild to moderate TAO.
Scientific Poster 137
Eight-Year Experience With Transcanalicular Laser-
Assisted Dacryocystorhinostomy
Presenting Author: Brigita Drnovsek Olup MD PhD*
Co-Author(s): Matej Beltram*
Purpose: To present 8 years of experience with minimally invasive transcanalicular laser-
assisted dacryocystorhinostomy (TCL-DCR) with a 980-nm diode laser. Methods: We per-
formed 332 consecutive TCL-DCR procedures with silicone stent intubation, under general 
or local anesthesia. The approach to osteotomy is via the anatomical pathway of tears, 
and a 980-nm diode laser is used with a power of 10 W. The silicone stents have been 
removed on average 4 months postoperatively and patency of the nasolacrimal duct has 
been assessed at up to 48 months follow-up. Results: 249 out of 301 patients had a pat-
ent nasolacrimal duct after removal of the silicone stents, yielding a success rate of 83%. 
Conclusion: The 980-nm diode laser is an effective tool for TCL-DCR, with a success rate 
higher than other endoscopic DCR procedures.
Scientific Poster 138
Experience With Medpor-Coated Tear Drainage Tube: A 
Retrospective Chart Review
Presenting Author: Vasudha Gupta MD
Co-Author(s): Ritesh Gupta, Jerrod S Kent MD, Yasser A Khan MD
Purpose: To analyze the outcomes of lacrimal bypass surgery with Medpor-coated tear 
drainage tube. Methods: A retrospective chart review was performed on all patients who 
had placement of a Medpor-coated tear drain between 2010 and 2012. The data collection 
included patient demographics, length of follow-up, patient comfort, position and function 
of tube, and any associated complications. Results: A total of 9 patients who had place-
ment of 11 tubes were identified. There were 3 females and 6 males, mean age of 50 years, 
with follow-up averaging 289 days. Only 1 case (9%) had extrusion. The most common 
complications were granuloma formation (n = 5, 45%), followed by conjunctival overgrowth 
(n = 2, 18%). Conclusion: Medpor-coated Jones tubes offer a lower rate of extrusion with 
longer-term placement.
Scientific Poster 139
Ocular Complications After Acoustic Neuroma Resection
Presenting Author: Srinivas Sai Kondapalli MD
Co-Author(s): Ian Kirchner, David K Yoo MD, Charles S Bouchard MD
Purpose: To evaluate ophthalmic complications following acoustic neuroma resection 
(ANR). Methods: Records of patients undergoing ANR from 1988 to 2012 were reviewed. 
Operative approach and tumor size were noted. Postoperative ocular complications and 
trigeminal nerve palsy were recorded. Results: 352 patient records were reviewed. 152 of 
these patients (43%) had ocular complications, the most common of which were dry eye 
and epiphora. Fifty-seven patients (16%) had trigeminal nerve palsy manifesting predomi-
nantly as corneal hypoesthesia. Translabyrintine / transcochlear surgical approach in ANR 
had the highest complication rate, of 67%. Tumors > 2.0 mm resulted in greater paresis (P < 
.001). Conclusion: ANR can result ocular complications. Preoperative knowledge of surgi-
cal approach and tumor size may predict the postoperative course.
Scientific Poster 140
Cosmetic and Quality of Life Outcomes of the Direct Brow 
Lift
Presenting Author: Srinivas Sai Kondapalli MD
Co-Author(s): Craig N Czyz DO, Jill Annette Foster MD FACS*, Kenneth V Cahill MD 
FACS
Purpose: Retrospective study to evaluate the postoperative changes in quality of life in pa-
tients who underwent direct browplasty. Methods: Patients who underwent direct brow-
plasty surgery alone were asked to participate in a 14-question survey. Results: Twenty-
five patients participated in the study. Ninety-two percent of patients responded favorably 
when asked if they were happy with the results of the surgery. Overall, 15 patients noted 
an improvement in vision, and 14 participants denied having a visible facial scar. Moreover, 
21 patients denied light sensitivity, 25 denied any new headaches/pain, and 24 denied 
forehead/scalp numbness. Conclusion: Direct browplasty provides an improvement in 
patients’ quality of life, and issues with visible facial scars may be overstated.
Scientific Poster 141
Evaluation of Morfometric Data and Topographic Changes 
Before and After Application of Botulinum Toxin-A in 
Patients With Hemifacial Spasm
Presenting Author: Teissy H Osaki MD
Co-Author(s): Midori H Osaki MD, Tammy H Osaki MD, Mauro S Campos MD
Purpose: To evaluate the eyelid fissure and corneal topography in patients with hemifa-
cial spasm (HS) before and 15 days after botulinum toxin-A treatment (BTX-A).  Methods: 
Photographs and corneal topography in patients with HS were performed before and 15 
days after treatment with BTX-A.  Results: We evaluated 15 patients with HS. The mean 
values of the eyelid fissure (Image J software) were 7.08 and 9.61 mm (P < .05), and the 
mean steep Ks were 45.12 D and 44.97 D (P > .05) before and after treatment, respectively, 
in the treated eye. A correlation was observed after BTX-A application: the lower the eyelid 
fissure, the higher the steep K. Conclusion: The increase of the eyelid fissure was statisti-
cally significant 15 days after treatment with BTX-A. A larger series and longer follow-up 
are needed to permit further considerations.
Scientific Poster 142
A Predictive Model of Temporal Artery Biopsy Outcomes: 
A Validation Study
Presenting Author: Chris T Waite MD
Co-Author(s): Ezekiel Weis MD
Purpose: Validation of a predictive model for temporal artery biopsy. Methods: A prior 
analysis of 119 cases revealed that a simple model including ESR, CRP, and platelets could 
predict a subset of patients (40%) with a 100% pretest probability. No case was misclas-
sified. This current study utilized a retrospective case-control series of patients undergo-
ing temporal artery biopsy to validate this original model. Results: 136 new consecutive 
patients from a different institution were analyzed. The previously defined thresholds suc-
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cessfully predicted a large subset of patients (38%) in which the biopsy result could be 
predicted with 100% certainty. Conclusion: Utilizing a simple clinically applicable predic-
tive model of the pretest probability, 38%-40% of temporal artery biopsies can be avoided.
Scientific Poster 143
Comparison of Fasanella-Servat and Small-Incision 
Techniques for Involutional Ptosis Repair
Presenting Author: Mahsa A Sohrab MD
Co-Author(s): Gary Stephen Lissner MD
Purpose: To compare small-incision external and Fasanella-Servat internal approaches for 
involutional ptosis. Methods: Retrospective review of 104 procedures by the same surgeon 
(GSL). Main outcome measures included patient satisfaction, marginal reflex distance one 
(MRD1), surgical complications, and operating time. Results: MRD1 increased an average 
of 3.38 mm (±0.79) in the Fasanella-Servat group and 2.79 mm (±0.8) in the small incision 
group (P < .01). Preoperative MRD1 was lower in the Fasanella-Servat group (P < .01), but 
similar postoperatively in the 2 groups (P = .5). Average operating time was 53 and 27 
minutes in the small-incision and Fasanella-Servat groups, respectively (P < .01). Conclu-
sion: The Fasanella-Servat approach provides a shorter operating time, with equivalent 
postoperative MRD1 and satisfaction.
Scientific Poster 144
Clamp-Assisted Retractor Advancement for Lower Eyelid 
Involutional Entropion
Presenting Author: Nicholas Siu Kay Fung MBCHB MRSCED(OPHTH)
Co-Author(s): Marcus M Marcet MD
Purpose: To describe a novel approach to internal repair of lower lid entropion using the 
Putterman clamp. Methods: Retrospective, consecutive case series of patients with en-
tropion who underwent retractor advancement using the clamp. Results: Seven eyes of 
6 patients (average age: 80; 4 women and 2 men) were analyzed. Complete resolution 
was achieved in 5 of the 6 patients (83.3%). The 1 patient with recurrence had 2 previous 
entropion surgeries on each eye over the past 4 years; there was lid laxity, and horizontal 
tightening was needed. No severe adverse events occurred in the patients. Conclusion: 
Clamp-assisted lower lid retractor advancement offers a safe and effective, minimally in-
vasive approach to involutional entropion. Further study is needed to assess its role in 
recurrent entropion.
Scientific Poster 145
Corneal Biomechanical Properties of Patients With 
Thyroid-Associated Ophthalmopathy
Presenting Author: Ahmet M Sarici MD
Co-Author(s): Velittin Oguz MD**, Mustafa Hepokur MD, Burcu Balta, Ahmet Ozkok MD
Purpose: To compare the biomechanical properties of the cornea and IOP between patients 
with Graves ophthalmopathy (GO) and healthy individuals. Methods: Forty-two healthy 
individuals (control group) and 42 patients with GO (study group) underwent Reichert ocu-
lar response analyzer (ORA) measurements prospectively. Corneal hysteresis (CH), corneal 
resistance factor (CRF), and Goldman-related IOP (IOPg) were recorded. Results: Mean CH 
was 10.2 ± 0.6 mmHg and 11.3 ± 1.3 (P = .1); mean CRF was 9.7 ± 1.1 mmHg and 11.9 ± 1.5 
mmHg, P = .02); mean IOP(g) was 13.9 ± 2.9 mmHg and 14.9 ± 2.6 mmHg in the study group 
and control group (P = .3), respectively. There were no statistically significant differences 
between groups. Conclusion: Biomechanical properties of the cornea are not altered in 
patients with GO compared with normal controls.
Scientific Poster 146
Preorbital and Orbital Volume in Blowout Fractures
Presenting Author: Emile Sharifi MD
Co-Author(s): Thao Phuong Le MD, Lee M Mitsumori MD**, Arash Jian-Amadi MD
Purpose: To explore orbital tissue volume relating to the mechanism of blowout fractures. 
Methods: We performed retrospective measurements of CT-based orbital scans, measur-
ing orbital and preorbital volumes. Fifty scans of patients with unilateral orbital blowout 
fractures were measured and compared to a control group of 50 patients with unilateral 
globe rupture. Results: Patients with blowout fractures had on average 1.23 cm3 less 
preorbital volume, Student t-test P-value of .04 and 1.83 cm3 less orbital tissue volume, 
Student t-test P-value of .0004, compared to volumes in patients with open globe injuries. 
Conclusion: The distribution of orbital tissue volume is inversely correlated with the de-
gree of bony damage in patients suffering unilateral blunt trauma.
SESSION TWO
Scientific Poster 392
Determinative Factors in Surgical Planning of Cosmetic 
and Reconstructive Eyebrow Surgery
Presenting Author: Ali Makateb MD
Co-Author(s): Mohammad Taher Rajabi MD**
Purpose: To identify different factors that an oculoplastic surgeon should consider while 
practicing cosmetic or reconstructive eyebrow surgery in order to have the patient’s final 
satisfaction. Methods: Five photographs were taken from 60 females while demonstrat-
ing their preferred eyebrow position with fingers. Eyebrow landmarks measured in ideal 
brow position. Results: Most of subjects (49%) preferred a wider brow angle. Location of 
brow peak was transferred to the lateral canthus in desired position. The desired eyebrow 
apex angle in 2 age groups of > 40 years and ≤ 40-year-old subjects was not statistically 
different. Conclusion: Oculoplastic surgeons should consider the difference of culture, 
race, age, and desire of the patients to have their surgical plans for every individual patient 
preference.
Scientific Poster 393
The Versatility of the Temporoparietal Fascial Graft in 
Orbital Implant Exposure
Presenting Author: Liam Daniel Turner MBBS
Co-Author(s): Anjana H aridas BMBCH MA MRCOPHTH, Timothy J Sullivan MBBS
Purpose: To demonstrate the versatility of the temporoparietal fascial graft (TPFG) in or-
bital implant exposures of varying duration, implant types, and patient age as well as for 
recurrent exposure. Methods: Retrospective, interventional, noncomparative case series. 
Results: Twelve patients (13 grafts) are presented with a mean follow-up of 9.5 months. 
The duration of exposure prior to grafting ranged from 1 to 11 months occurring in bioc-
eramic, hydroxyapatite, porous polyethylene, and acrylic implant types. There were 2 graft 
failures (success rate, 84.6%), 1 of which was treated with a second TPFG. Two of the cases 
were from the pediatric age group. Conclusion: This study provides further supporting 
evidence for the safety and efficacy of the TPFG and demonstrates the use of this graft in a 
variety of different clinical situations.
Scientific Poster 394
Lacrimal Canalicular Compression and Discharging 
Concretions Through the Puncta Without Canaliculotomy: 
A Minimally Invasive Surgical Procedure for Primary 
Canaliculitis
Presenting Author: Tu Yunhai MD
Co-Author(s): Jia Qu MD**, Jialiang Zhao Sr MD**
Purpose: To evaluate treatment results of manual lacrimal canalicular compression and 
discharging the concretions through the puncta without canaliculotomy for primary canalic-
ulitis. Methods: Twenty-eight patients with primary canaliculitis who were treated by this 
method. The concretions were sent to culture evaluation and histopathologic examination. 
The rigid microendoscopes with irrigation channels (PolyDiagnost GmbH; Germany) were 
performed through the puncta to confirm there were no concretions in the lacrimal system 
of any patients. Results: All patients were cured after primary treatment. The concretions 
were removed completely by this method, which was confirmed by rigid microendoscopes. 
Conclusion: This procedure may be a simple and highly effective treatment method for 
primary canaliculitis that is minimally invasive to the lacrimal system.
Scientific Poster 395
The Predictive Value of Probing and Irrigation in 
Congenital Nasolacrimal Obstruction
Presenting Author: Tsvi Sheleg MD**
Co-Author(s): Yanir Kassif MD, Shimon Rumelt MD MPA
Purpose: To evaluate which steps of probing and irrigation (P&I) predict the need for ad-
ditional intervention (AI). Methods: Comparison between the success of P&I and success 
of P&I steps: first–irrigation, probing– and second–irrigation. Results: Of 101 consecutive 
procedures, 14 (14%) required AI. Twenty percent of unsuccessful and 3% of successful 
first irrigation required AI (P = .011). Sixty-two percent of unsuccessful and 2% of successful 
second irrigation required AI (P < .001). Thirteen percent of easy and 33% of difficult probing 
required AI (P = .054). Seventeen percent of those in which the probe was visualized and 
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22% of those in which it was not required AI (P = .553). Conclusion: Failure of second 
irrigation was a predictor for failure of P&I and for AI. AI may be performed in the same 
setting of P&I if second irrigation fails.
Scientific Poster 396
Clinical Profile and Survival Factors in Orbital 
Mucormycosis: A Large Case Series
Presenting Author: Farzad Pakdel MD
Co-Author(s): Gholamhoseyn Aghai MD, Mitra Oghazian, Mehdi Modarres MD, Mohsen 
B Kashkouli MD**
Purpose: To determine the clinical profile and survival factors in patients with orbital mu-
cormycosis (OM) in a large case series. Methods: Clinical data of patients with OM from 
March 2008 to March 2012 were reviewed. Forty-two consecutive patients with biopsy-
proven OM were included. Mean age was 49.5 (range: 5-80) years. Proptosis, orbital apex 
syndrome (OAS) periorbital swelling, and eschar were seen in 41.5%, 75.6%, 97.6%, and 
31%, respectively. Overall mortality was 35.7%. OAS did not increase mortality (P = .929). 
Facial palsy was seen in 19.4%. Mortality was significantly less in exenterated patients (15 
vs. 0 patients in nonexenterated and exenterated groups, respectively) (P < .018). Conclu-
sion: OAS and facial palsy could be regarded as hallmarks of the disease. Timely exentera-
tion can significantly increase survival.
Scientific Poster 397
 h  Evaluating the Staging of Pediatric Orbital Cellulitis 
Utilizing Computerized Tomography
Presenting Author: Tran D Le MD
Co-Author(s): Eugene S Liu MD, Feisal A Adatia MD*, J Raymond Buncic MD, Susan 
Blaser MD
Purpose: To characterize significant radiological signs in children with orbital cellulitis 
(OC). Methods: Retrospective 11-year review of patients with orbital computerized tomog-
raphy (CT) querying OC at the Hospital for Sick Children, Canada. Results: In 101 cases of 
OC, 71 were managed with systemic antibiotic(s), and 30 required surgeries. Bony destruc-
tion was associated with surgical intervention (P-value = .02). The sensitivity and specificity 
of using subperiosteal abscess (SPA) size of 3.8 mL as a cut-off for determining whether 
the OC case will require surgery is 76% and 85%. The likelihood of surgery for SPA less 
than 3.8 mL is 14%, greater than 3.8 mL is 70% (P-value < .0001). Conclusion: Children 
with OC who have bony destruction on CT and SPA greater than 3.8 mL are more likely to 
require surgical intervention.
Scientific Poster 398
The Physics Behind Bleb-Induced Lid Retraction: 
Implications for Treatment and Prevention During Ptosis 
Repair
Presenting Author: Thomas Clark
Co-Author(s): Carolyn D Quinn MD**, Erin Shriver MD, Juan F Batlle MD*
Purpose: To propose a mechanism for bleb-induced lid retraction based on vector forces 
at the lid-bleb interface. Methods: A retrospective review of 4 patients with an analysis of 
the vector forces involved. Results: The net force vector, the summation of all forces act-
ing at the lid-bleb interface, is directed vertically and displaces the lid superiorly. Our case 
series includes 1 patient with resolution of lid retraction immediately after takedown of the 
bleb, 1 who was difficult to adjust during ptosis repair, and 2 patients successfully treated 
with botulinum toxin. Conclusion: Our vector force theory for bleb-induced lid retraction is 
based on intraoperative case experience and has significant implications for ptosis repair in 
patients with blebs. We are also the first to report treatment with botulinum toxin.
Scientific Poster 399
The Use of Neuronavigation in Recurrent Orbital Tumors
Presenting Author: Ihab S Othman MD
Purpose: To evaluate the infrared-based neuronavigation system VectorVision (BrainLab) 
in surgical removal of recurrent orbital tumors. Methods: Four recurrent tumors were 
evaluated. All patients underwent spiral CT scanning preoperatively, and the CT data was 
imported to the BrainLab navigation system. Tumors were nasally located in 2 patients 
and temporally located in 2 cases and extending to the orbital apex in all cases. Pathol-
ogy was recurrent deep dermoid, isolated neurofibroma, pseudo-orbital inflammation, and 
rhinoscleroma invading orbit. Results: Complete tumor excision could be performed in all 
cases. Accurate intraoperative surgical localization was successful. No recurrences were 
observed over a mean of 18 months follow-up. Conclusion: Through the use of intraopera-
tive acquisition of CT images, surgical precision can be improved.
Scientific Poster 400
Relationship Between Lower Eyelid Epiblepharon and 
Epicanthus in Korean Children: A Matched Case-Control 
Study
Presenting Author: Kyung In Woo MD
Co-Author(s): Yoon-Duck Kim MD
Purpose: To investigate the effect of epicanthus on epiblepharon. Methods: 119 children 
who received epiblepharon repair from 2010 to 2012 and 119 age-sex matched control 
group were reviewed. Type of epicanthus, intercanthal distance ratio (ICD ratio: intercan-
thal distance / 0.5 interpupillary distance) were measured. Results: Mean age was 5.7 
years (range: 2-16) in both groups. Epicanthus closer to lower eyelid margin was more prev-
alent in epiblepharon than in control group (P = .028). ICD ratio was higher in epiblepharon 
group (mean 1.394 vs. 1.343, P < .001), which was significant, especially in the age group 
of 4 or more years. ICD ratio decreased with growing in control group, but remained higher 
in epiblepharon group. Conclusion: Epicanthus closer to lower eyelid margin and high ICD 
ratio was associated with epiblepharon in Asians.
Scientific Poster 401
Outcomes of Posterior-Approach “Levatorpexy” in 
Congenital Ptosis Repair
Presenting Author: Suresh R Sagili MBBS
Co-Author(s): Alabbadi Alabbadi, Raman Malhotra MBChB FRCOphth
Purpose: We describe a minimally invasive technique and report our experience of posteri-
or approach levator plication (“levatorpexy”) for congenital ptosis. Methods: Retrospective 
review of 16 patients. Surgical procedure involves exposing posterior surface of the levator 
muscle through a transconjunctival approach. Levator muscle is advanced and plicated us-
ing a suture passed through its posterior surface to tarsal plate and tied on the skin. No 
tissues (conjunctiva, Muller muscle, levator) are excised during this procedure. Results: 
Fourteen patients (87%) achieved the desired eyelid height and fulfilled our criteria set for 
success. Conclusion: Posterior approach levatorpexy appears to be a safe and effective 
procedure for correction of congenital ptosis, particularly with moderate or better levator 
function.
Scientific Poster 402
 h  The New Bicanalicular Double Silicone Encirclage 
Technique in Canalicular Laceration Reconstruction
Presenting Author: Yongju Song MD
Co-Author(s): Seong-Won Yang MD PhD
Purpose: To introduce the new bicanalicular double silicone encirclage in canalicular lacer-
ation. Methods: Fifty-six patients were reviewed. Thirty-two were treated with mono sili-
cone tube (A) and 24 with bicanalicular double encirclage (B). Group A was subdivided with 
monocanalicular intubation (Aa), bicanalicular intubation (Ab), and bicanalicular encirclage 
(Ac). The outcome was analyzed by the timing of management, operation methods, type of 
tubes, and suture knot count. Results: The success rate of Groups A and B were 72% and 
96%. The operation duration was shorter in Group B. There was a significant difference of 
success rate by the operation method, suture knot count, and number of tubes, whereas no 
difference of success rate by the timing of management or type of tubes. Conclusion: The 
new encirclage is time-saving, easy, and a more effective technique.
Scientific Poster 403
Changes in Choroidal Perfusion After Orbital 
Decompression Surgery for Graves Ophthalmopathy
Presenting Author: Chrysavgi Adamopoulou MD
Co-Author(s): Narieman A Nik MD**, Marianna Derdzakyan**, Robert P Murphy MD, 
Adam B Sise MD
Purpose: To assess choroidal perfusion before and after orbital decompression surgery in 
patients with thyroid ophthalmopathy. Methods: Noncomparative case series. Pre- and 
postoperative high-speed indocyanine green angiography (ICG) was performed on 3 pa-
tients undergoing orbital decompression surgery for Graves ophthalmopathy. Results: Four 
eyes of 3 patients underwent orbital decompression surgery. Abnormal choroidal perfusion 
196
Session One is Saturday and Sunday, Nov. 16 & 17. Session Two is Monday and Tuesday, Nov. 18 & 19. Refer to page 156 for poster presentation and tour schedule. 
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.  
No asterisk indicates that the presenter has no financial interest.
Scientific Posters
Sc
ie
nt
ifi
c 
Po
st
er
s
was documented preoperatively on ICG. Postoperatively, there was amelioration in choroi-
dal perfusion as well as visual acuity, color vision, decrease in IOP, and an absence of an af-
ferent pupillary defect. Conclusion: Patients with thyroid ophthalmopathy have abnormal 
choroidal perfusion even in the absence of optic neuropathy. Orbital decompression surgery 
can ameliorate the orbital and choroidal perfusion.
Pediatric Ophthalmology, Strabismus
SESSION ONE
Scientific Poster 147
Effect of IOL Asphericity on Quality of Vision After Cataract 
Extraction in Pediatric Eyes
Presenting Author: Anika Gupta MBBS
Co-Author(s): Usha K Raina MD, Gauri Bhushan MBBS, Vasu Kumar MBBS, Meenakshi 
Thakar**
Purpose: To compare the optical performance of 2 aspheric IOLs with different asphericity 
in pediatric eyes after cataract surgery. Methods: Twenty eyes in the age group 6-16 years 
with developmental cataract were randomly assigned to receive either of the two aspheric 
IOLs (Tecnis ZCB00 or AcrySof IQ SN60WF). At 3 months postoperatively, the outcomes 
compared between the 2 groups were BCVA, contrast sensitivity (CS), and wavefront aber-
rometry. Results: The eyes with AcrySof IQ showed significantly better CS at 3, 6, and 12 
cpd (P < .05). The difference in total ocular aberrations, higher-order aberrations (HOA), and 
spherical aberrations (SA) between the 2 groups was not significant. Conclusion: AcrySof 
IQ results in better contrast sensitivity than Tecnis in children.
Scientific Poster 148
Clinical Comparison of the Optical Performance of 
Spherical and Aspheric IOLs in Pediatric Eyes
Presenting Author: Gauri Bhushan MBBS
Co-Author(s): Usha K Raina MD, Anika Gupta MBBS, Vishaal R Bhambhwani MBBS, 
Basudeb Ghosh**
Purpose: Comparison of optical performance of aspheric vs. spherical IOLs in pediatric cat-
aract. Methods: Forty eyes in the age group 6-16 years with developmental cataract were 
randomly assigned to receive a spherical IOL (AcrySof SN60AT) or an aspheric IOL (Tec-
nis ZCB00 or AcrySof IQ SN60WF). At 3 months postoperatively, the outcomes compared 
between the 2 groups were BCVA, contrast sensitivity (CS), and wavefront aberrometry. 
Results: The aspheric IOL group showed better CS at 1.5, 3, and 6 cpd. Total ocular aber-
rations, higher-order aberrations (HOA), and spherical aberrations (SA) were significantly 
lower in the aspheric group (P < .05). Conclusion: Aspheric IOLs result in better CS and 
decreased ocular aberrations in children.
Scientific Poster 149
Preoperative, Intraoperative, and Postoperative Outcome 
of Cataract Surgery in Children With Down Syndrome
Presenting Author: Rupal H Trivedi MBBS MS*
Co-Author(s): M Edward Wilson Jr MD*, Muralidhar Ramappa MBBS
Purpose: To report outcome of cataract surgery in children diagnosed with Down syn-
drome. Methods: Review of surgery for bilateral pediatric cataract. Results: Twenty-four 
of 640 children (4%). Age at surgery: 1.9 ± 3.7 years. Preop axial length (AL): 19.9 ± 2.8 
mm. Nuclear and cortical were the most common types. Fourteen eyes received primary 
IOL, 10 aphakic, of which 4 received secondary IOL. Follow-up: 6.0 ± 4.7 years. Postop 
complications in 14 eyes with primary IOL: surgical removal of posterior capsule opacifica-
tion (1), removal of dislocated IOL (2) , IOL reposition (2), endophthalmitis (1, after surgery 
for IOL dislocation). IOL reposition / dislocated was noted in 4/14 eyes (29%) with primary 
IOL implantation. Median postop visual acuity: 20/35. Postoperative AL: 23.3 ± 2.1 mm. 
Conclusion: Postoperative complications related to IOL (reposition/removal of dislocated 
IOL) were seen frequently in children with Down syndrome.
Scientific Poster 150
Visual Outcome in Children Who Develop Endophthalmitis 
Following Cataract Surgery
Presenting Author: Vikas Khetan DO
Co-Author(s): Sandeep Mark Thirumalai MD, Tarun Sharma MBBS, Sumita S Agarkar 
MBBS
Purpose: To study the visual outcome in 4 cases of endophthalmitis following cataract 
surgery in children. Methods: Retrospective review of 4 cases of endophthalmitis follow-
ing uneventful cataract surgery from 1997 to 2012 was done. The first symptom and sign, 
investigations, interventions, causative organisms, the final visual acuity achieved were 
recorded. Results: Final visual acuity was 6/12, 6/18, and 6/24 in 2 cases. Acinetobacter 
calcoaceticus was isolated in 2 cases; Pseudomonas stutzeri was isolated in 1. Interven-
tions required included intravitreal injections, vitrectomy, IOL removal, and retinal detach-
ment surgery. Conclusion: Fairly good visual outcome can be achieved with aggressive 
intervention in cases of endophthalmitis following cataract surgery in children.
Scientific Poster 151
Results of Fibrillin-1 Sequencing in Children With Lens 
Subluxation From Inbred Families
Presenting Author: Arif O Khan MD
Co-Author(s): Hanno Jörn Bolz MD, Carsten Bergmann MD**
Purpose: To report the results of fibrillin-1 (FBN1) sequencing for consecutive referred 
children with lens subluxation without broken zonules, cataract, or vitreoretinal degen-
eration in Saudi Arabia, where recessive genetic cause may be more common because 
consanguineous and/or endogamous marriage is customary. Methods: Retrospective case 
series (2009-2012). Results: Out of 8 children, 7 harbored dominant mutations and 1 had 
recessive mutation with unaffected parents (the fourth such family to date). Seven of 8 had 
facial and/or skeletal features suggestive of type 1 fibrillinopathy. Conclusion: Despite the 
setting of consanguinity and/or endogamy in this population, dominant type 1 fibrillinopa-
thy was the major cause for lens subluxation in this cohort. This has important implications 
for genetic counselling and systemic assessment.
Scientific Poster 152
Pediatric Dacryocystorhinostomy: A Success Story
Presenting Author: Sabita Katoch MBBS MD
Co-Author(s): Santanu Mitra MBBS
Purpose: To assess the results of external dacryocystorhinostomy (DCR) in children. Meth-
ods: Eighty-nine DCRs done in 83 patients. Age ranged from 3.3 years to 15 years. Single 
anterior flap anastomosis without intubation was done. Results: Overall success rate was 
93.26%. Of 8 failed cases, 1 cleared on probing, 1 on revision diode laser DCR, and 2 
were partially patent. One in 3 cases with Down syndrome failed. Conclusion: Pediatric 
DCRs have excellent results. Syndromes associated with facial anomalies could worsen 
the prognosis.
Scientific Poster 153
 h  SmartTools in the Toolbox: Smartphone Applications in 
Pediatric Ophthalmology and Strabismus
Presenting Author: Timothy P Lindquist MD
Co-Author(s): Scott E Olitsky MD
Purpose: To demonstrate use of smartphone applications in clinical practice of pediatric 
ophthalmology and strabismus. Methods: Smartphone applications on the iOS, Android, 
and Windows platforms were used to demonstrate the following measurements and cal-
culations: (1) degree of angle for head tilt, face turn, and chin position, (2) degrees of cy-
clotorsion in conjunction with Maddox rod testing, Angle of axis for application of Fresnel 
prism, (3) final prescription from over-refraction, and (4) contact lens power from refrac-
tion. Results: Pictorial demonstrations of each application will be included. Conclusion: 
Smartphone applications can enhance the ease, accuracy, and precision of measurements 
and calculations in clinical practice.
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Scientific Poster 154
An iPhone Application to Measure Corneal Diameter in 
Children
Presenting Author: Mosa AlHarby MD
Co-Author(s): Mohammed A Alshamrani MBBS, Deepak Paul Edward MD
Purpose: To compare an iPhone app for noncontact measurement of corneal diameter 
(CD) to the contact caliper method. Methods: Multiple CD measurements in one eye with 
the “multimeasure iPhone” app and calipers in children (n = 20) under anesthesia by two 
observers. iPhone CD was measured on corneal photographs taken with the head facing 
straight and at a tilt. Results: Caliper CD (11.68 ± 0.41 mm) was not significantly different 
from the iPhone app (11.85 ± 0.28 mm) in the straight position. In contrast, head tilt CD 
(11.34 ± 0.47 mm) resulted in a significant deviation from the mean values obtained with 
the other two measures. Conclusion: CD measurements using an iPhone app might be 
a useful noncontact method of measuring diameter in children. Head position plays an 
important role in accurate measurements.
Scientific Poster 155
A Fresh Look at the iScreen Utilizing the New American 
Association for Pediatric Ophthalmology and Strabismus 
Referral Criteria
Presenting Author: David I Silbert MD*
Co-Author(s): Noelle S Matta COT
Purpose: To evaluate the iScreen photoscreener in detecting amblyopia risk factors in chil-
dren age 6 and under using the newly revised 2013 American Association for Pediatric Oph-
thalmology and Strabismus (AAPOS) referral criteria. Methods: Retrospective review of 
children who had an iScreen as part of a pediatric ophthalmology exam. Amblyopia risk fac-
tors were based on the current AAPOS criteria. Results: 184 children were examined. Fifty-
six percent were found to have amblyopia risk factors. The iScreen was found to have a 
sensitivity of 93% and specificity of 91%. Conclusion: The iScreen photoscreener is a fast, 
user-friendly, portable tool for the detection of amblyopia risk factors in children. iScreen’s 
reading center has continued to improve their interpretation paradigms and seems to have 
improved both sensitivity and specificity for the newly revised AAPOS referral criteria.
Scientific Poster 156
 h  Retinopathy of Prematurity Screening Outcomes and 
Treatment for 23 Weeks Gestational Age Infants: Seven 
Years’ Experience
Presenting Author: Juan Ayala Haedo MD
Co-Author(s): Majd Dardas, Mina Chung MD*, Sanjiv B Amin MBBS MD MS
Purpose: To evaluate adequacy of initiating screening at 30 weeks postmenstrual age 
(PMA) to detect threshold ROP in 23 weeks gestational age (GA) infants. Methods: ROP 
results of 23 weeks GA infants born between Jun 2005 and July 2012 were reviewed. 
Results: Forty-one infants with mean GA of 23.6 weeks (23.1-23.9) were cared for at our 
NICU. Nineteen (46.3%) had ROP exams and 22 (53.6%) died before being screened at 30 
weeks. ROP exams performed at:00 PMA 30, 31.6, and 33.3 weeks showed that 3 (15.8%), 
10 (52.6%), and 16 (84.2%) infants had evidence of any ROP, respectively. Seven (36.8%) 
required laser surgery at mean PMA of 38.1 weeks (33.6-45.7). Following laser, 4 showed 
complete and 3 showed partial regression of ROP by 40 weeks PMA. Conclusion: Our data 
suggest that initiating screening at 30 weeks PMA is adequate to detect threshold ROP in 
23-week GA infants.
Scientific Poster 157
Zone I and Posterior Zone II Retinopathy of Prematurity
Presenting Author: Milad Modabber MS
Co-Author(s): Sourabh Arora MD*, Gloria M Isaza-Zapata MD**
Purpose: To compare clinical presentation and progression to treatment for infants clas-
sified as zone I (Z1) and posterior zone II (PZ2) ROP. Methods: A retrospective analysis 
of 50 infants with Z1 and PZ2 ROP assessed for postmenstrual age (PMA) at first ROP 
diagnosis and treatment. Retinal photographs were also analyzed. Results: Of the 50 in-
fants, 14 (28%) were Z1 ROP and 36 (72%) were PZ2 ROP. The incidence of treatment was 
higher in Z1 ROP (79%) than in PZ2 ROP (47%). In Z1 ROP, 64% had an elapsed time of ≤ 
2 weeks from ROP diagnosis to treatment, compared with 50% of PZ2 infants. Retinal 
images reflected the differential presentation of ROP across these zones. Conclusion: 
Despite similar clinical courses, Z1 ROP infants required treatment earlier and more often 
than PZ2 ROP patients.
Scientific Poster 158
Comparative Outcomes of Intravitreal Bevacizumab 
vs. Laser Photocoagulation for Type 1 Retinopathy of 
Prematurity
Presenting Author: Christopher Hwang
Co-Author(s): G Baker Hubbard MD, Amy K Hutchinson MD, Scott R Lambert MD*
Purpose: To determine the efficacy of intravitreal bevacizumab (IVB) vs. laser photocoagu-
lation (LP) for the treatment of zone I ROP and the recurrence rate for zone I/II ROP treated 
with LP. Methods: Data from consecutive infants treated with Type 1 ROP from 2008-2012 
were analyzed. Results: The recurrence rates were similar with both treatments for zone I 
(IVB, 3/22 (14%) eyes; LP, 1/14 (7%) eyes; P = 1.0), but the time to re-treatment was longer 
with IVB (IVB, 7.5 weeks; LP, 2.6 weeks). The recurrence rate for zone I/II ROP treated with 
LP (1/51 eyes, 2%) was significantly lower than the rate reported in the BEAT-ROP study 
(23%) (P = .002). No infant treated with IVB died; 2 infants treated with LP died. Conclu-
sion: Recurrence rates for zone I ROP after IVB vs. LP were similar, and the recurrence rate 
for ROP treated with LP was low.
Scientific Poster 159
Overcorrection Shift Following Surgery for Hypertropia in 
Superior Oblique Palsy
Presenting Author: Kyle Cox MD
Co-Author(s): Quynh Tran PhD, Natalie Kerr MD
Purpose: To determine if inferior rectus (IR) recession on adjustable suture is a risk factor 
for overcorrection shift in patients operated for superior oblique palsy (SOP). Methods: 
Retrospective chart review of patients with SOP undergoing either single inferior oblique 
(IO) or IR on adjustable suture, recording postoperative shift during the 2 months following 
surgery. Results: IO group (n = 26) had 8 (34.7%) overcorrection shifts of ≥ 2 PD. The IR 
group (n = 11) had 5 (45.4%) overcorrection shifts (P = ). The amount of overcorrection was 
not different (P = .6354). Conclusion: Overcorrection shifts occur with similar frequency 
and magnitude after IO or IR recession in SOP patients, suggesting that overcorrection in 
SOP may not be caused by slippage of the IR.
Scientific Poster 160
Ocular Alignment After Bilateral Lateral Rectus Recession 
in Exotropic Children With Cerebral Palsy
Presenting Author: So Young Han MD
Co-Author(s): Hyesun Kim MD, Jong Bok Lee MD
Purpose: To evaluate surgical outcome for patients in cerebral palsy (CP). Methods: The 
medical records of 30 exotropia patients with CP were retrospectively reviewed from De-
cember 2005 to October 2011. All underwent bilateral lateral rectus recession based on the 
larger angle deviation at distance and near. Surgical success was categorized as esotropia 
or exotropia of ≤ 10 PD. Results: Among the 8 failures, 2 (6.7%) were overcorrected and 6 
(20.0%) undercorrected. With the generalized estimate equation, postoperative exotropic 
drift was time dependent, and the mean of exotropic drift at 24 months was 5.57 PD (95% 
CI, 2.06-9.08), which was in the success range. Conclusion: CP patients with exotropia 
showed successful outcome with standardized surgical table.
Scientific Poster 161
A New Approach of Inferior Oblique Over Action Without 
Cyclotorsion
Presenting Author: Birsen Gokyigit MD
Co-Author(s): Serpil Akar MD, Ebru Demet Aygt MD, Engin Bilge Ozgurhan BSB, Ahmet 
Demirok MD, Omer Faruk Yilmaz MD*
Purpose: To introduce a new operation technique for inferior oblique overaction (IOOA). 
Methods: Following all evaluation of inferior oblique (IO) activity, 9 patients who had no 
cyclotorsion but notable hypertropia underwent the new operation technique. All patients 
had +4 IOOA with mean 14.6 PD hypertropia . Through a peripheral radial conjunctiva inci-
sion, the IO muscle was found and approximately 6-7/8 of posterior fibers were released 
from insertion, cleared from adjacent tissues and anterior part. A locking vicryl suture was 
placed on posterior parts of the muscle and attached 1 mm lateral and 5 mm distant from 
insertion to the inferior rectus. Results: Patients’ IOOA decreased between 0 and +1, and 
vertical deviation decreased a mean of 1.42 PD (P < .05). Conclusion: The new technique 
was found effective for treatment of the patients with IOOA without cyclotorsion.
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Scientific Poster 162
Prediction of Trochlear Nerve Absence by Superior 
Oblique Muscle Volumetry in Congenital Superior Oblique 
Palsy
Presenting Author: Daeseung Lee MD
Co-Author(s): Hee Kyung Yang MD, Sang Beom Han, Jae Hyoung Kim MD**, Jeong-Min 
Hwang MD
Purpose: To evaluate the predictability of superior oblique muscle volumetry in diagnosing 
trochlear nerve absence in congenital superior oblique palsy (SOP). Methods: Retrospec-
tive study of congenital SOP with (present group, n = 38) and without a trochlear nerve 
(absent group, n = 87) and controls (n = 34) using high-resolution MRI to analyze superior 
oblique muscle volume (SOV) and trochlear nerve absence. Results: The paretic SOV was 
significantly smaller than the normal SOV only in the absent group (P < .001). The cut-off 
value of paretic/normal side SOV ratio for diagnosing trochlear nerve absence was ≤ 0.75 
(sensitivity 100%, specificity 100%). Conclusion: In congenital SOP, the paretic/normal 
side SOV ratio has an excellent predictability in diagnosing trochlear nerve absence.
SESSION TWO
Scientific Poster 404
Pattern of Strabismus in Children Who Undergo Cataract 
Surgery
Presenting Author: Shilpa Devidas Sonarkhan Sr MS
Co-Author(s): Ramesh Kekunnaya MBBS MD
Purpose: To study pattern of strabismus in children who undergo cataract surgery. Meth-
ods: Retrospective case series involving 179 children who presented from January 2007 
to August 2012 and underwent cataract surgery. Results: Group 1 (61 patients) had uni-
lateral, Group 2 (81 patients) had bilateral symmetrical, and Group 3 (37 patients) had bi-
lateral asymmetrical cataracts. In Group 1, 60.66% had exotropia (P = .001), and in Group 
3, 64.86% had exotropia (P = .005). In Group 2, 41.98% had esotropia and 38.27% had 
exotropia (P = .74). Conclusion: Exotropia is more common with unilateral and bilaterally 
asymmetrical cataracts, while esotropia and exotropia is found equally in bilaterally sym-
metrical cataracts.
Scientific Poster 405
Refractive Growth in Pseudophakic Children Age 2-6 Years
Presenting Author: Bharti Kishore Nihalani Gangwani MD
Co-Author(s): Deborah K VanderVeen MD*
Purpose: To assess early myopic shift in children operated between the ages of 2 and 
6 years. Methods: Chart review of pseudophakic children with minimum follow-up of 3 
years. Refraction was recorded 1-2 months after surgery and then yearly. Refractive change 
in each year was used to calculate mean myopic shift and rate of refractive growth. Re-
sults: Forty-two eyes of 27 children were studied. Refractive change in each year was not 
significantly different by age groups: 2-3 years (n = 12) had mean shift of -1.2 D/yr, 3-4 years 
(n = 14) had -1.4 D/yr, and 4-6 years (n = 16) had -1.3 D/yr. Patients with unilateral cataract 
had slightly higher myopic shift than bilateral cases (-1.5 vs. -1.2 D/yr). Conclusion: Myo-
pic shift is similar between ages 2 and 6 years.
Scientific Poster 406
 h  Myopic Shift 3 years After IOL Implantation in the 
Infant Aphakia Treatment Study
Presenting Author: David R Weakley Jr MD
Co-Author(s): Michael J Lynn MS, Deborah K VanderVeen MD*, Scott R Lambert MD*
Purpose: To report the myopic shift after cataract surgery with IOL implantation for infants 
enrolled in the Infant Aphakia Treatment Study. Methods: Refractions were performed 
at 1 month and every 3 months postoperatively. The change in refraction over time was 
estimated by linear mixed model analysis. Results: IOL implantation was completed in 56 
eyes; 43 were analyzed. Exclusions were as follows: glaucoma (11), IOL exchange (1), and 
Stickler syndrome (1). Mean (± SD) refraction was +6.7 ± 2.4 D at 1 month and -0.8 ± 3.6 D 
at 36 months. The rate of change was -0.54 D per month until age 1 year (P < .0001) and 
then -0.11 D per month afterward (P < .0001). The mean myopic shift 3 years after surgery 
was almost 7 D. Conclusion: After IOL implantation during infancy, the largest myopic 
shift occurs during the first year of life.
Scientific Poster 407
Sutureless 25-Gauge Vitrectomy System in Management of 
Pediatric Cataract in Infants
Presenting Author: Usha K Raina MD
Co-Author(s): Vishaal R Bhambhwani MBBS, Anika Gupta MBBS, Gauri Bhushan MBBS, 
Anisha Seth MS
Purpose: To compare 25-gauge vitrectomy system use by anterior (transcorneal) and pos-
terior (Pars plana) routes in congenital cataracts. Methods: Twelve patients (< 1 year) with 
bilateral congenital cataract were included. Eyes were randomized and operated by either 
transcorneal or pars plana route and left aphakic. Intra- and postoperative results were 
compared. Results: All cases had clear visual axis at 6 months. Mean spherical equivalent 
(SE) was 15.58 D; and mean astigmatism, 0.33 D in the transcorneal group, whereas in the 
pars plana group SE was 15.79 D and astigmatism was 0.25 D, the difference being insig-
nificant. Conclusion: 25-gauge systems allow sutureless surgery, excellent intraoperative 
control, minimal postoperative inflammation and astigmatism via both routes.
Scientific Poster 408
A Twenty-Year Follow-up Study of Primary Developmental 
Glaucomas: The Experience of a Single Surgeon at a 
Tertiary Eye Care Center in Southern India
Presenting Author: Anil K Mandal MD
Purpose: To determine the surgical outcome of children with primary developmental glau-
comas (PDG) operated over a 20-year period (1991-2010). Methods: 1128 eyes of 653 con-
secutive patients who underwent primary combined trabeculotomy-trabeculectomy (CTT) 
by a single surgeon were studied. Results: Kaplan-Meier survival analysis revealed 24-, 
48-, 72-, 96-, and 120-month success (IOP < 16 mmHg) rates of 93.4% ± 1.3%, 89.0% ± 
1.8%, 82.4% ± 2.5%, 80.2% ± 2.7%, and 69.8% ± 3.9%, respectively. At the last follow-
up visit, 92 patients (27.6%) achieved normal visual acuity (ie, no visual impairment), 145 
patients (43.5%) had low vision, and 96 (28.8%) were blind as defined by the WHO criteria 
of vision loss. Conclusion: CTT is safe and successful in the management of primary de-
velopmental glaucomas.
Scientific Poster 409
Reimbursement Trends Among U.S. Pediatric 
Ophthalmologists for Emergency Department Call 
Coverage
Presenting Author: Rebecca B Mets MD
Co-Author(s): Robert W Enzenauer MD MPH*
Purpose: We sought to determine trends in reimbursement among U.S. pediatric oph-
thalmologists. Methods: We sent a survey to all 1145 pediatric ophthalmologists on the 
American Association for Pediatric Ophthalmology and Strabismus contact list and ana-
lyzed the results. Results: Out of 483 returned surveys, 16% reported compensation for 
covering emergency department (ED) calls. Thirteen reported being paid per patient seen, 
averaging $369.71 paid to carry a pager, averaging $327 per night. Compensation is more 
common for those covering general ophthalmology and when ED call is not required for 
hospital privileges. The dollar amount was similar across academic and private practices, 
but greater for those who practice in the Midwest. Conclusion: In order to provide wide-
spread, timely care for ophthalmic emergencies, it may become necessary for hospitals to 
reimburse physicians.
Scientific Poster 410
Excision of Eyelid Along Eyelash Line for Cilial Entropion 
in Patients With Down Syndrome
Presenting Author: Yumi Suzuki MD
Co-Author(s): Hama Yukiko MD, Izumi Yoshikawa-Kobayashi MD, Kaoru Tomita, Makoto 
Inoue MD*, Akito Hirakata MD*
Purpose: To describe a surgical procedure for excising the eyelid margin along the eyelash 
line to treat cilial entropion in patients with Down syndrome. Methods: Twenty-four Down 
syndrome patients with bilateral cilial entropion underwent root excision of the eyelid mar-
gin. The area and density of fluorescein staining of the superficial punctate keratoplasty 
(SPK; 0 = none to 3 = wide or severe) and the frequency of spectacle wear (0 = no wear to 
2 = all-day wear) was evaluated. Results: The dacryorrhea was abated after the surgery. 
The postoperative area and density of the SPK improved significantly (P < .001). The score 
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of spectacle wear improved significantly from 1.3 ± 0.8 to 1.7 ± 0.5 after surgery (P = .018). 
Conclusion: Eyelash line excision is effective for cilial entropion and medial epiblepharon 
in patients with Down syndrome.
Scientific Poster 411
Ten-Year Review of Pediatric Uveitis at Children’s Medical 
Center of Dallas
Presenting Author: Monica P Bratton MD
Co-Author(s): Jess Thomas Whitson MD FACS*, Yu-Guang He MD
Purpose: To describe the clinical features of pediatric uveitis. Methods: Retrospective 
review of 46 children treated between 2001 and 2011. Uveitis classified by the Standard-
ization of Uveitis Nomenclature grading scheme. Statistical analysis performed by Mann-
Whitney rank sum and t-test. Results: Median age at diagnosis = 9.2 years. Females = 
males. Most common etiology = idiopathic. Anterior chamber cell (D1.66), flare (D0.96), 
and vitreous cell (D0.8) improved significantly at final exam. Complications (73.9%), recur-
rence (23.9%), and surgical interventions (30.4%) were common. Hispanics were similar to 
others but had poorer visual outcomes. Conclusion: Pediatric uveitis is an uncommon but 
potentially devastating disease often requiring both medical and surgical therapy.
Scientific Poster 412
Macular OCT Findings in Retinopathy of Prematurity 
Patients Treated With Both Laser and Bevacizumab
Presenting Author: Cristina Moreira Dos Santos MD
Co-Author(s): Susana P Lopes MD, Mario Rui Rosado Ramalho MD, Ines Corga Morais 
Coutinho, Catarina Pedrosa MD, Graca Barbas Pires MD**, Susana Maria P Teixeira 
Semedo de Sousa MD**
Purpose: To describe macular OCT findings in children with history of ROP treated with 
both laser and bevacizumab. Methods: Clinical records and OCT (Stratus OCT, Carl Zeiss 
Meditec) findings of the first 3 patients treated with both laser and bevacizumab at our 
hospital were reviewed. Control group were patients who only had laser treatment. One 
eye from each patient was randomly chosen. The main outcome measure was foveal and 
parafoveal retinal thickness. Results: Seven patients with type 1 (stage 3+) ROP were stud-
ied. The Wilcoxon rank-sum test showed no statistical difference between both groups. 
Conclusion: We report a similar OCT macular profile in ROP patients treated only with 
laser and with both laser and bevacizumab.
Scientific Poster 413
Posterior Zone 1 Retinopathy of Prematurity: Spectrum and 
Outcome After Laser Treatment
Presenting Author: Mangat R Dogra MBBS
Co-Author(s): Kanika Aggarwal**, Swapnil Madhukar Parchand MBBS, Sunil Chaudhary 
MD MBBS, Dr Deeksha Katoch, Gaurav Sanghi MD
Purpose: To report spectrum of posterior zone I ROP and outcome after laser treatment. 
Methods: Retrospective chart review and RetCam images. Results: Twenty-three babies 
(46 eyes) were included, with a mean birth weight of 1153.04 grams (range: 700-1600 g), 
mean gestational age of 28.65 weeks (range: 25-34 weeks). Twenty-nine eyes had flat neo-
vascularization, 10 in addition had nasal tractional retinal detachment, 5 had hybrid ROP, 2 
stage 3 ROP. Thirty eyes (65.2%) had unfavorable outcome. Four eyes had stable stage 4a 
ROP at last follow-up. Conclusion: Laser treatment demonstrated unfavorable outcome in 
majority of eyes with posterior zone I ROP.
Scientific Poster 414
Accuracy of the Plusoptix Photoscreening Device in 
Detecting Esotropia and Exotropia
Presenting Author: Jillian Silbert
Co-Author(s): Noelle S Matta COT, David I Silbert MD*
Purpose: We evaluate the accuracy of the Plusoptix to detect strabismus in children with 
and without significant refractive error. Methods: A retrospective review of 1306 children 
who had photoscreening performed as part of an examination. All children who had esotro-
pia or exotropia with cross-cover testing and a Plusoptix photoscreening performed were 
included. Results: 217 children with esotropia were included and 85 with exotropia. The 
Plusoptix had a sensitivity and false negative rate of 87% and 13% in esotropes and a sen-
sitivity of 78% and a false negative rate of 22% in exotropes. Conclusion: The Plusoptix is 
effective in referring large angle but is less effective when the angle is smaller; there is no 
significant refractive error for intermittent exotropia.
Scientific Poster 415
Surgical Outcome of Exotropic Duane Retraction 
Syndrome
Presenting Author: Shailja Tibrewal MS
Co-Author(s): Ramesh Kekunnaya MBBS MD
Purpose: To evaluate the outcome of strabismus surgery in exotropic Duane retraction 
syndrome (DRS) (Types 1, 2, and 3). Methods: An interventional case series of 31 subjects 
operated between January 2008 and December 2012. Results: Median follow-up was 4 
months. The mean exodeviation reduced from 19.7 to 4.8 PD (P-value = 0.00). Success rate 
(alignment within 8 PD of orthotropia and/or correction of anomalous head posture [AHP] 
to less than 5°) was 71%. AHP was corrected in 89.7%. Globe retraction and overshoot 
was reduced in 61.3% and 91.7%, respectively. Conclusion: Unilateral or bilateral lateral 
rectus recession with or without Y-splitting can successfully treat exotropic DRS.
Scientific Poster 416
The Measurement of the Limbus-Horizontal Muscle 
Insertion With Anterior Segment OCT
Presenting Author: Ju Yeon Lee MD
Co-Author(s): Kyung Ah Park, Sei Yeul Oh MD**
Purpose: To evaluate the limbus-insertion distance of lateral rectus (LR) and medial rectus 
(MR) muscles with anterior segment OCT (AS-OCT) according to the fixation. Methods: To-
tal 29 adults without strabismus were included. The distance was measured with AS-OCT 
by 2 examiners. Patients were required to make lateral gaze with 40’, 50’, and 60’ fixation. 
The intraclass correlation coefficient (ICC) and mixed model were used to evaluate the 
degree of agreement between examiners and between the methods of measurement. Re-
sults: ICC showed high agreement between examiners. The mean distances of LR and MR 
measure showed no significant difference between the methods. Conclusion: There was 
no significant difference between different fixations in measuring distances with AS-OCT.
Scientific Poster 417
The Change of Lateral Rectus Muscle Insertion After 
Strabismus Surgery
Presenting Author: Ju Yeon Lee MD
Co-Author(s): Kyung Ah Park, Sei Yeul Oh MD**
Purpose: To evaluate the longitudinal transition of lateral rectus (LR) muscle after strabis-
mus surgery. Methods: The patients who underwent LR muscle recession were recruited. 
The limbus-insertion distance of LR muscle was measured with anterior segment OCT pre-
operatively and 1 and 3 months after surgery. Paired t test was used for statistic analysis. 
Results: Total 8 eyes of 5 patients were included. The mean distances of LR measure 
were 5.5 ± 0.72 mm preoperatively, 9.28 ± 1.16 mm for 1 month, and 9.84 ± 1.10 mm for 3 
months after surgery. The mean difference between 1 month and 3 months after surgery 
was 0.56 ± 0.34 mm. The distance was significantly different between follow-up visits (P 
< .01). Conclusion: The insertion site of LR muscle moves back after strabismus surgery.
Scientific Poster 418
Squinting and Photophobia in Intermittent Exotropia
Presenting Author: Baek-Lok Oh MD
Co-Author(s): Soh-youn Suh MD, Hokyung Choung**, Seong-Joon Kim MD Ph
Co-Author(s): D, Sang In Khwarg MD
Purpose: To report pre- and postoperative factors associated with squinting and photo-
phobia in intermittent exotropia (IXT). Methods: Ninety-nine patients were divided into 
2 groups according to preoperative squinting and photophobia, respectively. Symptomatic 
groups were further categorized into 2 subgroups, each according to postoperative im-
provement. The extensive list of characteristics was compared. Results: The onset age 
was younger in the photophobia group (P = .033). Poor fusional state at near range (P = 
.021) and superior oblique overaction (P = .03) were more common in the squinting group. 
Early surgical correction (P = .001) and successful outcomes (P =.022) were associated with 
squinting-improvement. Conclusion: These findings may provide further insights into the 
mechanisms underlying these symptoms in IXT.
200
Session One is Saturday and Sunday, Nov. 16 & 17. Session Two is Monday and Tuesday, Nov. 18 & 19. Refer to page 156 for poster presentation and tour schedule. 
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.  
No asterisk indicates that the presenter has no financial interest.
Scientific Posters
Sc
ie
nt
ifi
c 
Po
st
er
s
Refractive Surgery
SESSION ONE
Scientific Poster 163
The Visual Impact of Decentering a Hydrogel Presbyopia-
Correcting Corneal Inlay
Presenting Author: Gregory Parkhurst MD*
Purpose: To evaluate the effect on UCVA of placement accuracy of the Raindrop Near 
Vision Inlay. Methods: 125 subjects were implanted, targeting the light constricted pupil 
center, at 2 clinical sites. Wavefront aberrometry determined inlay position, and UCVA was 
assessed via ETDRS charts. Results: Inlay positions within 0.9 mm of target (98%) showed 
no decentration influence on treated eye UCVA at 1 month postop; 0.1 logMAR mean for 
near, intermediate, and distance. Outside 0.9 mm to the 1.25 mm worst case, only near 
acuity appeared to decrease. Conclusion: Placing the Raindrop inlay within an effective 
region of the cornea is straightforward.
Scientific Poster 164
A Hydrogel Corneal Inlay for the Surgical Correction 
of Presbyopia in a High-volume LASIK Practice: The 
UltraLase Experience
Presenting Author: Mark T Wevill MBCHB*
Co-Author(s): Gerry N Kervick MD, Vinod kumar Gupta FRCOPHTH FRCS, Jay Dermott OD
Purpose: To evaluate patient satisfaction with the Raindrop Near Vision Inlay into a high-
volume LASIK center. Methods: The Raindrop Near Vision Inlay was implanted under a 
150-mn femtosecond laser-created flap of 58 nondominant eyes on routine LASIK surgery 
lists. Near and distance visual acuities were measured at 1, 3, and 6 months. Patient satis-
faction was evaluated. Results: With at least 1 month follow-up, 96% of treated eyes saw 
0.3 logMAR or better uncorrected near visual acuity (UNVA). Binocularly, 96% of patients 
saw 0.1 logMAR uncorrected distance visual acuity and 78.3% saw 0.1 logMAR UNVA. 
Regarding patient satisfaction, 93% of patients reported their results as “Satisfied” or bet-
ter. No patient “regretted having it done.” Conclusion: The Raindrop Near Vision Inlay 
is effective and can be incorporated into a high-volume LASIK practice as a presbyopia 
treatment.
Scientific Poster 165
Visual Acuity Outcomes for Combined LASIK KAMRA, 
Pocket Emmetropic KAMRA, and Post-LASIK KAMRA 
Performed to Correct Presbyopia
Presenting Author: Sheldon Herzig MD
Co-Author(s): Jacqueline Freudenthal MD
Purpose: To evaluate visual acuity (VA) outcomes following the implantation of the Kamra 
corneal inlay to correct presbyopia, with combined LASIK Kamra (CLK), pocket emmetropic 
Kamra (PEK), or post-LASIK Kamra (PLK). Methods: This prospective, nonrandomized, com-
parative study analyzed 3 procedures in 10 patients selected: (a) CLK with an iFS femto-
second flap created at 200 µs in the nondominant eye, (b) PEK, and (c) PLK with a temporal 
lamellar pocket. Results: Means from Day 1 to Week 1: CLK uncorrected distance VA 
(UDVA) improved from 20/50 to 20/30. Uncorrected near VA (UNVA) was unchanged at J1. 
PLK UDVA went from 20/25 to 20/30. UNVA improved from J2 to J1. PEK: UDVA went from 
20/30 to 20/40, UNVA went from J2 to J3. Conclusion: UNVA outcomes following Kamra 
placement do not seem to be influenced by the technique performed; however, UDVA out-
comes may be impacted.
Scientific Poster 166
Refractive Outcomes Following Post-LASIK Femtosecond 
Cataract Surgery
Presenting Author: Kerry Assil MD*
Purpose: To assess the feasibility of laser cataract surgery in post-LASIK cataract pa-
tients. Methods: Single-center prospective evaluation. Results: Twenty-six eyes of 20 
patients were enrolled, with 23 eyes completing 1 month follow-up and 16 eyes completing 
3 months follow-up. Mean attempted correction was 1.82 (1.47) D. Mean achieved correc-
tions (SD) at 1 and 3 months were 1.90 (1.53) (R2 = 0.94) and 1.99 (1.26) D (R2 = 0.77). Mean 
deviation from target was 0.25 (0.26) D at 1 month and 0.48 (0.40) at 3 months. LogMAR 
uncorrected distance visual acuity (Snellen) was 0.15 (20/28) at 1 month and 0.13 (20/27) 
at 3 months. Conclusion: Laser cataract surgery can be reliably performed in post-LASIK 
IOL implantation.
Scientific Poster 167
A Prospective Study of Corneal Sensation Following 
Myopic LASIK With 2 Femtosecond Lasers
Presenting Author: Jennifer S Kung MD
Co-Author(s): Edward E Manche MD*
Purpose: To prospectively compare corneal sensation following 2 femtosecond laser mo-
dalities. Methods: 120 eyes of 60 patients underwent LASIK: one eye with a 150-kHz fem-
tosecond laser using a 130-degree inverted side-cut and the fellow eye with a 60-kHz fem-
tosecond laser using a 70-degree conventional side-cut. Cochet-Bonnet esthesiometry (CB) 
measured corneal sensation preop and at postop months 1, 3, and 6. Results: CB values 
were equal at preop. Postop CB values were greater with inverted vs. conventional side-
cuts with means of 1.45 > 1.32 (P = .08) at 1 month, 2.49 > 1.84 (P < .01) at 3 months, and 
5.12 > 4.26 (P < .01) at 6 months, respectively. Conclusion: Eyes treated with an inverted 
side-cut had a greater recovery of corneal sensation compared to a conventional side-cut.
Scientific Poster 168
Traumatic Bilateral LASIK Flap Dislocation
Presenting Author: Ananda Kalevar MD
Co-Author(s): Devinder Paul Cheema MD**
Purpose: To report the first case of a patient who developed bilateral corneal flap dehis-
cence 2 years after LASIK following trauma. Methods: Clinical presentation, mechanism 
of injury, complications, treatment, and outcome were studied. Results: Case involved a 
41-year-old who presented with bilateral flap dislocation, epithelial ingrowth, and macros-
triae. UCVA was 20/400 O.D. and 20/200 O.S. Immediate lift of both flaps with removal of 
the epithelium ingrowth from the stromal beds was completed. The flaps were refloated 
and repositioned. Final BCVA was 20/20 O.D. and 20/25 O.S., with mild microstriae and 
mild focal areas of epithelial ingrowth O.U. Conclusion: Flap dehiscence is a rare com-
plication of LASIK. This is the first case report to have traumatic flap dislocation bilaterally 
years after surgery.
Scientific Poster 169
 h  Fellow-Eye Comparison of Dry Eye Symptoms in LASIK 
Patients After Standard vs. Inverted Side Cut Femtosecond 
Flaps
Presenting Author: Christopher S Sales MD
Co-Author(s): Edward E Manche MD*
Purpose: To compare dry eye symptoms after standard LASIK with those after inverted 
side cut LASIK flaps. Methods: The dominant eye of 61 myopic LASIK patients was ran-
domized to receive a 9-mm, 105-µm thick, superiorly hinged flap with either a 70-degree 
side cut (60-kHz IntraLase FS) or a 130-degree inverted side cut (150-kHz IntraLase iFS); the 
nondominant eye received the alternative. Subjects completed a subjective questionnaire 
assessing dry eye symptoms preoperatively and postoperatively. Results: There were no 
statistically significant differences between the groups for light sensitivity, dry eye, and 
foreign body sensation at 6 months (all P > .05). Conclusion: Inverted side cut flaps may 
not affect dry eye symptoms.
Scientific Poster 170
Fellow-Eye Comparison of Quality of Vision Outcomes 
in LASIK Patients After Standard vs. Inverted Side Cut 
Femtosecond Flaps
Presenting Author: Christopher S Sales MD
Co-Author(s): Edward E Manche MD*
Purpose: To compare subjective outcomes of standard LASIK with those of inverted side 
cut LASIK flaps. Methods: The dominant eye of 61 myopic LASIK patients was random-
ized to receive a 9-mm, 105-µm thick, superiorly hinged flap with either a 70-degree side 
cut (60-kHz IntraLase FS) or a 130-degree inverted side cut (150-kHz IntraLase iFS); the 
nondominant eye received the alternative. Subjects completed the validated, Rasch-tested, 
linear-scaled quality of vision (QoV) questionnaire preoperatively and postoperatively. Re-
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sults: There were no statistically significant differences between the groups for the 30 QoV 
parameters at 6 months (all P > .05). Conclusion: Inverted side cut flaps may not affect 
subjective quality of vision outcomes.
Scientific Poster 171
Comparison of the Changes in Corneal Biomechanical 
Properties of High Myopic Patients After Femtosecond 
LASIK and Laser-Assisted Subepithelial Keratomileusis
Presenting Author: Fei Ma PhD
Co-Author(s): Jinhui Dai MD PhD**, Xingtao Zhou MD PhD
Purpose: To observe and compare the corneal biomechanical properties of high myopic 
patients after femto-LASIK and LASEK. Methods: Corneal hysteresis (CH) and corneal 
resistance factor (CRF) were measured with the Ocular Response Analyzer (Reichert Oph-
thalmic Instruments) in 40 consecutive patients (40 eyes) who underwent Femo-LASIK and 
LASEK, respectively. Results: The CH at 3 months postoperatively was decreased signifi-
cantly after LASEK and Femo-LASIK (P < .001). There was a significant correlation between 
the amount of myopic correction and changes in biomechanical properties after LASEK and 
Femo-LASIK (P < .05, r1 = .315; r2 = .308). Conclusion: From a biomechanical viewpoInt, 
LASEK may be a less invasive surgical approach for the correction of high myopia than 
Femo-LASIK.
Scientific Poster 172
The Effect of Ocular Dominance on Stereoacuity in 
Experimentally Induced Anisometropia
Presenting Author: Minoo Azadeh MD
Co-Author(s): Reza Nabie MD, Dima Andalib
Purpose: To evaluate the effect of ocular dominance on stereoacuity in experimentally in-
duced anisometropia. Methods: Anisometropia (unilateral myopia) was induced by placing 
trial lenses over the dominant and nondominant eyes in 1 D increments ranging from 1-3 D. 
Stereoacuity was measured using TNO, Randot, and Titmus tests. Values were converted 
into Neperian logarithm (ln) and compared between the two eyes. Results: Sixty healthy 
individuals were enrolled. Stereoacuity was reduced proportionate to the degree of aniso-
metropia. Mean stereoacuity was 4.3, 5.5, and 7.4 ln for dominant eyes and 4.1, 5.4, and 7.3 
ln for nondominant eyes using TNO by applying 1, 2, and 3 D lenses, respectively (P > .05). 
Conclusion: Experimentally induced anisometropia could reduce stereoacuity. However, 
ocular dominance has no effect on the amount of stereoacuity reduction.
Scientific Poster 173
Safety and Efficacy of a Presbyopic Algorithm in Post-
LASIK Eyes
Presenting Author: Robert Edward T Ang MD*
Purpose: To determine the safety and efficacy of an excimer laser treatment for presbyopic 
post-LASIK patients. Methods: A single-center, single-surgeon, prospective study of 30 
post-LASIK patients who underwent a monolateral Supracor LASIK treatment (Bausch + 
Lomb Technolas). Visual acuity, safety, refraction, and a subjective patient questionnaire 
were assessed. Follow-up was 6 months postop. Results: Monocular uncorrected near vi-
sual acuity (UNVA) was 69% at 1.0 or better 6 months postoperatively compared with 22% 
at 0.8 preoperatively; monocular uncorrected distance visual acuity (UDVA) remained stable 
postoperatively. Patients had a good level of satisfaction. Conclusion: The Supracor LASIK 
procedure is a safe and effective treatment option for post-LASIK patients with presbyopia.
Scientific Poster 174
The Influence of Pupil Size on Visual Acuity Following 
KAMRA Inlay Implantation
Presenting Author: Minoru Tomita MD PhD*
Co-Author(s): George O Waring MD*, Tukezban Huseynova
Purpose: To investigate the influence of pupil size on the visual acuity following Kamra 
inlay implantation. Methods: 684 presbyopic eyes were evaluated. Uncorrected near vi-
sual acuity (UNVA), uncorrected distance visual acuity (UDVA), corrected distance visual 
acuity (CDVA), and corrected near visual acuity (CNVA) were measured. Two groups were 
classified, with mesopic and photopic pupil size parameters. The follow-up was 6 months. 
Results: There were no significant differences between groups in UNVA and CNVA. Mean 
UDVA and CDVA was 20/20 or better for both groups. Conclusion: Pupil size has no influ-
ence on visual acuity following Kamra inlay implantation.
Scientific Poster 175
The Influence of 3% Trehalose Solution on the Quality of 
Vision in Patients After Refractive Surgery
Presenting Author: Ewa Mrukwa-Kominek MD PhD*
Co-Author(s): Monika Sarnat, Beata Jolanta Bubala-Stachowicz
Purpose: Function of vision in patients after photorefractive keratectomy (PRK) with uses 
of trehalose were assessed. Methods: Eighty eyes after PRK were divided into 2 groups 
of 40 eyes each: Group I, treated with a solution of 3% trehalose, and Group II, treated 
with preservative-free artificial tears. There were assessed: UCVA, fluorescein tear breakup 
time (fTBUT), mean spherical equivalent (SEq), keratometric values, optical aberrations, 
and confocal microscopy. Results: There were no differences between the groups in mean 
UCVA, SEq, keratometric values, or corneal aberration. Significant differences in corneal 
fluorescein staining test and fTBUT were found. Three eyes in Group II experienced delayed 
epithelialization longer than 7 days after surgery. Conclusion: Three percent trehalose 
solution after PRK is reasonable due to the efficient regeneration of the corneal epithelium 
and tear film stability.
Scientific Poster 176
Stereoacuity After Photorefractive Keratectomy in 
Anisometropia
Presenting Author: Hamidreza Hasani MD
Co-Author(s): Farid Karimian MD, Nooshin Dadbin**
Purpose: To determine the changes of stereoacuity in anisometropic myopic eyes after 
PRK.Methods: This study was performed in myopic anisometropic patients who underwent 
PRK. Changes in stereoacuity were observed by TNO and butterfly stereoacuity test (BFSA) 
before and after PRK. Results: Ninety-eight eyes of 49 patients (71.4% male) with mean 
age of 28 ± 5.5 years and mean myopia of -3.32 ± 1.74 D and mean astigmatism of 1.3 ± 
1.3 D were enrolled in the study. The preoperative mean stereoacuity values 102 ± 103.44 
sec/arc and 56.8 ± 41 sec/arc by TNO and BFSA test changed to 90 ± 110.52 sec/arc (P = 
.009), and 56.5 ± 41.3 sec/arc (P = .805), respectively at 3 months after PRK. Conclusion: 
Stereoacuity improves after photorefractive keratectomy in anisometropic myopic patients. 
This improvement is better diagnosed with TNO test than BFSA test.
Scientific Poster 177
Angle Kappa Measurements in Corneal Refractive Surgery
Presenting Author: Walter Benjamin Kunz MD
Co-Author(s): Michael Karon MD, Hoon C Jung MD**
Purpose: To analyze angle kappa measurements before and after excimer laser corneal 
refractive surgery. Methods: Retrospective observational study of 125 myopic patients, 
250 eyes. Analysis was made pre- and postoperatively using Placido disc-based corneal to-
pography. Results: Spherical equivalent of eyes undergoing treatment ranged from -0.375 
to -7.875 D. Average preoperative angle kappa was 5.55, and average postoperative angle 
kappa was 5.53. T-test of angle kappa before and after surgery showed no statistically sig-
nificant change (P = .70). Linear correlation testing revealed no linear relationship between 
spherical equivalent and change in angle kappa (r = 0.022). Conclusion: There is no evi-
dence that current treatment algorithms induce any postoperative change in angle kappa.
Scientific Poster 178
Visual Outcome and Higher-Order Aberrations in 
Wavefront-Guided LASIK and PRK
Presenting Author: Yashpal Goel MBBS
Co-Author(s): Ritu Arora MD MBBS, Jawahar Lal Goyal MD**, Gaurav Goyal MBBS, 
Deepa Gupta MBBS, Arushi Garg MBBS, Trushaa Garg MS
Purpose: To compare visual outcome and higher-order aberrations (HOA) between wave-
front-guided LASIK (WF-LASIK) and wavefront guided PRK (WF-PRK) in patients with high 
preoperative HOA. Methods: Eighty myopic eyes with preoperative HOA > 0.35 µm un-
derwent WF-LASIK (Group A) or WF-PRK (Group B) on Zyoptix platform over 2 years (40 
eyes each). Patients were followed up for 6 months. Results: At 6 months, mean UCVA 
(logMAR) in Group A was -0.01 ± 0.04 and Group B was 0.00 ± 0.07 (P = .23). HOA RMS 
(6-mm pupil) in Group A was 0.61 ± 0.24 µm and Group B was 0.55 ± 0.25 µm. The increase 
was statistically significant in both the groups (P < .05). Both groups showed similar ef-
ficacy, predictability, and safety. Conclusion: WF-LASIK and WF-PRK have similar efficacy, 
safety, and predictability, though WF-PRK induces less HOA.
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Scientific Poster 419
Corneal Asphericity: Distribution and Epidemiological 
Characteristics
Presenting Author: Naji E Waked MD
Co-Author(s): Naji E Waked MD, Elyse Jabbour, Joelle Antoun
Purpose: To determine the repartition of the corneal asphericity (Q) and evaluate its pos-
sible associations with age, sex, and central corneal thickness (CCT). Methods: On 10,038 
eyes of 5019 subjects examined over a period of 50 months with the high-resolution Pen-
tacam Corneal Topography System (WaveLight Allegro Oculyzer), we evaluated different 
parameters including Q, central and thinnest corneal thickness, age, and gender. Results: 
The mean Q was -0.31 ± 0.12. 98.9% of the corneas were prolate, and 1.1% were oblate. 
A statistically significant correlation was found between Q and CCT, but not between Q 
and each of age and gender. Conclusion: Corneas in our population were oblate in 110 
eyes and presented high variability in Q value ranging between -0.90 and +0.42. When CCT 
decreases, the cornea becomes less prolate.
Scientific Poster 420
Risk of Corneal Ectasia: Inter-rater Agreement and 
Comparison to a New Software
Presenting Author: Florence A Cabot MD
Co-Author(s): Sonia H Yoo MD*, Alain Saad MD*, George D Kymionis MD PhD, Ana P 
Fraga Santini Canto MD, Damien Gatinel MD*
Purpose: To assess the level of agreement between 5 refractive surgeons and a new soft-
ware in detecting corneal ectasia risk. Methods: Retrospective multicenter study including 
168 eyes of 84 patients. Three attending ophthalmologists and 2 cornea fellows reviewed 
168 corneal topographic maps and determined whether a refractive surgery was advis-
able or not. The same maps were also screened by a new corneal ectasia risk detection 
software (the SCORE Analyzer) combined with the Orbscan (Bausch + Lomb; Rochester, NY, 
USA). Results: The overall rate of agreement was 0.56, and the fixed marginal kappa coef-
ficient was 0.24. Conclusion: The inter-rater agreement between surgeons from different 
backgrounds is low. The SCORE analyzer provides valuable information to help surgeons in 
refractive surgery evaluation.
Scientific Poster 421
Understanding Post-Refractive Surgery Keratoneuralgia: 
Symptomatic, Clinical and Imaging Assessment
Presenting Author: Yureeda Qazi MBBS
Co-Author(s): Shruti Aggarwal MBBS, Bernardo Menelau Cavalcanti MD, Leslie Jan Wu, 
Perry Rosenthal MD, Pedram Hamrah MD*
Purpose: To correlate signs and symptoms of post-refractive keratoneuralgia with sub-
basal corneal nerve and immune cell changes by in vivo confocal microscopy (IVCM). 
Methods: Seventeen patients and 62 controls were assessed by history, Ocular Surface 
Disease Index (OSDI) questionnaire, ocular surface examination, and corneal IVCM. Re-
sults: Patients had minimal corneal staining (0.5 ± 0.8) but constant pain. Photophobia 
(94%) and sensitivity to air (47%) correlated with corneal immune cell densities (R = 0.8, P 
< .001; R = 0.6, P < .001), and sensitivity to chemical fumes (47%) with nerve tortuosity (r = 
0.5, P < .001), whereas OSDI scores with total nerve length (R = -0.7, P < .001) and immune 
cell density (R = 0.7, P < .001). Conclusion: Despite minimal clinical findings, symptoms 
correlated strongly with corneal nerve and immune cell changes on IVCM.
Scientific Poster 422
Comparison of Elliptical vs. Circular flaps With the iFS 
Femtosecond Laser LASIK Surgery
Presenting Author: Suruchi Gupta MBBS
Co-Author(s): Amit Gupta MBBS, Aniruddha K Agarwal MBBS
Purpose: To compare the visual performance, corneal asphericity, corneal biomechanics, 
and corneal aberrations of elliptical to those of circular flap LASIK. Methods: 145 LASIK 
patients (290 eyes) were divided into Group I (elliptical flap) and Group II (circular flap). 
Descriptive statistics to compare relevant parameters. Results: Group I vs. Group II, change 
in MRSE (-4.20 ± 2.15 vs. -4.31 ± 2.10), corneal asphericity (-0.52 vs. -0.64), corneal hyster-
esis (1.82 vs. 2.39), corneal resistance factor (2.31 vs. 3.48), vertical coma (0.23 vs. 0.92), 
trefoil 900 (0.016 vs. -0.04), tetrafoil 900 (0.03 vs. 0.005) was noted. Conclusion: Elliptical 
flap LASIK was associated with improved biomechanical profile and induced lesser ocular 
aberrations.
Scientific Poster 423
Higher-Order Aberrations and Corneal Asphericity in 
Wavefront-Guided and Aspheric LASIK for Myopia
Presenting Author: Arushi Garg MBBS
Co-Author(s): Jawahar Lal Goyal MD**, Ritu Arora MD MBBS, Deepa Gupta MBBS, 
Gaurav Goyal MBBS, Yashpal Goel MBBS, vikas veerwal MBBS
Purpose: To compare visual outcome, higher-order aberrations (HOA), and corneal asphe-
ricity (Q value) between wavefront-guided (WFG) and aspheric LASIK (Asp). Methods: 
Eighty eyes with -2 to -8 D myopia, 0 to 2.5 D astigmatism, underwent WFG or Asp LASIK 
(40 eyes each) on Zyoptix platform over 2 years. Results: At 6 months, Asp group had 
significantly better uncorrected visual acuity and lower mean residual spherical error than 
WFG. Mean change in HOA-RMS at 6 mm pupil was 0.16 ± 0.17 µm, 0.27 ± 0.28 µm after 
Asp and WFG LASIK (P = .02), with lower induced spherical aberrations in the Asp group 
(P < .01). Change in Q value was 0.91 ± 0.3, 0.53 ± 0.31 following WFG and Asp LASIK, 
significantly lower in ASP (P < .01). Conclusion: Asp LASIK induced lesser change in HOAs, 
spherical aberrations, and corneal asphericity than WFG LASIK, with better visual outcome.
Scientific Poster 424
Precision of Corneal Flaps Created With a New 
Femtosecond Laser
Presenting Author: Michael J Endl MD*
Co-Author(s): Thomas R Elmer MD*
Purpose: To assess the precision (thickness) of LASIK corneal flaps created with a new 
femtosecond laser. Methods: A newly FDA-approved femtosecond laser (Victus, Bausch 
+ Lomb) was used to create a corneal flap in 48 eyes of 24 patients prior to LASIK surgery. 
One month postoperatively, OCT (Visante, Zeiss) was used to measure flap thickness and 
uniformity. Results: The intended flap thickness was 120 µm; the mean OCT-measured 
flap thickness was 119.16 µm. No flap complications or loss of best corrected preoperative 
vision was observed. Conclusion: Corneal flaps created with this new femtosecond laser 
demonstrate reproducibility within 10 µm of the intended thickness.
Scientific Poster 425
Effect of a Surgical Safety Checklist for Refractive 
Procedures
Presenting Author: Catherine J Choi MD
Co-Author(s): Marie-Claude Robert MD, Fred E Shapiro, Samir A Melki MD PhD*
Purpose: To identify potential sources of error in refractive surgery and to measure the ef-
fect of a surgical safety checklist to prevent errors. Methods: A single-center, prospective 
study of standard preoperative and intraoperative steps in refractive surgery was undertak-
en to identify potential sources of error. A new safety checklist was designed and validated 
in 1500 eyes. Results: The most common potential sources of error included identification 
of the correct patient, eye, procedure, eye-specific refractive aim, nomogram, optical zone, 
and laser entry. A new safety protocol addressing each of these sources achieved a 0% 
error rate in 1500 eyes. Conclusion: Multiple potential sources of error exist in refrac-
tive surgery. A new surgical safety checklist seems to be effective in minimizing and/or 
preventing errors.
Scientific Poster 426
 h  Corneal Refractive Surgery for High Hyperopia and 
High Astigmatism: U.S. Air Force Experience
Presenting Author: Matthew C Caldwell MD
Co-Author(s): James R Townley MD, Vasudha A Panday MD
Purpose: To compare outcomes of PRK and LASIK in hyperopia and mixed astigmatism 
(MA) on two different excimer lasers. Methods: Retrospective chart review of 180 hy-
peropic, 480 MA treatments using wavefront optimized or wavefront guided platform 
at Lackland AFB from 2006 to 2011. Refractive error ranged from +0.25 to +5 D and MA 
cylinder from +0.25 to +4.75 D. Primary outcome measures included UCVA and BCVA at 
1, 3, and 6 months. Results: Approximately 50% of treatments were performed on each 
laser. Although not statistically significant, LASIK had better UCVA at all time points across 
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both groups regardless of platform. The MA group showed trend toward better UCVA on 
wavefront-guided laser. Conclusion: LASIK may be superior to PRK in this population; 
wavefront-guided treatments may give better results in mixed astigmatism.
Scientific Poster 427
Corneal Sensation After Small-Incision Lenticule 
Extraction Compared to Previous LASIK Studies
Presenting Author: Dan Z Reinstein MD*
Co-Author(s): Marine Gobbe PhD, Elena Bartoli MD, Timothy J Archer MS
Purpose: To measure the change in central corneal sensation (CCS) after small-incision 
lenticule extraction (SMILE) and to compare results to published LASIK studies. Methods: 
Cochet-Bonnet esthesiometry was done before and 1 day, 1 week, and 1, 3, and 6 months 
after SMILE in 156 eyes. Data were averaged for 20 LASIK studies reporting CCS. Results: 
Mean max myopia was -7.16 D (up to -12.78 D). Median age was 33 years (19-66). After 
SMILE, CCS was 54 mm (preop), 32 mm (day 1), 40 mm (1 wk), 44 mm (1 mo), 49 mm (3 mo), 
and 50 mm (6 mo). CCS was at baseline by 3 months in 77% of eyes. After LASIK (mean 
SEQ treated, -4.3 D; mean age, 34.2 years), CCS was 56 mm (preop), 9 mm (day 1), 15 mm 
(1 wk), 22 mm (1 mo), 33 mm (3 mo), 44 mm (6 mo). Conclusion: There was less reduction 
in CCS after SMILE at all timepoints. CCS recovered to baseline by 3 months in most eyes 
after SMILE.
Scientific Poster 428
Reliability of Intraoperative Measurement of Residual 
Stromal Bed Thickness Using Noncontact Spectral 
Domain OCT
Presenting Author: Vishal Jhanji MBBS
Co-Author(s): Marco Yu, Christopher Kai-shun Leung MD MBChB*
Purpose: To compare intraclass correlation coefficient (ICC) for residual stromal bed thick-
ness (RSBT) measurements with spectral domain OCT (SD-OCT) and ultrasound pachymetry 
(USP). Methods: RSBT was measured intraoperatively in 14 eyes undergoing LASIK using 
USP and SD-OCT. Three measurements were obtained with each instrument. Results: Both 
instruments demonstrated adequate reliability (both ICC > 0.9). The reproducibility coef-
ficients was slightly better for USP (8.7 and 7.0, respectively; P = .240). Bland-Altman plot 
showed no significant systemic (P = .155) or scaling bias (P = .561). The 95% limits of agree-
ment were relatively large (-48.5 to 32.0). Conclusion: Intraoperative RSBT measurement 
with USP and SD-OCT showed adequate reliability. SD-OCT has a an advantage of being a 
noncontact technique.
Scientific Poster 429
Central Toxic Keratopathy After Photorefractive Surgery
Presenting Author: Hossein Mohammad Rabie MD
Co-Author(s): Ahmad Shojaei-Baghini MD, Kourosh Sheibani
Purpose: To report a distinct clinical syndrome, central toxic keratopathy, as a cause of 
early postoperative corneal opacity. Methods: Twelve eyes from 6 patients who presented 
with decreased vision 3 to 9 days postoperatively accompanied by central corneal opac-
ity, corneal melting, and hyperopic shift are presented. They underwent PRK (3 patients), 
LASEK (1 patient), and epi-LASIK (2 patients); and mitomycin C (0.02% dilution) had been 
applied for all of them. Results: The opacification persisted for a minimum of 2 months to 
a maximum of 6 months before clearing. One to 2 line loss of BCVA persisted in 2 patients 
after 6 months. Conclusion: In central toxic keratopathy, despite the clearance of opacity 
in most cases, an irreversible complication might remain in a few patients.
Scientific Poster 430
 h  Six-Year Follow-up of Posterior Chamber Phakic IOLs 
(ICL/TICL) for High Myopia in China
Presenting Author: Xiaoying Wang MD
Co-Author(s): Xingtao Zhou MD PhD, Yi Lu MD**
Purpose: To evaluate the long-term safety, efficacy, predictability, and stability of ICL/
TICL implantation for high myopia. Methods: 1360 eyes of 743 patients were included in 
this retrospective study. Results: 933 eyes were implanted with ICL, and 427 eyes were 
implanted with TICL. The preoperative and postoperative mean spherical equivalent refrac-
tions (SE) were -14.74 D ± 4.95 SD and -0.85 D ± 1.95 SD, respectively. The mean change 
in refraction was -0.87 ± 0.34 SD from 1 week to 6 years. The preoperative and postopera-
tive mean UCVA and BCVA were 0.06 ± -0.08, 0.65 ± 0.40, 0.76 ± 0.33, and 0.88 ± 0.25, 
respectively (P < .001). Predictability was achieved within ± 0.50 D in 1086 eyes and within 
± 1.00 D in 1289 eyes. Fifteen eyes developed anterior subcapsular cataract. Conclusion: 
ICL/TICL implantation was good for long-term safety, efficacy, predictability, and stability 
for correction of high myopia.
Scientific Poster 431
The Study of the Rotational Stability of the Posterior 
Chamber Toric Phakic IOL
Presenting Author: Jin Zhou MBBS
Purpose: To evaluate the rotational stability of toric phakic IOL (Visian ICL, Staar Surgical) 
implantation for high myopic astigmatism. Methods: This retrospective study evaluated 
337 eyes of 202 patients who underwent toric ICL implantation for the correction of high 
myopic astigmatism. We assessed the safety, efficacy, and stability of the surgery of toric 
ICL implantation. Results: At 1 year, the mean postoperative spherical equivalent was 
-0.04 ± 0.63 D, and the refractive cylinder was -0.61 ± 0.52 D; the postoperative rotation 
was within 15 degrees in 100%, within 10 degrees in 94.2%, and within 5 degrees in 81.5% 
Conclusion: Toric ICL implantation was good in all measures of safety, efficacy, and stabil-
ity for the correction high myopic astigmatism throughout 1 year.
Scientific Poster 432
Posterior Chamber Phakic IOLs for Correction of Refractive 
Error After Deep Anterior Lamellar Keratoplasty
Presenting Author: Sherif S Tolees MD
Co-Author(s): Alaa M Eldanasoury MD*
Purpose: To assess outcomes after posterior chamber phakic IOL (P-IOL) (ICL and TICL) in 
patients who have had deep anterior lamellar keratoplasty (DALK). Method: DALK eyes 
unable to wear glasses, contact lenses, or where corneal laser surgery was contraindi-
cated. Results: Sixteen eyes. Preop spherical equivalent: -6.80 D ± 4.14 D (range: -14.75 to 
-1.00) reduced to -0.36 D ± 0.37 D (range: -0.75 to 0.25) at 1 year; preop sphere was -5.78 
D ± 4.31 D (range: -14.50 to 0.50), reduced to mean 0.07 D ± 0.31 D° (range: -0.50 to 0.50) 
after 1 year; preop ref cyl -2.05 D ± 1.60 D° (range: -5.00 to 0.00), reduced to -0.86 D ± 0.61 
D° (range: -1.50 to -0.25) at 1 year. UCVA was 20/40 or better in 88%, refractive outcome 
92% within ± 1.00 D and a gain of at least 2 lines in 31% of eyes with no loss of BSCVA. 
Endothelial cell count loss as compared with preoperatively was 9.8% ± 11.7% (n = 12) at 
1 year postop. No graft rejections occurred. Conclusion: Posterior chamber P-IOLs were 
safe and effective in correcting error of refraction after DALK.
Retina, Vitreous
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Microvesicles/Exosomes in Vitreous
Presenting Author: Michael Hughes
Co-Author(s): Nadia A Atai MD PhD, JamieLynne Metzinger MS, Vimal Sarup MBBS, 
Claudia P Castiblanco MD, Henk Albertus vanVeen Sr BSMT, Rienk Nieuwland PhD**, 
Sarada Sivaraman, C Stephen Foster MD*, Fred H Hochberg MD
Purpose: To evaluate vitreous microvesicles (MCV) as a novel diagnostic tool for uveitis. 
Methods: Vitreous from diagnostic vitrectomy was examined by transmission electron 
microscopy (TEM) in 7 cases of inflammatory / malignant uveitis: malignancy (n = 1), au-
toimmune disease (n = 4), and idiopathic (n = 2). NanoSight analysis was performed in 
additional cases. Results: All 7 samples contained MCV with diameter 50 nM — 400 
nM with “autoimmune” specimens numerous and clustered in size of 100 nM, while 
“idiopathic”specimens trended larger in size; the lymphoma specimen showed rare exo-
somes. NanoSight data will be presented. Conclusion: This is the “First in Man” descrip-
tion of MCV in vitreous fluid. As MCV contain RNA, ncRNA, and mRNA, their analysis offers 
important diagnostic potential.
Scientific Poster 180
Symptomatic Posterior Vitreous Detachment: Assessing 
Quality of Care
Presenting Author: Stephen J Sramek MD PhD
Co-Author(s): David Lee Ennis CPC
Purpose: To improve the assessment of patients with posterior vitreous detachment (PVD). 
Methods: Chart review: (1) PVD patients before/after provider education to determine per-
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cent evaluated with dilated fundus examination (DFE) and scleral depression (SD). (2) Tear/
rhegmatogenous retinal detachment (RRD) consults after education. Results: Before/after 
education DFE was done in 40%/85%, and SD in 11%/38%. After education 30 of 376 were 
referred and 5 subsequently were found to have a tear. In a series of 21 consecutive RRDs, 
9 (4 had SD) had a prior fundus exam. Prior exams were normal. Conclusion: Education 
increased the percent of PVD patients receiving DFE and SD. Prior DFE/SD exam did not 
find the pathology in all patients with PVD. A high index of suspicion remains critical for the 
referring provider; patient education is needed.
Scientific Poster 181
The Use of the Argus II Retinal Prosthesis to Identify 
Common Objects in Blind Subjects With Outer Retinal 
Dystrophies
Presenting Author: Yvonne Hsu-Lin Luo
Co-Author(s): Lyndon daCruz FRANZO FRCOPHTH*, Francesco Merlini MS*, Fatima 
Anaflous*, Maura Arsiero MS PhD*, Paulo E Stanga MD*
Purpose: To determine if blind retinitis pigmentosa patients with Argus II Retinal Pros-
thesis can differentiate a range of common objects chosen by them. Methods: Argus II 
subjects were asked to identify 8 light-hued solid objects (SOb) presented against a dark 
background, in a forced-choice, closed-set series of tests. The SObs were then modified to 
enhance their outlines (outlined objects, OOb), and the tests were repeated. Results: All 
the subjects performed better with the device on than off for both SOb and OOb identifica-
tion (P = .071 for SOb, P = .026 for OOb, Wilcoxon signed rank test). When the signals were 
scrambled, identification was statistically better with device on for OOb (P = .043), but not 
for SOb (P = .891). Conclusion: Argus II helps subjects to identify daily objects by the 
shape and reflectivity.
Scientific Poster 182
Real-world Monitoring of Patients Treated With Anti-VEGF 
Agents in Common Retinal Diseases
Presenting Author: Szilard Kiss MD*
Co-Author(s): Ying Liu PhD*, Joseph N Brown MBA*, Nancy M Holekamp MD*, 
Arghavan Almony MD, Joanna Campbell PhD*, Jonathan Kowalski*
Purpose: To assess patient monitoring after initiating anti-VEGF therapy for AMD, branch 
retinal and central retinal vein occlusion (BRVO, CRVO) and diabetic macular edema (DME). 
Methods: A large U.S. insurance database with 64 million unique patients was analyzed. 
Results: From 2008 to 2010, mean annual ophthalmologist visits ranged from 8.6 to 8.7 
(AMD) for ranibizumab, and from 6.8 to 7.2 (AMD), 5.1 to 5.6 (BRVO), 5.8 to 6.5 (CRVO), and 
4.4 to 5.3 (DME) for bevacizumab patients. Mean annual OCT exams ranged from 5.8 to 
6.7 (AMD) for ranibizumab, and from 4.8 to 5.4 (AMD), 3.7 to 3.9 (BRVO), 3.4 to 3.8 (CRVO), 
and 3.1 to 3.8 (DME) for bevacizumab patients. Conclusion: Real-world patients were 
monitored less frequently than those enrolled in major anti-VEGF trials. The impact of this 
reduced patient monitoring on visual outcomes needs to be further elucidated.
Scientific Poster 183
Clinical Feasibility and Utility of Ultrawide-field 
Indocyanine Green Angiography
Presenting Author: Szilard Kiss MD*
Co-Author(s): Anton Orlin MD, Matthew T Witmer MD**, Matthew M Wessel MD, 
Swetangi D Bhaleeya MD, Sarju S Patel MD
Purpose: Given the increasing importance of ultrawide-field (UWF) imaging, the aim of 
this study was to determine the feasibility and clinical utility of UWF indocyanine green 
angiography (ICGA). Methods: A modified Optos P200Tx UWF device with a near infrared 
laser and filters was used to image 40 eyes of 20 patients. Results: Eyes included posterior 
uveitis (8 patients), central serous chorioretinopathy (CSCR, 6 patients), AMD (4 patients), 
macular dystrophy (1 patient), and retinal degeneration (1 patient). Both peripheral and 
central choroidal and retinal vasculature was well visualized in all eyes. Thirty-five percent 
of eyes had pathology in the posterior pole, and 10% showed largely peripheral pathol-
ogy; the remaining 22 eyes exhibited both central and peripheral pathology. Conclusion: 
UWF ICGA is clinically practical and most valuable in posterior uveitis (eg, sarcoidosis and 
birdshot) and in CSCR.
Scientific Poster 184
Ophthalmology Consultation for Inpatients With Positive 
Blood Cultures: Risk Factors of Disseminated Retinal 
Lesions
Presenting Author: Yuki Nagasako MD
Co-Author(s): Masafumi Hamada MD**, Keiji Inagaki MD, Gautam A Deshpande MA 
MD, Kishiko Okoshi MD
Purpose: To clarify risk factors for disseminated retinal lesions in patients with positive 
fungal or bacterial blood cultures (BC). Methods: Retrospective cross-sectional study of 
462 BC-positive inpatients with ophthalmology consultation between January 2006 and 
September 2012. Results: Thirty-two patients had retinal lesions (50%, bacterial; 40.6%, 
fungal; 9.4%, both). Staphylococcus aureus and Candida albicans were the most common 
organisms. In multivariate analysis, candidemia, infective endocarditis (IE), and broad-
spectrum antibiotic use (P < .05 for all) were independent risk factors for presence of retinal 
lesions. Conclusion: Ophthalmic consultation is warranted in cases of candidemia, IE, or 
broad-spectrum antibiotic use. Ophthalmic consultation may not be necessary for bactere-
mic patients without definitely diagnosed IE.
Scientific Poster 185
Is Aflibercept More Effective in the Treatment of Retinal 
Pigment Epithelial Detachments?
Presenting Author: Lingmin He MD*
Co-Author(s): Amila Ruwan Silva MD, Theodore Leng MD*
Purpose: To describe the outcomes of patients with retinal pigment epithelial detach-
ments (PED) previously treated with bevacizumab or ranibizumab after switching to afliber-
cept. Methods: Retrospective review of vision and size of PED on high-resolution spectral-
domain OCT in eyes switched to aflibercept from Nov. 2011 to Feb. 2013. Results: Of 131 
eyes switched, 25 had PEDs. Baseline vision was 0.5 ± 0.5 logMAR, and PEDs measured 
220 ± 124 µm tall. After 3 injections, PED height decreased to 179 ± 137 µm (P = .02). At 
the last visit (7 ± 2 injections), acuity was stable at 0.7 ± 0.6 logMAR (P = .10) and PED 
height was still significantly lower at 171.82 ± 97.79 µm (P < .01). Conclusion: Aflibercept 
maintained stable vision and significantly reduced PED height for patients previously on 
bevacizumab or ranibizumab.
Scientific Poster 186
 h  Impact of New Genes and Number of Genes on 
Prediction of Advanced Macular Degeneration Subtypes
Presenting Author: Johanna M Seddon MD*
Purpose: To determine whether genes in multiple biologic pathways contribute to pre-
diction of AMD progression. Methods: Among 2734 individuals in the Age-Related Eye 
Disease Study, 777 progressed to geographic atrophy or neovascular disease. Genotypes 
for 24 AMD loci were determined. Cox proportional hazards analyses were performed, and 
predictive models were compared. Results: New genetic loci were significantly related 
to progression: R1210C in CFH, COL8A1, and RAD51B, controlling for drusen and stage of 
AMD, smoking, BMI, and 6 common variants. Genetic information contributed to prediction 
models (odds ratio [OR] 3.3, P < .001 for genes vs. no genes, and OR 2.7, P < .001 for the 6 vs. 
9 loci model). Conclusion: Genes contribute predictive information for advanced AMD be-
yond macular and behavioral phenotypes, and more genetic loci enhance predictive power.
Scientific Poster 187
Intravitreal Aflibercept for Polypoidal Choroidal 
Vasculopathy After Developing Ranibizumab 
Tachyphylaxis
Presenting Author: Masahiro Miura MD*
Co-Author(s): Takuya Iwasaki**, Hiroshi Goto MD
Purpose: To evaluate the effect of switching to aflibercept after developing ranibizumab 
tachyphylaxis for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: 
Twenty-five eyes of 25 patients with PCV who developed ranibizumab tachyphylaxis were 
reviewed. Therapeutic responses were evaluated from the OCT findings. Results: Mean 
number of intravitreal ranibizumab treatments before intravitreal aflibercept was 13.3 ± 
4.2. Twenty-four of 25 eyes (96%) had positive therapeutic responses after 1 injection of 
aflibercept. Mean central retinal thickness was significantly decreased from 416 ± 178 to 
196 ± 84 µm (P = .001) after 1 injection of aflibercept. Conclusion: Switching therapy to 
aflibercept is effective for patients with PCV who develop tachyphylaxis to ranibizumab.
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Scientific Poster 188
Ranibizumab Leads to Lesion and Choroidal 
Neovascularization Regression: Correspondence With 
Thickness on Spectral Domain OCT
Presenting Author: Nikolas J London MD
Co-Author(s): Paul E Tornambe MD*, Howard Shapiro PhD
Purpose: To examine the effect of ranibizumab (RBZ) on lesion and CNV size in the High-
Dose Ranibizumab for Neovascular AMD (HARBOR) study. Methods: Patients (n = 1097) 
were randomized to intravitreal RBZ 0.5 mg or 2.0 mg monthly (M) or p.r.n. after 3 loading 
doses. Change from baseline in lesion and CNV area was evaluated by fluorescein angi-
ography (FA) and thickness by spectral domain OCT (SD-OCT) at Months 3, 6, 12, and 24. 
Results: At Month 24, mean change in the 0.5-mg or 2.0-mg groups was as follows: lesion 
size (disc areas) -1.6, -2.1 for M, -1.1, -1.4 for p.r.n.; CNV size: -2.0, -2.6 for M, -1.6, -1.9 for 
p.r.n.; lesion thickness on SD-OCT (µm): -205.5, -232.3 for M, -200.9, -224.5 for p.r.n.; CNV 
thickness: -26.5, -61.5 for M, -22.3, -36.0 for p.r.n. Conclusion: RBZ provided consistent 
regression in lesion and CNV size on FA as well as lesion and CNV thickness on SD-OCT 
over time in all treatment groups and for all 4 outcome measures.
Scientific Poster 189
Risk Factors in Pure Phenotypes of Reticular Macular 
Disease
Presenting Author: Sucharita Boddu
Co-Author(s): Michele Danielle Lee, Marcela Marsiglia MD PhD, Michael Marmor PhD*, 
K Bailey Freund MD*, R Theodore Smith MD
Purpose: To investigate risk factors for reticular macular disease (RMD) among patients 
with AMD. Methods: Scanning laser ophthalmoscopy identified 30 cases of pure RMD 
among 72 AMD patients genotyped for ARMS2 and CFH. Results: RMD patients were 
more often female (83.3% vs. 50%, P = .004); older (median 87 vs. 81 years; P = .05); and 
older at age at onset of AMD (median 83 vs. 70 years; P = .0007); ARMS2 and CFH frequen-
cies did not differ. Age at onset and sex remained significant in multivariable modeling. 
Conclusion: RMD was associated with older age of onset of AMD and being female.
Scientific Poster 190
Pigment Epithelial Detachment Improvement in Non-naive 
Neovascular AMD Patients After Intravitreal Aflibercept: 
One-Year Results
Presenting Author: James C Major MD PhD*
Co-Author(s): Daniel Croft**, Angeline Mariani, David Brown MD FACS*, Charles C 
Wykoff MD PhD*
Purpose: To examine the effect of aflibercept on recalcitrant pigment epithelial detach-
ments (PEDs) in anti-VEGF-treated non-naïve exudative AMD patients. Methods: This 
retrospective spectral domain OCT study reviewed 65 eyes unresponsive to 2 or more in-
travitreal injections of bevacizumab or ranibizumab. Endpoints were mean changes in PED 
height at 1, 6, and 12 months after initial aflibercept injection. Results: The mean number 
of previous anti-VEGF injections was 24.2. Overall PED improvement was noted in 55/63 
(87%), 38/47 (81%), and 37/47 (79%) visits at Months 1, 6, and 12, respectively. PED height 
was reduced by 14%, 18%, and 22% at Months 1, 6, and 12, respectively. Conclusion: 
Intravitreal aflibercept resulted in significant, persistent reduction in recalcitrant PEDs in 
non-treatment-naïve patients.
Scientific Poster 191
A Vitreous Proteomic Biomarker Panel That Can Guide the 
Choice of Patients With Wet AMD Who Will Respond to 
Treat and Extend Therapy: Personalized Medicine Applied 
to AMD
Presenting Author: Joshua Hines BSMT*
Co-Author(s): Stephanie Marie Ecker*, Bert M Glaser MD*
Purpose: To use vitreous proteomics to guide the choice of wet AMD (wAMD) patients 
who will respond to treat-and-extend therapy (TER). Methods: Levels of a large range of 
proteins were measured in preinjection in-office vitreous aspirates from wAMD patients 
during the monthly injection phase before initiating TER. Response to TER was divided into 
2 groups: Stable visual acuity (VA) = VA decreased by < 10 letters; and Worsening VA = VA 
decreased ≥ 10 letters. Proteins were measured using reverse phase microarrays. Results: 
PDGFRb Y751 and VEGFR2 Y951 were elevated in the vitreous of patients who responded 
with worsening VA during TER (P = .0270 and P = .0256); as a panel, significance strength-
ens to P = .0041. Conclusion: The vitreous proteome can guide in identifying candidates 
for TER and will improve the management of wAMD, allowing personalized retinal care.
Scientific Poster 192
Multilaminar Subretinal Pigment Epithelium Hyper-
reflectivity in Regressing Drusen
Presenting Author: Giuseppe Querques MD
Co-Author(s): Anouk Georges, Naima Benmoussa MD, Eric H Souied MD PhD*
Purpose: To describe a multilaminar sub-retinal pigment epithelium (RPE) hyper-reflectivity 
in regressing drusen. Methods: Twenty-three patients with regressing calcific drusen due 
to non-neovascular AMD were submitted to spectral-domain OCT (SD-OCT). Results: The 
multilaminar hyper-reflectivity localized to beneath the RPE and above the outer Bruch 
membrane (oBM), characterized by an intense signal originating from the inner Bruch 
membrane (iBM), and by an intense signal originating from the oBM and showed different 
degrees of fragmentation from both the iBM and oBM. Conclusion: We describe a novel 
SD-OCT finding appearing as multilaminar sub-RPE intense hyper-reflectivity in eyes with 
regressing drusen
Scientific Poster 193
Focal Choroidal Elevations
Presenting Author: Eric J Sigler MD
Co-Author(s): Rocio Diaz
Purpose: To describe the clinical and imaging characteristics of focal chorioretinal contour 
changes overlying specific large choroidal vessels, or focal choroidal elevations. Methods: 
Enhanced depth imaging OCT was performed on consecutive patients presenting for reti-
nal evaluation over a 2-month study period. Results: Thirty-eight of 787 patients (4.8%) 
presented with focal choroidal elevation. Metamorphopsias in the absence of additional 
pathology were demonstrated in 17/38 (55%), all of which were subfoveal. Conclusion: 
Focal choroidal elevations are relatively common lesions in AMD, high myopia, and age-
related choroidal atrophy. The lesions may simulate pigment epithelial detachments or 
chorioretinal folds, and have a distinct OCT appearance.
Scientific Poster 194
Predicting Progression to Advanced Disease from Spectral 
Domain OCT Analysis of Intermediate AMD
Presenting Author: Cynthia A Toth MD*
Co-Author(s): Francisco A Folgar MD, Molly Harrington MS*, Katrina Postell Winter, 
Sina Farsiu PhD*, Stefanie G Schuman MD, Wai T Wong MD PhD, Michelle Norton 
McCall, G Baker Hubbard MD, Sunil K Srivastava MD*, Traci E Clemons PhD, Emily Y 
Chew MD
Purpose: To determine spectral domain OCT (SD-OCT) findings that predict progression 
from intermediate AMD to central geographic atrophy (CGA) or neovascular (nv) AMD. 
Methods: Characteristics from SD-OCT image analysis of one eye per subject at baseline 
were compared to progression. Results: In 308 eyes, those with retinal pigment epithelial 
(RPE) atrophy/absence, highly reflective drusen, or hyper-reflective foci were more likely to 
progress to CGA than eyes without. Eyes with subretinal or sub-RPE fluid on OCT were more 
likely to progress to nvAMD. Median RPE+drusen volume was greater for eyes that pro-
gressed to nvAMD. Conclusion: Review and segmentation of SD-OCT macular volumes 
revealed OCT-unique factors predicting AMD progression.
Scientific Poster 195
Morphologic and Angiographic Changes of Retinal 
Periphery in Patients With Age-Related Macular Disease: 
The OPERA Study
Presenting Author: Zoran Vatavuk MD**
Co-Author(s): Biljana Andrijevic Derk, Tamara Knezevic MD, Goran Bencic*, Thomas R 
Friberg MD*
Purpose: To show the morphologic and angiographic peripheral retinal changes of patients 
with age related macular disease (AMD) using the wide-field fundus camera, Optomap 
P200 MA (Optos). Methods: Study included 150 patients with AMD signs and 150 healthy 
controls. Peripheral retinal changes were studied according to type, frequency, distribution 
extension, and localization. Results: Drusen were present in 68% of eyes with AMD, and 
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in 25% of control eyes. Reticular pigmentary changes (RPC) were observed in 41% of AMD 
eyes and in 8% of control eyes. Pavingstone degenerations (PS) were seen in 18% of AMD 
eyes, and in 3% of control eyes. Conclusion: Drusen, RPC, and PS occur more frequently, 
with statistical significance, in the AMD group.
Scientific Poster 196
Prospective Randomized Controlled Study on the 
Efficacy of 0.16-mg Intravitreal Bevacizumab Injection for 
Proliferative Diabetic Retinopathy
Presenting Author: Ayumu Manabe MD
Co-Author(s): Hiroyuki Shimada MD
Purpose: To verify the usefulness of 0.16 mg/0.05 ml of intravitreal bevacizumab (IVB) 
given 1 day before vitrectomy. Methods: Fifty-nine eyes were assigned randomly to a sham 
group (31 eyes) and an IVB group (28 eyes). One day following injection, vitreous samples 
were collected at the start of surgery, and intraoperative and postoperative complications 
were evaluated. Results: The VEGF concentrations were 26 ± 14 pg/ml in the IVB group 
and 1273 ± 1047 pg/ml in the sham group, with a significant difference (P < .0001). The 
incidence of postoperative vitreous hemorrhage (PVH) and the reoperation for PVH were 
significantly lower in the IVB group than in the sham group(P = .008 and .035, respectively). 
Conclusion: 0.16 mg/0.05 ml IVB given 1 day before surgery blocked VEGF in the vitreous 
and reduced the rates of PVH and reoperations for PVH.
Scientific Poster 197
Influence of Laser Photocoagulation and Ranibizumab 
Injections on Biomarkers in Serum of Patients With 
Diabetic Macular Edema
Presenting Author: Jessica Voegeler PHARMD*
Co-Author(s): Sandra Liakopoulos*, Claudia Weiss*, Sandra Y Hu MD, Gabriele E Lang 
MD**, Rainer H Straub, Lothar Faerber MD**
Purpose: Beside influence of treatment on biomarkers over time, correlation of serum 
levels with morphologic characteristics and visual acuity (VA) at baseline was evaluated. 
Methods: 128 patients were randomized to laser photocoagulation plus ranibizumab or 
sham injection. Visual acuity and morphologic changes were investigated up to 12 months. 
Serum biomarker samples were analyzed for 114 patients using Luminex or ELISA. Results: 
VEGF serum levels were stable in the combined group, but some biomarkers (eg, VCAM-1) 
changed over time. No correlation was found between VA, morphologic characteristics, 
and serum biomarker levels at baseline. Conclusion: Repeated anti-VEGF treatment with 
ranibizumab did not result in lower systemic VEGF levels. Analyzed serum biomarkers were 
no predictors for baseline disease severity.
Scientific Poster 198
Scotopic Contrast Sensitivity in Diabetic Patients With No 
Diabetic Retinopathy
Presenting Author: Hamid Ahmadieh MD
Co-Author(s): Eduardo Solessio MS PHD, Afsaneh Raeesi II**, Sare Safi MS, 
Mohammad Haeri PHD, Mojtaba Malek**, Mehdi Yaseri PhD
Purpose: To evaluate scotopic contrast sensitivity (CS) in diabetic patients with no diabetic 
retinopathy (DR) in comparison to normal controls. Methods: In this comparative cross-
sectional study, 47 patients with BCVA of 20/20 and no sign of DR were compared with 47 
healthy matched controls. CS was evaluated employing the CSV-1000 device (Vector Vision, 
Inc.) under scotopic conditions (less than 2 lux). Results: In diabetic subjects, scotopic CS 
was 1.53 ± 0.2, 1.8 ± 0.22, 1.38 ± 0.3, and 0.96 ± 0.33 (log units) at 3, 6, 12, and 18 cycles 
per degree, respectively. Corresponding values were 1.68 ± 0.15, 1.93 ± 0.25, 1.60 ± 0.25, 
and 1.18 ± 0.30 among controls (P < .001). Conclusion: Significant scotopic CS reduction 
occurs in diabetic subjects before the appearance of DR.
Scientific Poster 199
Driving Ability Reported by Patients With Diabetic 
Macular Edema Receiving Ranibizumab in the RESTORE 
Extension Study
Presenting Author: Paul Mitchell MD PhD*
Co-Author(s): Susan B Bressler MD*, Pascale G Massin MD*, Jennifer Petrillo PhD*, 
Cheryl Coon PhD*, Alberto Ferreira PhD*, Neil M Bressler MD*
Purpose: To examine changes in self-reported driving ability in the Ranibizumab Plus La-
ser in Diabetic Macular Edema (RESTORE) Extension Study. Methods: Post hoc analysis 
of the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) driving subscale 
among participants driving at baseline with visual impairment due to DME randomized for 
12 months to ranibizumab+sham laser (R, n = 52), ranibizumab+laser (R+L, n = 54), or sham 
injection+laser (L, n = 48) followed by open-label treatment with ranibizumab as needed 
for 24 months. Results: At 36 months, the LS mean (standard error) change from baseline 
in driving subscale were -1.4 (4.2), -2.1 (4.1), and -7.5 (4.3) in the R, R+L, and L groups, 
respectively. Conclusion: Patients treated with ranibizumab 0.5-mg as needed throughout 
the study reported stable NEI VFQ-25 driving subscale scores at 36 months; those initially 
treated with laser reported a loss of driving function.
Scientific Poster 200
 h  Effect of Intravitreal Ranibizumab Administration on 
Aqueous Levels of IL8 and IL6 in Patients With Diabetic 
Macular Edema
Presenting Author: Yasir Jamal Sepah MBBS
Co-Author(s): Alyssa Morimoto*, Kyu Hee Hong MS, Diana Do MD*, Menno Campagne 
PhD*, Quan Dong Nguyen MD*, Mohamed A Ibrahim Ahmed MBBCH, Mauricio Maia 
PhD*
Purpose: To determine changes in levels of cytokines in the aqueous fluid of patients with 
diabetic macular edema (DME), treated with ranibizumab (RBZ). Methods: Aqueous levels 
IL6 and IL8 were measured in serial samples of 131 patients at baseline (BL) and Months 3, 
6, 9, and 12. Results: A decreasing trend was noted in the levels of IL8 from BL to Month 
12. The mean changes at Months 3, 6, 9, and 12 were -2.4 pg/mL, -3.4 pg/mL, -4.7 pg/mL 
(P < .02), and -5.0 pg/mL (P < .01), respectively, when compared to BL. An increasing trend 
was noted in the levels of IL6, BL to Month 12. The mean changes at Months 3, 6, 9, and 
12 were +21.4 pg/mL, +35.0 pg/mL, +5.8 pg/mL, and +42.7 pg/mL (P < .05), respectively, 
when compared to BL. Conclusion: IL-8 may act downstream of VEGF and play a role in 
the VEGF-dependent development of DME, while the levels of IL-6 are regulated indepen-
dently of VEGF.
Scientific Poster 201
A Phase 2a Study of Darapladib, an Oral Lipoprotein-
Associated Phospholipase A2 Inhibitor, in Diabetic 
Macular Edema
Presenting Author: Giovanni Staurenghi MD*
Co-Author(s): Li Ye MS*, Mindy Magee PHARMD*, Ronald Peter Danis MD*, Megan 
McLaughlin MS*
Purpose: This is the first study to evaluate darapladib, an oral lipoprotein-associated 
phospholipase A2 inhibitor, for diabetic macular edema (DME). Methods: A randomized, 
double-masked, placebo-controlled study of 160-mg oral darapladib administered daily for 
3 months to subjects with center-involved DME. Results: Darapladib (D) and placebo (P) 
were well tolerated in 36 and 18 subjects, respectively. Five subjects were rescued with 
anti-VEGF (2D and 3P). A mean (95% CI) increase of 4 (2.3, 5.8) ETDRS letters BCVA and a 
decrease of -57 (-84, -30) microns OCT center subfield were observed in the darapladib arm. 
Conclusion: The efficacy and safety of darapladib in DME was observed in Phase 2a, and 
it warrants further investigation.
Scientific Poster 202
Cone Structure in Achromatopsia
Presenting Author: Venki Sundaram BMBCh
Co-Author(s): Caroline Louise Wilde MBCHB, Marko Nardini*, Robin Ali PhD**, James 
W Bainbridge MA PhD FRCOphth*, Michel Michaelides**
Purpose: Recent studies suggest that cone loss occurs with age in achromatopsia (ACHM). 
We further investigate cone structure in ACHM to help identify potential patients for gene 
therapy. Methods: Forty patients (mean age: 24.9 years) underwent spectral domain OCT 
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(SD-OCT) imaging. Images were graded into 5 categories: (1) continuous inner segment 
ellipsoid (ISe), (2) ISe disruption, (3) ISe absence, (4) hyporeflective zone (HRZ) presence, 
and (5) outer retinal atrophy. Results: 22.5% had a continuous ISe layer, 27.5% had ISe 
disruption, 20% had an absent ISe layer, 22.5% had a HRZ, and 7.5% had outer retinal 
atrophy. No difference in age of subjects between the SD-OCT categories occurred (P = .77). 
Conclusion: SD-OCT changes were not present in an age-dependent manner, suggesting 
the window of opportunity for gene therapy may extend into adulthood.
Scientific Poster 203
Outer Retina Analysis by OCT in Cone-Rod Dystrophy 
Patients
Presenting Author: Luiz Lima MD
Co-Author(s): Juliana M F Sallum MD, Richard F Spaide MD*
Purpose: To analyze the outer retina with spectral domain OCT (SD-OCT) in patients with 
cone-rod dystrophy (CRD). Methods: Using SD-OCT, the outer retina was retrospectively 
evaluated in 24 eyes of 12 CRD patients. The 4 studied hyper-reflective outer retinal bands 
were labeled as follows: Band 1, the external limiting membrane (ELM), Band 2, the ellip-
soid zone (EZ), Band 3, the interdigitation zone (IZ) between the cone outer segments, and 
Band 4, the retinal pigment epithelium (RPE). Results: There was an absence of IZ in the 
entire length of SD-OCT scan in all 24 study eyes. Outside the foveal area, the ELM and EZ 
were intact. Within the foveal area, there was loss of the ELM and EZ in 20 (83%) and 22 
eyes (92%), respectively. The RPE was identified in all study eyes. Conclusion: SD-OCT 
scans demonstrated complete absence of the IZ in CRD patients.
Scientific Poster 204
Martinique (West Indies) Crinkled Retinal Pigment 
Epitheliopathy
Presenting Author: Albert Jean-Charles MD
Co-Author(s): Salomon Y Cohen MD*, Isabelle A Meunier MD, Gabriel G Quentel MD*, 
Alain Gaudric MD*, Harold R Merle MD
Purpose: To revisit a peculiar autosomal dominant retinal dystrophy, ie, crinkled retinal 
pigment epithelium, noted in a large family of black Martinique patients. Methods: An-
giography and spectral domain OCT were studied. Results: Eleven out of 35 patients (3 
generations, age 10 to 87 years) were affected. OCT showed a striking and specific crinkled 
pattern of slightly elevated retinal pigment epithelium in the posterior pole and midperiph-
ery, giving an image of dry desert land in angiography. Conclusion: The observed pattern 
appeared different from previously described dystrophies and could be referred to as “Mar-
tinique crinkled retinal pigment epitheliopathy.”
Scientific Poster 205
 h  Adult-Onset Vitelliform Macular Dystrophy Caused by 
Mutations in IMPG1 and IMPG2 Interphotoreceptor Matrix 
Genes
Presenting Author: Isabelle A Meunier MD
Co-Author(s): Gaël Manes PhD, Béatrice Bocçuet PhD, Christian Hamel
Purpose: To identify the phenotype of macular dystrophies associated with IMPG1 and 
IMPG2 mutations. Methods: Both genes were systematically screened in 98 probands 
of unrelated registered families with autosomal dominant hereditary macular dystrophy. 
Results: A c.713T>G (p.Leu238Arg) IMPG1 mutation was found and segregates in 3 fami-
lies. In 1 family, affected patients have a bilateral macular vitelliform lesion. In the other 1 
families, patients have a multifocal vitelliform dystrophy. A c.3230G>T (p.C1077F) IMPG2 
mutation was noted in only 1 family with a multifocal vitelliform dystrophy. Patients with 
IMPG1 and IMPG2 mutations have a moderate visual impairment observed after the age of 
40. Conclusion: IMPG1 and IMPG2 are new causal genes of autosomal dominant adult-
onset vitelliform macular dystrophy.
Scientific Poster 206
Ocular Involvement in Patients With Fungemia: A Meta-
analysis
Presenting Author: Mohammad H Dastjerdi MD
Co-Author(s): Rebecca A Linquist MD, Jennifer A Spiegel MD, Thomas J Whittaker MD
Purpose: To determine the prevalence and patterns of ocular involvement in patients with 
fungemia. Methods: A systematic review and meta-analysis of the literature describing 
fungemia with ocular involvement. Results: Eighteen studies involving 1662 patients with 
fungemia were included. The pooled relative risks for chorioretinitis and endophthalmitis 
were 5.5% (95% CI, 3.3%-8.9%) and 1.6% (95% CI, 1.0%-2.4%), respectively. Only 6 pa-
tients (0.4% of total patients) required intravitreal injections or vitrectomy. In subgroup 
analyses, the overall pooled percentage of ocular involvement prior to year 2001 was 5.7%, 
which significantly decreased to 1.9% after year 2001. Conclusion: The current preva-
lence of disseminated ocular fungal infection in patients with fungemia is low.
Scientific Poster 207
Presentation of Fungal Endophthalmitis Outbreak 
Following Intravitreal Injections of Triamcinolone 
Contaminated by a Compounding Pharmacy
Presenting Author: Kent W Small MD
Purpose: To report a series of cases with fungal endophthalmitis following intravitreal 
triamcinolone injection derived from a single lot prepared by a compounding pharmacy 
(Franck’s). Methods: A retrospective review of 15 patients who received intravitreal in-
jections of triamcinolone obtained from Franck’s compounding pharmacy that was later 
found to be contaminated with the plant fungus Bipolaris hawaiiensis. Results: Infection 
developed in 82% of the exposed eyes. Mean onset was 183 days. Most common signs 
and symptoms included decreased vision and vitreous cell. Detection of fungus by cytology 
or cultures was poor. Conclusion: Fungal endophthalmitis can have an extremely delayed 
clinical onset, making it difficult to manage.
Scientific Poster 208
Analysis of Prognostic Factors in Vogt-Koyanagi-Harada 
Disease
Presenting Author: Yoko Okunuki MD
Co-Author(s): Yoshihiko Usui MD, Takeshi Kezuka MD PhD, Hiroshi Goto MD
Purpose: To identify pretreatment ocular findings predicting chronicity in Vogt-Koyanagi-
Harada (VKH) disease. Methods: 210 eyes of 105 patients with new-onset active VKH 
disease were reviewed retrospectively. The association of each pretreatment ocular find-
ing with chronicity was evaluated. Results: Seventy-three eyes had chronic disease. In 
multivariate logistic regression analysis adjusted for age, sex, interval between onset and 
treatment initiation, and first-month steroid dose, only severity of anterior inflammation 
among the ocular findings evaluated was associated with chronicity (odds ratio 2.11, P = 
.004). Older age was also significantly associated with chronicity in multivariate model. 
Conclusion: Anterior inflammation and age may be prognostic factors for chronicity in 
VKH disease.
Scientific Poster 209
Role of Ultrawide-field Imaging and Fluorescein 
Angiography in the Management of Tuberculous Retinal 
Vasculitis
Presenting Author: Priya Srinivasan
Co-Author(s): Padmamalini Mahendradas MBBS DO DNB, Garima Lakhotia MBBS, Rohit 
Shetty MD MBBS
Purpose: To determine the usefulness of ultrawide-field imaging and fluorescein angiogra-
phy (UWFIFA) in the management of tuberculous retinal vasculitis. Methods: Prospective 
interventional case series of 10 patients of diagnosed tuberculous retinal vasculitis who 
underwent UWFIFA using the Optos panoramic P200 imaging system. Results: Ultrawide-
field angiography showed active inflammatory disease in 4 eyes of 2 patients that had 
no clinical evidence of active posterior segment inflammation. Retinal neovascularization 
was noted in 4 eyes of 3 patients. Treatment decision was altered in 6 eyes of 4 patients. 
Conclusion: Ultrawide-field imaging and fluorescein angiography is a very useful tool in 
the management of tuberculous retinal vasculitis.
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Scientific Poster 210
Combined Treatment of Intravitreal Bevacizumab and 
Intravitreal Triamcinolone for Macular Edema Associated 
With Central Retinal Vein Occlusion
Presenting Author: Saurabh Arora MS
Co-Author(s): Vijayalaxmi Satyanarayanrao Bezankiwar, Sarvesh Tiwari**, George 
Manayath, V R Saravanan, Narendran Venkatapathy MBBS**, Sandeep Bachu, George 
Manayath, Veerappan Saravananan**
Purpose: To compare the efficacy and safety of intravitreal bevacizumab and triamcinolone 
(IVBT) with bevacizumab (IVB) for treatment of macular edema (ME) in central retinal vein 
occlusion CRVO. Methods: Twenty-eight eyes were each treated with IVBT and IVB. Re-
peat injections were given if ME persisted on OCT 1 month after the first treatment or BCVA 
loss of at least 2 lines. Results: In IVBT, mean BCVA was logMAR 0.71, compared to 0.76 
in IVB, whereas mean macular thickness (MT) in IVBT was 390 microns, compared to 396 
in the IVB group at 6 months, with no statistical difference. The mean numbers of reinjec-
tions were 1.04 in IVBT compared to 2.43 in IVB. A significant mean IOP rise was noted in 
IVBT. Conclusion: IVBT and IVB improve BCVA and reduce MT; however, IVBT offers an 
advantage of fewer injections with due risk of IOP hike.
Scientific Poster 211
Oral Kallidinogenase Improved Retinal Blood Flow Levels 
and Visual Acuity in Diabetic Macular Edema Patients
Presenting Author: Eiko Tsuiki DOMS
Co-Author(s): Kiyoshi Suzuma MD, Makiko Matsumoto MBCB MD DOMS, Takashi 
Kitaoka MD**
Purpose: We investigated the influence of oral kallidinogenase on retinal blood flow in 
diabetic macular edema (DME) patients who received focal laser for clinically significant 
macular edema. Methods: Retinal blood flow was measured by laser speckle flowgraphy 
in 21 patients (12 with and 9 without kallidinogenase) and evaluated using the mean blur 
rate (MBR). Results: Although MBR of 6 months after significantly decreased to 83.8% in 
patients without kallidinogenase (P = .01), it was maintained at 99.5% in patients with kal-
lidinogenase. BCVA significantly improved in patients with kallidinogenase (P < .05) and has 
a significant correlation with retinal blood flow levels (r = 0.69, P = .009). Conclusion: Kal-
lidinogenase is able to improve retinal blood flow levels and visual acuity in DME patients.
Scientific Poster 212
 h  Intraoperative OCT Evaluation of Macular Thickness 
Following Membrane Peeling
Presenting Author: Hideyasu Oh MD PhD
Co-Author(s): Tomoyuki Chihara, Takeshi Moriya**, Toshitaka Bun MD**, Takafumi 
Hirashima, Takao Utsumi**
Purpose: To evaluate the immediate effect of membrane peeling on macular thickness 
(MT) using intraoperative OCT (iOCT). Methods: Twenty-one subjects with either epiretinal 
membrane (ERM) or diabetic macular edema (DME) were analyzed with iOCT. Both epireti-
nal membrane, if present, and internal limiting membrane were removed during surgery. 
Results: Following membrane peeling, MT in the ERM group decreased by 11% (P = NS) 
and 21% in the DME group (P < .01). The mean decreases in MT were 53 µm for the ERM 
group and 114 µm for the DME group. Conclusion: The changes in MT analyzed with iOCT 
highlight the immediate effects of membrane peeling on intraoperative macular morphol-
ogy during surgery for these macular diseases.
Scientific Poster 213
 h  One-Year Results of Intravitreal Dexamethasone 
Implant in Drug-Naive Patients With Diabetic Macular 
Edema
Presenting Author: Patricia Udaondo MD
Co-Author(s): Ana Hervas, Salvador Garcia-Delpech MD, Manuel Diaz Llopis MD PhD**, 
Begona Pina MD**
Purpose: To determine the effectiveness of intravitreal dexamethasone implant (Ozurdex) 
for diabetic macular edema (DME). Methods: Twelve-month pilot study including drug-na-
ïve patients with DME treated with dexamethasone implant and followed by re-treatment 
based on central macular thickness (CMT) and vision loss. Results: Sixty-eight naïve eyes 
of 58 patients were enrolled. The mean re-treatment time was 5 months, and the mean 
number of implants was 2.6. Both visual acuity and CMT improvement were statistically 
significant. Security profile: 6.5% of cataract surgery and 9.2% of patients needed topical 
treatment for IOP. No other side effects during follow-up. Conclusion: Intravitreal dexa-
methasone implant was well tolerated and was effective in the management of DME in 
this study.
Scientific Poster 214
 h  Systemic Safety Profile of Ranibizumab in AMD, 
Retinal Vein Occlusion, and Diabetic Macular Edema: A 
Comprehensive Patient-Level Meta-analysis
Presenting Author: Baruch D Kuppermann MD PhD*
Co-Author(s): Phillip C Lai MD*, Daniel S Reshef MD PhD*, Aaron Osborne MRCOphth*, 
Lisa Tuomi, Steven F Francom*
Purpose: To better characterize the systemic safety profile of ranibizumab (RBZ) in AMD, 
diabetic macular edema (DME), and retinal vein occlusion (RVO). Methods: This meta-
analysis of 14 Phase 2-3b RBZ clinical trials (6504 patients; 7544 patient-years) included 
pairwise comparisons for 0.5 mg or 0.3 mg vs. control and 0.5 mg vs. 0.3 mg. Results: 
In patients with AMD or RVO, no imbalances were observed. In DME, small numerical 
imbalances were noted for wound healing complications, and for stroke and death in Year 
2 of monthly treatment. Conclusion: Ranibizumab is a Fab fragment without a Fc region 
designed to minimize systemic exposure. Event rates were low for all groups. These results 
are consistent with the established RBZ safety profile.
Scientific Poster 215
Bevacizumab Plus Laser vs. Laser Alone for Diabetic 
Macular Edema: A Prospective Randomized Trial
Presenting Author: Alicia C Pareja Rios MD
Co-Author(s): Isabel M Lopez Galvez MD*, Elena Maria De Armas Ramos MD**, Pablo 
Airam Pareja-Rios RN, Wladimiro Pareja-Rios Sr PA, Romero P Aroca MD, Eugenio Jose 
Pareja-Rios, Alejandro Quijada-Fumero MD, Miguel Angel Reyes-Rodriguez MD, Miguel 
A Serrano MD**
Purpose: To prospectively compare 1-year outcomes of patients receiving either focal/
grid photocoagulation or bevacizumab + laser for diffuse diabetic macular edema (DME). 
Methods: Fifty-three eyes with DME involving the fovea and visual acuity (VA) 20/32 to 
20/320 randomly received focal/grid photocoagulation (n = 28) or bevacizumab + laser (n = 
25). There were no significant intergroup differences in VA at baseline. Results: At 1 year 
the difference in VA was 10 ± 10 letters in favor of patients receiving bevacizumab + laser 
(P < .05). The most notable improvements occurred in patients who had subretinal fluid 
pattern on OCT before receiving bevacizumab treatment. Conclusion: Bevacizumab + laser 
significantly improved VA at 1 year compared with laser alone.
Scientific Poster 216
Efficacy of Intravitreal Dexamethasone Implant (Ozurdex) 
in Recalcitrant Nonuveitic Macular Edema
Presenting Author: Chetan Rao MBBS
Co-Author(s): Vikas Khetan DO, Tarun Sharma MBBS
Purpose: To study the efficacy of Ozurdex on visual acuity and OCT in recalcitrant nonu-
veitic macular edema. Methods: Retrospective case series of 25 patients (14 venous oc-
clusions, 8 diabetic maculopathy, 3 choroidal neovascular complex). Results: At 3 months 
follow-up, in patients with venous occlusions, visual acuity improved by 2 lines (Snellen) 
in 35% of eyes and mean OCT thickness reduced by 289 microns; no such significant im-
provement was observed in the other groups. Conclusion: Dexamethasone implant was 
efficacious in reducing macular edema and improving visual acuity in one-third of eyes with 
recalcitrant macular edema caused by venous occlusions.
Scientific Poster 217
Longitudinal Assessment of Macular Pigment Parameters 
in Patients With Macular Telangiectasia Type 2
Presenting Author: Simona Degli Esposti MD
Co-Author(s): Catherine Ann Egan MBBS FRANZCO*, Anthony G Robson PhD
Purpose: To monitor macular pigment optical density (MPOD) parameters in MacTel type 
2 patients. Methods: Two-wavelength fundus autofluorescence was used to quantify the 
spatial profile and total amount of MP (OD units) within the central 21° in 40 patients 
with MacTel type 2. Measurements were repeated over 12-52 months (mean: 29 months). 
Results: All eyes had a paracentral distribution of MP (mean peak MPOD 0.1; mean ec-
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centricity: 4.5°; mean total amount: 3410). The mean changes in peak OD and eccentricity 
were -0.02 (SD 0.04) and +0.36 degrees (SD 1.13). Mean change in total MP was -360 
(SD 1225); reduction was greater than 1000 units in 11 cases. Conclusion: Most patients 
with MacTel Type 2 have an abnormal but relatively stable distribution of MP. Some show 
progressive loss of MP over time.
Scientific Poster 218
Change in Subfoveal Choroidal Thickness Using Enhanced 
Depth Imaging Spectral Domain OCT After Treatment 
for Extramacular Choroidal Melanoma With Plaque 
Radiotherapy
Presenting Author: Juan David Arias MD
Co-Author(s): Shripaad Y Shukla MD, Haitham Al-Mahrouqi MBCHB, Arman Mashayekhi 
MD, Carol L Shields MD, Jerry A Shields MD, Enzo M Fulco MD
Purpose: To evaluate the change in subfoveal choroidal thickness (SFCT) using enhanced 
depth imaging spectral domain OCT (EDI-OCT) after plaque radiotherapy of extramacular 
choroidal melanoma. Methods: SFCT was measured with EDI-OCT before and 1 year after 
plaque radiotherapy of choroidal melanoma. Results: Of 22 study eyes, mean SFCT was 
280 ± 59 microns at baseline and 245 ± 59 microns after treatment (P = .003). The change in 
SFCT was borderline related to radiation dose at tumor base (P = .054) but was not related 
to radiation dose at foveola (P = .445) or optic disc (P = .327). Conclusion: SFCT decreases 
significantly following plaque radiotherapy of extramacular choroidal melanoma and ap-
pears related to tumor basal radiation dose.
Scientific Poster 219
 h  Long-term Results of Ranibizumab for Myopic 
Choroidal Neovascularization
Presenting Author: Salomon Y Cohen MD*
Co-Author(s): Minh-Huyen Nghiem-Buffet MD*, Typhaine Grenet**, Lise Dubois, 
Sandrine Ayrault, Franck Fajnkuchen MD*, Gabriel G Quentel MD*
Purpose: To evaluate the long-term efficacy of ranibizumab for myopic CNV (mCNV). 
Methods: Monocentric, retrospective analysis of consecutive patients with naïve juxtafo-
veal or subfoveal mCNV, treated with intravitreal ranibizumab (IVR) on a pro re nata basis, 
for at least 24 months. Results: Fifty-one patients (51 eyes), 12 men and 39 women (mean 
age: 64 years) were included. Visual acuity improved from 58.7 to 66.3 letters (P < .001, 
mean visual gain: 7.62 ± 15 letters). Mean number of IVR was 3.5 (range: 1-12), during 
a mean follow-up of 39.3 months (range: 24-69). Conclusion: IVR resulted in long-term 
efficacy for treating mCNV.
Scientific Poster 220
Follow-up of Patients With Hydroxychloroquine Toxicity
Presenting Author: Reshma Katira MD
Co-Author(s): Jonathan S Lyons MD, James M Osher MD
Purpose: To use multifocal electroretinography (mfERG) to follow retinal function in pa-
tients who stopped taking hydroxychloroquine (HCQ). Methods: A retrospective review of 
89 patients with HCQ retinal toxicity. Following cessation of HCQ, multiple variables were 
evaluated, including changes in mfERG ring ratio, visual acuity, and fundus examination. 
Results: Twenty-three female patients, median age 57 years, with retinal toxicity from 
HCQ use were included in this study. Mean follow-up was 23 months (3.5-78), and cumula-
tive dose was 2147 grams (1015-3625). Using ring ratio patterns on mfERG, 8/23 (34.8%) 
worsened, 9/23 (39.1%) had no change, and 6/23 (26.1%) showed improvement during the 
follow-up period. Conclusion: This study shows that a significant proportion of patients 
had an improved mfERG after cessation of HCQ.
Scientific Poster 221
Estimation of Oxidative Stress Level in Central Serous 
Retinopathy
Presenting Author: Aniruddha Maiti MD
Co-Author(s): Surajit Bose Sr, Chirag Dilip Bhatt MBBS MS, Dr Ratish Chandra Paul IV**
Purpose: To estimate the oxidative stress levels in central serous retinopathy (CSR). 
Methods: Twenty cases and 22 age-matched controls were tested within a period of 6 
months. After clinical diagnosis supported by OCT and DFA the patients’ blood was tested 
for lipid peroxidation product (LPP). To determinate the LPP level, thiobarbituric acid was 
added to plasma sample and the absorption of color that developed after heating was 
estimated spectrophotometrically. The concentration was expressed in nmol/ml of malo-
ndialdehyde (MDA). MDA is a biomarker of the oxidative stress. Results: Average age was 
40.9 years, and 90% were males. The results were evaluated using a 2 sample t-test. Mean 
LPP in the CSR patients was statistically significant (P-value < 7.8 X 10 -9]. Conclusion: 
The oxidative stress levels are high in CSR.
Scientific Poster 222
Aflibercept (Eylea) for Radiation Retinopathy
Presenting Author: Liliya Shevchenko DO
Co-Author(s): Thomas M Aaberg Jr MD*, James Robert Singer DO*
Purpose: To report the results of using intravitreal aflibercept (Eylea) in patients with ra-
diation-related complications. Methods: A list of patients who received intravitreal injec-
tions of Eylea (IVE) as treatment for radiation-related complications was compiled. The fol-
lowing data were analyzed: visual acuity, central macular thickness, number of injections, 
complications encountered, and prior treatments. Results: Twenty patients received IVE. 
There was a statistically significant improvement in visual acuity after the third injection 
and a statistically significant decrease in central retinal thickness after the first injection. 
Conclusion: Intravitreal aflibercept improved or maintained visual acuity, decreased cen-
tral retinal thickness, and reversed anterior segment neovascularization in patients with 
radiation-related complications.
Scientific Poster 223
Predictive Value of Pharmacological Pupillary Dilation in 
Retinopathy of Prematurity Diagnosis
Presenting Author: Mohammad Riazi Esfahani MD
Co-Author(s): Reza Karkhaneh MD**, Ramak Roohipour MD, Nazanain Ebrahimiadib 
MD**
Purpose: To assess whether pupillary response to mydriatics can predict ROP and its se-
verity. Methods: Pupillary diameter was measured with a ruler. Results: 134 eyes of pre-
mature infants (< 33 weeks, < 2000 g) were enrolled. ROP was diagnosed in 38.81%. 19.4% 
had poor response to mydriatics (final dilation < 6 mm) Final pupil diameter after mydriatic 
administration in patients with ROP was significantly lower than in those without ROP (P 
= .001) as well as those with plus disease compared to subjects without plus disease (P 
< .001). The best cut-off value seems to be 5.6 mm because it is able to differentiate in-
volvement of zone I from zone II and III with a sensitivity of 80% and a specificity of 100%. 
Conclusion: Rigid pupil is indicative of plus disease and high stages of ROP, but it is not 
recommended to be used as a screening test due to its low sensitivity.
Scientific Poster 224
Ocriplasmin for the Treatment of Vitreomacular Traction: 
Clinical Indications and Predictors of Success
Presenting Author: Daniel B Roth MD*
Co-Author(s): Kunjal K Modi, Howard F Fine MD MHS*, Matthew Wheatley MD
Purpose: To evaluate eyes treated with intravitreal ocriplasmin and determine predictors 
of success. Methods: Retrospective review of 21 eyes with symptomatic VMA was per-
formed. Each eye was treated with a single pars plana injection of ocriplasmin. Results: 
Mean Snellen visual acuity was 20/92. Mean length of VMA on OCT was 935 µm and 340 
µm in eye with macular hole (MH). Ocriplasmin injection induced a vitreomacular separa-
tion in 33% of all eyes and 71% of eyes with MH. However, MH closure was seen in only 
29% of these eyes. Fifty-three percent of eyes had worsening of vision at the 1-week fol-
low-up visit. Successful vitreomacular separation was associated with presence of MH and 
short length of vitreomacular attachment. Conclusion: Case selection and appropriate pa-
tient expectations are important in the management of symptomatic VMA with ocriplasmin.
Scientific Poster 225
 h  Post-Intravitreal Injection Mycobacterium abscessus 
Nodular Scleritis Outbreak
Presenting Author: Steven M Cohen MD
Co-Author(s): Laura Tonjes Muller MD, Edgar M Espana MD, Scott C Behler MD
Purpose: To report a Mycobacterium abscessus nodular scleritis outbreak following in-
travitreal injection for wet macular degeneration. Methods: Chart review. Results: Ten 
patients presented with a painful nodular scleritis 27 days (7-52 days) following intravitreal 
injection administered by the same surgeon in the same office. The source of the infection 
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was probably contaminated tap water used to rinse glutaraldehyde-soaked lid specula. Six 
eyes were culture positive for M abscessus. Scleritis resolved following treatment with 
topical amikacin, oral clarithromycin or azyihromycin, and surgical debridement. Conclu-
sion: M abscessus nodular scleritis can occur following intravitreal injection. Treatment 
with topical and systemic antibiotics as well as prompt surgical debridement is effective.
Scientific Poster 226
Study of Corneal Sensitivity After Circumferential 
Photocoagulation With Argon or Diode Laser for Retinal 
Detachment
Presenting Author: Alexis Pinel MD
Co-Author(s): Lucie Biard MD, Pierre-Kahn Vincent SR MD
Purpose: To compare the corneal sensitivity after circumferential intraocular laser pho-
tocoagulation using 810-nm diode laser or 532-nm argon laser for retinal detachment sur-
gery. Methods: Corneal sensitivity was measured using a Cochet-Bonnet esthesiometer in 
patients treated by circumferential intraocular laser photocoagulation with diode or argon 
laser for retinal detachment and in control patients. Results: Median corneal sensitivity 
was lower (P < .001) in eyes treated with laser photocoagulation (n = 33) compared to 
control eyes (n = 28) and lower in the diode laser group than in the argon laser group (P < 
.001). Conclusion: Corneal sensitivity is impaired after circumferential intraocular photo-
coagulation, more so with diode laser than with argon laser.
Scientific Poster 227
Occurrence of Retinal Detachment in Japanese Patients 
With Stickler Syndrome
Presenting Author: Hiroyuki Kondo MD
Co-Author(s): Takaaki Hayashi MD, Mineo Kondo MD PhD**, Masahito Ohji MD*
Purpose: To investigate the occurrence of retinal detachment (RD) in Japanese patients 
with genetically confirmed Stickler syndrome (STL). Methods: A review of medical records 
was conducted for 18 families with STL. The diagnosis was established by detecting muta-
tions in the COL2A1 gene. Results: Of the 43 members of the 18 families, 29 had RD: 14 
had bilateral and 15 had unilateral RD. Twenty-three eyes (82%) presented RD under the 
age of 20. For 9 patients who had bilateral RD, 5 patients were diagnosed at one time and 
4 patients suffered RD at an interval ranging from 3 to 6 years. Conclusion: A risk of de-
veloping RD is as high in Japanese patients with STL as in whites. The mutational analysis 
is efficient in determining STL.
Scientific Poster 228
The Association of Oral Fluoroquinolone Use With the 
Need for Retinal Detachment or Tear Repair
Presenting Author: Kian Eftekhari MD
Co-Author(s): Devon H Ghodasra MD, Jinbo Chen PhD**, John H Kempen MD*, Kevin 
Haynes PHARMD*, Brian L VanderBeek MD MPH
Purpose: To determine if oral fluoroquinolone (FQ) exposure is associated with retinal 
break repair (RB). Methods: Nested case-control study in The Health Improvement Net-
work (THIN) cohort database. Cases: subjects undergoing a procedure for retinal detach-
ment or tear (RB). The outcome measure was the odds ratio of FQ exposure for RB within 
8, 45, and 180 days of the index date. Results: Cases (3099) with a RB were matched 
to 10926 controls. A total of 8238 prescriptions for oral FQ were written for both cases 
and controls. Logistic regression did not detect an association between FQ exposure and a 
procedure to repair a RB at any of the time points. Conclusion: Our results do not support 
an association between oral FQ use and the need for a procedure to repair a retinal break.
Scientific Poster 229
Heavy Silicone Oil in Inferior Retinal Detachments
Presenting Author: Sundaram Natarajan MD
Co-Author(s): Pandurang Kulkarni MS**, Rishi Bhardwaj MS, Anoop Sivaraman
Purpose: To evaluate effectiveness of heavy silicon oil in inferior retinal detachment. 
Methods: Consecutive case series of 37 eyes with inferior rhegmatogenous retinal de-
tachment included. Patients underwent vitrectomy followed by heavy silicon oil, a mixture 
of 69.5% ultrapure polydimethylsiloxane and 30.5% ultrapure perfluorohexyloctane infu-
sion. Each patient was evaluated at 1 day, 6 weeks, and 6 months. Results: At 6 weeks, 
anatomic success was observed in 91% of eyes; this was reduced to 75% at 6 months (P 
= .058). Twenty-four percent of eyes developed redetachment after surgery at the end of 6 
months. Macular attachment was observed in 83.7% of eyes at 6 months as compared to 
43.2% eyes preoperatively. Conclusion: Recurrent and inferior retinal detachments can be 
effectively managed with heavy silicon oil with statistically significant anatomic success.
Scientific Poster 230
Double Endotamponade With Perfluorodecalin and 
Silicone Oil in Retinal Detachment Surgery: A Clinical 
Study
Presenting Author: Pavel Lyskin MD
Co-Author(s): Elena Kazimirova, Alexander A Shpak MD
Purpose: To assess the safety and efficacy of double endotamponade (DT) with perfluoro-
decalin and silicone oil. Methods: Inclusion criteria: total retinal detachment with retinal 
breaks located in both upper and lower retina. All patients underwent vitrectomy and pho-
tocoagulation. In a study group (n = 26), DT was performed. In a control group (n = 20), sur-
gery was finished with silicone oil tamponade. Tamponade duration: 30 days. Examinations: 
standard + OCT + microperimetry (MP). Results: Anatomic success and BCVA difference 
between the groups were insignificant, but there was a trend to better anatomic outcome 
in the study group (81% vs. 65%). OCT and MP data had no significant differences between 
the groups. Conclusion: Thirty-day DT is safe. DT shows a trend toward better anatomic 
success of surgery.
Scientific Poster 231
Intraoperative Spectral Domain OCT During Pars Plana 
Vitrectomy for Macula Involving Retinal Detachments
Presenting Author: Sunil K Srivastava MD*
Co-Author(s): Peter K Kaiser MD*, Alex Yuan MD, Rishi P Singh MD*, Daniel F Martin 
MD, Justis P Ehlers MD*
Purpose: To describe the intraoperative spectral domain OCT (iSD-OCT) findings of macula 
involving retinal detachments and their relationship to visual outcomes. Methods: A ret-
rospective review was performed of patients who had undergone repair via vitrectomy and 
who had iSD-OCT performed. Results: Intraoperative imaging findings included persistent 
subretinal fluid after perfluoro-n-octane (PFO) tamponade (29/29). Full thickness macular 
holes were noted in 3 eyes. Stage 1 macular hole under PFO was noted in 15/26 eyes. The 
ability to identify the outer retinal layers after tamponade was seen more often in eyes with 
postoperative visual acuity greater than 20/50. Conclusion: OCT is feasible during PPV for 
retinal detachments. The identification of outer retinal layers after PFO tamponade was 
more likely in eyes with good postop vision.
Scientific Poster 232
OCT Angiography of Optic Nerve Head Perfusion in 
Multiple Sclerosis Patients
Presenting Author: Xiaogang Wang
Co-Author(s): Yali Jia PhD*, Rebecca Spain MD, James Fujimoto PhD*, David Huang MD 
PhD*, Joachim Hornegger PhD
Purpose: To investigate optic nerve head (ONH) perfusion in multiple sclerosis (MS) by OCT 
angiography. Methods: Twenty-seven MS without optic neuritis (MS-ON) eyes, 3 fellow 
eyes, 7 MS with ON eyes (MS+ON), and 21 normal eyes were scanned by high-speed 1050-
nm swept-source OCT. Flow was detected by the split-spectrum amplitude-decorrelation 
angiography algorithm, and ONH flow index (FI) was computed from 4 registered scans. 
Results: A significantly (P = .038) higher percentage of MS+ON eyes (43%) had abnormally 
low ONH FI (< 2.33 standard deviations below mean) compared to normal subjects (5%). 
Thirty-three percent of fellow eyes and 11% of MS-ON eyes also had reduced FI. Conclu-
sion: OCT angiography may be useful in the evaluation of ONH damage in MS.
Scientific Poster 233
Macular Ganglion Cell-Inner Plexiform Layer Thickness 
Change After Internal Limiting Membrane Peeling During 
Vitrectomy for Idiopathic Macular Hole
Presenting Author: Hyung Woo Kwak MD PhD
Co-Author(s): Seung Young Yu MD, Ji-Ho Yang MD
Purpose: To evaluate macular ganglion cell-inner plexiform layer (GCIPL) thickness chang-
es after vitrectomy with internal limiting membrane (ILM) peeling in eyes with idiopathic 
macular hole (MH). Methods: Fifty-two eyes with an idiopathic MH treated by vitrectomy 
with ILM peeling were studied. The macular GCIPL thickness was measured by the Cirrus 
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HD-OCT using the ganglion cell analysis (GCA) before and at 1 and 6 months after vitrec-
tomy. Results: The mean GCIPL thickness at 1 and 6 months after surgery was significantly 
reduced from 78.75 ± 10.73 to 70.83 ± 8.90 and to 67.06 ± 12.94 µm, respectively (P < .001). 
The postoperative GCIPL thickness was thinner than that of the group without ILM peel-
ing at 6 months postoperatively (P < .001). Conclusion: Reduction of the macular GCIPL 
thickness was observed after vitrectomy for idiopathic MH that may be associated with 
ILM peeling.
Scientific Poster 234
Spectral Domain OCT Features of Silicone Oil Interface
Presenting Author: Navneet Mehrotra
Co-Author(s): Manish Nagpal MD*, Rituraj Videkar MS, Gaurav S Paranjpe
Purpose: To objectively determine the silicon oil (SO)-retinal interface, macular status, and 
tamponade effect in SO-filled eyes using spectral domain OCT (SD-OCT). Methods: 104 
eyes underwent SD-OCT examination. Horizontal and vertical macular scans were taken. 
Results: Incomplete tamponade was noted in n = 12; complete tamponade, in n = 92. 
Deposits, n = 12; foveal thickening, n = 22; epiretinal membrane, n = 13; foveal thinning, n 
= 6; subfoveal fluid, n = 8; subsilicon membranes, n = 4; emulsified SO, n = 4; macular hole, 
n = 2. Conclusion: SD-OCT is a useful tool to assess the SO–retina interface, tamponade 
effect, and macular status in SO-filled eyes.
Scientific Poster 235
Relationship of Choroidal Thickness Using Enhanced 
Depth Imaging OCT and Visual Acuity in High Myopes of 
Asian Indians
Presenting Author: Ashish Sharma MBBS*
Co-Author(s): Jay Umed Sheth Doms MD, Baruch D Kuppermann MD PhD*
Purpose: To examine predictive factors for visual acuity in high myopes. Methods: Im-
ages were obtained in highly myopic eyes (≥ 6 D). Correlation among subfoveal choroidal 
thickness (CT), age, refractive error, photoreceptor inner segment outer segment (PRISOS) 
length, and visual acuity was analyzed. Generalized estimating equation models were used 
to identify predictors of visual acuity. Results: The mean refractive error of 86 eyes was 
-9.5 D. The mean subfoveal CT was 204.4 µm and was correlated negatively with age 
(P < .0001, r = - 0.452), refractive error (P < .0001, r = -0.745), and visual acuity (P < .0001, r = 
- 0.462). The only significant predictor in the pooled data for the visual acuity was subfoveal 
CT (P =.037). Conclusion: Subfoveal CT is an important predictor of visual acuity in high 
myopes.
Scientific Poster 236
Comparison of OCT Characteristics in Patients With 
Multifocal Choroiditis and Punctate Inner Choroidopathy
Presenting Author: Roomasa Channa MD
Co-Author(s): Mohamed A Ibrahim Ahmed MBBCH, Daniel A Ferraz MD, Syed Mahmood 
Shah MBBS, Millena Gomes Bittencourt MD, Yasir Jamal Sepah MBBS, Quan Dong 
Nguyen MD*
Purpose: To determine if multifocal choroiditis (MFC) and punctate inner choroidopathy 
(PIC) can be distinguished using spectral domain OCT (SD-OCT). Methods: Two graders 
independently evaluated lesions on SD-OCT. Generalized linear latent and mixed models 
were used for analysis. Results: Forty-two lesions included: 48% MFC, 52% PIC. Retinal 
pigment epithelium (RPE) elevation was identified in 20% of MFC and 36% of PIC lesions (P 
= .409). RPE disruption was identified in 50% of MFC and 54% of PIC lesions (P = .788). IS/
OS disruption was identified in 90% of MFC and 64% of PIC lesions (P = .044). Conclusion: 
Inner segment / outer segment disruption was significantly more common in MFC lesions.
Scientific Poster 237
Measuring Macular Choroidal Thickness in Reticular 
Pseudodrusen Using High-penetrating Swept-Source OCT
Presenting Author: Sotaro Ooto MD
Co-Author(s): Naoko Ueda-Arakawa MD, Abdallah Ahmed Ellabban, Akitaka Tsujikawa 
MD PhD*, Nagahisa Yoshimura MD PhD*
Purpose: To measure macular choroidal thickness in reticular pseudodrusen (RPD) using 
high-penetrating swept-source OCT (SS-OCT). Methods: Forty-two patients with RPD and 
15 age-matched volunteer subjects underwent SS-OCT. Mean regional choroidal thickness 
measurements were obtained by 3-D raster scanning. Results: The mean choroidal thick-
ness of each sector was significantly smaller in RPD eyes compared with normal eyes (P 
< .01 for all). The mean choroidal thickness of each sector was similar in 22 RPD eyes 
with late AMD and 20 RPD eyes without it (P > .05 for all). Conclusion: SS-OCT revealed 
decreased choroidal thickness throughout the entire macular area in RPD.
Scientific Poster 238
The Role for Ophthalmoscopy in Ongoing Management of 
Retinal Disease in the Current Era of High-resolution OCT 
Imaging
Presenting Author: Paul Hahn MD PhD
Purpose: To elucidate the role for ophthalmoscopy vs. OCT in the ongoing management 
of retinal diseases. Methods: 100 consecutive retina clinic return records were retrospec-
tively reviewed for clinical exam and imaging findings and documented assessment and 
treatment plan. Results: Ninety-nine percent of patients were imaged with OCT. Of 30 pa-
tients followed for neovascular AMD, 2 had new subretinal heme seen on ophthalmoscopy; 
management was otherwise solely OCT-guided. Management of dry AMD, nonproliferative 
diabetic retinopathy, central serous retinopathy, and epiretinal membrane was exclusively 
OCT-guided. Management of proliferative diabetic retinopathy, chronic retinal detach-
ments, and other peripheral pathology was primarily ophthalmoscopy guided. Conclusion: 
Ophthalmoscopy is still important for management of peripheral retinal pathology, but cur-
rent management of macular disease is almost exclusively guided by OCT imaging alone.
Scientific Poster 239
Spectralis-Obtained Spectral Domain OCT Is Superior to 
Cirrus in Accuracy as well as Reproducibility of Retinal 
Thickness and Volume Measurements
Presenting Author: K V Chalam MD PhD
Co-Author(s): Shailesh K Gupta MD**, Sandeep Grover MD*
Purpose: To compare coefficient of reproducibility (COR) of retinal measurements from 
OCT images of spectral domain (Cirrus and Spectralis) instruments. Methods: A prospec-
tive observational study of persons (N = 46) with macular edema (CSF thickness ≥ 320 
µm). Each study eye underwent 2 replicate Cirrus/Spectralis scans. Central subfield thick-
ness (CST) and retinal volume (RV) were used in reproducibility analyses. Results: COR for 
change in CST was lower on Spectralis than on Cirrus (2%, 14%; P < .01). Mean difference 
in CST was 24 µ vs. 47 µ (P < .01). COR for change in RV was lower on Spectralis than on 
Cirrus (1%, 12%; P < .01). Mean difference in RV was 0.28 vs. 1.18 cu.mm (P < .01). Conclu-
sion: Spectralis is superior to Cirrus in reproducing CST as well as RV, probably because 
of its tracking ability.
Scientific Poster 240
 h  High-Power Blue Laser Pointer-Induced Maculopathy
Presenting Author: Saba Al Rashaed MD
Co-Author(s): Sulaiman M Alsulaiman MD, Emad Bishara Abboud MD, Nicola G Ghazi 
MD, Jluwi S Almasaud MD, J Fernando Arevalo MD FACS*
Purpose: To report various types of maculopathy induced by high-power blue handheld 
laser. Methods: Fourteen eyes with a history of handheld laser with mean power of 450-
nm exposure were identified. Results: Macular hole in 4 eyes, intraocular hemorrhage in 
7 eyes; the remaining 3 eyes had an outer retinal disruption, epiretinal membrane , and a 
schisis-like cavity. Vision improved in 4 eyes (29%) spontaneously, whereas 10 eyes (71%) 
were managed with Nd:YAG hyaloidotomy or surgery. Pars plana vitrectomy was success-
ful to close all 4 full-thickness macular hole cases. Final BCVA improved in all cases with 
a mean of 20/40. Conclusion: Visual acuity improved in all patients spontaneously or fol-
lowing intervention. High-power handheld lasers are extremely dangerous to the eye and 
public awareness should be encouraged.
Scientific Poster 241
Photodynamic Therapy With Verteporfin in Circumscribed 
Choroidal Hemangioma
Presenting Author: Fairooz Puthiyapurayil Manjandavida MBBS
Co-Author(s): Arman Mashayekhi MD, Marco Pellegrini MD, Jerry A Shields MD, Carol 
L Shields MD
Purpose: To study the effect of photodynamic therapy (PDT) on tumor thickness, subreti-
nal fluid (SRF), and BCVA in eyes with symptomatic circumscribed choroidal hemangioma 
(CCH). Methods: Retrospective series of 54 eyes with symptomatic CCH undergoing stan-
dard PDT with verteporfin (50 J/cm2 over 83 s) over 10 years. Results: The mean initial 
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tumor thickness was 3.0 (range: 2 to 6) mm. CCH was macular in 48%, and there was SRF 
in 93%. The mean number of PDT sessions was 1.5 (range: 1 to 6). Over a mean follow-up 
of 42 months, there was 35% reduction in mean tumor thickness. SRF resolved in 80% at a 
median of 3 months. The BCVA improved by ≥ 2 Snellen lines in 50% and remained stable 
in 19%. Conclusion: Standard PDT causes tumor regression and SRF resolution and stabi-
lizes or improves BCVA in a majority of treated eyes with symptomatic CCH.
Scientific Poster 242
Dexamethasone Intravitreal Implants as Initial or 
Subsequent Treatment for Macular Edema in Retinal Vein 
Occlusion
Presenting Author: Pravin U Dugel MD*
Purpose: To evaluate safety and efficacy of ≥ 2 dexamethasone (DEX) implants in treat-
ment-naïve (TN) vs. previously treated (PT) patients with retinal vein occlusion (RVO). 
Methods: Subgroup analysis of 26-center chart review of 289 patients (39 TN, 250 PT) 
treated with ≥ 2 implants, followed 3-6 months after last implant. Results: Mean gain from 
baseline (BL) BCVA range after implants 1-6 was 3.0-8.0 lines in TN vs. 0.9-2.4 in PT. Mean 
decrease from BL central retinal thickness range was 241-459 µm in TN vs. 137-164 in PT. 
Increased IOP was the most common adverse event. Conclusion: Improvements in BCVA 
were larger in treatment-naïve than in previously treated patients. No new safety concerns 
arose with multiple implants.
Scientific Poster 243
Changes in Central Retinal Venous Pressure After Central 
Retinal Vein Occlusion and Correlation With Visual 
Outcome and Retinal Ischemia
Presenting Author: Mei Hong Tan MbBCh BAO
Co-Author(s): Lynne Anne Smithies PhD, Ian L McAllister MD*
Purpose: To investigate central retinal venous pressure (CVP) changes following central 
retinal vein occlusion (CRVO) and correlate with visual acuity (VA), capillary nonperfusion 
(CNP), and rubeosis. Methods: 104 patients diagnosed with CRVO were followed prospec-
tively for 18 months. At each visit, measurements of CVP, VA, and CNP, and evaluation for 
rubeosis were performed. Results: At 18 months, mean BCVA was 31.2, 9.5, and 0 letters 
(P < .0001) and rubeosis was present in 4.0%, 24.4%, and 57.1% (P = .03) in CVP groups low, 
moderate, and high, respectively. CVP lowering was seen in 36.4%; where 59.4% gained 
≥ 5 letters, 25% remained stable, and 15.6% lost vision. Early CVP lowering was associ-
ated with higher rates of visual improvement. CNP increased significantly with higher CVP 
and progressed with time. Conclusion: CVP may have prognostic significance for visual 
outcome, CNP and rubeosis following CRVO.
Scientific Poster 244
Dexamethasone Implant Improves Retinal Function in 
Retinal Vein Occlusion Recalcitrant to Anti-VEGF Therapy
Presenting Author: Josh O Wallsh
Co-Author(s): Ron Gallemore MD PhD**, Behnam Sharareh, Samantha Y Lui
Purpose: To assess macular function with multifocal electroretinogram (mfERG) in anti-
VEGF resistant patients with retinal vein occlusions (RVO) rescued with dexamethasone 
(DEX) implants. Methods: Patients were randomized to DEX implant treatment every 16 
weeks vs. p.r.n. for the 48-week study. Results: In studied eyes (N = 9) mfERG mean cen-
tral amplitude improved significantly from 4.9 ± 0.7 to 25.9 ± 5.4 nv/deg2 (P < .05). Visual 
acuity improved in 5 eyes (55%), and central retinal thickness on view permitting OCT (n 
= 6) decreased significantly by 33.3 µm (P < .05) at 2 and 4 months, respectively. Posterior 
subcapsular cataract progression limited these measures at study completion, increasing 
an average of 1.4 points in phakic eyes. Conclusion: DEX implant improves macular func-
tion in RVO patients resistant to anti-VEGF therapy alone.
Scientific Poster 245
Monotherapy vs. Combination Therapy With 
Dexamethasone Intravitreal Implant in Retinal Vein 
Occlusion
Presenting Author: Antonio Capone Jr MD*
Co-Author(s): Michael A Singer MD*, David Gary Dodwell MD, Daniel B Roth MD*, 
John G Walt MBA*, Lanita C Scott MD*, David Hollander MD*
Purpose: To evaluate safety and efficacy of ≥ 2 dexamethasone (DEX) implants as mono-
therapy (MT) vs. DEX combined with other treatments (CT) for retinal vein occlusion (RVO)-
associated macular edema. Methods: Subgroup analysis of 26-center chart review of 289 
patients (84 MT, 205 CT) treated with ≥ 2 implants, followed 3-6 months after last implant. 
Results: Mean gain from baseline (BL) BCVA range was 0.3-3.1 lines after implants 1-6 in 
MT vs. 1.1-2.7 in CT; mean decrease from BL central retinal thickness range was 165-230 
µm in MT vs. 136-175 in CT. Increased IOP was the most common adverse event. Conclu-
sion: Use of ≥ 2 DEX implants alone or in combination with other RVO treatments is safe 
and effective for both reducing central retinal thickness and improving BCVA.
Scientific Poster 246
External Limiting Membrane: The Best Predictor of Visual 
Improvement after Epiretinal Membrane Surgery
Presenting Author: Arnab Das MBBS MD
Co-Author(s): Tushar K Sinha MBBS
Purpose: To evaluate and compare the predictors of visual improvement in idiopathic 
epiretinal membrane (ERM) cases treated with surgery. Methods: Prospective, interven-
tional, masked study included 88 consecutive eyes with idiopathic ERMs, who underwent 
ERM removal surgery. Spectral domain OCT variables including inner segment/outer seg-
ment (IS/OS) junction, external limiting membrane (ELM) integrity, central foveal thickness 
(CFT), and visual acuity (VA) were evaluated before and 3 and 6 months after surgery. Re-
sults: A strong correlation was found between the preoperative ELM status and final VA 
(r = -0.76, P < .001) and that was higher than that of IS/OS (r = -0.68, P < .001). Final visual 
improvement most strongly correlated with baseline ELM grade (P = .0217).Preoperative 
CFT did not correlate significantly with final VA or visual improvement. Conclusion: ELM 
status is a better predictor than IS/OS in ERM cases.
Scientific Poster 247
Outcome of Surgical Treatment of Symptomatic Inner 
Lamellar Macular Hole With and Without Endotamponade
Presenting Author: Arnab Das MBBS MD
Co-Author(s): Santanu Mandal MBBS
Purpose: To see if endotamponading is necessary for successful surgical treatment of 
inner lamellar macular hole (ILMH). Methods: Prospective study of 82 eyes with symptom-
atic ILMH. Each case underwent 23-gauge vitrectomy with epiretinal membrane removal 
and internal limiting membrane peeling, then randomly assigned to Group I (28 eyes), gas 
tamponade; Group II (25 eyes), air tamponade, or Group III (29 eyes), no tamponade. Follow-
up minimum, 1 year. Results: Mean visual acuity (VA) improved significantly in all groups, 
with no significant intergroup difference. OCT showed improved foveal contour with reduc-
tion in metamorphopsia in all cases. The diameter of the lamellar defect was not found to 
be a factor influencing closure or final VA within a particular group, nor also in intergroup 
comparison. Conclusion: Endotamponade is not crucial in achieving closure and VA im-
provement in ILMH.
Scientific Poster 248
 h  Open-Angle Glaucoma Following Uncomplicated 
Pars Plana Vitrectomy: Results of the Pan American 
Collaborative Retina Study Group
Presenting Author: Natalia Alpizar-Alvarez MD
Co-Author(s): Lihteh Wu MD*, Maria H Berrocal MD*, Francisco J Rodriguez MD*, 
Mauricio Maia MD, Virgilio Morales-Canton MD*, Marta Figueroa MD*, Martin A 
Serrano MD, J Fernando Arevalo MD FACS*, Rodrigo Milan Navarro MD, Hector 
Homero Hernandez Torres MD
Purpose: To report the rates of open-angle glaucoma (OAG) following uncomplicated pars 
plana vitrectomy (PPV) and compare it to the unoperated fellow eye. Methods: Retrospec-
tive multicenter study of 198 patients who underwent PPV for an idiopathic epiretinal mem-
brane. Patients had at least 12 months of follow-up. Results: Patients were followed for 
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an average of 47.3 ± 24 months (range: 12-106 months). In the vitrectomized eyes, 38/198 
(19.2%) developed OAG compared to 9/198 unoperated fellow eyes (4.5%) (P < .0001 Fisher 
exact test; OR 4.988). Possible risk factors include a family history of OAG (P = .0004 Fisher 
exact test; OR 7.206) and cataract surgery (P = .0303 Fisher exact test; OR 2.731). Conclu-
sion: Uncomplicated PPV appears to increase IOP which may lead to glaucomatous dam-
age if not managed appropriately.
Scientific Poster 249
Inverted Internal Limiting Membrane Flap Technique in 
Macular Hole Associated With Pathological Myopia
Presenting Author: Jerzy Nawrocki MD PhD
Co-Author(s): Karolina Dulczewska-Cichecka**, Zofia Michalewska MD
Purpose: To present the anatomic and functional results of vitrectomy with the ‘inverted 
ILM flap technique’ in high myopic macular holes without retinal detachment. Methods: 
A prospective, interventional study of 19 eyes. The main outcome measure was visual out-
come and macular hole closure rate in spectral domain OCT. Results: Mean visual acuity 
improved from 1.2 to 0.56 logMAR. Macular holes were closed in all cases. Photoreceptor 
and external limiting membrane defects improved during the first 12 months after surgery. 
Conclusions: We propose expanding the indications for vitrectomy with the inverted ILM 
flap technique to include myopic macular holes. The process of normalization of foveal 
architecture after surgery for myopic macular holes lasts at least 12 months.
Scientific Poster 250
Prospective Analysis of Intraoperative OCT for 
Vitreoretinal Surgery: PIONEER 18-Month Results
Presenting Author: Justis P Ehlers MD*
Co-Author(s): Peter K Kaiser MD*, Rishi P Singh MD*, Daniel F Martin MD, Alex Yuan 
MD, Sunil K Srivastava MD*
Purpose: To assess the use of intraoperative OCT (i-OCT) for vitreoretinal (VR) surgery. 
Methods: Prospective study examining i-OCT during ophthalmic surgery. An imaging pro-
tocol and microscope-mounted spectral domain OCT probe were utilized. Image analysis 
was performed. Results: At 18 months, 196 eyes were identified within the PIONEER VR 
surgery arm. Successful i-OCT imaging was obtained in 188 of 196 eyes (96%). Common 
surgical indications included ERM (n = 73), macular hole (43), RD (31), and PDR (27). Mi-
croarchitectural alterations were frequently noted following surgical maneuvers. No i-OCT 
complications occurred. Conclusion: Using i-OCT, rapid feedback is obtained regarding 
completion of surgical objectives and architectural alterations are well-visualized that oc-
cur during surgical maneuvers.
Scientific Poster 251
Temporal Macular Thinning After Inner Limiting 
Membrane Peeling
Presenting Author: Antonio P Ciardella MD
Co-Author(s): Francesco Pichi MD, Chiara Veronese, Maria Chiara Morara MD, Gian P 
Giuliari MD, Paolo Nucci MD*
Purpose: To quantitatively assess postoperative changes in macular thickness in eyes with 
epiretinal membrane and macular hole that underwent internal limiting membrane (ILM) 
peeling. Methods: 195 consecutive patients who underwent pars plana vitrectomy and 
ILM peeling between January 2009 and May 2012. The macular area was scanned with 
spectral domain OCT preoperatively and at 7 days and 1, 3, 6, 9, and 12 months postopera-
tively. Results: The mean difference in retinal thickness was -66.65 µm and -6.14 µm, in the 
temporal and nasal macula respectively, at 2-3 mm from the foveal center, before surgery 
and after 12 ± 2 months (P < .05). Conclusion: We report a postoperative increased thick-
ness of the outer nuclear layer and the ganglion cell layer of the nasal parafovea, whereas 
the layers in the temporal macula showed a progressive reduction of macular volume.
Scientific Poster 252
Modified Retinopathy of Prematurity Screening Guidelines 
Using Birth Weight
Presenting Author: Shailesh K Gupta MD**
Co-Author(s): K V Chalam MD PhD, Sandeep Grover MD*, Keyvan Koushan MD
Purpose: To investigate whether a birth weight (BW) of 1250 grams (g) would provide a 
safe criteria for ROP screening. Methods: Retrospective chart review of 1387 premature 
infants with BW ≤ 1500 g were screened for ROP by ophthalmoscopy. Results: 2.9 % (n 
= 13/437) of Group A infants (> 1250 g) had ROP, as compared to 32.5% (n = 309/950) of 
Group B (≤ 1250 g). Of 322 infants with ROP (23.2%) (BW 852.6), 13 had BW > 1250 g (stage 
1 disease) and did not need intervention. The mean ROP stage was 1.79, 138 eyes (27%) 
had ≥ stage 3 disease (BW 795.2), 164 (32%) had stage 2 disease, and 48 (4.9%) required 
intervention (BW 733.5 g; P < .05). Conclusion: BW ≤ 1250 g is a dependable criterion 
for ROP screening and reduces screening visits by 26% without missing treatable disease.
SESSION TWO
Scientific Poster 433
Impact of Antibiotic Prophylaxis on the Conjunctival Flora 
of Patients Receiving Intravitreal Anti-VEGF Injections
Presenting Author: Maria Picoto Rodrigues MD
Co-Author(s): Joana Portelinha Padua Figueiredo MD, Teresa Pacheco**, Antonio J E 
Rodrigues MD**, Fernanda Maria Vaz MD
Purpose: To characterize the conjunctival flora of patients receiving antibiotic (AB) be-
fore intravitreal (IVT) anti-VEGF injections. Methods: We studied 31 eyes, all given 3-day 
preinjection topical ofloxacin. Conjunctival cultures from the injection site were collected 
before AB prophylaxis (Sample A) and on the injection day, both before (Sample B) and 
after (Sample C) povidone-iodine application. Results: Culture positivity was significantly 
different between Samples A (50%) and C (4.5%) (P < .001), and between B (30.4%) and 
C (P = .015) but not between A and B. Positive cultures were mainly coagulase-negative 
staphylococci (SCN) (57% of A, 62.5% of B, and 100% of C samples) and susceptible to van-
comycin (100%), moxifloxacin (90%), and ofloxacin (60%). Conclusion: Povidone-iodine 
application, but not AB, reduced culture positivity.
Scientific Poster 434
Electroretinographic Changes in the Sound Eyes of 
Patients With Unilateral Necrotizing Herpetic Retinitis
Presenting Author: Mohsen Azarmina MD
Co-Author(s): Siamak Moradian MD, Masoud Soheilian MD, Hamid Ahmadieh MD
Purpose: To evaluate electroretinogram (ERG) changes in the sound eyes of patients with 
unilateral necrotizing herpetic retinitis (NHR). Methods: In 20 sound eyes of 20 patients 
with NHR, ERGs and BCVAs were evaluated before initiation of classic treatment with 
acyclovir, 1 and 3 months thereafter. Results: Although ERG b-wave amplitudes decreased 
significantly before treatment in the sound eyes of patients with NHR, they reached to the 
normal level 3 months after treatment (P < .001). Conclusion: ERG b-wave amplitude de-
creased in the sound eyes of patients with NHR that reached to the normal level 3 months 
after treatment.
Scientific Poster 435
Long-term Safety of Intravitreal Aflibercept Injection in 
Neovascular AMD
Presenting Author: W Lloyd Clark MD*
Purpose: To assess long-term safety and tolerability of intravitreal aflibercept injection 
(IAI) in patients completing the 2-year VEGF Trap-Eye (VIEW 1) study. Methods: After com-
pleting VIEW 1, patients were eligible for an open-label extension study receiving manda-
tory quarterly dosing (later amended to every 2 months) of 2-mg IAI; treatment as often as 
monthly was allowed. Results: 323 VIEW 1 patients previously treated for 96 weeks with 
IAI or ranibizumab were enrolled. Initial BCVA was 65.3 ± 15.95 (mean ± SD), an increase of 
about 10 letters over baseline BCVA in VIEW 1. Approximately 2/3 of enrolled patients have 
completed 96 weeks of IAI treatment in this ongoing study. Conclusion: Visual outcomes 
achieved by the end of VIEW 1 were largely maintained during this extension study. No new 
safety signals compared with known profile of IAI were noted.
Scientific Poster 436
Visual and Anatomic Outcomes for Anti VEGF Therapy for 
Exudative AMD Associated With Vitreomacular Interface 
Disease
Presenting Author: Meena Chakrabarti MBBS
Co-Author(s): Arup Chakrabarti MBBS, Sonia Rani John MS
Purpose: To describe outcome of eyes with vitreomacular interface disease (VMID) treated 
with anti-VEGF injections for wet AMD. Method: Retrospective case series of 36 eyes 
with VMID. Results: Thirty-six eyes with VMID received 5 injections of bevacizumab in 1 
year. Posterior vitreous separation occurred in 18 eyes with VMID (50%), with reduction in 
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central retinal thickness (318 ± 17 µm vs. 400 ± 24 µm) and improvement in visual acuity (2 
lines), and eyes required fewer injections (2 injections) subsequently. Conclusion: Induc-
tion of posterior vitreous detachment following intravitreal anti-VEGF therapy is beneficial 
in arresting progression of wet AMD and helps the eye to respond better to each subse-
quent injection.
Scientific Poster 437
Treat and Extend vs. Treat and Observe in Wet AMD 
Patients Treated With Ranibizumab: A 3-Year Follow-up 
Study
Presenting Author: Pilar Calvo MD PhD
Co-Author(s): Antonio Ferreras MD PhD*, Yao Wang BHSc, Robert G Devenyi MD FACS 
FRCSC MBA, Wai-Ching Lam MD*, Michael Henry Brent MD*
Purpose: To compare two strategies in wet AMD patients treated exclusively with ranibi-
zumab over 3 years. Methods: Treat-and-extend (TaE) dosing group (n = 43) and treat-and-
observe (TaO) dosing group (n = 34) were retrospectively analyzed. Survival rates (SR) based 
on visual acuity (VA) were calculated and compared. Results: At 36 months, Kaplan-Meier 
SRs were 90.9% for TaE and 89.7% for TaO (loss < 0.3 units logMAR). VA improved in 42.4% 
and 24.1%, while 33.4% and 62.1% remained stable for TaE and TaO groups, respectively. 
No final VA differences were found between both therapeutic strategies (P > .05, log-rank 
test). Conclusion: Both regimens showed similar visual outcomes after a 3-year period.
Scientific Poster 438
Aflibercept for the Treatment of Polypoidal Choroidal 
Vasculopathy
Presenting Author: Di Zhou
Co-Author(s): Sabah A Shah MD, Jason S Slakter MD*
Purpose: To evaluate treatment outcomes of aflibercept for polypoidal choroidal vas-
culopathy (PCV). Methods: Forty-seven eyes with PCV were treated with aflibercept, of 
which 44 were previously treated with ranibizumab and/or bevacizumab. Results: The 
mean visual acuity (VA) before and after ranibizumab and/or bevacizumab was 20/53.3 and 
20/67.5, respectively. There was a decrease in largest polyp height by 15% on OCT with the 
medications. The mean VA before and after aflibercept treatment was 20/67.5 and 20/57.9, 
respectively (P < .05). A mean reduction of 30.9% in height and 14.0% in width of the larg-
est polyp after the third aflibercept injection (P < .05) was seen. Conclusion: Aflibercept 
appears to be more effective than ranibizumab and/or bevacizumab in improving VA and 
reducing polyp size of PCV.
Scientific Poster 439
Long-term Characteristics of Exudative AMD in Japanese 
Patients
Presenting Author: Masaaki Saito MD
Co-Author(s): Tomohiro Iida MD*, Ichiro Maruko MD, Kanako Itagaki**, Tetsuju Sekiryu 
MD**
Purpose: To evaluate the clinical characteristics of exudative AMD in Japanese patients 
for 10 years. Methods: We retrospectively reviewed 1587 naïve patients (mean age: 75.0 
years) with AMD from March 2003 to Febr. 2013. Results: Of 1587 patients, 714 (45.0%), 
734 (46.2%), and 90 (5.7%) patients were diagnosed with typical AMD, polypoidal choroi-
dal vasculopathy, (PCV), and retinal angiomatous proliferation. The remaining 49 patients 
(3.1%) had both typical AMD in one eye and PCV in the other. The mean visual acuity at 
baseline (289 patients) and at 2 years (401 patients) were 20/100 and 20/60 (P < .0001). 
Conclusion: PCV has been highly prevalent in Japanese AMD compared with in the white 
population. The annually better baseline visual acuity may be considerably related to de-
velopment of treatment.
Scientific Poster 440
The Role of Genetics in Response to Anti-VEGF Therapy for 
Wet AMD
Presenting Author: Jaclyn L Kovach MD
Co-Author(s): Stephen G Schwartz MD MBA*, Anita Agarwal MD, Milam A Brantley Jr 
MD, William Cade PhD**, William Scott PhD*, Jonathan L Haines PhD**, Margaret A 
Pericak-Vance PhD
Purpose: To evaluate the relationship between high-risk genetic polymorphisms and the 
response to anti-VEGF therapy in wet AMD. Methods: Forty-three patients with wet AMD 
treated with anti-VEGF therapy were followed for 1 year. Individuals were classified as 
good responders, poor responders, and maintainers based on visual acuity and OCT appear-
ance. Patients were genotyped, and risk scores (RS) were created. The 16RS considered 16 
SNPs identified as loci reaching genome-wide significance, and the 4RS considered CFH, 
C2/CFB, ARMS2, and C3. Results: Average 16RS (P = .0197), 4RS (P = .0186), and individual 
risk allele frequencies for the 4 major SNPs were significantly lower in good responders 
compared to maintainers. Conclusion: Individuals that maintained stable vision with anti-
VEGF therapy had greater genetic risk than those with good responses.
Scientific Poster 441
Serum and Whole-Blood TNF-a and MCP-1 Levels in 
Patients With Neovascular AMD
Presenting Author: Tsutomu Sakai MD
Co-Author(s): Kiichiro Okano**, Hideo Kohno MD
Purpose: To investigate the involvement of TNF-a and MCP-1 in the serum and periph-
eral blood in patients with neovascular AMD (nAMD). Methods: The study population 
consisted of 21 patients with nAMD as well as 20 healthy volunteers as control. TNF-a 
and MCP-1 concentration levels in the serum and whole-blood samples were measured by 
ELISA. Whole-blood samples were obtained by lysing cell membranes of peripheral blood 
cells. Results: The serum and whole-blood TNF-a and MCP-1 levels in the patients with 
nAMD were significantly higher than controls (P < .05). In subgroup analysis, the patients 
with polypoidal choroidal vasculopathy showed higher serum and whole-blood levels of 
MCP-1 than those in the typical AMD group. Conclusion: We found a close relationship 
between the cell-associated TNF-a and MCP-1 and nAMD.
Scientific Poster 442
Pazopanib Eye Drops vs. Ranibizumab Intravitreal 
Injections for Neovascular AMD
Presenting Author: Karl G Csaky MD*
Co-Author(s): Ronald Peter Danis MD*, Pravin U Dugel MD*, Deborah S Kelly MD*, Amy 
Pierce*, Michael Fries*, Trupti Trivedi*, Mohammad Hossain PhD*, John Wurzelmann*
Purpose: To determine if pazopanib eye drops could maintain or improve visual acuity 
(VA) and reduce continual need for ranibizumab. Methods: Prospective study: N = 510 
with 7 arms: 5 daily-dosed pazopanib eye drops (n = 364) and 1 placebo eye drops (n = 73), 
all with as-needed (p.r.n.) ranibizumab; and 1 monthly ranibizumab (n = 73). Results: The 
addition of pazopanib eye drops was noninferior to both monthly and p.r.n. ranibizumab for 
maintaining VA over 1 year. Pazopanib (up to 1 gtt 10 mg/mL q.i.d.) did not displace 50% 
or more p.r.n. ranibizumab injections, the prespecified minimal success criteria for efficacy. 
Administration of pazopanib eye drops for 1 year was safe and well tolerated. Conclusion: 
Pazopanib eye drops when added to p.r.n. ranibizumab did not demonstrate additional ef-
ficacy or added benefit at any dose.
Scientific Poster 443
Aflibercept and the Functional Treatment Response in 
Neovascular AMD: Correlating Retinal Sensitivity Change 
and Spectral Domain OCT Morphology Up to 12 Months
Presenting Author: Florian Sulzbacher
Co-Author(s): Christopher G Kiss MD, Marion Ronit Munk MD, Katharina Eibenberger 
MD, Stefan Sacu MD*, Ursula M Schmidt-Erfurth MD*
Purpose: To evaluate the OCT-related functional treatment response after aflibercept 
therapy in patients with neovascular AMD. Methods: A point-to-point analysis of 22 eyes 
examined with the Spectralis-OCT and the Nidek MP-1 up to 12 months. Results: Loci of 
initial subretinal or intraretinal fluid were associated with a median retinal sensitivity gain 
of 5 dB, quartiles (0 dB; 9 B) or 2 dB (0 dB; 7 dB), respectively. Loci of an initial neovascular 
complex showed a median retinal sensitivity change of 4 dB (0 dB; 11 dB). An initial serous 
or fibrovascular pigment epithelial detachment was associated with a median retinal sensi-
tivity increase of 6 dB (1 dB; 9 dB) or 7 dB (-1.5 dB; 8 dB), respectively. Conclusion: Precise 
anatomical classification of spectral domain OCT findings has predictive capability for the 
functional treatment response of Aflibercept in neovascular AMD.
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Scientific Poster 444
Vascular Structure Changes of Choroidal 
Neovascularization in Indocyanine Green Angiography 
After Intravitreal Ranibizumab Injection
Presenting Author: Ji Eun Lee MD
Co-Author(s): Joo Eun Lee MD, Hyun Woong Kim MD**, Sang-Joon Lee MD
Purpose: To describe vascular structure changes of choroidal neovascularization (CNV) 
after intravitreal ranibizumab using indocyanine green angiography (ICGA). Methods: 
Thirty-one patients having CNV whose vessels were identifiable in ICGA were investi-
gated prospectively. Ranibizumab was injected 3 times monthly and then as-needed to 6 
months. Results: The patients were categorized into 3 groups. In the regressed group (10 
eyes, 31%), usually capillary components were resolved at 3 months without regrowth. In 
the matured group (7 eyes, 23%), distinct vascular structures were observed at 3 and 6 
months. In the regrowing group (14 eyes, 45%), capillary growth was noted between 3 and 
6 months. Conclusion: Vascular structures of CNV changed variously after ranibizumab 
injections. Regrowth of CNV was noted during as-needed treatment.
Scientific Poster 445
OCT and Vision Results at 6 Months After Transition 
to Aflibercept for Patients on Prior Ranibizumab or 
Bevacizumab Therapy for Exudative AMD
Presenting Author: Clement K Chan MD*
Co-Author(s): Atul K Jain MD*, Srinivas R Sadda MD, Neeta Varshney MD*
Purpose: To compare visual acuity (VA)/OCT results for eyes on aflibercept (A) after con-
version from prior bevacizumab (B), ranibizumab (R), or mixed therapy (Mx). Methods: Ret-
rospective study assessing 6-month VA/OCT (Cirrus) data for eyes converted to A. Same 
masked investigator made all OCT measurements. Results: 161 eyes (87 B, 64 R, and 10 
Mx) were converted to A (Nov. 2011 – Febr. 2012). Baseline traits for all groups were alike. 
At 6 months, post- vs. preconversion VA was improved by 4.1 letters, and OCT (SRF/CME/
PED, Ht, and Vol) measures for all groups were improved (no intergroup differences; all 
P ≤ .004). Postconversion VA/OCT results were better for eyes with incomplete but not 
complete responses to B/R (all P ≤ .002). Retinal pigment epithelial tear in 1 eye was the 
only complication. Conclusion: Postconversion VA/OCT results were improved and similar 
for all drug groups, with rare complications.
Scientific Poster 446
Reticular Pseudodrusen in Early AMD Is Associated With 
fl-zone Peripapillary Atrophy
Presenting Author: Aakriti Garg
Co-Author(s): Dana Blumberg MD, Lama A Al-Aswad MD, Max Forbes MD**, Hamed 
B Bazargan Lari MD, Suzanne Yzer DOMS**, Rando Allikmets PhD*, Srilaxmi Bearelly 
MD*
Purpose: To determine if an association exists between reticular pseudodrusen (RPD) and 
glaucoma in early AMD. Methods: Cross-sectional study of age- and sex-matched early 
AMD subjects, 44 RPD (61 eyes) and 37 non-RPD (64 eyes). Exclusion criteria were myopia 
> -6 D, prior vitreoretinal surgery, and poor imaging. Chart review yielded ocular history and 
IOP. Masked glaucoma specialists graded b-peripapillary atrophy (b-PPA) and cup-to-disc 
ratio (CDR) on nonstereoscopic fundus photographs. Results: b-PPA was more prevalent 
in RPD than non-RPD (49% vs. 21%, P = .0002). Pre-existing glaucoma diagnosis, IOP, and 
CDR did not differ. Conclusion: RPD in early AMD may be associated with b-PPA, which 
has been linked to normotensive glaucoma.
Scientific Poster 447
Angiographic Factors Related to Surgical Outcome of 
Diabetic Macular Edema
Presenting Author: Jeong Mo Han MD
Co-Author(s): Hyeong G Yu MD*
Purpose: To identify angiographic prognostic factors in vitrectomy for the management of 
diabetic macular edema. Methods: Fifty-five eyes of 47 patients that underwent vitrec-
tomy and removal of epiretinal membrane for diabetic macular edema were prospectively 
reviewed. Results: The early foveal leakage at arteriovenous phase was significantly de-
creased at 3 and 6 months after vitrectomy (P = .031). Moreover, the eyes with early foveal 
leakage before vitrectomy showed better visual improvement and more decrease in central 
macular thickness (P < .05). On the other hand, the size of foveal avascular zone did not 
change after vitrectomy and was not related to the visual outcome. Conclusion: The eyes 
with early foveal leakage may have a greater visual benefit from vitrectomy for the manage-
ment of diabetic macular edema.
Scientific Poster 448
Comparison of Panretinal Photocoagulation for High-risk 
Proliferative Diabetic Retinopathy Using Single Session of 
Pattern Scan Laser vs. Multiple Sessions of Conventional 
Laser
Presenting Author: Goktug Seymenoglu MD
Co-Author(s): Ozcan R Kayikcioglu MD, Esin Fatma Baser MD, Oguz mahmut Ulusoy
Purpose: To evaluate the results of panretinal photocoagulation (PRP) via a single session 
of pattern scan laser (PASCAL) in comparison with multiple sessions of conventional laser 
in patients with proliferative diabetic retinopathy. Methods: Charts of 35 eyes treated with 
PASCAL (Group 1) and 35 eyes treated with conventional laser (Group 2) were reviewed. 
Persistence and/or recurrence of neovascularization, incidence of complications, total 
number of laser spots, and mean power used were compared Results: Group 1 received 
significantly higher number of laser spots than Group 2 (2885 vs. 1642, P = .001). The groups 
required an average power of 650 vs. 330 mw, respectively (P = .001). Treatment failure 
rates were similar in both groups (14% vs. 11%, p > .05). Conclusion: Both treatment 
modalities have similar efficacy and side-effect profiles.
Scientific Poster 449
Combination of Anti-VEGF Injections and Navigated Laser 
Photocoagulation for Diabetic Macular Edema: Twelve-
Month Results
Presenting Author: Marcus Kernt MD*
Co-Author(s): Michael W Ulbig MD*, Igor Kozak MD*, William R Freeman MD*, 
Aljoscha S Neubauer MD*, Anselm Kampik MD
Purpose: To evaluate the number of anti-VEGF injections needed in diabetic macular 
edema (DME) patients using a protocol with navigated laser. Methods: Three groups out 
of 76 DME eyes: (1) Three initial ranibizumab injections (n = 27), (2) three initial ranibizumab 
injections followed by navigated laser (n = 15), (3) monthly ranibizumab injections until CRT 
≥ 450 µm followed by navigated laser (n = 34). After, anti-VEGF injections were reinitiated 
if DME recurred. BCVA and CRT were evaluated. Results: VA improved in all groups. After 
the initial 3 injections, at 12 months Group 1 needed an average of 5.2 ± 3.2 injections; in 
Group 2 and 3 the required number of injections ranged from 0.5 to 0.8 injections. Conclu-
sion: Combining anti-VEGF with navigated laser showed similar visual improvements to 
those of anti-VEGF monotherapy, with significantly fewer injections.
Scientific Poster 450
Comparison of Incidence of Diabetic Ischemic 
Maculopathy in Patients With and Without Metabolic 
Syndrome
Presenting Author: Sriram S Thirumalai MBBS
Co-Author(s): Usha K Raina MD, Richa Vaishya MD, Meenakshi Thakar**, Vasu Kumar 
MBBS
Purpose: To examine the role of metabolic syndrome (MetS) as an additional risk factor in 
diabetic maculopathy. Methods: This observational study recruited 58 patients with non-
proliferative diabetic retinopathy (NPDR) and clinically significant macular edema (CSME), 
who were divided into 2 groups (50 eyes each) depending on the presence or absence 
of MetS. Both groups underwent examination, biochemical tests, fluorescein angiography, 
and OCT. Results: Ischemic maculopathy was seen in 79.4 % of patients with MetS, but 
was only seen in 20.6% of those without MetS—a significant difference (P < .001). Con-
clusion: A significant increase in incidence of ischemic maculopathy was observed in pa-
tients with MetS. Thus control of MetS can decrease incidence of ischemic maculopathy.
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Scientific Poster 451
Intravitreal Ranibizumab Therapy Improves Resolution of 
Hard Exudates in Patients With Diabetic Macular Edema
Presenting Author: Amitha Domalpally MBBS
Co-Author(s): Michael S Ip MD*, Jason S Ehrlich MD*
Purpose: To analyze the effect of monthly 0.3- and 0.5-mg ranibizumab (RBZ) therapy on 
hard exudates (HE) in participants from the RIDE and RISE Phase 3 trials of RBZ in diabetic 
macular edema. Methods: The presence and severity of HE in study eyes (N = 739; 1 
per patient) was categorized at each time point as absent, definite, obvious, moderate, or 
severe. Results: The proportion of eyes without HE in the sham, RBZ 0.3-mg and 0.5-mg 
groups increased from 20.9%, 22.1%, and 23.6% at baseline to 36.3%, 61.3%, and 62.0% 
at Month 24, respectively. Decrease in HE was evident after 12 months of RBZ treatment. 
There was no correlation between HE in the macula and visual acuity. Conclusion: RBZ 
therapy may be associated with reduction in the area of HE in patients with DME.
Scientific Poster 452
 h  Systemic Oxygen Therapy vs. Enalapril for Treatment of 
Diabetic Macular Ischemia: A Randomized Controlled Trial
Presenting Author: Masoud Soheilian MD
Co-Author(s): Mohammad Reza Razzaghi MD, Farideh Sharifipour MD, Alireza Ramezani 
MD, Mohsen Azarmina MD, Roham Soheilian Jr
Purpose: To evaluate the effects of systemic oxygen and oral enalapril on diabetic macular 
ischemia (DMI). Methods: In this 3-armed trial, 101 cases with foveal avascular zone (FAZ) 
> 1000 µ were randomized to 3-month treatment with either 100% normobaric oxygen (flow 
rate = 10 L/min) or enalapril (5 mg/day) or considered as control. Results: In the oxygen 
group, central macular thickness decreased (from 367 ± 62 to 355 ± 67 µm), FAZ decreased 
(from 0.773 to 0.759 mm2), and VA improved (from 0.57 to 0.48 logMAR) significantly (P < 
.001 for all) at 6 months. However, no significant change was observed in enalapril and 
control groups. Conclusion: Normobaric oxygen therapy might improve anatomical and 
functional outcomes in eyes with DMI.
Scientific Poster 453
Early Neural Retinal Changes Previous to Microangiopathy 
on Patients With Type 2 Diabetes Mellitus
Presenting Author: Eduardo B Rodrigues MD*
Co-Author(s): Muller Gonçalves Urias, Fernando M Penha MD*, Eduardo Amorim Novais 
MD, Michel Eid Farah MD
Purpose: To investigate retinal changes in patients with type II diabetes mellitus (DM) on 
OCT. Methods: Three groups of patients were evaluated with Cirrus OCT software 6.0: (1) 
controls (n = 20), (2) patients with DM but no diabetic retinopathy (DR) (n = 46), (3) patients 
with mild DR (n = 28). Macular cube 200x200 scan provided automated analysis: central 
subfield thickness (CST), mean thickness average (TA), retinal nerve fiber layer (RNFL), 
and ganglion cell layer and inner plexiform layer (GCL+IPL) thickness. Results: Mean CST 
thickness was thinner in DM than in no-DR patients (245.46 ± 24.36 µm). There was a 
progressive reduction in the GCL+IPL thickness (A: 80.8 ± 6.9 µm; B: 79.8 ± 7.3 µm; C: 74.0 
± 10.6 µm; P = .006). Conclusion: This study supports the concept that early DR includes 
neurodegeneration.
Scientific Poster 454
Characterization of Ultrawide-field Fundus 
Autofluorescence Patterns in Retinal Dystrophies
Presenting Author: Georgios Trichonas MD
Co-Author(s): Elias I Traboulsi MD*, Justis P Ehlers MD*
Purpose: To describe the ultrawide-field fundus autofluorescence (FAF) patterns in retinal 
dystrophies and their genotypic / phenotypic associations Methods: FAF imaging was per-
formed with the Optos 200Tx system. Clinical variables, genotypes, and phenotypic char-
acteristics were analyzed. Results: Thirty-two patients were included. Diagnoses included 
retinitis pigmentosa (n = 11) , Stargardt disease (7), Leber congenital amaurosis (4), rod-
cone dystrophy (3), congenital stationary night blindness (2), pattern dystrophy (2), North 
Carolina macular dystrophy (1), Doyne honeycomb macular dystrophy (1), and enhanced 
S-cone syndrome (1). Macular FAF abnormalities were noted in 100% of cases, with pe-
ripheral FAF abnormalities noted in 48% of cases. Conclusion: Distinctive macular and 
peripheral FAF patterns are identified with ultrawide-field imaging in a large percentage of 
patients with retinal dystrophies.
Scientific Poster 455
Leber Congenital Amaurosis: Noninvasive Testing 
Feasibility, and Novel Phenotypic Retinal Cell Function
Presenting Author: Radwan S Ajlan MBBCH
Co-Author(s): Leah Marie Wood MS, Jamie Koenekoop, Irma Lopez-Solache, Vafa 
Keser**, Ayesha Khan FRCS(ED), Huanan Ren MS, Rui Chen PhD, Robert K Koenekoop 
MD PhD**, Sorath Siddiqui
Purpose: This is a feasibility study of pupillometry in blind subjects with Leber congenital 
amaurosis (LCA) due to various genotypes. Methods: We genotyped 30 LCA subjects. Spe-
cific spectral bands (640 ± 10 nm, 467 ± 17 nm) were used to test cone, rod, and ganglion 
cell functions using different luminance intensities of 1, 10, and 100 cd/m2. Results: Most 
patients showed significant pupillary responses despite nonrecordable electroretinograms. 
Stimulating the intrinsically photosensitive melanopsin ganglion cells was found to gener-
ate the most prominent response when present (P-value < .001). Conclusion: Pupillometry 
testing is feasible for testing different retinal cell types noninvasively while bypassing cor-
tical processing. Our data also describes cells mostly affected in different LCA genotypes, 
as well as providing evidence of viable cells previously thought to be lost.
Scientific Poster 456
Spectral Domain OCT Progressive Alterations in a Family 
Affected With Müller Cell Sheen Dystrophy
Presenting Author: Jose Dalma MD
Co-Author(s): Valentina Franco Cardenas MD, Rosa Martinez, Alejandro Dalma MD
Purpose: Müller cell sheen dystrophy is an AD disorder characterized by a wrinkled sheen-
like appearance in the posterior pole. We describe the spectral-domain OCT (SD-OCT) find-
ings at different stages of the disease. Methods: Forty-eight patients spanning 3 genera-
tions underwent full ophthalmic evaluation and SD-OCT. OCT was evaluated for posterior 
vitreous detachment, cyst location, thickness, and inner segment/outer segment disruption. 
Findings were cross-related to visual acuity and age. Results: Ten affected patients pre-
sented with macular alterations on SD-OCT. These consisted of cystic spaces progressing to 
retinal disruption and atrophy. SD-OCT alterations correlated with advancing age and visual 
decline. Conclusion: SD-OCT changes appear around the fifth-sixth decade of life. Their 
progression correlates with visual acuity, age, and reported electroretinographic changes.
Scientific Poster 457
Cone-Rod Dystrophy With Macular Cystic Degeneration 
From Recessive CRB1 Mutation
Presenting Author: Arif O Khan MD
Co-Author(s): Mohammed Abdullah Aldahmesh PHD, Leen Abu Safieh PhD, Fowzan S 
Alkuraya MD**
Purpose: To determine the genetic mutation underlying childhood cone-rod dystrophy with 
macular cystic degeneration in 3 siblings and rod-cone dystrophy in their parents, who were 
first cousins. Methods: Clinical examination, homozygosity-analysis guided candidate 
gene analysis. Results: At 11 years old the proband had cone-rod dystrophy and bilateral 
macular cystic degeneration, as did his 15-year-old sister and his 7-year-old brother. Both 
the father (45 years old) and mother (35 years old) had early adult-onset rod-cone dystro-
phy with eventual macular atrophy. Homozygosity-analysis guided candidate gene testing 
revealed a homozygous CRB1 mutation (c.80G>T [p.Cys27Phe]) in affected family members. 
Conclusion: Cone-rod dystrophy with cystic macular degeneration is an additional CRB1-
related phenotype.
Scientific Poster 458
Longitudinal Changes in Peripheral Autofluorescence in 
Patients With Retinitis Pigmentosa
Presenting Author: Akio Oishi MD PhD
Co-Author(s): Ken Ogino MD, Yukiko Makiyama MD, Norimoto Gotoh MD, Masafumi 
Kurimoto MD, Nagahisa Yoshimura MD PhD*
Purpose: To evaluate the longitudinal changes in peripheral hypoautofluorescence area 
in patients with retinitis pigmentosa (RP). Methods: We measured the area of 40 patchy 
hypoautofluorescent regions in 14 patients with RP at baseline and after 1 year. Results: 
The mean area of patchy hypoautofluorescent region enlarged from 11,905 pixels to 13,465 
pixels. (P < .001) The average rate of enlargement was 27.3% per year. Conclusion: The 
patchy hypoautofluorescent regions enlarge at a significant speed in patients with RP. 
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Quantified observation of the regions would be useful in monitoring patients with RP. The 
longitudinal enlargement of the region is consistent with the previous finding that the area 
of the regions is associated with duration of the disease.
Scientific Poster 459
The Role of Topical Antibiotic Prophylaxis in Preventing 
Endophthalmitis After Intravitreal Injection
Presenting Author: Philip Storey MD
Co-Author(s): Michael Dollin MD, John D Pitcher MD, Natalie Fang-Yen BA, James F 
Vander MD, Jason Hsu MD*, Sunir J Garg MD*
Purpose: To compare the incidence of endophthalmitis following intravitreal injection 
with and without postinjection antibiotic prophylaxis. Methods: Endophthalmitis cases 
and number of injections between 2009 and 2012 were determined from billing data and 
infection log, with case confirmation via chart review. A 28-month period when topical 
antibiotics were prescribed following injection was compared to a 9-month period when no 
antibiotics were prescribed. Results: 121,492 intravitreal injections were performed during 
the study period. The use of topical antibiotics was associated with an increased risk of 
presumed endophthalmitis (0.050% with antibiotics vs. 0.035% without antibiotics; odds 
ratio 1.40; 95% CI, 0.73-2.68). Conclusion: Postinjection antibiotics are associated with a 
trend toward higher endophthalmitis rates.
Scientific Poster 460
Microbial Spectrum and Outcomes in Endophthalmitis 
Following Intravitreal Injection vs. Pars Plana Vitrectomy
Presenting Author: Michael Dollin MD
Co-Author(s): Philip Storey MD, John D Pitcher MD, James F Vander MD, Jason Hsu 
MD*, Sunir J Garg MD*
Purpose: To compare causative organisms and visual outcomes in endophthalmitis after 
intravitreal injection (IVI) with those after pars plana vitrectomy (PPV).  Methods: Retro-
spective case series of all patients with suspected endophthalmitis after IVI or PPV be-
tween January 1, 2009, and October 1, 2012. Results: Thirty-six cases of endophthalmitis 
after IVI and 16 cases of endophthalmitis after PPV were reviewed. Culture positivity rates 
were similar (44.4% IVI vs. 43.8% PPV, P = 1.000). IVI patients were more likely to have 
lost ≥ 3 lines of visual acuity at final follow-up (86.7% vs. 20.0%, P = .014). 56.3% of 
culture-positive IVI cases were due to bacteria associated with oral flora vs. none among 
PPV cases (P = .019).  Conclusion: Oral flora and poorer outcomes are more likely seen in 
endophthalmitis after IVI than after PPV.
Scientific Poster 461
 h  Prospective Comparison of 2 Interferon-g Release 
Assays for Tuberculous Uveitis
Presenting Author: Han Nian Marcus Ang MBBS
Co-Author(s): Wan Ling Wong, SiehYean Kiew MBCHB, Soon-Phaik Chee MD*
Objective: Head-to-head comparison of QuantiFERON Gold-in-tube (QFT) (Cellestis, Inc.; 
Australia) to T-SPOT.TB (Oxford Immunotech; UK) to diagnose tuberculous (TB) uveitis. 
Methods: We prospectively enrolled 106 consecutive patients with uveitis, who under-
went full ocular examination and systemic review, including QFT and T-SPOT.TB, and fol-
lowed up for 1 year. Results: Mean age was 48 ± 16 years, majority Chinese race, present-
ing with anterior uveitis (59.9%). QFT was more sensitive (66.1% vs. 55.9%) and specific 
(93.0% vs. 81.6%) than T-SPOT.TB. Statistical decision analysis revealed QFT to be the 
best first-line test to diagnose TB uveitis. Conclusion: To our knowledge, this is the first 
prospective direct comparative study demonstrating that QFT is superior to T-SPOT.TB in 
the diagnosis of TB uveitis.
Scientific Poster 462
Noninfectious Inflammation After Intravitreal Aflibercept 
Injection
Presenting Author: Roger A Goldberg MD*
Co-Author(s): Chirag P Shah MD*, Jeffrey S Heier MD*, Torsten W Wiegand MD PhD
Purpose To report the clinical features and outcomes of noninfectious inflammation after 
intravitreal aflibercept injection (IAI). Methods: Retrospective noncomparative consecutive 
case series. Results  Twelve patients developed inflammation, presenting 1-13 days after 
IAI. All presented with decreased visual acuity (VA); only 1 (8.3%) had pain or conjunctival 
injection. No patient had hypopyon, though all had vitritis. All received topical steroids and 
eventually regained their preinjection VA (range: 13-73 days). The incidence of inflamma-
tion after IAI was 0.3% (injections) or 1.6% (patients). Conclusion: Noninfectious inflam-
mation after IAI should be carefully distinguished from endophthalmitis. Lack of hypopyon, 
pain, or conjunctival injection can be helpful clues, as is a prompt response to topical ste-
roids. Outcomes are generally favorable, though recovery can take weeks.
Scientific Poster 463
 h  Postoperative Bacterial Endophthalmitis: Tap/Inject vs. 
Sutureless Vitrectomy
Presenting Author: John O Mason MD
Co-Author(s): Lauren Mason**, Thomas P Lindquist MD, Lauren Mason**, Gerald 
McGwin PhD, John O Mason IV, Duncan A Friedman MD, Robert E Morris MD, Matthew 
H Oltmanns MD**, Amanda Dinsmore
Purpose: To compare sutureless vitrectomy (VIT) with vitreous tap/injection (TAP) in eyes 
with postoperative endophthalmitis. Methods: Retrospective study of 126 consecutive 
eyes that underwent VIT (82) or TAP (44) between 2005 and 2011. Outcomes measures 
were postintervention visual acuity (VA) and complications. Results: Mean preop VA was 
20/2000 in VIT and 20/1800 in TAP (P = .30), while postop VA was 20/160 in VIT and 20/125 
in TAP (P = .18). If presenting VA was < 20/400, postop vision was better in VIT than in TAP 
(P = .05). Retinal detachment occurred in 12 eyes (9.5%), only in the VIT group. Conclusion: 
Sutureless vitrectomy was more beneficial than TAP in eyes with < 20/400 vision. VIT and 
TAP are similar in eyes with 20/400 or better VA.
Scientific Poster 464
Vitreoretinal Surgical Outcomes Performed by Supervised 
Retina Fellows vs. Attending Faculty Surgeons
Presenting Author: John O Mason MD
Co-Author(s): John O Mason IV, Lauren Mason**, Gerald McGwin PhD, Thomas A Finley 
MD, Duncan A Friedman MD, Dustin Pomerleau MD, Richard M Feist MD, Martin Lee 
Thomley MD, Michael A Albert MD
Purpose: To evaluate outcomes of common vitreoretinal surgeries performed by retina 
fellows under direct faculty supervision, compared to experienced faculty. Methods: Ret-
rospective cohort study of 592 eyes undergoing surgery from 2009 to 2011. Three fellows 
performed 390 cases (all under direct faculty supervision), while 4 faculty performed 202 
cases. Results: Mean postop visual improvement was statistically significant and equal in 
all groups, as well as between each physician (P = .0001). Complications occurred in 29/592 
(4.8%), with reoperations in 30/512 (5%), and were equally distributed across all physician 
groups (P = .1002), as well as among individual physicians (P = .1311). Conclusion: With 
proper supervision retina fellows achieved similar surgical success, with low complication 
and reoperation rates, compared to experienced faculty.
Scientific Poster 465
 h  Comparative Efficiency of 27-Gauge Vitrectomy and 
25-Gauge Vitrectomy
Presenting Author: Kazuhisa Mitsui MD
Co-Author(s): Jiro Kogo MD, Akira Shiono MD, Hiroki Sasaki MD, Hitoshi Takagi MD 
PhD
Purpose: To compare 25-gauge (G) with 27G microincision vitrectomy (MIV) in patients 
with epiretinal membrane (ERM). Methods: We prospectively evaluated 45 ERM patients 
(47 eyes) who underwent 25G or 27G MIV. Results: No differences between the 27G and 
25G groups were found in flare value (18.7 vs. 17.2), IOP (8.8 vs. 9.7 mmHg), rate of hy-
potony (30% vs. 35%), and duration of wound closure (9.7 vs. 10.7 weeks), evaluated 1 day 
postoperatively by OCT. The mean operation time was significantly longer in the 27G group 
than the 25G group (31.2 ± 12.6 vs. 24.7 ± 13.1 min, respectively, P < .05). Conclusion: 
Both systems are safe and useful for ERM vitrectomy. However, these systems could be 
improved further to reduce surgical time.
Scientific Poster 466
Ranibizumab for Diabetic Macular Edema: Long-term 
Open-Label Extension of the Phase 3 RIDE and RISE Trials
Presenting Author: David S Boyer MD*
Co-Author(s): Karen Basu PhD*, Jason S Ehrlich MD*
Purpose: To determine if the efficacy and safety achieved with monthly ranibizumab (RBZ) 
could be maintained long term with less-than-monthly treatment. Methods: Diabetic 
macular edema (DME) patients (n = 759) were randomized to monthly 0.5-mg or 0.3-mg 
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RBZ or sham. In Year 3 the sham group could cross over to 0.5-mg RBZ. After Month 36 
remaining patients received open-label 0.5-mg RBZ based on changes in vision or OCT. 
The visit interval could be extended from 30 to 60 or 90 days for patients who did not 
need monthly treatment. Results: Through 36 months, 36.8%-51.2% of patients originally 
randomized to RBZ gained ≥ 15 letters from baseline. Lesser gains were seen at Month 36 
with delayed treatment in sham patients. Conclusion: Efficacy outcomes with monthly 
RBZ were sustained through 3 years. Extension phase data on less-than-monthly dosing 
will be discussed.
Scientific Poster 467
Factors Affecting Frequency of Intravitreal Aflibercept 
Injections During PRN Phase of COPERNICUS and 
GALILEO
Presenting Author: Julia A Haller MD*
Purpose: To identify factors at end of fixed dosing (Week 24) predicting number and odds 
of having ≥ 3 intravitreal aflibercept injections (IAI) in p.r.n. phase (6 months). Methods: 
Analyses included central retinal vein occlusion (CRVO) patients with macular edema re-
ceiving 6 monthly 2-mg IAI (2 mg every 4 weeks, abbrev. 2q4; n = 207) or sham (n = 60) 
followed by IAI p.r.n., with known fluid status at Week 24. Results: Dry vs. wet patients at 
Week 24 received 2.4 vs. 3.9 injections in 2q4-p.r.n. and 1.8 vs. 4.6 injections in sham-IAI 
p.r.n., respectively. Proportions of dry vs. wet patients requiring ≥ 3 injections were 47.4% 
vs. 75.9% in 2q4-p.r.n. and 33.3% vs. 86.7% in sham-IAI p.r.n. Wet vs. dry patients at Week 
24 were 1.6 and 2.6 times more likely to have ≥ 3 injections in 2q4-p.r.n. and sham-p.r.n., 
respectively. Conclusion: Initial treatment and fluid status at end of fixed dosing were 
associated with the number of injections in p.r.n. phase.
Scientific Poster 468
IOP Trends Following Intravitreal Injections of Anti-VEGF 
Agents for Diabetic Macular Edema
Presenting Author: Sawsan R Nowilaty MD
Co-Author(s): Abdulelah Al-Abdullah, Nicola G Ghazi MD
Purpose: To study IOP trends after intravitreal antivascular endothelial growth factor (IVA-
VEGF) agents in diabetic macular edema (DME). Methods: Review of 486 patients (age: 
28-83 years) who received IVA-VEGF agents. Results: Over a mean follow-up of 18 months, 
760 eyes received 1-24 injections. Persistent IOP elevation (> 20% from baseline [BL] or > 
24 mmHg) occurred in 45 eyes (5.9%). Final IOP was higher in this group than in the rest 
of the eyes (mean: 20.8 vs. 17.2, P < .001) despite similar BL IOP (P = .1). IOP rise was as-
sociated with a higher number of injections (mean: 5 vs. 3.2, P = .001) and shorter interval 
between injections (mean: 3.4 vs. 6.3 months, P < .0001). Conclusion: A higher frequency 
of anti-VEGF injections appears to increase the risk of IOP elevation in DME.
Scientific Poster 469
Macular Edema and Laser for Retinopathy of Prematurity: 
Relationship Assessed by OCT
Presenting Author: Ramiro S Maldonado MD
Co-Author(s): Du Tran-Viet, Dordi Austeng, David K Wallace MD MPH*, Sharon F 
Freedman MD*, Cynthia A Toth MD*
Purpose: To examine impact of laser treatment for retinopathy of prematurity (ROP) on 
macular edema of prematurity (MEOP). Methods: MEOP characteristics and foveal thick-
ness (FT) were assessed in infants with portable spectral domain OCT (SD-OCT) 0-2 weeks 
before and after laser. Results: In 26 eligible eyes, MEOP decreased in prevalence (42% 
pre, 26% after). Twelve eyes did not have MEOP and 4 eyes had MEOP before and after; 
7 eyes had MEOP resolved and 3 eyes had new MEOP onset. The mean FT change was 
+7, -159, -95, and +297 microns, respectively (P < .001). Conclusion: MEOP diminishes 
in some eyes after laser treatment, possibly due to VEGF effects or, alternatively, due to 
natural history of MEOP. Changes in retinal microanatomy after ROP treatment may provide 
new insight into disease pathophysiology.
Scientific Poster 470
Efficacy and Safety of Alternate Ranibizumab Dosing in 
Retinal Vein Occlusion: The SHORE Study
Presenting Author: Charles C Wykoff MD PhD*
Co-Author(s): Linda Yau*, Gary Sternberg MBA MD*
Purpose: To compare the efficacy of ranibizumab (RBZ) given monthly or p.r.n. following ≥ 7 
monthly doses in retinal vein occlusion (RVO). Methods: Phase 4, randomized, open-label, 
15-month study. RVO patients (n = 202) with macular edema were treated monthly with 
RBZ 0.5 mg. After dose 7, once visual acuity and spectral domain OCT stability criteria were 
met, patients were randomized to either continue monthly dosing or p.r.n. dosing. Results: 
Change in BCVA at Month 15 was 18.7 (ETDRS letters) in monthly, 21.0 in p.r.n., and 14.5 
in nonrandomized (NR). Change in central foveal thickness was -289.9 µm, -247.8 µm, and 
-93.2 µm in monthly, p.r.n., and NR groups, respectively. Incidence of serious adverse events 
was 3.0% ocular (study eye), 14.9% systemic. Conclusion: After ≥ 7 monthly doses, ef-
ficacy with p.r.n. RBZ 0.5-mg in RVO was comparable to monthly treatment.
Scientific Poster 471
Enhanced Depth Imaging of the Choroid and Retina in 
Macular Edema
Presenting Author: Ella H Leung MD
Co-Author(s): Patricia MT Garcia MD, Richard Rosen MD*
Purpose: To investigate the relationship between choroidal and retinal thickness in macu-
lar edema, and to identify risk factors for choroidal thinning. Methods: Retrospective case-
control study of 70 eyes (46 with macular edema, 24 controls). The choroid and retina were 
measured at the fovea, 500 µm, 1000 µm, 1500 µm, and 2000 µm nasal, inferior, temporal, 
and superior to the fovea. Results: Eyes with and without macular edema showed no 
statistically significant difference in choroidal thickness (P = .278). In eyes with vascular 
occlusion, however, the choroid was thinner compared to controls (P = .00484). There was 
no difference between diabetic eyes and controls (P = .135). Conclusion: Choroidal thick-
ness is not correlated with macular thickness, but the choroid may be thinner in eyes with 
vascular occlusion.
Scientific Poster 472
The Use of Nonsteroidal Anti-inflammatory Medicines for 
the Treatment of Central Serous Chorioretinopathy
Presenting Author: Andrew N Antoszyk MD*
Co-Author(s): Michael A Singer MD*, Angela Herro MD, Sharif Sabbah
Purpose: To determine if nonsteroidal anti-inflammatory (NSAID) medicines increase the 
time to resolution of symptoms in patients with central serous chorioretinopathy (CSCR). 
Methods: Multicentered chart review of patients treated with NSAID drops were com-
pared to control patients with CSCR to determine the time to resolution of macular edema 
on OCT and restoration of vision to 20/20. Time course was up to 1 year without any inter-
vention. Results: Thirty-eight patients were treated with NSAIDs (13 Nephanac, 25 Brom-
fenac) vs. 52 control patients. Mean time to resolution was 42 days (14-95) in the NSAID 
arm and 127 days in the control (12-362) (P < .0001). Mean time to resolution was also 
highly significant individually (P < .001) vs. control. Conclusion: NSAID drops are effective 
in reducing time to resolution in of CSCR.
Scientific Poster 473
Retrospective Comparison of 25-Gauge Vitrectomy With 
and Without Air Tamponade to Repair Lamellar Macular 
Hole
Presenting Author: Tatsuhiko Sato MD
Co-Author(s): Kazuyuki Emi MD, Hajime Bando MD**, Tomohiro Ikeda MD**
Purpose: To compare the surgical outcomes of vitrectomy with or without air tamponade 
for the repair of lamellar macular hole (LMH). Methods: Twenty-three eyes underwent 
25-gauge (G) vitrectomy with air tamponade, and 18 eyes underwent 25G vitrectomy alone. 
Results: The pre- and postoperative BCVAs were 0.26 ± 0.27 and 0.12 ± 0.15 logMAR units 
in cases with tamponade, and 0.35 ± 0.30 and 0.14 ± 0.23 logMAR units in cases without 
tamponade. The postoperative BCVA was significantly improved in cases with tamponade 
(P = .023) and without tamponade (P < .001). None of the cases developed full-thickness MH 
postoperatively. Conclusion: These results suggest that tamponade may be not necessary 
to achieve visual improvement and anatomical closure in eyes with LMH.
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Scientific Poster 474
Retrospective Comparison of 25-Gauge Vitrectomy for 
Repair of Proliferative Vitreoretinopathy With vs. Without 
Anterior Proliferation
Presenting Author: Tatsuhiko Sato MD
Co-Author(s): Kazuyuki Emi MD, Hajime Bando MD**, Tomohiro Ikeda MD**
Purpose: To compare the surgical outcomes of 25-gauge (G) vitrectomy for the repair of 
proliferative vitreoretinopathy (PVR) with anterior PVR (A-PVR) with those without A-PVR. 
Methods: Twenty-two eyes of PVR with A-PVR and 10 eyes of PVR without A-PVR under-
went 25G vitrectomy. Results: The number of eyes requiring retinotomy was significantly 
greater in eyes with A-PVR (P = .005). The surgical time was significantly longer in eyes with 
A-PVR (P = .002). There were no significant differences in the anatomical success rate or in 
the postoperative visual acuity between the 2 groups. Conclusion: These results suggest 
that 25G vitrectomy can achieve equal surgical outcomes for PVR with and without A-PVR. 
However, cases with A-PVR may need retinotomy more often and may require longer surgi-
cal times.
Scientific Poster 475
Focal Choroidal Excavation in Patients With Central 
Serous Chorioretinopathy
Presenting Author: Fiona O Luk MBChB*
Co-Author(s): Andrew Chung-tin Fok MBChB, Allie Lee MBBS MRCSED**, Andrea Tin 
Wai liu MBBS, Timothy Y Lai MBBS*
Purpose: To determine the prevalence of focal choroidal excavation (FCE) on spectral-
domain OCT in patients presenting with central serous chorioretinopathy (CSC). Methods: 
Review of OCT and angiographic findings of consecutive patients presenting with CSC. 
Results: Among 77 CSC patients, FCE was found in 9 eyes of 6 patients (7.8%). FCE was 
associated with subretinal fluid in 3 cases; and serous pigment epithelial detachment, in 
2 cases. The mean central foveal thickness of FCE patients was 281.5 µm, compared with 
377.6 µm in patients without FCE. All FCE patients had focal leakage on fluorescein angi-
ography and choroidal hyperpermeability on indocyanine green angiography. Conclusion: 
FCE is not an uncommon feature in patients with CSC and might be associated with choroi-
dal hemodynamic disturbances.
Scientific Poster 476
Prevalence of Vitreomacular Interface Abnormalities and 
Candidates for Ocriplasmin Therapy
Presenting Author: Omar S Punjabi MD
Co-Author(s): Lucy T Xu, Jack Z Shao MD, Justis P Ehlers MD*, Sunil K Srivastava MD*, 
Rishi P Singh MD*, Daniel F Martin MD, Peter K Kaiser MD*
Purpose: To evaluate the prevalence of different vitreomacular interface (VMI) diseases 
and to determine candidates for ocriplasmin therapy. Methods: A retrospective, consecu-
tive study was performed on all patients with a diagnosis of macular cyst, hole, pseudohole, 
and VMT using OCT. Results: 426 eyes of 365 patients were included. Thirty-nine eyes 
(10.7%) had macular cyst without hole, 53 (12.4%) had lamellar hole, 66 (15.5%) had pseu-
dohole, and 30 (7%) had VMT. Among 216 eyes (50.7%) with full-thickness hole (FTMH), 
73 (17.1%) were < 250 µm in size, 47 (11.0%) were 250-400 µm and 96 (22.5%) were > 
400 µm. Twenty-two fellow eyes (10.2%) of FTMH had VMA (Stage 0 MH). Seventy-eight 
eyes (18.3%) had symptomatic VMT and were candidates for ocriplasmin therapy based 
on clinical trials. Conclusion: We present a novel OCT-based classification system of VMI 
diseases.
Scientific Poster 477
Oral Rifampin for the Treatment of Long-standing Chronic 
Central Serous Chorioretinopathy
Presenting Author: Shiri Shulman MD
Co-Author(s): Michaella Goldstein MD*, Dafna Goldenberg*, Zohar Habot-Wilner MD, 
Anat Loewenstein MD*
Purpose: To prospectively investigate the effect of oral rifampin for central serous chorio-
retinopathy (CSCR). Methods: Patients with chronic CSCR and persistent subretinal fluid 
(SRF) for at least 3 months were treated with rifampin 300 mg twice daily for 3 months. 
Clinical examinations and spectral domain OCT were performed at 1, 2, 3, 4, and 6 months. 
Results: Twelve eyes of 10 patients (7 men) were included. Mean age was 62.5 years, 
mean SRF duration was 28.4 months, mean visual acuity at presentation was 6/18, improv-
ing to 6/15 and 6/12 at Months 3 and 6, respectively (P > .05). Mean central retinal thick-
ness at presentation was 353 µ, improving to 260 µ, 280 µ, and 275 µ at Months 1, 2, and 3, 
respectively (P < .05). Mean choroidal thickness at presentation was 476 µ (SD 188 µ) and 
427 µ (SD 125 µ) after 3 months. Five eyes (28.4%) had no SRF after 3 months. Conclusion: 
Oral rifampin may be an effective treatment for longstanding chronic CSCR.
Scientific Poster 478
Spironolactone for Central Serous Retinopathy
Presenting Author: Rocio Blanco-Garavito MD
Co-Author(s): Nathalie Puche**, Jennyfer Zerbib MD*, Hassiba Oubraham-Mebroukine 
MD*, Farah Feriel-Soraya Gherdaoui**, Eric H Souied MD PhD*
Purpose: To evaluate the effect of oral spironolactone on the course of chronic central 
serous retinopathy (CSC). Methods: Ten eyes of 8 patients with chronic CSC were included. 
Patients were treated with 75 mg a day of oral spironolactone. Main outcome measures 
were visual acuity and macular and choroidal thickness on OCT. Results: Visual acuity 
improved by 0.07 logMAR. Macular thickness and choroidal thickness on OCT did not vary 
greatly. Conclusion: We found no significant effect of spironolactone on chronic CSC.
Scientific Poster 479
The Use of Topical 2% Lidocaine Gel in Panretinal 
Photocoagulation With Pattern Scan Laser: A Double-
Blind Randomized Controlled Trial
Presenting Author: Man Kit Tong MBBS
Co-Author(s): Michelle Fan MBBS, NgaKwan Bonnie Choy MBBS MRSCED(OPHTH), 
Derek K Yu MBBS, Kenneth K W Li MBCHB
Purpose: To assess whether the use of topical 2% lidocaine gel can further reduce pain 
in pattern scan laser panretinal photocoagulation (PRP). Methods: Forty-two consecutive 
treatment naïve patients requiring PRP were prospectively recruited and randomized into 
methylcellulose group (0.4% Novain + methylcellulose gel) or lidocaine group (0.4% Novain 
+ 2% lidocaine gel). Primary outcome measure was pain level utilizing the Numerical Pain 
Scale (NPS). Results: The lidocaine group had statistically significant lower pain scores 
immediately after the laser (NPS: 3.41 ± 1.07 vs. 1.91 ± 2.49; P = .015) but not during the 
insertion of contact lens (P = .754) or during the laser procedure (P = .673). Conclusion: 
The use of supplementary 2% lidocaine gel can significantly improve patient comfort in 
pattern scan laser PRP.
Scientific Poster 480
Ocular Findings In Aplastic Anemia: Multicenter Study and 
Literature Review
Presenting Author: Ramzi Alameddine MD
Co-Author(s): Ahmad M Mansour MD, Seungah Yahng MD, Kyu Seop Kim, Maha 
Shahin, Nelson Hamerschlak MD PhD, Rubens Belfort MD PhD, Shree Kumar Kurup MD 
MB*
Purpose: To report ocular findings in aplastic anemia (AA). Methods: Retrospective 
series of 719 AA patients followed at a hematology center. Results: 156 patients had 
retinal exam; 37 patients (23.7%) had retinal hemorrhage with mean hemoglobin (Hb) 6.6 
g/dl (range: 2.7-12.6)—similar to mean Hb 6.7 g/dl in 104 subjects without retinal hemor-
rhage—and platelet count 18.8x109/L (range: 4-157). Nine patients had central retinal vein 
occlusion-like picture with similar rheology to rest of subjects. A literature review (1958-
2010) of 200 AA cases revealed retinopathy in 20%-28.3%, vs. 69% with concomitant 
anemia and thrombocytopenia. Conclusion: Around one-quarter of AA subjects develop 
retinal hemorrhage and around two-thirds when there is concomitant thrombocytopenia.
Scientific Poster 481
Retinal Arterial Macroaneurysms: Natural History vs. 
Treatment
Presenting Author: Baseer U Ahmad MD
Co-Author(s): Gaurav K Shah MD*
Purpose: To compare long-term clinical course of patients with treated retinal arterial 
macroaneurysms (RAMs) with those of observed patients. Methods: Retrospective chart 
review of patients from 2003-2012 with ≥ 6 months follow-up. Thirteen treated eyes and 14 
observed eyes were assessed for visual outcomes. Results: Both groups had similar base-
line demographics. Average follow-up times were 24 and 18 months for the treated and 
observed groups. Initial logMAR visual acuities (VA) were 1.14 and 1.11 in the treated and 
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observed groups. Final logMAR VAs were 0.51 and 0.77 in the groups. All patients showed 
resolution or near resolution of hemorrhage and macular edema at final visit. Conclusion: 
The natural history of RAM shows gradual improvement of clinical signs and visual acuity 
over time. However, laser treatment appears associated with greater improvement in VA 
and decreased scar formation.
Scientific Poster 482
Retinal Blood Flow Levels Improved by Oral 
Kallidinogenase in Central Retinal Vein Occlusion Patients
Presenting Author: Makiko Matsumoto MBCB MD DOMS
Co-Author(s): Kiyoshi Suzuma MD, Eiko Tsuiki DOMS, Azusa Fujikawa, Takashi Kitaoka 
MD**
Purpose: We investigated the influence of oral kallidinogenase on retinal blood flow in 
central retinal vein occlusion (CRVO) patients. Methods: Mean blur rate (MBR), which 
represents retinal blood flow, was measured by laser speckle flowgraphy in 26 patients 
(13 with and 13 without kallidinogenase). Results: At their last visits (mean follow-up 
duration: 18.6 ± 9.8 months), MBR was higher with than without kallidinogenase in the 
fellow eyes (P = .11). A significant difference was seen in CRVO eyes (P = .02). Conclusion: 
Kallidinogenase may improve retinal blood flow levels in both eyes of CRVO patients, with 
greater sensitivity seen in affected eyes.
Scientific Poster 483
The Coefficient of Repeatability for Multifocal 
Electroretinography Measurements in Normal Volunteers 
and Patients Taking Hydroxychloroquine
Presenting Author: David J Browning MD PhD*
Co-Author(s): Chong Lee COA
Purpose: To estimate the size of changes in multifocal electroretinography (mfERG) 
variables that exceed noise in hydroxychloroquine (HC) screening. Methods: Duplicate 
measurements of NP amplitudes and ring ratios were made in 21 normal controls and 44 
hydroxychloroquine (HC) users. Bland-Altman plots were analyzed. Results: In normals, the 
coefficients of repeatability (COR) for R1 amplitude, R2 amplitude, and R1/R2 ratio were 
51%, 43%, and 43%, respectively. In HC users, the analogous values were 60%, 53%, and 
47%, respectively. Conclusion: These estimates permit clinicians to determine if changes 
in mfERG variables exceed measurement variability (noise). If a change exceeds the COR 
for a variable, the probability exceeds 95% that the change is real and not measurement 
variability. The CORs for commonly studied mfERG variables are large, confounding inter-
pretation of testing.
Scientific Poster 484
The Relative Sensitivity and Specificity of 10-2 Visual 
Fields, Multifocal Electroretinography, and Spectral 
Domain OCT in Detecting Hydroxychloroquine Retinopathy
Presenting Author: David J Browning MD PhD*
Co-Author(s): Chong Lee COA
Purpose: To determine the relative sensitivity and specificity of 10-2 visual fields (VF), 
multifocal electroretinography (mfERG), and spectral domain OCT (SD-OCT) in screening for 
hydroxychloroquine (HC) retinopathy. Methods: Retrospective review of 100 patients with 
all 3 tests. Results: Retinopathy, defined as cessation of HC by the doctor, was present in 
11 and absent in 89. The sensitivities of 10-2 VF, mfERG, and SD-OCT in detecting retinopa-
thy were 81.8%, 90.9%, and 72.7%, respectively. The specificities were 92.1%, 86.5%, and 
96.6%, respectively. Positive likelihood ratios were 10.4, 6.7, and 21.6, respectively. For 
pretest probabilities ranging from 0.1% to 5%, the increase in post-test probability implied 
by a positive mfERG or SD-OCT was small, regardless of the result of the 10-2 VF. Conclu-
sion: Appropriate use of mfERG and SD-OCT in screening for HC retinopathy will probably 
be selective rather than universal.
Scientific Poster 485
Anterior Chamber Migration of the Dexamethasone 
Implant (Ozurdex) May Result in Corneal Decompensation
Presenting Author: Rahul Khurana MD*
Co-Author(s): Suri N Appa MD, Colin McCannel MD*, Michael J Elman MD**, Susan 
Wittenberg MD, David J Parks MD, Saad Ahmad MD, Steven Yeh MD*
Purpose: To describe the migration of a dexamethasone (DEX) implant (Ozurdex) into the 
anterior chamber. Methods: Fifteen patients had 18 episodes of anterior chamber migra-
tion of a DEX implant. Results: All 15 patients had prior pars plana vitrectomy, and 14 
(93%) had no lens capsule. Among those eyes undergoing surgical removal of the implant, 
earlier intervention reduced the likelihood of permanent corneal edema (0.5 days vs. 5.5 
days, P = .04). Among the 14 patients with corneal edema, the corneal edema did not 
resolve in 10 patients (71%), and 6 patients (43%) required corneal transplantation. Con-
clusion: Absence of lens capsule and prior vitrectomy are risk factors for anterior chamber 
migration of the DEX implant. Early implant removal may be necessary to minimize the risk 
of chronic corneal edema.
Scientific Poster 486
Histopathologically Confirmed Vitreous Cavity and Retina 
Surface Epithelial Downgrowth in Enucleated Specimens 
and in Eyes With Visual Potential
Presenting Author: Aleksandra V Rachitskaya MD
Co-Author(s): Audina Berrocal MD*, Rehan Hussain MD, Sander Dubovy MD
Purpose: To report vitreous cavity and retina epithelial downgrowth. Methods: Retro-
spective 15-year review of Florida Lions Ocular Pathology Laboratory slides for cytokeratin-
positive epithelium in the vitreous cavity or on the retina surface. Results: Six of 122 eyes 
(5%) with epithelial downgrowth had vitreous and retina involvement. Three were enucle-
ation specimens. Three with visual potential had more prior surgeries (P = .03), including 
keratoprosthesis implant; cytokeratin-positive epiretinal membranes were peeled during 
vitrectomy for tractional retinal detachment. The final vision was HM to LP. Conclusion: 
Vitreous cavity and retina epithelial downgrowth occurs after multiple surgeries. In the 
eyes with visual potential, keratoprosthesis might be a predisposing factor. The treatment 
is challenging, with poor outcomes.
Scientific Poster 487
Sub-Silicone Oil Triamcinolone Acetonide Drops: A New 
Approach Against Proliferative Vitreoretinopathy
Presenting Author: Subhendu K Boral MBBS
Co-Author(s): Tushar K Sinha MBBS
Purpose: To detect efficacy of sub-silicone oil (SO) triamcinolone acetonide (TA) crystal 
application over relaxing retinotomy (RR). Methods: TA-assisted 23-gauge vitrectomy done 
in 74 complex retinal detachments (RD)—A: primary, n = 43, and B: failed, n = 31)—divided 
into Subgroup I-A (n = 21) and I-B (n = 17), where additional TA crystals were applied on 
the RR margin, after laser and before injecting SO, and Subgroup II-A (n = 22) and II-B (n = 
14), where no additional TA was applied. Results: Post-SO removal, epimacular membrane 
(EMM) was noted in 19.05% (I) and 54.55% (II) (P < .05) (A) and 11.76% (I) and 64.29% (II) (P 
< .005) eyes (B). Marginal PVR changes in 17.65% vs. 71.43% (P < .005) (B) eyes. Conclu-
sion: Sub-silicone oil additional TA crystals over RR significantly decrease EMM in both 
groups and marginal PVR in failed RDs.
Scientific Poster 488
Oral Fluoroquinolones and the Incidence of 
Rhegmatogenous Retinal Detachment and Symptomatic 
Retinal Breaks: A Population-Based Study
Presenting Author: Andrew J Barkmeier MD
Co-Author(s): Kapil G Kapoor MD, David O Hodge MS, Jennifer StSauver PhD
Purpose: To investigate whether oral fluoroquinolones increase the risk of retinal detach-
ment (RD) and breaks. Methods: We identified patients age ≥ 18 prescribed oral fluoro-
quinolones in Olmsted County, Minn., from Jan. 2003 to June 2011 with macrolide and 
beta-lactam comparison cohorts. RD repair and prophylaxis CPT codes identified patients 
treated ≤ 1 year from prescription dates. Results: Oral fluoroquinolones were prescribed 
for 38,071 unique patients during the study period (macrolide, n = 48,052; beta-lactam, n 
= 69,159). Risk of RD repair and laser procedures within 7, 30, 90, and 365 days of the first 
prescription were calculated for each cohort and compared using Cox proportional hazard 
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models (age- and sex-adjusted P-values not significant for all comparisons). Conclusion: 
Oral fluoroquinolones do not confer a clinically relevant risk of rhegmatogenous retinal 
detachment.
Scientific Poster 489
Influence of Persistent Submacular Fluid on Structural 
Recovery of Retina After Successful Repair of Macula-off 
Retinal Detachment
Presenting Author: Yong-Kyu Kim MD
Co-Author(s): Yong-Woo Kim MD, Se Joon Woo MD, Jeeyun Ahn MD, DuckJin Hwang 
MD, Kyu Hyung Park**
Purpose: To determine the influence of persistent submacular fluid (SMF) after success-
ful treatment of macula-off rhegmatogenous retinal detachment on structural recovery of 
retina. Methods: We retrospectively investigated the medical record of 106 patients. We 
divided patients into 2 groups according to the absence (Group 1) or presence (Group 2) 
of persistent SMF at 1 month postoperatively, and compared OCT findings. Results: In 
patients with preoperative visual acuity (VA) worse than 20/200, Group 1 showed better 
visual gain and higher recovery rate of retina in the first postoperative 6 months, but no 
significant differences thereafter. Conclusion: The persistent SMF delayed functional and 
structural recovery of retina, especially in those with poor preoperative VA. However, it did 
not affect final visual or structural outcome.
Scientific Poster 490
Clinical Profile and Long-term Outcome of Scleral Buckle 
Infection: Retrospective Study
Presenting Author: Jay K Chhablani MD
Co-Author(s): Sameera Nayak MD, Avinash Pathengay FRCS, Subhadra Jalali MS, Annie 
Mathai MBBS
Purpose: To study the clinical profile and long-term outcome of scleral buckle (SB) infec-
tion. Methods: 112 eyes undergoing buckle removal for SB infection, presented between 
July 1991 and June 2012, were analyzed. Results: Commonest complaints were pain 
(64%) and watering (33%). Mean follow-up was 35.71 months. Inciting event was pres-
ent in 8 eyes. Unusual presentations were subconjunctival hemorrhage (3 eyes), panoph-
thalmitis (3 eyes), and orbital cellulitis (2 eyes). Recurrent retinal detachment was present 
in 2 eyes after buckle removal. Conclusion: Presentations of SB infection can vary from 
subconjunctival hemorrhage to panophthalmitis. Recurrent retinal detachment following 
buckle removal is uncommon.
Scientific Poster 491
Decentralizing OCT Testing Increases Vitreoretinal Clinic 
Efficiency
Presenting Author: Theodore Leng MD*
Purpose: To reduce wait times and total time in clinic for return patients. Methods: Dur-
ing March 2013, patients were randomized to have OCT testing performed in a centralized 
photography department (Photo) or by an ophthalmic technician during initial workup and 
dilation (tech). Total time in clinic and wait times were recorded. Results: Seventy-four 
patients were randomized (42 photo, 32 tech). Mean wait times were 21.5 min for the 
photo group and 5.6 min for the tech group (P < .01). Mean total time in clinic was 63.8 min 
for the photo group and 40.9 min for the tech group (P < .01). This represented a 15.9 min 
(74%) reduction in wait time and a 22.9 min (36%) reduction in total clinic time. Conclu-
sion: Placing an OCT device in the technician screening room can significantly increase 
clinic efficiency.
Scientific Poster 492
Analysis of Topographic Correlation Between Reticular 
Pseudodrusen and the Choroidal Vasculature Using En 
Face OCT
Presenting Author: Jonathan Chou
Co-Author(s): Dilraj Singh Grewal MBBS, Stuart D Rollins, Samira Khan MD**, Amani 
Fawzi MD
Purpose: To analyze the topographic correlation between reticular pseudo-drusen (RPD) 
on infrared reflectance (IR) and choroidal vasculature using en face OCT. Methods: Topo-
graphic map of superficial choroid was generated using a 6x6 mm cube (Cirrus HD-OCT). 
Independent masked observers defined RPD, generated random dots for “control RPD,” and 
thresholded choroidal map using ImageJ. Results: Seventeen eyes (11 patients, 9 female, 
mean age 78 ± 13.7 years), with average of 414 ± 72 RPD each were analyzed. 49.6% of 
RPD overlaid choroidal vessels, greater than the 45.4% controls (P < .02). 50.4% of RPD 
overlaid choroidal stroma, of which 76.5% were ≤ 3 pixels from vessels, greater than the 
controls (P < .02). Conclusion: RPD appear to follow underlying choroidal vessels, suggest-
ing their correlation with choroidal pathology.
Scientific Poster 493
OCT Imaging Features of Large Choroidal Blood Vessels in 
Central Serous Chorioretinopathy
Presenting Author: Sung Yong Park MD
Co-Author(s): Sang Jin Kim MD PhD, Sung Min Kim MD, Don-Il Ham MD
Purpose: To identify morphological features of large choroidal blood vessels in central 
serous chorioretinopathy (CSC) using enhanced depth imaging (EDI) OCT. Methods: Large 
choroidal blood vessels in EDI OCT raster scan images were analyzed. The presence and 
prevalence of characteristic sign were investigated. Results: The characteristic sign of 
dilated large choroidal blood vessels was found at areas showing retinal pigment epithelial 
abnormalities. It was significantly more prevalent in CSC eyes (86.4%, 57/66) than in unaf-
fected fellow eyes (30%, 15/50) or in healthy eyes (9.5%, 11/116). Conclusion: Eyes with 
CSC have the characteristic sign of large choroidal blood vessels, which could be helpful for 
the diagnosis and the evaluation of CSC.
Scientific Poster 494
Adaptive Optics Fluorescein Angiography of Diabetic 
Retinopathy
Presenting Author: Richard Rosen MD*
Co-Author(s): Joseph J Carroll*, Michael Dubow, Alexander Pinhas, Nishit Shah, Rishard 
Weitz MBA, Joseph B Walsh MD
Purpose: To investigate the ability of fluorescein angiography (FA) performed using an 
adaptive optics scanning laser ophthalmoscope (AO SLO) to reveal histopathological fea-
tures in diabetic patients. Methods: An AO SLO modified to enable FA imaged diabetics 
with various stages of retinopathy. Oral fluorescein was utilized to maintain sustained fluo-
rescence over extended imaging sessions. Results: AO SLO FA demonstrated structural 
details of diabetic lesions previously seen only in pathology slides. Microaneurysms, capil-
lary remodeling, and exudates showed complexity that challenge conventional therapeutic 
approaches. Conclusion: AO SLO FA provides a new level of clinical detail of common 
diabetic lesions and the opportunity to study the dynamic response of these features to 
therapy.
Scientific Poster 495
Pre- and Post-treatment Enhanced Depth Imaging OCT 
Choroidal Thickness Measurements in Polypoidal 
Choroidal Vasculopathy
Presenting Author: Nicola Y Gan MBBS
Co-Author(s): Colin S Tan MBBS*, Nikolle WH Tan MBBS*
Purpose: To evaluate baseline and post-treatment choroidal thickness (CT) in polypoidal 
choroidal vasculopathy (PCV) with enhanced depth imaging/spectral domain OCT. Meth-
ods: Baseline and 3-month CT of 23 PCV eyes treated with photodynamic therapy/focal 
laser ± anti-VEGF agents were measured at a few locations: subfoveal (F), underlying ac-
tive/leaking polyps (AP), and branching vascular network (BVN). Results: At 3 months, F (P 
< .001), AP (P = .003), and BVN (P < .001) were thinner than baseline. Eyes with recurrent 
/ persistent leakage between Months 3 and 12 had thicker baseline mean F (318.6 vs. 
238.4 µm, P = .022), AP (312.1 vs. 220.2 µm, P = .004), BVN (334.0 vs. 212.8 µm, P = .005), 
and 3-month mean F (P = .014), AP (P = .008), BVN (P = .005) compared to quiescent eyes. 
Conclusion: Baseline CT was thicker in eyes with persistent / recurrent leakage and may 
be useful in predicting treatment response.
Scientific Poster 496
Relevance of Indocyanine Green Angiography for the 
Diagnosis of Noninflammatory Chorioretinal Diseases
Presenting Author: Salim Ben Yahia MD*
Co-Author(s): Rim Kahloun MD, Sonia Attia, Cyrine Hamdi, Moncef Khairallah MD
Purpose: To assess the relevance of indocyanine green angiography (ICGA) for the diag-
nosis of noninflammatory chorioretinal diseases. Methods: Retrospective review of 918 
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patients with noninflammatory chorioretinal disease examined by ICGA. We reviewed 
pathologies for which ICGA was strongly contributive to establish definitive diagnosis. Re-
sults: ICGA was imperative for the definitive diagnosis of choroidal hemangioma (n = 6), 
complicated retinal or optic disc macroaneurysms (n = 7), polypoidal choroidal vasculopathy 
(n = 5), choroidal neovascularization (n = 15), atypical central serous chorioretinopathy (n = 
10), complicated osteoma (n = 1), and amyloidosis (n = 1). Conclusion: ICGA may strongly 
help to establish the definitive diagnosis in a subset of patients with specific chorioretinal 
diseases.
Scientific Poster 497
Adaptive Optics Imaging of Eyes With Epiretinal 
Membrane Before and 6 Months After Surgery
Presenting Author: Mario Stirpe MD
Co-Author(s): Fabio Scarinci Sr, Gaetano Cupo, Marco Andrea Pileri**, Sebastiano 
Serrao MD PhD, Marco Lombardo
Purpose: To investigate the epiretinal membrane (ERM) abnormalities before and 6 months 
after ERM peeling using an adaptive optics (AO) retinal camera and a spectral-domain OCT 
(SD-OCT). Methods: Images of the inner retinal surface (IRS) were obtained via AO and 
SD-OCT in 15 eyes of 15 patients with ERM. Results: Before surgery, “microfolds” (MI), “ 
macrofolds” (MA), and “hyper-reflective lines” (HRL) were identified in AO images of the 
IRS of each eye. After surgery, the density of MI and MA was greatly reduced. The HRL 
were reduced in number, however, with variation between eyes. The nerve fiber bundles 
were imaged with more details than preoperatively. Conclusion: AO retinal imaging pro-
vides new insights into the surgically induced changes of the IRS.
Scientific Poster 498
Pseudo-PCV: Lessons Learned From Screen-Failures in 
a Randomized Controlled Trial for Polypoidal Choroidal 
Vasculopathy
Presenting Author: Colin S Tan MBBS*
Co-Author(s): Wei Kiong Ngo MBBS, Nikolle WH Tan MBBS*, Tock H Lim MBBS FRCSE*
Purpose: To describe screen-failures of the EVEREST Study, a randomized controlled trial 
for polypoidal choroidal vasculopathy (PCV). Methods: Standardized confocal scanning 
laser indocyanine green angiography (ICGA) images were graded by a Central Reading Cen-
ter. Results: Of 95 cases, 34 were excluded: 13 PCV not treatable, 10 small-dot hyperfluo-
rescence < 150 µm, 1 double pathology, and 10 “pseudo-PCV”: 1 microaneurysm, 1 retinal 
angiomatous proliferation, 1 retinochoroidal anastomosis, 3 retinal pigment epithelial (RPE) 
staining/defect, 1 choroidal neovascularization, 1 disciform scar, and 2 choroidal vascular 
knuckle. Additional detailed grading using stereoimaging and dynamic ICGA reliably distin-
guished pseudo-PCV from true PCV. Conclusion: Image grading methods can effectively 
differentiate pseudo-PCV from actual PCV.
Scientific Poster 499
Vitreoretinal Surgery for Shotgun Eye Injuries Related to 
Hunting Accidents
Presenting Author: Alexandre C Assi MD
Co-Author(s): George Michel Cherfan MD**
Purpose: To analyze the anatomic and functional outcomes in addition to complications in 
shotgun injuries. Methods: Retrospective review of 20 consecutive cases with a minimum 
follow-up of 1 year. Results: BCVA at presentation ranged from perception of light (PL) to 
20/200. Ten eyes had a penetrating injury, and 10 others had a perforating injury. All eyes 
underwent a vitrectomy with internal tamponade in 15 cases and a scleral buckle in 12 
cases. Nine cases required further surgery. At last follow-up BCVA ranged from no PL to 
20/20 and was 20/100 or better in with 10 eyes. All patients had a flat retina except for 2 
cases that developed severe proliferative vitreoretinopathy. No cases of endophthalmitis 
were reported. Conclusion: Vitreoretinal surgery can offer good visual rehabilitation in 
patients with shotgun eye injuries.
Scientific Poster 500
Retinal Detachment After Open Globe Injuries
Presenting Author: Tomasz Stryjewski MD
Co-Author(s): Christopher M Andreoli MD, Dean Eliott MD*
Purpose: To characterize retinal detachment (RD) after open globe injury (OGI). Methods: 
Retrospective review of 893 open globe injuries presenting to Massachusetts Eye and Ear 
Infirmary. Results: An RD incidence of 29% was identified after OGI; 27% (69/255) de-
tached within 24 hours of primary open globe repair, 47% (119/255) detached within 1 
week, 72% (183/255) within 1 month. Multivariable regression analysis revealed vitreous 
hemorrhage, zone of injury, and visual acuity to be associated with retinal detachment. A 
screening tool, the Retinal Detachment after Open Globe Injury (RD-OGI) Score, was cre-
ated. Conclusion: RD is common after open globe trauma, though often not appearing 
until days to weeks after the traumatic event. The RD-OGI score is a useful predictor of 
retinal detachment following open globe injuries.
Scientific Poster 501
Photodynamic Therapy of Choroidal Metastasis and 
Evaluation of Response With Enhanced Depth Imaging 
OCT
Presenting Author: Hakan Demirci MD
Co-Author(s): Alexis Cullen, Jeffrey M Sundstrom MD
Purpose: To evaluate photodynamic therapy (PDT) in the management of choroidal me-
tastasis. Methods: Retrospective review of 7 tumors in 6 eyes of 6 patients. Results: Six 
tumors were treated with 1 session; and 1 tumor, with 3 sessions of PDT. The mean basal 
diameter was 9 mm. All tumors were associated with subretinal fluid, which resolved in 
all eyes after PDT. The mean increase in Snellen visual acuity was 3 lines. Tumor thickness 
decreased from a mean of 1100 µm to 655 µm in enhanced depth imaging OCT (EDI-OCT) 
and from 1300 µm to 300 µm in ultrasonography. In 4 tumors, post-treatment thickness 
could be measured with only EDI-OCT. In EDI-OCT, internal tumor reflectivity changed from 
hyporeflective to hyper-reflective in all tumors. Conclusion: PDT can be an alternative 
therapy for selected choroidal metastasis.
Scientific Poster 502
Choroidal Thickness After Treatment of Uveal Melanoma 
With Plaque Brachytherapy
Presenting Author: Kavitha R Sivaraman MD
Co-Author(s): Clement C Chow MD, William F Mieler MD*
Purpose: To quantify choroidal thickness in eyes with radiation retinopathy after plaque 
brachytherapy for uveal melanoma. Methods: Retrospective chart review of 31 eyes of 31 
patients. Postoperative subfoveal choroidal thickness was measured by enhanced-depth 
imaging OCT. The contralateral eye served as a control. Results: At a mean of 25 months 
postbrachytherapy, eyes with active radiation retinopathy (n = 5) had a greater mean 
change in choroidal thickness than eyes without retinopathy (n = 26) when compared to 
the contralateral eye (+120 vs. -17 microns; P < .05). These 5 eyes also had a greater mean 
choroidal thickness compared to the contralateral eye (380 vs. 260 microns; P = .056). Con-
clusion: Choroidal thickness appears to increase in active radiation retinopathy.
Scientific Poster 503
Neovascular Events in Eyes With Central Retinal Vein 
Occlusion Undergoing Intravitreal Anti-VEGF Therapy
Presenting Author: Bozho Todorich MD PhD
Co-Author(s): Francis C DeCroos MD, Rayan A Alshareef, Allen C Ho MD*, Carl D Regillo 
MD FACS*, Marc J Spirn MD, Sharon Fekrat MD
Purpose: To characterize the onset and type of neovascular complications in patients with 
central retinal vein occlusion (CRVO) undergoing anti-VEGF therapy. Methods: Retrospec-
tive review of 30 eyes in 30 consecutive patients with CRVO at Wills Eye and Duke Eye 
Center undergoing serial anti-VEGF therapy between 2005 and 2012. Results: Patients 
received mean of 5 anti-VEGF injections prior to any neovascularization (NV), with mean 
time to NV of 14.3 months. NV of the iris (NVI) / NV of the angle (NVA) was observed in 
60%, vitreous hemorrhage in 27%, and NV of the disc in 20% eyes. Observed trend toward 
earlier onset and higher number of NVI/NVA complications in pseudophakic patients was 
not statistically significant. All NV events were treated with panretinal photocoagulation, 
and 20% of eyes required glaucoma shunt surgery. Conclusion: Anti-VEGF therapy may 
delay rather than eliminate neovascular complications in some eyes with CRVO.
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Scientific Poster 504
Aqueous Levels of Erythropoietin in Acute Retinal Vein 
Occlusion With Macular Edema
Presenting Author: Hyun Jin Shin MD
Purpose: To investigate aqueous erythropoietin (EPO) levels and associated factors in 
acute retinal vein occlusion (RVO). Methods: Aqueous EPO level was measured in patients 
with branch RVO (BRVO) or central RVO (CRVO). We also evaluated whether aqueous level 
of EPO was associated with factors such as central macular thickness (CMT) and nonper-
fusion area. Results: Sixteen BRVO, 11 CRVO, and 9 control subjects (cataract patients) 
were enrolled. Aqueous EPO level was higher in RVO (68 ± 54) than in controls (12 ± 5). 
Aqueous EPO level (mU/ml) was higher in CRVO (118 ± 52) than in BRVO (33 ± 10). Aqueous 
EPO level had a positive correlation with CMT (r = 0.66) and more elevated in the ischemic 
subgroup than in the nonischemic subgroup. Conclusion: Aqueous EPO level could be as-
sociated with retinal ischemia and may be involved in the pathogenesis of macular edema 
secondary to RVO.
Scientific Poster 505
Guarded 360° Supraciliary Drainage (360-CB): A New 
Surgical Approach to Reverse Silicone Oil-Associated 
Chronic Hypotony
Presenting Author: William Eric Sponsel MD*
Purpose: To devise a safe surgical method to restore aqueous secretion and visual func-
tion in severely hypotonous eyes on the verge of phthisis, when ultrabiomicroscopy (UBM) 
cannot be used because of retained oil. Methods: Three eyes with IOP < 2 mmHg for > 
12 months after silicone-oil complex retinal detachment repair, with severe corneoscleral 
decompensation and recalcitrant to standard surgical therapy, underwent a circumlinear 
360° partial-thickness sclerostomy with ruby-knife laminar step incision over the ciliary 
body. Multiple offset circumferential diamond-blade sclerostomies were made beneath the 
scleral shelf, and eyes were reconstituted with viscoelastic. Results: All 3 eyes resumed 
aqueous production, with major improvements in function and cosmesis. Conclusion: The 
360-CB procedure may be an effective restorative option where UBM is impossible.
Scientific Poster 506
Endolaser Associated With Cystoid Macular Edema and 
Epiretinal Membrane Formation Following Small-gauge 
Retinal Detachment Repair
Presenting Author: Tanuj Banker MD
Co-Author(s): Kyle Godfrey MD, Eric D Weichel MD
Purpose: To analyze the relationship between endolaser spots used during small-gauge 
(23/25-gauge) pars plana vitrectomy (PPV) repair of uncomplicated primary retinal de-
tachment (RD) and the development of postoperative cystoid macular edema (CME) and 
epiretinal membrane (ERM). Methods: A review of 117 cases of primary RD repair using 
23/25-gauge PPV. All eyes underwent focal laser to the break with or without 360 degree 
laser. ERM/CME was confirmed using spectral domain OCT and fluorescein angiography. 
Results: The mean number of laser spots was higher in eyes with CME (1015 vs. 784) 
than without CME (P < .03). The mean number of laser spots was higher in eyes with ERM 
(915 vs. 704) than in eyes without postoperative ERM (P < .02). Conclusion: Increased 
endolaser spots during RD repair may be a risk factor for CME/ERM. A greater number of 
endolaser spots is significantly related to increased severity of ERM and need for secondary 
PPV/membrane peeling.
Scientific Poster 507
Natural Course and Surgical Management of High Myopic 
Foveoschisis
Presenting Author: Amanda Rey
Co-Author(s): Ignasi Jurgens MD, Xavier Maseras MD**
Purpose: To describe spectral-domain OCT characteristics, natural course, and surgical 
management in myopic foveoschisis. Methods: The medical records of 39 patients (56 
eyes) with myopic foveoschisis were retrospectively reviewed. Pars plana vitrectomy with 
internal limiting membrane peeling was performed in 16 symptomatic eyes (14 patients). 
Results: OCT at baseline showed an isolated foveoschisis in 62.5% of the eyes, foveal 
detachment in 21.4%, and lamellar hole in 16.1%. After a mean follow-up of 15.7 months, 
1.8% developed a full-thickness macular hole and 28.5% required surgery, with an ana-
tomical success rate of 75%. Conclusion: Myopic foveoschisis remained stable in most 
eyes. However, 28.5% required surgery, with both anatomical and visual improvement.
Scientific Poster 508
A Multicentered Randomized Clinical Trial Comparing 
Epiretinal Membrane Surgery With and Without 
Indocyanine Green-Assisted Internal Limiting Membrane 
Peeling
Presenting Author: Tran D Le MD
Co-Author(s): Wai-Ching Lam MD*, Mark S Mandelcorn MD**, Rajeev H Muni MD, 
Efrem D Mandelcorn MD*, Peter J Kertes MD*
Purpose: To compare the efficacy of epiretinal membrane (ERM) surgery with and without 
indocyanine green (ICG)-assisted internal limiting membrane (ILM) peeling. Methods: Pa-
tients scheduled for ERM surgery were randomized to Group 1 (ERM surgery without ILM 
peeling) or Group 2 (ERM surgery with ICG-assisted ILM peeling). Results: At baseline, 
visual acuity (VA) for Groups 1 (n = 26) and 2 (n = 18) were 0.63 and 0.55 logMAR (P = .15), 
central macular thickness (CMT) for Groups 1 and 2 were 456 and 487 µm (P = .32). At 
postoperative Month 6, the mean reduction in CMT for Groups 1 and 2 were 81 and 89 µm 
(P = .81). There was an improvement in VA by 0.165 and 0.007 logMAR for Groups 1 and 2 
(P = .09). At postoperative Month 6, residual ERM were found in 47% of subjects in Group 1 
and 43% in Group 2. Conclusion: ERM surgery with and without ICG-assisted ILM peeling 
had similar postop CMT and VA outcomes.
Scientific Poster 509
Mechanism of Macular Hole Closure in Postoperative Eyes 
as Assessed by OCT
Presenting Author: Samish Amit Patel MD
Co-Author(s): Sunil Patel MD PhD*
Purpose: To assess the rate of closure of macular holes (MH) in postoperative eyes by OCT. 
Methods: We retrospectively reviewed 16 eyes that had pars plana vitrectomy, internal 
limiting membrane peeling, gas/oil tamponade, and face down positioning for stages 2-4 
MHs. OCT was performed within a day to assess the size of MH under tamponade. Detailed 
measurements of MH parameters were performed by OCT. Results: Eyes had complete 
closure of the MHs (size 107-668 µm diameter) by 3.5 to 26.4 hours. Rate of closure was 
350.9-3.7x104 µm2/hr. The mean retinal area elevated by subretinal fluid was 1.5x106 µm2, 
and the mean area for cuff of fluid was 1.3x106 µm2 (P = .853). Conclusion: The data 
suggest that there is sufficient retinal tissue over the cuff of fluid for complete MH closure 
within hours after surgery.
Scientific Poster 510
Retinal Migration Toward the Optic Disc in Eyes 
Undergoing Vitrectomy for Idiopathic Macular Hole
Presenting Author: Masahiro Ishida MD
Co-Author(s): Rieko Higashida MD, Yoshikazu Ichikawa, Yutaka Imamura MD PhD
Purpose: To examine the retinal migration following idiopathic macular hole surgery with 
internal limiting membrane peeling using spectral-domain OCT. Methods: Distances be-
tween optic disc and retinal vessels temporal to the fovea were measured manually before 
(A) and 2 weeks after surgery (B). Results: Twenty-one eyes of 21 patients (9 male; mean 
age: 64.6 ± 8.4 years) were retrospectively studied. Retina migrated towards the optic disc 
with the distance of 260.8 ± 145.8 mm postoperatively. The ratio of retinal movement [(A-
B)/A] significantly correlated with the maximum size of macular hole (Spearman rank cor-
relation, P = .017). Conclusion: Retina moves toward the optic nerve after vitrectomy in 
idiopathic macular hole.
Scientific Poster 511
Outcomes of Endoscopic Vitrectomy for Retinal 
Detachment in Retinopathy of Prematurity
Presenting Author: S Chien Wong MBBS FRCS*
Co-Author(s): Emil Anthony T Say MD, Thomas Lee MD*
Purpose: To evaluate outcomes of endoscopic vitrectomy (Endo-Vit) in stage 4 and 5 ROP. 
Methods: Retrospective review of 48 eyes with stage 4A, 4B, or 5 ROP, including combined 
traction rhegmatogenous retinal detachment (5-CTRRD). Results: Mean gestational age 
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was 24.8 weeks. Median age at surgery was 44 weeks postmenstrual age. Mean follow-up 
was 17 months. Overall, partial, or complete retinal reattachment occurred in 64% across 
all groups; in stage 4A, 4B, 5, and 5-CTRRD, reattachment occurred in 83%, 47%, 25%, and 
80%, respectively. Of the 33 eyes with visual outcome data, 70% had ≥ fix and follow (FF); 
in the 5-CTRRD group, 100% (5/5) had light perception or FF. Phthisis bulbi occurred in 13%. 
Conclusion: Endo-Vit appears to be a useful technique for stage 4 and 5 ROP, particularly 
for 5-CTRRD.
Vision Rehabilitation
SESSION ONE
Scientific Poster 253
 h  Electronic Tablet (iPad) Improves Reading Ability 
as well as Quality of Life of Patients With Poor Vision 
Secondary to Macular Degeneration
Presenting Author: Shailesh K Gupta MD**
Co-Author(s): K V Chalam MD PhD, Sandeep Grover MD*
Purpose: To evaluate the effect of the iPad as a low visual aid in improving the read-
ing ability of low vision patients. Methods: All patients (N = 228) with BCVA < 20/200 
were included. Low vision was secondary to dry AMD. Reading ability was assessed both 
with the patients’ own spectacles and with the iPad. Modified VF-14 QOL Questionnaire 
was administered for measuring quality of life (QOL). Patients were encouraged to enlarge 
the reading material until they could read comfortably. Results: Initial median BCVA was 
20/800 and N30. With the assistance of the iPad, 94% of patients were able to read N8 or 
smaller text (P < .01). VF-14 subscale score improved from 2.0 to 4.4 (P < .01). Conclusion: 
The iPad is an effective low vision aid and improved reading ability of 9 out of 10 patients 
as well as their QOL (VF-14 subscale score of reading ability).
Scientific Poster 254
Validation of the Burden Index of Caregivers for U.S. 
Patients With Severe Visual Impairment
Presenting Author: Puneet Singh Braich MD
Co-Author(s): Sai B Gandham MD, Maria Ciarleglio PhD, David Almeida MD PhD MBA
Purpose: To validate a novel care burden scale for the caregivers of patients with severe 
visual impairment in the United States. Methods: The Burden Index of Caregivers (BIC) 
was completed by 463 caregivers of legally blind patients in the United States. Validity 
of the instrument was compared to the Short Form-8, the Epidemiologic Depression Scale 
(CES-D), and the Zarit Burden Interview (ZBI). Reliability was performed by retesting respon-
dents after 3 weeks. Results: Validity assessments showed adequate to strong correla-
tions between BIC and the 3 instruments mentioned above (r = 0.54, r = 0.63, r = 0.81, re-
spectively). The intraclass correlation coefficient was 0.82. Conclusion: The BIC is reliable 
and valid for assessing the burden among caregivers of patients with visual impairment.
Scientific Poster 255
Educational and Vision-Assistive Smartphone Apps for 
Patients: A Quantitative Evaluation
Presenting Author: Stephanie N Kletke
Co-Author(s): Feisal A Adatia MD*
Purpose: To identify and evaluate educational and vision-assistive smartphone apps for 
patients. Methods: iPhone and Android webstores were searched. Quantitative evaluation 
was performed using the Quality Component Scoring system (QCS), Technical Component 
Score system (TCS) for educational apps, and usability parameters for assistive apps. Re-
sults: 200 apps (173 vision assistive, 27 educational) were included. Assistive apps had 
a combined QCS/usability score of 13.38 ± 3.04 (max score: 23). Magnifiers (49%) and 
accessibility-related (20%) were most common. Combined QCS/TCS for educational apps 
was 14.15 ± 6.37 (max score: 29). Text-based (63%) and video/audio-based (15%) were 
most common. Conclusion: This study will allow patients to access apps, and physicians 
to make recommendations.
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WHERE ALL OF OPHTHALMOLOGY MEETS
Saturday – Tuesday, Nov. 16 - 19
Best of Show Videos
This year’s Video Program comprises 66 videos. The “Best of Show” award winners are indicated by 
a  h .
Videos on Demand
Hall C, Booth 100
All videos are available to view at your convenience at the Videos on Demand computer terminals. 
This service is also available through the Mobile Meeting Guide, www.aao.org/mobile, or on the 
Academy’s website, www.aao.org/meeting-resources. After Dec. 1 view Videos online: www.aao.
org/aao-archives.
Learning Lounge
Hall G, Booth 3647
The Learning Lounge is hosting several “At the Movies” sessions screening scientific videos from the 
Video Program with the Producers on hand to discuss. A full schedule is available on page page 246 or 
through the Mobile Meeting Guide, www.aao.org/mobile.
Selection Committees
The Annual Meeting Program Committee selected all videos. See page page 33 for committee details.
Video Program
Video Program
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 h  Video #1
Lessons Learned: Complications of Glued IOL
Sr. Producer: Athiya Agarwal MD*
Glued IOL is a technique to fix a secondary IOL in eyes without any capsule. 
Complications are part and parcel of any procedure, and we would like to 
highlight the complications in this technique and how to manage them.
Video #2
Glued IOL Scaffold
Sr. Producer: Athiya Agarwal MD*
Glued IOL scaffold helps manage nuclear fragments if one has got a 
posterior capsular rupture. It combines the IOL scaffold and the glued IOL 
technique.
Video #3
Traumatic Cataract: Managing Vitreous Prolapse
Sr. Producer: David F Chang MD*
This case of a traumatic cataract with a truncated lens equator demon-
strates several pearls regarding the prevention and management of vitre-
ous prolapse. A dispersive ophthalmic viscosurgical device can be used 
to the wall of the area of zonular dialysis, and capsule retractors help to 
prevent further zonular dialysis. Bimanual irrigation-aspiration dissociates 
the infusion and aspiration ports to minimize posterior misdirection of 
irrigation fluid. Following insertion of a capsular tension ring, sulcus place-
ment of a 3-piece IOL with continuous curvilinear capsulorrhexis capture 
ensures IOL stability and centration. Finally, triamcinolone staining reveals 
occult vitreous prolapse that can be managed with a pars plana anterior 
vitrectomy to remove and prevent further vitreous prolapse into the ante-
rior chamber.
Video #4
An Unsung Hero—Hydrodissection in Cataract Surgery
Sr. Producer: Arup Chakrabarti MBBS
Co-Producer(s): Sonia Rani John MS, Meena Chakrabarti MBBS
Hydrodissection, an unsung hero in the game of phaco, plays a crucial role 
in the overall safety and success of the procedure. This film will trace the 
evolution of hydrodissection, teach instrumentation, correct techniques, 
and subtle maneuvers to achieve a successful hydrodissection in various 
types of cataracts. The difficulties, potential complications and their solu-
tions will also be demonstrated. After watching this film a novice surgeon 
will be able to perform hydrodissection successfully in all his cases, and 
will learn of cases where this step is contraindicated and how to deal with 
complications.
 h  Video #5
Napkins and Postage Stamps: The Femtosecond Laser 
Capsulotomy
Sr. Producer: Robert P Rivera MD*
Co-Producer(s): Phillip Hoopes MD*
This video examines the different types of anterior capsulotomies that we 
observed were created by the two femtosecond cataract laser systems 
we acquired in our practice, the Alcon LenSx and the Optimedica Catalys 
Precision Laser System. Using the analogy of napkins and postage stamps, 
complete free-floating capsulotomies are shown to be comparable to the 
napkin, while incomplete capsulotomies with tags are better compared 
to postage stamps. Reasons for incomplete capsulotomies are further ex-
plored and described.
Video #6
Novel Combination of Femtosecond Laser and 
Nanosecond Laser Completion of Bladeless Clear Cornea 
Cataract Extraction
Sr. Producer: A John Kanellopoulos MD*
Co-Producer(s): George Asimellis PhD*
Purpose: Presentation and safety evaluation of this novel combination. 
Methods: Cornea incisions, capsulorrhexis, and lens fragmentation per-
formed with the LenSx. Quadrants were viscoelastically hydrodissected. 
The Cetus nanolaser probe fragmented and removed the quadrants within 
the iris plane/anterior chamber. Results: Uncorrected distance visual acu-
ity improved from 20/100 to 20/20; corrected distance visual acuity from 
20/40 to 20/15; spherical equivalent from 3.7 to 0.5 D; cylinder, -2.25 to 
-0.55 D; capsulorrhexis diameter, 5.0 mm; ECC, from 1,950 to 1,850; and 
mean energy used by nanolaser, 0.8 J. Conclusions: This novel, all-laser 
surgery appears safe and effective, with significantly less energy compared 
with standard phacoemulsification and no thermal exposure within the 
main corneal incision.
Video #7
Reduction of Femtosecond Astigmatic Keratotomy 
Regression With Combined Simultaneous High-Fluence 
Corneal Collagen Cross-Linking: A Novel Refractive 
Procedure
Sr. Producer: Ioanna Kontari
Co-Producer(s): A John Kanellopoulos MD*
Purpose: Safety, efficacy, and clinical parameters evaluation of high-flu-
ence corneal collagen cross-linking (hfCXL). Methods: Fifteen eyes evalu-
ated for vision, refraction, cylinder, and cylinder change. Two 30-degree 
arcuate optical coherence tomography-guided femtosecond astigmatic 
keratotomy (fsAK) incisions performed with the LenSx laser (7-mm optical 
zone, 85 percent depth). Following manual incision separation with Sinskey 
hook, one drop of 0.1 percent riboflavin was administered in one incision, 
with 60 seconds of soak. Results: CXL incisions statistically significant 
in meridional astigmatic change to the non-CXL incisions—day 1 (2.25 to 
1.75 D), week 1 (2.25 to 1.65 D), month 1 (2.1 to 1.45 D), and month 3 (2.05 
to 1.25 D). Conclusions: hfCXL significantly enhances fsAK efficacy, al-
lowing for smaller arc, treatment, higher stability, and lesser symptoms.
Video #8
21st-Century COAX: New-Generation Phacoemulsification
Sr. Producer: Arun K Galli Lakshmi Narayanan MBBS
Co-Producer(s): Sivagnanam Subbiah
In recent years, there has been an increased concern among ophthalmolo-
gists about the phacoemulsification incision stability in a standard 2.8-mm 
incision, and increasing evidence indicates that smaller microcoaxial phaco 
incisions made with 1.8- and 2.2-mm-sized blades offer greater ocular sta-
bility. This video explains how to optimize the Incision size of microcoaxial 
phaco surgery and also emphasizes the understanding of 1.8- and 2.2-mm 
microphacoemulsification by analyzing various aspects, such as the active 
and passive wound size measurements, fluidics behavior, and the proce-
dure to implant microincision IOLs. To technically analyze these microinci-
sions, a computational fluid dynamics study is also performed with differ-
ent input parameters applied in a specialized software.
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Video #9
The Road Not Taken
Sr. Producer: Abhay Raghukant Vasavada MBBS FRCS*
Co-Producer(s): Viraj A Vasavada MD**, Shetal Raj MD, Mamidipudi Praveen 
DO**, Samaresh Srivastava BMBS MS, Vandana Nath**
In the eventuality of a posterior capsule rupture (PCR), anterior segment 
surgeons usually perform a limbal anterior vitrectomy. This film highlights 
the value of the pars plana approach for vitrectomy in the event of a PCR 
and also guides the anterior segment surgeon stepwise to safely perform 
pars plana vitrectomy.
Video #10
Temporary Haptic Externalization and Double-Point 
Fixation to Enhance Stabilization in IOL Scleral Fixation
Sr. Producer: Kyu Hwan Jang MD
Co-Producer(s): Joo Young Shin MD, Hum Chung MD, Jang Won Huh
Two strands of 10-0 Prolene were threaded through two points 2 mm from 
the corneal limbus and 2 mm from each other at 12 to 6 o’clock. The 12 
o’clock strands were pulled out through a 9 o’clock clear corneal incision, 
and the 6 o’clock strands through a 3 o’clock incision. The IOL was injected 
using an injector, and the haptics were partially externalized at each inci-
sion. The Prolene strands were fixed on the haptics at two points 2 mm 
apart, respectively. The IOL was inserted and fixed, and the lens showed 
good centering and minimal tilting. Lens astigmatism was significantly 
smaller than conventional single-point fixation. By double-point fixation, 
lens tilting can be minimized, and the possibility of IOL dislocation in the 
long term may be decreased.
Video #11
Holistic Approach in the Management of Pediatric 
Cataract
Sr. Producer: Muralidhar Ramappa MBBS
Co-Producer(s): Amit Gupta MD, Sunita Chaurasia MD, Shobha Mocherla
This video highlights the detailed preoperative evaluation of the morphol-
ogy of cataract and underlying systemic disorder, if any, the surgical op-
tions indicated for different types of cataract, postoperative care, and early 
vision rehabilitation. The indication, timing of surgical intervention, ap-
propriate surgical technique, types of IOLs, timing of IOL implantation, and 
considerations for primary posterior capsulorrhexis with anterior vitrectomy 
are presented as an algorithm.
 h  Video #12
Pearls to Shorten the Learning Curve for the Novice 
Femtosecond Laser Cataract Surgeon
Sr. Producer: Dilraj Singh Grewal MBBS
Co-Producer(s): Surendra Basti MBBS*
Femtosecond cataract surgery is an important recent advance, with the 
potential to provide enhanced safety and improved outcomes. Despite the 
semiautomated nature of the procedure, there is a learning curve for both 
experienced and novice cataract surgeons transitioning to this technology. 
In this video, we demonstrate potential difficulties with patient position-
ing, performing the laser procedure, and cataract removal following laser 
lens fragmentation. We describe our modifications to different stages of 
the surgical procedure, along with their rationale. Knowledge about these 
pearls and pitfalls will shorten the learning curve and avoid undue compli-
cations.
Video #13
Femtosecond Laser-Assisted Cataract Surgery in 
Presence of a Hydrogel Intracorneal Inlay
Sr. Producer: Gregory Parkhurst MD*
The patient had a Raindrop hydrogel inlay (ReVision Optics, Lake Forest, 
CA) in their nondominant eye for three years with uncorrected distance vi-
sual acuity (UDVA) and uncorrected near visual acuity (UNVA) of 20/20 and 
20/32, respectively. The patient experienced glare and halos due to cata-
ract. Following IOL power selection biometry, a 21-D monofocal IOL was 
implanted in the inlay eye after performing the incision, rhexis, and lenticu-
lar fragmentation using a femtosecond laser (Alcon LenSx, Fort Worth, TX). 
UDVA and UNVA at one-month postop were 20/25 and J2, with excellent 
patient satisfaction. The transparent Raindrop corneal inlay did not impede 
the cataract surgical procedure using femtosecond laser technology.
 h  Video #14
T-Fixation Technique Used for Intrascleral Haptic Fixation 
of Posterior Chamber IOL
Sr. Producer: Toshihiko Ohta MD PhD
We report a new surgical technique that allows intrascleral fixation of a 
posterior chamber IOL without sutures. The technique (the T-fixation tech-
nique) does not involve complicated intraocular manipulation and achieves 
safe, sutureless fixation. First, a T-shaped incision is made in the sclera and 
a 23-gauge microvitreoretinal (MVR) knife is used to create the sclerotomy 
instead of a needle. The T-shaped incision eliminates the need to raise a 
lamellar scleral flap, while performing sclerotomy with the 23-gauge MVR 
knife simplifies extraction of the haptic and greatly improves wound clo-
sure. This technique is a method that achieves both anatomical and optical 
stability.
Video #15
Spider IRIS
Sr. Producer: Amina Berraho MD
Co-Producer(s): Selmane Tabetaoul MD DOMS, Bekkay Rezzoug MD**
Two cases with the obturant form of persistent pupillary membrane are 
reported, to which an early surgical excision has been recommended in 
order to avoid deprivation amblyopia. This surgical technique is simple and 
consists of realizing clear corneal wounds. We will try to describe a safe 
method to remove the pupillary membrane by using vitreoretinal scissors 
after it has been elevated with viscoelastic.
Video #16
Small Corneal Lesions: Big Problems for Premium IOL 
Surgeons!
Sr. Producer: Samar K Basak MD DNB MBBS*
This video demonstrates two important small corneal problems that may 
be missed by cataract surgeons during routine examination. These are 
epithelial basement membrane dystrophy and Salzmann nodular degenera-
tion. These so-called small lesions are important, because they can give 
rise to faulty IOL power calculations and faulty axis of corneal cylinder, 
which are so important for premium and toric IOL implantation in phaco-
emulsification. This video also shares tips on how to treat these conditions 
for the general ophthalmologists.
228
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.  
No asterisk indicates that the presenter has no financial interest.
 Video Program
Vi
de
o 
Pr
og
ra
m
Video #17
Simple Limbal Epithelial Transplant (S.L.E.T): Simple 
Answer to a Difficult Problem
Sr. Producer: Santanu Mitra MBBS
Co-Producer(s): Samar K Basak MD DNB MBBS*
This video demonstrates the autologous simple limbal epithelial transplant 
in unilateral limbal stem cell deficiency diseases. A block of 3- x 2-mm 
limbal tissue is taken from the contralateral eye. This tissue is then cut into 
eight or more smaller pieces. The surface of diseased cornea is clearly dis-
sected. First, amniotic membrane is pasted with fibrin glue on the cleared 
surface. Fibrin glue is again spread over the amniotic membrane. Small 
bits of limbal tissue are placed all over the cornea closer to the limbus. At 
the end of the procedure, a bandage contact lens is given. This procedure 
is a very simple one-stage, economical procedure compared with ex vivo 
cultivation of limbal cells. The results are quite satisfactory.
Video #18
Live Floating Larva in Anterior Chamber
Sr. Producer: Hamidreza Hasani MD
Co-Producer(s): Mohammad Reza Jafarinasab MD, Roghiyeh Shamsoddinimotlagh
Purpose: To describe an interesting case with a live floating larva in 
anterior chamber. Case report: A 12-year-old boy presented with blurred 
vision and red eye since some weeks ago following swimming in the river. 
In ophthalmic examination, a conjunctival redness and a live floating micro-
organism were seen in slit-lamp biomicroscopy. Other exams were normal. 
Under general anesthesia, first, intracameral acethylcholine (Miochol) was 
injected to induce miosis to prevent larval migration into posterior cham-
ber, which led to larval immobilization and death, and then it was removed 
from the eye. Conclusion: It is recommended to be careful in ocular exam 
to explore any probable foreign body, including live larva intracamerally, 
especially in pediatric group patients.
Video #19
New Technique for the Safe Creation of a Big Bubble in 
Deep Anterior Lamellar Keratoplasty
Sr. Producer: Jorge L Alio MD PhD*
Co-Producer(s): Felipe A Soria MD
Achieving a big bubble during a deep anterior lamellar keratoplasty proce-
dure through a clear cornea is still a blind maneuver, especially when lack-
ing certainty about where the air is injected and the depth of the injection. 
The color differences of the limbal region occur because of interdigitation 
of the corneal fibers into scleral fibers, which may help to perform the air 
injection in a safe manner. The junction of blue and white zones of the 
limbus demarcates the mid-limbus, where it overlies the Schwalbe line. It 
is in this anatomical site where we can have a greater certainty of where 
Descemet’s membrane is located in order to achieve a big bubble.
Video #20
Pearls and Pitfalls of Descemet’s Membrane Endothelial 
Keratoplasty
Sr. Producer: Robert L Schultze MD*
Co-Producer(s): Adam G Chun MD, Amit Todani MD
Purpose: To demonstrate the surgical pearls and complications encoun-
tered in the first 10 Descemet’s membrane endothelial keratoplasty (DMEK) 
cases performed by the author. Methods: Surgical video will demonstrate 
eye bank prestripped tissue inserted with a novel, inexpensive shooter de-
vised by the authors utilizing common equipment already readily available 
(Schultze Shooter). Results: Evolution of the author’s surgical technique 
will be discussed along with complications encountered along the way. 
Conclusions: DMEK represents a promising future with a substantial 
learning curve. Despite impressive clinical outcomes, the procedure re-
mains technically challenging and demands open exchange of information 
among surgeons to improve outcomes and minimize complications.
Video #21
Evaluation of Cornea Topography, Astigmatism With the 
Use of Tissue Adhesive in Sutureless DSAEK
Sr. Producer: Ioanna Kontari
Co-Producer(s): A John Kanellopoulos MD*
Purpose: Tissue adhesive (TA) (ReSure Adherent Ocular Bandage) in Des-
cemet’s stripping automated endothelial keratoplasty: safety and efficacy. 
Methods: Twenty-three consecutive cases, randomly assigned. In group 
A, sutures were employed to close the cornea, and in group B, the TA 
was used. All cases were evaluated for uncorrected distance visual acu-
ity, corrected distance visual acuity, refraction, and topographic cylinder. 
Follow-up was eight to 21 months. Results: Cylinder change was 2.2 D for 
group A and 1.1D for group B. There were two repositionings in group A 
only. Conclusions: TA may be a valuable adjunct in clear-cornea cataract 
surgery in reducing astigmatic change, graft dislocation, and the risk of 
endophthalmitis due to early wound ingress.
Video #22
Long-Term Follow-Up of the Athens Protocol: Combined 
Topography-Guided Partial PRK and CXL in 212 
Keratoconus Eyes
Sr. Producer: George Asimellis PhD*
Co-Producer(s): A John Kanellopoulos MD*
Purpose: Safety, efficacy, and potential complications evaluation of the 
Athens protocol (AP). Methods: Two hundred and twelve keratoconus 
cases treated with AP (combined topo-guided photorefractive keratectomy, 
higher fluence corneal collagen cross-linking, 10 mW/cm2, 10 minutes) 
were evaluated over 72 months for uncorrected distance visual acuity 
(UDVA), corrected distance visual acuity (CDVA), refractive error, keratom-
etry, topometry, and pachymetry. Results: No further ectasia progression 
was encountered. UDVA improved from 0.3 to 0.5 and CDVA from 0.5 to 
0.8; index of height decentration improved by 55 percent, spherical equiva-
lent from -3.8 to -1.6 D, and mean keratometry from 51.5 to 47.5 D. Fifty 
percent of cases gained two, and 35 percent gained three lines. Conclu-
sion: The AP appears safe and effective in halting ectasia progression and 
improving visual function.
Video #23
Extreme Toric IOLs for Keratoconus and Following 
Penetrating Keratoplasty
Sr. Producer: Alejandro Navas MD*
Co-Producer(s): Arturo J Ramirez-Miranda MD*, Diana F Rodriguez-Matilde MD, 
Angie De La Mota MD, Enrique O Graue Hernandez MD
This video shows important concepts and considerations for the manage-
ment of high-toricity (keratoconus and following keratoplasty) cases with 
in-the-bag IOLs. In these cases, we performed phacoemulsification and im-
planted hydrophilic acrylic plate with hydrophobic surface toric IOLs of up 
to 12 D of cylinder (AT TORBI 709M, Carl Zeiss Meditec, Jena, Germany), 
obtaining excellent outcomes. In addition to higher toric IOL calculations 
and surgical methods, the video emphasizes the proper and strict patient 
selection criteria.
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Video #24
Descemet’s Membrane Detachment Secondary to Deep 
Blue Dot Degeneration Seen in Saudi Arabia
Sr. Producer: Ali A AlRajhi MD
Deep blue dot degeneration is a new corneal entity characterized by the 
presence of histologically proven amyloid present between Descemet’s 
membrane (DM) and stroma that has never been described before. This 
material predisposes for easy DM detachment during or following phaco-
emulsification and deep lamellar keratoplasty. This video will illustrate 
these findings clinically and pathologically and demonstrate video cases 
with spontaneous DM detachment and attachment. Recognition of this 
entity will help to avoid or manage this complication.
Video #25
Cut and Paste: Sutureless Peripheral Lamellar 
Keratoplasty for Limbal Dermoid
Sr. Producer: Himanshu P Matalia MBBS
Co-Producer(s): Ashwini Ranganath, Anupama Kumar**, Sharon D’Souza MBBS, 
Rohit Shetty MD MBBS
This video demonstrates technique and outcome of limbal dermoid exci-
sion with sutureless peripheral lamellar keratoplasty. Following peritomy 
around the lesion, partial trephination of the dermoid was done. Lamellar 
dissection was done with crescent blade. Donor button was prepared with 
the same diameter as recipient bed with automated microkeratome used 
in Descemet’s stripping automated endothelial keratoplasty. Donor was 
secured to recipient bed with fibrin glue. Bandage contact lens was placed 
and removed after 15 days. This technique provided better cosmetic out-
come compared with other methods. Thus, sutureless peripheral lamellar 
keratoplasty is a safe and cosmetic procedure for dermoid management.
Video #26
A Mysterious, Apparently Conjunctival, Cyst in Two 
Unrelated Children
Sr. Producer: Fathy F Morkos MD FRCS
Two unrelated children presented with a unilateral, progressively enlarging 
mass on the white of their eyes. A tense cystic lesion close to the limbus 
was found, with no signs of inflammation or excessive vascularization. 
Ultrasound biomicroscopy was done. Differential diagnosis was a long list. 
Surgical exposure showed an identical picture in both cases. It was found 
that each of these lesions was an intrascleral cyst with an intraocular com-
munication through a minute track. External scleral cyst wall was surgically 
shortened and tightened, and the track was closed. A pathologist reported 
normal scleral tissue. Both kids did very well; my theory is that these were 
firework injuries. The intraocular communication was created by a micro-
explosion.
Video #27
Deep Anterior Lamellar Keratoplasty in Children
Sr. Producer: Muralidhar Ramappa MBBS
Co-Producer(s): Sunita Chaurasia MD, Shobha Mocherla
This video illustrates the various surgical techniques in the management of 
eyes with anterior corneal opacity and highlights the indication, timing of 
surgical intervention, appropriate surgical technique, intraoperative chal-
lenges, postoperative care, and early visual rehabilitation.
Video #28
Descemet’s Stripping Endothelial Keratoplasty in 
Pediatric Age Group
Sr. Producer: Muralidhar Ramappa MBBS
Co-Producer(s): Sunita Chaurasia MD, Shobha Mocherla
This video illustrates the various surgical techniques in the management of 
eyes with endothelial dysfunction. The preoperative evaluation and surgi-
cal considerations for the better surgical outcomes are highlighted.
 h  Video #29
Small Bubble Technique for Deep Anterior Lamellar 
Keratoplasty
Sr. Producer: Massimo Busin MD*
Co-Producer(s): Paolo Santorum MD, Stefano DeAngelis MD, Vincenzo Scorcia 
MD
The “small bubble” deep anterior lamellar keratoplasty includes microker-
atome-assisted removal with a 200-mm head of a 9-mm anterior lamella, 
small bubble creation in the central 6 mm of the residual stromal bed, 
excision of the dissected stroma up to Descemet’s membrane, and sutur-
ing in place of a 9-mm donor anterior lamella prepared with a 300-mm 
microkeratome head. This novel technique shares the optic advantages of 
a 9-mm diameter graft and the reduced risk of perforation of a 6-mm area 
of Descemet baring. If necessary, conversion to mushroom keratoplasty 
with a 6-mm stem is possible instead of performing a 9-mm penetrating 
keratoplasty.
Video #30
Dia-DALK: Holy Grail in Surgical Management of 
Keratoconus?
Sr. Producer: Rasik B Vajpayee MD
Co-Producer(s): Namrata Sharma MD MBBS, Prafulla Maharana MD, Tushar 
Agarwal MD, Vishal Jhanji MBBS, Ross B MacIntyre MD
We describe a new technique of diamond knife-assisted deep anterior 
lamellar keratoplasty (Dia-DALK) in keratoconus. A circular 8-mm mark 
is made on the host cornea. Intraoperative ultrasonic pachymetry is done 
between the 11 and 1 o’clock positions. Diamond knife set at depth 30 
mm less than this is used to make an incision of 2 mm, which is extended 
circumferentially. Centripetal lamellar dissection is done to excise central 
stromal disc, leaving a thin residual stromal bed. A 0.25-mm, oversized 
donor button is then sutured. Dia-DALK was done successfully in 19 eyes 
with no intraoperative problems. Postoperative astigmatism was 3 D in all 
eyes. Dia-DALK is safe and predictable, has a minimal learning curve, and 
can be done by novice corneal surgeons.
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 h  Video #31
Handling Descemet’s Membrane Endothelial Keratoplasty
Sr. Producer: Massimo Busin MD*
Co-Producer(s): Paolo Santorum MD, Vincenzo Scorcia MD
Descemet’s membrane endothelial keratoplasty (DMEK) is modified to 
include pneumatic dissection of the donor endothelium and Descemet, 
preparation of a 1-mm-square handle of deep stroma attached to the 
DMEK graft (diameter = 8.5 mm), pulling the handle of the graft loaded in 
a cartridge inserted into a nasal incision across the anterior chamber and 
through the temporal 1-mm side entry, from which it is left protruding, easy 
display and attachment of the endothelial graft anchored to the recipient 
cornea, and removal of the handle and air-tight suturing of all the incisions. 
Handling DMEK facilitates graft delivery, unfolding, and precise placement.
 h  Video #32
Perfect Pannus Excision: Step One Towards Successful 
Surgery in Severe Ocular Surface Disease
Co-Producer(s): Virender S Sangwan MBBS, Somasheila I Murthy MD
Pannus dissection is the most crucial step of surgery in end-stage ocular 
surface disorders with limbal stem cell deficiency such as chemical and 
thermal injury, Steven-Johnson syndrome, and ocular cicatricial pemphi-
goid. The various steps of pannus dissection, including symblepharon 
release, finding the correct plane of pannus, removal of any residual chemi-
cal or foreign material, and accessing the thickness of cornea to prevent 
intraoperative perforation, are demonstrated. After achieving a perfect 
dissection of pannus, human amniotic membrane with the cultivated limbal 
epithelial cells or a direct, simple limbal epithelial transplant can then be 
performed.
Video #33
Leaking Blebs: Grafts, Patches, and Rotational Flaps
Sr. Producer: Amar Agarwal MD*
Leaking blebs are a tricky situation to be in. One can treat them by grafts or 
patches. A new technique is to use a rotational scleral flap to seal the leak.
Video #34
Ab Interno Removal of Malpositioned Ex-PRESS Shunt
Sr. Producer: Davinder S Grover MD*
Co-Producer(s): Ronald Leigh Fellman MD OCS*
The authors describe an ab interno technique for removal of a failed and/
or malpositioned Ex-PRESS shunt in two cases. The first case had well-
controlled IOP but developed debilitating ocular pain due to a malposi-
tioned shunt. Following removal of the device, her pain was successfully 
treated and bleb function preserved. This technique was used in a second 
case with a failed bleb and a well-positioned device; the authors removed 
the shunt during another glaucoma procedure. In conclusion, ab interno 
removal of an Ex-PRESS shunt is a safe and effective method that allows 
for continued bleb function without disturbing the conjunctiva. We also 
describe a new finding, eye pain from the internal malposition of the shunt, 
which was completely relieved by the shunt’s removal.
Video #35
Tectonic Scleral Autograft for Treatment of Mitomycin C 
Scleral Fistula
Sr. Producer: Juan Carlos Mesa Gutierrez MD
Co-Producer(s): Jairo Enrique Hoyos Chacon MD, Antonio Rouras Lopez MD**
The authors report a surgical procedure for the correction of a scleral 
fistula in a patient with late hypotony secondary to mitomycin C in a previ-
ous deep sclerectomy (DS). A partial-thickness scleral graft using a 2-mm 
dermatological punch was harvested. Necrotic tissue lining the scleral 
fistula was excised with the same punch and the original DS flap sutured 
to the scleral graft. A double conjunctival flap covered the scleral graft. 
Patient’s vision improved to 20/40, with an IOP of 10 mmHg. A functioning 
bleb was obtained from the first moment and maintained its function after 
18 months’ follow-up.
Video #36
Correlation Between Episcleral Venous Channel Outflow 
and Circumferential Extent of Canal-Based Surgery
Sr. Producer: Ronald Leigh Fellman MD OCS*
Co-Producer(s): Davinder S Grover MD*
Blebless canal procedures reduce IOP by increasing flow into the patient’s 
natural collector system. We do not have a readily available method of 
evaluating flow into the aqueous collector channels as we do for external 
filtration, such as a bleb. The authors previously described the episcleral 
venous fluid wave (EFW), a surge of fluid seen in the episcleral veins during 
phacotrabectome, as a method to determine intraoperative patency of the 
collector system. The authors demonstrate the EFW and, in addition, show 
that it correlates with the extent of angle either cleaved open or stented 
during canal surgery. The EFW is a new method to visualize patency of the 
collector system at the time of canal-based surgery and may correlate with 
reduction in postoperative IOP.
Video #37
Baerveldt Tube Replacement Following Spontaneous 
Extrusion of the Intraocular Portion of the Tube
Sr. Producer: Nicholas K Wride MBChB*
A Baerveldt tube had been placed in an eye with primary angle-closure 
glaucoma with a very shallow anterior chamber. The intraocular portion 
of the tube had spontaneously extruded, and cataract had developed. A 
second operation comprising phacoemulsification of the lens and replace-
ment of the glaucoma drainage device with a new Baerveldt tube in the 
superotemporal quadrant was undertaken. Along with a description of the 
procedure, this video also demonstrates how to plan the removal of a glau-
coma drainage device and when to consider this course of action.
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Video #38
Implantable Collamer Lens Explantation With 
Trabeculectomy
Sr. Producer: Senthil Sirisha
Co-Producer(s): John Praveen Janjarapu MBBS MS, Pravin Vaddavalli MD, 
Chandra Shekhar Garudadri MD*
A 24 year old with a best-corrected vision of 20/20 developed secondary 
glaucoma following a fulminant course of postoperative inflammation 
after posterior chamber implantable collamer lens (ICL) implantation for 
correction of high myopia. The medically uncontrolled IOP necessitated 
explantation of ICL combined with trabeculectomy. Glaucoma, though rare, 
is a vision-threatening complication following ICL implantation. In this 
video, we demonstrate the management of this serious sight-threatening 
complication.
Video #39
Placement of Glaucoma Tube Implants in Patients With 
Conjunctival Adhesions or Scarring
Sr. Producer: Alfred M Solish MD*
Many physicians avoid placement of tube implants in quadrants with scar-
ring from previous surgery. In this video, I demonstrate a technique for 
successful placement of a tube implant (Baerveldt) in a patient with firm 
conjunctival/scleral adhesions secondary to uveitis. A previous attempt at 
filtration surgery by another surgeon was abandoned due to an inability 
to dissect a conjunctival flap. A split-thickness scleral dissection is made 
allowing the implant to be placed in its usual posterior location in the su-
perotemporal quadrant.
Video #40
Ahmed Glaucoma Valve Implantation in Iridocorneal 
Endothelial Syndrome
Sr. Producer: Kumar Ravi
Co-Producer(s): Nikhil Shreeram Choudhari, Chandra Shekhar Garudadri MD*
Implantation of an Ahmed glaucoma valve (AGV) in an eye with iridocorne-
al endothelial (ICE) syndrome is associated with difficulties. As a proliferat-
ing abnormal endothelial cell layer may hypothetically close the osteum 
and thereby reduce the success rate of trabeculotomy in ICE syndrome, 
AGV implantation may serve as a useful alternative in the management of 
glaucoma in ICE syndrome. The conservative management of wound dehis-
cence in the early postoperative period by the addition of oral doxycycline 
to the postoperative regimen is described.
Video #41
Malignant Glaucoma: Can It Be Benign?
Sr. Producer: Siddharth Dikshit
Co-Producer(s): Senthil Sirisha, Chandra Shekhar Garudadri MD*
A shallow or flat anterior chamber following an intraocular surgery char-
acterizes malignant glaucoma in the presence of patent iridotomy and 
absent suprachoroidal fluid, usually with high IOP. The condition is severe 
and progresses relentlessly, hence the name. Diagnosis and management 
of this condition is a big challenge. In this video, we demonstrate a simple 
approach to diagnose malignant glaucoma and also present a stepladder 
approach, including antiglaucoma medications with cycloplegics for phakic 
eyes and laser capsulo-hyaloidotomy for pseudophakic eyes as the first-
line modalities and vitrectomy with hyaloido-zonulo-capsulo-iridectomy 
and cyclophotocoagulation as second-line therapies for the successful 
management of malignant glaucoma.
 h  Video #42
Conjunctival Melanoma: What You Should Know
Sr. Producer: Fairooz Puthiyapurayil Manjandavida MBBS
Co-Producer(s): Sara E Lally MD, Jerry A Shields MD, Carol L Shields MD
Conjunctival melanoma is a distinct entity in the group of ocular and ad-
nexal melanoma. It can arise from primary acquired melanosis, nevus or de 
novo. Differentiation from other pigmented conjunctival lesion is essential. 
Conjunctival melanoma has high potential for regional and systemic metas-
tasis. Overall, metastatic spread is 25 percent in 10 years and 30 percent in 
15 years. This video illustrates the clinical presentations, warning signs for 
early detection, and meticulous surgical technique to prevent recurrences.
Video #43
Management of Exposed Porous Orbital Implants of Large 
Size
Sr. Producer: Junghyun Ahn MD
Co-Producer(s): Yoon-Duck Kim MD, Kyung In Woo MD
Exposure of porous orbital implants is the most frequent serious complica-
tion of porous implants after evisceration and enucleation. Even though 
every effort has to be made to salvage the exposed implant, removal of the 
entire implant is necessary to repair large, recurrent exposures, especially 
if infection is accompanied. For those cases, if adequate conjunctival tis-
sues exist, we inserted secondary implant into intraconal space posterior 
to Tenon’s capsule after removal of exposed implant. In cases of conjuncti-
val insufficiency, we performed implant removal with dermis fat graft. We 
achieved a good result without further infection or re-exposure.
Video #44
Interpretation of Orbital CT Scan: Principles and Normal 
Anatomy
Sr. Producer: Aditi Pujari
Co-Producer(s): Milind N Naik MBBS**, Swathi Kaliki MD
Computed tomography (CT) is an indispensable imaging tool in the evalu-
ation of orbital lesions. The use of thin sections with multiplanar scanning 
and three-dimensional reconstruction permits thorough evaluation of orbit-
al pathology. For proper interpretation of abnormal findings, ophthalmolo-
gists should be well versed with the normal anatomic landmarks on a CT 
scan. This video introduces the novice ophthalmologist to the terminology 
and basics of orbital CT and the important normal anatomical structures of 
the orbit.
Video #45
Use the Ultrasonic Osteotome (Misonix Bone Scalpel) in 
the External Dacryocystorhinostomy
Sr. Producer: Eladio Chourio Ortiz MD
This is a conventional dacryocystorhinostomy variant that uses an ultra-
sonic osteotome. This innovative device allows the surgeon to perform 
precise cuts as bone thin as approximately 0.5 mm, while preserving the 
underlying soft tissue. This will potentially reduce the risk of damage to 
other tissues, reduce inflammation and intraoperative bleeding, and allow 
precise demarcation of the area you want to extract.
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Video #46
Say Cheese! External Ophthalmic Photography: Doing It 
the Right Way
Sr. Producer: Akshay Gopinathan Nair MD
Co-Producer(s): Swathi Kaliki MD, Milind N Naik MBBS**
External ophthalmic photography involves photographic documentation, 
which helps in preoperative planning, documentation of progression of a 
disease, teaching, publishing, and pre and postoperative comparisons. Ex-
ternal photography in ophthalmic and facial plastic surgery, like any other 
specialty too, has standardized guidelines. Basic photography techniques, 
standardized and reproducible angles, such as frontal, oblique, and lateral 
views, and specific photographic angles for conditions such as ptosis and 
proptosis are shown in this video. Use of photography accessories, post-
production, and a few tips on how to click good photographs in your exami-
nation room and achieve consistency in photography are also presented in 
this video.
Video #47
Clutch-and-Conquer Anterior Route Lensectomy
Sr. Producer: Bhamy Hariprasad Shenoy
Co-Producer(s): Maneck D Nicholson MD, Ramesh Kekunnaya MBBS MD
Lensectomy in children can be performed through the pars plana/pars pli-
cata approach or the limbal/corneal approach. Pediatric anterior segment 
surgeons prefer a more familiar limbal approach. This video demonstrates 
our modification of the anterior route lensectomy, which involves clutching 
the lens by its capsule with a pediatric capsulorrhexis forceps and then 
conquering it with an automated vitrector. Lens clutching also helps in 
centering the lens, thereby facilitating a complete lensectomy. The clutch-
and-conquer lensectomy is fast and efficient. No conjunctival incision is 
needed, and it causes minimal surgical trauma. This is an efficient tech-
nique for the management of pediatric spherophakia, microspherophakia, 
and ectopia lentis and is likely to lead to gratifying results.
Video #48
Cataract Surgery in Retinoblastoma: Tips and Technique
Sr. Producer: Shailja Tibrewal MS
Co-Producer(s): Ramesh Kekunnaya MBBS MD
Cataract is a common complication of treatment of retinoblastoma, espe-
cially following radiation therapy. Surgical removal of this cataract involves 
unique challenges. This video illustrates the surgical technique of cataract 
removal in retinoblastoma patients, including the necessary modifications 
of the standard pediatric cataract surgery. Additionally, it aims to educate 
the viewer about the indications and timing of surgery, preoperative as-
sessment, intraoperative precautions, and postoperative care involved in 
the treatment of retinoblastoma cataracts. It provides useful practical tips 
in a simple fashion, knowledge of which can help avoid undue complica-
tions.
Video #49
Congenital Rubella Cataract: A Systematic Management 
Approach
Sr. Producer: Vivek Warkad
Co-Producer(s): Ramesh Kekunnaya MBBS MD
Pediatric cataract associated with any anomaly can challenge the best of 
surgeons. In this video, we shall demonstrate a systematic approach for 
the surgical management of congenital rubella cataract, including preop-
erative evaluation and postoperative care. Special emphasis is given to 
the modification of the standard technique of pediatric cataract surgery in 
difficult situations, such as microcornea, nondilating small pupil, absorbed 
cataract, fibrosed and calcified anterior and posterior capsule, and total 
milky white cataract, that may be encountered in this situation. This video 
will help the viewer to avoid needless complications and achieve success-
ful outcomes.
Video #50
The Double Trouble in Pediatric Cataract Surgery
Sr. Producer: Shilpa Devidas Sonarkhan Sr MS
Co-Producer(s): Ramesh Kekunnaya MBBS MD
Lenticonus, both anterior and posterior, is not uncommon in pediatric 
patients. In these cases, high irregular astigmatism or cataract forma-
tion due to spontaneous rupture of the thin capsule need prompt surgical 
intervention. Also, surgical modifications are required, while performing 
anterior capsulorrhexis, using visco surgical devices, aspirating cortical 
matter, performing posterior capsulorrhexis, and implanting an IOL, to 
tackle problems caused by the thin, fragile, or pre-existing dehiscent ante-
rior or posterior capsule. Modifications in the surgical technique in various 
cases of anterior and posterior lenticonus associated with cataract are 
demonstrated to enhance knowledge and help the surgeon achieve better 
surgical outcomes.
Video #51
Treatment of Posttraumatic Epithelial Ingrowth in Visual 
Axis Area Two Years After LASIK Surgery: A Challenging 
Case
Sr. Producer: Denise Wajnsztajn MD
Co-Producer(s): David Kohn MD, Joseph Frucht-Pery MD
A 44-year-old male had a penetrating trauma in the visual axis area two 
years after right-eye LASIK. He had photophobia, epithelial ingrowth in 
the visual axis area, and decrease of uncorrected visual acuity (UCVA) to 
6/24. Surgical approach comprised partial lifting of the flap, scraping of 
the ingrowth, and suturing the flap to the cornea. To prevent the recur-
rence of the ingrowth through the cut, we placed alcohol 20 percent for 30 
seconds over the epithelium in the central 5 mm of the flap. Sutures were 
removed after two weeks. After nine months, there was no recurrence of 
the ingrowth, UCVA improved to 6/9, and the best-corrected visual acuity 
to 6/7.5. Patient’s symptoms resolved. Central posttraumatic epithelial in-
growth can be efficaciously treated using the presented surgical approach.
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Video #52
Management of Epithelial Ingrowth After LASIK: Case-
Based Scenarios
Sr. Producer: Jagadesh C Reddy MD
Co-Producer(s): Christopher Rapuano MD*, Huan N Pham MD, Pravin Vaddavalli 
MD
LASIK involves the creation of a corneal stromal flap, which generates a 
unique set of potential problems, including epithelial ingrowth. Epithelial 
ingrowth occurs when epithelial cells are implanted or migrate under the 
stromal flap after LASIK. Epithelial ingrowth can be minimal, asymptomatic 
or large, and progressive. Surgical intervention usually involves mechani-
cal removal of the ingrowth and replacement of the flap with or without 
sutures, resulting in elimination of the ingrowth and improved visual and 
discomfort symptoms, with a low chance of significant recurrence. In this 
video, we will be highlighting the risk factors, pattern of presentation, and 
invasive and noninvasive management options available for managing epi-
thelial ingrowth after LASIK.
Video #53
Early Approach in Epithelial Ingrowth After LASIK
Sr. Producer: Luciano Sandrin MD
Co-Producer(s): Leda Das Neves Almeida Sandrin MD
The objective of this video is to show an early approach in epithelial in-
growth cases. This consists of flap border lifting three or four days after 
the LASIK procedure with a 27-gauge sterile needle in order to take out 
the epithelial ingrowth. This procedure is performed in the office, using an 
anesthetic eyedrop. Results include low recurrence, minimal trauma during 
the lifting, and easy extraction of epithelial tissue.
Video #54
Autofluorescence Basics and Applications
Sr. Producer: Jay K Chhablani MD
Co-Producer(s): Deepa Muthugaduru Jagadish MS, Priyanka Gogte Jr
Fundus autofluorescence imaging is a novel noninvasive imaging method 
that allows one to assess the status of the retinal pigment epithelium 
(RPE). Fundus autofluorescence is affected by a balance between accu-
mulation and clearance of lipofuscin in RPE cells. The confocal scanning 
laser ophthalmoscope overcomes the limitations of a conventional camera 
and achieves high-quality autofluorescence images. This video describes 
the basic principle, interpretation of autofluorescence findings, and its 
application in the management of various retinal diseases along with its 
limitations.
Video #55
Bimanual Vitrectomy for Diabetic Combined Retinal 
Detachment
Sr. Producer: Jay K Chhablani MD
Co-Producer(s): Riddhima Suneel Deshpande, Nitin Ganesh Dhira DOMS MBBS**
In advanced proliferative diabetic retinopathy, conventional three-port pars 
plana vitrectomy may lead to incomplete removal of fibrovascular mem-
brane and is associated with bleeding and iatrogenic retinal breaks. The 
safer alternative is to use bimanual vitrectomy with chandelier light and 
two instruments, forceps and scissors, to segment and delaminate firmly 
adherent diabetic membranes with least trauma to thin retina. This video 
shows bimanual vitrectomy in an eye with combined retinal detachment in 
a diabetic subject leading to successful attachment of the retina.
 h  Video #56
OutVitting the Humor! The Art of PVD Induction
Sr. Producer: Manish Nagpal MD*
Co-Producer(s): Navneet Mehrotra, Sidharth Satyendrakumar Bhardwaj MS**
Posterior vitreous detachment (PVD) has become an integral aspect of 
vitreous surgery. Successful detachment of the hyaloid allows for complete 
removal of the vitreous and prevents future complications and failures re-
lated to the gel remnants. The outcome of the surgery depends on the ac-
complishment of this surgical step. This video demonstrates the techniques 
used for PVD creation in a variety of conditions, such as macular holes, 
vitreo macular traction, detached retina, diabetic retinopathy, etc.
Video #57
When Death Race Followed Boston K- Pro-1
Sr. Producer: Subhendu K Boral MBBS
Co-Producer(s): Samar K Basak MD DNB MBBS*
This video describes the hurdles in managing two cases of complex retinal 
detachments post Boston keratoprosthesis-1. Challenges in these post-
Boston K-pro-1 eyes were thin sclera, recurrent hypotony, and limited 
visibility. Hurdles faced included suprachoroidal infusion, intraoperative re-
current choroidal detachments (fluid leaks around the cannulas), retropros-
thetic membrane, and difficulty in base excision. Intravitreal injection of sa-
line built up IOP to introduce infusion tip. Membranectomy was performed, 
wide-angle visualization systems were used, and bimanual approaches 
were taken. All ports had to be sutured. One case resulted in phthisical 
eye, and another gained finger-counting vision at six months’ follow-up.
Video #58
Surgical Treatment of Retinal Detachment After 
Posttraumatic Expulsive Suprachoroidal Hemorrhage
Sr. Producer: Jeroni Nadal Reus MD
We present the case of a posttraumatic expulsive hemorrhage with retinal 
and vitreous herniation and total retinal detachment (in an ophthalmolo-
gist who underwent penetrating keratoplasty in both eyes 30 years ago for 
keratoconus). We analyze the various surgical steps and procedures that 
we performed to reattach the retina and treat the complications encoun-
tered postoperatively.
Video #59
Transscleral 9-0 Prolene Fixation of In-the-Bag Dislocated 
Silicone Plate Posterior Chamber IOL
Sr. Producer: Steven M Cohen MD
This 85-year-old woman has an in-the-bag dislocated silicone plate pos-
terior chamber IOL in her right eye. She has chronic macular edema in 
her fellow eye, which, five years previously, had the same problem, and 
underwent a pars plana vitrectomy, removal of the dislocated lens, and 
placement of an anterior chamber IOL. The video shows the surgery in the 
right eye: a pars plana vitrectomy and transscleral 9-0 Prolene fixation of 
the dislocated lens. The silicone plate lens is particularly suited to this 
fixation technique because the positioning holes in the lens can be used 
to reliably secure the 9-0 Prolene sutures. The sutures are passed through 
23-gauge sclerotomies, and the knots securing the 9-0 Prolene suture are 
rotated into the eye.
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Video #60
Unfolding a Macular Fold: A Clinical Challenge
Sr. Producer: Avnindra Gupta MS
Co-Producer(s): Lalit Verma MD, Arindam Chakravarti, Dinesh Talwar MBBS 
MD**, Hem K Tewari MBBS
A macular fold is a rare complication of detachment surgery. Treatment 
is not defined in literature. We will show a unique video of unfolding the 
fold. After doing a total vitrectomy, internal limiting membrane was peeled 
to remove any preretinal fibrosis. The retina was then detached with bal-
anced salt solution. Once the macula was detached, we tried to flatten 
the retina with perfluorocarbon liquid but did not succeed. So we used 
the bimanual stretching of the retina with a diamond-dusted membrane 
scraper in the opposite direction under torpedo light to unfold the retina. 
This technique of unfolding the macular fold is, to date, not reported in the 
literature.
Video #61
Vitrectomy With Choroid-RPE Patch Graft for Massive 
Hemorrhage Associated With Neovascular ARMD
Sr. Producer: Sengul C Ozdek MD*
Co-Producer(s): Berati Hasanreisoglu MD
This is a video of a patient with age-related macular degeneration who had 
a macular scar in his right eye and a new subretinal massive hemorrhage 
causing hemorrhagic retinal detachment in his left eye, which used to be 
his better eye. A cataract surgery combined with pars plana vitrectomy 
with 360-degree retinotomy, removal of subretinal hemorrhage, blood clots 
and choroidal neovascular membrane, and choroid-retina pigment epithe-
lial (RPE) patch graft was performed. The postoperative fundus pictures, 
together with optical coherence tomography (demonstrating the graft), 
indocyanine green (demonstrating the vascularization of the graft), and 
autofluorescence (demonstrating the healthy RPE) of the eye, will be pre-
sented with the video. The patient’s visual acuity is 20/60 for far and 20/20 
with +4.00 for near at the last visit.
Video #62
First Argus II Implant Performed in the Middle East
Sr. Producer: J Fernando Arevalo MD FACS*
Co-Producer(s): Saba Al Rashaed MD
A retinal prosthesis was implanted for the first time in the Middle East 
on Feb. 2, 2013 in a patient at the King Khaled Eye Specialist Hospital in 
Riyadh, Saudi Arabia. We performed the implantation of the Argus II, and 
the patient, who presented with an advanced form of retinitis pigmentosa, 
is progressing well. At two months, he is already able to see doors, people 
passing by, and buildings outside. The video will demonstrate the first pro-
cedure performed in the Middle East.
Video #63
Ultrasound B-Scan: Different Cases, Ultrasonic 
Characteristics, and Their Interpretation
Sr. Producer: Devendra Venkatramani
Co-Producer(s): Subhadra Jalali MS, Jay K Chhablani MD
B-scan ultrasonography is a noninvasive and commonly used diagnostic 
tool in the clinical assessment of a variety of ocular and orbital diseases. 
With proper utilization of the ultrasound technique, a vast amount of 
information can be gathered, which is not possible with clinical examina-
tion alone. The echographic examination of the human eye and orbit is 
described, and a general understanding of the echographic characteristics 
of various ocular pathologies are illustrated.
Video #64
Bimanual Removal of Large Foreign Bodies With the Use 
of a Suture Loop and a Newly Designed Foreign Body 
Forceps
Sr. Producer: Nur Acar MD
Intraocular foreign bodies (IOFBs) can present in various shapes and sizes. 
Several instruments available can be sometimes limited. In this video, a 
suture loop consisting of a 20-gauge angiocatheter and 6-0 polypropylene 
suture is shown. Its construction is very simple. Also, a newly designed 
IOFB forceps is demonstrated. This suture loop effectively grasps large 
IOFBs, both metallic and nonmetallic. The use of a bimanual technique in 
which the IOFB is surrounded with the suture loop with a forceps provides 
better control and enables the surgeon to place the suture loop along the 
desired axis of the IOFB so that it can be removed through a shorter inci-
sion. This may decrease surgical trauma at the incision site. The newly 
designed forceps adds additional control and safety for the surgeon.
Video #65
Combined Peeling of Epiretinal and Internal Limiting 
Membranes in One Step After Dying With Brilliant and 
Trypan Blue Mixture
Sr. Producer: Nur Acar MD
Epiretinal membranes (ERMs) are sometimes multilayered, which requires 
peeling more than once during vitrectomy. Different dyes with multiple 
times of injections may be used to stain ERM and internal limiting mem-
brane (ILM). In this video, combined peeling of ERM and ILMs in a single 
step after dying with brilliant and trypan blue mixture in ERMs is demon-
strated. The main objective is to decrease mechanical trauma of sequential 
peeling while avoiding injecting dyes more than once to eliminate potential 
concern of toxicity for exposed retina. After a single injection, peeling of 
ILM and ERM is started somewhere near the arcades and completed in the 
macula. The technique is found to be effective, avoiding the recurrence of 
ERMs and injecting dyes more than once during the surgery.
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Video #66
Posttraumatic Aniridia: Artificial Iris Combined With IOL 
Implantation
Sr. Producer: Cesare Forlini MD
Co-Producer(s): Matteo Forlini MD
In case of posttraumatic aniridia or large iris coloboma, the artificial iris 
offers us the best aesthetic solution. The video shows our first experience 
using the artificial iris and our way to correct the refraction at the same 
time. After our first experience with an unsuccessful iris claw implant, we 
found the solution with a foldable IOL sutured on the artificial iris surface. 
The video shows our strategy to suture a foldable IOL on the back surface 
of the artificial iris to achieve a cosmetic and refractive result. In this way, 
we can obtain a good anatomical, functional, and aesthetic result.
Video #67
What Happens When You Have a Break During ROP 
Surgery?
Sr. Producer: Sengul C Ozdek MD*
Co-Producer(s): Berati Hasanreisoglu MD
This video is about vitreoretinal surgery for retinopathy of prematurity 
(ROP)-related retinal detachment. We will present how to handle a retinal 
break, which complicated a three-port 23-gauge vitrectomy for stage 4a-4b 
ROP surgery. The most important determinant for the result is the size and 
place of the iatrogenic break; if it is small and on a silent area, it can be 
managed even with a gas tamponade; however, if it is large and on the 
area of the most prominent fibrovascular proliferation and traction, it is 
very unlikely to manage the break and have the retina attached.
Only at the 2013 Annual Meeting
Personalize Videos at the Academy’s 
Video Production Studio 
Videos enhance patient education and boost practice promotion. 
Take advantage of the Academy’s video personalization service during 
the 2013 Annual Meeting and the significant savings it offers. 
This is a once-a-year opportunity to:
•   Personalize the Academy’s 
videos for patients, including 
the new Retina Informed 
Consent Video Collection
•   Film a promotional video for 
your website or social media sites
•   Create a public health-
awareness video
Visit the Video Production Studio 
today at the Academy Resource 
Center, Hall G, Booth 3239, 
during exhibit hall hours.
NEW! Add your very own introduction to the Academy’s 
just-released Retina Informed Consent Video Collection.
Business Operations | Coding and Reimbursement | EHR | Financial Management
AAOE is a division of the American Academy of Ophthalmology and  
the leading practice management and coding resource in ophthalmology.
An effective practice management  
team is the backbone of every  
successful practice.
Ensure your administrators, managers, billers and coders are members of the  
American Academy of Ophthalmic Executives (AAOE). From coding tips to practical 
guidance for complying with new regulations, AAOE’s solutions cover all of the  
critical issues facing today’s practices. 
Sign up your staff today at www.aao.org/joinaaoe.
Find out more about AAOE at the 2013 Annual Meeting!
Visit the AAOE Practice Management and Coding Booth at the  
Academy Resource Center, Hall G, Booth 3239.
CONGRESSIONAL
ADVOCACY DAY
April 9 – 10, 2014
Washington, DC
Save the Date!
There’s strength in numbers. Lobby on Capitol Hill for 
ophthalmology’s top legislative issues including advocating 
for fair Medicare physician payment, reducing regulatory 
burdens and vision research. Meet face-to-face with your 
Members of Congress and show the might of our members 
at this important opportunity. It’s the most effective way to 
protect the interests of our profession and our patients.
“Congressional Advocacy Day  
is a vital part of your membership  
and a fantastic opportunity  
to get updated on critical issues  
related to ophthalmic advocacy. 
Each year hundreds of Academy 
members advocate for our  
profession and patients.  
Join me and your colleagues  
in Washington, D.C. in 2014”
Paul Sternberg, Jr., MD
Academy President
Registration opens in January 2014. 
Congressional Advocacy Day is open to all  
Academy members and registration is free.
www.aao.org/myf
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In partnership with the 
European Society of Ophthalmology
The American Academy of Ophthalmology is accredited by the Accreditation Council for 
Continuing Medical Education to provide continuing medical education for physicians.
AAO 2014
October 18–21
Subspecialty Day
October 17–18
AAOE Program
October 18–21
SAVE THE DATE!
Learn in hands-on Skills Transfer labs and 
lively small-group sessions. Collaborate 
in thought-provoking presentations from 
ophthalmology luminaries. Interact in face-to-
face conversations with colleagues from around 
the world. Engage! Only at AAO 2014.
ENGAGE!
AAO 2014
Where all of ophthalmology meets
www.aao.org/2014  Chicago
MuseuM  
of Vision
Visit us at Booth #3147  
or on-line at www.museumofvision.org
Ophthalmodouleia by George Bartisch, 1583 (reproduction)
//  GLAUCOMA MANAGEMENT 
     MAdE by ZEiss
The moment you are certain it is glaucoma.  
This is the moment we work for. 
ZEISS empowers you to manage the challenges  
of glaucoma diagnosis
• Structure and Function Combined Reports
•  Guided Progression Analysis™ (GPA™) for both structure  
and function in the lane
• Patient data and test results at your fingertips
NEW! FORUM® Glaucoma Workplace 
Debuting Booth 1919
Not all products, services or offers are approved or offered in every market and approved labeling and instructions  
may vary from one country to another. For country specific product information, see your local representative. 
Carl Zeiss Meditec, Inc.    www.meditec.zeiss.com
COR.5605 Rev.B © 2013 Carl Zeiss Meditec, Inc. All copyrights reserved.
Structure + Function
Visit us  at Booth
1919
//  PRECISION 
     madE by ZEISS
Introducing the ZEISS Cataract Suite  
Designed to work together for expert outcomes. 
Carl Zeiss Meditec, Inc.  www.meditec.zeiss.com
SUR.5617 Rev.B © 2013 Carl Zeiss Meditec, Inc. All copyrights reserved.
Achieve the postoperative results you want and patients expect. 
•	 IOLMaster® 500– Fastest, most accurate optical biometer1
•	 OPMI LUMERA® 700 – Voted #1 surgical microscope by ophthalmic surgeons2
•	 CALLISTO eye® – Revolutionary computer-assisted surgical system
To  learn more, visit us at Booth 1919 
1 Chen YA, Hirnschall N, Findl O. Evaluation of 2 new optical biometry devices and comparison with the current gold standard biometer.                                                         
J Cataract Refract Surg. Mar. 2011, 37(3):513-517.
2 Packer, M. Do you have a preferred surgical microscope? Premier Surgeon 250 Survey.http://www.premiersurgeon.com/index.php/may-june-2011-ps250-survey.  
   Published May/June 2011. Accessed November 13, 2012.
Visit us  at Booth
1919
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Academy Café
Free Coffee.  
Your Questions.  
Expert Panels.  
Lively Conversation.
Room 271
Come join the conversation. Bring your cell phone, smartphone or laptop and text message your questions to the panel. Note: Academy Cafe 
sessions are eligible for CME credit;  see page 317 for additional information.
How to submit a question: Point the browser on your laptop or wireless mobile device to  http://ai.acuport.org and log in with your Badge 
ID and Password or send SMS text to 41411 with the keyword ACafe followed by a space and your question (example: “ACafe Here is my 
question”).
Note: For SMS, standard text messaging fees may apply based on your wireless plan.
Academy Café
Sunday, Nov. 17
SYM46
Oculoplastics
10:30 - 11:45 AM
Moderator: Stuart R Seiff MD
Panel: Suzanne K Freitag MD, Jeffrey A Nerad MD, Brian S Sires MD PhD
SYM47
Cornea, External Disease
1:00 - 2:15 PM
Moderator: Edward J Holland MD*
Panel: Clara C Chan MD*, Douglas A Katsev MD*, Neda Shamie 
MD*, William Barry Lee MD*
SYM48
Retina
2:30 - 3:45 PM
Moderator: Thomas R Friberg MD*
Panel: Carl C Awh MD*, Alan F Cruess MD*, K Bailey Freund MD*, 
Brian B Berger MD*
Saturday, Nov. 16
SYM45
Maintenance of Certification Update
1:00 - 2:15 PM
Moderator: R Michael Siatkowski MD*
Panel: John G Clarkson MD, Keith Hugh Baratz MD*, Bhavna P Sheth 
MD, Meghan Smith, Wallace Jones
SYM44
Cataract
2:30 - 3:45 PM
Moderator: Terry Kim MD*
Panel: Rosa Braga-Mele MD*, Quentin B Allen MD*, John P Berdahl 
MD*, Christopher E Starr MD*, Elizabeth Yeu MD*
Monday, Nov. 18
SYM49
Glaucoma
8:30 – 9:45 AM
Moderator: Thomas W Samuelson MD*
Panel: Anjali M Bhorade MD, Reay H Brown MD*, Marlene R Moster 
MD*, Nathan M Radcliffe MD*, Kuldev Singh MD MPH*
SYM50
Uveitis
10:30 - 11:45 AM
Moderator: Justine R Smith MD*
Panel: Russell W Read MD PhD*, Jennifer E Thorne MD PhD*,  
Howard H Tessler MD*, Daniel V Vasconcelos-Santos MD PhD
Tuesday, Nov. 19
SYM51
Cataract
8:30 - 9:45 AM
Moderator: Sonia H Yoo MD*
Panel:  Lisa B Arbisser MD*, George Beiko MD*, Richard S Hoffman 
MD*, Richard Tipperman MD*, Michael E Snyder MD*,  
David T Vroman MD*
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WHERE ALL OF OPHTHALMOLOGY MEETS
Friday – Wednesday, Nov. 15 - 20
Special Meetings & Events are free of charge, unless otherwise noted. They are not eligible for 
CME credit.
 SO   Endorsed by Senior Ophthalmologist Committee
 YO   Endorsed by Young Ophthalmologist Committee
Special Meetings and Events
Special Meetings & Events
Special Meetings and Events
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Friday, Nov. 15
DICOM Working Group 9 - Eye Care
Event No: SPE01 7:30 AM - 3:00 PM
Fee: FREE
Room: Marriott New Orleans, Tchoupitoulas
Presenter(s): Mark B Horton MD, Linda L Wedemeyer MD
Digital Imaging and Communications in Medicine (DICOM) is a standard 
for integrating different imaging data sources so that they can be readily 
transferred, stored and exchanged. Working Group 9, a DICOM committee 
sponsored by the Academy, focuses on digital imaging standards for eye 
care (e.g., fundus imaging, ophthalmic tomography, biometry, visual fields 
and macular thickness mapping). This meeting is open to vendors, oph-
thalmologists, IT professionals, ophthalmic photographers and ophthalmic 
technicians interested in advancing digital imaging.
Saturday, Nov. 16
 S  Selling and Purchasing on eBay, Craigslist, and 
other Mediums: How to Clean Your Office with Profit
Event No: SPE05 9:00 AM - 12:00 PM
Fee: FREE
Room: 350
Presenter(s): Andrew P Doan MD PhD**
This course will offer an overview of how to shop, sell and make money on 
the Internet, as well as tips for protecting yourself from fraud and phishing 
schemes.
For more information, go to the SO website. 
Note: Attendees must bring their own laptop. Although this event is compli-
mentary, space is limited and registration is still required.
 S  Use Blogging & Social Networking to Super Charge 
Your Website & Internet Marketing
Event No: SPE08 1:00 - 4:00 PM
Fee: FREE
Room: 350-351
Presenter(s): Randall V Wong MD*, Andrew P Doan MD PhD**
This course provides hands-on, step-by-step instruction in how to construct 
your Internet blog and publish articles to use the power of search engines 
to attract people to your practice, website or business.
For more information, go to the SO website.
Note: Attendees must bring their own laptop. Although this event is compli-
mentary, space is limited and registration is still required.
Q&A with FDA
Event No: SPE26 2:00 - 3:00 PM
Fee: FREE
Room: 224
Presenter(s): Wiley Andrew Chambers MD, Malvina Eydelman MD**
Have questions about the drug and device approval process? Want to talk 
about new FDA initiatives? Need answers about the latest news affecting 
ophthalmic products? Join FDA ophthalmic drug and device experts for a 
session with a new format driven entirely by you.
Sunday, Nov. 17
28th Annual Run for Vision
Event No: SPE25 6:30 AM - 7:30 PM
Fee: $50
Bausch + Lomb and the Eye Bank Association of America (EBAA) invite 
you to participate in the 28th Annual Run for Vision 5k benefit run/walk. 
For more information and to register visit www.restoresight.org/upcoming-
events/runforvision.
 YO  2013 Young Ophthalmologist Program — It’s YO 
World: Jumpstart Your Career
Event No: SPE10 10:00 AM - 2:00 PM
Fee: FREE
Room: 252
Presenter(s): Paul Sternberg MD, Natasha L Herz MD, Ajit Nemi MD, Janice 
C Law MD, Katherine A Lane MD**, Derek A Preece MBA*, Brad H Feldman 
MD*, Eliza N Hoskins MD**, Diana R Shiba MD**, Ruben N Sanchez MD, 
Rajiv R Rathod MD, Lawrence Geller MBA*, Jeff H Pettey MD*, Richard G 
Morshedi MD**, Robert F Melendez MD MBA, Andrew P Doan MD PhD**, 
Sue J Vicchrilli COT OCS, Keith D Carter MD FACS, Ruth D Williams MD, 
Randall V Wong MD*, James C Tsai MD MBA*, Thomas A Oetting MD, Gary S 
Schwartz MD, Ron W Pelton MD PhD*, Maria Mendicino Aaron MD, Michael 
J Parshall*, Vikas Chopra MD*, Christian C Hester MD, Meher Yepremyan 
MD**, William Lloyd III MD, Azadeh Khatibi MD
Young ophthalmologists (YOs) face a unique set of demands in their transi-
tion from training to practice. It’s a challenging world, but it’s ‘YO’ world — 
so join your YO colleagues and make the most of it. Not sure how? Attend 
the fast-paced, interactive 2013 YO Program to learn about the key issues 
that affect YOs today. Choose your track — members-in-training, YOs in 
one to five of practice, or both. From contract negotiation to coding, to 
marketing and choosing your practice type, your YO Committee and expert 
consultants have got you covered. Gain confidence, jump start your career 
and take control of your future now!
For more information, go to www.aao.org/yo.
Annual Business Meeting
Event No: SPE11 10:00 - 10:30 AM
Fee: FREE
Room: The Great Hall
Fall Council Meeting
Event No: SPE24 11:30 AM - 5:00 PM
Fee: FREE
Room: Sheraton, Grand Ballroom C
Presenter(s): David W Parke II MD*, Paul Sternberg MD, Gregory L Skuta MD*, 
Cynthia Ann Bradford MD, Daniel J Briceland MD*, Ann A Warn MD MBA*, 
Russell N Van Gelder MD PhD*
Members of the Academy’s Council, an advisory body to the Board of Trust-
ees, and leaders of ophthalmic state, subspecialty and specialized inter-
est societies will meet to discuss the latest advocacy news and provide 
take-home messages and action items as part of the Fall Council meeting’s 
Council of Advocates session. In addition, Academy leaders will provide 
updates regarding priority activities and strategic issues, such as the oph-
thalmic registry, compounding pharmaceuticals and health care reform. 
The Council will also meet by region to discuss issues common to certain 
areas of the country. Requires separate registration. www.aao.org/council.
244
 Special Meetings & Events
 S
pe
ci
al
 M
ee
tin
gs
  
&
 E
ve
nt
s
Sunday, Nov. 17 (cont.)
2014 Medicare Update
Event No: SPE12 12:15 - 1:45 PM
Fee: FREE
Room: New Orleans Theater C
This program will provide vital information and updates on the important 
Medicare issues impacting your practice. Hear about changes that will im-
pact payments and the latest on Medicare’s Physician Quality Reporting 
System and eRx programs. What other new regulations and/or require-
ments will your practice need to focus on? Attend this session to hear all 
the latest updates that will impact ophthalmology in 2013.
Ergonomics/Musculoskeletal Disorders in 
Ophthalmologists
Event No: SPE13 12:45 - 1:45 PM
Fee: FREE
Room: 342
Presenter(s): Martin Wand MD, Jeffrey L Marx MD*, Keith Hugh Baratz MD*, 
Renee Ostertag MD
Self-reported musculoskeletal disorder (MSD) symptoms have been report-
ed in up to 50 percent of ophthalmologists. In a recent study, ophthalmolo-
gists had a significantly increased rate of MSD symptoms compared with 
a family medicine physician control group. Identification of risk factors and 
modification of these activities will decrease the risk of MSDs. This sym-
posium will include presentations from ergonomics specialists focusing on 
practical recommendations to decrease risk of injury in the office, clinic 
and operating rooms. In addition, a physical therapist will demonstrate 
exercises and stretching routines that can be performed during the day at 
work and at home.
The Resident Hub User Group Session
Event No: SPE14 12:45 - 1:45 PM
Fee: FREE
Room: 223
Presenter(s): Jean Hausheer MD
The Resident Hub is an online learning portal for residency programs that 
includes high-quality resources such as videos, courses and self-assess-
ment exams as well as tools for building multimedia courses, assigning 
learning plans and more. 
This session will include a brief demonstration of the learning portal’s 
functions and features, followed by a user group meeting. Users of The 
Resident Hub are encouraged to attend this meeting to share ideas for de-
sirable enhancements and to learn about new content, features and plans 
for future changes.
For more information, go to www.aao.org/thehub
American Board of Ophthalmology: Panel 
Presentation and Q&A with Board of Directors
Event No: SPE15 12:45 - 1:45 PM
Fee: FREE
Room: 222
Directors of the American Board of Ophthalmology (ABO) outline the his-
tory, values and requirements of the ABO’s Maintenance of Certification 
programs and discuss updates and new information on activities for 2013 
and beyond. Directors will also respond to questions from diplomats at the 
end of the presentation.
OMIC Annual Members Meeting
Event No: SPE16 1:30 - 1:45 PM
Fee: FREE
Room: 224
Presenter(s): John W Shore MD*, Timothy J Padovese**
This annual meeting is held to elect directors of the company and to trans-
act other business as may come before the meeting. The OMIC president 
and CEO will report on the company’s latest results. The meeting usually 
lasts about 15 minutes.
The Bruce E Spivey MD Lecture in Risk Management 
& Patient Safety and OMIC Forum
Event No: SPE17 2:00 - 4:00 PM
Fee: FREE
Room: New Orleans Theater C
Presenter(s): Susan H Day MD, Steven I Rosenfeld MD FACS*, Denise R 
Chamblee MD**, Timothy J Padovese**, Hans Bruhn**
The inaugural Bruce E Spivey MD Lecture in Risk Management & Patient 
Safety will be given by Susan H Day MD, past president of the Academy 
(2005). Dr. Day will lecture on risk management and patient safety risks 
as they relate to ophthalmology. The lecture will be followed by the OMIC 
Forum, which highlights the successful strategies OMIC has developed in 
collaboration with the Academy to decrease the frequency and severity of 
claims against ophthalmologists.
Monday, Nov. 18
 YO  Welcome to the Real World: Reality 101 for 
Residents and Fellows
Event No: SPE19 12:30 - 1:45 PM
Fee: FREE
Room: 252
Presenter(s): K David Epley MD*
In this interactive forum, residents and fellows will learn about the non-
medical aspects of practicing ophthalmology and get their questions an-
swered. Panelists will discuss their personal experiences and highlight 
practice options, networking and referrals, advantages and disadvantages 
of fellowship training and other resources available to assist residents and 
fellows. This forum will also discuss how membership and active involve-
ment within state ophthalmology societies and the Academy can be of 
benefit.
VA and DOD: Leading the Way in Simulation in Eye 
Care
Event No: SPE21 12:45 - 1:45 PM
Fee: FREE
Room: 217
Simulation technology has rapidly evolved over the past few decades and 
can provide ophthalmologists with new perspectives on how to handle real 
medical situations. During this meeting, Department of Veterans Affairs 
(VA) and Department of Defense (DOD) ophthalmologists will discuss how 
the VA and DOD health care systems are advancing the use of simulation 
technologies in eye care. Topics for discussion include residency training, 
skills transfer and trauma training, improving patient safety and compe-
tency maintenance. Speakers will also examine the future of simulation 
technology in eye care. A question-and-answer period will follow.
245
Special Meetings & Events
 Special M
eetings  
&
 Events
Monday, Nov. 18 (cont.)
Ethics and Risk Management Issues Facing 
Ophthalmology, Featuring Robin Cook
Event No: SPE20 2:00 - 3:00 PM
Fee: FREE
Room: New Orleans Theater C
Presenter(s): Christie L Morse MD*, Tamara R Fountain MD*, Ron W Pelton 
MD PhD*
There is a clear nexus between author Robin Cook’s body of work and the 
ethical, socio-economic and professional liability issues facing ophthalmol-
ogists. His books “Crisis”, “Nano”, “Cure” and “Intervention” delve into 
these issues. The Academy Ethics Committee and OMIC often encounter 
ophthalmologists who struggle with the ethical and professional liability 
issues of managing a practice in challenging economic times while provid-
ing quality care to patients. Dr. Cook will lecture and moderate a panel 
discussion and question and answer session addressing these issues with 
Ethics Committee members and OMIC.
 S  Senior Ophthalmologist Special Program and 
Reception
Event No: SPE22 2:30 - 5:00 PM
Fee: FREE
Room: 252
Don’t miss these two vibrant speakers and authors: 
The Accidental City: Improvising New Orleans is the latest book by Profes-
sor Lawrence N. Powell, emeritus faculty for the department of history at 
Tulane University. He specializes in Civil War and Reconstruction; Southern 
history; Louisiana history and politics; and the Holocaust.
Gifts of Sight is written by SO Committee member, M. Bruce Shields, MD, 
past Marvin L. Sears professor and chairman for the department of ophthal-
mology and visual sciences at Yale University School of Medicine and past 
president of the American Glaucoma Society.
Both authors will have their books available for purchase onsite and will 
sign copies. Plus, we’ll present the 2013 EnergEYES Award. The EnergEYES 
Award was created in 2009 to recognize and honor an ophthalmologist who 
demonstrates exemplary leadership skills by energizing others to improve 
ophthalmology. This individual is one who mentors young ophthalmolo-
gists, serves as a strong role model and displays high energy that moti-
vates them to get involved.
For more information, go to www.aao.org/so.
Wednesday, Nov. 20
Lo Mejor de la Academia en Español
Event No: SPE23 7:00 AM - 5:00 PM
Fee: See below
Room: Sheraton, Armstrong Ballroom
Presenter(s): Guillermo A Pereira MD**, Jose Roca Fernandez MD**, Jose 
Gomes MD*, Lihteh Wu MD*, Hernan V Iturriaga MD**, Peter A Quiros MD, 
Abelardo A Rodriguez MD**, Luis Izquierdo Jr MD, Ashley Behrens MD**, 
Zelia M Correa MD, Fernando L Colombo MD**, Jerome C Ramos-Esteban 
MD**, Enrique O Graue Hernandez MD, Arturo J Ramirez-Miranda MD*, 
Francisco Arnalich-Montiel MD**, Gerardo F Graue-Moreno MD**, Valentina 
Franco Cardenas MD, Manuel Diaz Llopis MD PhD**, Javier Cordoba Umana 
MD**, J Fernando Arevalo MD FACS*, Cristian F Luco MD**, Eduardo Arenas 
MD**, Juan Murube MD**, Margarita I Estribi MD, Francisco J Rodriguez 
MD*, Hilda Capo MD, Ivan R Batlle MD**, Jose Morales MD**, Gregorio F 
Gabela MD, Miguel A Materin MD, Daniel H Scorsetti MD, Federico A Graue-
Wiechers MD, Natalio J Izquierdo MD**, Victor H Gonzalez MD*, Jose Claros 
MD**, Benjamin Zagorin MD**, Armando G Sandoval MD**, Elena Jarrin MD 
DOMS**
La Academia Americana de Oftalmolog’a (AAO) y la Asociación Panameri-
cana de Oftalmolog’a (PAAO) auspiciarán una reunión de un d’a en la cual 
se presentarán y discutirán, por oftalmólogos de habla hispana, los aspec-
tos más importantes en 2013 ya sean en oftalmolog’a general o en las di-
versas subespecialidades. Nueva literatura e instrumentos oftalmológicos 
serán evaluados en forma objectiva. Despuçs del 15 de Octubre y en el sitio 
(on site), la inscripcion sera de $40 para Miembros Titulares PAAO/AAO, y 
$50 para Asociados/No Socios, y $25 para Residentes/Fellows. Inscr’base 
por internet en www.paao.org buscando ‘Lo Mejor’. 
The Academy and the Pan-American Association of Ophthalmology (PAAO) 
will sponsor a one-day meeting that will summarize the important presen-
tations in general ophthalmology and all subspecialty fields at the 2013 
Annual Meeting. New ophthalmic literature and instruments will also be 
objectively evaluated. The presenting panels will be composed of Spanish-
speaking ophthalmologists. Please note that panel topics and/or times may 
change. Registration fees after Oct. 15 and onsite are as follows: Active 
PAAO/Academy Members, $40; Associate Members/Nonmembers, $50 
and Residents/Fellows, $25 (with letter or appropriate Annual Meeting 
badge). Register online at the PAAO website, using keyword ‘Lo Mejor’.
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WHERE ALL OF OPHTHALMOLOGY MEETS
Saturday – Tuesday, Nov. 16 - 19
Hall G, Booth 3647
Visit the Learning Lounge to participate in informal, small group facilitated discussions led by experts in 
the field and continue the conversation with your colleagues. 
Float among groups, new topics begin every 15 minutes.
For the most up-to-date schedule visit: www.aao.org/mobile. 
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Saturday, Nov. 16
Theater 1 Theater 2 Theater 3
Managing the Posterior Capsular Tear
Louis D Skip Nichamin MD,  
Nick Mamalis MD and Mark K Walsh MD
Corneal Considerations in Cataract Surgery
William Barry Lee MD Presbyopia Correcting IOLs
Samuel Masket MD, Nicole R Fram MD,  
and Daniel H Chang MD
Femtosecond Laser Cataract Surgery  
in Challenging Cases 
Dense Lens, Small Pupil, Morgagnian Lens
Mark Packer MD and Jonathan D Solomon MD
Microinvasive Glaucoma Surgery 
Husam Ansari MD PhD Updates in IOL Power Calculations  
after LASIK/PRK
Douglas D Koch MD and Samuel Masket MD
GLObAL OPHTHALMOLOGY
Volunteer Experiences
Timothy P Page MD
GLObAL OPHTHALMOLOGY
Rotary Guest Presentations
Kenneth D Tuck MD FACS and  
Baxter F McLendon MD FACS
GLObAL OPHTHALMOLOGY
Global Ophthalmology Video Courses
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Sunday, Nov. 17
Theater 1 Theater 2 Theater 3
Opening Session: Live Broadcast Opening Session: Live Broadcast Opening Session: Live Broadcast
Complicated and Challenging Cases in Cataract Surgery
Rosa Braga-Mele MD, Lisa B Arbisser MD, Terry Kim MD, and 
Robert J Cionni MD
Advances in Pediatric Cataract Surgery
M Edward Wilson Jr MD Treating Diabetic Macular Edema in 2014
Diana V Do MD
Advanced Techniques in Strabismus Surgery
Edward G Buckley MD COnTInuE THE COnvERSATIOn
Jackson Memorial Lecture
Mark S Blumenkranz MD
COnTInuE THE COnvERSATIOn
Innovation in Ophthalmology:  
From Theory to Therapy
Emmett T Cunningham Jr MD PhD MPH, Gilbert H Kilman MD, 
William Link PhD, Eugene De Juan Jr MD, Daniel M Schwartz MD, 
Richard L Lindstrom MD, and Mark S Blumenkranz MD
Everything You Wanted to Know About ACA and 
Physician Payment - Now You Can Ask the Academy 
Experts
Michael X Repka MD MBA, Gregory P Kwasny MD OCS, 
Trexler M Topping MD, and Stephen A Kamenetzky MD OCS
What’s New in ROP
David K Wallace MD 
Surgical Pharmacology---the Need for a Clinical and 
Basic Research Approach
Henry F Edelhauser PhD
COnTInuE THE COnvERSATIOn
Innovations in Pediatric Eye Surgery 
Daniel E Neely MD, Erick D Bothun MD, 
and Sharon Freedman MD
Biologics Agents for Uveitis
Alan Gary Palestine MD
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Monday, Nov. 18
Theater 1 Theater 2 Theater 3
AT THE MOvIES
Femtolaser Cataract Surgery
Moderator: Mitchell P Weikert MD
Napkins and Postage Stamps: The Femtosecond Laser 
Capsulotomy (Robert P River MD); Novel Combination of 
Femtosecond Laser and Nanosecond Laser Completion 
of Bladeless Clear Cornea Cataract Extraction (A John 
Kanellopoulos MD); Pearls to Shorten the Learning  
Curve for the Novice Femtosecond Laser Cataract Surgeon 
(Dilraj Grewal MD)
AT THE MOvIES
Glaucoma
Moderator: Carla J Siegfried MD
Correlation Between Episcleral Venous Channel Outflow 
and Circumferential Extent of Canal-Based Surgery (Ronald 
Leigh Fellman MD); Ahmed Glaucoma Valve Implantation in 
Iridocorneal Endothelial Syndrome (Kumar Ravi); Malignant 
Glaucoma: Can It Be Benign? (Siddharth Dikshit)
AT THE MOvIES
DALK and Pediatric Ophthalmology
Moderator: Terri L Young MD
Small Bubble Technique for Deep Anterior Lamellar 
Keratoplasty (Massimo Busin MD); Dia-DALK: Holy 
Grail in Surgical Management of Keratoconus? (Rasik 
B Vajpayee MD); Deep Anterior Lamellar Keratoplasty 
in Children (Muralidhar Ramappa MBBS); Descemet’s 
Stripping Endothelial Keratoplasty in Pediatric Age Group 
(Muralidhar Ramappa MBBS)
Preparing for Retirement: Financially and 
Emotionally
Thomas M Aaberg Sr MD MSPH FACS
Glaucoma Surgery: Trabeculectomy, Tube Shunt, 
Minimally Invasive Technologies
Dale K Heuer MD, Brian A Francis MD, and 
Richard A Lewis MD
COnTInuE THE COnvERSATIOn
Advnaces in Keratoplasty:  
Where We Are in 2013
Woodford S Van Meter MD FACS and 
Steven I Rosenfeld MD FACS
COnTInuE THE COnvERSATIOn
Boston Mass Casualties
Allen B Thach MD, Henry D Hacker MD, and 
Jorge G Arroyo MD
Making Sense of Glaucoma RCTs
Mark A Latina MD, Steven T Simmons MD, and 
L Jay Katz MD
COnTInuE THE COnvERSATIOn
Introduction to Cornea and Lens-Based Refractive 
Surgery for Residents
Ronald R Krueger MD and  
J Bradley Randleman MD
ABO - MOC  
Certification and Your First MOC Cycle
R. Michael Siatkowski MD, Amy S Chomsky MD, and 
H. Culver Boldt MD
 
Corneal Infections
Elmer Y Tu MD
YOunG OPHTHALMOLOGY 
Growing YOur Business with Social Media 
Marketing
Robert F Melendez MD MBA, Purnima S Patel MD, James G 
Chelnis MD, Randall V Wong MD, and Edward H Hu MD PhD
AT THE MOvIES
IOL
Moderator: William J Fishkind MD FACS
Lessons Learned: Complications of Glued IOL (Athiya 
Agarwal MD); T-Fixation Technique Used for Intrascleral 
Haptic Fixation of Posterior Chamber IOL (Toshihiko Ohta MD 
PhD); Small Corneal Lesions: Big Problems for Premium IOL 
Surgeons! (Samar K Basak MD FRCS MBBS); Extreme Toric 
IOLs for Keratoconus and Following Penetrating Keratoplasty 
(Alejandro Navas MD)
Ocular Surface Disease
Andrew J Huang MD MPH
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Tuesday, Nov. 19
Theater 1 Theater 2 Theater 3
AT THE MOvIES
Cataract/Cornea
Moderator: Kathryn A Colby MD PhD
Traumatic Cataract: Managing Vitreous Prolapse (David F 
Chang MD); Perfect Pannus Excision: Step One Towards 
Successful Surgery in Severe Ocular Surface Disease (Arjun 
Srirampur); Conjunctival Melanoma: What You Should Know 
(Fairooz Puthiyapurayil Manjandavida MBBS)
AT THE MOvIES
Oculopastics
Management of Exposed Porous Orbital Implants of Large 
Size (Junghyun Ahn MD); Say Cheese! External Ophthalmic 
Photography: Doing It the Right Way (Akshay Gopinathan 
Nair MD)
Ergonomics for Ophthalmologists
Martin Wand MD
COnTInuE THE COnvERSATIOn
A Multidisciplinary Approach to Emerging 
Therapies in Neuro-Ophthalmology
Madhu R Agarwal MD and  
Matthew Dean Kay MD
Fillers and Botox Basics
Jeffrey A Nerad MD
9:00
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WHERE ALL OF OPHTHALMOLOGY MEETS
Saturday – Tuesday, Nov. 16 - 19
Hall I1, Booth 5145
Academy members and independent consultants offer user-friendly instruction on all things high-
tech for business, clinical and academic applications. Stop by for presentations on:
• The latest in hardware, from mobile devices to wireless computing.
• Internet, social networking, productivity and mobile software topics.
• Software for medical records, presentations, image manipulations and more.
• Benefits of the Mobile Meeting Guide.
Technology Pavilion
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Presentation Schedule
Saturday 11/16 Sunday 11/17 Monday 11/18 Tuesday 11/19
9:30-11:00
Using Microsoft Office 13 / Office 
365
9:30-11:00
Smartphone Update and Disruptive 
Technologies
9:30-10:30 
Step-by-Step: Edit Video Like a Pro
9:30-10:30 
Internet Privacy and Wireless 
Security
11:00-12:00
Fully Integrated DICOM Imaging 
in EHR
11:00-12:30 Microsoft Windows/
Office: Ask the Expert11:30-12:00
The Mobile Meeting Guide
11:30-12:00
The Mobile Meeting Guide
12:30-1:30
Privacy Breach: Now What?
12:30-2:00
A Social Media Primer
12:30-1:30 
Introducing the Academy’s IRIS™ 
Registry
2:00-3:00
ONE® Network 2.0 and The 
Resident Hub™
2:00-3:30 
Mobile Computing Update
2:30-3:30
EHR 101
3:30-5:00
Windows Update: Windows 8, RT 
and Phone 4:00-5:00
Tele-Ophthalmology Talking Points
4:00-5:00
Social Media Influences the Doctor-
Patient Relationship
Indicates IHE session
Saturday, Nov. 16
9:30 – 11:00 AM 
Using Microsoft Office 2013 / Office 365
Jude Brown, Senior Instructor, Digital Acumen, Inc.
Microsoft Office is now available in several versions for home and work, 
including the familiar format Office 2013 and newer cloud-based Office 
365. We will highlight the included programs in each and how they 
integrate tasks, as well as see how these two versions stack up in terms 
of features, benefits and costs. As always, our instructor is happy to field 
your Office-related questions.
11:30 AM – 12:00 PM 
Get the Most from the Academy’s Mobile Meeting Guide
Jude Brown, Senior Instructor, Digital Acumen, Inc.
This quick session introduces users to the basics and benefits of using 
the Academy’s powerful Mobile Meeting Guide to help plan and navigate 
the 2013 Annual Meeting. Learn how to sign in, find sessions, create your 
Personal Planner, as well as get an overview of the wealth of content and 
features it contains. Did you know you can view Academy posters and 
videos, fill out course evaluations, take notes and even ask questions live 
during certain sessions through the Mobile Meeting Guide? If not, this 
session is for you!
(Repeated on Sunday, 11:30 AM –12:00 PM)
12:30 – 1:30 PM
Privacy Breach: Now What? 
H Jay Wisnicki MD, Medical Director, Union Square Eye Care Professor of 
Clinical Ophthalmology & Visual Sciences and Pediatrics, Albert Einstein 
College of Medicine
Rainer Waedlich, President IOTA (International Ophthalmic Technology 
Association)
Neil H Ekblom, Health Care Attorney, LeClairRyan
There are many benefits of consolidating patient records electronically, 
but what if someone accesses your patient information without authoriza-
tion? What are your legal and regulatory obligations? How can staff train-
ing and the EMR technology itself be used to limit and mitigate exposure? 
This open discussion provides valuable perspectives from a tech savvy 
ophthalmologist, an experienced EHR/EMR vendor and a lawyer with a 
rare focus on ophthalmic practice as they examine the myriad issues in 
this sensitive but important subject. Bring your questions and join this 
interactive panel discussion.
9:30
 
10:30
11:00
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12:00
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4:30
5:00
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Saturday, Nov. 16 (cont.)
2:00 – 3:00 PM
ONE® Network 2.0 and The Resident Hub™
Robert F Melendez MD MBA, Editor-in-Chief of the ONE Network 
Dale Fajardo EdD, Director of Online Education and the ONE Network at 
the American Academy of Ophthalmology 
Sarah Page MA, E-Learning Project Manager at the American Academy of 
Ophthalmology 
The Ophthalmic News and Education (ONE®) Network is a comprehensive 
educational resource which provides members and subscribers the ability 
to quickly and effectively access relevant clinical information from an ex-
tensive, up-to-date knowledge base. In this presentation we will provide 
an update on the ONE Network, which has recently undergone a major 
redesign and includes many new features designed to help you get to the 
content you need. Included in this presentation will be a demonstration of 
The Resident Hub™, a powerful online tool that ophthalmology residency 
programs use to facilitate, measure and track ophthalmic resident educa-
tion.
3:30 – 5:00 PM
Windows Update: Windows 8, RT and Phone
Jude Brown, Senior Instructor, Digital Acumen, Inc.
See what’s new with Microsoft’s Windows 8, Windows RT and Windows 
Phone. Learn how these three platforms differ but also work together with 
Microsoft SkyDrive to provide seamless access to your files, photos and 
contacts across an array of desktop and mobile devices. See “Blue,” the 
latest version of Windows 8, as well as the Surface tablet and Windows 
Phone in action. Strengths and weaknesses of each will be reviewed, as 
well as how they integrate Microsoft Office, Internet Explorer 10 and the 
new Windows Store for downloadable Apps. Bring your questions.
Sunday, Nov. 17  
9:30 – 11:00 AM
Smartphone Update and Disruptive Technologies
Vinay A Shah MD, Dean McGee Eye Institute, University of Oklahoma
Rohit Krishna MD, University of Missouri - Kansas City
R Ken Lord MD, Retina Associates of Southern Utah 
Learn about smartphone trends and how you can put the mobile power 
of smartphones and tablets to work to simplify your life and maximize 
productivity in your practice. Topics include the current developments in 
the mobile computing industry as well as effective medical and personal 
use Apps such as for clinical reference, education, increasing efficiency 
and practice branding and marketing. The session will conclude with a 
discussion and audience questions.
11:30 AM – 12:00 PM 
Get the Most from the Academy’s Mobile Meeting Guide
Jude Brown, Senior Instructor, Digital Acumen, Inc.
This quick session introduces users to the basics and benefits of using 
the Academy’s powerful Mobile Meeting Guide to help plan and navigate 
the 2013 Annual Meeting. Learn how to sign in, find sessions, create your 
Personal Planner, as well as get an overview of the wealth of content and 
features it contains. Did you know you can view Academy posters and 
videos, fill out course evaluations, take notes and even ask questions live 
during certain sessions through the Mobile Meeting Guide? If not, this 
session is for you! 
12:30 – 2:00 PM 
A Social Media Primer
Jude Brown, Senior Instructor, Digital Acumen, Inc.
LinkedIn, Facebook, Twitter, Google+, Snapchat, Vine…you’ve heard the 
names, but what are they and how does one differ from another? This 
basic session for the Social Media novice will give you a grounding in the 
terms and technologies at the heart of Web 2.0 and have you “tweeting” 
in no time. Tips for checking and protecting your “online reputation” will 
also be reviewed.
2:30 – 3:30 PM *
EHR 101
Colin A McCannel MD FACS, Associate Professor of Clinical 
Ophthalmology, Jules Stein Eye Institute UCLA
David Silverstone MD, Clinical Professor of Ophthalmology, Yale School of 
Medicine
This overview course is intended to familiarize the attendee with the 
implications of adopting an EHR system. A wide range of topics will be 
covered, including characteristics of good EHR systems, selection criteria 
that should be considered, possible impact on the practice and work 
flow, information technology considerations and the importance of EHR 
standards. This course will provide the knowledge framework about EHR 
systems relevant to the purchase, implementation, maintenance and 
utilization of an EHR system.
4:00 – 5:00 PM 
Tele-Ophthalmology Talking Points
Ingrid Zimmer-Galler MD, Associate Professor, Johns Hopkins Wilmer Eye 
Institute
In this session we will review the current state of telemedicine in 
ophthalmology with an emphasis on remote retinal imaging for diabetic 
retinopathy assessment.  We will also discuss current challenges and 
barriers to wide-spread implementation of telemedicine technologies in 
the delivery of ophthalmic care.
Monday, Nov. 18 
9:30 – 10:30 AM
Step-by-Step: Edit Video Like a Pro
Jude Brown, Senior Instructor, Digital Acumen, Inc.
Want to upload professional looking videos to YouTube/Facebook or 
embed them in PowerPoint Presentations?  Learn step-by-step how to 
make the most of inexpensive software to acquire, edit and profession-
ally polish your own videos. Topics include adding transitions, effects and 
mixing music as well as best practices for exporting to other formats. In 
particular, importing video for use in PowerPoint and uploading for sharing 
sites on the web will be demonstrated.
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Monday, Nov. 18 (cont.)
11:00 AM – 12:00 PM *
Using a Fully Integrated DICOM Imaging and EHR system
Jeffrey Marx MD, Chair, Dept of Ophthalmology, Lahey Clinic; Chief 
Medical Officer, Lahey Medical Center Peabody
DICOM is the established medical image formatting standard, allowing 
the EHR to “talk to” the imaging and diagnostic devices in an office net-
work. Tremendous progress has been made in the use of DICOM imaging 
in Ophthalmology, and refinements will assist workflow in ordering, test-
ing, interpreting and billing.  Data extraction from images can be utilized 
for graphing and improving patient care. Dr. Marx will describe how his 
integrated DICOM imaging and EHR system has improved the quality of 
patient care and the efficiency of his practice.  
12:30 – 1:30 PM
Introducing the Academy’s IRIS™ Registry:  How to Meet 
Regulatory Requirements for Quality Measures
William L Rich III MD Medical Director of Health Policy, American 
Academy of Ophthalmology and Senior Partner, Northern Virginia 
Ophthalmology Associates
The Academy is launching the IRIS™ Registry, an EHR-based approach to 
collecting data that can be used for quality improvement, qualification for 
PQRS incentives or avoidance of penalty, and qualification for one menu 
measure in the Meaningful Use incentives for EHR usage. This presenta-
tion will explain how the registry works through systems integration with 
your EHR, and how it can bring value to participants.
2:00 – 3:30 PM
Mobile Computing Update
Darwin J Liao MD MPH
Learn about the latest trends in hardware and software in Mobile 
Computing. Will the popular iOS, Android and Windows Mobile platforms 
be threatened or complemented by the emerging category of over-
sized phone tablets (“phablets”) or wearable electronics embedded in 
eyeglasses and watches? Included will be a discussion of general and 
healthcare-specific software solutions, as well as highlights of the latest 
version of Apple’s popular iOS for iPhones and iPads.
4:00 – 5:00 PM
Social Media Influences the Doctor-Patient Relationship
Andrew Doan MD PhD; Deputy Editor, AAO ONE Network
With smart phones, computers and world-wide Internet connectivity, pa-
tients are “Googling” individual doctors 30 to 100 times daily on average. 
The Internet search results they see influence what and how the patients 
feel about their doctors. In this session, Dr. Doan discusses high-yield tips 
for physicians to help improve their patient-doctor relationship using the 
Internet.
Tuesday, Nov. 19  
9:30 – 10:30 AM 
Internet Privacy and Wireless Security Best Practices
Jonathon Santilli, Senior Network Engineer, Digital Acumen, Inc.
You can connect to your email, the web or your office EHR anywhere with 
a Wi-Fi hotspot, including your home or local Starbucks, but who might 
be eavesdropping on your private communication and what steps can 
you take to protect your wireless connections? This session will review 
best-practice procedures you can use to secure your email and network 
connections when you roam, how to set up a secure “Virtual Private 
Network” (VPN) between home and office and what questions you should 
ask your IT department at work to minimize the chances of someone 
intercepting your private information.
11:00 AM – 12:30 PM
Microsoft Windows/Office: Ask the Expert 
Jude Brown, Senior Instructor, Digital Acumen, Inc.
This custom-tailored, interactive session provides an audience-driven 
overview of the Windows Operating Systems, Office 365, Office 2013 
and Video Editing.  Ask our expert any questions that remain unanswered 
after the other overview sessions or about solving a particular problem 
you have had using Windows or Office tools in the past.
255Academy staff are available at the Academy Resource Center, Hall G, Booth 3239, to answer any questions you may have.
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Informational Posters
Saturday – Tuesday, Nov. 16 - 19
Hall I1, Booth 5113
View Informational Posters during exhibit hall hours presented by organizations that serve allied health 
and ophthalmological societies as well as the visually impaired.
Informational Posters
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Poster 1
Mahatme Eye Bank & Hospital
Offers hands on surgical training courses and International Council 
of Ophthalmology fellowships. 
Poster 2
Mission Cataract USA 
Encourages and assists ophthalmologists to provide free cataract 
surgery to the poor and uninsured in their community.
Poster 3
The Glaucoma Foundation
Presenting groundbreaking research funded by the Foundation.
Poster 4
American Society of Ocularists (ASO)
Presenting conditions requiring prosthetic eyes and scleral shells. 
Handouts available.
Poster 5
LIGA International
Presenting information about the Eye Clinic in El Furete, Mexico.
Poster 6
Lighthouse for Christ Mission and Eye Centre
A mission eye hospital in Mombasa, Kenya seeking short-term 
volunteer ophthalmologists to serve 1-2 weeks throughout the year.
Poster 7
Himalayan Cataract Project
Presenting programmatic efforts in Asia and Sub-Saharan Africa to 
eradicate preventable and treatable blindness.
Poster 8
Chinese American Ophthalmological Society, Inc.
Advances medical knowledge, research and assists in the training of 
ophthalmologists of Chinese descent.
Poster 9
Vision Health International
Delivers vision health care services–free of charge–to the medically 
underserved in Latin America.
Poster 10
Volunteer Eye Surgeons International
Sends eye surgeons and paramedical personnel to developing 
countries where they teach the latest surgical techniques to local 
eye surgeons.
Poster 11
Pediatric Keratoplasty Association
Disseminates information on the clinical management of corneal 
diseases in infants and children.
Poster 12
The Sturge-Weber Foundation
Sturge Weber syndrome Gene Mutation identified! Clinical and 
scientific materials on display for patients and healthcare providers.
Poster 13
Eye Foundation of America Inc.
Combating preventable blindness through service, education, and 
research.
Poster 14
World Cataract Foundation
Working to eliminate cataract blindness in the developing world 
through surgery, training and providing equipment.
Poster 15
Christian Ophthalmology Society
Describes the organization’s mission and activities.
Poster 16
International Eye Foundation
Promotes increasing affordability and access to quality, comprehen-
sive and sustainable eye care services around the world.
Poster 17
International Eye Foundation
Shares information on SightReach Surgical, a social enterprise 
program to reduce the cost of eye care.
Poster 18
Centro Cristiano de Servicios  
Humanitarios de Honduras (CCSHH)
A full service eye clinic located in El Progreso, established to serve 
the indigent, welcomes volunteer medical personnel to assist our 
permanent staff.
Poster 19
International Symposium on Ocular Pharmacology and 
Therapeutics (ISOPT)
Find the latest updates on treatments of ocular diseases at ISOPT 
2014, June 19-22 in Reykjavik, Iceland.
Poster 20
New Mexico Eye Injury Registry
Reports on traumatic eye injuries and compares the data for New 
Mexico to that of the entire United States.
Poster 21
International Eye Clinic
Promotes healthy vision through public education and establishment 
of eye care centers in underdeveloped communities.
Poster 22
Retinitis Pigmentosa International
Established to find and fund the cure for Retinitis Pigmentosa and 
related degenerative eye diseases.
Poster 23
American Foundation for the Blind
Find helpful, downloadable tips to help your patients cope with 
vision loss at visionaware.org/getting started.
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WHERE ALL OF OPHTHALMOLOGY MEETS
AAOE Program / Practice Management
AAOE Program
Saturday – Tuesday, Nov. 16 - 19
AAOE Program: Rooms 285 -297
Locations: All rooms are in Morial Convention Center unless other-
wise indicated.
The AAOE Program is the most comprehensive practice manage-
ment program, with over 100 courses to choose from, including a 
new physician/administrator collaboration track. 
Academy Plus Course Pass
All AAOE instruction courses are part of the Academy Plus course 
pass. Academy Plus offers maximum convenience, with unlimited 
access to all Academy and AAOE instruction courses. Individual 
tickets for Academy and AAOE instruction courses will no longer be 
sold. 
Note: Due to Fire Marshal regulations, seating capacities are 
limited. Seating is available on a first-come basis, so please plan 
accordingly.
Network 
AAOE Member Lounge, Room 298
Saturday, 8:00 AM – 3:30 PM
Sunday, 9:30 AM – 5:00 PM
Monday, 8:30 AM – 5:30 PM
Tuesday, 8:30 AM – 2:00 PM
Not yet a member? Join AAOE at a discounted rate during the Meet-
ing by visiting the Academy Resource Center, Hall G, Booth 3239.
AAOE General Session
SPE09, Sunday, Nov. 17
10:00 AM - 12:00 PM
Room 291
“Creating the Ultimate Patient Experience” promises to excite and 
invigorate while sharing strategies to ensure that your practice is 
the most prominent and well regarded BRAND in your area. 
Sponsored by Genentech and ALCON, INC.
Member Appreciation Reception
Sunday, Nov. 17
6:00 PM - 7:30 PM
Loews New Orleans Hotel
The AAOE Member Appreciation Reception is open exclusively to 
AAOE members and their guests.
Sponsored by ALCON, INC.
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide con-
tinuing medical education for physicians.
AAOE Program /
Practice Managment
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The following coding sessions take place concurrently with the Academy’s Annual Meeting as part of the AAOE program. These intensive sessions 
enhance participants’ knowledge of appropriate coding and documentation in order to receive proper reimbursement. Separate registration is 
required to attend these events, they are not included in the Academy Plus course pass. Members and nonmembers can register for the AAOE Coding 
sessions without registering for the 2013 Annual Meeting.
 C   J  Conquering ICD-10-CM for Ophthalmology
Instructor(s): Elizabeth Cottle CPC OCS, Raj Rathod MD MBA, Sue Vic-
chrilli COT OCS, Joy Woodke COE OCS
Prepare for ICD-10, the biggest change happening to coding in over 30 
years. This three-hour interactive course will address what practices 
must know in order get paid timely and correctly starting Oct. 1, 2014. 
Topics include: ICD-10 terminology and guidelines for usage, what 
administrators must know, what technicians must do, what coders and 
billers must know and implement and what physicians cannot delegate. 
The course will present in-depth case studies across all subspecialties.
Time: 8:00 - 11:00 AM
Fee: $340
ICD-10-CM for Ophthalmology book included with registration.
 C   J  Coding Camp
Offered in collaboration with the Annual Commission on Allied Health 
Personnel in Ophthalmology (JCAHPO)
Moderator: Sue Vicchrilli COT OCS
Instructor(s):  Elizabeth Cottle CPC OCS, Stephen Kamenetzky MD OCS, 
Michael X Repka MD MBA OCS, Joy Woodke COE OCS
Sharpen your coding and documentation skills while boosting your coding 
confidence at this three-hour intermediate/advanced course. Learn 
to receive proper reimbursement for all the claims you submit. Topics 
include modifier application to optimize reimbursement, the ten most 
common testing service denials, the 10 most common surgical denials 
and tips to successfully navigate federal and commercial payer audits.
Time: Time: 12:30 - 3:30 PM
Fee: $280
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical 
education for physicians.
Saturday, Nov. 16
Room 293
 C  American Academy of Professional Coders
 J  JCAHPO
AAOE Coding Sessions
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Ambulatory Surgery Centers
 A  Ophthalmic ASC Administration, Operations and 
Procedures
Course: 193 Sunday
Room: 290 2:00 - 3:00 PM
Education Level: INT Target Audience: ALL
Synopsis: This course will provide an overview of core competencies and essential 
tools and resources for running the ophthalmic ASC. As costs continue to go up, the ASC 
owner needs to know how to manage all costs and revenues to survive and thrive in the 
competitive health care markets of the 21st century.
Objective: To provide ASC managers with helpful tools to improve performance in a 
hands-on introduction to the process of reviewing operations of the ASC.
Senior Instructor(s): Kent L Jackson**
Presenter(s): Louis Sheffler MPS, Maria Tietjen BSN, and Carl Desch MBA
 A  How to Develop a Successful Ophthalmic Ambulatory 
Surgery Center
Course: 519 Tuesday
Room: 290 9:00 - 10:00 AM
Education Level: INT Target Audience: ADMIN
Synopsis: This course will show from A to Z the difficulties of developing a successful 
ophthalmic ASC. It will discuss the various development options and pitfalls to avoid. 
Everything from revenue generation to the costs of rent, equipment, staffing, supplies, 
and other expenses will be covered. The pearls garnered in helping develop over 350 
ASCs will be thoroughly discussed. Because the ASC industry including allowable proce-
dures, CMS payments, architectural requirements, and morei s constantly changing, this 
presentation changes from year to year.
Objective: By the conclusion of this course, attendees will be able to independently 
develop their own strategic ASC business plan. This business plan will allow attendees 
to determine the feasibility of adding an ASC to their own practice. This course will help 
attendees navigate the rocky waters between them and a successful ophthalmic ASC.
Senior Instructor(s): John A Marasco*
 A  ASC Benchmarking
Course: 546 Tuesday
Room: 290 10:15 - 11:15 AM
Education Level: INT Target Audience: ALL
Synopsis: This course will provide an overview of benchmarking for the ophthalmic 
ASC, including a brief history, reasons for benchmarking, processes involved, and high-
lights from the 2013 Outpatient Ophthalmic Surgery Society Benchmarking Survey, in-
cluding instructions for participation. Presenters will introduce examples based on case 
studies and engage the audience in hands-on discussion of how to gather and apply key 
benchmarks to their facilities.
Objective: To provide ASC staff with a compelling rationale for benchmarking and a 
hands-on introduction to the process.
Senior Instructor(s): Kent L Jackson**
Instructor(s): Maureen Waddle MBA*, Albert Castillo
Business Operations & Finance
 NEW   SO   A  Top 10 Topics Ophthalmology Practices Ask Us 
About
Course: 173 Sunday
Room: 286 2:00 - 3:00 PM
Education Level: BAS Target Audience: ALL
Synopsis: This course will review and discuss the 10 most relevant topics presented 
to us by our ophthalmology clients from around the country throughout the year prior 
to the meeting. The course will cover an assortment of questions and issues spanning 
business, practice management, tax, and legal issues that are certain to be relevant to 
ophthalmology practices of all sizes. Attendees will learn about the variety of questions 
and issues confronting other ophthalmology practices, and recommendations for how to 
handle them, from experienced attorneys / consultants with more than 50 years com-
bined experience working with ophthalmology practices. By covering a wide range of 
different topics that have been actually presented to us by our ophthalmology clients, at-
tendees will gain knowledge and understanding of the business, practice management, 
tax, and legal issues that can arise in an ophthalmology practice on a day-to-day basis.
Senior Instructor(s): Mark E Kropiewnicki JD LLM*
Instructor(s): Daniel M Bernick JD*
 NEW   A  Internal Financial Controls for the Small Practice
Course: 194 Sunday
Room: 296 2:00 - 3:00 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: Internal financial controls prevent or detect errors, safeguard assets (espe-
cially cash) from being misappropriated, and encourage staff adherence to prescribed 
managerial policies. Frequently, controls are not implemented because they are per-
ceived as time consuming or as indicating management’s mistrust of the staff. On the 
contrary, internal controls allow management to monitor process, rather than employees, 
which is more secure and efficient and actually increases trust of the staff. They prevent 
or detect errors and efforts to circumvent the established policies and procedures of the 
organization.
Objective: Understanding the risks that arise when sufficient controls are not in place 
will help administrators to understand that controls critical to the health of a practice are 
often very straightforward to implement.
Senior Instructor(s): Andrew Wang
 YO   A  Doctors and Administrators: Working Together to 
Make Sound Financial Decisions
Course: 195 Sunday
Room: 288 2:00 - 4:15 PM
Education Level: INT Target Audience: ALL
Synopsis: The dramatic changes in healthcare that are affecting ophthalmology prac-
tices make financial decisions more critical than ever. This course is designed to help 
doctors and administrators work together more effectively as they make major financial 
decisions. Discussion and case studies will focus on both capital investment and op-
erational expense decisions and will address the tension between clinical needs and 
financial realities.
Senior Instructor(s): Derek A Preece MBA*
Instructor(s): Robert E Wiggins MD MHA*
 SO   A  How to Monitor and Maintain an Efficient Practice
Course: 211 Sunday
Room: 294 3:15 - 4:15 PM
Education Level: INT Target Audience: ALL
Synopsis: This course will provide examples of how to evaluate practice efficiency 
in models that all size/sub-specialty practices should benefit from. These models will 
be demonstrated by a Physician and his administrator. Concepts will include: review 
of RVU’s, general productivity utilizing RVU’s/pt counts, staffing allocation, monitoring 
growth, identifying practice’s own benchmarks.
Objective: To provide practices with formulas and tools to measure doctor’s efficiency 
in relation to staffing productivity.
Senior Instructor(s): Steven V L Brown MD*
Instructor(s): Nicole E Kesten OCS
 NEW   A  Strategic Planning by Fact
Course: 212 Sunday
Room: 293 3:15 - 4:15 PM
Education Level: INT Target Audience: ALL
Synopsis: Many practices struggle when assessing practice growth opportunities be-
cause they have little upon which to base their decisions, other than their impressions. 
Today’s digital society has amassed information that can inform decisions, for those who 
know where to find it.
AAOE Instruction Courses
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Objective: Participants will learn what information is available within their practice 
and from outside sources, and how to use that information to inform practice develop-
ment. They will come away with an understanding of data sources, key demographic 
characteristics and ratios, and mapping techniques to visualize the information.
Senior Instructor(s): Michael J Parshall*
 YO   A  Financial Analysis and Reporting
Course: 225 Sunday
Room: 283 4:30 - 5:30 PM
Education Level: INT Target Audience: ALL
Synopsis: This course is designed to provide tools and techniques for prospectively and 
retrospectively analyzing an ophthalmology practice’s financial performance.
Objective: By the conclusion of this course, attendees should be able to (1) describe 
the range of analyses to be done, (2) present the methodologies for each analysis, (3) 
present the reporting for each analysis, (4) provide the tools for the methodologies to be 
applied to other analyses, and (5) describe the actions to be taken based on the results 
of the analyses.
Senior Instructor(s): Ron Rosenberg PA MPH*
 NEW   A  Financial Benchmarking for the Retina Practice
Course: 230 Sunday
Room: 296 4:30 - 5:30 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: This course will highlight the numerous changes and trends in retina prac-
tices over the last few years as they relate to the financial health of the practice. This 
course will also serve as an introduction to financial benchmarking for the retina special-
ist, including recommendations and healthy ranges for what specific productivity and ef-
ficiency ratios to track. Case studies will be used throughout the presentation to provide 
real-world examples to attendees.
Objective: At the conclusion of this course, the attendee will be able to (1) define 
benchmarking and understand how to use healthy ranges to set goals for practices, (2) 
understand how the evolution of retina practices in recent years has increased the need 
for organizations to regularly analyze their benchmarking results, (3) have a working 
knowledge of how current and future market trends will impact retina practices, and (4) 
use benchmarking results to create goals and action plans to foster practice improve-
ment.
Senior Instructor(s): Andrew Maller MBA*
 YO   A  Ophthalmology Practice Buy-In and Pay-Out 
Arrangements
Course: 236 Sunday
Room: 294 4:30 - 5:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: Learn how to structure fair and reasonable financial, legal, and practical 
arrangements for ophthalmology practice buy-ins and pay-outs from attorneys consul-
tants who have more than 50 collective years of experience and have done thousands 
of practice buy-ins and pay-outs. This course will describe and explain appropriate buy-
in arrangements for associates as well as customary pay-out arrangements for owners 
leaving a practice. This course will cover the valuation and goodwill of an ophthalmology 
practice as well as the factors affecting the entry or exit of an ophthalmologist from a 
practice.
Objective: By the conclusion of this course, participants will learn how to structure 
buy-in pay-out arrangements that are fair and reasonable both to practice owners and 
to joining or departing ophthalmologists. Participants will also gain an understanding of 
ophthalmology practice values and learn about the practical considerations, limitations, 
and protections needed when establishing buy-in pay-out arrangements.
Senior Instructor(s): Mark E Kropiewnicki JD LLM*
Instructor(s): Daniel M Bernick JD*
 NEW   A  Creating a Clinical Trial Unit
Course: 303 Monday
Room: 297 9:00 - 10:00 AM
Education Level: BAS Target Audience: ALL
Synopsis: The attendees at this course will have an understanding of what it takes to 
create and manage a clinical trial unit within the physician office or as part of a hospital, 
heath system, or institution. The materials will include the necessary parties and their 
roles, delineation of responsibilities, negotiating the clinical trial agreement including 
the budget, getting through institutional review board and informed consent issues, en-
rollment of study subjects, reporting of adverse events, completing an analysis of third 
party payer billing requirements and policies for study subjects, and monitoring the study 
through its conclusion.
Objective: At the conclusion of this course, attendees will know what they need to 
create a clinical trial unit, negotiate a clinical trial agreement and budget, and manage 
the study to its conclusion.
Senior Instructor(s): Brenda Laigaie JD
 NEW   A  Advanced Ophthalmology Billing
Course: 317 Monday
Room: 296 9:00 - 10:00 AM
Education Level: INT Target Audience: ALL
Synopsis: This course will provide the tools and techniques to move billing and collec-
tion performance from acceptable to outstanding.
Objective: At the completion of the course, attendees will have the knowledge and 
tools to (1) achieve optimal collection performance, (2) successfully appeal denied 
claims, (3) manage the administration of insurance contracts, (4) keep up to date on cod-
ing changes, including procedures, diagnoses, modifiers, Correct Coding Initiative, and 
frequency filters, (5) use the most advantageous coding for maximum reimbursement, (6) 
manage physician behavior on coding and documentation, (7) ensure that all services are 
captured as charges, and (8) manage staff performance.
Senior Instructor(s): Ron Rosenberg PA MPH*
Instructor(s): Donna Connolly*
 SO   A  Securing Access in the Age of ACOs
Course: 324 Monday
Room: 286 9:00 - 10:00 AM
Education Level: INT Target Audience: ALL
Synopsis: Access to our current and future patients will become more complex. Oph-
thalmology groups must collaborate with payers, ACOs and other health systems. At-
tendees to this course will learn how to identify sources of referrals and strategies to 
continue and/or create new referrals sources. Attendees will learn how to position an 
ophthalmology practice to remain independent while participating in ACOs. The risks for 
an ophthalmology practice in an era of powerful, large integrated health systems will be 
discussed. Finally, some tips for cultivating mediation skills will be presented. The format 
of the course will be interactive and discussion will be encouraged.
Senior Instructor(s): Ruth D Williams MD
Instructor(s): David B Dopp**
 NEW   A  Key Performance Indicators: Numbers Can Lie
Course: 327 Monday
Room: 283 9:00 - 10:00 AM
Education Level: INT Target Audience: ADMIN
Synopsis: Using information from real practices, this course will describe (1) the key 
practice performance and financial indicators that every practice owner or administrator 
should understand, (2) how these indicators should be tracked / monitored, (3) how to use 
the benchmarks to improve performance, (4) how to compare an individual practice with 
others, (5) how numbers (benchmarks) can be misleading and lead to the wrong manage-
ment decisions, and (6) how to avoid the pitfalls of misleading benchmarks.
Objective: By the conclusion of this course, attendees will be able to (1) use key perfor-
mance indicators, such as profit margin, return on equity, facilities expense ratio, practice 
expense ratio, etc., to make management decisions, (2) use “healthy ranges” for each 
benchmark and compare themselves to these “healthy ranges” (4) use key performance 
indicators to improve their practices, spot problem areas, and create strategic plans, 
and (5) avoid being misled into poor decisions (or into making no decision) by “following 
misleading numbers.”
Senior Instructor(s): Jeff Grant*
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 NEW   A  Budgeting for the Ophthalmology Practice
Course: 329 Monday
Room: 294 9:00 - 10:00 AM
Education Level: BAS Target Audience: ADMIN
Synopsis: This course will provide a practical and simple approach for implementing a 
practice budget. Specific methods will be introduced related to examining historical and 
current results, assessing future changes in the practice, forecasting future results, and 
integrating the results with financial reporting efforts.
Objective: At the conclusion of this course, the attendee will be able to (1) understand 
the process of budgeting and how to get started, (2) use current practice results to ac-
curately predict future performance, (3) perform a thorough review of practice goals and 
initiatives for the coming year that will assist in forecasting results, and (4) integrate bud-
get results into comparative monthly and annual management and benchmarking reports.
Senior Instructor(s): Andrew Maller MBA*
 A  Income Division for Group Practices: Structuring 
Appropriate Physician Compensation Arrangements
Course: 338 Monday
Room: 296 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: This course will explore different models for dividing income in a group prac-
tice, with emphasis on creating incentives, responses to incentives, legal and regulatory 
concerns, and modeling different structures. A case study will be employed to illustrate 
the process.
Objective: To provide an understanding of the variety of income division models avail-
able to choose from, the equities of each and their legal and regulatory concerns (Stark 
fraud and abuse), and the process of developing the right model for one’s group.
Senior Instructor(s): Robert J Landau JD
Instructor(s): Robert A Wade JD
 NEW   A  Strategic Planning for Ophthalmology Practices
Course: 342 Monday
Room: 294 10:15 - 11:15 AM
Education Level: BAS Target Audience: ALL
Synopsis: Many factors are combining to make the future more perilous for ophthalmol-
ogy practices while at the same time opening up new opportunities. Proper decision mak-
ing is paramount for success. This course will describe the basic elements of strategic 
planning in order to help ophthalmologists and administrators plan for the future. It will 
explain the differences between objectives, strategies, and tactics and how to use them 
to position your practice for the future. SWOT analysis (Strengths, Weaknesses, Oppor-
tunities, and Threats) and PERT analysis (Program Evaluation and Review Technique) will 
be discussed. A real-life example will be used to describe some of the challenges faced 
and opportunities available.
Objective: At the conclusion of this course, attendees will be able to understand the 
steps involved in ordered decision making along with how to perform SWOT and PERT 
analysis. They will be able to apply these concepts to develop practice goals and properly 
position themselves in their local market.
Senior Instructor(s): Peter Wasserman MD*
 NEW   A  Step 1 to Running on Time: Scheduling
Course: 343 Monday
Room: 291 10:15 - 11:15 AM
Education Level: INT Target Audience: ADMIN
Synopsis: This course will look at historic methods for scheduling and make recom-
mendations for scheduling by type. We will review the steps of conducting a thorough 
evaluation of doctor and patient behavior patterns. Examples of time flow studies and 
how they are used to develop scheduling systems will be reviewed. Duel scheduling in 
order to manage tech and equipment resources will also be discussed.  Sample schedul-
ing templates will be discussed and set up during the course.
Objective: Upon completion of this course, attendees will be able to: 1) Understand 
“type” scheduling, 2) Understand time-flow studies and how to use them in creating a 
schedule, 3) Based on the examples, create appointment types for their own practice, 4) 
Account for emergencies and no show rates, and 5) Set up a variety of schedules to meet 
patient and doctor demands.
Senior Instructor(s): Maureen Waddle MBA*
 A  Going Lean: Tools for Efficiency and Effectiveness in the 
Ophthalmology Practice
Course: 345 Monday
Room: 283 10:15 - 11:15 AM
Education Level: INT Target Audience: ALL
Synopsis: Concerns about health care quality and cost have moved to the forefront in 
discussions on the evolution of the U.S. health care system. It is no longer a question 
of whether health care organizations should focus on these issues, but rather how to 
do so in order to ensure their survival. The purpose of this course is to expand on the 
lean approach to quality improvement and efficiency, which has been introduced in prior 
courses. Specific examples will be given that can be applied to the attendees’ practices 
to reduce waste and that will demonstrate the value of this methodology in improving 
both quality and efficiency.
Objective: At the conclusion of this course, the participant should have an understand-
ing of Lean Healthcare and of tools that can be applied in an ophthalmology practice to 
improve both quality and efficiency.
Senior Instructor(s): Robert E Wiggins MD MHA*
Instructor(s): Denise C Fridl COT COE, Susie Winterling
 A  Tracking Your Dollars: Financial Policies to Avoid Fraud 
and Embezzlement
Course: 346 Monday
Room: 293 11:30 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: In times of increasing costs and decreasing reimbursement, it is crucial that 
physician owners and administrators keep a finger on the pulse of practice finances. 
This course will share a financial policy written to help physicians, administrators, and 
staff in understanding, monitoring, and following all the various financial flows in today’s 
practices.
Objective: Upon completion of this course, the participants will understand the revenue 
cycle process of an ophthalmic practice, have the tools and knowledge to write their own 
financial policies, and have an understanding and knowledge of what is important in 
making financial information transparent, available, and understandable.
Senior Instructor(s): Albert Castillo
 NEW   A  Yes, It Can be Done ... Creating a Workable Master 
Schedule
Course: 383 Monday
Room: 296 2:00 - 3:00 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: This course will examine the elements to be considered when creating or 
changing a master schedule template. The areas to address are space, staff, and other 
fixed and variable resources.
Objective: At the conclusion of this course, the attendee should be able to (1) list the 
major considerations for building an ophthalmic schedule, (2) discuss the relationship 
between clinical staffing and patient load, (3) discuss diagnostic testing as it pertains to 
schedule creation, and (4) explain the impact of multiple providers, scheduled simultane-
ously, on patient flow.
Senior Instructor(s): Jane T Shuman COE COT MSM OCS*
Instructor(s): Jeri R Screnci MBA
 NEW   A  The Art of Benchmarking
Course: 384 Monday
Room: 295 2:00 - 3:00 PM
Education Level: INT Target Audience: ADMIN
Synopsis: This course will review the most commonly used national benchmarks and 
their formulas. The course will focus on making practical use of the information to im-
prove your individual practice. Case studies will be used to help sharpen analytical skills 
and understand the importance of customizing benchmark reports for your practice.
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Objective: At the conclusion of this course, the attendee will be able to (1) calculate 
financial, productivity, and staffing benchmarks, (2) use benchmarking information to 
identify opportunities, (3) recognize potential pitfalls in looking at benchmarking data, 
and (4) create goals and action plans to improve practice performance.
Senior Instructor(s): Maureen Waddle MBA*
 A  How to Run a Lean, Mean Refractive Practice in Today’s 
Tough Economic Times
Course: 385 Monday
Room: 297 2:00 - 3:00 PM
Education Level: INT Target Audience: ALL
Synopsis: In this course you will learn whether to buy your own equipment or take ad-
vantage of the lease options available. You will learn how to price yourself in the market-
place today. We will discuss what your retained earnings after market share calculation 
should be. We will discuss what you should be paying for your full-time equivalents. You 
will find out if you are competitive in the marketplace.
Objective: This course will help you to (1) make sure your practice is competitive, (2) 
make sure you are getting the most profit you can out of your refractive practice, and (3) 
make sure you are making the right business decisions.
Senior Instructor(s): Michael D Brown*
 NEW   A  Capital Budgeting Basics: Can I Afford This New 
Piece of Equipment?
Course: 391 Monday
Room: 293 2:00 - 3:00 PM
Education Level: INT Target Audience: ALL
Synopsis: Capital investment decisions are among the most important financial deci-
sions in which a practice administrator will participate. Whether the purchase under 
consideration is an OCT, femtosecond laser, or electronic health records system, a capital 
budget should be developed. This course will introduce the participant to the basic con-
cepts necessary to understand and develop a capital budget and analyze the profitability 
and break-even point for any expensive equipment purchase. Examples of how this infor-
mation can be used in an ophthalmology practice will be presented.
Objective: At the conclusion of this course, each participant will be able to conduct and 
understand a capital budget analysis prior to the purchase of a major piece of equipment. 
The participant will be able to state the benefits and limitations of such an analysis and 
understand the key factors that impact the profitability of a new piece of equipment in 
his or her own organization.
Senior Instructor(s): Robert E Wiggins MD MHA*
Large Practice Executive Forum
Course: 397 Monday
Room: 293 3:15 - 5:30 PM
Education Level: INT Target Audience: ALL
Synopsis: Managing a practice with ten or more doctors presents unique challenges 
not shared by those from smaller practices. In this informal and interactive discussion, 
you will have the opportunity to share your challenges and insights with participants 
from other large practices. Attend this workshop and come away with new ideas to 
solve your HR, patient flow, optical, ASC, EMR, satellite offices, financial management, 
or other practice challenges. Seating is limited.
Senior Instructor(s): Tim Couch
 A  Getting Clean Data: Practice Management Software 
Setup
Course: 400 Monday
Room: 295 3:15 - 4:15 PM
Education Level: INT Target Audience: ALL
Synopsis: This course will provide tools and techniques for setting up practice manage-
ment software to enable accurate and cogent management reporting.
Objective: By the conclusion of this course, attendees will learn to (1) establish the fee 
schedule, (2) develop the procedure table, (3) develop the insurance tables, (4) categorize 
insurances into classes, (5) develop a set of journal codes, and (6) design management 
reports.
Senior Instructor(s): Ron Rosenberg PA MPH*
 NEW   A  Step 1 to Running on Time: Scheduling
Course: 419 Monday
Room: 286 4:30 - 5:30 PM
Education Level: INT Target Audience: ADMIN
Synopsis: This course will look at historic methods for scheduling and make recom-
mendations for scheduling by type. We will review the steps of conducting a thorough 
evaluation of doctor and patient behavior patterns. Examples of time-flow studies and 
how they are used to develop scheduling systems will be reviewed. Duel scheduling in 
order to manage tech and equipment resources will also be discussed. Sample schedul-
ing templates will be discussed and set up during the course.
Objective: Upon completion of this course, attendees will be able to (1) understand 
“type” scheduling, (2) understand time-flow studies and how to use them in creating a 
schedule, (3) based on the examples, create appointment types for their own practices, 
(4) account for emergencies and no show rates, and (5) set up a variety of schedules to 
meet patient and doctor demands.
Senior Instructor(s): Maureen Waddle MBA*
 NEW   A  Big Practice Problems: What the Experts 
Recommend
Course: 502 Tuesday
Room: 295 9:00 - 11:15 AM
Education Level: INT Target Audience: ALL
Synopsis: This course will cover many areas of concern in a medical practice. We will 
talk about staffing, overhead, expenses, collections, number of work hours per week, 
managed care contracts, etc. We will involve the audience and ask for specific problems 
they have in their offices. We will cover standard protocol and what your office policies 
should be. We will give recommendations on how to negotiate with third-party carriers.
Objective: Attendees will get to see what their office problems are compared to other 
offices. We will show you how to alleviate or reduce your problem areas. We will give 
you guidelines to put in place in your practice to make sure it is successful.
Senior Instructor(s): Michael D Brown*
 A  Tools and Tips to Build a Budget for a Dynamic Practice
Course: 528 Tuesday
Room: 283 9:00 - 10:00 AM
Education Level: BAS Target Audience: ALL
Synopsis: With continual changes in the health care climate, medical practices need 
to develop more effective business practices. Planning and developing a budget is one 
way to develop strong financial controls within your organization. We will look at key 
elements of budget development and budget control, with an eye to meeting the plan 
and goals of the practice. Participants will be introduced to new ways to use benchmarks 
in budget development and maintenance. The presentation will examine the budget in 
terms of how it can help with the effects of growth and expansion opportunities.
Objective: The goal of this presentation is to enable practices to transform the budget 
planning cycle into an evolutionary process, bringing both intangible and tangible returns 
to the organization and allowing management leadership to own the results of the bud-
geting process. Concepts and ideas of the presentation are designed to help practices 
building their first budget as well as groups looking to evolve their current budget.
Senior Instructor(s): Mark S O’Conner MBA
 NEW   YO   A  Billing for Beginners
Course: 529 Tuesday
Room: 296 9:00 - 10:00 AM
Education Level: BAS Target Audience: ALL
Synopsis: This course will introduce physicians and administrators without any billing 
experience to the essential concepts of billing for ophthalmology services.
Objective: At the completion of this course, attendees will (1) know what components 
must to be in place to bill and receive payments, (2) have a basic understanding of the 
components, and (3) know what resources are available to gain in-depth knowledge of 
each component.
Senior Instructor(s): Ron Rosenberg PA MPH*
Instructor(s): Donna Connolly* 
CANCELED
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 A  Optimizing Patient and Staff Efficiency and Satisfaction 
Through Facility Design
Course: 535 Tuesday
Room: 286 10:15 - 11:15 AM
Education Level: BAS Target Audience: ADMIN
Synopsis: This course will show how to best address the key services of clinic, optical, 
laser vision correction, and ambulatory surgery in a state-of-the-art ophthalmic facility. 
Design methodologies that enhance patient and staff efficiency and satisfaction will be 
discussed in detail. The course will also show how to best incorporate key subspecialties 
like pediatrics, retina, oculoplastics, and even hearing services.
Objective: By the conclusion of this course, attendees will understand the design 
implications of combining the typical services present in a state-of-the-art full-service 
ophthalmic center. The attendees will be able to recognize and appropriately address 
various design environments that should be present in any well-organized ophthalmic 
facility, new or old. These methodologies will help attendees improve their patient and 
staff efficiency and satisfaction. The pearls of over 30 years of ophthalmic center design 
development will be discussed.
Senior Instructor(s): John A Marasco*
 A  Let’s Make a (Practice) Deal: A Step-by-Step Approach
Course: 545 Tuesday
Room: 297 10:15 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: Many ophthalmologists fail to sell their practices because they do not know 
how to correctly go about a practice sale, or because they believe there are no buyers. 
This course teaches a proven method developed over 20 years that has resulted in many 
practice sales.
Objective: At the conclusion of this course, participants will understand the process 
involved in successful practice sales, what information to provide, how to attract quali-
fied buyers, buyers’ motivations and fears, valuation methods, and the different types of 
transactions. They will come away with an understanding of common terms and condi-
tions, negotiation tactics, and most importantly, what to say and what not say to bring 
a sale to closure.
Senior Instructor(s): Michael J Parshall*
 NEW   SO   A  Valuing, Buying, Selling, and Transitioning 
Your Practice
Course: 558 Tuesday
Room: 286 11:30 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: Considering retirement? Selling or wanting to buy a practice? Making such 
a transition requires planning and sufficient time to accomplish this effectively for your 
patients, staff, and family. Learn creative strategies to help you accomplish your goals. 
This seminar will discuss the options, including bringing in an associate, recruiting, or 
selling the practice. Also included will be the latest information on valuation methodol-
ogy for selling, divorce, or estate planning.
Senior Instructor(s): Debra L Phairas
 A  Financial Decision Making in the Eye Care Practice
Course: 567 Tuesday
Room: 290 11:30 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: In this course attendees will have a chance to see accounting basics, ration 
analysis and benchmarking, overhead and expense management, cost analysis and con-
tracting and accounts receivable management. We will cover the different accounting 
methods. Critical financial statements will be discussed. We will cover benchmarks for 
your practice. This course will cover all of the financial areas of your practice to help you 
run as lean, mean, and effective as possible.
Objective: This course is designed to help you (1) obtain benchmarks and ratios to com-
pare your practice to other practices, (2) make sure you are operating efficiently and 
effectively, (3) ensure you understand your financial statements, (4) make sure your ac-
counts receivables are where they should be.
Senior Instructor(s): Michael D Brown*
 SO   A  Buying or Selling a Practice: Creating Win-Win 
Transactions
Course: 554 Tuesday
Room: 288 12:45 - 3:00 PM
Education Level: INT Target Audience: ALL
Synopsis: Using some real-life examples (names and some other information changed 
to protect the innocent), this course will present the prospective buyer and seller of a 
practice with a rubric that helps ensure that each gets what they need. The course will 
look at where to find sellers and buyers, how to price a practice, what is included in the 
sale, and the art of negotiating, as well as crafting letters of intent, exclusivity or “no-
shop” clauses, and the salient deal points and legal issues to be covered in a practice 
sale / purchase. Also to be covered are due diligence, financing, post-sale transition, 
employment of the seller, office staff, patient notifications, and restrictive covenants.
Objective: Through lecture and Q&A, participants will learn how to craft “win-win” 
practice sales and purchases.
Senior Instructor(s): Robert A Wade JD
Instructor(s): Mark D Abruzzo JD, Caroline Patterson
Coding & Reimbursement
 C   J   A  Audits: It’s Not a Matter of If, but When
Course: 180 Monday
Room: 288 9:00 - 11:15 AM
Education Level: BAS Target Audience: ALL
Synopsis: Being the subject of an audit is stressful and time consuming for physicians 
and staff. Given the way audits are conducted, both by Medicare Part B as well as all 
other third-party payers, most physicians will be audited by some payer at some time 
during their careers. This course will present real-life audit scenarios of Focus Medi-
cal Review, Comprehensive Error Rate Testing, Recovery Audit Contractors (RACs), Zone 
Physician Integrity Program (ZPIC), and Office of Inspector General (OIG) Investigations.
Objective: Upon completion of this course, the participant should be able to (1) recog-
nize that there are numerous types of audits conducted by all payers as well as govern-
ment agencies, (2) understand the variety of audits to which physicians are subject, and 
(3) learn the steps to take when one receives the request for documentation.
Senior Instructor(s): Sue J Vicchrilli COT OCS
Instructor(s): Stephen A Kamenetzky MD OCS*, Cherie McNett
 NEW   C   J   A  ICD-10-CM: Simplifying the Complex
Course: 238 Sunday
Room: 291 4:30 - 5:30 PM
Education Level: INT Target Audience: ALL
Synopsis: ICD-10-CM represents the largest reorganization of the diagnostic code set 
in its history. On Oct. 1, 2014, we move from approximately 13,000 codes to over 68,000. 
There is an entirely new alpha-numeric code set. The codes have been reorganized, and 
the nomenclature updated. But there is also good news: the underlying basic coding 
principles remain as the foundation of diagnostic coding. This course will (1) provide an 
overview of ICD-10-CM, (2) explore what is new and what is the same as ICD-9-CM, (3) 
review the basic underlying coding principles, and (4) help prepare the way to move from 
ICD-9-CM to ICD-10-CM.
Objective: Upon completion of this course, the attendee will better understand the or-
ganization of ICD-10-CM, its principles, and where it is similar and where it is different 
from ICD-9-CM. The attendee will be better prepared to make a seamless transition into 
ICD-10-CM.
Senior Instructor(s): Gordon Johns MD*
 C   J   A  When to Use E/M and When to Use Eye Codes
Course: 307 Sunday
Room: 283 2:00 - 4:15 PM
Education Level: BAS Target Audience: ALL
Synopsis: When do you bill an E/M, and when do you bill an eye code? Physicians tend 
to code far more exams than tests or surgical procedures, but for the financial success 
of the practice, it is vital to clear up the confusion. This course will explain the rules and 
distinctions. Medical vs. wellness and vision coverage will also be addressed.
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Objective: Upon completion of this course, the participant should be able to (1) distin-
guish the differences between medical, vision, and wellness exam documentation, (2) 
understand Medicare and non-Medicare payer documentation rules, and (3) recognize 
the importance of the chief exam and patient expectations.
Senior Instructor(s): Sue J Vicchrilli COT OCS
Instructor(s): Joy Woodke COE OCS*
 C   J   A  Making the Most With Modifiers
Course: 361 Monday
Room: 288 11:30 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: Understanding modifiers and their appropriate use impacts reimbursement 
significantly. This course will walk you through some common everyday scenarios to help 
you understand the concepts of modifiers and apply this understanding in your practice.
Senior Instructor(s): Elizabeth D Cottle CPC OCS
Instructor(s): Heather Hambrick Dunn COA
 NEW   C   J   A  Coding for Ophthalmic Testing Services
Course: 370 Monday
Room: 294 2:00 - 3:00 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: Coding and billing for diagnostic testing is a major part of the work of any 
ophthalmic practice, but more so for subspecialties such as retina, cornea, and glauco-
ma. Many practices are not sufficiently aware of current Medicare regulations that guide 
the reimbursement of these tests. This presentation will include information on docu-
mentation requirements, unilateral vs. bilateral payment, multiple testing reimbursement 
policies, recognition of which tests can be billed together on the same day, diagnosis 
coverage, and supervision rules for ophthalmic testing services.
Objective: Upon completion of this course, the participant should be able to (1) iden-
tify proper code selection for each test performed, (2) recognize documentation require-
ments, including what is meant by interpretation and report, (3) understand the impact 
of the Correct Coding Initiative, (4) learn that common sense does not always equal 
a covered diagnosis, and (5) identify situations where an Advance Beneficiary Notice 
should be used.
Senior Instructor(s): Joy Woodke COE OCS*
Instructor(s): Michell Miller-Ballard OCS CPC
 C   J   A  Surgery Billing Made Easy for All Specialties
Course: 382 Monday
Room: 291 2:00 - 4:15 PM
Education Level: BAS Target Audience: ALL
Synopsis: Most of the revenue generated by the ophthalmic practice is from surgery. 
Accurate surgery coding and understanding of the various rules is essential.
Objective: Attendees will learn the various aspects of surgical coding and how to ac-
cess the right tools for correct reimbursement.
Senior Instructor(s): Elizabeth D Cottle CPC OCS
 C   J   A  Comprehensive Cataract Coding
Course: 404 Monday
Room: 296 3:15 - 5:30 PM
Education Level: INT Target Audience: ALL
Synopsis: What are visual acuity requirements (if any)? What makes cataract surgery 
complex? Is the postop complication separately billable even when performed in my of-
fice? What is the impact of Correct Coding Initiative edits on combined cataract, retina, 
cornea, and/or glaucoma cases? End the confusion about pre-, intra-, and postoperative 
care for the number 1 surgery performed in the United States.
Objective: Upon completion of this course, the participant should be able to (1) distin-
guish between Medicare and non-Medicare payer documentation rules prior to surgery, 
(2) understand what makes the surgery complex , (3) code correctly for combined cata-
ract, retina, cornea, and/or glaucoma cases, and (4) recognize which complications are 
separately billable and which are considered postop.
Senior Instructor(s): Sue J Vicchrilli COT OCS
Instructor(s): Kristin Carter MD*
 C   J   A  Medicare Postoperative Cataract Eyewear: Coding, 
Billing, and Supplier Compliance
Course: 415 Monday
Room: 295 4:30 - 5:30 PM
Education Level: ADV Target Audience: ALL
Synopsis: The Affordable Care Act has had a major impact on durable medical equip-
ment (DME) suppliers of eyewear for use after cataract surgery. This course will cover 
supplier enrollment or revalidation, enrollment in the Provider Enrollment, Chain and 
Ownership System (PECOS), surety bonds, electronic funds transfer, par provider agree-
ment, Provider Transaction Access Number (PTAN), National Provider Identifier (NPI), 
passing DME inspection, required patient documentation (ABN, etc.), Common Electronic 
Data Interchange (CEDI) processing, billing, coding, and modifiers. The course content 
will include tips on filling out the 1500 form. The instructor is the optical industry repre-
sentative on the Provider Outreach and Education Advisory Committees of three of the 
nation’s regional Centers for Medicare and Medicaid Services DME Medicare Adminis-
trative Contractors: NHIC, National Government Services, and Noridian.
Objective: By the conclusion of this course, attendees will have learned how to enroll 
as a DME supplier or how to pass the revalidation process, how to make a practice DME 
supplier compliant, and how to undertake the process of coding, billing, and maximizing 
patient reimbursement.
Senior Instructor(s): Pamela Fritz
 J   A  CodeFest
Course: 503 Tuesday
Room: 291 9:00 - 10:00 AM
Education Level: BAS Target Audience: ALL
Synopsis: Join your physician, technician, administrator, biller, and coder colleagues 
in the first-ever live coding challenge. In game format, two teams will be selected, each 
including a physician, an administrator, a technician, and a biller / coder. The moderator 
will present the prewritten coding questions with multiple answer options. Through an 
automated response system, audience members will be able to play against the two 
teams.
Objective: Upon completion of this course, the participant should be able to (1) deter-
mine the appropriate level of history, exam, and medical decision making for exams and 
(2) identify the correct modifier in exams, tests, and surgical cases that ophthalmology 
practices face daily.
Senior Instructor(s): Sue J Vicchrilli COT OCS
 NEW   J  Ophthalmic Coding Specialist Prep Course
Course: 541 Tuesday
Room: 296 10:15 - 11:15 AM
Education Level: INT Target Audience: ALL
Synopsis: Demonstrate your coding competency by passing the Ophthalmic Coding 
Specialist (OSC) Exam. The OCS exam is an open-book, 100-question, multiple choice, 
online exam. Everyone in the office who is involved in chart documentation and claim 
submission should demonstrate their coding competency. This one-hour course will pre-
pare physicians, technicians, administrators, and billers to test in 18 content areas of 
ophthalmic coding. This is the best way to learn and subsequently appropriately code 
for proper reimbursement.
Objective: Upon completion of this course, the participant will be able to (1) identify 
and discuss the value of the OCS designation, (2) pass 10 questions with 80% proficiency, 
(3) identify the appropriate study guides necessary to pass the OCS exam, and (4 identify 
appropriate online tools to assist in passing the OCS exam.
Senior Instructor(s): Jennifer Carol Arbuckle
 C   J   A  Steps for Successful Retina Coding
Course: 584 Tuesday
Room: 295 12:45 - 3:00 PM
Education Level: INT Target Audience: ALL
Synopsis: The revenue cycle of the retina practice can be quite complex. Multiple fac-
tors impact a successful practice. This course will teach attendees what impacts their 
reimbursement the most and how to apply tools in their own practices for success.
Senior Instructor(s): Elizabeth D Cottle CPC OCS
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Compliance and Risk Management
 NEW   SO   A  Compounding Pharmacies: Legal and 
Regulatory Issues
Course: 182 Sunday
Room: 291 2:00 - 3:00 PM
Education Level: INT Target Audience: ALL
Synopsis: This course will give an overview of the legal and regulatory issues around 
compounding pharmacies. Materials will include a look at the lessons learned from the 
New England Compounding Center meningitis outbreak, current regulations in the United 
States, including those from the FDA and congress, and the effect of Supreme Court deci-
sion in “Thompson v. Western States Medical Center”. Additional materials will look at 
the role of the states and issues in contracting with compounding pharmacies.
Objective: At the conclusion of this course, attendees will have a better understanding 
of this complicated issue and its current state of affairs. Attendees will be able to recog-
nize and respond to the issues in contracting with compounding pharmacies and liability 
exposure for the physician and practice.
Senior Instructor(s): Brenda Laigaie JD
Instructor(s): Robert A Wade JD
 A  A Physician’s Guide to Avoiding Embezzlement
Course: 205 Sunday
Room: 295 3:15 - 4:15 PM
Education Level: ADV Target Audience: ALL
Synopsis: It has been estimated that one in six doctors will experience embezzlement 
at some time during their practice years. A busy doctor is an easy target for embezzle-
ment, and in a down economy, a doctor may be even more at risk. The importance of 
education, credit checks, and drug screening will be covered, as well as practice policies 
and procedures implementation. Savvy embezzlers can fool even the most experienced 
employers, so learn how to protect yourself. Real-life case examples will be discussed.
Objective: At the conclusion of this course, physicians will have learned how to protect 
their practices from employee embezzlement by instituting accounting controls and ef-
fective screening and management techniques.
Senior Instructor(s): Debra L Phairas
 A  Independent Contractors vs. Employees: The Risks of 
Misclassification
Course: 331 Monday
Room: 295 9:00 - 10:00 AM
Education Level: BAS Target Audience: ALL
Synopsis: This course is intended to educate the attendee on the commonly misunder-
stood laws regarding employee / independent contractor classification and on the risks 
and potential consequences of misclassification.
Objective: To educate attendees on the commonly misunderstood laws regarding em-
ployee vs. independent contractor classification, including the factors cited by the Inter-
nal Revenue Service and Department of Labor and used to determine worker classifica-
tion. The course will focus primarily on classification of specialist and nonspecialist phy-
sicians and optometrists by group practices and on the risks and potential consequences 
of misclassification (and, in some cases, the consequences of correct classification!).
Senior Instructor(s): Jill S Garabedian JD
Instructor(s): Mark D Abruzzo JD
 NEW   YO   A  Social Media and Social Networking in the 
Physician Office
Course: 340 Monday
Room: 293 10:15 - 11:15 AM
Education Level: BAS Target Audience: ADMIN
Synopsis: More than a billion people around the world use social media daily. It is 
imperative that providers and business managers learn how to manage and utilize this 
communication channel, particularly as it relates to them as employers, health care pro-
viders, and business owners. This course will discuss the use of social media in the 
physician practice and how best to address certain issues, including HIPAA and confi-
dentiality, reputation control, using social media to conduct informal background checks, 
and looking at employee use of social media in and out of the workplace from a legal 
standpoint.
Objective: At the end of this course, participants will have a basic understanding of the 
various social media and social networking sites and the laws involved with their use in 
their practices so that they will be able to draft effective policies, monitor the Internet for 
reputation management, and successfully promote and market their practices.
Senior Instructor(s): Jill S Garabedian JD
Instructor(s): Caroline Patterson
 NEW   A  Getting Ready for 2014: Compliance! Compliance! 
Compliance!
Course: 373 Monday
Room: 288 2:00 - 4:15 PM
Education Level: BAS Target Audience: ALL
Synopsis: Government efforts to get money back from providers (or even avoid paying 
it out) is a good way to close budget gaps. Recently loosened rules concerning what 
constitutes a false claim, who can bring whistleblower actions, and knowledge require-
ments for liability, plus even more aggressive data mining before payments are made, 
increased audit activity, and aggressive fraud and abuse and program integrity activity, 
should make compliance a huge concern for all practices. This course will review the 
basic areas of concern, highlight recent changes in the law, and hone in on how to avoid 
getting caught in the crosshairs of an investigation and what to do if investigated.
Objective: Participants will leave this course knowing the basic areas of concern with 
regard to compliance, how recent changes in the law increase the need for stepped-up 
compliance efforts, and strategies to employ to stay out of trouble.
Senior Instructor(s): Robert A Wade JD
Instructor(s): Brenda Laigaie JD, Mark D Abruzzo JD, Jill S Garabedian JD
 NEW   A  HIPAA Privacy and Security: Trends, 
Developments, and Issues
Course: 423 Monday
Room: 291 4:30 - 5:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: This course will provide an update on the Health Insurance Portability and 
Accountability Act (HIPAA), the Health Information Technology for Economic and Clinical 
Health (HITECH) Act, as well as cover developments in new enforcement efforts. Materi-
als will include a look at the HIPAA statute, the HITECH Act, and privacy and security 
rules, and the course will provide strategies for effective compliance. Material will in-
clude the breach notification rule and recent developments in enforcement.
Objective: At the conclusion of this course, attendees will have a greater understand-
ing of HIPAA and the HITECH Act, as well as the privacy and security rules and breach 
notification rules. Participants will leave the course with strategies for compliance in the 
face of new developments in enforcement activities.
Senior Instructor(s): Brenda Laigaie JD
Instructor(s): Robert J Landau JD
 NEW   A  Analyzing Medical Legal Tools: The Key to Lawsuit 
Prevention and Tax Reduction
Course: 504 Tuesday
Room: 294 9:00 - 10:00 AM
Education Level: INT Target Audience: ALL
Synopsis: This course is about proper structuring of medical professionals’ legal enti-
ties (living trusts, family limited partnerships, C and S corporations, and LLCs).
Objective: To enable participants to accomplish the following: (1) understanding correct 
legal deductions of each entity and correct partnership structuring for lawsuit prevention 
and tax reduction, (2) structuring the practice for maximum tax reduction and malpractice 
protection and prevention, (3) maintaining the focus of their practice on improved patient 
care rather than malpractice defense, (4) ensuring 100% protection of their personal and 
professional assets from lawsuit through applied risk management, (5) reducing malprac-
tice insurance costs and taxes, and (6) keeping the focus on patients (not legal defense, 
taxes, etc.) while keeping medical practice costs and patient costs down.
Senior Instructor(s): Carol Foster*
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 NEW   SO   A  Compounding Pharmacies: Legal and 
Regulatory Issues
Course: 532 Tuesday
Room: 288 10:15 - 11:15 AM
Education Level: INT Target Audience: ALL
Synopsis: This course will give an overview of the legal and regulatory issues around 
compounding pharmacies. Materials will include a look at the lessons learned from the 
New England Compounding Center meningitis outbreak, current regulations in the United 
States including the FDA, Congress, and the effect of Supreme Court decision in Thomp-
son v. Western States Medical Center. Additional materials will look at the role of the 
states and issues in contracting with coompounding pharmacies.
Objective: At the conclusion of this course, attendees will have a better understanding 
of this complicated issue and its current state of affairs. Attendees will be able to recog-
nize and respond to the issues in contracting with compounding pharmacies and liability 
exposure for the physcian and practice.
Senior Instructor(s): Brenda Laigaie JD
Instructor(s): Robert A Wade JD
Electronic Health Records
 NEW   A  Meaningful Use Stage 2 and How to Survive a 
Meaningful Use Audit
Course: 210 Sunday
Room: 291 3:15 - 4:15 PM
Education Level: INT Target Audience: ALL
Synopsis: Recently the U.S. Department of Health and Human Services announced the 
release of the meaningful use Stage 2 and updated certification criteria. Starting as early 
as 2014, physician practices will be required to achieve more difficult
Objective: to demonstrate meaningful use of electronic health records to earn federal 
bonuses and prevent future penalties. The final rule mandates that doctors meet a larger 
number of core ––and stricter guidelines for some of those already in place––during the 
next part of the 3-stage program. Physicians also must adopt and demonstrate meaning-
ful use of EHR systems by Oct. 1, 2014, or be assessed a 1% penalty by Medicare. In 
addition to the announcement of new meaningful use rules, Stage 2 also brings audits 
and additional requirements for certified EHR vendors. With a ton of cash, up to $44,000 
per eligible provider, scrutiny is sure to follow.
Senior Instructor(s): Jeffery Daigrepont
Instructor(s): Kelsey A Lang MPP
 NEW   A   EHR  Top 10 Success Tips for Your EHR 
Implementation
Course: 215 Sunday
Room: 288 4:30 - 5:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: Attending this course, participants will identify some of the lessons learned 
from electronic health record (EHR) implementations . This course will demonstrate the 
most valuable tips, using examples of workflow changes, positive employee transition, 
communication techniques, training and assessment tools, and more. This personal and 
animated approach to sharing real-life experiences will allow the participants to envision 
the adoption of EHR technology in their own practices, using these proven techniques 
and management tools.
Objective: By the completion of this course, participants will be able to (1) recognize 
the value of EHRs for the ophthalmic practice, and identify resources that can streamline 
the process, (2) analyze some of the steps involved in an electronic conversion and iden-
tify a strategy for conversion, based on their own unique practice needs, (3) identify tools 
to increase efficiency during and after the ophthalmic EHR implementation, and (4) devel-
op workflow and process improvement protocols for training and for post-EHR adoption.
Senior Instructor(s): Joy Woodke COE OCS*
Instructor(s): Brittney Wachter CPC OCS
 NEW   SO   A  Impact of Electronic Health Records on 
Malpractice Claims Against Ophthalmologists
Course: 228 Sunday
Room: 295 4:30 - 5:30 PM
Education Level: INT Target Audience: ALL
Synopsis: This course will review the professional liability risks and benefits when 
implementing an EHR system and will focus on the role and responsibility of scribes 
and privacy issues.
Objective: By the conclusion of this course, attendees will be able to identify different 
types of EHR systems available, identify potential professional liability risks related to 
electronic documentation, and implement risk management strategies to mitigate pro-
fessional liability risks.
Senior Instructor(s): Paul Weber JD
Instructor(s): Sharon Brown
 A   EHR  Electronic Health Records Implementation: 
Overcoming Resistance to Change
Course: 347 Monday
Room: 291 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: Several barriers to the adoption of electronic health records (EHRs) exist. 
The resistance to change is one obstacle facing ophthalmic practices during transition 
periods. In reviewing the process of change and recognizing the factors that contribute 
to resistance, leaders can develop tools to manage and minimize this potential barrier. 
This course will review how personnel from various generations may respond to change, 
and how their technological preferences may contribute to your successful transition. 
The instructors are ophthalmologists and an administrator with personal experience in 
change management during an EHR implementation.
Objective: By the conclusion of this course, attendees will (1) recognize common dif-
ficulties associated with EHR implementation and related to resistance to change, (2) 
understand effective change management techniques, (3) recognize phases of change 
and their effect on personnel, and (4) appreciate generation-specific skills and perspec-
tives and how they impact and can be beneficial to transition.
Senior Instructor(s): Joy Woodke COE OCS*
Instructor(s): Michele C Lim MD, Colin McCannel MD*
 NEW   A   EHR Questions About EHR Implementation? Ask 
Us!
Course: 394 Monday
Room: 294 3:15 - 4:15 PM
Education Level: BAS Target Audience: ALL
Synopsis: Migration to electronic health records (EHR) requires careful thought and 
planning by physician practices. Given the complexities involved, questions inevitably 
arise as to such issues as IT infrastructure and data backup, ophthalmic device inter-
faces, managing existing paper charts, and transitional workflow. This panel will feature 
different practices (small, large, academic) with mature EHR experience to share tips 
and answer questions from attendees in an interactive format. Attendees with specific 
questions about different aspects of EHR implementation will obtain guidance, tips, and 
strategies for success.
Senior Instructor(s): Julia Lee JD OCS
Instructor(s): Joy Woodke COE OCS*, Robert E Wiggins MD MHA*
 NEW   A   EHR  Questions About “Meaningful Use” EHR 
Incentives? Ask Us!
Course: 412 Monday
Room: 288 4:30 - 5:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: The electronic health record incentives being offered by the Medicare and 
Medicaid programs are now in the third year of Stage 1, with Stage 2 requirements 
soon to take effect. As more and more ophthalmologists seek to satisfy “meaningful 
use” requirements, specific questions about how to report and submit various measures 
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inevitably arise. This panel will feature different practices (small, large, academic) with 
mature EHR experience to share tips and answer questions from attendees in an interac-
tive format. The panel will also include the Academy’s health policy manager.
Objective: Attendees with specific questions about the EHR incentive programs will 
obtain guidance, tips, and strategies for successful reporting.
Senior Instructor(s): Julia Lee JD OCS
Instructor(s): K David Epley MD*, Kelsey A Lang MPP, Denise C Fridl COT COE, Joy 
Woodke COE OCS*
 NEW   A   EHR  Electronic Health Records: “Great 
Expectations”
Course: 544 Tuesday
Room: 291 10:15 - 11:15 AM
Education Level: INT Target Audience: ALL
Synopsis: Expectation setting can be the difference between a very good electronic 
health record (EHR) system implementation and a poor implementation. This course will 
discuss an approach to expectation setting that is critical to stakeholder buy-in and even-
tual EHR deployment success.
Objective: After attending EHR: “Great Expectations” audience members will have a 
game plan for attaining buy-in in their practices through expectation setting.
Senior Instructor(s): Jonathan Lohr
Human Resources
 NEW   A  Quit Writing Policies: Create a Culture Using Core 
Values
Course: 200 Sunday
Room: 294 2:00 - 3:00 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: Managing personnel continues to challenge managers. Managers may find 
success by helping staff members be better thinkers through definitive expectations 
rather than trying to “lay down the law” This course takes the foundation of core values 
and gives practical application to daily management to create the right culture. Using 
audience examples we will review the development of core values and their practical 
application in managing people, including the steps for approaching difficult employee 
situations. The audience will participate in finding the best approaches to handling daily 
challenges.
Objective: Attendees will be able to (1) develop core values with owners, (2) under-
stand the importance of core values in creating the work environment, (3) undertake a 
different approach when faced with disciplining difficult employees, (4) identify and hire 
people who match your culture / core values, and (5) coach other practice leaders about 
the practical management application of core values.
Senior Instructor(s): Maureen Waddle MBA*
 A  Forecasting Staffing Needs: A Volume-Based Model
Course: 209 Sunday
Room: 296 3:15 - 4:15 PM
Education Level: INT Target Audience: ADMIN
Synopsis: This course will introduce a tool to help owners and managers answer one 
of the most common practice questions: “Do I have the right number of staff members?” 
The course will provide an overview of industry staffing benchmarks and the pros and 
cons of that information. It will discuss the importance of time and flow studies to help 
improve operational efficiency and to predict staffing needs. After giving background on 
the development of the Excel Workbook, the tool will be reviewed using a case study. 
All attendees of the course will receive a copy of the Excel Workbook to use in their 
own practices.
Objective: Upon completion of this course, attendees will be able to (1) understand the 
challenges of predicting staffing needs, (2) develop measures and benchmarks that are 
customized to their practices, (3) create a quantitative formula for predicting staff needs, 
and (4) forecast when to add staff count according to volume/demand.
Senior Instructor(s): Maureen Waddle MBA*
 NEW   A  Payer Contracting and Payer Relations: What You 
Need to Know to Improve Your Rates and Contract Language
Course: 337 Monday
Room: 286 10:15 AM - 12:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: Payer contracting is difficult, with decreasing reimbursement rates, bun-
dling of key codes, and moves toward performance-based pay arrangements. However, 
through the creation of a payer relations committee within the practice, it is possible to 
contact the payer to create a relationship while improving the practice rates and contract 
language. Course materials will include strategies for presenting the practice in a favor-
able light for the payer, contracting language and rate issues, and strategies for policing 
your contract once concluded.
Objective: At the conclusion of this course, the attendees will have new strategies 
for negotiating with payers and new strategies for policing their contracts effectively in 
order to get the benefit of their negotiated arrangement.
Senior Instructor(s): Brenda Laigaie JD
Instructor(s): John Duemmel
 NEW   A  Managing Difficult Employees and Reducing 
Conflict in the Practice
Course: 341 Monday
Room: 295 10:15 - 11:15 AM
Education Level: INT Target Audience: ALL
Synopsis: Few medical schools teach physicians hands-on human resources manage-
ment skills and techniques. Consequently, physicians depend on medical office managers 
to manage challenging employees and reduce conflict in the office environment. This 
information-packed workshop will teach you the secrets of how to lead, coach, and man-
age difficult employees; set practice values; and create the teamwork and morale needed 
for harmony in the medical office.
Senior Instructor(s): Debra L Phairas
 A  Smile ... Even If It Kills You: Training for Excellent 
Customer Service
Course: 363 Monday
Room: 295 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: This course is geared toward training the entire staff for five-star, excellent 
customer service with a goal of creating a good work environment, a happy customer 
base, and a busy, healthy practice.
Objective: This course is designed to help participants identify the strengths and weak-
nesses in their practices and to learn ways to change a problematic culture. Attendees 
will also be able to identify a practice’s mission statement and learn how the entire team 
can improve by changing a few common yet undermining attitudes and habits.
Senior Instructor(s): Nancy Baker
 NEW   SO   A  Managing Generation Y Employees
Course: 380 Monday
Room: 286 2:00 - 3:00 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: Generation Y employees can be looked at as the most frustrating, self-in-
volved generation in history, or they can be regarded as the most educated, informed, 
and “plugged-in” workers we have ever had the privilege to hire. In either case, manag-
ing these employees brings a new set of challenges to the workplace. In order to hire, 
train and retain Generation Y employees, managers must employ completely different 
management techniques, which will be the focus of this course.
Objective: At the conclusion of the course, managers should understand that, with the 
right management approach, Generation Y employees should be the most sought-after 
employees in the workforce.
Senior Instructor(s): Bonnie Callahan Parker
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 NEW   A  Training the Front Office Staff
Course: 398 Monday
Room: 286 3:15 - 4:15 PM
Education Level: INT Target Audience: ADMIN
Synopsis: Your front office team is the face of the practice and sets the tone for each 
patient’s visit. Learn to set the right tone and maximize the leverage of the nonclinical 
staff.
Objective: At the conclusion of this course, attendees will be able to (1) hire the right 
people for the front office, (2) begin (and end) each visit on a positive note, (3) provide 
seamless service, and (4) utilize the front office team to grow patient base and revenue.
Senior Instructor(s): Brandi Allen
 NEW   A  Employee Discipline for the Smaller Practice: The 
New Manager, the Seasoned Manager, and the Doctor
Course: 405 Monday
Room: 283 3:15 - 4:15 PM
Education Level: BAS Target Audience: ALL
Synopsis: Small practices may not have the luxury of an in-house human resources 
representative, and in many cases the task is left to a manager / supervisor or physician 
who has no experience in this area. Without proper training and documentation, human 
resource / discipline issues can be costly to the practice and devastating to morale. This 
course will provide education, tools, and ideas for how to address discipline / perfor-
mance issues, from the verbal warning through termination.
Objective: At the conclusion of this course, attendees will have strategies (and ex-
amples) to implement in their practices as well as an understanding of the legalities 
involved in the discipline process. Interactive sharing will allow the group to discuss and 
work through potential situations.
Senior Instructor(s): Elise Levine MA CRC OCS
 A  Employment Law Basics for the Small Ophthalmology 
Practice
Course: 500 Tuesday
Room: 286 9:00 - 10:00 AM
Education Level: BAS Target Audience: ADMIN
Synopsis: Large practices often have access to expertise on human resources issues 
that small practices, with fewer than 30-35 employees, may not. Because of fiscal re-
straints, small practices often simply adopt, without modification, policies procedures 
that don’t make sense, given their size. However, being a practice or solo practitioner 
does not exempt you from laws. This course will identify the most common law issues 
facing small practices today clarify how to minimize exposure in areas like employment 
discrimination, wage hour violations (especially overtime), paid time off, drug alcohol 
use, confidentiality, privacy, email, Internet, and social media use.
Objective: By the conclusion of this course, participants will learn about the issues 
they face as employers, the laws governing those issues, and as a result, what kinds of 
provisions they should (or shouldn’t) put into their employee manuals.
Senior Instructor(s): Robert A Wade JD
Instructor(s): Jill S Garabedian JD, Caroline Patterson
 A  Do I Look Like Your Mother?! Or, How to Manage the 
Difficult Employee
Course: 536 Tuesday
Room: 283 10:15 AM - 12:30 PM
Education Level: INT Target Audience: ADMIN
Synopsis: The course is a humorous guide to dealing with noncompliant, subversive, 
or passive-aggressive employees, emphasizing the importance of a strong and clear em-
ployee manual as well as a policy and procedure manual.
Objective: The attendee should be able to leave the course with a list of tools and 
strategies to better address the problems of managing difficult employees. They should 
be able to set limits and establish clearly defined rules and codes of conduct for their 
practices, giving them more confidence in their own authority. Highlights will include ad-
dressing the “pot stirrers” passive-aggressive employees, the”skaters” around the edge 
of compliance, and the unique challenge of “inherited” employees. We will emphasize 
the importance of clear and complete documentation, knowledge of relevant state labor 
laws, having a complete employee manual reviewed by an attorney, as well as current 
policy and procedure manuals and job descriptions and understanding the difference 
between them.
Senior Instructor(s): Nancy Baker
Instructor(s): Elise Levine MA CRC OCS, Nancy L LaVergne OCS CPC
Information Technology
 NEW   A  Enhancing Your Practice With Mobile Technology 
and Social Media
Course: 387 Monday
Room: 290 2:00 - 4:15 PM
Education Level: INT Target Audience: ALL
Synopsis: The majority of patients, physicians, and practice administrators own a mo-
bile device. The appropriate use of a mobile device can assist an administrator in market-
ing a practice through social media, the Internet, and the app market. These devices will 
help practices be increasingly organized and efficient. Mobile technology enables your 
practice to be more connected with your wired patient. This course will help you enhance 
patient satisfaction and education while making your practice more efficient.
Objective: At the conclusion of this course, the attendees will understand and be able 
to use their mobile device not only as a powerful communication device and personal 
digital assistant but also for office efficiency, practice branding and marketing, and pa-
tient care.
Senior Instructor(s): Vinay A Shah MD*
Instructor(s): Judith Lee*, Rohit Krishna MD*, Ron K Lord MD*, Alex W Cohen MD PhD
 NEW   A  Toward the Electronic Practice
Course: 426 Monday
Room: 297 4:30 - 5:30 PM
Education Level: INT Target Audience: ALL
Synopsis: This course will describe and detail the current state of the art of practice 
management automation and present where the future might take us in further automa-
tion. Specific practice examples will be used.
Objective: Attendees will learn about tools they can use to improve the efficiency of 
their practice, about how to review and choose vendors of these tools, and about how to 
successfully implement these automation tools.
Senior Instructor(s): Jeff Grant*
Marketing & Business Development
 YO   A  Website 101: Three Steps to Creating Your First 
Website
Course: 188 Sunday
Room: 295 2:00 - 3:00 PM
Education Level: BAS Target Audience: ALL
Synopsis: Learn the basics of creating any website. While creating a website may 
seem an overwhelming task for the first-timer, this course will simplify the process. Cre-
ating and hosting your own website can be simple, inexpensive, and fun, and it is a great 
way to market yourself, or your practice, build relationships with your patients, attract 
new patients, and provide patient education.
Objective: At the conclusion of the course, attendees will be able to choose a domain 
name, implement software, and choose a hosting service in preparation to launching 
their first website. The attendee will also learn to avoid the most common mistakes 
made by the first-timer.
Senior Instructor(s): Randall V Wong MD*
Instructor(s): Amy Wong**
 A  Website Design and Marketing Fundamentals
Course: 332 Monday
Room: 297 10:15 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: This course will provide step-by-step instruction for implementing a success-
ful medical website marketing plan, including strategies that focus on new business 
development and reducing overhead expenses.
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Objective: To identify website design and marketing strategies that transform the 
ophthalmology practice website from an overhead cost into a revenue-producing asset.
Senior Instructor(s): David Swink*
 A  Success Traits of Market Leaders
Course: 334 Monday
Room: 290 10:15 - 11:15 AM
Education Level: BAS Target Audience: ALL
Synopsis: This course will present the common traits of successful practices gathered 
over 20 years spent observing over 500 practices. These management traits can be as-
similated into any practice, regardless of size or location, and are the hallmarks of market 
leading practices.
Objective: Participants will learn the importance of developing a winning business 
strategy that informs patient care, practice location, service mix, staff selection and or-
ganization, and performance monitoring. Participants will learn how to compete more 
effectively by adopting market leaders’ tactics.
Senior Instructor(s): Michael J Parshall*
 NEW   YO   A  How to Be Seen: A How to Guide to Medical 
Marketing
Course: 416 Monday
Room: 290 4:30 - 5:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: This course will offer insight into the marketing side of a medical practice. 
Whether in a solo or group practice, a new or established practice, marketing is the 
epicenter in this technological age. We will cover a wide variety of practices and options 
tailored to each individual scenario and will tackle the major questions, like how to get 
referrals, how to be recognized in the community, and how to understand your individual-
ity as a practice. We will combine a mixture of grassroots methodology with the most 
cutting-edge technology and give you guidelines on how to take advantage of social 
networking with just the “right amount” of involvement.
Objective: Proper marketing strategies can be highly effective without having to be 
highly expensive. We will take an in-depth look at a variety of options, varying from no-
budget to high-budget approaches, that are effective in establishing market visibility. By 
the end of the session you will be able to understand and build a marketing plan.
Senior Instructor(s): Donna W Howell JD
 A  Content Marketing: Getting Your Web Page Ranked
Course: 511 Tuesday
Room: 288-289 9:00 - 10:00 AM
Education Level: BAS Target Audience: ALL
Synopsis: Want your website to rank highly? Social media, email campaigns, banner 
ads, Adsense / Adwords are not sustainable methods and are of little use to your medical 
practice. The only way to achieve, and maintain, high rankings for your Web page is to 
understand content marketing. Applying search engine optimization (SEO) techniques to 
the content of your website will boost your Search Engine Results Page rankings.
Objective: At the conclusion of this course, the attendee will be able to understand the 
relationship between SEO and content marketing and how to achieve high Web page 
rankings.
Senior Instructor(s): Randall V Wong MD*
Instructor(s): Amy Wong**
Optical Dispensing
 NEW   A  Optical Dispensing: Is It Financially Feasible for 
Your Practice?
Course: 232 Sunday
Room: 290 4:30 - 5:30 PM
Education Level: INT Target Audience: ADMIN
Synopsis: The continued threat of managed-care reimbursements has inspired many 
practices to consider expanding their scope of services. For some, optical dispensing has 
proven to be a financially rewarding addition. However, adding an optical dispensary is 
not a guarantee of success for every practice. Before making the investment to set up an 
optical dispensary, it is important to evaluate the feasibility of this new endeavor. Do you 
have the patient volume to support an optical? Do you have the necessary space? And 
what operational steps are vital to ensuring success? This course will review the feasibil-
ity of adding optical services and the initial steps required for success.
Senior Instructor(s): Carolyn Salvato*
 A  How to Create an Effective Dispensary Website Tab That 
Gets Results
Course: 328 Monday
Room: 290 9:00 - 10:00 AM
Education Level: INT Target Audience: ALL
Synopsis: Most ophthalmology websites devote woefully little space to their optical 
dispensaries, yet those dispensaries will generate about 30% of practice revenues. By 
contrast, the nation’s largest optical retailers devote as many as 40 website pages to 
eyeglass and contact lens issues. This course will look at the Web pages that every 
dispensing ophthalmology practice should consider adding to their website and discuss 
why most ophthalmology practices should consider building them.
Objective: At the end of this course, the attendee will be able to (1) describe why 
their dispensing ophthalmology practice should have a robust optical dispensary tab and 
a comprehensive series of pages devoted to dispensing, (2) name the most important 
pages the practice should consider having on its website, and (3) describe why add-
ing the recommended pages will encourage dispensary sales and increase dispensary 
customer satisfaction.
Senior Instructor(s): Arthur L De Gennaro*
 NEW   A  How To Diagnose a Sick Dispensary
Course: 354 Monday
Room: 290 11:30 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: Many ophthalmologists are not satisfied with the sales and profit their dis-
pensaries generate. This course looks at the key areas of practice and dispensary life that 
affect the growth of dispensary sales and retention of profits. Participants will estimate 
their dispensaries’ potential by viewing an actual pro forma and completing a worksheet 
in class. Emphasis will be placed on developing a written plan of action.
Objective: Upon completion of this course, the attendee will be able to (1) recognize 
the signs of a “sick” dispensary, (2) know how to “make a diagnosis” (3) explain the 
importance of integrating the dispensary and the practice, (4) name the 3 factors that 
affect revenue, and (5) name the 4 factors that affect profitability.
Senior Instructor(s): Arthur L De Gennaro*
 NEW   A  Opening an Ophthalmology Optical Dispensary
Course: 409 Monday
Room: 297 3:15 - 4:15 PM
Education Level: ADV Target Audience: ALL
Synopsis: Here are the basics of how to open an optical dispensary, from the ground 
up! What are the project management tips you need to know? This course will cover 
a check-list of items not to miss if your optical dispensary is to achieve financial and 
operational success: Working with contractors, designers, architects, and dispensary 
furnishings. Setting timetables. Financial projections and budgets. Capture rate logistics: 
servicing your patient demographics. Hiring optical staff. Negotiating with lab and frame 
vendors. Optical software options. Optical management and operations basics: policies, 
procedures, and protocols. Accepting insurance.
Objective: At the conclusion of this course, the attendee will have all the basics tools 
needed to open an optical dispensary.
Senior Instructor(s): Pamela Fritz
Instructor(s): Patrick Boys Smith
 A  Optical Shops: Sales Strategies for Today’s Economy
Course: 526 Tuesday
Room: 293 9:00 - 10:00 AM
Education Level: INT Target Audience: ADMIN
Synopsis: Today’s consumers have more information at their disposal than ever be-
fore. The options for prescription eyewear are limitless. Because of ubiquitous advertis-
ing from retail chains, private optical offices frequently must overcome preconceived 
opinions about price, quality, and service. Advertisements promoting deep discounts are 
intensifying the perception that the private optical is more expensive. The sales train-
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ing, techniques, and strategies pervasive in the private sector have not been updated 
in decades, nor have they been modified to meet today’s current economic climate. This 
course will review sales strategies and techniques designed to entice and encourage 
patients to purchase from the private optical office.
Objective: This course will enable participants to initiate new sales techniques de-
signed to uncover the patient’s top priorities, establish low-cost package options as an 
added offering, and implement internal marketing strategies to promote the optical busi-
ness.
Senior Instructor(s): Carolyn Salvato*
 A  Detecting and Preventing Fraud and Abuse in the Optical 
Dispensary and Medical Practice
Course: 538 Tuesday
Room: 293 10:15 AM - 12:30 PM
Education Level: ADV Target Audience: ALL
Synopsis: Learn the methods of detection and prevention before fraud and abuse hap-
pen. Set up systems of accounting and financial management with the right system of 
checks and balances. Topics covered in this course include identifying types of fraud in 
the business practice and optical dispensary, the warning signs that fraud exists, steps 
to take to combat fraud and abuse, what to do if you suspect employee theft, software 
security, establishing operational protocols, and security systems and methods to deter 
external theft in the optical dispensary.
Objective: By the end of this course, attendees will have become aware of the internal 
and external signals that can mean fraud and abuse are occurring in their medical prac-
tice or optical dispensary. They will have learned the steps to take to correctly handle 
the situation if fraud and abuse do occur, and how to set up policies, procedures, and 
protocols that will prevent fraud and abuse from happening in the optical dispensary and 
medical business practice.
Senior Instructor(s): Pamela Fritz
Instructor(s): Patrick Boys Smith
Professional Growth
 YO   A  A Practical Guide to Understanding and Negotiating 
Your First Employment Agreement
Course: 202 Sunday
Room: 297 2:00 - 4:15 PM
Education Level: BAS Target Audience: COMPSUB
Synopsis: This course will address the various practical, business, and legal aspects 
of reviewing and negotiating an initial employment agreement. Issues covered in the 
course include understanding the business and legal terms of the proposed employment 
arrangement, the fundamentals of a contract, and tips on how to negotiate the deal with 
the prospective employer.
Objective: This course will leave attendees with an understanding of the entire em-
ployment and contracting process so that they approach their first contract experience 
with knowledge and confidence.
Senior Instructor(s): Robert J Landau JD
Instructor(s): Mark D Abruzzo JD
 NEW   C   J   A  
Ophthalmology for Non-Clinical Personnel 
Course: 204 Sunday
Room: 293 2:00 - 3:00 PM
Education Level: BAS Target Audience: ADMIN
Synopsis: This course will help administrative personnel, especially those new to oph-
thalmology or the medical field, navigate the clinic better through a greater understand-
ing of what occurs in the exam room, testing areas, and ASC. Attendees will learn basic 
eye anatomy and medical terminology used in the ophthalmic practice, with some discus-
sion of common eye diseases and triage. The course will be lecture style with interactive 
discussions raised by audience questions.
Senior Instructor(s): Dooho Brian Kim MD
 NEW   YO   A  How to Become a Better Leader
Course: 213 Sunday
Room: 290 3:15 - 4:15 PM
Education Level: BAS Target Audience: ALL
Synopsis: The ability to effectively lead is an essential skill for anyone running a high-
performing private or academic practice. Leadership training is part of the core curricu-
lum in all business schools; however, it is overlooked in medical school. As the practice 
of medicine becomes increasingly influenced by business culture, it is critical that physi-
cians and practice managers understand basic leadership principles in order to help their 
organization achieve goals and successfully navigate change.
Objective: The goal of this course is to give learners (1) an overview of why leadership 
is important and (2) practical insights and tips on how to become a better leader.
Note: Attendees are advised to download and review the course handout from present-
er central PRIOR to attending the course to facilitate case study discussion
Senior Instructor(s): Bernard F Godley MD PhD FACS MBA
Instructor(s): James C Tsai MD MBA*
 NEW   YO   A  Transition From Training to Practice
Course: 231 Sunday
Room: 293 4:30 - 5:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: This workshop is presented because most medical schools, internships, and 
residency and fellowship programs do not offer courses or guidance to help the individual 
physician make successful choices for the practice opportunity that best fits that doctor’s 
needs. This workshop will give the physician practical tools to assess the various prac-
tice options, learn about the common practice structures, salary, benefits, buy-ins, and 
common contract terms, and learn how to navigate the road to partnership.
Senior Instructor(s): Debra L Phairas
 YO   A  The First Few Years of Practice: Some Key Concepts 
for Young Ophthalmologists
Course: 233 Sunday
Room: 297 4:30 - 5:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: In residency and fellowship programs, ophthalmologists are well trained in 
the practice of medicine, but not in the business of medicine. All too often they are not 
exposed to information that focuses on how to be successful in business. This course is 
designed for a broad spectrum of participants, from those in the first few years of private 
practice to those transitioning to private practice from academic medicine. Topics will 
include patient satisfaction and customer service, the importance of state licensure and 
managed care credentialing well in advance of practicing, negotiating an employment 
contract, understanding managed care plans and fee schedules, knowing your numbers, 
and maximizing use of the Internet.
Objective: By the conclusion of this course attendees will (1) know the factors to con-
sider in deciding whether to start their own practice or join a practice, (2) understand 
the issues associated with each option, (3) understand insurance and setting up a fee 
schedule, and (4) recognize strategies for building a practice.
Senior Instructor(s): Lawrence Geller MBA*
 A  Managing Up!
Course: 315 Monday
Room: 293 9:00 - 10:00 AM
Education Level: BAS Target Audience: ADMIN
Synopsis: This course will focus on the challenging role of the middle manager, who is 
called upon to manage in both directions: up and down. It will teach middle managers to 
successfully supervise staff, or “manage down” and to achieve results by successfully 
presenting recommendations to their physician bosses by “managing up”
Objective: At the conclusion of this course, managers will have a better working re-
lationship with their physicians based on clear expectations and defined, agreed-upon 
goals and performance measurements.
Senior Instructor(s): Debra L Phairas
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 A  Hanging a Shingle in the 21st Century: Is a Start-up Solo 
Practice Possible in 2013?
Course: 352 Monday
Room: 294 11:30 AM - 12:30 PM
Education Level: BAS Target Audience: ALL
Synopsis: This course will detail the challenges faced by physicians wishing to open 
a solo practice in the 21st century and how these challenges can be overcome. The 
presenters, who have all opened solo practices in highly competitive markets, will share 
their experiences, from strategy to tactical execution of planning, financing, building, 
credentialing, opening, and growing a practice built from scratch.
Objective: Attendees will understand the hurdles involved in starting a solo practice 
from scratch and walk away with a road map of how this can be done today.
Senior Instructor(s): Edwin S Chen MD
Instructor(s): Ajit Nemi MD, Ravi D Patel MD
 A  American Academy of Ophthalmic Executives Book Club: 
Professional Growth and Development
Course: 364 Monday
Room: 283 11:30 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: As a practice administrator or ophthalmologist, it is easy to get caught up in 
the day-to-day tasks of running a practice. Often not enough time is given to personal and 
professional development. One way to nurture our own development is through reading, 
but many busy professionals lack the time to sort through or read the business literature. 
Books reviewed in 2012 by a spectrum of leaders in the field of ophthalmology included 
Flipping the Switch, If Disney Ran Your Hospital, What Every Doctor Should Know but 
Was Never Taught in Medical School, Not Everyone Gets a Trophy, Predictably Irrational: 
The Hidden Forces That Shape Our Decisions, and Likeable Social Media.
Objective: At the conclusion of this course, the participant will have actionable ideas 
from top business books that can be applied to his or her professional development.
Senior Instructor(s): Robert E Wiggins MD MHA*
Instructor(s): David A Durfee MD, K David Epley MD*, Tamara R Fountain MD*, Timothy J 
Padovese**, Ron W Pelton MD PhD*
 NEW  SO   A  Incorporating the Four Agreements Into Your 
Practice
Course: 378 Monday
Room: 283 2:00 - 3:00 PM
Education Level: BAS Target Audience: ALL
Synopsis: The Four Agreements by Don Miguel Ruiz is a book about personal effective-
ness that can also be used in the medical practice to develop employees and increase 
efficiencies while removing obstacles to success.
Objective: At the conclusion of this course, attendees will have learned what the Four 
Agreements are and how to apply them personally and professionally. Examples of how 
to utilize them in day-to-day practice will be given, and group interaction will focus on 
problem solving and barriers to implementation.
Senior Instructor(s): Elise Levine MA CRC OCS
 NEW   SO   A  Seeking Shelter Under the Hospital Umbrella: 
From Employment Agreements to Professional Services 
Agreements
Course: 422 Monday
Room: 294 4:30 - 5:30 PM
Education Level: INT Target Audience: ALL
Synopsis: Physician hospital integration is back -- with a vengeance. Uncertainties as-
sociated with healthcare reform, the near monopoly power of many managed care plans, 
changes in Medicare reimbursement and increased healthcare regulation are driving 
ophthalmologists to consider ways to partner with hospitals. Perhaps the most obvious 
of those options is to become a hospital employee, although that can come with a loss of 
autonomy. A professional services agreement (PSA) is another model that provides many 
of the benefits of physician-hospital integration while avoiding some perceived down-
sides. This course addresses the latest industry trends in hospital employment and PSAs.
Objective: Attendees will be able to articulate the keys to success & avoid potential 
mistakes in physician hospital integration, explore the latest trends in compensation un-
der the employment PSA models and determine the appropriateness of each model and 
the best way to structure it.
Senior Instructor(s): Lawrence Geller MBA*
 YO   A  Negotiating Your Buy-In
Course: 516 Tuesday
Room: 297 9:00 - 10:00 AM
Education Level: INT Target Audience: ALL
Synopsis: This course will address, from the young doctor’s perspective, the negotiat-
ing, practical, business, and legal aspects of the buy-in to a solo or group practice and 
other associated entities.
Objective: To leave attendees with an understanding of how to negotiate and evaluate 
a buy-in offer from a financial and legal perspective, including the various other “partner-
ship” terms that comprise a buy-in offer, including but not limited to terms pertaining to 
purchase price and payment, management and voting rights, partnership compensation, 
buy-sell arrangements (ie, “buy-outs”) and “senior doctor” rights and preferences.
Senior Instructor(s): Mark D Abruzzo JD
Instructor(s): Richard C Koval MPA CMPE*, Robert J Landau JD
 NEW   A  Associate Employment Contracts: How to Avoid 
Signing a Bad Contract
Course: 542 Tuesday
Room: 294 10:15 - 11:15 AM
Education Level: BAS Target Audience: ALL
Synopsis: What are the current “normal” employment agreement terms for an associ-
ate joining a practice? Are these norms changing in light of health care reform and chang-
ing economics? The employment contract an associate signs is important. You need to 
make sure that your contract protects your interests and is competitive. The employment 
contract should also outline future buy-in arrangements to address your long-term expec-
tations and concerns. Learn what is a fair and reasonable new associate employment ar-
rangement from experienced attorneys / consultants with more than 50 years combined 
experience who have done thousands of new associate employment contracts.
Objective: This course will provide participants with the range of terms presently be-
ing offered to associates by practices. Learn national norms for salary, incentive bonus, 
benefits, and business expenses, as well as other standard contract terms. Also learn 
what should be said in the contract about future buy-in and partnership.
Senior Instructor(s): Mark E Kropiewnicki JD LLM*
Instructor(s): Daniel M Bernick JD*
 NEW   SO   YO   A  Hiring an Ophthalmologist for Your 
Practice: Avoiding the Pitfalls
Course: 548 Tuesday
Room: 294 11:30 AM - 12:30 PM
Education Level: INT Target Audience: ALL
Synopsis: Adding an associate to the practice requires careful planning and attention 
to detail. Whether or not you are hiring your first associate, this course will provide an un-
derstanding of the steps that should be taken in a practice to have a successful outcome.
Objective: At the conclusion of this course, the attendee will understand the process 
and issues to address in adding an associate to the practice. Attendees will learn the key 
elements of a good employment agreement, how to design a reasonable compensation 
package for the associate, and how to structure a model for an associate’s buy-in. Partici-
pants will also learn how to use an Excel spreadsheet to set up an incentive bonus model.
Senior Instructor(s): Lawrence Geller MBA*
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Saturday, Nov. 16
 A  The Profitable Practice: Managing Your Billing 
Operations
Event No: SPE06 8:00 AM - 12:00 PM
Fee: $345
Room: 286
Sr. Instructor(s): Ron Rosenberg PA MPH*
Instructor(s): Donna Connolly, Curt P Hill
Learn all of the steps involved in billing and receivables management. Also, 
how to monitor collections performance, deploy and manage billing staff, 
identify and correct operational problems that cause rejected and/or de-
layed claims, and obtain benchmarks for staff and cost of billing.
 A  Whiz Through Excel — Your Data Management 
Wizard
Event No: SPE03 8:30 AM - 12:30 PM
Fee: $345
Room: 290
Presenter(s): Andrew Maller
Learn how to get the most out of Excel and efficiently create quality, real-
time reports that monitor monthly and year-to-date revenue, expense, and 
productivity key indicators. Once developed, these reports can be used 
to effectively communicate results to business owners, allowing them to 
make better business decisions and drive practice results. 
This Microsoft Excel training is designed specifically for the ophthalmology 
practice. The instructor will walk attendees through some of the most com-
monly used Excel functions and introduce some easy, but powerful tools 
such as the Physician Productivity Dashboard, Staffing Efficiency Report 
by Department, and New Equipment Purchase Feasibility Analyzer. NOTE: 
Each attendee is required to bring a computer (laptop or netbook) 
to this class. Bring a mouse for ease of use. Participants will re-
ceive sample documents and workbooks prior to the course.
 A  Keeping Your Practice Out of Legal Hot Water: An 
HR and Compliance Workshop
Event No: SPE04 9:00 AM - 4:00 PM
Fee: $495
Room: 283
Sr. Instructor(s): Robert A Wade JD
Instructor(s): Mark D Abruzzo JD, John Duemmel, Jill S Garabedian JD, David 
Laigaie, Brenda Laigaie JD, Robert J Landau JD, Caroline Patterson
Enhance your knowledge about regulatory compliance and human resource 
law at this intensive one-day workshop. The morning session will cover 
the regulatory landscape and challenges facing practices and its intersec-
tion with compliance and human resources concerns. The afternoon will 
consist of break-out sessions, allowing participants to select from several 
in-depth discussions on topics presented earlier in the day. The program 
will be a combination of lecture and moderated panel discussion. There 
will be questions and answers, interactive dialogue using case studies, 
role-playing and other hands-on techniques.
Bending the ASC Performance Curve
Event No: SPE07 12:00 - 4:00 PM
Fee: FREE
Room: 288
Presenter(s): Bradley C Black MD*, Regina Boore RN BSN MS**, Kevin J 
Corcoran*, Kent L Jackson**, Bruce S Maller*, Mike Romansky**
This hands-on symposium is designed for surgeons, owners, administra-
tors, clinical staff and other industry experts committed to shaping the tra-
jectory for ophthalmic ASC performance. 
NOTE: Although this event is complimentary, space is limited.
Sunday, Nov. 17
AAOE General Session: Creating the Ultimate Patient 
Experience and Patients for Life!
Event No: SPE09 10:00 AM - 12:00 PM
Fee: FREE
Room: 291
You may not realize that your practice is a ‘brand.’ Many organizations 
spend millions of dollars every year to develop their brand and increase 
sales and customer retention. An ophthalmology practice, no matter how 
large or small, IS a brand. Your patients ARE customers. What do they think 
of when they see or hear your name? In other words — how powerful is 
your brand? AAOE is pleased to present Scott Deming to help you create 
the Ultimate Patient Experience. Scott will show you how to engender 
the most loyal patients and the most powerful brand in your area — help-
ing your practice thrive in a continually changing healthcare world. 
Sponsored by Genentech and Alcon, Inc.
AAOE Special Meetings & Events
www.reichert.com
Made in the USA. © 2013 AMETEK, Inc & Reichert, Inc. (09-2013)  All rights reserved.
The Tono-Pen AVIA® Tonometer fits comfortably in your hand. Its ready-to-use, calibration-free operation 
fits your busy practice. Over 30 years of trusted accuracy and reliability fits your highest expectations.  
Visit us at Booth 2545 or online at tonopen.com
One button operation.
Large LCD display on 
both sides for right  
or left handed use.
Protect your 
investment with 
affordable  
 OCU-FILM® +  
Tip Covers.
Long life battery 
with on-screen 
indicator.
Award-winning, 
ergonomic design. 
Made in the USA.
No calibration required.
Soft touch grips 
ensure stability.
Tono-Pen® just fits.
www.reichert.com
Made in the USA. © 2013 AMETEK, Inc & Reichert, Inc. (09-2013)  All rights reserved.
Of course the Auto Phoroptor RS® Auto Refraction System connects seamlessly  
to EMR systems and Reichert brand auto refractors, lensometers and acuity  
systems, including the ClearChart® 2 Digital Acuity System. But did you know  
the Auto Phoroptor RS also connects to many other brands of vision testing  
devices available today? Reichert has you connected.  
Visit us at Booth 2545 or online at reichert.com/exam
Reichert® connects.
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1-800-DOCTORS ...............................................2004
66 Vision Tech Co., Ltd. ...................................131
A
A Fashion Hayvin, Inc.  .....................................1465 
A Royal Treasure NEW!...................................3700
A.R.C. Laser GmbH ........................................4119
AA Vision, Inc. ..................................................3712
AAO Meetings On Demand .............................  3643
Aaren Scientific, Inc. .....................................1701
Abbott Medical Optics (AMO)/ 
OptiMedica ................................................1326
AccuLens, Inc. ...................................................2400
Accutome h .....................................................2245
ACIGI Relaxation/FUJIIRYOKI ..........................4447
Action Medical Pvt. Ltd. NEW! .......................5338
Addition Technology, Inc. .................................4125
Advanced Data Systems ..................................4516
Aeon Astron Europe B.V. ..................................1855
AIT Industries ....................................................1026
Ajinomoto Trading, Inc. ....................................1111
AKAS Medical NEW! ......................................4720 
Akorn Pharmaceuticals h ................................2838
AKtive Srl ..........................................................1960
AL.CHI.MI.A. S.r.l. .............................................3021
Alcon Laboratories, Inc. h ...........................417
Alimera Sciences .........................................4429
Allergan  h .....................................................1344
Alphaeon Corporation  NEW! ...........................101
Altaire Pharmaceuticals, Inc. ...........................4839
Althoraya Company For Import & Export .........2209
Ambler Surgical ................................................2500
American Academy of Ophthalmology  
(AAO) ................................................................ 3239
American Academy of Ophthalmic Executives  
(AAOE).............................................................. 3239
American Express OPEN ..................................5138
American Optisurgical, Inc. ..............................1301
American Society of Cataract &  
Refractive Surgery (ASCRS) ........................1125
American Society of Ophthalmic  
Administrators  (ASOA) ...............................1125
AMO/OptiMedica .............................................1416 
Anadolu Tip A.S. ...............................................1061
Angie’s List ..........................................................802
Angiotech h .......................................................311
Anodyne Surgical .............................................1853
AO Lab - American Ophthalmic Lab ...................900
Appasamy Associates ......................................1201
Apramed Medical Devices ...............................3305
ARCADOPHTA  ..................................................1731
ArticDX, Inc .......................................................4518 
Asia-Pacific Academy of Ophthalmology 
(APAO) ..........................................................3505
ASICO, LLC  h ................................................2225
Association for Research in Vision and 
Ophthalmology (ARVO) ..................................804
Audio-Digest Foundation .................................3306
Aumed Group Corp. ..........................................1908
Aurolab..............................................................1913
Aurora Surgical, LLC .........................................1818
Avada Hearing Care Centers ............................2411
Avedro, Inc. .......................................................4020
Avellino Lab USA, Inc.  NEW! .........................2005
B
Bank of America Practice Solutions ..................923
Bascom Palmer Eye Institute ...........................5142
Bausch + Lomb  h ............................................2325
Bayou Ophthalmic Instruments, Inc. ..................958
Beaver - Visitec International  h .....................1945
Beijing Outsmarting Dacone Instrument  
Co., Ltd.  NEW! ...........................................2566
Bell Ophthalmic Technology h ........................1411
Belrose Refracting Equipment  
Company  h .................................................3513
Benign Essential Blepharospasm Research 
Foundation ...................................................5023
BioD, LLC  NEW! ..............................................5043
Bioptigen, Inc. ...................................................4813
Biosyntrx ...........................................................1002
BioTech Vision Care Pvt.,  Ltd. ............................359
Bio-Tissue, Inc. ................................................117
Bistro AAO Café  ................................................. 5223
BJB Medical Associates ..................................1013
Brevium .............................................................4523
BrightFocus Foundation  NEW! .......................5022
Bruder Healthcare Company ............................1823
Brumaba USA, Inc. .............................................760
Brymill Cryogenic Systems ...............................2501
Bryn Mawr Communications LLC .....................1910
BSM Consulting  NEW! ...................................1036
C
C.S.O. srl ...........................................................2828
Calhoun Vision, Inc.  NEW! ...............................663
Cambrian Medical, Inc. ....................................1934
Canon U.S.A., Inc. h ........................................3028
CareCredit .........................................................3005
Carl Zeiss Meditec h ...................................1919
Castle Biosciences, Inc. ....................................1704
Ceatus Media Group ........................................3224
Centervue  NEW! .............................................2308
Chace and Associates ........................................859 
Charmant, Inc. .....................................................921
Chona Surgical Co. ...........................................5012
Chongqing Sunkingdom Medical  
Instruments Co., Ltd.......................................960
Cilita, Ltd. ..........................................................1805
CIMA Technology, Inc. h .................................4519
Clarity Medical Systems, Inc. ....................2939
Clearwave Corporation NEW! ........................5243 
ClientTell, Inc. ...................................................1826
Cloud Nine Development, LLC .........................5242
Compulink Business Systems, Inc. ..................4028
Conestoga Equipment Finance Corp. ...............1405
Crestpoint Management ..................................1001
Croma Pharma ..................................................3713
CYQ Medical Co., Ltd.  NEW! ...........................961
D
DavLong Business Solutions ............................3052
Delta Life Science, LLC .....................................1464
Demandforce ....................................................1262
DermaMed Solutions, LLC ...............................1513
Designs For Vision, Inc. h ................................1012
Device Optical ...................................................1821
Dexta Corporation h ........................................1401
DGH Technology, Inc. h ...................................4131
Diagnosys, LLC..................................................3413
Diamatrix, Ltd. ..................................................1052
DigiSight Technologies, Inc. .............................1905
Diopsys, Inc. ......................................................4520
Dioptics Medical Products, Inc. .........................426
Doctor’s Advantage Products, LLC. ..................1024
Doctors Allergy Formula  NEW! ......................5129
Doctors Internet  NEW! ...................................4513
Doctors Optimal Formula  NEW! ....................5131
Doctorsoft .........................................................2263
DORC International, bv .....................................3827
Dove Medical Press, Ltd...................................4321
DSS, Inc.............................................................4419 
Duckworth & Kent, Ltd. ....................................1001
Dutch Ophthalmic, USA ...............................3827
E
Eagle Labs .........................................................1845
Eagle Vision, Inc. h ..........................................3046
Eidolon Optical ..................................................3517
Einstein Medical ...............................................4451
Electro-Diagnostic Imaging, Inc. ........................949
Ellex ...................................................................1117
Ellman International h.....................................4113
Elsevier h .........................................................4413
Endo Optiks, Inc. ...............................................2217
Enhanced Vision  ..............................................1717
Entod Pharmaceuticals, Ltd.  NEW! ..................865
Epsilon EyeCare, USA .........................................701
Eschenbach Optik ...............................................937
European Association For Vision and Eye  
Research (EVER) ...........................................5120
European Society of Cataract & Refractive  
Surgeons (ESCRS) ........................................3405
European Society of Ophthalmology (SOE) .....3504
European Society of Retina Specialists  
(EURETINA) ..................................................3401
Exhibitor Locator - American Academy of 
Ophthalmology ............................................... 3105
Exhibitor Lounge - American Academy of 
Ophthalmology ............................................... 2571
Expeditor Systems, Inc. ....................................1819
Exhibition, Indexes
Exhibitors
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Eye Care and Cure ............................................4929
Eye Designs, LLC h ............................................645
Eye Med Management Solutions ....................2330
Eye Photo Systems, Inc. .....................................957
Eye Shield Technology ......................................1308
EyeCanHear, LLC ...............................................2326
Eyedetec Medical, Inc. .....................................5228 
EyeIC, Inc...........................................................1958
EyeKon Medical h ...........................................1501
Eyekor, LLC ........................................................1962 
Eyemaginations ..................................................217
EyeMD EMR Healthcare Systems, Inc. ...........5029
EyeNet - American Academy of  
Ophthalmology ............................................... 4422
EYEOL UK LIMITED ...........................................3205
EyePhotoDoc  NEW! ..........................................659
EyeQuick, LLC ......................................................420
EyeSys Vision ......................................................653
EyeTechCare .......................................................424
F
Fallon Wellness Pharmacy .................................909
Fashion Optical Displays  ..........................1016
FCI Ophthalmics ................................................1023
Feather Safety Razor Co., Ltd. ..........................3516
Fera Pharmaceuticals .........................................762
First Insight Corporation ...................................4548
Fischer Surgical, Inc. ........................................1058
Florida Eye Equipment ......................................4747
Fortifeye Vitamins .............................................4418 
Forus Health NEW! ..........................................4923 
Foundation of the American Academy of 
Ophthalmology (FAAO) ................................. 3239 
Foxfire Systems Group NEW! .........................4717 
Freedom Ophthalmic Pvt., Ltd. .........................1907
Freedom Scientific ............................................5232
Fresnel Prism & Lens Co...................................1901
Fundus Photo ......................................................911
G
Geisinger Health System  NEW! ......................959
GENENTECH ...................................................4539
General Medical Services NEW! ....................4425 
Geuder AG ........................................................1001
Glacial Multimedia ...........................................2203
Glaucoma Research Foundation ......................5013
Glaukos Corporation .........................................1963
Global Sight Alliance ........................................5112
Good-Lite ..........................................................1601
Gulden Ophthalmics .........................................2503
H
H&O Equipments, Inc.  NEW! .........................2565
Haag-Streit AG ...................................................745
Haag-Streit Group h ......................................745
Haag-Streit Surgical GmbH ................................745
Haag-Streit UK....................................................745
HAI Laboratories, Inc. .......................................2109
Hangzhou MuleTech Co., Ltd. ..........................1161
Hausted .............................................................4715 
Healthcare Phones NEW! ...............................1564 
Heidelberg Engineering ................................445
Heine  ................................................................4329
Henan Universe IOL R&M Co., Ltd. ..................1305
Highlights of Ophthalmology h .......................4412
HIMS, Inc. .........................................................1506
Howard Instruments, Inc. h ..............................917
Hoya Surgical Optics, Inc. ............................125
HRA Healthcare Research & Analytics ...........5240 
Huaian Frimen Co., Ltd. ......................................758
HUCO.................................................................2508
Hurricane Medical ............................................2201
Huvitz Co., Ltd. ..................................................5047
I
Icare USA ............................................................231
ICS Software, Ltd.  NEW! ...............................4449
ifa systems AG..................................................4728 
ifa united i-tech, Inc..........................................4728
Images en Ophtalmologie ................................4812
imatters .............................................................3120
I-MED Pharma ..................................................1916
i-Medical Ophthalmic  
International Gmbh NEW! ..........................4455
iMedicWare, Inc. ..............................................4847
Imperial Medical Technologies, Inc. ................2104
Inami & Co., Ltd. .................................................801
INDO WEBAL SURGICAL....................................764
Indo-German Surgical Corporation ..................4823
Infinite Therapeutics .........................................5239
Infinitt North America  NEW!..........................4619
Innova Systems, Inc. .........................................4046
Innovative Visual Systems ...............................1809
Insight Instruments, Inc. ...................................4527
Institute For Continuing Healthcare  
Education .......................................................422
Integrated Orbital Implants, Inc. ......................1038
Integrity Digital Solutions, LLC ........................4829
International Agency for the Prevention of  
Blindness (IAPB) ...........................................5015
International Center - American Academy of 
Ophthalmology ............................................... 5313
International Council of Ophthalmology  
(ICO) ..............................................................3501
International Sight Restoration ........................2401
International Society of Refractive  
Surgery (ISRS) ..............................................3239 
IO Practiceware ................................................4047
IOP Ophthalmics ...............................................3421
i-Optics Corporation .........................................2163
IRIDEX ...............................................................1135
iScience Interventional .....................................1163
J
Jaggi Ophthalmic Instrument Co. ....................1213
Jaypee-Highlights Medical Publishers h .......4412
JCAHPO ............................................................3742
JCB Laboratories  NEW! .................................4423
JEDMED Instrument Company ..........................345
Jingming Science & Technology Co., Ltd. .......2405
K
KAI Industries, Ltd. ...........................................1954
Katalyst Surgical, LLC. ........................................353
Katena Products, Inc. h ...................................2101
Keeler Instruments, Inc. h ...............................2245
KeyMedical Software, Inc. .................................317
Khosla Surgical Industries h ...........................1849
King Khaled Eye Specialist Hospital ................5133
Kirwan Surgical Products LLC h .....................1200
Knobbe Martens, LLP  NEW! ..........................1956
Konan Medical USA .........................................1709
Koryo Eyetech Co., Ltd. .....................................3222
Kowa Optimed, Inc. h .....................................3739
Krebs Instruments h ........................................2336
Kugler Publications h ......................................4325
L
Labtician Ophthalmics, Inc. ................................601
Lacrimedics, Inc. ...............................................4623
LacriSciences, LLC ............................................2409
Latham & Phillips Ophthalmic ..........................1837
Learning Lounge - American Academy of 
Ophthalmology ............................................... 3647
Leica Microsystems ..........................................2516
Leiter’s Pharmacy ..............................................4138
LENSAR .............................................................2154
Lenstec, Inc. ........................................................509
Leoni Fiber Optics, Inc. .....................................2512
Lianyungang Weidir Impex  
Trading Co., Ltd. ...........................................4713
LIGHTMED Corporation ......................................457
Lions Clubs International Foundation ..............5017
Lippincott Williams & Wilkins h ....................4213
Live Eyewear, Inc. .............................................1825
LKC Technologies, Inc. h .................................1044
Lombart Instrument h .....................................1029
Lumenis Vision h .............................................2144
Lutein Pharmaceutical Co., Ltd. China .............5018
M
M&S Technologies, Inc. ...................................3945
Macular Health .................................................4350
MacuLogix, Inc.  NEW! ...................................2304
Madhu Instruments ..........................................1607
ManagementPlus .............................................3820
MANI.................................................................1000
Marasco & Associates, Healthcare Architects  
& Consultants ................................................907
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Marco Ophthalmic h .......................................2846
Market Scope, LLC  NEW! ..............................3201
Mastel Precision Surgical Instruments, Inc. ......601
Mayo Clinic .......................................................1310
McKesson Medical - Surgical NEW! ..............4816 
MDIntellesys .....................................................4344
MDoffice, Inc. ...................................................3213
Meccanottica Mazza S.r.L ................................1946
Meda Co., Ltd. ..................................................2211
MedDev Corporation ........................................2100
MedEdicus ..........................................................661
Medennium, Inc. ...............................................1500
Medflow, Inc. ....................................................3313
Medi Instruments, Inc. .....................................3614
Medical Eye Glass Center NEW! ....................2328 
Medical Ministry International ........................5021
Medical Planning, Inc. h .................................2000
Medicel AG .......................................................2905
MEDICEM International ...................................4758 
Medicure Instruments ......................................4912
MediKits  NEW! ..............................................4722
Medimaging Integrated Solutions, Inc.  
(MiiS)  NEW! .................................................963
Medinformatix, Inc. ............................................325
Mediphacos ......................................................1763
Medisurg Research & Management Corp.......5339 
Med-Logics, Inc. ...............................................1209
MedNet Technologies ......................................3613
MedNetworx  NEW! .......................................3300
MedOne Surgical, Inc. ......................................1727
MEDVISION ......................................................4659 
Mercoframes Optical Corp. ..............................3600
Mercy Ships ......................................................5019
Merge Healthcare h ........................................1402
Merrill Lynch .....................................................1004
Metrovision .......................................................3612
Micro Medical Devices, Inc. ............................1811
MICROspecialties, Inc. .....................................1409
MID Labs, Inc. ...................................................1801
Mid-Gulf Instruments, Inc. ...............................2901
Midwest Business Capital  NEW! ..................2207
Miraflex .............................................................4416 
Mobile Device Charging Stations 
Rest Stops ............................................153 & 5444 
Mobius Therapeutics, LLC ..................................563
Modernizing Medicine .....................................4947
Montefiore Medical Center ..............................3100
MORIA h ..........................................................3128
Moss Vision Inc., Ltd. .......................................1861
MSI Precision Instruments ...............................2012
MST (MicroSurgical Technology) .....................4038
MTI ....................................................................4225
Museum of Vision - Foundation of the  
American Academy of Ophthalmology .... 3147
MyEyeStore  NEW! .........................................2205
N
Nadia International, Inc. ...................................2324
Neitz Instruments Co., Ltd. ...............................1928
NeoMedix Corporation ................................1608
Neotech Medical Pvt., Ltd. ...............................1512
NeurOptics ........................................................4524
New World Medical, Inc. ...................................237
NexTech ............................................................2819
NextGen Healthcare .........................................3624
Nicox, Inc. .........................................................4719
Nidek, Inc. h ....................................................1045
Noir Laser h .....................................................2001
Nordic Naturals NEW! ....................................5059 
Notal Vision ....................................................2063
NUMEDIS, Inc. ..................................................1504
O
OA Systems, Inc. ..............................................1204
OASIS Medical, Inc. h .....................................4012
Ocular Instruments, Inc. h .................................331
Ocular Surgery News (OSN) h ........................1101
Ocular Systems, Inc. .........................................2311
Ocular Therapeutix, Inc. .....................................416
Oculus, Inc. h ................................................1628
Oculus Surgical, Inc.  NEW! ............................1735
OcuScience, Inc. NEW! ...................................4658 
OCuSOFT, Inc. ...................................................4139
Odyssey Medical, Inc. ......................................1944
Oertli Instrumente AG ........................................245
OFCOR ...............................................................5041
OMIC-Ophthalmic Mutual Insurance  
Company ......................................................3139
Omni Lens Pvt., Ltd. ..........................................1835
OPHMED Co., Ltd. .............................................4820
Ophsurin Co., Ltd.  NEW! ................................1364
OPHTEC ...............................................................223
OphthalMed, LLC  NEW! .................................2402
Ophthalmic Instrument Co., Inc. .......................3738
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WHERE ALL OF OPHTHALMOLOGY MEETS
CME & CE Credit
CME Mission Statement
The purpose of the American Academy of Ophthalmology’s Continuing Medical Education (CME) program is to 
present ophthalmologists with the highest quality lifelong learning opportunities that promote improvement 
and change in physician practices, performance or competence, thus enabling such physicians to maintain or 
improve the competence and professional performance needed to provide the best possible eye care for their 
patients.
The American Medical Association has determined that non–U.S. licensed physicians who participate in this 
CME activity are eligible for AMA PRA Category 1 Credits™. 
Attendees registered as exhibitors, spouses or guests are not eligible to receive CME credit.
2013 Annual Meeting CME Credit
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical 
Education to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this live activity for a maximum of 33 AMA PRA Cat-
egory 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation 
in the activity.
Portions of the meeting identified for credit include Annual Meeting scientific sessions, instruction courses, 
Skills Transfer courses, Breakfast With the Experts, AAOE Saturday Program, Scientific Papers and Posters, 
the Video Program, and the Jackson Memorial Lecture at the Opening Session.
Portions of the meeting not eligible for credit include, but are not limited to, committee meetings, viewing 
exhibits, attending Special Meetings & Events, the AAOE General Session, social networking and any affiliate 
event.
2013 Annual Meeting Learning Objectives
Upon completion of this activity, participants should be able to:
• Identify recent advances in the diagnosis and treatment of eye diseases.
• Identify major advances in key areas of cutting-edge research and technology in ophthalmology.
• Incorporate skills and techniques from the hands-on Skills Transfer courses into their daily practice.
• Integrate practice management strategies to address critical business and operational tasks in the ophthal-
mologist’s practice.
• Develop strategies to identify and address their own individual professional practice gaps.
2013 Annual Meeting Target Audience
This activity has been designed to meet the educational needs of ophthalmologists, nurses, ophthalmic tech-
nicians and other allied health personnel who are engaged in the diagnosis and treatment of eye diseases, as 
well as business managers responsible for managing the business aspects of an ophthalmic practice.
CME & CE Credit
318 Academy staff are available at the Academy Resource Center, Hall G, Booth 3239, to answer any questions you may have.
 CME & CE Credit
CM
E 
&
 C
E 
Cr
re
di
t
2013 Subspecialty Day CME Credit
The American Academy of Ophthalmology is accredited by the 
Accreditation Council for Continuing Medical Education to provide 
continuing medical education for physicians.
Subspecialty Day Activities for Retina and Refractive Surgery
The American Academy of Ophthalmology designates this live activity 
for a maximum of 14 AMA PRA Category 1 Credits™. Physicians 
should claim only the credit commensurate with the extent of their 
participation in the activity.
Subspecialty Day Activities for Cornea, Glaucoma, Neuro-
Ophthalmology, Oculofacial Plastic Surgery, and Pediatric 
Ophthalmology
The American Academy of Ophthalmology designates this live activity 
for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should 
claim only the credit commensurate with the extent of their participa-
tion in the activity.
Self-Assessment Credit
Portions of these activities meet the Self-Assessment CME 
requirements defined by the American Board of Ophthalmology 
(ABO). Please be advised that the ABO is not an accrediting body 
for purposes of any CME program.  ABO does not sponsor this or 
any outside activity, and ABO does not endorse any particular CME 
activity.  Complete information regarding the ABO Self-Assessment 
CME Maintenance of Certification requirements are available at:  
http://abop.org/maintain-certification/part-2-lifelong-learning-
self-assessment/cme. 
This year’s Subspecialty Day meetings (Cornea, Glaucoma, Neuro-
-Ophthalmology, Oculofacial Plastic Surgery, Pediatric Ophthal-
mology, Refractive Surgery and Retina) as well as the Cataract 
Spotlight within the Annual Meeting have been pre-approved as 
self-assessment credit. 
NOTE: Credit designated as “self-assessment” is AMA PRA 
Category 1 Credit™ and is also pre-approved by the ABO for the 
Maintenance of Certification (MOC) Part II CME requirements.
2013 AAOE Coding CME Credit
The American Academy of Ophthalmology is accredited by the 
Accreditation Council for Continuing Medical Education to provide 
continuing medical education for physicians.
Coding Sessions
The American Academy of Ophthalmology designates this live activity 
for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should 
claim only the credit commensurate with the extent of their participa-
tion in the activity.
Teaching at a Live Activity
Teaching instruction courses, or delivering a scientific paper or 
poster are not AMA PRA Category 1 Credit™ activities and should 
not be included when calculating your total AMA PRA Category 
1 Credit™. Presenters may claim AMA PRA Category 1 Credit™ 
through the American Medical Association. Please contact the 
AMA to obtain an application form at www.ama-assn.org.
 
Scientific Integrity and Disclosure of Financial Interest
The American Academy of Ophthalmology is committed to ensuring 
that all continuing medical education (CME) information is based 
on the application of research findings and the implementation of 
evidence-based medicine. It seeks to promote balance, objectivity and 
absence of commercial bias in its content. All persons in a position to 
control the content of this activity must disclose any and all finan-
cial interests. The Academy has mechanisms in place to resolve all 
conflicts of interest prior to an educational activity being delivered to 
the learners.
Attendance Verification for CME Reporting
Before processing your requests for CME credit, the Academy must 
verify your attendance at Subspecialty Day and/or the Annual Meet-
ing. In order to be verified for CME or auditing purposes, you must 
either:
• Register in advance, receive materials in the mail and turn in 
the Final Program and/or Subspecialty Day Syllabus exchange 
voucher(s) onsite;
• Register in advance and pick up your badge onsite if materials did 
not arrive before you traveled to the meeting;
• Register onsite; or
• Scan the barcode on your badge
Session Scanning – What Does It Mean? 
New this year: There will be a bar code on your Annual Meeting 
badge. Staff stationed at each course room will scan your badge. 
At the end of each day, an e-mail will be sent confirming the 
instruction courses at which your badge was scanned, with links 
directly to their evaluations. Your participation in the evaluation 
process is critical for maintaining a high-quality program. 
What about CME? Getting your badge scanned does not automati-
cally grant CME. You still need to record your own educational ac-
tivities. You can do so either in New Orleans at a designated CME 
Reporting station or online after the Annual Meeting. Please note: 
You should claim only the credit commensurate with the extent of 
your participation in the activity.
CME Credit Reporting
Lobby B2, Lobby G & Academy Resource Center, Booth 3239,  
Hall G
Attendees whose attendance has been verified at the 2013 An-
nual Meeting can claim their CME credit online during the meeting. 
Registrants will receive an email during the meeting with the link and 
instructions on how to claim credit. Onsite, you may report credits 
earned during Subspecialty Day and/or the Annual Meeting at the 
CME Credit Reporting booth.
Note: If you prefer to complete a paper CME form, copies will be 
available at the Membership Booth in the Resource Center (Hall G, 
Booth 3239) and the Meetings Office (Room 265).
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Academy Members
The CME credit reporting receipt is not a CME transcript. CME 
transcripts that include 2013 Annual Meeting credits entered onsite 
will be available to Academy members on the Academy’s website 
beginning Dec. 10, 2013. 
NOTE: CME credits must be reported by Jan. 15, 2014. After the 2013 
Annual Meeting, credits can be claimed at www.aao.org/cme.
The Academy transcript cannot list individual course attendance. 
It will list only the overall credits spent in educational activities at 
Subspecialty Day and/or the Annual Meeting.
Nonmembers
The Academy will provide nonmembers with verification of credits 
earned and reported for a single Academy sponsored CME activity, 
but it does not provide CME credit transcripts. To obtain a printed 
record of your credits, you must report your CME credits onsite at the 
CME Credit Reporting booths.
Proof of Attendance
The following types of attendance verification will be available during 
the Annual Meeting and Subspecialty Day for those who need it for 
reimbursement or hospital privileges, or for nonmembers who need it 
to report CME credit:
• CME credit reporting/proof-of attendance letters
• Onsite Registration
• Instruction Course Verification
Visit the Academy’s website for detailed CME reporting information.
AAPC Continuing Education Credit
The American Academy of Professional Coders (AAPC) reviews and 
selects courses towards the maintenance of CPC, CPC-H and CPC-P 
certification. Approved courses are identified in the Annual Meeting 
programs with a  C . Granting of prior approval in no way constitutes 
endorsement by the AAPC of the program content or the program 
sponsor. A certificate of completion is included in the Coding Sessions 
Workbook for AAPC and JCAHPO attendance verification. Visit www.
aapc.com for more information.
NOTE: AAPC credits cannot be claimed on the Academy’s online CME 
system. 
NBCOE Continuing Education Credit
The National Board for the Certification of Ophthalmic Executives 
(NBCOE) reviews the American Academy of Ophthalmic Executives 
(AAOE) program for COE Category A credit hours. Approved courses 
are identified in the Annual Meeting programs by a  A . In 2013, all 
AAOE instruction courses (AAOEIC) are eligible for NBCOE credit, 
except AAOEIC 541. All Category A activities yield a 1:1 credit ratio 
for hours spent to hours earned. Visit www.asoa.org for more 
information.
JCAHPO Continuing Education Credit
The Annual Commission on Allied Health Personnel in Ophthalmology 
(JCAHPO) reviews courses for continuing education credit toward 
certification or recertification in ophthalmic medical assisting for 
COA, COT and COMT levels. Approved courses are designated in the 
Annual Meeting programs by a  J  and classified as either Group A 
or Group B. Though JCAHPO may award continuing education credit 
for specified courses, JCAHPO does not sponsor these or any other 
review course. A certificate of completion is included in the Coding 
Sessions Workbook for AAPC and JCAHPO attendance verification. 
Visit www.jcahpo.org for more information.
NOTE: JCAHPO credits cannot be claimed on the Academy’s online 
CME system. Attendees completing JCAHPO approved courses will 
receive their credit certificate onsite. 
 Future Meeting Dates & Locations
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AAO 2014 
Chicago 
Oct. 18 – 21
Subspecialty Day 
Oct. 17 & 18
In partnership with the  
European Society of  
Ophthalmology (SOE)
AAO 2015
Las Vegas
Nov. 14 – 17
Subspecialty Day 
Nov. 13 & 14
AAO 2016 
Chicago
Oct. 15 – 18
Subspecialty Day 
Oct. 14 & 15
Future Meeting Dates & Locations
IMPORTANT SAFETY INFORMATION
CAUTION: Federal (USA) law restricts this device to sale by, or on the 
order of, a physician.
As part of a properly maintained surgical environment, it is recommended 
that a backup IOL Injector be made available in the event the AutoSert® 
IOL Injector Handpiece does not perform as expected.
INDICATION: The CENTURION® Vision System is indicated for 
emulsification, separation, irrigation, and aspiration of cataracts, residual 
cortical material and lens epithelial cells, vitreous aspiration and cutting 
associated with anterior vitrectomy, bipolar coagulation, and intraocular 
lens injection. The AutoSert® IOL Injector Handpiece is intended to deliver 
qualified AcrySof® intraocular lenses into the eye following cataract 
removal.
The AutoSert® IOL Injector Handpiece achieves the functionality of 
injection of intraocular lenses. The AutoSert® IOL Injector Handpiece is 
indicated for use with the AcrySof® lenses SN6OWF, SN6AD1, SN6AT3 
through SN6AT9, as well as approved AcrySof® lenses that are specifically 
indicated for use with this inserter, as indicated in the approved labeling 
of those lenses.
WARNINGS: Appropriate use of CENTURION® Vision System parameters 
and accessories is important for successful procedures. Use of low vacuum 
limits, low flow rates, low bottle heights, high power settings, extended 
power usage, power usage during occlusion conditions (beeping tones), 
failure to sufficiently aspirate viscoelastic prior to using power, excessively 
tight incisions, and combinations of the above actions may result in 
significant temperature increases at incision site and inside the eye, and 
lead to severe thermal eye tissue damage.
Good clinical practice dictates the testing for adequate irrigation and 
aspiration flow prior to entering the eye. Ensure that tubings are not 
occluded or pinched during any phase of operation. 
The consumables used in conjunction with ALCON® instrument 
products constitute a complete surgical system. Use of consumables and 
handpieces other than those manufactured by Alcon may affect system 
performance and create potential hazards.  
AEs/COMPLICATIONS: Inadvertent actuation of Prime or Tune while a 
handpiece is in the eye can create a hazardous condition that may result 
in patient injury.  During any ultrasonic procedure, metal particles may 
result from inadvertent touching of the ultrasonic tip with a second 
instrument. Another potential source of metal particles resulting from 
any ultrasonic handpiece may be the result of ultrasonic energy causing 
micro abrasion of the ultrasonic tip.
ATTENTION: Refer to the Directions for Use and Operator’s Manual for a 
complete listing of indications, warnings, cautions and notes.
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You Deserve the Best.
 
Complete
Solutions
Cataract
Beaver® Safety Knives 
Beaver-Visitec International, Inc. | 411 Waverley Oaks Road Waltham, MA 02452 USA | BVI, BVI Logo and all other trademarks (unless noted otherwise) are property of a Beaver-Visitec International (“BVI”) company © 2013 BVI
For more information, call 1.866.906.8080 or visit us at www.beaver-visitec.com
Visitec® Instruments and CannulaeThe Most Trusted Ophthalmic Brands
Beaver-Visitec International (BVI) is proud to offer 
you a complete solution for all your cataract surgery 
needs. With over 80 years of experience, Beaver-Visitec 
brings together some of the most trusted ophthalmic 
brands all with a longstanding tradition of precision, 
innovation and quality. 
Our Complete Family of Brands 
Wet-Field®                    ReadyPak™
Atomic Edge®              Osher ThermoDot™
Accu-Temp®                 CustomEyes®
Merocel® Spears and Fluid Control
NEW — The Parasol® Punctal Occluder
Visit us at booth  #1944/1945
NEW 
WELCOME TO THE 
ERA OF CENTURION®
Active Fluidics™
Automatically optimizes chamber stability 
by allowing surgeons to customize and 
control IOP throughout the procedure.
Balanced Energy™
Enhances cataract emulsification efficiency 
using OZil® Intelligent Phaco and the new 
INTREPID® Balanced Tip design.
Applied Integration™
Designed to work seamlessly with other 
Alcon technologies for an integrated 
cataract procedure experience.
Optimize every moment of your cataract removal 
procedure with the NEW CENTURION® Vision System.
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Learn more about the new era of cataract procedures. 
Visit MyAlcon.com.
For important safety information, please see adjacent page.
THE CATARACT REFRACTIVE SUITE BY ALCON
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